0001492298-24-000008.txt : 20240227 0001492298-24-000008.hdr.sgml : 20240227 20240227160844 ACCESSION NUMBER: 0001492298-24-000008 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 119 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240227 DATE AS OF CHANGE: 20240227 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sabra Health Care REIT, Inc. CENTRAL INDEX KEY: 0001492298 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] ORGANIZATION NAME: 05 Real Estate & Construction IRS NUMBER: 272560479 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34950 FILM NUMBER: 24686687 BUSINESS ADDRESS: STREET 1: 18500 VON KARMAN STREET 2: SUITE 550 CITY: IRVINE STATE: CA ZIP: 92612 BUSINESS PHONE: 888-393-8248 MAIL ADDRESS: STREET 1: 18500 VON KARMAN STREET 2: SUITE 550 CITY: IRVINE STATE: CA ZIP: 92612 10-K 1 sbra-20231231.htm 10-K sbra-20231231
00014922982023FYfalsehttp://fasb.org/us-gaap/2023#HealthCareResidentServiceMemberhttp://fasb.org/us-gaap/2023#HealthCareResidentServiceMemberhttp://fasb.org/us-gaap/2023#HealthCareResidentServiceMemberP5YP3Yhttp://fasb.org/us-gaap/2023#OtherOperatingIncomeExpenseNethttp://www.sabrahealth.com/20231231#AccountsReceivablePrepaidExpensesDeferredFinancingCostsAndOtherAssetsNethttp://www.sabrahealth.com/20231231#AccountsReceivablePrepaidExpensesDeferredFinancingCostsAndOtherAssetsNethttp://fasb.org/us-gaap/2023#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrenthttp://fasb.org/us-gaap/2023#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrenthttp://fasb.org/us-gaap/2023#LineOfCredit http://fasb.org/us-gaap/2023#LoansPayableToBankhttp://www.sabrahealth.com/20231231#AccountsReceivablePrepaidExpensesDeferredFinancingCostsAndOtherAssetsNethttp://fasb.org/us-gaap/2023#LineOfCredit http://fasb.org/us-gaap/2023#LoansPayableToBankhttp://www.sabrahealth.com/20231231#AccountsReceivablePrepaidExpensesDeferredFinancingCostsAndOtherAssetsNetP3Y00014922982023-01-012023-12-3100014922982023-06-30iso4217:USD00014922982024-02-20xbrli:shares00014922982023-10-012023-12-3100014922982023-12-3100014922982022-12-31iso4217:USDxbrli:shares00014922982022-01-012022-12-3100014922982021-01-012021-12-310001492298sbra:TripleNetPortfolioMember2023-01-012023-12-310001492298sbra:TripleNetPortfolioMember2022-01-012022-12-310001492298sbra:TripleNetPortfolioMember2021-01-012021-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMember2023-01-012023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMember2022-01-012022-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMember2021-01-012021-12-310001492298us-gaap:CommonStockMember2020-12-310001492298us-gaap:AdditionalPaidInCapitalMember2020-12-310001492298us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2020-12-310001492298us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-3100014922982020-12-310001492298us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2021-01-012021-12-310001492298us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310001492298us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310001492298us-gaap:CommonStockMember2021-01-012021-12-310001492298us-gaap:CommonStockMember2021-12-310001492298us-gaap:AdditionalPaidInCapitalMember2021-12-310001492298us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2021-12-310001492298us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-3100014922982021-12-310001492298us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2022-01-012022-12-310001492298us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310001492298us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310001492298us-gaap:CommonStockMember2022-01-012022-12-310001492298us-gaap:CommonStockMember2022-12-310001492298us-gaap:AdditionalPaidInCapitalMember2022-12-310001492298us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2022-12-310001492298us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001492298us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2023-01-012023-12-310001492298us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310001492298us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-310001492298us-gaap:CommonStockMember2023-01-012023-12-310001492298us-gaap:CommonStockMember2023-12-310001492298us-gaap:AdditionalPaidInCapitalMember2023-12-310001492298us-gaap:AccumulatedDistributionsInExcessOfNetIncomeMember2023-12-310001492298us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001492298us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-12-31sbra:variableInterestEntitysbra:investment0001492298us-gaap:LandImprovementsMembersrt:MinimumMember2023-12-310001492298us-gaap:LandImprovementsMembersrt:MaximumMember2023-12-310001492298srt:MinimumMemberus-gaap:BuildingAndBuildingImprovementsMember2023-12-310001492298us-gaap:BuildingAndBuildingImprovementsMembersrt:MaximumMember2023-12-310001492298srt:MinimumMembersbra:FurnitureAndEquipmentMember2023-12-310001492298srt:MaximumMembersbra:FurnitureAndEquipmentMember2023-12-310001492298sbra:RevenueFromContractWithCustomerExcludingAssessedTaxMember2023-01-012023-12-310001492298sbra:RevenueFromContractWithCustomerExcludingAssessedTaxMember2022-01-012022-12-310001492298sbra:RevenueFromContractWithCustomerExcludingAssessedTaxMember2021-01-012021-12-310001492298sbra:IncomeLossFromEquityMethodInvestmentsMember2023-01-012023-12-310001492298sbra:VandalismAndTheftMember2023-01-012023-12-310001492298us-gaap:FireMember2023-01-012023-12-31xbrli:puresbra:segment0001492298sbra:SkilledNursingTransitionalCareFacilitiesMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2023-01-012023-12-31sbra:property0001492298sbra:SeniorHousingFacilitiesLeasedMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2023-01-012023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2023-01-012023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2022-01-012022-12-310001492298sbra:BehavioralHealthMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2022-01-012022-12-310001492298sbra:SeniorHousingFacilitiesManagedCommunitiesProprietaryDevelopmentPipelineMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2022-01-012022-12-310001492298us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2023-12-310001492298us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2022-12-310001492298sbra:TenantOriginationAndAbsorptionCostsMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2023-12-310001492298sbra:TenantOriginationAndAbsorptionCostsMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2022-12-310001492298sbra:TenantRelationshipMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2023-12-310001492298sbra:TenantRelationshipMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2022-12-310001492298sbra:TenantOriginationAndAbsorptionCostsMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2023-01-012023-12-310001492298sbra:TenantRelationshipMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2023-01-012023-12-310001492298sbra:TenantOriginationAndAbsorptionCostsMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2022-01-012022-12-310001492298sbra:TenantRelationshipMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2022-01-012022-12-310001492298us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2023-01-012023-12-310001492298us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2022-01-012022-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2023-04-012023-06-300001492298sbra:SeniorHousingFacilitiesManagedPortfolioMemberus-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2023-06-300001492298sbra:SkilledNursingTransitionalCareFacilitiesMemberus-gaap:OperatingSegmentsMember2023-12-31sbra:facilitysbra:bed0001492298sbra:SeniorHousingFacilitiesLeasedMemberus-gaap:OperatingSegmentsMember2023-12-310001492298us-gaap:OperatingSegmentsMembersbra:SeniorHousingFacilitiesManagedPortfolioMember2023-12-310001492298us-gaap:OperatingSegmentsMembersbra:BehavioralHealthMember2023-12-310001492298us-gaap:OperatingSegmentsMembersbra:SpecialtyHospitalsAndOtherMember2023-12-310001492298us-gaap:OperatingSegmentsMember2023-12-310001492298us-gaap:CorporateMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMemberus-gaap:OperatingSegmentsMember2022-12-310001492298sbra:SeniorHousingFacilitiesLeasedMemberus-gaap:OperatingSegmentsMember2022-12-310001492298us-gaap:OperatingSegmentsMembersbra:SeniorHousingFacilitiesManagedPortfolioMember2022-12-310001492298us-gaap:OperatingSegmentsMembersbra:BehavioralHealthMember2022-12-310001492298us-gaap:OperatingSegmentsMembersbra:SpecialtyHospitalsAndOtherMember2022-12-310001492298us-gaap:OperatingSegmentsMember2022-12-310001492298us-gaap:CorporateMember2022-12-310001492298srt:MinimumMembersbra:SeniorHousingFacilitiesManagedPortfolioMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersrt:MaximumMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMember2023-12-310001492298sbra:NoncashRentReceivableMembersbra:AvamereFamilyOfCompaniesMember2021-01-012021-12-310001492298sbra:AvamereFamilyOfCompaniesMember2022-02-012022-02-010001492298sbra:AvamereFamilyOfCompaniesMember2022-01-012022-01-310001492298sbra:NorthAmericanHealthCareIncMember2022-01-012022-12-310001492298sbra:HealthCareResidentServiceAncillaryServiceMember2023-01-012023-12-310001492298sbra:HealthCareResidentServiceAncillaryServiceMember2022-01-012022-12-310001492298sbra:HealthCareResidentServiceAncillaryServiceMember2021-01-012021-12-310001492298sbra:SeniorHousingFacilitiesMembersbra:SiennaJointVentureMember2023-12-310001492298sbra:SiennaJointVentureMember2023-12-310001492298sbra:SiennaJointVentureMember2022-12-310001492298sbra:SeniorHousingFacilitiesMembersbra:MarlinSpringJointVentureMember2023-12-310001492298sbra:MarlinSpringJointVentureMember2023-12-310001492298sbra:MarlinSpringJointVentureMember2022-12-310001492298sbra:MarlinSpringJointVentureMembersbra:SeniorHousingFacilitiesMember2023-12-310001492298sbra:MarlinSpringJointVentureMembersbra:SeniorHousingFacilitiesMember2022-12-310001492298sbra:MarlinSpringJointVentureMembersbra:SeniorHousingFacilitiesMember2023-01-012023-12-31iso4217:CAD0001492298sbra:MarlinSpringJointVentureMembersbra:SeniorHousingFacilitiesMember2022-01-012022-12-310001492298sbra:MarlinSpringJointVentureMembersbra:SeniorHousingFacilitiesMembersbra:MarlinSpringJointVentureMember2023-12-310001492298sbra:MarlinSpringJointVentureMembersbra:SeniorHousingFacilitiesMembersbra:MarlinSpringJointVentureMember2022-12-310001492298sbra:SeniorHousingFacilitiesMembersbra:SiennaJointVentureMember2022-12-310001492298sbra:SeniorHousingFacilitiesMembersbra:SiennaJointVentureMember2022-01-012022-12-310001492298sbra:SeniorHousingFacilitiesMembersbra:SiennaJointVentureMembersbra:SiennaSeniorLivingMember2022-12-310001492298sbra:EnlivantJointVentureMember2021-06-300001492298sbra:EnlivantJointVentureMember2021-04-012021-06-300001492298sbra:EnlivantJointVentureMember2022-10-012022-12-310001492298sbra:EnlivantJointVentureMember2023-12-310001492298sbra:EnlivantJointVentureMember2022-12-310001492298sbra:EnlivantJointVentureMember2023-01-012023-12-310001492298sbra:EnlivantJointVentureMember2022-01-012022-12-310001492298sbra:EnlivantJointVentureMember2021-01-012021-12-310001492298sbra:EnlivantJointVentureMember2023-01-012023-12-310001492298sbra:EnlivantJointVentureMember2022-01-012022-12-310001492298sbra:EnlivantJointVentureMember2021-01-012021-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMember2022-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMember2023-01-012023-03-310001492298sbra:FacilitiesMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2023-01-012023-12-310001492298sbra:FacilitiesMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2022-01-012022-12-310001492298sbra:FacilitiesMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2021-01-012021-12-310001492298us-gaap:AboveMarketLeasesMember2023-12-310001492298us-gaap:AboveMarketLeasesMember2022-12-310001492298sbra:TenantOriginationAndAbsorptionCostsMember2023-12-310001492298sbra:TenantOriginationAndAbsorptionCostsMember2022-12-310001492298sbra:TenantRelationshipMember2023-12-310001492298sbra:TenantRelationshipMember2022-12-310001492298us-gaap:AboveMarketLeasesMembersbra:AvamereFamilyOfCompaniesMember2021-01-012021-12-310001492298sbra:MortgageLoansReceivableMember2023-12-31sbra:loan0001492298sbra:MortgageLoansReceivableMember2022-12-310001492298sbra:OtherMember2023-12-310001492298sbra:OtherMember2022-12-31sbra:preferredEquityInvestment0001492298sbra:FutureFundingOnInvestmentMember2023-12-310001492298us-gaap:FinancialAssetAcquiredWithCreditDeteriorationMember2023-12-310001492298us-gaap:FinancialAssetAcquiredWithCreditDeteriorationMember2022-12-310001492298us-gaap:NonperformingFinancingReceivableMember2023-12-310001492298us-gaap:NonperformingFinancingReceivableMember2022-12-310001492298us-gaap:SecuredDebtMembersbra:FixedRateMortgagesMember2023-12-310001492298us-gaap:SecuredDebtMembersbra:FixedRateMortgagesMember2022-12-310001492298us-gaap:SecuredDebtMember2023-12-310001492298us-gaap:SecuredDebtMember2022-12-310001492298us-gaap:SecuredDebtMember2022-01-012022-12-310001492298us-gaap:SecuredDebtMember2021-01-012021-12-310001492298sbra:A5.125SeniorUnsecuredNotesDue2026Memberus-gaap:SeniorNotesMember2023-12-310001492298sbra:A5.125SeniorUnsecuredNotesDue2026Memberus-gaap:SeniorNotesMember2022-12-310001492298sbra:A5.88SeniorUnsecuredNotesDue2027Memberus-gaap:SeniorNotesMember2023-12-310001492298sbra:A5.88SeniorUnsecuredNotesDue2027Memberus-gaap:SeniorNotesMember2022-12-310001492298sbra:A3.90SeniorUnsecuredNotesDue2029Memberus-gaap:SeniorNotesMember2023-12-310001492298sbra:A3.90SeniorUnsecuredNotesDue2029Memberus-gaap:SeniorNotesMember2022-12-310001492298us-gaap:SeniorNotesMembersbra:A320SeniorUnsecuredNotesDue2031Member2023-12-310001492298us-gaap:SeniorNotesMembersbra:A320SeniorUnsecuredNotesDue2031Member2022-12-310001492298us-gaap:SeniorNotesMember2023-12-310001492298us-gaap:SeniorNotesMember2022-12-310001492298us-gaap:SeniorNotesMembersbra:A4.80SeniorUnsecuredNotesDue2024Member2019-05-290001492298us-gaap:SeniorNotesMembersbra:A4.80SeniorUnsecuredNotesDue2024Member2019-05-292019-05-290001492298us-gaap:SeniorNotesMembersbra:A4.80SeniorUnsecuredNotesDue2024Member2021-10-070001492298us-gaap:SeniorNotesMembersbra:A4.80SeniorUnsecuredNotesDue2024Member2021-10-072021-10-070001492298sbra:A5.125SeniorUnsecuredNotesDue2026Memberus-gaap:SeniorNotesMember2017-08-170001492298sbra:A5.125SeniorUnsecuredNotesDue2026Memberus-gaap:SeniorNotesMember2017-08-172017-08-170001492298sbra:A5.88SeniorUnsecuredNotesDue2027Memberus-gaap:SeniorNotesMember2017-08-170001492298sbra:A5.88SeniorUnsecuredNotesDue2027Memberus-gaap:SeniorNotesMember2017-08-172017-08-170001492298sbra:A3.90SeniorUnsecuredNotesDue2029Memberus-gaap:SeniorNotesMember2019-10-070001492298sbra:A3.90SeniorUnsecuredNotesDue2029Memberus-gaap:SeniorNotesMember2019-10-072019-10-070001492298us-gaap:SeniorNotesMembersbra:A5.375SeniorUnsecuredNotesDue2023Member2019-10-070001492298sbra:A3.90SeniorUnsecuredNotesDue2029Memberus-gaap:DebtInstrumentRedemptionPeriodOneMemberus-gaap:SeniorNotesMember2019-10-072019-10-070001492298sbra:A3.90SeniorUnsecuredNotesDue2029Memberus-gaap:SeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMember2019-10-072019-10-070001492298us-gaap:SeniorNotesMembersbra:A320SeniorUnsecuredNotesDue2031Member2021-09-300001492298us-gaap:SeniorNotesMembersbra:A320SeniorUnsecuredNotesDue2031Member2021-09-302021-09-300001492298sbra:U.S.DollarTermLoanMember2021-09-302021-09-300001492298us-gaap:DebtInstrumentRedemptionPeriodOneMemberus-gaap:SeniorNotesMembersbra:A320SeniorUnsecuredNotesDue2031Member2021-09-302021-09-300001492298us-gaap:SeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMembersbra:A320SeniorUnsecuredNotesDue2031Member2021-09-302021-09-300001492298sbra:A5.125SeniorUnsecuredNotesDue2026Memberus-gaap:SeniorNotesMember2023-01-012023-12-310001492298us-gaap:SeniorNotesMembersbra:A320SeniorUnsecuredNotesDue2031Member2023-01-012023-12-310001492298sbra:A3.90SeniorUnsecuredNotesDue2029Memberus-gaap:SeniorNotesMember2023-01-012023-12-310001492298us-gaap:RevolvingCreditFacilityMembersbra:CreditAgreementMember2019-09-090001492298sbra:U.S.DollarTermLoanMembersbra:CreditAgreementMember2019-09-090001492298sbra:CanadianDollarTermLoanMembersbra:CreditAgreementMember2019-09-090001492298us-gaap:LineOfCreditMembersbra:CreditAgreementMember2019-09-090001492298sbra:U.S.DollarTermLoanMembersbra:CreditAgreementMember2022-01-012022-12-310001492298sbra:U.S.DollarTermLoanMembersbra:CreditAgreementMember2021-01-012021-12-310001492298us-gaap:RevolvingCreditFacilityMemberus-gaap:PrimeRateMembersbra:CreditAgreementMember2023-01-012023-12-310001492298us-gaap:RevolvingCreditFacilityMembersbra:CreditAgreementMemberus-gaap:BaseRateMember2023-01-012023-12-310001492298srt:MinimumMemberus-gaap:RevolvingCreditFacilityMembersbra:CreditAgreementMembersbra:LondonInterbankOfferedRateLIBOR1Member2023-01-012023-12-310001492298us-gaap:RevolvingCreditFacilityMembersbra:CreditAgreementMembersrt:MaximumMembersbra:LondonInterbankOfferedRateLIBOR1Member2023-01-012023-12-310001492298srt:MinimumMemberus-gaap:RevolvingCreditFacilityMembersbra:CreditAgreementMemberus-gaap:BaseRateMember2023-01-012023-12-310001492298us-gaap:RevolvingCreditFacilityMembersbra:CreditAgreementMembersrt:MaximumMemberus-gaap:BaseRateMember2023-01-012023-12-310001492298srt:MinimumMemberus-gaap:RevolvingCreditFacilityMembersbra:CreditAgreementMember2023-01-012023-12-310001492298us-gaap:RevolvingCreditFacilityMembersbra:CreditAgreementMembersrt:MaximumMember2023-01-012023-12-310001492298srt:MinimumMembersbra:U.S.DollarTermLoanMembersbra:CreditAgreementMembersbra:LondonInterbankOfferedRateLIBOR1Member2023-01-012023-12-310001492298sbra:U.S.DollarTermLoanMembersbra:CreditAgreementMembersrt:MaximumMembersbra:LondonInterbankOfferedRateLIBOR1Member2023-01-012023-12-310001492298srt:MinimumMembersbra:U.S.DollarTermLoanMembersbra:CreditAgreementMemberus-gaap:BaseRateMember2023-01-012023-12-310001492298sbra:U.S.DollarTermLoanMembersbra:CreditAgreementMembersrt:MaximumMemberus-gaap:BaseRateMember2023-01-012023-12-310001492298srt:MinimumMembersbra:CanadianDollarOfferRateCDORMembersbra:CanadianDollarTermLoanMembersbra:CreditAgreementMember2023-01-012023-12-310001492298sbra:CanadianDollarOfferRateCDORMembersbra:CanadianDollarTermLoanMembersbra:CreditAgreementMembersrt:MaximumMember2023-01-012023-12-310001492298sbra:CreditAgreementMember2023-12-310001492298sbra:U.S.DollarTermLoanMembersbra:CreditAgreementMember2023-01-012023-12-310001492298us-gaap:RevolvingCreditFacilityMembersbra:CreditAgreementMember2023-01-040001492298sbra:U.S.DollarTermLoanMembersbra:CreditAgreementMember2023-01-040001492298sbra:CanadianDollarTermLoanMembersbra:CreditAgreementMember2023-01-040001492298us-gaap:LineOfCreditMembersbra:CreditAgreementMember2023-01-04sbra:extensionOption0001492298us-gaap:RevolvingCreditFacilityMembersbra:CreditAgreementMember2023-01-042023-01-040001492298us-gaap:RevolvingCreditFacilityMembersbra:CreditAgreementMember2023-12-310001492298us-gaap:RevolvingCreditFacilityMemberus-gaap:PrimeRateMembersbra:CreditAgreementMember2023-01-042023-01-040001492298us-gaap:RevolvingCreditFacilityMembersbra:CreditAgreementMemberus-gaap:BaseRateMember2023-01-042023-01-040001492298srt:MinimumMemberus-gaap:RevolvingCreditFacilityMembersbra:CreditAgreementMembersbra:SecuredOvernightFinancingRateSOFRMember2023-01-042023-01-040001492298us-gaap:RevolvingCreditFacilityMembersbra:CreditAgreementMembersrt:MaximumMembersbra:SecuredOvernightFinancingRateSOFRMember2023-01-042023-01-040001492298srt:MinimumMemberus-gaap:RevolvingCreditFacilityMembersbra:CreditAgreementMemberus-gaap:BaseRateMember2023-01-042023-01-040001492298us-gaap:RevolvingCreditFacilityMembersbra:CreditAgreementMembersrt:MaximumMemberus-gaap:BaseRateMember2023-01-042023-01-040001492298srt:MinimumMemberus-gaap:RevolvingCreditFacilityMembersbra:CreditAgreementMember2023-01-042023-01-040001492298us-gaap:RevolvingCreditFacilityMembersbra:CreditAgreementMembersrt:MaximumMember2023-01-042023-01-040001492298srt:MinimumMembersbra:U.S.DollarTermLoanMembersbra:CreditAgreementMembersbra:SecuredOvernightFinancingRateSOFRMember2023-01-042023-01-040001492298sbra:U.S.DollarTermLoanMembersbra:CreditAgreementMembersrt:MaximumMembersbra:SecuredOvernightFinancingRateSOFRMember2023-01-042023-01-040001492298srt:MinimumMembersbra:U.S.DollarTermLoanMembersbra:CreditAgreementMemberus-gaap:BaseRateMember2023-01-042023-01-040001492298sbra:U.S.DollarTermLoanMembersbra:CreditAgreementMembersrt:MaximumMemberus-gaap:BaseRateMember2023-01-042023-01-040001492298sbra:U.S.DollarTermLoanMembersbra:CreditAgreementMember2023-12-310001492298srt:MinimumMembersbra:CanadianDollarOfferRateCDORMembersbra:CanadianDollarTermLoanMembersbra:CreditAgreementMember2023-01-042023-01-040001492298sbra:CanadianDollarOfferRateCDORMembersbra:CanadianDollarTermLoanMembersbra:CreditAgreementMembersrt:MaximumMember2023-01-042023-01-040001492298sbra:CanadianDollarTermLoanMembersbra:CreditAgreementMember2023-12-310001492298us-gaap:InterestRateSwapMembersbra:U.S.DollarTermLoanMembersbra:CreditAgreementMember2023-12-310001492298us-gaap:InterestRateSwapMembersbra:CanadianDollarTermLoanMembersbra:CreditAgreementMember2023-12-310001492298us-gaap:LineOfCreditMember2023-12-310001492298us-gaap:LoansPayableMember2023-12-310001492298us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2023-01-012023-12-310001492298us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2023-12-310001492298us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-12-310001492298us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2023-12-310001492298us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMember2022-12-310001492298us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310001492298us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310001492298us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:NondesignatedMember2023-12-310001492298us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:NondesignatedMember2022-12-310001492298us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2023-12-31sbra:derivative0001492298us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMembersbra:InterestRateSwapOneMember2023-12-310001492298us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMembersbra:InterestRateSwapTwoMember2023-12-31sbra:instrument0001492298us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2022-12-310001492298us-gaap:DesignatedAsHedgingInstrumentMembersbra:InterestRateCollarMemberus-gaap:CashFlowHedgingMember2023-12-310001492298us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMembersbra:InterestRateCollarMember2023-12-310001492298us-gaap:DesignatedAsHedgingInstrumentMembersbra:InterestRateCollarMemberus-gaap:CashFlowHedgingMember2022-12-310001492298sbra:ForwardStartingInterestRateSwapsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2023-12-310001492298sbra:ForwardStartingInterestRateSwapsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CashFlowHedgingMember2022-12-310001492298us-gaap:DesignatedAsHedgingInstrumentMember2023-12-310001492298us-gaap:DesignatedAsHedgingInstrumentMember2022-12-310001492298sbra:LongTermLineOfCreditMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2023-12-310001492298sbra:LongTermLineOfCreditMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2022-12-310001492298us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMembersbra:LoansPayableToBankMember2023-12-310001492298us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMembersbra:LoansPayableToBankMember2022-12-310001492298us-gaap:InterestRateContractMember2023-01-012023-12-310001492298us-gaap:InterestRateContractMember2022-01-012022-12-310001492298us-gaap:InterestRateContractMember2021-01-012021-12-310001492298us-gaap:ForeignExchangeContractMember2023-01-012023-12-310001492298us-gaap:ForeignExchangeContractMember2022-01-012022-12-310001492298us-gaap:ForeignExchangeContractMember2021-01-012021-12-310001492298us-gaap:RevolvingCreditFacilityMemberus-gaap:CurrencySwapMember2023-01-012023-12-310001492298us-gaap:RevolvingCreditFacilityMemberus-gaap:CurrencySwapMember2022-01-012022-12-310001492298us-gaap:RevolvingCreditFacilityMemberus-gaap:CurrencySwapMember2021-01-012021-12-310001492298us-gaap:CurrencySwapMember2023-01-012023-12-310001492298us-gaap:CurrencySwapMember2022-01-012022-12-310001492298us-gaap:CurrencySwapMember2021-01-012021-12-310001492298us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2021-01-012021-12-310001492298us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2022-01-012022-12-310001492298us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2023-01-012023-12-310001492298us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NondesignatedMember2023-01-012023-12-310001492298us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NondesignatedMember2022-01-012022-12-310001492298us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NondesignatedMember2021-01-012021-12-310001492298us-gaap:CreditRiskContractMember2023-12-310001492298srt:MinimumMemberus-gaap:MeasurementInputDiscountRateMember2023-12-310001492298srt:MaximumMemberus-gaap:MeasurementInputDiscountRateMember2023-12-310001492298srt:WeightedAverageMemberus-gaap:MeasurementInputDiscountRateMember2023-12-310001492298us-gaap:SecuredDebtMembersrt:WeightedAverageMemberus-gaap:MeasurementInputDiscountRateMember2023-12-310001492298us-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310001492298us-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310001492298us-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001492298us-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001492298us-gaap:SeniorNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310001492298us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:SeniorNotesMember2023-12-310001492298us-gaap:SeniorNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001492298us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:SeniorNotesMember2022-12-310001492298us-gaap:SecuredDebtMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310001492298us-gaap:SecuredDebtMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310001492298us-gaap:SecuredDebtMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001492298us-gaap:SecuredDebtMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001492298us-gaap:FairValueMeasurementsRecurringMember2023-12-310001492298us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-12-310001492298us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001492298us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001492298us-gaap:FairValueMeasurementsRecurringMemberus-gaap:SeniorNotesMember2023-12-310001492298us-gaap:FairValueMeasurementsRecurringMemberus-gaap:SeniorNotesMemberus-gaap:FairValueInputsLevel1Member2023-12-310001492298us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:SeniorNotesMember2023-12-310001492298us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:SeniorNotesMember2023-12-310001492298us-gaap:SecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001492298us-gaap:SecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-12-310001492298us-gaap:SecuredDebtMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001492298us-gaap:SecuredDebtMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001492298us-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001492298us-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-12-310001492298us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001492298us-gaap:FairValueInputsLevel3Memberus-gaap:InterestRateSwapMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001492298us-gaap:FairValueMeasurementsRecurringMembersbra:InterestRateCollarMember2023-12-310001492298us-gaap:FairValueMeasurementsRecurringMembersbra:InterestRateCollarMemberus-gaap:FairValueInputsLevel1Member2023-12-310001492298us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMembersbra:InterestRateCollarMember2023-12-310001492298sbra:ForwardStartingInterestRateSwapsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001492298sbra:ForwardStartingInterestRateSwapsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-12-310001492298sbra:ForwardStartingInterestRateSwapsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001492298sbra:ForwardStartingInterestRateSwapsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001492298us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001492298us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-12-310001492298us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001492298us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001492298sbra:A2019ATMProgramMember2019-12-112019-12-110001492298sbra:A2019ATMProgramMember2021-01-012021-12-310001492298sbra:A2019ATMProgramForwardFeatureMember2021-01-012021-12-310001492298sbra:A2019ATMProgramForwardFeatureMembersrt:WeightedAverageMember2021-01-012021-12-310001492298sbra:PriorATMProgramMember2021-08-062021-08-060001492298sbra:PriorATMProgramForwardFeatureMember2021-01-012021-12-310001492298sbra:PriorATMProgramMember2021-01-012021-12-310001492298sbra:PriorATMProgramForwardFeatureMember2022-01-012022-11-090001492298sbra:UnderwrittenPublicOfferingMember2021-10-152021-10-150001492298sbra:UnderwrittenPublicOfferingMember2021-10-150001492298sbra:ATMProgramMember2023-02-232023-02-230001492298sbra:ATMProgramMember2023-01-012023-12-310001492298sbra:ATMProgramMember2023-12-310001492298us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-310001492298us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001492298us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001492298us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310001492298us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310001492298us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-310001492298us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310001492298srt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-310001492298us-gaap:RestrictedStockUnitsRSUMembersrt:MaximumMember2023-01-012023-12-310001492298srt:MinimumMembersbra:FundsFromOperationsUnitsMember2023-01-012023-12-310001492298sbra:FundsFromOperationsUnitsMembersrt:MaximumMember2023-01-012023-12-310001492298srt:MinimumMembersbra:TotalShareholderReturnUnitsMember2023-01-012023-12-310001492298srt:MaximumMembersbra:TotalShareholderReturnUnitsMember2023-01-012023-12-310001492298us-gaap:RestrictedStockUnitsRSUMember2022-12-310001492298us-gaap:RestrictedStockUnitsRSUMember2023-12-310001492298sbra:TotalShareholderReturnUnitsMember2023-01-012023-12-310001492298sbra:TotalShareholderReturnUnitsMember2022-01-012022-12-310001492298sbra:TotalShareholderReturnUnitsMember2021-01-012021-12-310001492298srt:MaximumMembersbra:TotalShareholderReturnUnitsMember2022-01-012022-12-310001492298srt:MaximumMembersbra:TotalShareholderReturnUnitsMember2021-01-012021-12-310001492298us-gaap:DomesticCountryMember2023-12-310001492298us-gaap:DomesticCountryMember2022-12-310001492298us-gaap:ForeignCountryMember2023-12-310001492298us-gaap:ForeignCountryMember2022-12-310001492298us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-310001492298us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001492298us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001492298sbra:ForwardEquitySaleAgreementSharesMember2022-01-012022-12-310001492298us-gaap:SubsequentEventMember2024-02-012024-02-010001492298sbra:BedfordNHMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:MilfordNHMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:NorthConwayNHMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:WolfeboroNHMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:MiddletownDEMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:DoverDEMember2023-12-310001492298sbra:WilmingtonDEMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:MillsboroDEMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:WarringtonPAMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:DuffieldVAMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:ArlingtonTXMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:RockportTXMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:LincolnNEMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:FremontNE1Member2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:FremontNE2Member2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:BartlesvilleOKMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:OklahomaCityOKMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:NormanOKMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:MinneapolisMNMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:EugeneOR1Member2023-12-310001492298sbra:LebanonORMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:PortlandORMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:TigardORMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:HillsboroORMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:JunctionCityORMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:EugeneOR2Member2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:CoosBayORMember2023-12-310001492298sbra:GladstoneORMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:NewportORMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:OregonCityORMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:TacomaWA1Member2023-12-310001492298sbra:ShorelineWAMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:BellinghamWAMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:SequimWAMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:TacomaWA2Member2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:TacomaWA3Member2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:VancouverWAMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:LakeOswegoORMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:MedfordOR1Member2023-12-310001492298sbra:SeattleWAMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:BoiseIDMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:SalemORMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:MedfordOR2Member2023-12-310001492298sbra:NorthglennCOMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:BrightonCOMember2023-12-310001492298sbra:SantaAnaCAMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:LaMesaCAMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:WestminsterMDMember2023-12-310001492298sbra:KansasCityMOMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:ParkersburgWVMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:CincinnatiOHMember2023-12-310001492298sbra:CharlottesvilleVAMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:AnnandaleVAMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:PetersburgVA1Member2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:PetersburgVA2Member2023-12-310001492298sbra:HagerstownMDMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:CumberlandMDMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:GilroyCAMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:MountPleasantSCMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:HarrogateTNMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:ConwaySCMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:BaytownTXMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:HuntsvilleTXMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:CenterTXMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:HumbleTX1Member2023-12-310001492298sbra:HoustonTX1Membersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:LindenTXMember2023-12-310001492298sbra:ShermanTXMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:MountPleasantTXMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:WaxahachieTXMember2023-12-310001492298sbra:GilmerTXMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:SparksNVMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:RichmondINMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:PetersburgINMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:MaryvilleMOMember2023-12-310001492298sbra:AshlandMOMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:St.LouisMOMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:DoniphanMOMember2023-12-310001492298sbra:DixonMOMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:ForsythMOMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:SeymourMOMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:SilexMOMember2023-12-310001492298sbra:ColumbiaMOMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:StraffordMOMember2023-12-310001492298sbra:WindsorMOMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:ConroeTXMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:HoustonTX2Member2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:HumbleTX2Member2023-12-310001492298sbra:MissouriCityTXMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:HoustonTX3Member2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:HoustonTX4Member2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:TopekaKSMember2023-12-310001492298sbra:SalinaKSMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:TerreHauteINMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:GasCityINMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:WinchesterINMember2023-12-310001492298sbra:ColumbusINMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:PortlandINMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:ClintonINMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:LasVegasNV1Member2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:LasVegasNV2Member2023-12-310001492298sbra:AlamedaCAMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:DoverNHMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:AugustaMEMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:BangorME1Member2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:BathMEMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:BrewerMEMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:KennebunkMEMember2023-12-310001492298sbra:NorwayMEMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:YarmouthMEMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:MarlboroughMAMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:BangorME2Member2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:OrangeCAMember2023-12-310001492298sbra:LancasterTXMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:GarlandTXMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:ClarksvilleTXMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:McKinneyTXMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:HopkinsMNMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:FlorenceWIMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:St.FrancisWIMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:RochesterMNMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:WisconsinDellsWIMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:SheboyganWIMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:HendersonvilleNCMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:BaytownTX1Member2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:BaytownTX2Member2023-12-310001492298sbra:HoustonTXMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:PasadenaTXMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:WebsterTXMember2023-12-310001492298sbra:BeaumontTXMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:OrangeTXMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:HuntsvilleALMember2023-12-310001492298sbra:TerreHauteIN1Membersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:MadisonTNMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:SavannahGA1Member2023-12-310001492298sbra:BowlingGreenKYMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:CalvertCityKYMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:WinchesterKYMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:CalhounKYMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:BremenINMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:MuncieINMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:LebanonINMember2023-12-310001492298sbra:MariettaGAMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:DanvilleKYMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:OwensboroKYMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:MemphisTNMember2023-12-310001492298sbra:NorfolkVAMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:HarrodsburgKYMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:CookevilleTNMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:WashingtonCourtHouseOHMember2023-12-310001492298sbra:GalionOHMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:RoanokeRapidsNCMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:KinstonNCMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:ChapelHillNCMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:ChillicotheOHMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:CoshoctonOHMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:PineKnotKYMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:BardstownKYMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:GlasgowKYMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:CarrolltonKYMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:HorseCaveKYMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:LawrenceburgKYMember2023-12-310001492298sbra:AnnvilleKYMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:LouisvilleKY1Member2023-12-310001492298sbra:LouisvilleKY2Membersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:TompkinsvilleKYMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:RadcliffKYMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:HartfordKYMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:LouisvilleKY3Member2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:LouisvilleKY4Member2023-12-310001492298sbra:LexingtonKYMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:ColumbiaKYMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:MonticelloARMember2023-12-310001492298sbra:BentonARMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:WynneARMember2023-12-310001492298sbra:MorriltonARMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:BryantARMember2023-12-310001492298sbra:SavannahGA2Membersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:DurhamNCMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:RaleighNC1Member2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:RaleighNC2Member2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:WilmingtonNCMember2023-12-310001492298sbra:WinstonSalemNCMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:LincolntonNCMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:MonroeNCMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:ZebulonNCMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:RockyMountNCMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:DeSotoTXMember2023-12-310001492298sbra:TrinityTXMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:KirbyvilleTXMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:MarshallTXMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:WarrenMIMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:HamburgNYMember2023-12-310001492298sbra:EastPatchogueNYMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:WilliamsvilleNYMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:CheektowagaNYMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:NorthTonawandaNYMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:WestSenecaNYMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:BeverlyMAMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:LancasterMAMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:NewLondonCTMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:EnfieldCTMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:QuincyMAMember2023-12-310001492298sbra:FishkillNYMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:HighlandNYMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:BeaconNYMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:SpringfieldMAMember2023-12-310001492298sbra:AndoverMAMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:ReadingMAMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:SudburyMAMember2023-12-310001492298sbra:LowellMAMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:WorcesterMAMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:W.SpringfieldMAMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:EastLongmeadowMAMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:LongBeachCA1Member2023-12-310001492298sbra:AnaheimCAMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:FairfieldCAMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:BaldwinParkCAMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:GrandTerraceCAMember2023-12-310001492298sbra:PacificaCAMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:BurienWAMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:SeattleWA1Member2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:HuntingtonBchCAMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:ChatsworthCAMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:WoodlandCA1Member2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:DanvilleCAMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:VanNuysCAMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:LomitaCAMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:SacramentoCAMember2023-12-310001492298sbra:IssaquahWAMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:LongBeachCA2Member2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:LongBeachCA3Member2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:LodiCAMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:RiversideCAMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:WoodlandCA2Member2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:BeeCaveTXMember2023-12-310001492298sbra:ElMonteCAMembersbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:ShorelineWA1Member2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:ElizabethtownKYMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:CrownPointINMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMembersbra:DyerINMember2023-12-310001492298sbra:SkilledNursingTransitionalCareFacilitiesMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:ExeterNHMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:NashuaNHMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:KeeneNHMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:DoverNHMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:GreenBayWIMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:RockportTXMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:CadillacMIMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:GreenvilleMIMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:ManisteeMIMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:MasonMIMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:AlpenaMIMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:FremontNEMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:NorfolkNEMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:FortWayneINMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:BrandonFLMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:LecantoFLMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:ZephyrhillsFLMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:SunCityWestAZMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:FredericksburgVAMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:RoundRockTXMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:SantaFeNM1Member2023-12-310001492298sbra:SantaFeNM2Membersbra:SeniorHousingFacilitiesLeasedMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:FranklinNHMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:HendersonNVMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:BrenhamTXMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:CedarParkTXMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:KeizerORMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:LawrenceKSMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:SalinaKSMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:TopekaKSMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:LafayetteCOMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:WinnebagoILMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:PewaukeeWI1Member2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:PewaukeeWI2Member2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:SarasotaFLMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:KnoxvilleTNMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:ShavanoParkTXMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:BeavercreekOHMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:McCordsvilleINMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:LouisvilleKYMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:SellersburgINMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:JasperINMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMembersbra:NormanOKMember2023-12-310001492298sbra:SeniorHousingFacilitiesLeasedMember2023-12-310001492298sbra:FrankenmuthMIMembersbra:SeniorHousingFacilitiesManagedPortfolioMember2023-12-310001492298sbra:GaylordMIMembersbra:SeniorHousingFacilitiesManagedPortfolioMember2023-12-310001492298sbra:EastTawasMIMembersbra:SeniorHousingFacilitiesManagedPortfolioMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:MarshfieldWIMember2023-12-310001492298sbra:WoodstockVAMembersbra:SeniorHousingFacilitiesManagedPortfolioMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:AllenTXMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:GainesvilleFLMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:McKinneyTXMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:RaleighNCMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:SanLuisObispoCAMember2023-12-310001492298sbra:WinstonSalemNCMembersbra:SeniorHousingFacilitiesManagedPortfolioMember2023-12-310001492298sbra:LongviewTXMembersbra:SeniorHousingFacilitiesManagedPortfolioMember2023-12-310001492298sbra:KansasCityMOMembersbra:SeniorHousingFacilitiesManagedPortfolioMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:YumaAZMember2023-12-310001492298sbra:NashvilleTNMembersbra:SeniorHousingFacilitiesManagedPortfolioMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:BranfordCTMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:RichmondVAMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:AuburnALMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:MenomoneeFallsWIMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:GlenvilleNYMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:EustisFLMember2023-12-310001492298sbra:PhoenixAZMembersbra:SeniorHousingFacilitiesManagedPortfolioMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:JonesboroARMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:OgdenUTMember2023-12-310001492298sbra:OlympiaWAMembersbra:SeniorHousingFacilitiesManagedPortfolioMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:WindsorONMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:LondonONMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:KelownaBCMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:WaterlooONMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:SarniaONMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:KamloopsBCMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:VernonBCMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:PentictonBCMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:CalgaryABMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:LakeStevensWAMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:EugeneORMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:TualatinORMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:SalemORMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:RamseyMNMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:MarshfieldWI1Member2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:DoverDEMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:CharlestonWVMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:WilliamsportPAMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:ReadingPAMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:ScottDepotWVMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:ClarksSummitPAMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:WyncotePAMember2023-12-310001492298sbra:DouglassvillePAMembersbra:SeniorHousingFacilitiesManagedPortfolioMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:MilfordDEMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:OakHillWVMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:LewisburgWVMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:StrasburgVAMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:RichardsonTXMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:PowayCAMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:NewBraunfelsTXMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:AugustaGAMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:AnchorageAKMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:LovelandOHMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:IndianapolisINMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:SaginawMIMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMembersbra:MadeiraOHMember2023-12-310001492298sbra:SeniorHousingFacilitiesManagedPortfolioMember2023-12-310001492298sbra:BehavioralHealthMembersbra:AuroraCOMember2023-12-310001492298sbra:ColoradoSpringsCO1Membersbra:BehavioralHealthMember2023-12-310001492298sbra:ColoradoSpringsCO2Membersbra:BehavioralHealthMember2023-12-310001492298sbra:BlufftonINMembersbra:BehavioralHealthMember2023-12-310001492298sbra:ElizabethtownKYMembersbra:BehavioralHealthMember2023-12-310001492298sbra:MorriltonARMembersbra:BehavioralHealthMember2023-12-310001492298sbra:GlendaleAZMembersbra:BehavioralHealthMember2023-12-310001492298sbra:BehavioralHealthMembersbra:TempeAZMember2023-12-310001492298sbra:CovinaCAMembersbra:BehavioralHealthMember2023-12-310001492298sbra:VenturaCAMembersbra:BehavioralHealthMember2023-12-310001492298sbra:SanDiegoCAMembersbra:BehavioralHealthMember2023-12-310001492298sbra:BehavioralHealthMembersbra:NewLondonCTMember2023-12-310001492298sbra:CarmelINMembersbra:BehavioralHealthMember2023-12-310001492298sbra:LouisvilleKYMembersbra:BehavioralHealthMember2023-12-310001492298sbra:MonroevillePAMembersbra:BehavioralHealthMember2023-12-310001492298sbra:GulfBreezeFLMembersbra:BehavioralHealthMember2023-12-310001492298sbra:GreenvilleSCMembersbra:BehavioralHealthMember2023-12-310001492298sbra:RaytownMOMembersbra:BehavioralHealthMember2023-12-310001492298sbra:BehavioralHealthMember2023-12-310001492298sbra:SunnyvaleTXMembersbra:SpecialtyHospitalsAndOtherMember2023-12-310001492298sbra:SpecialtyHospitalsAndOtherMembersbra:ArlingtonTXMember2023-12-310001492298sbra:SpecialtyHospitalsAndOtherMembersbra:ConroeTXMember2023-12-310001492298sbra:HoustonTXMembersbra:SpecialtyHospitalsAndOtherMember2023-12-310001492298sbra:SpecialtyHospitalsAndOtherMembersbra:SpringTXMember2023-12-310001492298sbra:SpecialtyHospitalsAndOtherMembersbra:OrangeCAMember2023-12-310001492298sbra:SpecialtyHospitalsAndOtherMembersbra:MaxwellTX1Member2023-12-310001492298sbra:SpecialtyHospitalsAndOtherMembersbra:MaxwellTX2Member2023-12-310001492298sbra:SpecialtyHospitalsAndOtherMembersbra:MaxwellTX3Member2023-12-310001492298sbra:SpecialtyHospitalsAndOtherMembersbra:SanMarcosTXMember2023-12-310001492298sbra:SpecialtyHospitalsAndOtherMembersbra:SeguinTX1Member2023-12-310001492298sbra:SpecialtyHospitalsAndOtherMembersbra:SeguinTX2Member2023-12-310001492298sbra:KingsburyTXMembersbra:SpecialtyHospitalsAndOtherMember2023-12-310001492298sbra:SpecialtyHospitalsAndOtherMembersbra:SeguinTX3Member2023-12-310001492298sbra:FlorenceKYMembersbra:SpecialtyHospitalsAndOtherMember2023-12-310001492298sbra:SpecialtyHospitalsAndOtherMember2023-12-310001492298us-gaap:OperatingSegmentsMember2023-12-310001492298us-gaap:CorporateNonSegmentMember2023-12-310001492298us-gaap:MortgagesMembersbra:RiverVistaMember2023-01-012023-12-310001492298us-gaap:MortgagesMembersbra:RiverVistaMember2023-12-310001492298sbra:RecoveryCentersOfAmericaMemberus-gaap:MortgagesMember2023-01-012023-12-310001492298sbra:RecoveryCentersOfAmericaMemberus-gaap:MortgagesMember2023-12-310001492298us-gaap:MortgagesMember2023-12-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 FORM 10-K
 
(Mark One)
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2023
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission file number 001-34950
 SABRA HEALTH CARE REIT, INC.
(Exact Name of Registrant as Specified in Its Charter)
 
Maryland 27-2560479
(State of Incorporation) (I.R.S. Employer Identification No.)
1781 Flight Way
Tustin, CA 92782
(888) 393-8248
(Address, zip code and telephone number of Registrant)
 
Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading SymbolName of Each Exchange on Which Registered
Common Stock, $0.01 par valueSBRAThe Nasdaq Stock Market LLC
Securities registered pursuant to Section 12(g) of the Act: None
 
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes     No  
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes     No  
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer x  Accelerated filer 
Non-accelerated filer   Smaller reporting company 
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b).
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  
State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter: $2.7 billion
As of February 20, 2024, there were 231,476,751 shares of the registrant’s $0.01 par value Common Stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the Proxy Statement for the registrant’s 2024 Annual Meeting of Stockholders, to be filed with the Securities and Exchange Commission not later than 120 days after December 31, 2023, are incorporated by reference in Part III herein.



SABRA HEALTH CARE REIT, INC. AND SUBSIDIARIES
Index
 
F-1
 


1


References throughout this document to “Sabra,” “we,” “our,” “ours” and “us” refer to Sabra Health Care REIT, Inc. and its direct and indirect consolidated subsidiaries and not any other person.
STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
Certain statements in this Annual Report on Form 10-K (this “10-K”) contain “forward-looking” information as that term is defined by the Private Securities Litigation Reform Act of 1995. Any statements that do not relate to historical or current facts or matters are forward-looking statements. Examples of forward-looking statements include all statements regarding our expected future financial position, results of operations, cash flows, liquidity, financing plans, business strategy, tenants, borrowers and Senior Housing - Managed communities (as defined below), the expected amounts and timing of dividends and other distributions, projected expenses and capital expenditures, competitive position, growth opportunities, potential investments, potential dispositions, plans and objectives for future operations, and compliance with and changes in governmental regulations. You can identify some of the forward-looking statements by the use of forward-looking words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend,” “should,” “may” and other similar expressions, although not all forward-looking statements contain these identifying words.
Our actual results may differ materially from those projected or contemplated by our forward-looking statements as a result of various factors, including, among others, the following:
increased labor costs and historically low unemployment;
increases in market interest rates and inflation;
pandemics or epidemics, including COVID-19, and the related impact on our tenants, borrowers and Senior Housing - Managed communities;
operational risks with respect to our Senior Housing - Managed communities;
competitive conditions in our industry;
the loss of key management personnel;
uninsured or underinsured losses affecting our properties;
potential impairment charges and adjustments related to the accounting of our assets;
the potential variability of our reported rental and related revenues as a result of Accounting Standards Update (“ASU”) 2016-02, Leases, as amended by subsequent ASUs;
risks associated with our investment in our unconsolidated joint ventures;
catastrophic weather and other natural or man-made disasters, the effects of climate change on our properties and a failure to implement sustainable and energy-efficient measures;
increased operating costs and competition for our tenants, borrowers and Senior Housing - Managed communities;
increased healthcare regulation and enforcement;
our tenants’ dependency on reimbursement from governmental and other third-party payor programs;
the effect of our tenants, operators or borrowers declaring bankruptcy or becoming insolvent;
our ability to find replacement tenants and the impact of unforeseen costs in acquiring new properties;
the impact of litigation and rising insurance costs on the business of our tenants;
the impact of required regulatory approvals of transfers of healthcare properties;
environmental compliance costs and liabilities associated with real estate properties we own;
our tenants’, borrowers’ or operators’ failure to adhere to applicable privacy and data security laws;
a material breach of our or our tenants’, borrowers’ or operators’ information technology;
our concentration in the healthcare property sector, particularly in skilled nursing/transitional care facilities and senior housing communities, which makes our profitability more vulnerable to a downturn in a specific sector than if we were investing in multiple industries;
the significant amount of and our ability to service our indebtedness;
covenants in our debt agreements that may restrict our ability to pay dividends, make investments, incur additional indebtedness and refinance indebtedness on favorable terms;
adverse changes in our credit ratings;
our ability to make dividend distributions at expected levels;
our ability to raise capital through equity and debt financings;
changes and uncertainty in macroeconomic conditions and disruptions in the financial markets;
risks associated with our ownership of property outside the U.S., including currency fluctuations;
the relatively illiquid nature of real estate investments;
our ability to maintain our status as a real estate investment trust (“REIT”) under the federal tax laws;
compliance with REIT requirements and certain tax and tax regulatory matters related to our status as a REIT;
changes in tax laws and regulations affecting REITs;
2


the ownership limits and takeover defenses in our governing documents and under Maryland law, which may restrict change of control or business combination opportunities; and
the exclusive forum provisions in our bylaws.
We urge you to carefully consider these risks and review the additional disclosures we make concerning risks and other factors that may materially affect the outcome of our forward-looking statements and our future business and operating results, including those made in Part I, Item 1A, “Risk Factors” in this 10-K, as such risk factors may be amended, supplemented or superseded from time to time by other reports we file with the Securities and Exchange Commission (the “SEC”), including subsequent Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. We caution you that any forward-looking statements made in this 10-K are not guarantees of future performance, events or results, and you should not place undue reliance on these forward-looking statements, which speak only as of the date of this report. We do not intend, and we undertake no obligation, to update any forward-looking information to reflect events or circumstances after the date of this 10-K or to reflect the occurrence of unanticipated events, unless required by law to do so.
TENANT AND BORROWER INFORMATION

This 10-K includes information regarding our tenants that lease properties from us and our borrowers, most of which are not subject to SEC reporting requirements. The information related to our tenants and borrowers that is provided in this 10-K has been provided by, or derived from information provided by, such tenants and borrowers. We have not independently verified this information. We have no reason to believe that such information is inaccurate in any material respect. We are providing this data for informational purposes only.
3



PART I
 
ITEM 1. BUSINESS
Overview
We operate as a self-administered, self-managed REIT that, through our subsidiaries, owns and invests in real estate serving the healthcare industry.
Our primary business consists of acquiring, financing and owning real estate property to be leased to third-party tenants in the healthcare sector. We primarily generate revenues by leasing properties to tenants and owning properties operated by third-party property managers throughout the United States (“U.S.”) and Canada.
Our investment portfolio is primarily comprised of skilled nursing/transitional care facilities, senior housing communities (“Senior Housing - Leased”), behavioral health facilities, and specialty hospitals and other facilities, in each case leased to third-party operators; senior housing communities operated by third-party property managers pursuant to property management agreements (“Senior Housing - Managed”); investments in joint ventures; loans receivable; and preferred equity investments.
We expect to grow our investment portfolio while diversifying our portfolio by tenant, facility type and geography within the healthcare sector. We plan to achieve these objectives primarily through making investments directly or indirectly in healthcare real estate, including the development of purpose-built healthcare facilities with select developers. We also intend to achieve our objective of diversifying our portfolio by tenant and facility type through select asset sales and other arrangements with our tenants.
We employ a disciplined approach in our healthcare real estate investment strategy by investing in assets that provide attractive opportunities for dividend growth and appreciation of asset values, while maintaining balance sheet strength and liquidity, thereby creating long-term stockholder value.
We commenced operations on November 15, 2010, and we elected to be treated as a REIT with the filing of our U.S. federal income tax return for the taxable year beginning January 1, 2011. We believe that we have been organized and have operated, and we intend to continue to operate, in a manner to qualify as a REIT. We operate through an umbrella partnership, commonly referred to as an UPREIT structure, in which substantially all of our properties and assets are held by Sabra Health Care Limited Partnership, a Delaware limited partnership (the “Operating Partnership”), of which we are the sole general partner and a wholly owned subsidiary of ours is currently the only limited partner, or by subsidiaries of the Operating Partnership.
We maintain a website at www.sabrahealth.com. Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) are made available free of charge on our website as soon as reasonably practicable after such information has been filed or furnished with the SEC.
Our Industry
We operate as a REIT that holds investments in income-producing healthcare facilities located in the U.S. and Canada. We invest primarily in the U.S. nursing home industry, including skilled nursing and transitional care facilities, the U.S. and Canadian senior housing industry, which includes independent living, assisted living, memory care and continuing care retirement communities, select behavioral health and addiction treatment centers, and acute care and other hospitals. The primary growth drivers of the nursing home and senior housing industries – an aging population and longer life expectancies – present attractive investment opportunities for us. According to the 2023 National Population Projections published by the U.S. Census Bureau, the number of Americans age 75 and older is projected to grow at a compounded annual growth rate of 10.1% between 2022 and 2035. Further, life expectancy is expected to increase to 85.6 years in 2060 from 79.7 years in 2017. In addition, the highly-fragmented nature of the skilled nursing and senior housing industries presents additional investment opportunities.
Demand for senior housing is expected to increase as a result of an aging population and an increase in acuity across the post-acute landscape. Cost containment measures adopted by the federal government have encouraged patient treatment in more cost-effective settings, such as skilled nursing facilities. As a result, high acuity patients that previously would have been treated in long-term acute care hospitals and inpatient rehabilitation facilities are increasingly being treated in skilled nursing facilities. According to the National Health Expenditure Projections for 2022-2031 published by the Centers for Medicare & Medicaid Services (“CMS”), nursing home expenditures are projected to grow from approximately $194 billion in 2022 to approximately
4


$283 billion in 2031, representing a compounded annual growth rate of 4.3%. This focus on high acuity patients in skilled nursing facilities has resulted in the typical senior housing resident requiring more assistance with activities for daily living, such as assistance with bathing, grooming, dressing, eating, and medication management; however, many older senior housing communities were not built to accommodate a resident who has more needs as well as increased mobility and cognitive issues than in the past. We believe that these trends will create an emphasis on operators who can effectively adapt their operating model to accommodate the changing nursing home patient and senior housing resident and will result in increased demand for purpose-built properties that are complementary to this new system of healthcare delivery.
The hospital industry is broadly defined to include addiction treatment centers and acute care, long-term acute care, rehabilitation and behavioral hospitals. Hospital services comprise one of the largest categories of healthcare expenditures. According to the CMS National Health Expenditure Projections for 2022-2031, hospital care expenditures are projected to grow from approximately $1.3 trillion in 2022 to approximately $2.3 trillion in 2031, representing a compounded annual growth rate of 6.4%. According to the 2022 National Survey on Drug Use and Health, addiction and mental illness are ongoing public health crises in the U.S. with approximately 55 million people classified as needing substance abuse treatment but more than 75% not receiving such treatment and approximately 15 million people identified with serious mental illness but more than 30% not receiving treatment, including inpatient or outpatient mental health services, prescription medication for a mental health issue or virtual (i.e., telehealth) services. Hospitals offer a wide range of services, both inpatient and outpatient, in a variety of settings. We believe that demand will increase for innovative means of delivering those services and present additional investment opportunities.
While the factors described above indicate projected growth for our industry, increases in interest rates, labor shortages, supply chain disruptions, high inflation and increased volatility in public equity and fixed income markets have led to increased costs and limited the availability of capital. In addition, these factors, together with the impact of COVID-19, have resulted in decreased occupancy and increased operating costs for our tenants and borrowers, which have negatively impacted their operating results. It is difficult to predict the duration of the effects of these economic and market conditions and of COVID-19 on the industry.
We compete for real property investments with other REITs, investment companies, private equity and hedge fund investors, sovereign funds, healthcare operators, lenders and other investors. Some of our competitors are significantly larger and have greater financial resources and lower costs of capital than we do. Increased competition makes it more challenging to identify and successfully capitalize on acquisition opportunities that meet our investment objectives. Our ability to compete is also impacted by national and local economic trends, availability of investment alternatives, availability and cost of capital, construction and renovation costs, existing laws and regulations, new legislation and population trends.
In addition, revenues from our properties are dependent on the ability of our tenants and Senior Housing - Managed communities to compete with other healthcare operators. These operators compete on a local and regional basis for residents and patients, and the operators’ ability to successfully attract and retain residents and patients depends on key factors such as the number of facilities in the local market, the types of services available, the quality of care, reputation, age and appearance of each facility, and the cost of care in each locality. Private, federal and state payment programs and the effect of other laws and regulations may also have a significant impact on the ability of our tenants and Senior Housing - Managed communities to compete successfully for residents and patients at the properties.
Portfolio of Healthcare Investments
We have a geographically diverse portfolio of healthcare investments across the U.S. and Canada that offer a range of services including skilled nursing/transitional care, assisted and independent living, memory care and select behavioral health and addiction treatment centers and hospitals. As of December 31, 2023, our investment portfolio consisted of 378 real estate properties held for investment, 14 investments in loans receivable, five preferred equity investments and two investments in unconsolidated joint ventures. Of our 378 properties held for investment as of December 31, 2023, we owned fee title to 373 properties and title under ground leases for five properties.
Our portfolio consisted of the following types of healthcare facilities as of December 31, 2023:
Skilled Nursing/Transitional Care Facilities
Skilled nursing facilities. Skilled nursing facilities provide services that include daily nursing, therapeutic rehabilitation, social services, activities, housekeeping, nutrition, medication management and administrative services for individuals requiring certain assistance for activities in daily living. A typical skilled nursing facility includes mostly one and two bed units, each equipped with a private or shared bathroom and community dining facilities.
5


Transitional care facilities/units. Transitional care facilities/units are licensed nursing facilities or distinct units within a licensed nursing facility that provide short term, intensive, high acuity nursing and medical services. These facilities tend to focus on delivering specialized treatment to patients with cardiac, neurological, pulmonary, orthopedic, and renal conditions. Length of service is typically 30 days or less with the majority of patients returning to prior living arrangements and functional abilities. Generally, transitional care facilities/units provide services to Medicare, managed care and commercial insurance patients.
Senior Housing Communities
 
Independent living communities. Independent living communities are age-restricted multi-family properties with central dining facilities that provide services that include security, housekeeping, activities, nutrition and limited laundry services. Our independent living communities are designed specifically for independent seniors who are able to live on their own, but desire the security and conveniences of community living. Independent living communities typically offer several services covered under a regular monthly fee.
Assisted living communities. Assisted living communities provide services that include assistance for activities in daily living and permit residents to maintain some of their privacy and independence as they do not require constant supervision and assistance. Services bundled within one regular monthly fee usually include three meals per day in a central dining room, daily housekeeping, laundry, medical reminders and 24-hour availability of assistance with the activities of daily living, such as eating, dressing and bathing. Professional nursing and healthcare services are usually available at the community on call or at regularly scheduled times. Assisted living communities typically are comprised of studios and one- and two-bedroom suites equipped with private bathrooms and efficiency kitchens.
Memory care communities. Memory care communities offer specialized options, services and clinical programs for individuals with Alzheimer’s disease and other forms of dementia. Purpose-built memory care communities offer a more residential environment than offered in a secured unit of a nursing facility. These communities offer dedicated care and specialized programming from specially trained staff for various conditions relating to memory loss in a secured environment that is typically smaller in scale and more residential in nature than traditional assisted living communities. Residents require a higher level of care, a secure environment, customized therapeutic recreation programs and more assistance with activities of daily living than in assisted living communities. Therefore, these communities have staff available 24 hours a day to respond to the unique needs of their residents.
Continuing care retirement communities. Continuing care retirement communities, or CCRCs, provide, as a continuum of care, the services described above for independent living communities, assisted living communities, memory care communities and skilled nursing facilities in an integrated campus.
Behavioral Health Facilities
Addiction treatment centers. Addiction treatment centers provide treatment services for chemical dependence and substance addictions, which may include inpatient care, outpatient care, medical detoxification, therapy and counseling.
Behavioral hospitals. Behavioral hospitals provide inpatient and outpatient care for patients with mental health conditions, chemical dependence or substance addictions.
Specialty Hospitals and Other Facilities
Acute care hospitals. Acute care hospitals provide emergency room, inpatient and outpatient medical care and other related services for surgery, acute medical conditions or injuries (usually for a short-term illness or condition).
Long-term acute care hospitals. Long-term acute care hospitals provide care for patients with complex medical conditions that require longer stays and more intensive care, monitoring or emergency back-up than that available in most skilled nursing facilities.
Rehabilitation hospitals. Rehabilitation hospitals provide inpatient and outpatient care for patients who have sustained traumatic injuries or illnesses, such as spinal cord injuries, strokes, head injuries, orthopedic problems, work-related disabilities and neurological diseases.
Residential services facilities. Residential services facilities provide services in home and community-based settings, which may include assistance with activities of daily living.
6


Other facilities. Other facilities include facilities other than those described above that are not classified as skilled nursing/transitional care, senior housing or behavioral health.
Geographic and Property Type Diversification
The following tables display the geographic concentration by property type and by investment and the distribution of beds/units for our real estate held for investment as of December 31, 2023 and exclude our unconsolidated joint ventures which consist of 16 facilities and 1,256 units (pro rata) (dollars in thousands):
Geographic Concentration — Property Type
LocationSkilled Nursing / Transitional Care  Senior Housing - Leased  Senior Housing - Managed ConsolidatedBehavioral
Health
Specialty
Hospitals and Other
Total% of Total
Texas34 — 13 57 15.1 %
California24 — 30 7.9 
Kentucky24 — 28 7.4 
Indiana14 — 21 5.6 
Oregon15 — — 19 5.0 
North Carolina13 — — — 15 4.0 
Missouri12 — — 14 3.7 
Washington12 — — — 14 3.7 
Massachusetts12 — — — — 12 3.2 
New York— — — 10 2.6 
Other (29 states & Canada)72 32 44 10 — 158 41.8 
Total241 43 61 18 15 378 100.0 %
        
% of Total63.7 %11.4 %16.1 %4.8 %4.0 %100.0 %
Distribution of Beds/Units
 Property Type
LocationTotal
Number of
Properties
Skilled Nursing / Transitional CareSenior Housing - LeasedSenior Housing - Managed ConsolidatedBehavioral
Health
Specialty
Hospitals and Other
Total% of Total
Texas57 4,325 470 736 — 325 5,856 15.5 %
Kentucky28 2,486 142 — 172 40 2,840 7.5 
California30 2,058 — 160 313 27 2,558 6.8 
Indiana21 1,651 545 169 138 — 2,503 6.6 
Oregon19 1,520 215 162 — — 1,897 5.0 
North Carolina15 1,454 — 237 — — 1,691 4.5 
New York10 1,566 — 107 — — 1,673 4.4 
Washington14 1,309 — 165 — — 1,474 3.9 
Massachusetts12 1,469 — — — — 1,469 3.9 
Virginia10 894 60 186 — — 1,140 3.0 
Other (29 states & Canada)162 8,037 2,041 4,119 536 — 14,733 38.9 
Total378 26,769 3,473 6,041 1,159 392 37,834 100.0 %
% of Total70.7 %9.2 %16.0 %3.1 %1.0 %100.0 %

7


Geographic Concentration — Investment (1)
Property Type
LocationTotal Number of PropertiesSkilled Nursing / Transitional CareSenior Housing - LeasedSenior Housing - Managed ConsolidatedBehavioral
Health
Specialty
Hospitals and Other
Total% of Total
Texas57 $347,245 $55,818 $173,043 $— $187,387 $763,493 13.5 %
California30 435,612 — 59,434 217,764 7,743 720,553 12.8 
Indiana21 196,544 120,197 47,861 12,155 — 376,757 6.7 
Oregon19 261,316 33,002 54,214 — — 348,532 6.2 
New York10 298,004 — 20,688 — — 318,692 5.8 
Kentucky28 244,385 23,668 — 15,165 30,313 313,531 5.6 
Washington14 158,674 — 41,142 — — 199,816 3.5 
North Carolina15 124,449 — 75,251 — — 199,700 3.5 
Arizona— 10,348 39,656 121,757 — 171,761 3.0 
Canada (2)
— — 159,550 — — 159,550 2.8 
Other (30 states)170 984,632 330,241 618,646 129,896 — 2,063,415 36.6 
Total378 $3,050,861 $573,274 $1,289,485 $496,737 $225,443 $5,635,800 100.0 %
% of Total  54.1 %10.2 %22.9 %8.8 %4.0 %100.0 %  
(1)    Represents the undepreciated book value of our real estate held for investment as of December 31, 2023.
(2)    Investment balance in Canada is based on the exchange rate as of December 31, 2023 of 0.7546 per 1 CAD.

Loans Receivable and Other Investments
As of December 31, 2023 and 2022, our loans receivable and other investments consisted of the following (dollars in thousands):
December 31, 2023
InvestmentQuantity
as of
December 31, 2023
Property Type
Principal Balance as of December 31, 2023 (1)
Book Value
as of
December 31, 2023
Book Value
as of
December 31, 2022
Weighted Average Contractual Interest Rate / Rate of ReturnWeighted Average Annualized Effective Interest Rate / Rate of ReturnMaturity Date
as of
December 31, 2023
Loans Receivable:
MortgageBehavioral Health$319,000 $319,000 $319,000 7.6 %7.6 %11/01/26 - 01/31/27
Other12 Multiple53,873 50,440 47,936 7.7 %7.4 %10/01/23 - 05/01/29
14 372,873 369,440 366,936 7.7 %7.6 %
Allowance for loan losses— (6,665)(6,611)
$372,873 $362,775 $360,325 
Other Investments:
Preferred EquitySkilled Nursing / Senior Housing57,681 57,849 51,071 11.0 %11.0 %N/A
Total19 $430,554 $420,624 $411,396 8.1 %8.1 %
(1)    Principal balance includes amounts funded and accrued unpaid interest / preferred return and excludes capitalizable fees.
Significant Credit Concentrations
For the year ended December 31, 2023, no tenant relationship represented 10% or more of our total revenues.
See “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Concentration of Credit Risk” in Part II, Item 7 for additional information, including risks and uncertainties, regarding tenant concentration.
8


Investment Financing Strategy
We expect that future investments in properties, including any improvements or renovations of current or newly-acquired properties, will depend on and will be financed, in whole or in part, by our existing cash, borrowings available to us under our Revolving Credit Facility (as defined below) and proceeds from issuances of common stock, preferred stock, debt or other securities. In addition, we may seek financing from U.S. government agencies, including through Fannie Mae, Freddie Mac and the U.S. Department of Housing and Urban Development (“HUD”), in appropriate circumstances in connection with acquisitions. We also use derivative instruments in the normal course of business to mitigate interest rate and foreign currency risk.
Competitive Strengths
We believe the following competitive strengths contribute significantly to our success:
Diverse Property Portfolio
Our portfolio of 378 properties held for investment as of December 31, 2023 is broadly diversified by location across the U.S. and Canada. Our properties in any one state or province did not account for more than 16% of our total beds/units as of December 31, 2023. Our geographic diversification will limit the effect of a decline in any one regional market on our overall performance. We have also been able to diversify, through acquisitions and dispositions, the extent to which our revenues are dependent on our tenants’, borrowers’ and equity investees’ revenues from federal, state and local government reimbursement programs.
Long-Term, Triple-Net Lease Structure
As of December 31, 2023, the substantial majority of our real estate properties held for investment (excluding 61 Senior Housing - Managed communities) were leased under triple-net operating leases with expirations ranging from one year to 19 years, pursuant to which the tenants are responsible for all facility maintenance, code compliance, insurance required in connection with the leased properties and the business conducted on the leased properties, taxes levied on or with respect to the leased properties and all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties. As of December 31, 2023, the leases had a weighted-average remaining term of eight years. The leases generally include provisions to extend the lease terms and other negotiated terms and conditions. We, through our subsidiaries, retain substantially all of the risks and benefits of ownership of the real estate assets leased to tenants. We may receive additional security under these operating leases in the form of letters of credit and security deposits from the lessee or guarantees from the parent of the lessee. In addition, certain of our tenants have deposited amounts with us for future real estate taxes, insurance expenditures and tenant improvements related to our properties and their operations.
Senior Housing - Managed Structure

As of December 31, 2023, our real estate properties held for investment included 61 Senior Housing - Managed communities operated by 11 third-party property managers pursuant to property management agreements. The Senior Housing - Managed structure gives us direct exposure to the risks and benefits of the operations of the communities. We generally utilize the Senior Housing - Managed structure when properties present growth opportunities that may be achievable through capital investment and/or property managers providing scale, operating efficiencies and/or ancillary services. The third-party property managers manage our communities in exchange for the receipt of a management fee, and as such, we are not directly exposed to the credit risk of the property managers in the same manner or to the same extent as we are to our triple-net tenants. However, we rely on the property managers’ personnel, expertise, technical resources and information systems, proprietary information, good faith and judgment to manage our communities efficiently and effectively. We also rely on the property managers to set appropriate resident fees and otherwise operate our communities in compliance with the terms of our management agreements and all applicable laws and regulations.
Strong Relationships with Operators
The members of our management team have developed an extensive network of relationships with qualified local, regional and national operators of skilled nursing/transitional care facilities and senior housing communities across the U.S. and Canada. This extensive network has been built by our management team through more than 100 years of combined operating experience, involvement in industry trade organizations and the development of banking relationships and investor relations within the skilled nursing and senior housing industries. We believe these strong relationships with operators help us to source investment opportunities.
9


Our relationships with operators include pipeline agreements that we have entered into with certain operators that provide for the acquisition of, and interim capital commitments for, various healthcare facilities. These pipeline agreements, together with repeat transactions with other operators, help support our future growth potential by providing additional investment opportunities with lower acquisition costs than would be required for investments with new operators.
Ability to Identify Talented Operators
As a result of our management team’s operating experience, network of relationships and industry insight, we have been able and expect to continue to be able to identify qualified local, regional and national operators. We seek operators who possess local market knowledge, demonstrate hands-on management, have proven track records, and focus on quality care and clinical outcomes. These operators are often located in secondary markets, which generally have lower costs to build and favorable demographics as demonstrated by the fact that the percentage of the population over the age of 65 is greater in the markets where we have invested than in the U.S. as a whole. We believe our management team’s experience gives us a key competitive advantage in objectively evaluating an operator’s financial position, focus on care and operating efficiency.
Significant Experience in Proactive Asset Management
The members of our management team have significant experience developing systems to collect and evaluate data relating to the underlying operational and financial success of healthcare companies and healthcare-related real estate assets. We are able to utilize this experience and expertise to provide our tenants, when requested, with assistance in the areas of marketing, development, facility expansion and strategic planning. We also use information technology that allows us to efficiently and effectively collect tenant, financial, asset management and acquisitions information. Leveraging this allows us to be lean in our operations and proactive in sharing information with our tenants where we can be helpful to them. We actively monitor the operating results of our tenants, and, when requested, we offer support to our operators to identify and capitalize on opportunities to improve the operations of our facilities and the overall financial and operating strength of our operators.
Business Strategies
We pursue business strategies focused on opportunistic acquisitions and property diversification where such acquisitions meet our investing and financing strategy. We also intend to continue to curate our portfolio to optimize diversification and financial performance, and to maintain a mix of assets well-positioned for the future of healthcare delivery.
The key components of our business strategies include:
Diversify Asset Portfolio
We expect to grow our investment portfolio while diversifying our portfolio by tenant, facility type and geography within the healthcare sector. We plan to achieve these objectives primarily through making investments directly or indirectly in healthcare real estate, including the development of purpose-built healthcare facilities with select developers. We also intend to achieve our objective of diversifying our portfolio by tenant and facility type through select asset sales and other arrangements with our tenants.
We expect to grow our portfolio primarily through the acquisition of assisted living, independent living and memory care communities in the U.S. and Canada and through the acquisition of skilled nursing/transitional care, addiction treatment centers and behavioral health facilities in the U.S. We have and expect to continue to opportunistically acquire other types of healthcare real estate, originate financing secured directly or indirectly by healthcare facilities and invest in the development of senior housing communities and skilled nursing/transitional care facilities. We also expect to expand our portfolio through the development of purpose-built healthcare facilities through pipeline agreements and other arrangements with select developers. We further expect to work with existing operators to identify strategic development opportunities. These opportunities may involve replacing, renovating or expanding facilities in our portfolio that may have become less competitive and new development opportunities that present attractive risk-adjusted returns. In addition to pursuing acquisitions with triple-net leases, we expect to continue to pursue other forms of investment, including investments in Senior Housing - Managed communities, mezzanine and secured debt investments, and joint ventures for senior housing communities and skilled nursing/transitional care facilities. We also expect to continue to enhance the strength of our investment portfolio by selectively disposing of or repositioning underperforming facilities or working with new or existing operators to transfer underperforming but promising properties to new or other existing operators.
With respect to our debt and preferred equity investments, in general, we originate loans and make preferred equity investments when an attractive investment opportunity is presented and (a) the property is in or near the development phase, (b) the development of the property is completed but the operations of the facility are not yet stabilized or (c) the loan investment will provide capital to existing relationships. A key component of our development strategy related to loan originations and
10


preferred equity investments is having the option to purchase the underlying real estate that is owned by our borrowers (and that directly or indirectly secures our loan investments) or by the entity in which we have an investment. These options become exercisable upon the occurrence of various criteria, such as the passage of time or the achievement of certain operating goals, and the method to determine the purchase price upon exercise of the option is set in advance based on the same valuation methods we use to value our investments in healthcare real estate. This proprietary development pipeline strategy allows us to diversify our revenue streams and build relationships with operators and developers, and provides us with the option to add new properties to our existing real estate portfolio if we determine that those properties enhance our investment portfolio and stockholder value at the time the options are exercisable.
Maintain Balance Sheet Strength and Liquidity
We seek to maintain a capital structure that provides the resources and flexibility to support the growth of our business. As of December 31, 2023, we had approximately $946.9 million in liquidity, consisting of unrestricted cash and cash equivalents of $41.3 million and available borrowings under our Revolving Credit Facility (as defined below) of $905.6 million. The Credit Agreement (as defined below) also contains an accordion feature that can increase the total available borrowings to $2.75 billion (from U.S. $1.4 billion plus CAD $150.0 million), subject to terms and conditions.
We have filed a shelf registration statement with the SEC that expires in November 2025, which allows us to offer and sell shares of common stock, preferred stock, warrants, rights, units, and certain of our subsidiaries to offer and sell debt securities, through underwriters, dealers or agents or directly to purchasers, on a continuous or delayed basis, in amounts, at prices and on terms we determine at the time of the offering, subject to market conditions.
We intend to maintain a mix of Revolving Credit Facility debt, term loan debt, secured debt and unsecured term debt, which, together with our anticipated asset sales as well as our anticipated ability to complete future equity financings, we expect will fund the growth of our operations. Further, we may opportunistically seek access to U.S. government agency financing, including through Fannie Mae, Freddie Mac and HUD, in appropriate circumstances in connection with acquisitions.
Develop New Investment Relationships
We seek to cultivate our relationships with tenants and healthcare providers in order to expand the mix of tenants operating our properties and, in doing so, to reduce our dependence on any single tenant or operator. As of December 31, 2023, we had 63 relationships. We expect to continue to develop new investment relationships as part of our overall strategy to acquire new properties and further diversify our overall portfolio of healthcare properties.
Capital Source to Underserved Operators
We believe that there is a significant opportunity to be a capital source to healthcare operators through the acquisition of healthcare properties that are consistent with our investment and financing strategy, but that, due to size and other considerations, are not a focus for other healthcare REITs. We utilize our management team’s operating experience, network of relationships and industry insight to identify financially strong and growing operators in need of capital funding for future growth. In appropriate circumstances, we may negotiate with operators to acquire individual healthcare properties from those operators and then lease those properties back to the operators pursuant to long-term triple-net leases or refinance new projects.
Strategic Capital Improvements
We intend to continue to support our tenants by providing capital to them for a variety of purposes, including for capital expenditures and facility modernization. We expect to structure the majority of these investments as either lease amendments that produce additional rents or as loans that are repaid by our tenants during the applicable lease term.
Pursue Strategic Development Opportunities
We expect to work with existing operators to identify strategic development opportunities. These opportunities may involve replacing, renovating or expanding facilities in our portfolio that may have become less competitive and new development opportunities that present attractive risk-adjusted returns. In addition to pursuing acquisitions with triple-net leases, we expect to continue to pursue other forms of investment, including investments in Senior Housing - Managed communities, mezzanine and secured debt investments, and joint ventures for senior housing and skilled nursing/transitional care facilities.
11


 Human Capital Matters
Experienced Management Team
Our management team has extensive healthcare and real estate experience. Richard K. Matros, Chief Executive Officer, President and Chair of Sabra, has more than 40 years of experience in the acquisition, development and disposition of healthcare assets, including nine years at Sun Healthcare Group, Inc. Michael Costa, Chief Financial Officer, Secretary and Executive Vice President of Sabra, is a finance professional with more than 20 years of experience in commercial real estate finance and accounting. Talya Nevo-Hacohen, Chief Investment Officer, Treasurer and Executive Vice President of Sabra, is a real estate finance executive with more than 25 years of experience in real estate finance, acquisition and development, including three years of experience managing and implementing the capital markets strategy of an S&P 500 healthcare REIT. Through years of public company experience, our management team also has extensive experience accessing both debt and equity capital markets to fund growth and maintain a flexible capital structure.
Teammates and Equal Opportunity
As of December 31, 2023, we employed 48 full-time employees (our teammates), including our executive officers, none of whom is subject to a collective bargaining agreement. As of December 31, 2023, women comprised 54% of our workforce and 67% of our management level/leadership roles. As of December 31, 2023, 31% of our teammates self-identified as being members of one or more ethnic minorities. We believe our ethnic diversity is higher than this reported percentage as another 15% of our teammates chose not to self-identify. We believe that a diverse workforce is essential to our continued success and gives us a competitive advantage. We take pride in having a diverse workforce in the real estate sector where women and minorities remain underrepresented. We sustain diversity by maintaining a fair, healthy and safe work environment. And we have established a culture that promotes engagement, inclusion, equity and diversity for all teammates.
We recognize that attracting and retaining talent at all levels is vital to our continued success. We ensure that all teammates receive competitive salaries and benefits, and we aim to attract professionals who will uphold our values of social and environmental stewardship. We promote a sustainable work-life balance and invest in our teammates’ well-being through high-quality benefits. We offer a hybrid work model and have strong IT support to enable our flexible working arrangements.
We have fostered a collaborative culture and workplace that motivate and drive engagement. It is important that teammates feel valued and are committed to achieving goals. We create value by providing the tools and support each teammate needs to be successful in their roles. We also encourage team activities that create a sense of belonging and emotional well-being, which we know positively impact retention and engagement. To evaluate an individual teammates’ level of engagement, our management team and human resources department conduct periodic check-in meetings. In addition, company-wide subject-driven surveys are used to gauge levels of engagement and satisfaction. Based on feedback and suggestions received, we thoughtfully implement changes that will have the highest impact on engagement.
To plan for the future, our performance management program proactively reviews our teammates’ evolving roles to address the current and future needs of our business. We invest in their development so that we have the right people with the right skills at the right time. The program provides leadership coaching for select management-level teammates with an external group of professionals and employs annual performance reviews that include self-assessments and 360-degree feedback. Our teammates’ development efforts are focused on aligning our talent strategy with our business strategy. We also connect our teammates with our accomplished board of directors through quarterly board of directors dinner events.
We support volunteerism and organize opportunities for our teammates as a group to volunteer within the community. Various company events, including life event celebrations, dinners and other social outings, are held regularly throughout the year, as well as an annual all-teammate retreat. We believe that all of these activities increase job satisfaction and support collaboration and team bonding.
Government Regulation
Our tenants are subject to extensive and complex federal, state and local healthcare laws and regulations, including anti-kickback, anti-fraud and abuse provisions codified under the Social Security Act. These provisions prohibit certain business practices and relationships that might affect the provision and cost of healthcare services reimbursable under Medicare and Medicaid. Sanctions for violating these anti-kickback, anti-fraud and abuse provisions include criminal penalties, civil sanctions, fines and possible exclusion from government programs such as Medicare and Medicaid. If a facility is decertified as a Medicare or Medicaid provider by CMS or a state, the facility will not thereafter be reimbursed for caring for residents that are covered by Medicare and Medicaid, and the facility would be forced to care for such residents without being reimbursed or to transfer such residents.
12


Most of our tenants’ skilled nursing/transitional care, assisted living and mental health facilities are licensed under applicable state law. Most of our skilled nursing/transitional care facilities and mental health facilities are certified or approved as providers under the Medicare and Medicaid programs. Some of our assisted living facilities are certified or approved as providers under various state Medicaid and/or Medicaid waiver programs. Similarly, the operators of our specialty hospitals must meet the applicable conditions of participation established by the U.S. Department of Health and Human Services and comply with state and local laws and regulations in order to receive Medicare and Medicaid reimbursement. State and local agencies survey all skilled nursing/transitional care facilities and some assisted living facilities on a regular basis to determine whether such facilities are in compliance with governmental operating and health standards and conditions for participation in government sponsored third-party payor programs. Under certain circumstances, the federal and state agencies have the authority to take adverse actions against a facility or service provider, including the imposition of a monitor, the imposition of monetary penalties and the decertification of a facility or provider from participation in the Medicare and/or Medicaid/Medicaid waiver programs or licensure revocation. Challenging and appealing notices or allegations of noncompliance can require significant legal expenses and management attention.
Various states in which our tenants operate our facilities have established minimum staffing requirements or may establish minimum staffing requirements in the future. Failure to comply with such minimum staffing requirements may result in the imposition of fines or other sanctions. Most states in which our tenants operate have statutes requiring that prior to the addition or construction of new nursing home beds, to the addition of new services or to certain capital expenditures in excess of defined levels, the tenant first must obtain a certificate of need, which certifies that the state has made a determination that a need exists for such new or additional beds, new services or capital expenditures. The certification process is intended to promote quality healthcare at the lowest possible cost and to avoid the unnecessary duplication of services, equipment and centers. This certification process can restrict or prohibit the undertaking of a project or lengthen the period of time required to enlarge or renovate a facility or replace a tenant.
In addition to the above, those of our tenants who provide services that are paid for by Medicare and Medicaid are subject to federal and state budgetary cuts and constraints that limit the reimbursement levels available from these government programs. Changes to reimbursement or methods of payment from Medicare and Medicaid could result in a substantial reduction in our tenants’ revenues. Various healthcare reform measures became law upon the enactment of the Patient Protection and Affordable Care Act of 2010 (the “Affordable Care Act”) and the Tax Cuts and Jobs Act (the “2017 Tax Act”), which amends certain provisions of the Affordable Care Act. Future Presidential and Congressional elections in the U.S. could result in further changes. Amendments to, repeal of or legal challenges to the Affordable Care Act and regulatory changes could impose further limitations on government payments to our tenants. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Skilled Nursing Facility Reimbursement Rates” in Part II, Item 7 for additional information.
As of December 31, 2023, our subsidiaries owned eight healthcare facilities (five senior housing communities and three skilled nursing/transitional care facilities) with mortgage loans that are guaranteed by HUD. Those facilities are subject to the rules and regulations of HUD, including periodic inspections by HUD, although the tenants of those facilities have the primary responsibility for maintaining the facilities in compliance with HUD’s rules and regulations. The regulatory agreements entered into by each owner and each operator of the property restrict, among other things, any sale or other transfer of the property, modification of the lease between the owner and the operator, use of surplus cash from the property except upon certain conditions and renovations of the property, all without prior HUD approval.
In addition, as an owner of real property, we are subject to various federal, state and local environmental and health and safety laws and regulations. These laws and regulations address various matters, including asbestos, fuel oil management, wastewater discharges, air emissions, medical wastes and hazardous wastes. The costs of complying with these laws and regulations and the penalties for non-compliance can be substantial. For example, although we do not generally operate or actively manage our properties, we may be held primarily or jointly and severally liable for costs relating to the investigation and cleanup of any property from which there has been a release or threatened release of a regulated material as well as other affected properties, regardless of whether we knew of or caused the release. In addition to these costs, which are typically not limited by law or regulation and could exceed the property’s value, we could be liable for certain other costs, including governmental fines and injuries to persons, property or natural resources. See “Risk Factors—Regulatory Risks—Environmental compliance costs and liabilities associated with real estate properties owned by us may materially impair the value of those investments.” in Part I, Item 1A.

13


ITEM 1A. RISK FACTORS
The following describes the risks and uncertainties that could cause our actual results to differ materially from those presented in our forward-looking statements. The risks and uncertainties described below are not the only ones we face but do represent those risks and uncertainties that we believe are material to us. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also harm our business.
Risks Related to Our Business/Operations
Increased labor costs and historically low unemployment may adversely affect our business, results of operations, cash flows and financial condition.
The market for qualified personnel is highly competitive and our tenants, borrowers and Senior Housing - Managed communities have experienced and may continue to experience difficulties in attracting and retaining such personnel, in particular due to a reduction in the supply of such personnel and wage increases relating to the COVID-19 pandemic and inflation. An inability to attract and retain trained personnel has negatively impacted, and may continue to negatively impact, our occupancy rates, operating income and the ability of our tenants and borrowers to meet their obligations to us. A shortage of caregivers or other trained personnel, minimum staffing requirements or general inflationary pressures on wages may continue to force tenants, borrowers and Senior Housing - Managed communities to enhance pay and benefits packages to compete effectively for skilled personnel, or to use more expensive contract personnel, and they may be unable to offset these added costs by increasing the rates charged to residents and patients. Any further increase in labor costs or any failure by our tenants, borrowers and Senior Housing - Managed communities to attract and retain qualified personnel could adversely affect our cash flow and have a materially adverse effect on our results of operations.
 An increase in market interest rates could increase our interest costs on borrowings on our Revolving Credit Facility and future debt and could adversely affect our stock price.
Interest rates rose substantially in 2022 and 2023 and may continue to rise. Increases in interest rates could increase our interest costs for borrowings on our Revolving Credit Facility and any new debt we may incur. This increased cost could make the financing of any new investments more costly. Rising interest rates could limit our ability to refinance existing debt when it matures or cause us to pay higher interest rates upon refinancing. In addition, an increase in interest rates could negatively impact the access to and cost of financing available to third parties interested in purchasing assets we may make available for sale, thereby decreasing the amount they are willing to pay for those assets, and consequently limit our ability to reposition our portfolio promptly in response to changes in economic or other conditions.
Inflation could adversely impact our operating expenses, as well as the operating expenses of our tenants, borrowers and Senior Housing - Managed communities, and could rise at rates that outpace increases in rental income.
Increased costs due to inflation may have material adverse effects on our operating expenses, as well as the operating expenses of our tenants and borrowers and their ability to meet their obligations to us. Inflation also increases the costs for us to make capital improvements to our facilities. With respect to our Senior Housing - Managed communities, we bear the impact of any increases in costs of labor, goods and services and may not be able to pass those cost increases on to the residents in those communities, in which case the profitability of the communities will suffer, which could in turn have a material adverse effect on our financial position and results of operations.
Pandemics or epidemics, including COVID-19, may have a material adverse effect on our business, results of operations, cash flows and financial condition.
The COVID-19 pandemic has negatively impacted us and our operations. As a result of decreased occupancy and increased operating costs for our tenants and borrowers, our tenants’ and borrowers’ ability to meet their obligations as they come due, including their obligation to make full and timely rental payments and debt service payments, respectively, to us has been and may continue to be impacted. In some cases, we have had, and may in the future have, to restructure our tenants’ long-term rent obligations and may not be able to do so on terms that are as favorable to us as those currently in place. Reduced or modified rental and debt service amounts could result in the determination that the full amounts of our investments are not recoverable, which could result in an impairment charge. The operating results of our Senior Housing - Managed portfolio and our unconsolidated joint ventures have been and may continue to be impacted as well. Prolonged deterioration in the operating results for these investments could result in the determination that the full amounts of our investments are not recoverable, which could result in an impairment charge. We may experience these or other negative effects as the result of future pandemics or epidemics as well.
14


In addition, if there are significant disruptions to our business due to a future pandemic or epidemic, our credit ratings may be adversely impacted and we may breach covenants in our debt agreements and be unable to service our debt. Further, significant disruption could cause us to reduce or suspend our dividend.
The duration and extent of the effects of the COVID-19 pandemic, or a future pandemic or epidemic, on our operational and financial performance are uncertain and difficult to predict and we may experience adverse impacts to our business, financial condition, results of operations and prospects.
We are exposed to operational risks with respect to our Senior Housing - Managed communities.
We are exposed to various operational risks with respect to our Senior Housing - Managed communities that may increase our costs or adversely affect our ability to generate revenues. These risks are similar to the ones described above and below with respect to our tenants and include fluctuations in occupancy and private pay rates; economic conditions; competition; federal, state, local, and industry-regulated licensure, certification and inspection laws, regulations, and standards; the availability and increases in cost of general and professional liability insurance coverage; lawsuits and other legal proceedings arising out of our alleged actions or the alleged actions of our operators; state regulation and rights of residents related to entrance fees; and the availability and increases in the cost of labor (as a result of a shortage of caregivers or other trained personnel, minimum staffing requirements or general inflationary pressures on wages or otherwise). Any one or a combination of these factors may adversely affect our business, financial position or results of operations.
Further, our third-party operators are ultimately in control of the day-to-day business of the properties that they operate. We depend on third parties to operate these properties in a manner that complies with applicable law and regulation, minimizes legal risk and maximizes the value of our investment. The failure by these third parties to operate these properties efficiently and effectively and adequately manage the related risks could adversely affect our business, financial condition and results of operations.
Real estate is a competitive business and this competition may make it difficult for us to identify and purchase suitable healthcare properties, to finance acquisitions on favorable terms, or to retain or attract tenants.
We operate in a highly competitive industry and face competition from other REITs, investment companies, private equity and hedge fund investors, sovereign funds, healthcare operators, lenders and other investors, some of whom are significantly larger than us and have greater resources and lower costs of capital than we do. This competition makes it more challenging to identify and successfully capitalize on acquisition opportunities that meet our investment objectives. Similarly, our properties face competition for patients and residents from other properties in the same market, which may affect our ability to attract and retain tenants or may reduce the rents we are able to charge. If we cannot identify and purchase a sufficient quantity of healthcare properties at favorable prices, finance acquisitions on commercially favorable terms, or attract and retain profitable tenants, our business, financial position or results of operations could be materially adversely affected.
If we lose our key management personnel, we may not be able to successfully manage our business and achieve our objectives.
Our success depends in large part upon the leadership and performance of our executive management team, particularly Mr. Matros, our President and Chief Executive Officer. If we lose the services of Mr. Matros, we may not be able to successfully manage our business or achieve our business objectives.
Additionally, attracting and retaining talent at all levels is vital to our continuing success. If we are unable to provide competitive salaries, benefits, or a diverse and inclusive workplace for our personnel, our business may be adversely affected.
We may experience uninsured or underinsured losses, which could result in a significant loss of the capital we have invested in a property, decrease anticipated future revenues or cause us to incur unanticipated expenses.
While our lease agreements and property management agreements require that comprehensive insurance and hazard insurance be maintained by our tenants, there are certain types of losses, generally of a catastrophic nature, such as earthquakes, hurricanes and floods, as well as losses caused by health pandemics including the COVID-19 pandemic, that may be uninsurable or not economically insurable. Insurance coverage may not be sufficient to pay the full current market value or current replacement cost of a loss. Inflation, changes in building codes and ordinances, environmental considerations, and other factors also might make it infeasible to use insurance proceeds to replace properties after they have been damaged or destroyed. Under such circumstances, the insurance proceeds received might not be adequate to restore the economic position with respect to a damaged property.
15


Our assets, including our real estate and loans, are subject to impairment charges, and our valuation and reserve estimates are based on assumptions and may be subject to adjustment.
Our investment portfolio consists of real estate and mortgage loans, which are subject to write-downs in value. From time to time, we close facilities and actively market such facilities for sale. To the extent we are unable to sell these properties for our book value, we may be required to take a non-cash impairment charge or loss on the sale, either of which would reduce our net income. In addition, on a recurring basis, we evaluate our real estate investments and other assets for impairment indicators, and we establish general and specific reserves for our issued loans at least quarterly. The quarterly evaluation of our investments for impairment may result in significant fluctuations in our provision for credit losses or real estate impairments from quarter to quarter, impacting our results of operations. Judgments regarding the existence of impairment indicators or loan reserves are based on a number of factors, including market conditions, financial performance and legal structure, which may involve estimates. If we determine that a significant impairment has occurred, we are required to make an adjustment to the net carrying value of the asset, which could have a material adverse effect on our results of operations. Our estimates of loan reserves, and other accounting estimates, are inherently uncertain and may be subject to future adjustment, leading potentially to an increase in reserves.
Our reported rental and related revenues may be subject to increased variability as a result of Accounting Standards Update (“ASU”) 2016-02, Leases, as amended by subsequent ASUs (“Topic 842”).
In February 2016, the Financial Accounting Standards Board issued Topic 842, which supersedes guidance related to accounting for leases and provides for the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous accounting guidance. The objective of Topic 842 is to establish the principles that lessees and lessors shall apply to report useful information to users of financial statements about the amount, timing and uncertainty of cash flows arising from a lease. We elected to adopt Topic 842 on January 1, 2019 using the modified retrospective transition method. Among other things, under Topic 842, if at any time we cannot determine that it is probable that substantially all rents over the life of a lease are collectible, rental revenue will be recognized only to the extent of payments received and all receivables associated with the lease will be written off, irrespective of amounts expected to be collectible. Recoveries of these amounts will be recorded in future periods upon receipt of payment. Under Topic 842, future write-offs of receivables and any recoveries of previously written-off receivables will be recorded as adjustments to rental revenue. As a result, the adoption of this new accounting standard could cause increased variability related to our reported rental and related revenues, which could increase the volatility in the market price of our common stock.
We are subject to risks and liabilities in connection with our investment in our unconsolidated joint ventures.
Our investments in unconsolidated joint ventures involve risks not present with respect to our wholly owned properties, including the following:
We may be unable to take specific major actions, or such actions may be delayed, if the counterparties to the joint ventures disagree with such action, due to arrangements that require us to share decision-making authority over major decisions affecting the ownership or operation of the joint ventures and any property owned by the joint ventures such as the sale or financing of the property or the making of additional capital contributions for the benefit of the property;
The counterparties to the joint ventures may take actions with which we disagree;
Our ability to sell or transfer our interest in the joint ventures on advantageous terms when we so desire may be limited or restricted under the terms of our agreements with the counterparties in the joint ventures;
We may be required to contribute additional capital if the counterparties in the joint ventures fail to fund their share of required capital contributions;
Our equity interest in the joint ventures will be adversely impacted if the joint ventures are not able to maintain compliance with the terms of the agreements underlying their indebtedness;
The counterparties to the joint ventures might have economic or other business interests or goals that are inconsistent with our business interests or goals, including with respect to the timing, terms and strategies for investment, which could increase the likelihood of disputes regarding the ownership, management or disposition of the properties owned by the joint ventures;
Disagreements with the counterparties to the joint ventures could result in litigation or arbitration that increases our expenses, distracts our officers and directors, and disrupts the day-to-day operations of the properties owned by the joint ventures, including by delaying important decisions until the dispute is resolved; and
16


We may suffer losses to our investment in the joint ventures as a result of actions taken by the counterparties to the joint ventures.
Catastrophic weather and other natural or man-made disasters, the physical effects of climate change and a failure to implement sustainable and energy-efficient measures could affect our properties.
Some of our properties are located in areas susceptible to catastrophic weather and natural disasters, including fires, snow or ice storms, windstorms or hurricanes, earthquakes, flooding, or other severe conditions. These adverse weather and natural or man-made events could cause substantial damage or loss to our properties which could exceed applicable property insurance coverage. Such events could also have a material adverse impact on our tenants’ operations and ability to meet their obligations to us. In the event of a loss in excess of insured limits, we could lose our capital invested in the affected property, as well as anticipated future revenue from that property. Any such loss could materially and adversely affect our business financial condition and results of operations.
Climate change may also have indirect effects on our business by increasing the cost of (or making unavailable) property insurance on terms we find acceptable. To the extent that significant changes in the climate occur in areas where our properties are located, we may experience more frequent extreme weather events which may result in physical damage to or a decrease in demand for properties located in these areas or affected by these conditions. In addition, changes in federal and state legislation and regulation on climate change could result in increased capital expenditures to improve the energy efficiency of our existing properties and could also require us to spend more on our new development properties without a corresponding increase in revenue. Should the impact of climate change be material in nature, including destruction of our properties, or occur for lengthy periods of time, our financial condition or results of operations may be adversely affected.
As an environmentally responsible company, we strive to implement sustainable and energy-efficient measures throughout our portfolio. We engage in and discuss sustainable property management practices with our tenants and operators to identify measures that increase energy efficiency and water conservation and enhance safety and quality. If we or our tenants and operators fail to identify such measures, we may be unable to realize annual utility cost savings, which may affect our ability to maximize property and portfolio values and could have a material adverse effect on our business.
Risks Related to Our Tenants, Borrowers and Senior Housing - Managed Communities
Increased operating costs as well as increased competition could result in lower operating income for our tenants, borrowers and Senior Housing - Managed communities and may affect the ability of our tenants and borrowers to meet their obligations to us.
Because our tenants are typically required to pay all property operating expenses, increases in property-level expenses at our leased properties generally do not directly affect us. However, increased operating costs could have an adverse impact on our tenants if increases in their operating expenses exceed increases in their revenue, which may adversely affect our tenants’ ability to pay rent owed to us.
An increase in our tenants’, borrowers’ or Senior Housing - Managed communities’ expenses and a failure of their revenues to increase at least with inflation could adversely impact our tenants’, borrowers’, Senior Housing - Managed communities’ and our financial condition and our results of operations. Furthermore, expenses for the facilities of our tenants, borrowers and Senior Housing - Managed communities are primarily driven by the costs of labor, food, utilities, taxes, insurance and rent, and these operating costs continue to increase for our tenants, borrowers and Senior Housing - Managed communities.
In addition, the long-term healthcare industry is highly competitive and we expect that it may become more competitive in the future. Our tenants, borrowers and Senior Housing - Managed communities compete with other healthcare operators on a local and regional basis for residents and patients. The occupancy levels at, and results of operations from, our or our borrowers’ facilities are dependent on the ability of our tenants, borrowers and Senior Housing - Managed communities to compete with other tenants and operators on a number of different levels, including the quality of care provided, reputation, the physical appearance of a facility, price, the range of services offered, family preference, amenities, alternatives for healthcare delivery, the supply of competing properties, physicians, staff, referral sources, location, and the size and demographics of the population in the surrounding area. Our tenants, borrowers and Senior Housing - Managed communities also compete with numerous other companies providing similar healthcare services or alternatives such as home health agencies, life care at home and community-based service programs. Further, many competing companies may have resources and attributes that are superior to those of our tenants, borrowers and Senior Housing - Managed communities. Our tenants, borrowers and Senior Housing - Managed communities may encounter increased competition in the future that could limit their ability to attract residents or expand their businesses and therefore affect their operating income and ability to pay their lease or mortgage payments and meet their obligations to us. Private, federal and state payment programs and the effect of other laws and
17


regulations may also have a significant impact on the ability of our tenants, borrowers and Senior Housing - Managed communities to compete successfully for residents and patients at the properties.
Our tenants, borrowers and Senior Housing - Managed communities may be adversely affected by increasing healthcare regulation and enforcement.
Over the last several years, the regulatory environment of the long-term healthcare industry has intensified both in the amount and type of regulations and in the efforts to enforce those regulations. This is particularly true for large for-profit, multi-facility providers. The extensive federal, state and local laws and regulations affecting the healthcare industry include those relating to, among other things, licensure, conduct of operations, ownership of facilities, addition of facilities and equipment, allowable costs, services, prices for services, qualified beneficiaries, quality of care, patient rights, fraudulent or abusive behavior, and financial and other arrangements that may be entered into by healthcare providers. Changes in enforcement policies by federal and state governments have resulted in a significant increase in the number of inspections, citations of regulatory deficiencies and other regulatory sanctions, including terminations from the Medicare and Medicaid programs, bars on Medicare and Medicaid payments for new admissions, civil monetary penalties and even criminal penalties.
If our tenants, borrowers or Senior Housing - Managed communities fail to comply with the extensive laws, regulations and other requirements applicable to their businesses and the operation of our properties, they could become ineligible to receive reimbursement from governmental and private third-party payor programs, face bans on admissions of new patients or residents, suffer civil or criminal penalties or be required to make significant changes to their operations or face adverse publicity and reputational harm. Our tenants, borrowers and Senior Housing - Managed communities also could be forced to expend considerable resources responding to an investigation, lawsuit or other enforcement action under applicable laws or regulations. In such event, the results of operations and financial condition of our Senior Housing - Managed communities and of our tenants and borrowers and the results of operations of our properties operated by those entities could be adversely affected, which, in turn, could have a material adverse effect on us. We are unable to predict future federal, state and local regulations and legislation, including the Medicare and Medicaid statutes and regulations, or the intensity of enforcement efforts with respect to such regulations and legislation, and any changes in the regulatory framework could have a material adverse effect on our tenants or borrowers, which, in turn, could have a material adverse effect on us.
Our tenants and borrowers depend on reimbursement from governmental and other third-party payor programs, and reimbursement rates from such payors may be reduced.
Many of our tenants and borrowers depend on third-party payors, including Medicare, Medicaid or private third-party payors, for the majority of their revenue. The reduction in reimbursement rates from third-party payors, including insurance companies and the Medicare and Medicaid programs, or other measures reducing reimbursements for services provided by our tenants and borrowers, may result in a reduction in our tenants’ and borrowers’ revenues and operating margins. In addition, reimbursement from private third-party payors may be reduced as a result of retroactive adjustment during claims settlement processes or as a result of post-payment audits. Furthermore, new laws and regulations could impose additional limitations on government and private payments to healthcare providers. For example, our tenants and borrowers may be affected by health reform initiatives that modify certain payment systems to encourage more cost-effective care and a reduction of inefficiencies and waste (e.g., the implementation of a voluntary bundled payment program and the creation of accountable care organizations). We cannot assure you that adequate reimbursement levels will continue to be available for the services provided by our tenants and borrowers. Although moderate reimbursement rate reductions may not affect our tenants’ or borrowers’ ability to meet their financial obligations to us, significant limits on reimbursement rates or on the services reimbursed could have a material adverse effect on their business, financial position or results of operations, which could materially adversely affect their ability to meet their financial obligations to us.
While reimbursement rates have generally increased over the past few years, President Biden and members of the U.S. Congress may approve or propose new legislation, regulation changes and reform initiatives that could result in changes (including substantial reductions in funding) to Medicare, Medicaid or Medicare Advantage Plans. In addition, a number of states are currently managing budget deficits, which may put pressure on states to decrease reimbursement rates for our tenants and borrowers with a goal of decreasing state expenditures under their state Medicaid programs. Any such existing or future federal or state legislation relating to deficit reduction that reduces reimbursement payments to healthcare providers could have a material adverse effect on our tenants’ business, financial position or results of operations, which could materially adversely affect their ability to meet their financial obligations to us and could have a material adverse effect on us.
We face potential adverse consequences of bankruptcy or insolvency by our tenants, operators, borrowers and other obligors.
We are exposed to the risk that our tenants, operators or borrowers could become bankrupt or insolvent. Although our lease and lending agreements provide us with the right to exercise certain remedies in the event of default on the obligations
18


owing to us or upon the occurrence of certain insolvency events, the bankruptcy and insolvency laws afford certain rights to a party that has filed for bankruptcy or reorganization. For example, a lessee may reject its lease with us in a bankruptcy proceeding. In such a case, our claim against the lessee for unpaid and future rents would be limited by the statutory cap of the U.S. Bankruptcy Code. This statutory cap could be substantially less than the remaining rent actually owed under the lease, and any claim we have for unpaid rent might not be paid in full. In addition, a lessee may assert in a bankruptcy proceeding that its lease should be re-characterized as a financing agreement. If such a claim is successful, our rights and remedies as a lender, compared to a landlord, are generally more limited.
Furthermore, the automatic stay provisions of the U.S. Bankruptcy Code would preclude us from enforcing our remedies unless we first obtain relief from the court having jurisdiction over the bankruptcy case. This would effectively limit or delay our ability to collect unpaid rent or interest payments, and we may ultimately not receive any payment at all. In addition, we would likely be required to fund certain expenses and obligations (e.g., real estate taxes, insurance, debt costs and maintenance expenses) to preserve the value of our properties, avoid the imposition of liens on our properties or transition our properties to a new tenant. Additionally, we lease many of our properties to healthcare providers who provide long-term custodial care to the elderly. Evicting tenants for failure to pay rent while the property is occupied typically involves specific procedural or regulatory requirements and may not be successful. Even if eviction is possible, we may determine not to do so due to reputational or other risks. Bankruptcy or insolvency proceedings typically also result in increased costs to the tenant or borrower, significant management distraction and performance declines.
We may be unable to find a replacement tenant for one or more of our leased properties or we may be required to incur substantial renovation costs to make our healthcare properties suitable for such tenants.
We may need to find a replacement tenant for one or more of our leased properties for a variety of reasons, including upon the expiration of the lease term or the occurrence of a tenant default. During any period in which we are attempting to locate one or more replacement tenants, there could be a decrease or cessation of rental payments on the applicable property or properties. We cannot be sure that any of our current or future tenants will elect to renew their respective leases upon expiration of the terms thereof. Similarly, we cannot be sure that we will be able to locate a suitable replacement tenant or, if we are successful in locating a replacement tenant, that the rental payments from the new tenant would not be significantly less than the existing rental payments. Our ability to locate a suitable replacement tenant may be significantly delayed or limited by various state licensing, receivership, certificate of need or other laws, as well as by Medicare and Medicaid change-of-ownership rules. We also may incur substantial additional expenses in connection with any such licensing, receivership or change-of-ownership proceedings. Any such delays, limitations and expenses could delay or impact our ability to collect rent, obtain possession of leased properties or otherwise exercise remedies for default, which could materially adversely affect our business, financial condition and results of operations.
In addition, healthcare facilities are typically highly customized and may not be easily adapted to non-healthcare-related uses. The improvements generally required to conform a property to healthcare use are costly and at times tenant-specific. A new or replacement tenant may require different features in a property, depending on that tenant’s particular operations. If a current tenant is unable to pay rent and vacates a property, we may incur substantial expenditures to modify a property before we are able to secure another tenant. Our ability to make required modifications and/or renovations may involve costs associated with volatility in materials and labor prices and approvals of authorities or compliance with governmental regulations, including the Americans with Disabilities Act, which could result in increased costs and delays in transitioning a facility to a new tenant. Further, changes in federal and state legislation and regulation on climate change could result in increased capital expenditures to improve the energy efficiency of our existing properties and could also require us or our tenants to spend more on our new development properties. These expenditures or renovations and delays could materially adversely affect our business, financial condition or results of operations.
Potential litigation and rising insurance costs may affect our tenants’ and borrowers’ ability to obtain and maintain adequate liability and other insurance and their ability to make lease or loan payments and fulfill their insurance and indemnification obligations to us.
Our tenants and borrowers may be subject to, and the COVID-19 pandemic has increased the potential for, lawsuits filed by advocacy groups that monitor the quality of care at healthcare facilities or by patients, facility residents or their families. Significant damage awards are possible in cases where neglect has been found. This litigation has increased our tenants’ and borrowers’ costs of monitoring and reporting quality of care and has resulted in increases in the cost of liability and medical malpractice insurance. These increased costs may materially adversely affect our tenants’ and borrowers’ ability to obtain and maintain adequate liability and other insurance; manage related risk exposures; fulfill their insurance, indemnification and other obligations to us under their leases or loan agreements, as applicable; or make lease or loan payments to us, as applicable.
19


In addition, from time to time, we may be subject to claims brought against us in lawsuits and other legal proceedings arising out of our alleged actions or the alleged actions of our tenants and operators for which such tenants or operators may have agreed to indemnify, defend and hold us harmless. An unfavorable resolution of any such pending or future litigation could materially adversely affect our liquidity, financial condition and results of operations and have a material adverse effect on us in the event that we are not ultimately indemnified by our tenants or operators. Furthermore, negative publicity, including the ongoing publicity related to the COVID-19 pandemic, with respect to any lawsuits, claims or other legal or regulatory proceedings may also negatively impact our, our tenants’, our borrowers’ or our operators’ reputations.
Regulatory Risks
Required regulatory approvals can delay or prohibit transfers of our healthcare properties, which could result in periods in which we are unable to receive rent for such properties.
Our tenants are operators of skilled nursing and other healthcare facilities, and accordingly must be licensed under applicable state law and, depending upon the type of facility, certified or approved as providers under the Medicare and/or Medicaid programs. Prior to the transfer of the operations of such healthcare properties to successor tenants, the new tenant generally must become licensed under state law and, in certain states, receive change-of-ownership approvals under certificate of need laws (which laws provide for a certification that the state has made a determination that a need exists for the beds located on the applicable property). If applicable, Medicare and Medicaid provider approvals may be needed as well. In the event that an existing lease is terminated or expires and a new tenant is found, then any delays in the new tenant receiving regulatory approvals from the applicable federal, state or local government agencies, or the inability of such tenant to receive such approvals, may prolong the period during which we are unable to collect the applicable rent. We could also incur substantial additional expenses in connection with any licensing, receivership or change-of-ownership proceedings.
Environmental compliance costs and liabilities associated with real estate properties owned by us may materially impair the value of those investments.
As an owner of real property, we or our subsidiaries are subject to various federal, state and local environmental and health and safety laws and regulations. Although we do not currently operate or manage the substantial majority of our properties, we or our subsidiaries may be held primarily or jointly and severally liable for costs relating to the investigation and clean-up of any property where there has been a release or threatened release of a hazardous regulated material as well as other affected properties, regardless of whether we knew of or caused the release. In addition to these costs, which are typically not limited by law or regulation and could exceed an affected property’s value, we could be liable for certain other costs, including governmental fines and injuries to persons, property or natural resources. Further, some environmental laws provide for the creation of a lien on a contaminated site in favor of the government as security for damages and any costs the government incurs in connection with such contamination and associated clean-up.
Although we require our tenants and operators to undertake to indemnify us for environmental liabilities they cause, the amount of such liabilities could exceed the financial ability of the tenant or operator to indemnify us. The presence of contamination or the failure to remediate contamination may adversely affect our ability to sell or lease the real estate or to borrow using the real estate as collateral.
A failure by our tenants, borrowers or operators to adhere to applicable privacy and data security laws could harm our business.
The majority of our tenants, borrowers and operators are subject to HIPAA and various other state and federal laws that relate to privacy and data security, including the reporting of data breaches involving personal information. Failure to comply with these requirements could have a materially adverse effect on our tenants, operators and borrowers and accordingly could have a materially adverse effect on our tenants’ and borrowers ability to meet their obligations to us and on our results of operations. Furthermore, the adoption of new privacy, security and data breach notification laws at the federal and state level could require our tenants, borrowers and operators to incur significant compliance costs. In addition, the cost and operational consequences of responding to cybersecurity incidents and implementing remediation measures could be significant.
A material failure or breach of our or our tenants’, borrowers’ or operators’ information technology, could harm our business.
We and our tenants, borrowers and operators rely on information technology networks and systems, including the Internet, to process, transmit and store electronic information, and to manage or support a variety of business processes, including financial transactions and records, personal identifying information, tenant and lease data. While we and our tenants, borrowers and operators maintain various physical, cyber and data security controls, incidents or breaches resulting from technical failures, natural hazards, theft and unintentional or deliberate acts by third parties or insiders attempting to obtain
20


unauthorized access to information, destroy or manipulate data, or disrupt or sabotage information systems do occur and they may have a material impact on our business. The risk of security incidents has generally increased as the number, intensity and sophistication of attacks and intrusions have increased, and we have seen a significant increase in cyber phishing attacks over the past few years. Additionally, cyber threats and the techniques used in cyberattacks change, develop and evolve rapidly, including from emerging technologies, such as advanced forms of artificial intelligence and quantum computing. We have engaged a third-party cybersecurity firm who serves as our dedicated information technology (“IT”) team and helps us oversee, implement and manage our processes and controls to assess, identify and manage risks from cybersecurity threats. It is possible that our processes and controls will not detect or protect against all cybersecurity threats or incidents. In addition, any failure on the part of our outsourced IT team to effectively monitor and protect our information systems could make us more vulnerable to cybersecurity incidents. Although, to our knowledge, no cybersecurity incident has been material to our business to date, we have been, and expect to continue to be, subject to cybersecurity threats and attacks of varying degrees, and there can be no assurance that we will not experience a material incident. A data security incident or breach occurring at or involving us could have a material adverse impact on our company. A data security incident or breach occurring at or involving a tenant, borrower or operator could jeopardize the tenant’s or operators ability to fulfill its obligations to us and could adversely impact our financial position and results of operations.
Furthermore, we purchase some of our information technology from vendors, on whom our systems depend. We rely on commercially available systems, software, tools and monitoring to provide security for processing, transmission and storage of confidential tenant, borrower and operator information, some of which may include individually identifiable information, including information relating to financial accounts. Although we have taken steps to protect the security of our information systems and the data maintained in those systems, it is possible that our safety and security measures will not be able to prevent the systems’ improper functioning or damage, or the improper access or disclosure of personally identifiable information such as in the event of a cyber-attack. Security breaches (including physical or electronic break-ins, computer viruses, phishing attacks, computer denial-of-service attacks, worms, covert introduction of malware to computers and networks, impersonation of authorized users, and efforts to discover and exploit any design flaws, bugs, security vulnerabilities or security weaknesses, as well as intentional or unintentional acts by our teammates or other insiders with access privileges, intentional acts of vandalism by third parties and sabotage) can create system disruptions, shutdowns or unauthorized disclosure of confidential information. Any failure to maintain proper function, security and availability of our information systems could interrupt our operations, damage our reputation, subject us to liability claims or regulatory penalties and could have a material adverse effect on our business, financial condition and results of operations.
Investment and Financing Risks
We depend on investments in the healthcare property sector, making our profitability more vulnerable to a downturn or slowdown in that specific sector than if we were investing in multiple industries.
We concentrate our investments in the healthcare property sector. As a result, we are subject to risks inherent to investments in a single industry, in real estate, and specifically in healthcare properties. A downturn or slowdown in the healthcare property sector would have a greater adverse impact on our business than if we had investments in multiple industries. Specifically, a downturn in the healthcare property sector could negatively impact the ability of our tenants and borrowers to meet their obligations to us, as well as the ability to maintain rental and occupancy rates. This could adversely affect our business, financial condition and results of operations. In addition, a downturn in the healthcare property sector could adversely affect the value of our properties and our ability to sell properties at prices or on terms acceptable to us.
We have substantial indebtedness and have the ability to incur significant additional indebtedness and other liabilities.
As of December 31, 2023, we had outstanding indebtedness of $2.4 billion, which consisted of $1.8 billion of Senior Notes (as defined below), $543.2 million in Term Loans (as defined below), $94.4 million outstanding under our Revolving Credit Facility and aggregate secured indebtedness to third parties of $48.1 million on certain of our properties, and we had $905.6 million available for borrowing under our Revolving Credit Facility. Our high level of indebtedness may have the following important consequences to us:
It may increase our cost of borrowing;
It may limit our ability to obtain additional financing to fund future acquisitions, working capital, capital expenditures or other general corporate requirements;
It may expose us to the risk of increased interest rates under debt instruments subject to variable rates of interest, such as our Revolving Credit Facility;
It may adversely impact our credit ratings;
It may limit our ability to adjust rapidly to changing market conditions and we may be vulnerable in the event of a downturn in general economic conditions or in the real estate and/or healthcare sectors;
21


It may place us at a competitive disadvantage against less leveraged competitors;
It may restrict the way in which we conduct our business because of financial and operating covenants in the agreements governing our existing and future indebtedness;
It may become more difficult for us to satisfy our obligations (including ongoing interest payments and, where applicable, scheduled amortization payments) with respect to the Senior Notes and our other debt; and
It may require us to sell assets and properties at an inopportune time.
In addition, the Senior Notes Indentures (as defined below) permit us to incur substantial additional debt, including secured debt (to which the Senior Notes will be effectively subordinated). If we incur additional debt, the related risks described above could intensify. Furthermore, the Senior Notes Indentures do not impose any limitation on our ability to incur liabilities that are not considered indebtedness under the Senior Notes Indentures.
The impact of any of these potential adverse consequences could have a material adverse effect on our results of operations, financial condition, and liquidity.
We may be unable to service our indebtedness.
Our ability to make scheduled payments on and to refinance our indebtedness depends on and is subject to our future financial and operating performance, which in turn is affected by general and regional economic, financial, competitive, business and other factors beyond our control, including the availability of financing in the international banking and capital markets. Our business may fail to generate sufficient cash flow from operations or future borrowings may be unavailable to us under our Revolving Credit Facility or from other sources in an amount sufficient to enable us to service our debt, to refinance our debt or to fund our other liquidity needs. If we are unable to meet our debt obligations or to fund our other liquidity needs, we will need to restructure or refinance all or a portion of our debt. We may be unable to refinance any of our debt, including our Term Loans (as defined below) and any amounts outstanding under our Revolving Credit Facility, on commercially reasonable terms or at all. If we were unable to make payments or refinance our debt or obtain new financing under these circumstances, we would have to consider other options, such as asset sales, equity issuances and/or negotiations with our lenders to restructure the applicable debt. Our Credit Agreement and the Senior Notes Indentures restrict, and market or business conditions may limit, our ability to take some or all of these actions. Any restructuring or refinancing of our indebtedness could be at higher interest rates and may require us to comply with more onerous covenants that could further restrict our business operations.
Covenants in our debt agreements restrict our and our subsidiaries activities and could adversely affect our business.
Our debt agreements, including the agreement governing our 2027 Notes (as defined below) and the Credit Agreement, contain various covenants that limit our ability and the ability of our subsidiaries to engage in various transactions including:
Incurring additional secured and unsecured debt;
Granting liens upon certain properties;
Paying dividends or making other distributions on, redeeming or repurchasing capital stock;
Entering into transactions with affiliates;
Issuing stock of or interests in subsidiaries;
Engaging in non-healthcare related business activities;
Creating restrictions on the ability of certain of our subsidiaries to pay dividends or other amounts to us;
Selling assets; or
Effecting a consolidation or merger or selling substantially all of our assets.
The agreement governing our 2027 Notes also restricts us from making certain investments. The indentures governing our 2026 Notes, our 2029 Notes and our 2031 Notes (each as defined below) contain certain of the above restrictions as well. These covenants limit our operational flexibility and could prevent us from taking advantage of business opportunities as they arise, growing our business or competing effectively. In addition, the Credit Agreement requires us to comply with specified financial covenants, which include a maximum total leverage ratio, a maximum secured debt leverage ratio, a minimum fixed charge coverage ratio, a maximum unsecured leverage ratio, a minimum tangible net worth requirement and a minimum unsecured interest coverage ratio. The indentures governing our 2026 Notes, our 2029 Notes and our 2031 Notes require us to comply with an unencumbered asset ratio, and the agreement governing our 2027 Notes requires us to comply with specified financial covenants, which include a maximum leverage ratio, a maximum secured debt leverage ratio, a maximum unsecured debt leverage ratio, a minimum fixed charge coverage ratio, a minimum net worth, a minimum unsecured interest coverage ratio
22


and a minimum unencumbered debt yield ratio. Our ability to meet these requirements may be affected by events beyond our control, and we may not meet these requirements.
A breach of any of the covenants or other provisions in our debt agreements could result in an event of default, which, if not cured or waived, could result in such debt becoming immediately due and payable. Further, certain change in control events could result in an event of default under the agreement governing our 2027 Notes. Any of these events of default, in turn, could cause our other debt to become due and payable as a result of cross-acceleration provisions contained in the agreements governing such other debt. We may be unable to maintain compliance with these covenants and, if we fail to do so, we may be unable to obtain waivers from the lenders and holders and/or amend the covenants. In the event that some or all of our debt is accelerated and becomes immediately due and payable, we may not have the funds to repay, or the ability to refinance, such debt.
Adverse changes in our credit ratings could impair our ability to obtain additional debt and equity financing on favorable terms, if at all, and negatively impact the market price of our securities, including our common stock.
Our credit ratings affect the amount and type of capital, as well as the terms of any financing we may obtain. Credit rating agencies continually revise their ratings for the companies that they follow, including us. The credit ratings of our debt are based on, among other things, our operating performance, liquidity and leverage ratios, overall financial position, level of indebtedness and pending or future changes in the regulatory framework applicable to our industry. The credit rating agencies also evaluate our industry as a whole and may change their credit ratings for us based on their overall view of our industry. If we are unable to maintain favorable credit ratings, we would likely incur higher borrowing costs, which would make it more difficult or expensive to obtain additional financing or refinance existing obligations and commitments.
Cash available for distribution to stockholders may be insufficient to make dividend distributions at expected levels and are made at the discretion of our board of directors.
If cash available for distribution generated by our assets decreases due to dispositions or otherwise, we may be unable to make dividend distributions at expected levels. Our inability to make distributions commensurate with market expectations would likely result in a decrease in the market price of our common stock. Further, all distributions are made at the discretion of our board of directors in accordance with Maryland law and depend on: (i) our earnings; (ii) our financial condition; (iii) debt and equity capital available to us; (iv) our expectations for future capital requirements and operating performance; (v) restrictive covenants in our financial or other contractual arrangements; (vi) maintenance of our REIT qualification; (vii) restrictions under Maryland law; and (viii) other factors as our board of directors may deem relevant from time to time.
Our ability to raise capital through equity financings is dependent, in part, on the market price of our common stock, which depends on market conditions and other factors affecting REITs generally.
Our ability to raise capital through equity financings depends, in part, on the market price of our common stock, which in turn depends on fluctuating market conditions and other factors including the following:
The reputation of REITs and attractiveness of their equity securities in comparison with other equity securities, including securities issued by other real estate companies;
Our financial performance and that of our tenants and borrowers;
Concentrations in our investment portfolio by tenant and property type;
Concerns about our tenants’ or borrowers’ financial condition, including as a result of uncertainty regarding reimbursement from governmental and other third-party payor programs;
Our ability to meet or exceed investor expectations of prospective investment and earnings targets;
The contents of analyst reports about us and the REIT industry;
Changes in interest rates on fixed-income securities, which may lead prospective investors to demand a higher annual yield from investments in our common stock;
Maintaining or increasing our dividend, which is determined by our board of directors and depends on our financial position, results of operations, cash flows, capital requirements, debt covenants (which include limits on distributions by us), applicable law, and other factors as our board of directors deems relevant; and
Regulatory action and changes in REIT tax laws.
The market value of a REIT’s equity securities is generally based upon the market’s perception of the REIT’s growth potential and its current and potential future earnings and cash distributions. If we fail to meet the market’s expectation with regard to future earnings and cash distributions, the market price of our common stock could decline, and our ability to raise capital through equity financings could be materially adversely affected.
23


Changes and uncertainty in macroeconomic conditions and disruptions in the financial markets could adversely affect the value of our real estate investments and our business, results of operations, cash flows and financial condition.
Concerns over economic recession, interest rate increases, policy priorities of the U.S. presidential administration, trade wars, labor shortages or inflation may contribute to increased volatility and diminished expectations for the economy and markets. Additionally, concern over geopolitical issues may also contribute to prolonged market volatility and instability. For example, the conflicts between Russia and Ukraine and in the Middle East have led to disruption, instability and volatility in global markets and industries. Such conditions could impact real estate fundamentals and result in lower occupancy, lower rental rates, and declining values in our real estate portfolio and in the real estate collateral securing any indebtedness. As a result, the value of our property investments could decrease below the amounts paid for such investments, the value of real estate collateral securing any indebtedness could decrease below the outstanding principal amounts of such indebtedness, and revenues from our properties could decrease due to fewer and/or delinquent tenants or lower rental rates. This could materially adversely affect our revenues, results of operations and financial condition.
Ownership of property outside the U.S. may subject us to different or greater risks than those associated with our U.S. investments, including currency fluctuations.
We have investments in Canada, and from time to time may seek to acquire other properties in Canada or otherwise outside the U.S. International development, investment, ownership and operating activities involve risks that are different from those we face with respect to our U.S. properties and operations. These risks include, but are not limited to, any gain recognized with respect to changes in exchange rates may not qualify under the income tests that we must satisfy annually in order to qualify and maintain our status as a REIT and fluctuations in the exchange rates between USD and the Canadian Dollar, which we may be unable to protect against through hedging. Although we have pursued hedging alternatives, by borrowing in Canadian dollar denominated debt and entering into cross currency swaps, to protect against foreign currency fluctuations, no amount of hedging activity can fully insulate us from the risks associated with changes in foreign currency exchange rates, and the failure to hedge effectively against foreign currency exchange rate risk could materially adversely affect our business, financial position or results of operations.
In addition, changes in Canadian political, regulatory, and economic conditions; challenges in managing Canadian operations; challenges of complying with a variety of Canadian laws and regulations, including those relating to real estate, healthcare operations, taxes, employment and legal proceedings, and lending practices; Canadian-specific business cycles and economic instability; and changes in applicable laws and regulations in the U.S. that affect our foreign operations could have a material adverse effect on our business, financial position or results of operations. A future pandemic or epidemic, may also subject our investments and operations in Canada to different or greater risks than those faced in the U.S., which may depend on factors including the duration and severity of outbreaks in Canada, the impact of new variants, the distribution of vaccines and boosters, and governmental or private actions taken in response to the pandemic or epidemic.
We may not be able to sell properties when we desire because real estate investments are relatively illiquid, which could have a material adverse effect on our business, financial position or results of operations.
Real estate investments generally cannot be sold quickly. In addition, some and potentially substantially all of our properties serve as collateral for our current and future secured debt obligations and cannot readily be sold unless the underlying secured indebtedness is concurrently repaid. We may not be able to vary our portfolio promptly in response to changes in the real estate market. A downturn in the real estate market, or the economy in general, could materially adversely affect the value of our properties and our ability to sell such properties for acceptable prices or on other acceptable terms. Furthermore, buyers of our properties generally require third-party financing in order to acquire our properties. Accordingly, the price they may be willing to pay for our properties may depend on the cost and availability of financing for such transactions. We also cannot predict the length of time needed to find a willing purchaser and to close the sale of a property or portfolio of properties. These factors and any others that would impede our ability to respond to adverse changes in the performance of our properties could have a material adverse effect on our business, financial position or results of operations.
Risks Associated with Our Status as a REIT
Our failure to maintain our qualification as a REIT would subject us to U.S. federal income tax, which could adversely affect the value of the shares of our common stock and would substantially reduce the cash available for distribution to our stockholders.
Our qualification and taxation as a REIT will depend upon our ability to meet on a continuing basis, through actual annual operating results, certain qualification tests set forth in the U.S. federal tax laws. Accordingly, given the complex nature of the rules governing REITs, the ongoing importance of factual determinations, including the potential tax treatment of
24


investments we make, and the possibility of future changes in our circumstances, no assurance can be given that our actual results of operations for any particular taxable year will satisfy such requirements.
If we fail to qualify as a REIT in any calendar year, we would be required to pay U.S. federal income tax (and any applicable state and local tax) on our taxable income at regular corporate rates, and dividends paid to our stockholders would not be deductible by us in computing our taxable income (although such dividends received by certain non-corporate U.S. taxpayers generally would currently be subject to a preferential rate of taxation). Further, if we fail to qualify as a REIT, we might need to borrow money or sell assets in order to pay any resulting tax. Our payment of income tax would decrease the amount of our income available for distribution to our stockholders. Furthermore, if we fail to maintain our qualification as a REIT, we no longer would be required under U.S. federal tax laws to distribute substantially all of our REIT taxable income to our stockholders. Unless our failure to qualify as a REIT was subject to relief under U.S. federal tax laws, we could not re-elect to qualify as a REIT until the fifth calendar year following the year in which we failed to qualify.
The REIT distribution requirement will decrease our liquidity and may limit our ability to engage in otherwise beneficial transactions.
To comply with the 90% taxable income distribution requirement applicable to REITs and to avoid the non-deductible excise tax, we must make distributions to our stockholders. The Senior Notes Indentures permit us to declare or pay any dividend or make any distribution that is necessary to maintain our REIT status if the aggregate principal amount of all outstanding Indebtedness of the Parent and its Restricted Subsidiaries on a consolidated basis at such time is less than 60% of Adjusted Total Assets (as each term is defined in the Senior Notes Indentures) and to make additional distributions if we pass certain other financial tests.
We are required under the Internal Revenue Code of 1986, as amended (the “Code”), to distribute at least 90% of our taxable income, determined without regard to the dividends-paid deduction and excluding any net capital gain, and the Operating Partnership (as defined below) is required to make distributions to us to allow us to satisfy the REIT distribution requirement. However, distributions may limit our ability to rely upon rental payments from our properties or subsequently acquired properties to finance investments, acquisitions or new developments.
Although we anticipate that we generally will have sufficient cash or liquid assets to enable us to satisfy the REIT distribution requirement, it is possible that, from time to time, we may not have sufficient cash or other liquid assets to meet the REIT distribution requirement. This may be due to the timing differences between the actual receipt of income and actual payment of deductible expenses, on the one hand, and the inclusion of that income and deduction of those expenses in arriving at our taxable income, on the other hand, which may cause us to fail to have sufficient cash or liquid assets to enable us to satisfy the REIT distribution requirement.
In the event that such an insufficiency occurs, in order to meet the REIT distribution requirement and maintain our status as a REIT, we may have to sell assets at unfavorable prices, borrow at unfavorable terms, make taxable stock dividends, or pursue other strategies. This may require us to raise additional capital to meet our obligations. The terms of our Credit Agreement and the terms of the Senior Notes Indentures may restrict our ability to engage in some of these transactions. Additionally, in the event that we have to declare dividends in-kind in order to satisfy the REIT annual distribution requirement, a holder of our common stock will be required to report dividend income as a result of such distributions even though we distributed no cash or only nominal amounts of cash to such stockholder.
We could fail to qualify as a REIT if income we receive is not treated as qualifying income, including as a result of one or more of the lease agreements we have entered into or assumed not being characterized as true leases for U.S. federal income tax purposes, which would subject us to U.S. federal income tax at corporate tax rates.
Under applicable provisions of the Code, we will not be treated as a REIT unless we satisfy various requirements, including requirements relating to the sources of our gross income. Rents received or accrued by us may not be treated as qualifying rent for purposes of these requirements if the lease agreements we have entered into or assumed (as well as any other leases we enter into or assume) are not respected as true leases for U.S. federal income tax purposes and are instead treated as service contracts, joint ventures, loans or some other type of arrangement. In the event that the lease agreements entered into with lessees are not characterized as true leases for U.S. federal income tax purposes, we may fail to qualify as a REIT. In addition, with certain exceptions, rents received by us from a lessee will not be treated as qualifying rent for purposes of these requirements if we are treated, either directly or under the applicable attribution rules, as owning 10% or more of a lessee’s stock, capital or profits. If we fail to qualify as a REIT, we would be subject to U.S. federal income tax on our taxable income at corporate tax rates, which would decrease the amount of cash available for distribution to holders of our common stock.
25


Complying with REIT requirements may cause us to forego otherwise attractive acquisition opportunities or liquidate otherwise attractive investments, which could materially hinder our performance.
To qualify as a REIT for U.S. federal income tax purposes, we must continually satisfy certain tests, including tests concerning the sources of our income, the nature and diversification of our assets, the amounts we distribute to our stockholders and the ownership of our stock. In order to meet these tests, we may be required to forego investments or acquisitions we might otherwise make. Thus, compliance with the REIT requirements may materially hinder our performance.
The tax imposed on REITs engaging in “prohibited transactions” may limit our ability to engage in transactions which would be treated as sales for U.S. federal income tax purposes.
A REIT’s net income from prohibited transactions is subject to a 100% penalty tax. In general, prohibited transactions are sales or other dispositions of property, other than foreclosure property, held primarily for sale to customers in the ordinary course of business. Although we do not intend to hold any properties that would be characterized as held for sale to customers in the ordinary course of our business, unless a sale or disposition qualifies under certain statutory safe harbors, such characterization is a factual determination and no guarantee can be given that the Internal Revenue Service (“IRS”) would agree with our characterization of our properties or that we will always be able to satisfy the available safe harbors.
Our charter restricts the transfer and ownership of our stock.
In order for us to maintain our qualification as a REIT, no more than 50% of the value of our outstanding stock may be owned, directly or constructively, by five or fewer individuals, as defined in the Code. For the purpose of preserving our REIT qualification, our charter prohibits, subject to certain exceptions, beneficial and constructive ownership of more than 9.9% in value or in number of shares, whichever is more restrictive, of our outstanding common stock or more than 9.9% in value of all classes or series of our outstanding stock. The constructive ownership rules are complex and may cause shares of stock owned directly or constructively by a group of related individuals to be constructively owned by one individual or entity.
Dividends payable by REITs do not qualify for the reduced tax rates available for some dividends.
The maximum income tax rate applicable to “qualified dividends” payable by non-REIT corporations to domestic stockholders taxed at individual rates is currently 20%. Dividends payable by REITs, however, generally are not eligible for the reduced rates. Although not adversely affecting the taxation of REITs or dividends payable by REITs, the more favorable rates applicable to regular corporate qualified dividends could cause investors who are taxed at individual rates to perceive investments in REITs to be relatively less attractive than investments in the stocks of non-REIT corporations that pay dividends treated as qualified dividend income, which could adversely affect the value of the stock of REITs, including our common stock.
Our ownership of and relationship with any taxable REIT subsidiaries that we have formed or will form will be limited and a failure to comply with the limits would jeopardize our REIT status and may result in the application of a 100% excise tax.
A REIT may own up to 100% of the stock of one or more taxable REIT subsidiaries (“TRSs”). A TRS may earn income that would not be qualifying income if earned directly by the parent REIT. Both the subsidiary and the REIT must jointly elect to treat the subsidiary as a TRS. A corporation (other than a REIT) of which a TRS directly or indirectly owns securities possessing more than 35% of the total voting power or total value of the outstanding securities of such corporation will automatically be treated as a TRS. Overall, no more than 20% of the value of a REIT’s total assets may consist of stock or securities of one or more TRSs. A domestic TRS will pay U.S. federal, state and local income tax at regular corporate rates on any income that it earns. The rules also impose a 100% excise tax on certain transactions between a TRS and its parent REIT that are not conducted on an arm’s length basis.
We may be subject to adverse legislative or regulatory tax changes that could reduce the market price of our common stock.
The rules dealing with U.S. federal income taxation are constantly under review by persons involved in the legislative process and by the IRS and the U.S. Department of the Treasury. Changes to the tax law, including the possibility of major tax legislation, possibly with retroactive application, could adversely impact us or our stockholders. We cannot predict with certainty whether, when, in what forms, or with what effective dates, the tax laws applicable to us or our stockholders may be changed.
26


Risks Related to Our Organization and Structure
Provisions of the Maryland General Corporation Law (the MGCL) and of our charter and bylaws could inhibit a change of control of Sabra or reduce the value of our stock.
Certain provisions of Maryland law, our charter and our bylaws may have an anti-takeover effect. Sabra is subject to the Maryland business combination statute, which, subject to certain limitations, impose a moratorium on business combinations with “interested stockholders” or affiliates thereof for five years and thereafter impose additional requirements on such business combinations. Our bylaws contain a provision exempting us from the control share provisions of the MGCL, which provide that holders of “control shares” of a corporation (defined as voting shares of stock that, if aggregated with all other shares of stock owned or controlled by the acquirer, would entitle the acquirer to exercise one of three increasing ranges of voting power in electing directors) acquired in a “control share acquisition” (defined as the direct or indirect acquisition of issued and outstanding “control shares”) have no voting rights except to the extent approved by the stockholders by the affirmative vote of at least two-thirds of all of the votes entitled to be cast on the matter, excluding all interested shares. There can be no assurance that this bylaw provision exempting us from the control share provisions will not be amended or eliminated at any time in the future.
We have also adopted other measures that may make it difficult for a third party to obtain control of us, including provisions of our charter authorizing our board of directors (all without stockholder approval) to classify or reclassify shares of our stock in one or more classes or series, to cause the issuance of additional shares of our stock, and to amend our charter to increase or decrease the number of shares of stock that we have authority to issue. Our charter contains transfer and ownership restrictions on the percentage by number and value of outstanding shares of our stock that may be owned or acquired by any stockholder.
Our bylaws require advance notice of stockholder proposals and director nominations. These provisions, as well as other provisions of our charter and bylaws, may delay, defer, or prevent a transaction or a change in control that might otherwise be in the best interests of our stockholders.
Our bylaws provide that the Circuit Court for Baltimore City, Maryland or the United States District Court for the District of Maryland, Baltimore Division will be the sole and exclusive forum for substantially all disputes between our company and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with our company or our directors, officers or other teammates.
Our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Circuit Court for Baltimore City, Maryland, or, if that court does not have jurisdiction, the United States District Court for the District of Maryland, Baltimore Division, will be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of our company, (ii) any action asserting a claim of breach of any duty owed by any director or officer or other teammate of our company to our company or to the stockholders of our company, (iii) any action asserting a claim against our company or any director or officer or other teammate of our company arising pursuant to any provision of Maryland law, our charter or our bylaws, or (iv) any action asserting a claim against our company or any director or officer or other teammate of our company that is governed by the internal affairs doctrine. This exclusive forum provision is intended to apply to claims arising under Maryland state law and would not apply to claims brought pursuant to the Exchange Act or the Securities Act of 1933, or any other claim for which the federal courts have exclusive jurisdiction. This exclusive forum provision will not relieve us of our duties to comply with the federal securities laws and the rules and regulations thereunder, and our stockholders will not be deemed to have waived our compliance with these laws, rules and regulations.
This exclusive forum provision may limit a stockholder’s ability to bring a claim in a judicial forum of its choosing for disputes with our company or our directors, officers or other teammates, which may discourage lawsuits against our company and our directors, officers and other teammates. In addition, stockholders who do bring a claim in the Circuit Court for Baltimore City, Maryland could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near Maryland. The Circuit Court for Baltimore City, Maryland may also reach different judgments or results than would other courts, including courts where a stockholder would otherwise choose to bring the action, and such judgments or results may be more favorable to our company than to our stockholders. However, the enforceability of similar exclusive forum provisions in other companies’ charters and bylaws has been challenged in legal proceedings, and it is possible that a court could find this type of provision to be inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings. If a court were to find the exclusive forum provision contained in our bylaws to be inapplicable or unenforceable in an action, we might incur additional costs associated with resolving such action in other jurisdictions.

27


ITEM 1B. UNRESOLVED STAFF COMMENTS
Not applicable.

ITEM 1C. CYBERSECURITY
We recognize the importance of assessing, identifying and managing material risks associated with cybersecurity threats. To assess and identify material risks from cybersecurity threats, our enterprise risk management (“ERM”) program considers cybersecurity threat risks alongside other Company risks as part of our overall risk assessment process. Our cybersecurity policies, standards, processes and practices are fully integrated into Sabra’s ERM program and are evaluated annually against recognized frameworks established by the National Institute of Standards and Technology, the International Organization for Standardization and other applicable industry standards.
Our approach is focused on preserving the confidentiality, security and availability of our data and systems. We have implemented several cybersecurity processes, technologies and controls to aid in our efforts to assess, identify and manage such risks.
Risk Management and Strategy
Our cybersecurity program includes the following key elements:
Continuous monitoring of our networks for any unusual activity by a dedicated, outsourced IT team.
Regular review by senior management of monitoring and logging across predefined metrics to identify suspicious activity.
Employment of technical safeguards including firewalls, switches and access controls, as well as full encryption of our server in transit and at rest, which is only accessible through our internal Virtual Private Network (VPN).
Use of preventative security measures for cloud and network security and end-user protection, including Multi-Factor Authentication (MFA), Intrusion Detection System (IDS), Intrusion Prevention System (IPS) and Advanced Threat Protection (ATP) functionality to protect against viruses, malware, ransomware and phishing attempts.
Review of applications from third-party service providers to ensure they meet the criteria of our security policies before implementation, and encryption of data that is transmitted over secured channels and ports from our application programming interfaces.
Education and awareness for Sabra teammates through communication of security and technology policies via the employee handbook, phishing campaigns and annual training on protecting data, phishing threats, cyber trends and other security measures.
Maintenance of cyber insurance and crime insurance policies for Sabra and requirements for certain of our tenants and operators to carry a specified dollar amount of cyber insurance coverage, including coverage for third parties.
Careful monitoring of emerging cybersecurity trends and developments.
Establishment and maintenance of a comprehensive incident response plan that guides our response to a cybersecurity incident based on established reporting categories and that is tested and evaluated on a periodic basis.
We periodically engage third parties to perform internal and external penetration testing. Additionally, our outsourced IT team conducts periodic internal vulnerability assessments. These tests and assessments of our information security control environment and operating effectiveness are performed with the intent of identifying areas for continued focus, improvement and/or compliance. The results are reported to our board of directors, and our cybersecurity policies, standards, processes and practices are adjusted as necessary based on the information provided by these audits, testing and assessments.
To date, cybersecurity incidents have not materially affected and are not reasonably likely to materially affect our Company. However, because cybersecurity incidents are sometimes difficult to detect and can remain disguised for an extended period of time or until a triggering event has occurred, we can give no assurance that we have detected all cybersecurity incidents. We describe how risks from such incidents may affect us, including our business, financial condition and results of operations in “Regulatory Risks” in Item 1A, “Risk Factors.”
Governance
Our board of directors, through direction of the Audit Committee, oversees our ERM process, including the management of risks arising from cybersecurity threats. At least annually, our board of directors receives a report on cybersecurity risks which addresses topics including current and emerging threat risks and our ability to mitigate such risks, recent developments, evolving standards, vulnerability assessments and third-party reviews.
28


Our cybersecurity risk management and strategy processes, which are discussed in greater detail above, are led by our Chief Executive Officer and Chief Financial Officer in conjunction with our dedicated, outsourced IT team led by our virtual Chief Information Officer who brings over 10 years of experience serving in various roles under information technology and holds a degree in computer science. These members of management are responsible for the operation of our incident response plan and, through ongoing communication with our IT team, are informed about and monitor the prevention, detection, mitigation and remediation of cybersecurity threats and incidents. Prompt and timely information regarding any cybersecurity incident that meets established reporting category designation criteria is reported to the applicable parties as identified in our incident response plan. As discussed above, these members of management provide a report on cybersecurity risks at least annually and report incidents when appropriate to the board of directors.

ITEM 2. PROPERTIES    
As of December 31, 2023, our investment portfolio consisted of 378 real estate properties held for investment (consisting of (i) 241 skilled nursing/transitional care facilities, (ii) 43 Senior Housing - Leased communities, (iii) 61 Senior Housing - Managed communities, (iv) 18 behavioral health facilities and (v) 15 specialty hospitals and other facilities), 14 investments in loans receivable (consisting of two mortgage loans and 12 other loans), five preferred equity investments and two investments in unconsolidated joint ventures. As of December 31, 2023, our real estate properties held for investment included 37,834 beds/units, spread across the U.S. and Canada. As of December 31, 2023, the substantial majority of our real estate properties (excluding 61 Senior Housing - Managed communities) were leased under triple-net operating leases with expirations ranging from one year to 19 years.
The following table displays the expiration of annualized contractual rental revenues under our lease agreements as of December 31, 2023, adjusted to reflect actual payments received related to the twelve months ended December 31, 2023 for leases no longer accounted for on an accrual basis, by year and property type (dollars in thousands) and, in each case, without giving effect to any renewal options:
 Skilled Nursing / Transitional CareSenior Housing
- Leased
Behavioral
Health
Specialty
Hospitals and
Other
Total Annualized Revenues% of Total
2024$6,276 $— $— $— $6,276 1.8 %
20256,311 2,515 — 1,495 10,321 2.9 %
202616,834 1,242 — — 18,076 5.1 %
202724,308 4,237 — — 28,545 8.1 %
202820,964 6,205 — 3,490 30,659 8.7 %
202947,705 4,907 — 6,138 58,750 16.7 %
2030— — — 3,158 3,158 0.9 %
203168,811 5,601 1,558 — 75,970 21.5 %
20325,785 1,667 32,821 3,749 44,022 12.5 %
2033— 3,015 5,311 — 8,326 2.4 %
Thereafter52,121 12,472 3,071 746 68,410 19.4 %
Total Annualized Revenues$249,115 $41,861 $42,761 $18,776 $352,513 100.0 %
We believe that all of our properties are adequately covered by insurance and are suitable for their intended uses as described in “Business—Portfolio of Healthcare Investments” in Part I, Item 1.
29


Occupancy Trends
The following table sets forth the occupancy percentages for our properties for the periods indicated:
Occupancy Percentage (1)
2023202220212020
2019 (2)
Skilled Nursing/Transitional Care76.4 %73.5 %71.4 %77.3 %82.1 %
Senior Housing - Leased90.0 %84.4 %78.1 %83.1 %87.0 %
Behavioral Health81.1 %84.0 %84.2 %83.5 %83.5 %
Specialty Hospitals and Other79.4 %77.4 %80.6 %76.5 %71.5 %
Senior Housing - Managed81.6 %82.1 %79.4 %80.0 %87.7 %
(1)    Occupancy percentage represents the facilities’ average operating occupancy for the period indicated and is calculated by dividing the actual census from the period presented by the available beds/units for the same period. Occupancy percentage includes only facilities owned by Sabra as of the end of the respective period for the duration that such facilities were classified as stabilized facilities and excludes facilities for which data is not available or meaningful. Occupancy is only included in periods subsequent to our acquisition and is presented for the trailing twelve month period and one quarter in arrears, except for Senior Housing - Managed, which is presented for the period indicated on a trailing three month basis. All facility financial performance information was provided by, or derived solely from information provided by, our tenants and operators without independent verification by us.
(2)    Reflects occupancy prior to the COVID-19 pandemic.
You should not rely upon occupancy percentages, either individually or in the aggregate, to determine the performance of a facility. Other factors that may impact the performance of a facility include the sources of payment, terms of reimbursement and the acuity level of the patients (i.e., the condition of patients that determines the level of skilled nursing and rehabilitation therapy services required).
See “Business—Portfolio of Healthcare Investments” in Part I, Item 1 for further discussion regarding the ownership of our properties and the types of healthcare facilities that comprise our properties.
Secured Indebtedness
As of each of December 31, 2023 and 2022, eight of our properties held for investment were subject to secured indebtedness to third parties. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources—Secured Indebtedness” in Part II, Item 7 for further discussion regarding our secured indebtedness. As of December 31, 2023 and 2022, our secured debt consisted of the following (dollars in thousands):
Principal Balance as of December 31, (1)
Weighted Average Effective Interest Rate at December 31, (2)
Interest Rate Type2023202220232022Maturity Date
Fixed Rate$48,143 $50,123 3.34 %3.33 %May 2031 - 
August 2051
(1)    Principal balance does not include deferred financing costs, net of $0.8 million and $0.9 million as of December 31, 2023 and 2022, respectively.
(2)    Weighted average effective interest rate includes private mortgage insurance.
Corporate Office
We are headquartered and have our corporate office in Tustin, California. We lease our corporate office from an unaffiliated third party.

ITEM 3. LEGAL PROCEEDINGS
For a description of our legal proceedings, see Note 15, “Commitments and Contingencies—Legal Matters” in the Notes to Consolidated Financial Statements included in this Annual Report on Form 10-K, which is incorporated by reference in response to this item.

ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.

30



PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
Stockholder Information
Our common stock is listed on The Nasdaq Stock Market LLC and trades on the Nasdaq Global Select Market under the symbol “SBRA.”
At February 20, 2024, we had approximately 4,044 stockholders of record.
We did not repurchase any shares of our common stock during the quarter ended December 31, 2023 or issue any shares of our common stock in a transaction that was not registered under the Securities Act of 1933.
To maintain REIT status, we are required each year to distribute to stockholders at least 90% of our annual REIT taxable income after certain adjustments. All distributions will be made by us at the discretion of our board of directors and will depend on our financial position, results of operations, cash flows, capital requirements, debt covenants (which include limits on distributions by us), applicable law, and other factors as our board of directors deems relevant. For example, while the Senior Notes Indentures and the Credit Agreement permit us to declare and pay any dividend or make any distribution that is necessary to maintain our REIT status, those distributions are subject to certain financial tests under the Senior Notes Indentures, and therefore, the amount of cash distributions we can make to our stockholders may be limited.
Distributions with respect to our common stock can be characterized for federal income tax purposes as taxable ordinary dividends, which may be non-qualified, long-term capital gain, or qualified, non-dividend distributions (return of capital) or a combination thereof. Following is the characterization of our annual cash dividends on common stock per share:
Year Ended December 31,
Common Stock202320222021
Non-qualified ordinary dividends$0.6837 $0.8742 $0.6250 
Non-dividend distributions0.5163 0.3258 0.5750 
$1.2000 $1.2000 $1.2000 
31


Stock Price Performance Graph
The following graph compares the cumulative total stockholder return of our common stock for the five-year period ending December 31, 2023.
The graph below assumes that $100 was invested at the close of market on December 31, 2018 in (i) our common stock, (ii) the Nasdaq Composite Index and (iii) the Nareit Health Care Property Sector Total Return Index and assumes the reinvestment of all dividends. Stock price performances shown in the graph are not necessarily indicative of future price performances.
Stock Chart 12.31.23.jpg
The above performance graph shall not be deemed to be soliciting material or to be filed with the SEC under the Securities Act of 1933 or the Securities Exchange Act of 1934 or incorporated by reference in any document as filed.

32


ITEM 6. RESERVED

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The discussion below contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those which are discussed in Part I, Item 1A, “Risk Factors.” Also see “Statement Regarding Forward-Looking Statements” preceding Part I.
The following discussion and analysis should be read in conjunction with our accompanying consolidated financial statements and the notes thereto.
Our Management’s Discussion and Analysis of Financial Condition and Results of Operations is organized as follows:
Overview
Critical Accounting Policies and Estimates
Recently Issued Accounting Standards Update
Results of Operations
Liquidity and Capital Resources
Concentration of Credit Risk
Skilled Nursing Facility Reimbursement Rates
Overview
We expect to grow our investment portfolio while diversifying our portfolio by tenant, facility type and geography within the healthcare sector. We plan to achieve these objectives primarily through making investments directly or indirectly in healthcare real estate, including the development of purpose-built healthcare facilities with select developers. We also intend to achieve our objective of diversifying our portfolio by tenant and facility type through select asset sales and other arrangements with our tenants.
Market Trends and Uncertainties
Our operations have been and are expected to continue to be impacted by economic and market conditions. Increases in interest rates, labor shortages, supply chain disruptions, high inflation and increased volatility in public equity and fixed income markets have led to increased costs and limited the availability of capital.
The above factors, together with the impact of COVID-19, have resulted in decreased occupancy and increased operating costs for our tenants and borrowers, which have negatively impacted their operating results and may adversely impact their ability to make full and timely rental payments and debt service payments, respectively, to us. Our Senior Housing - Managed portfolio has been similarly impacted, and we expect that decreased occupancy and increased operating costs will continue to negatively impact the operating results of these investments. While our tenants, borrowers and Senior Housing - Managed portfolio have experienced increases in occupancy, certain of those occupancy rates are still below pre-pandemic levels. Similarly, while our tenants, borrowers and Senior Housing - Managed portfolio have more recently experienced small, incremental improvements in both labor availability and overall labor costs, labor supply remains lower and costs remain higher than pre-pandemic levels. In some cases, we may have to restructure or temporarily defer tenants’ long-term rent obligations and may not be able to do so on terms that are as favorable to us as those currently in place. Reduced or modified rental and debt service amounts could result in the determination that the full amounts of our investments are not recoverable, which could result in an impairment charge. If our tenants and borrowers default on these obligations, such defaults could materially and adversely affect our results of operations and liquidity, in addition to resulting in potential impairment charges. Further, prolonged deterioration in the operating results for our investments in our Senior Housing - Managed portfolio could result in the determination that the full amounts of our investments are not recoverable, which could result in an impairment charge.
We regularly monitor the effects of economic and market conditions on our operations and financial position, as well as on the operations and financial position of our tenants and borrowers, in order to respond and adapt to the ongoing changes in our operating environment. See Part I, Item 1A, “Risk Factors” for additional discussion of these risks, as well as the uncertainties we and our tenants and borrowers may face as a result.
33


Investment in Unconsolidated Joint Venture
During the year ended December 31, 2023, our joint venture with Marlin Spring (the “Marlin Spring Joint Venture”) completed the acquisition of one additional senior housing community with a gross investment of CAD $30.0 million, excluding acquisition costs. In addition, the Marlin Spring Joint Venture assumed and financed an aggregate CAD $23.6 million of debt associated with the additional acquisition. Our equity investment in the additional acquisition was CAD $6.1 million. See Note 4, “Investment in Real Estate Properties—Investment in Unconsolidated Joint Ventures,” in the Notes to Consolidated Financial Statements for additional information regarding this investment.
Acquisitions
During the year ended December 31, 2023, we acquired two skilled nursing/transitional care facilities, one Senior Housing - Leased community and one Senior Housing - Managed community for aggregate consideration of $90.4 million, including acquisition costs. See Note 3, “Recent Real Estate Acquisitions,” in the Notes to Consolidated Financial Statements for additional information regarding these acquisitions.
Dispositions
During the year ended December 31, 2023, we completed the sale of 25 skilled nursing/transitional care facilities (including one leased to a tenant under a sales-type lease) and four senior housing communities for aggregate consideration, net of closing costs, of $281.2 million. The net carrying value of the assets and liabilities of these facilities was $357.8 million, which resulted in an aggregate $76.6 million net loss on sale. We continue to evaluate additional assets for sale as part of our initiative to recycle capital and further improve our portfolio.
Credit Agreement
Effective on January 4, 2023, we and certain of our subsidiaries entered into the Credit Agreement. See “—Liquidity and Capital Resources—Material Cash Requirements—Credit Agreement.”
At-The-Market Common Stock Offering Program
On February 23, 2023, we established the ATM Program (as defined below) pursuant to which shares of our common stock having an aggregate gross sales price of up to $500.0 million may be sold from time to time. See “—Liquidity and Capital Resources.”
Critical Accounting Policies and Estimates
Below is a discussion of the accounting policies that management considers critical in that they involve significant management judgments and assumptions, require estimates about matters that are inherently uncertain and because they are important for understanding and evaluating our reported financial results. These judgments affect the reported amounts of assets and liabilities and our disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. With different estimates or assumptions, materially different amounts could be reported in our financial statements. Additionally, other companies may utilize different estimates that may impact the comparability of our results of operations to those of companies in similar businesses. For more information regarding our critical accounting policies, see Note 2, “Summary of Significant Accounting Policies,” in the Notes to Consolidated Financial Statements.
Variable Interest Entities
U.S. generally accepted accounting principles (“GAAP”) requires us to identify entities for which control is achieved through voting rights or other means and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). A VIE is broadly defined as an entity with one or more of the following characteristics: (a) the total equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (b) as a group, the holders of the equity investment at risk lack (i) the ability to make decisions about the entity’s activities through voting or similar rights, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity; or (c) the equity investors have voting rights that are not proportional to their economic interests, and substantially all of the entity’s activities either involve, or are conducted on behalf of, an investor that has disproportionately few voting rights. If we were determined to be the primary beneficiary of the VIE, we would consolidate investments in the VIE. We may change our original assessment of a VIE due to events such as modifications of contractual arrangements that affect the characteristics or adequacy of the entity’s equity investments at risk and the disposal of all or a portion of an interest held by the primary beneficiary.
34


We identify the primary beneficiary of a VIE as the enterprise that has both: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. We perform this analysis on an ongoing basis.
As it relates to investments in loans, in addition to our assessment of VIEs and whether we are the primary beneficiary of those VIEs, we evaluate the loan terms and other pertinent facts to determine whether the loan investment should be accounted for as a loan or as a real estate joint venture. If an investment has the characteristics of a real estate joint venture, including if we participate in the majority of the borrower’s expected residual profit, we would account for the investment as an investment in a real estate joint venture and not as a loan investment. Expected residual profit is defined as the amount of profit, whether called interest or another name, such as an equity kicker, above a reasonable amount of interest and fees expected to be earned by a lender.
As it relates to investments in joint ventures, we assess any partners’ rights and their impact on the presumption of control of the partnership by any single partner. We also apply this guidance to managing member interests in limited liability companies. We reassess our determination of which entity controls the joint venture if: there is a change to the terms or in the exercisability of the rights of any partners or members, the general partner or managing member increases or decreases its ownership interests, or there is an increase or decrease in the number of outstanding ownership interests.
Real Estate Investments and Rental Revenue Recognition
Real Estate Acquisition Valuation
All assets acquired and liabilities assumed in an acquisition of real estate accounted for as a business combination are measured at their acquisition date fair values. For acquisitions of real estate accounted for as an asset acquisition, the fair value of consideration transferred by us (including transaction costs) is allocated to all assets acquired and liabilities assumed on a relative fair value basis. Tangible assets consist primarily of land, building and improvements. Identifiable intangible assets primarily consist of the above market component of in-place leases, tenant origination and absorption costs and tenant relationship intangibles, and identifiable intangible liabilities primarily consist of the below market component of in-place leases. Acquisition costs associated with real estate acquisitions deemed asset acquisitions are capitalized, and costs associated with real estate acquisitions deemed business combinations are expensed as incurred.
Estimates of the fair values of the tangible assets, identifiable intangibles and assumed liabilities require us to make significant assumptions to estimate market lease rates, property operating expenses, carrying costs during lease-up periods, discount rates, market absorption periods, and the number of years the property will be held for investment. We make our best estimate based on our evaluation of the specific characteristics of each tenant’s lease. The use of inappropriate assumptions would result in an incorrect valuation of our acquired tangible assets, identifiable intangibles and assumed liabilities, which would impact the amount of our net income.
Impairment of Real Estate Investments
We regularly monitor events and changes in circumstances, including investment operating performance and general market conditions, that could indicate that the carrying amounts of our real estate investments may not be recoverable. When indicators of potential impairment suggest that the carrying value of real estate investments may not be recoverable, we assess the recoverability by estimating whether we will recover the carrying value of our real estate investments through the undiscounted future cash flows and the eventual disposition of the investment. In some instances, there may be various potential outcomes for an investment and its potential undiscounted future cash flows. In these instances, the undiscounted future cash flows models used to assess recoverability are based on several assumptions and are probability-weighted based on our best estimates as of the date of evaluation. These assumptions include, among others, market rent, revenue and expense growth rates, absorption period, stabilized occupancy, holding period, market capitalization rates, and estimated market values based on analysis of letters of intent, purchase and sale agreements and recent sales data for comparable properties. When discounted cash flow is used to determine fair value, a discount rate assumption is also used. The assumptions are generally based on management’s experience in its local real estate markets, and the effects of current market conditions, which are subject to economic and market uncertainties. If, based on this analysis, we do not believe that we will be able to recover the carrying value of our real estate investments, we would record an impairment loss to the extent that the carrying value exceeds the estimated fair value of our real estate investments. We determine estimated fair value based primarily upon (i) estimated sale prices from signed contracts or letters of intent from third-party offers, (ii) discounted cash flow models of the investment over its remaining hold period, (iii) third-party appraisals and (iv) recent sales data for comparable properties.
35


Revenue Recognition
We recognize rental revenue from tenants, including rental abatements, lease incentives and contractual fixed increases attributable to operating leases, on a straight-line basis over the term of the related leases when it is probable that substantially all rents over the life of a lease are collectible. Certain of our leases provide for contingent rents equal to a percentage of the facility’s revenue in excess of specified base amounts or other thresholds. Such revenue is recognized when actual results reported by the tenant, or estimates of tenant results, exceed the applicable base amount or other threshold.
We assess the collectability of rents on a lease-by-lease basis, and in doing so, consider such things as historical bad debts, tenant creditworthiness, current economic trends, facility operating performance, lease structure, credit enhancements (including guarantees), current developments relevant to a tenant’s business specifically and to its business category generally, and changes in tenants’ payment patterns. Our assessment includes an estimation of a tenant’s ability to fulfill all of its rental obligations over the remaining lease term. In addition, with respect to tenants in bankruptcy, management makes estimates of the expected recovery of pre-petition and post-petition claims in assessing the estimated collectability of the related receivable. If at any time we cannot determine that it is probable that substantially all rents over the life of a lease are collectible, rental revenue will be recognized only to the extent of payments received, and all receivables associated with the lease will be written off irrespective of amounts expected to be collectible. Any recoveries of these amounts will be recorded in future periods upon receipt of payment. Write-offs of receivables and any recoveries of previously written-off receivables are recorded as adjustments to rental revenue.
Revenue from resident fees and services is recorded monthly as services are provided and includes resident room and care charges, ancillary services charges and other resident charges.
Investment in Unconsolidated Joint Ventures
We report investments in unconsolidated entities over whose operating and financial policies we have the ability to exercise significant influence under the equity method of accounting. Under this method of accounting, our share of the investee’s earnings or losses is included in our consolidated statements of income (loss). The initial carrying value of the investment is based on the amount paid to purchase the joint venture interest. Differences between our cost basis and the basis reflected at the joint venture level are generally amortized over the lives of the related assets and liabilities, and such amortization is included in our share of earnings of the joint venture. In addition, distributions received from unconsolidated entities are classified based on the nature of the activity or activities that generated the distribution.
We regularly monitor events and changes in circumstances, including investment operating performance, changes in anticipated holding period and general market conditions, that could indicate that the carrying amounts of our equity method investments may be impaired. An equity method investment’s value is impaired when the fair value of the investment is less than its carrying value and we determine the decline in value is other-than-temporary. The fair value is estimated based on discounted cash flows models that include all estimated cash inflows and outflows and any estimated debt premiums or discounts. The discounted cash flows are based on several assumptions, including management fee, absorption period, terminal capitalization rates, revenue and expense per bed, revenue and expense growth percentage, replacement reserve per unit, stabilized occupancy, stabilized operating margin, price per bed and discount rates. The assumptions are generally based on management’s experience in its local real estate markets, and the effects of current market conditions, which are subject to economic and market uncertainties. If we believe that there is an other-than-temporary decline in the value of an equity method investment, we would record an impairment loss to the extent that the carrying value exceeds the estimated fair value of such equity method investment.
Loans Receivable and Credit Losses
Loans Receivable
Loans receivable are reflected at amortized cost on our consolidated balance sheets. The amortized cost of a loan receivable is the outstanding unpaid principal balance, net of unamortized discounts, costs and fees directly associated with the origination of the loan.
Loans acquired in connection with a business combination are recorded at their acquisition date fair value. We determine the fair value of loans receivable based on estimates of expected discounted cash flows, collateral, credit risk and other factors. A valuation allowance is not established at the acquisition date, as the amount of estimated future cash flows reflects our judgment regarding their uncertainty. The difference between the acquisition date fair value and the total expected cash flows is recognized as interest income using the effective interest method over the life of the applicable loan. Any unamortized balances are immediately recognized in income if the loan is repaid before its contractual maturity.
36


Interest income on our loans receivable is recognized on an accrual basis over the life of the investment using the interest method. Direct loan origination costs are amortized over the term of the loan as an adjustment to interest income. When concerns exist as to the ultimate collection of principal or interest due under a loan, the loan is placed on nonaccrual status, and we will not recognize interest income until the cash is received, or the loan returns to accrual status. If we determine that the collection of interest according to the contractual terms of the loan or through the receipts of assets in satisfaction of contractual amounts due is probable, we will resume the accrual of interest. In instances where borrowers are in default under the terms of their loans, we may continue recognizing interest income provided that all amounts owed under the contractual terms of the loan, including accrued and unpaid interest, do not exceed the estimated fair value of the collateral, less costs to sell.
On a quarterly basis, we evaluate the collectability of our interest income receivable and establish a reserve for amounts not expected to be collected. Our evaluation includes reviewing credit quality indicators such as payment status, changes affecting the operations of the facilities securing the loans, and national and regional economic factors. The reserve is a valuation allowance that reflects management’s estimate of losses inherent in the interest income receivable balance as of the balance sheet date. The reserve is adjusted through provision for loan losses and other reserves on our consolidated statements of income (loss) and is decreased by charge-offs to specific receivables.
Credit Losses
On a quarterly basis, we evaluate the collectability of our loan portfolio, including the portion of unfunded loan commitments expected to be funded, and establish an allowance for credit losses. The allowance for credit losses is calculated using the related amortization schedules, payment histories and loan-to-value ratios. The following rates are applied to determine the aggregate expected losses, which is recorded as the allowance for credit losses: (i) a default rate, (ii) a liquidation cost rate and (iii) a distressed property reduction rate. If no loan-to-value ratio is available, a loss severity rate is applied in place of the liquidation cost rate and the distressed property reduction rate. The default rate is based on average charge-off and delinquency rates from the Federal Reserve, and the other rates are based on industry research and historical performance of a similar portfolio of financial assets. The allowance for credit losses is a valuation allowance that reflects management’s estimate of losses inherent in the loan portfolio as of the balance sheet date. The reserve is adjusted through provision for loan losses and other reserves on our consolidated statements of income (loss) and is decreased by charge-offs to specific loans.
Preferred Equity Investments and Preferred Return
Preferred equity investments are accounted for at unreturned capital contributions, plus accrued and unpaid preferred returns. We recognize preferred return income on a monthly basis based on the outstanding investment including any previously accrued and unpaid return. As a preferred member of the preferred equity joint ventures in which we participate, we are not entitled to share in the joint venture’s earnings or losses. Rather, we are entitled to receive a preferred return, which is deferred if the cash flow of the joint venture is insufficient to currently pay the accrued preferred return.
We regularly monitor events and changes in circumstances that could indicate that the carrying amounts of our preferred equity investments may not be recoverable or realized. On a quarterly basis, we evaluate our preferred equity investments for impairment based on a comparison of the fair value of the investment to its carrying value. The fair value is estimated based on discounted cash flows that include all estimated cash inflows and outflows over a specified holding period. If, based on this analysis, we do not believe that we will be able to recover the carrying value of our preferred equity investment, we would record an impairment loss to the extent that the carrying value exceeds the estimated fair value of our preferred equity investment.
Income Taxes
We elected to be treated as a REIT with the filing of our U.S. federal income tax return for the taxable year beginning January 1, 2011. We believe that we have been organized and have operated, and we intend to continue to operate, in a manner to qualify as a REIT. To qualify as a REIT, we must meet certain organizational and operational requirements, including a requirement to distribute at least 90% of our annual REIT taxable income to stockholders (which is computed without regard to the dividends-paid deduction or net capital gains and which does not necessarily equal net income as calculated in accordance with GAAP). As a REIT, we generally will not be subject to federal income tax on income that we distribute as dividends to our stockholders. If we fail to qualify as a REIT in any taxable year, we will be subject to U.S. federal income tax on our taxable income at regular corporate income tax rates and generally will not be permitted to qualify for treatment as a REIT for federal income tax purposes for the four taxable years following the year during which qualification is lost, unless the IRS grants us relief under certain statutory provisions. Such an event could materially and adversely affect our net income and net cash available for distribution to stockholders. However, we believe that we are organized and operate in such a manner as to qualify for treatment as a REIT.
37


As a result of certain investments, we record income tax expense or benefit with respect to certain of our entities that are taxed as taxable REIT subsidiaries under provisions similar to those applicable to regular corporations and not under the REIT provisions.
We account for deferred income taxes using the asset and liability method and recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in our financial statements or tax returns. Under this method, we determine deferred tax assets and liabilities based on the differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Any increase or decrease in the deferred tax liability that results from a change in circumstances, and that causes a change in our judgment about expected future tax consequences of events, is included in the tax provision when such changes occur. Deferred income taxes also reflect the impact of operating loss and tax credit carryforwards. A valuation allowance is provided if we believe it is more likely than not that all or some portion of the deferred tax asset will not be realized. Any increase or decrease in the valuation allowance that results from a change in circumstances, and that causes a change in our judgment about the realizability of the related deferred tax asset, is included in the tax provision when such changes occur.
We evaluate our tax positions using a two-step approach: step one (recognition) occurs when we conclude that a tax position, based solely on its technical merits, is more likely than not to be sustained upon examination, and step two (measurement) is only addressed if step one has been satisfied (i.e., the position is more likely than not to be sustained). Under step two, the tax benefit is measured as the largest amount of benefit (determined on a cumulative probability basis) that is more likely than not to be realized upon ultimate settlement. We will recognize tax penalties relating to unrecognized tax benefits as additional tax expense.
Fair Value Measurements
Under GAAP, we are required to measure certain financial instruments at fair value on a recurring basis. In addition, we are required to measure other financial instruments and balances at fair value on a non-recurring basis (e.g., carrying value of impaired loans receivable and long-lived assets). Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The GAAP fair value framework uses a three-tiered approach. Fair value measurements are classified and disclosed in one of the following three categories:
Level 1: unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities;
Level 2: quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which significant inputs and significant value drivers are observable in active markets; and
Level 3: prices or valuation techniques where little or no market data is available that requires inputs that are both significant to the fair value measurement and unobservable.
When available, we utilize quoted market prices from an independent third-party source to determine fair value and classify such items in Level 1 or Level 2. In instances where the market for a financial instrument is not active, regardless of the availability of a nonbinding quoted market price, observable inputs might not be relevant and could require us to make a significant adjustment to derive a fair value measurement. Additionally, in an inactive market, a market price quoted from an independent third party may rely more on models with inputs based on information available only to that independent third party. When we determine the market for a financial instrument owned by us to be illiquid or when market transactions for similar instruments do not appear orderly, we may use several valuation sources (including internal valuations, discounted cash flow analysis and quoted market prices) to establish a fair value. If more than one valuation source is used, we will assign weights to the various valuation sources. Additionally, when determining the fair value of liabilities in circumstances in which a quoted price in an active market for an identical liability is not available, we measure fair value using (i) a valuation technique that uses the quoted price of the identical liability when traded as an asset or quoted prices for similar liabilities or similar liabilities when traded as assets or (ii) another valuation technique that is consistent with the principles of fair value measurement, such as the income approach or the market approach.
Changes in assumptions or estimation methodologies can have a material effect on these estimated fair values. In this regard, the derived fair value estimates cannot be substantiated by comparison to independent markets and, in many cases, may not be realized in an immediate settlement of the instrument.
We consider the following factors to be indicators of an inactive market: (i) there are few recent transactions, (ii) price quotations are not based on current information, (iii) price quotations vary substantially either over time or among market makers (for example, some brokered markets), (iv) indexes that previously were highly correlated with the fair values of the asset or liability are demonstrably uncorrelated with recent indications of fair value for that asset or liability, (v) there is a
38


significant increase in implied liquidity risk premiums, yields, or performance indicators (such as delinquency rates or loss severities) for observed transactions or quoted prices when compared with our estimate of expected cash flows, considering all available market data about credit and other nonperformance risk for the asset or liability, (vi) there is a wide bid-ask spread or significant increase in the bid-ask spread, (vii) there is a significant decline or absence of a market for new issuances (that is, a primary market) for the asset or liability or similar assets or liabilities, and (viii) little information is released publicly (for example, a principal-to-principal market).
We consider the following factors to be indicators of non-orderly transactions: (i) there was not adequate exposure to the market for a period before the measurement date to allow for marketing activities that are usual and customary for transactions involving such assets or liabilities under current market conditions, (ii) there was a usual and customary marketing period, but the seller marketed the asset or liability to a single market participant, (iii) the seller is in or near bankruptcy or receivership (that is, distressed), or the seller was required to sell to meet regulatory or legal requirements (that is, forced), and (iv) the transaction price is an outlier when compared with other recent transactions for the same or similar assets or liabilities.
Recently Issued Accounting Standards Update
See Note 2, “Summary of Significant Accounting Policies,” in the Notes to Consolidated Financial Statements for information concerning recently issued accounting standards updates.
Results of Operations
As of December 31, 2023, our investment portfolio consisted of 378 real estate properties held for investment, 14 investments in loans receivable, five preferred equity investments and two investments in unconsolidated joint ventures. As of December 31, 2022, our investment portfolio consisted of 402 real estate properties held for investment, one investment in a sales-type lease, 12 investments in loans receivable, seven preferred equity investments and three investments in unconsolidated joint ventures. In general, we expect that income and expenses related to our portfolio will fluctuate in future periods in comparison to the corresponding prior periods as a result of investment and disposition activity and anticipated future changes in our portfolio. The results of operations presented are not directly comparable due to ongoing acquisition and disposition activity, including our capital recycling initiative.
A discussion of our results of operations for the year ended December 31, 2021 is included in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Results of Operations—Comparison of results of operations for the years ended December 31, 2022 and 2021” section in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2022.
39


Comparison of results of operations for the years ended December 31, 2023 and 2022 (dollars in thousands):
For the Year Ended December 31,Increase / (Decrease)Percentage Difference
Variance due to Acquisitions, Originations and Dispositions (1)
Remaining Variance (2)
20232022
Revenues:
Rental and related revenues$376,266 $400,586 $(24,320)(6)%$(17,315)$(7,005)
Resident fees and services236,153 186,672 49,481 27 %19,352 30,129 
Interest and other income35,095 37,553 (2,458)(7)%(3,508)1,050 
Expenses:
Depreciation and amortization183,087 187,782 (4,695)(3)%(6,647)1,952 
Interest112,964 105,471 7,493 %— 7,493 
Triple-net portfolio operating expenses17,932 19,623 (1,691)(9)%(1,220)(471)
Senior housing - managed portfolio operating expenses177,313 142,990 34,323 24 %11,266 23,057 
General and administrative47,472 39,574 7,898 20 %— 7,898 
Provision for loan losses and other reserves191 141 50 35 %232 (182)
Impairment of real estate14,332 94,042 (79,710)(85)%(86,978)7,268 
Other (expense) income:
Loss on extinguishment of debt(1,541)(411)(1,130)275 %— (1,130)
Other income (expense)2,598 (1,097)3,695 (337)%— 3,695 
Net loss on sales of real estate(76,625)(12,011)(64,614)538 %(64,614)— 
Loss from unconsolidated joint ventures(2,897)(98,032)95,135 (97)%95,135 — 
Income tax expense(2,002)(1,242)(760)61 %— (760)
(1)    Represents the dollar amount increase (decrease) for the year ended December 31, 2023 compared to the year ended December 31, 2022 as a result of investments/dispositions made after January 1, 2022.
(2)    Represents the dollar amount increase (decrease) for the year ended December 31, 2023 compared to the year ended December 31, 2022 that is not a direct result of investments/dispositions made after January 1, 2022.
Rental and Related Revenues
During the year ended December 31, 2023, we recognized $376.3 million of rental income compared to $400.6 million for the year ended December 31, 2022. The $24.3 million net decrease in rental income is related to (i) a $19.5 million decrease from properties disposed of after January 1, 2022, (ii) a $10.1 million decrease from properties that were transitioned to new operators, (iii) a $7.9 million decrease in earned cash rents and operating expense recoveries related to leases that are no longer accounted for on an accrual basis, (iv) a $7.4 million decrease in Genesis excess rents in accordance with the terms of the memorandum of understanding entered into in 2017 and (v) a $1.3 million decrease from facilities transitioned from triple-net lease to Senior Housing - Managed communities. These decreases are partially offset by (i) a $15.6 million decrease in straight-line rental income receivable write-offs primarily due to the termination of the North American leases in 2022, (ii) a $3.5 million increase due to lease amendments and annual rental increases based on changes in the Consumer Price Index, (iii) a $2.2 million increase from properties acquired after January 1, 2022 and (iv) a $1.1 million increase due to incremental revenue related to capital expenditures.
Our reported rental and related revenues may be subject to increased variability in the future as a result of lease accounting standards. If at any time we cannot determine that it is probable that substantially all rents over the life of a lease are collectible, rental revenue will be recognized only to the extent of payments received and all receivables associated with the lease will be written off, irrespective of amounts expected to be collectible. However, there can be no assurances regarding the timing and amount of these revenues. Amounts due under the terms of all of our lease agreements are subject to contractual increases, and contingent rental income may be derived from certain lease agreements. No material contingent rental income was derived during the years ended December 31, 2023 and 2022.
Our rental income in future years will be impacted by changes in inflation. Certain of our lease agreements provide for an annual rent escalator based on the percentage change in the Consumer Price Index (but not less than zero), subject to minimum or maximum fixed percentages that range from 1.0% to 5.0%.
40


Resident Fees and Services
During the year ended December 31, 2023, we recognized $236.2 million of resident fees and services compared to $186.7 million for the year ended December 31, 2022. The $49.5 million increase is due to (i) a $23.6 million increase related to nine facilities that were transitioned to Senior Housing - Managed communities after January 1, 2022, (ii) a $20.9 million increase from four Senior Housing - Managed communities acquired after January 1, 2022 and (iii) a $10.3 million increase related to increased occupancy and an increase in rates. These increases are partially offset by a $3.8 million decrease related to one community that was closed due to a fire and a $1.5 million decrease related to one Senior Housing - Managed community disposed of after January 1, 2022.
Interest and Other Income
Interest and other income primarily consists of income earned on our loans receivable investments and preferred returns earned on our preferred equity investments. During the year ended December 31, 2023, we recognized $35.1 million of interest and other income compared to $37.6 million for the year ended December 31, 2022. The net decrease of $2.5 million is due to a $4.0 million decrease in income from investments repaid after January 1, 2022 and $2.5 million lease termination payments primarily related to one skilled nursing/transitional care facility that sold in 2022, partially offset by (i) a $2.8 million increase from investments made after January 1, 2022, (ii) a $0.6 million increase due to increased fundings for existing investments and (iii) a $0.6 million increase in bank interest income.
Depreciation and Amortization
During the year ended December 31, 2023, we incurred $183.1 million of depreciation and amortization expense compared to $187.8 million for the year ended December 31, 2022. The $4.7 million net decrease is due to a $12.9 million decrease from properties disposed of after January 1, 2022 and an $8.8 million decrease due to assets that have been fully depreciated. The decreases are offset by (i) a $7.7 million increase due to accelerating the remaining useful life of a facility that was demolished, (ii) a $6.3 million increase from properties acquired after January 1, 2022 and (iii) a $3.0 million increase from additions to real estate.
Interest Expense
We incur interest expense comprised of costs of borrowings plus the amortization of deferred financing costs related to our indebtedness. During the year ended December 31, 2023, we incurred $113.0 million of interest expense compared to $105.5 million for the year ended December 31, 2022. The $7.5 million net increase is primarily related to borrowings outstanding under the Credit Agreement and an increase in interest rates.
Triple-Net Portfolio Operating Expenses
During the year ended December 31, 2023, we recognized $17.9 million of triple-net portfolio operating expenses compared to $19.6 million for the year ended December 31, 2022. The $1.7 million net decrease is related to a $1.2 million decrease due to properties disposed of after January 1, 2022, a $0.8 million net decrease due to facilities that have since transitioned to new operators who are now paying the property taxes directly and the remaining change is due to adjusting our estimates related to property taxes.
Senior Housing - Managed Portfolio Operating Expenses
During the year ended December 31, 2023, we recognized $177.3 million of Senior Housing - Managed portfolio operating expenses compared to $143.0 million for the year ended December 31, 2022. The $34.3 million net increase is due to (i) a $22.3 million increase related to nine facilities that were transitioned to Senior Housing - Managed communities after January 1, 2022, (ii) a $12.9 million increase related to four Senior Housing - Managed communities acquired after January 1, 2022, (iii) a $1.5 million increase in employee compensation primarily due to increased labor rates and staffing and (iv) a $0.6 million increase in dining expenses primarily due to increased occupancy. These increases are partially offset by a $2.2 million decrease in operating expenses related to one community that was closed due to a fire and a $1.7 million decrease related to one Senior Housing - Managed community disposed of after January 1, 2022.
General and Administrative Expenses
General and administrative expenses include compensation-related expenses as well as professional services, office costs, other costs associated with asset management, and merger and acquisition costs. During the year ended December 31, 2023, general and administrative expenses were $47.5 million compared to $39.6 million during the year ended December 31, 2022. The $7.9 million net increase is related to (i) a $6.7 million increase in compensation, including a $0.5 increase in stock-based compensation, for our teammates as a result of changes in performance-based payout assumptions on management
41


compensation, increased staffing and annual salary adjustments, (ii) a $0.7 million increase in insurance premiums and (iii) a $0.4 million increase in conference and travel expenses primarily related to the 2023 Sabra operator conference.
Provision for Loan Losses and Other Reserves
During the years ended December 31, 2023 and 2022, we recognized a $0.2 million and $0.1 million provision for loan losses and other reserves, respectively, associated with our loans receivable investments and sales-type lease that was terminated in March 2023.
Impairment of Real Estate
During the year ended December 31, 2023, we recognized $14.3 million of impairment of real estate related to three skilled nursing/transitional care facilities that have either sold or are closed. During the year ended December 31, 2022, we recognized $94.0 million of impairment of real estate related to ten skilled nursing/transitional care facilities that have sold.
Loss on Extinguishment of Debt
During the year ended December 31, 2023, we recognized a $1.5 million loss on extinguishment of debt related to write-offs of deferred financing costs in connection with amending and restating the fifth amended and restated unsecured credit agreement entered into by the Operating Partnership and Sabra Canadian Holdings, LLC and the other parties thereto on September 9, 2019 (“Prior Credit Agreement”). During the year ended December 31, 2022, we recognized a $0.4 million loss on extinguishment of debt related to write-offs of deferred financing costs in connection with the partial pay downs of the U.S. dollar term loan (“Prior Term Loan”) under our Prior Credit Agreement.
Other Income (Expense)
During the year ended December 31, 2023, we recognized $2.6 million of other income related to (i) a $3.7 million gain on insurance proceeds received related to property damage incurred at a vacant facility, (ii) $0.5 million of business interruption insurance income related to one Senior Housing - Managed community that was closed due to a fire and (iii) $0.3 million of income related to the sale of licensed beds. This income is partially offset by $1.5 million of transition-related expenses related to the transition of 14 Senior Housing - Managed communities to new operators in 2023. During the year ended December 31, 2022, we recognized $1.1 million of other expense consisting of a $2.2 million foreign currency transaction loss related to our Canadian borrowings, partially offset by $1.1 million of other income related to settlement payments received related to legacy Care Capital Properties investments.
Net Loss on Sales of Real Estate
During the year ended December 31, 2023, we recognized an aggregate net loss of $76.6 million related to the disposition of 24 skilled nursing/transitional care facilities, three Senior Housing - Leased communities and one Senior Housing - Managed community. During the year ended December 31, 2022, we recognized an aggregate net loss of $12.0 million related to the disposition of 13 skilled nursing/transition care facilities and five Senior Housing - Leased communities.
Loss from Unconsolidated Joint Ventures
During the year ended December 31, 2023, we recognized $2.9 million of loss, including $8.7 million of depreciation expense and $3.9 million of interest expense, related to 16 senior housing communities acquired by two joint ventures after January 1, 2022.
During the year ended December 31, 2022, we recognized $98.0 million of loss primarily from our joint venture with affiliates of TPG Real Estate, the real estate platform of TPG (the “Enlivant Joint Venture”), including a $57.8 million other-than-temporary impairment recorded during the year ended December 31, 2022 (see Note 4, “Investment in Real Estate Properties” in the Notes to Consolidated Financial Statements for additional information regarding the impairment). Effective January 1, 2023, we discontinued applying the equity method of accounting to the Enlivant Joint Venture and no loss was recognized during the year ended December 31, 2023. Effective May 1, 2023, we withdrew and resigned our membership in the Enlivant Joint Venture and accordingly, no longer have an equity interest in the Enlivant Joint Venture as of such date. We have not guaranteed any obligations of and are not required to provide any support to the Enlivant Joint Venture.
Income Tax Expense
During the year ended December 31, 2023, we recognized $2.0 million of income tax expense compared to $1.2 million for the year ended December 31, 2022. The $0.8 million increase is due to higher taxable income.
42


Funds from Operations and Adjusted Funds from Operations
We believe that net income as defined by GAAP is the most appropriate earnings measure. We also believe that funds from operations (“FFO”), as defined in accordance with the definition used by the National Association of Real Estate Investment Trusts (“Nareit”), and adjusted funds from operations (“AFFO”) (and related per share amounts) are important non-GAAP supplemental measures of our operating performance. Because the historical cost accounting convention used for real estate assets requires straight-line depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time. However, since real estate values have historically risen or fallen with market and other conditions, presentations of operating results for a REIT that use historical cost accounting for depreciation could be less informative. Thus, Nareit created FFO as a supplemental measure of operating performance for REITs that excludes historical cost depreciation and amortization, among other items, from net income, as defined by GAAP. FFO is defined as net income, computed in accordance with GAAP, excluding gains or losses from real estate dispositions and our share of gains or losses from real estate dispositions related to our unconsolidated joint ventures, plus real estate depreciation and amortization, net of amounts related to noncontrolling interests, plus our share of depreciation and amortization related to our unconsolidated joint ventures, and real estate impairment charges of both consolidated and unconsolidated entities when the impairment is directly attributable to decreases in the value of the depreciable real estate held by the entity. AFFO is defined as FFO excluding merger and acquisition costs, stock-based compensation expense, non-cash rental and related revenues, non-cash interest income, non-cash interest expense, non-cash portion of loss on extinguishment of debt, provision for loan losses and other reserves, non-cash lease termination income and deferred income taxes, as well as other non-cash revenue and expense items (including ineffectiveness gain/loss on derivative instruments, and non-cash revenue and expense amounts related to noncontrolling interests) and our share of non-cash adjustments related to our unconsolidated joint ventures. We believe that the use of FFO and AFFO (and the related per share amounts), combined with the required GAAP presentations, improves the understanding of our operating results among investors and makes comparisons of operating results among REITs more meaningful. We consider FFO and AFFO to be useful measures for reviewing comparative operating and financial performance because, by excluding the applicable items listed above, FFO and AFFO can help investors compare our operating performance between periods or as compared to other companies. While FFO and AFFO are relevant and widely used measures of operating performance of REITs, they do not represent cash flows from operations or net income as defined by GAAP and should not be considered an alternative to those measures in evaluating our liquidity or operating performance. FFO and AFFO also do not consider the costs associated with capital expenditures related to our real estate assets nor do they purport to be indicative of cash available to fund our future cash requirements. Further, our computation of FFO and AFFO may not be comparable to FFO and AFFO reported by other REITs that do not define FFO in accordance with the current Nareit definition or that interpret the current Nareit definition or define AFFO differently than we do.
43


The following table reconciles our calculations of FFO and AFFO for the years ended December 31, 2023, 2022 and 2021, to net income (loss), the most directly comparable GAAP financial measure, for the same periods (in thousands, except share and per share amounts):
Year Ended December 31,
202320222021
Net income (loss)$13,756 $(77,605)$(113,256)
Depreciation and amortization of real estate assets183,087 187,782 178,991 
Depreciation, amortization and impairment of real estate assets related to unconsolidated joint ventures8,697 22,095 26,129 
Net loss (gain) on sales of real estate76,625 12,011 (12,301)
Net (gain) loss on sales of real estate related to unconsolidated joint ventures— (220)33 
Impairment of real estate14,332 94,042 9,499 
Other-than-temporary impairment of unconsolidated joint ventures— 57,778 164,126 
FFO296,497 295,883 253,221 
Stock-based compensation expense7,917 7,453 7,914 
Non-cash rental and related revenues(8,699)2,183 25,823 
Non-cash interest income(372)(2,285)(1,988)
Non-cash interest expense12,265 11,094 8,368 
Non-cash portion of loss on extinguishment of debt1,541 411 4,426 
Provision for loan losses and other reserves191 141 3,935 
Deferred tax valuation allowance related to unconsolidated joint ventures— 19,613 — 
Other adjustments related to unconsolidated joint ventures502 (5,155)(5,051)
Other non-cash adjustments365 2,474 492 
AFFO$310,207 $331,812 $297,140 
 
FFO per diluted common share$1.27 $1.28 $1.15 
   
AFFO per diluted common share$1.33 $1.43 $1.35 
 
Weighted average number of common shares outstanding, diluted:
FFO232,792,778 231,851,542 220,102,563 
AFFO233,883,279 232,784,543 220,526,512 
 
The following table sets forth additional information related to certain other items included in net income (loss) above, and the portions of each that are included in FFO and AFFO, which may be helpful in assessing our operating results. Please refer to “—Results of Operations” above for additional information regarding these items (in millions):
Year Ended December 31,
202320222021202320222021202320222021
Net Income (Loss)FFOAFFO
Rental and related revenues:
Non-cash rental and related revenue write-offs / lease intangible amortization acceleration$2.5 $16.7 $44.0 $2.5 $16.7 $44.0 $— $— $— 
Interest and other income:
Lease termination income— 2.5 — — 2.5 — — 2.5 — 
Provision for loan losses and other reserves0.2 0.1 3.9 0.2 0.1 3.9 — — — 
Loss on extinguishment of debt1.5 0.4 34.6 1.5 0.4 34.6 — — 30.2 
Other income (expense):
Insurance income4.2 — — 4.2 — — 4.2 — — 
Other (expense) income(1.6)(1.1)0.4 (1.6)(1.1)0.4 (1.6)1.2 0.4 
44


Liquidity and Capital Resources
As of December 31, 2023, we had approximately $946.9 million in liquidity, consisting of unrestricted cash and cash equivalents of $41.3 million and available borrowings under our Revolving Credit Facility of $905.6 million. The Credit Agreement also contains an accordion feature that can increase the total available borrowings to $2.75 billion (from U.S. $1.4 billion plus CAD $150.0 million), subject to terms and conditions.
We have filed a shelf registration statement with the SEC that expires in November 2025, which allows us to offer and sell shares of common stock, preferred stock, warrants, rights, units, and certain of our subsidiaries to offer and sell debt securities, through underwriters, dealers or agents or directly to purchasers, on a continuous or delayed basis, in amounts, at prices and on terms we determine at the time of the offering, subject to market conditions.
On February 23, 2023, we established an at-the-market equity offering program (the “ATM Program”) pursuant to which shares of our common stock having an aggregate gross sales price of up to $500.0 million may be sold from time to time (i) by us through a consortium of banks acting as sales agents or directly to the banks acting as principals or (ii) by a consortium of banks acting as forward sellers on behalf of any forward purchasers pursuant to a forward sale agreement.
During the year ended December 31, 2023, no shares were sold under the ATM Program and we did not utilize the forward feature of the ATM Program. As of December 31, 2023, we had $500.0 million available under the ATM Program.
Our short-term liquidity requirements consist primarily of operating expenses, including our planned capital expenditures and funding commitments, interest expense, scheduled debt service payments under our loan agreements, dividend requirements, general and administrative expenses and other requirements described under “Material Cash Requirements” below. Based on our current assessment, we believe that our available cash, operating cash flows and borrowings available to us under our Revolving Credit Facility provide sufficient funds for such requirements for the next twelve months. In addition, we do not believe that the restrictions under our Senior Notes Indentures (as defined below) or Credit Agreement significantly limit our ability to use our available liquidity for these purposes.
Our long-term liquidity requirements consist primarily of future investments in properties, including any improvements or renovations of current or newly-acquired properties, as well as scheduled debt maturities. We expect to meet these liquidity needs using the sources above as well as the proceeds from issuances of common stock, preferred stock, debt or other securities, additional borrowings, including mortgage debt or a new or refinanced credit facility, and proceeds from the sale of properties. In addition, we may seek financing from U.S. government agencies, including through Fannie Mae, Freddie Mac and HUD, in appropriate circumstances in connection with acquisitions.
Cash Flows from Operating Activities
Net cash provided by operating activities was $300.6 million for the year ended December 31, 2023. Operating cash inflows were derived primarily from the rental payments received under our lease agreements, resident fees and services net of the corresponding operating expenses, and interest payments from borrowers under our loan and preferred equity investments. Operating cash outflows consisted primarily of interest payments on borrowings and payment of general and administrative expenses, including corporate overhead. Increases to operating cash flows primarily relate to completed investment activity, and decreases to operating cash flows primarily relate to disposition activity and interest expense from increased borrowing activity and higher interest rates. In addition, the change in operating cash flows was impacted by the timing of collections from our tenants and borrowers and fluctuations in the operating results of our Senior Housing - Managed communities. We expect our annualized cash flows provided by operating activities to fluctuate as a result of such activity.
Cash Flows from Investing Activities
During the year ended December 31, 2023, net cash provided by investing activities was $103.1 million and included $247.6 million of net proceeds from the sales of real estate, $25.5 million of net proceeds from the sale of a facility under a sales-type lease, $9.3 million in repayments of loans receivable, $5.8 million in insurance proceeds, $5.5 million in repayments of preferred equity investments and $0.5 million of distributions in excess of earnings from an unconsolidated joint venture, partially offset by $84.9 million used for additions to real estate, $78.5 million used for the acquisition of four facilities, $11.4 million used to provide funding for loans receivable, $11.0 million used to provide funding for preferred equity investments and $5.2 million used for the investment in an unconsolidated joint venture.
Cash Flows from Financing Activities
During the year ended December 31, 2023, net cash used in financing activities was $410.3 million and included $277.4 million of dividends paid to stockholders, $104.3 million of net repayments of our Revolving Credit Facility, $18.1 million of payments of deferred financing costs related to the Credit Agreement, $17.9 million of payments of contingent consideration,
45


$2.7 million of net costs related to payroll tax payments related to the issuance of common stock pursuant to equity compensation arrangements and our ATM Program and $2.0 million of principal repayments on secured debt, partially offset by $12.2 million of proceeds from Term Loans.
Please see the accompanying consolidated statements of cash flows for details of our operating, investing and financing cash activities.
Material Cash Requirements
Our material cash requirements include the following contractual and other obligations.
Senior Unsecured Notes. Our senior unsecured notes consisted of the following (collectively, the “Senior Notes”) as of December 31, 2023 (dollars in thousands):
TitleMaturity Date
Principal Balance (1)
5.125% senior unsecured notes due 2026 (the “2026 Notes”)
August 15, 2026$500,000 
5.88% senior unsecured notes due 2027 (the “2027 Notes”)
May 17, 2027100,000 
3.90% senior unsecured notes due 2029 (the “2029 Notes”)
October 15, 2029350,000 
3.20% senior unsecured notes due 2031 (the “2031 Notes”)
December 1, 2031800,000 
$1,750,000 
(1)    Principal balance does not include discount, net of $4.3 million and deferred financing costs, net of $10.5 million as of December 31, 2023.
See Note 8, “Debt,” in the Notes to Consolidated Financial Statements and “Subsidiary Issuer and Guarantor Financial Information” below for additional information concerning the Senior Notes, including information regarding the indentures and agreements governing the Senior Notes (the “Senior Notes Indentures”). As of December 31, 2023, we were in compliance with all applicable covenants under the Senior Notes Indentures.
Credit Agreement. Effective January 4, 2023, the Operating Partnership and Sabra Canadian Holdings, LLC (together, the “Borrowers”), and the other parties thereto entered into a sixth amended and restated unsecured credit agreement (the “Credit Agreement”). The Credit Agreement includes a $1.0 billion revolving credit facility (the “Revolving Credit Facility”), a $430.0 million U.S. dollar term loan and a CAD $150.0 million Canadian dollar term loan (collectively, the “Term Loans”). Further, up to $350.0 million of the Revolving Credit Facility may be used for borrowings in certain foreign currencies. The Credit Agreement also contains an accordion feature that can increase the total available borrowings to $2.75 billion, subject to terms and conditions
The Revolving Credit Facility has a maturity date of January 4, 2027, and includes two six-month extension options. The Term Loans have a maturity date of January 4, 2028.
The obligations of the Borrowers under the Credit Agreement are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by us and one of our non-operating subsidiaries, subject to release under certain customary circumstances.
See Note 8, “Debt,” in the Notes to Consolidated Financial Statements for additional information concerning the Credit Agreement, including information regarding covenants contained in the Credit Agreement. As of December 31, 2023, we were in compliance with all applicable covenants under the Credit Agreement.
Secured Indebtedness. As of December 31, 2023, eight of our properties held for investment were subject to secured indebtedness to third parties, and our secured debt consisted of the following (dollars in thousands): 
Interest Rate Type
Principal Balance (1)
Weighted Average Interest RateMaturity Date
Fixed Rate$48,143 2.85 %May 2031 - 
August 2051
(1)    Principal balance does not include deferred financing costs, net of $0.8 million as of December 31, 2023.
Interest. Our estimated interest and facility fee payments based on principal amounts of debt outstanding as of December 31, 2023, applicable interest rates in effect as of December 31, 2023, and including the impact of interest rate swaps and collars are $102.2 million in 2024, $103.5 million in 2025, $103.5 million in 2026, $66.1 million in 2027, $40.6 million in 2028 and $100.9 million thereafter.
46


Capital Expenditures and Other Expenditures and Funding Commitments. For the years ended December 31, 2023 and 2022 and 2021, our aggregate capital expenditures were $84.9 million, $54.5 million and $42.7 million, respectively. As of December 31, 2023, our aggregate commitment for future capital and other expenditures related to facilities leased under triple-net operating leases was approximately $27 million, of which $20 million will directly result in incremental rental income, and approximately $16 million will be spent over the next 12 months. We also expect to fund capital expenditures related to our Senior Housing - Managed communities.
In addition, as of December 31, 2023, we have committed to provide up to $0.5 million of future funding related to one loan receivable investment.
Dividends. To maintain REIT status, we are required each year to distribute to stockholders at least 90% of our annual REIT taxable income after certain adjustments. All distributions will be made by us at the discretion of our board of directors and will depend on our financial position, results of operations, cash flows, capital requirements, debt covenants (which include limits on distributions by us), applicable law, and other factors as our board of directors deems relevant.
We paid dividends of $277.4 million on our common stock during the year ended December 31, 2023. On February 1, 2024, our board of directors declared a quarterly cash dividend of $0.30 per share of common stock. The dividend will be paid on February 29, 2024 to common stockholders of record as of February 13, 2024.
Subsidiary Issuer and Guarantor Financial Information. In connection with the Operating Partnership’s assumption of the 2026 Notes, we have fully and unconditionally guaranteed the 2026 Notes. The 2029 Notes and 2031 Notes are issued by the Operating Partnership and guaranteed, fully and unconditionally, by us.
These guarantees are subordinated to all existing and future senior debt and senior guarantees of us, as guarantor, and are unsecured. We conduct all of our business through and derive virtually all of our income from our subsidiaries. Therefore, our ability to make required payments with respect to our indebtedness (including the Senior Notes) and other obligations depends on the financial results and condition of our subsidiaries and our ability to receive funds from our subsidiaries.
In accordance with Regulation S-X, the following aggregate summarized financial information is provided for Sabra and the Operating Partnership. This aggregate summarized financial information has been prepared from the books and records maintained by us and the Operating Partnership. The aggregate summarized financial information does not include the investments in, nor the earnings from, subsidiaries other than the Operating Partnership and therefore is not necessarily indicative of the results of operations or financial position had the Operating Partnership operated as an independent entity. Intercompany transactions have been eliminated. The aggregate summarized balance sheet information as of December 31, 2023 and 2022 and aggregate summarized statement of loss information for the year ended December 31, 2023 is as follows (in thousands):
As of December 31,
20232022
Total assets$72,730 $74,063 
Total liabilities2,272,119 2,275,511 
Year Ended December 31, 2023
Total revenues$730 
Total expenses137,422 
Net loss(139,639)
Concentration of Credit Risk
Concentrations of credit risk arise when a number of tenants or obligors related to our investments are engaged in similar business activities, or activities in the same geographic region, or have similar economic features that would cause their ability to meet contractual obligations, including those to us, to be similarly affected by changes in economic conditions. We regularly monitor our portfolio to assess potential concentrations of risks.
Management believes our current portfolio is reasonably diversified across healthcare related real estate and geographical location and does not contain any other significant concentration of credit risks. Our portfolio of 378 real estate properties held for investment as of December 31, 2023 is diversified by location across the U.S. and Canada.
For the year ended December 31, 2023, no tenant relationship represented 10% or more of our total revenues.
47


Skilled Nursing Facility Reimbursement Rates
For the year ended December 31, 2023, 42.0% of our revenues was derived directly or indirectly from skilled nursing/transitional care facilities. Medicare reimburses skilled nursing facilities for Medicare Part A services under the Prospective Payment System (“PPS”), as implemented pursuant to the Balanced Budget Act of 1997 and modified pursuant to subsequent laws, most recently the Patient Protection and Affordable Care Act of 2010. PPS regulations predetermine a payment amount per patient, per day, based on a market basket index calculated for all covered costs.
On October 1, 2019, a case-mix classification system called the skilled nursing facility Patient-Driven Payment Model (“PDPM”) became effective pursuant to a CMS final rule. PDPM focuses on clinically relevant factors, rather than volume-based service, for determining Medicare payment. PDPM adjusts Medicare payments based on each aspect of a resident’s care, most notably for non-therapy ancillaries, which are items and services not related to the provision of therapy such as drugs and medical supplies, thereby more accurately addressing costs associated with medically complex patients. It further adjusts the skilled nursing facility per diem payments to reflect varying costs throughout the stay and incorporates safeguards against potential financial incentives to ensure that beneficiaries receive care consistent with their unique needs and goals.
On July 29, 2022, CMS issued a final rule regarding fiscal year 2023 Medicare rates for skilled nursing facilities providing an estimated net increase of 2.7% compared to fiscal year 2022 comprised of an increase as a result of an update to the payment rates of 5.1% (which is based on (i) a market basket increase of 3.9% plus (ii) a market basket forecast error adjustment of 1.5% and less (iii) a productivity adjustment of 0.3%), partially offset by the recalibrated PDPM parity adjustment of 2.3% (the total PDPM parity adjustment is 4.6%, and it is being phased in over a two-year period). These figures do not incorporate any of the estimated value-based purchasing reductions for skilled nursing facilities. The new payment rates became effective on October 1, 2022.
On July 31, 2023, CMS issued a final rule regarding fiscal year 2024 Medicare rates for skilled nursing facilities providing an estimated net increase of 4.0% compared to fiscal year 2023 comprised of an increase as a result of an update to the payment rates of 6.4% (which is based on (i) a market basket increase of 3.0% plus (ii) a market basket forecast error adjustment of 3.6% and less (iii) a productivity adjustment of 0.2%), partially offset by the second phase of the recalibrated PDPM parity adjustment of 2.3%. These figures do not incorporate any of the estimated value-based purchasing reductions for skilled nursing facilities. The new payment rates became effective on October 1, 2023.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are exposed to various market risks, primarily related to adverse changes in interest rates and the exchange rate for Canadian dollars. We use derivative instruments in the normal course of business to mitigate interest rate and foreign currency risk. We do not use derivative financial instruments for speculative or trading purposes. See Note 9, “Derivative and Hedging Instruments,” in the Notes to Consolidated Financial Statements for further discussion of our derivative instruments.
Interest rate risk. As of December 31, 2023, our indebtedness included $1.8 billion aggregate principal amount of Senior Notes outstanding, $543.2 million in Term Loans, $94.4 million outstanding under the Revolving Credit Facility and $48.1 million of secured indebtedness to third parties on certain of the properties that our subsidiaries own. As of December 31, 2023, we had $637.6 million of outstanding variable rate indebtedness and $905.6 million available for borrowing under our Revolving Credit Facility.
We expect to manage our exposure to interest rate risk by maintaining a mix of fixed and variable rates for our indebtedness. We also may manage, or hedge, interest rate risks related to our borrowings through interest rate swap and collar agreements. As of December 31, 2023, we had interest rate swaps that fix and interest rate collars that set a cap and floor for the Secured Overnight Financing Rate (“SOFR”) portion of the interest rate for $430.0 million of SOFR-based borrowings under the U.S. dollar Term Loan at a weighted average rate of 2.69% and interest rate swaps that fix the Canadian Dollar Offered Rate (“CDOR”) portion of the interest rate for CAD $150.0 million of CDOR-based borrowings under the Canadian dollar Term Loan at 1.63%.
From time to time, we may borrow under the Revolving Credit Facility to finance future investments in properties, including any improvements or renovations of current or newly acquired properties, or for other purposes. Because borrowings under the Revolving Credit Facility bear interest on the outstanding principal amount at a rate equal to a ratings-based applicable interest margin plus, CDOR for Canadian dollar borrowings, or at the Operating Partnership’s option for U.S. dollar borrowings, either (a) Daily Simple SOFR, as defined in the Credit Agreement, or (b) a base rate determined as the greater of (i) the federal funds rate plus 0.5%, (ii) the prime rate, (iii) Term SOFR, as defined in the Credit Agreement, plus 1.0%, and (iv) 1.00%, the interest rate we will be required to pay on any such borrowings will depend on then applicable rates and may vary. An increase in interest rates could make the financing of any investment by us more costly. Rising interest rates could also limit
48


our ability to refinance our debt when it matures or cause us to pay higher interest rates upon refinancing and increase interest expense on refinanced indebtedness.
Assuming a 100 basis point increase or decrease in the index underlying our variable rate debt, and after giving effect to the impact of interest rate derivative instruments, interest expense would increase or decrease by $0.9 million, for the twelve months following December 31, 2023.
For a discussion of the interest rate risks related to the current capital and credit markets, see Part I, Item 1A, “Risk Factors.”
Foreign currency risk. We are exposed to changes in foreign exchange rates as a result of our investments in Canadian real estate. Our foreign currency exposure is partially mitigated through the use of Canadian dollar denominated debt totaling CAD $194.3 million as of December 31, 2023 and cross currency swap instruments. Based on our operating results for the three months ended December 31, 2023, if the value of the Canadian dollar relative to the U.S. dollar were to increase or decrease by 10% compared to the average exchange rate during the three months ended December 31, 2023, our cash flows would have decreased or increased, as applicable, by $0.2 million.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
See the Index to Financial Statements at page F-1 of this 10-K.

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
None.

ITEM 9A. CONTROLS AND PROCEDURES
Disclosure Controls and Procedures
As of the end of the period covered by this report, management, including our chief executive officer and chief financial officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures. Based upon, and as of the date of, the evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective as of December 31, 2023 to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our chief executive officer and our chief financial officer, as appropriate to allow timely decisions regarding required disclosure.
Management’s Annual Report on Internal Control over Financial Reporting
Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a–15(f) and 15d–15(f). Under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting using the criteria described in the 2013 Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based on our evaluation using the criteria described in Internal Control—Integrated Framework, our management concluded that our internal control over financial reporting was effective as of December 31, 2023.
The effectiveness of our internal control over financial reporting as of December 31, 2023 has been audited by PricewaterhouseCoopers LLP, the independent registered public accounting firm that audited the financial statements included in this Form 10-K, as stated in their attestation report which is included herein.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting during the quarter ended December 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

49


ITEM 9B. OTHER INFORMATION
Insider Trading Arrangements
None.

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS
Not applicable.

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
Except as provided below, the information required under Item 10 is incorporated herein by reference to our definitive proxy statement to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, 2023 in connection with our 2024 Annual Meeting of Stockholders.
Code of Conduct and Ethics
We have adopted a Code of Conduct and Ethics that applies to all of our directors and teammates, including our principal executive officer and principal financial officer. Our Code of Conduct and Ethics can be found in the Investors—Corporate Governance section of our website at www.sabrahealth.com. Waivers from, and amendments to, our Code of Conduct and Ethics that apply to our directors, executive officers or persons performing similar functions will be timely posted in the Investors—Corporate Governance section of our website at www.sabrahealth.com to the extent required by applicable rules of the Securities and Exchange Commission or the Nasdaq Stock Market LLC.

ITEM 11. EXECUTIVE COMPENSATION
The information required under Item 11 is incorporated herein by reference to our definitive proxy statement to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, 2023 in connection with our 2024 Annual Meeting of Stockholders.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
The information required under Item 12 is incorporated herein by reference to our definitive proxy statement to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, 2023 in connection with our 2024 Annual Meeting of Stockholders.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
The information required under Item 13 is incorporated herein by reference to our definitive proxy statement to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, 2023 in connection with our 2024 Annual Meeting of Stockholders.

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
The information required under Item 14 is incorporated herein by reference to our definitive proxy statement to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, 2023 in connection with our 2024 Annual Meeting of Stockholders.
50



PART IV

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
(a)    Documents filed as part of this 10-K:
(1)    Financial Statements
See the Index to Consolidated Financial Statements at page F-1 of this report.
(2)    Financial Statement Schedules
        The following financial statement schedules are included herein at pages
F-39
through
F-55
of this report:
Schedule III - Real Estate Assets and Accumulated Depreciation as of December 31, 2023
Schedule IV - Mortgage Loans on Real Estate as of December 31, 2023
All other schedules have been omitted because they are inapplicable or not required or the information is included elsewhere in the Consolidated Financial Statements or notes thereto.
(3)    Exhibits
The following exhibits are filed herewith or are incorporated by reference, as specified below, to exhibits previously filed with the SEC.

EXHIBIT LIST
Ex.  Description
3.1  
3.1.1
3.1.2
3.1.3
3.2  
4.1
4.2
4.2.2
4.3
4.4
51


Ex.  Description
4.4.1
4.4.2
4.4.3
4.4.4
4.5
4.6
4.6.1
4.7
4.8
10.1
10.1.1
10.2
Sixth Amended and Restated Credit Agreement, dated January 4, 2023, among Sabra Health Care Limited Partnership and Sabra Canadian Holdings, LLC, as Borrowers; Sabra Health Care REIT, Inc., as a guarantor; the other guarantors party thereto; the lenders party thereto; Bank of America, N.A., as Administrative Agent and L/C Issuer; Citizens Bank, National Association, Crédit Agricole Corporate and Investment Bank and Wells Fargo Bank, National Association, as Co-Syndication Agents and L/C Issuers; The Bank of Nova Scotia, Fifth Third Bank, JPMorgan Chase Bank, N.A., Keybank National Association, Mizuho Bank, Ltd., and Truist Bank, as Co-Documentation Agents; BofA Securities, Inc., as Joint Lead Arranger and Sole Bookrunner; and Citizens Bank, National Association, Crédit Agricole Corporate and Investment Bank and Wells Fargo Securities, LLC, as Joint Lead Arrangers (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on January 5, 2023).
10.3
10.4+
10.5+
10.6+
52


Ex.  Description
10.7+
10.8.1+
10.8.2+
10.8.3+
10.8.4+
10.8.5+
10.9+*
10.10
21.1*
22.1
23.1*
31.1*  
31.2*  
32.1**  
32.2**  
97.1*
101.INS*Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH*Inline XBRL Taxonomy Extension Schema Document.
101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104*Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
53


 
54


*Filed herewith.
**Furnished herewith.
+Designates a management compensation plan, contract or arrangement.

ITEM 16. FORM 10-K SUMMARY
    None.

F-55


INDEX TO CONSOLIDATED FINANCIAL STATEMENTS


F-1


REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Stockholders of Sabra Health Care REIT, Inc.
Opinions on the Financial Statements and Internal Control over Financial Reporting
We have audited the accompanying consolidated balance sheets of Sabra Health Care REIT, Inc. and its subsidiaries (the “Company”) as of December 31, 2023 and 2022, and the related consolidated statements of income (loss), of comprehensive income (loss), of equity and of cash flows for each of the three years in the period ended December 31, 2023, including the related notes and financial statement schedules listed in the index appearing under Item 15(a)(2) (collectively referred to as the “consolidated financial statements”). We also have audited the Company's internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.

Basis for Opinions
The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management’s Annual Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company’s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.
Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
F-2



Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

Impairment Assessments of Real Estate Investments
As described in Notes 2, 4 and 5 to the consolidated financial statements, the Company’s real estate investments net carrying value was $4.6 billion as of December 31, 2023. Management regularly monitors events and changes in circumstances, including investment operating performance and general market conditions, that could indicate that the carrying amounts of its real estate investments may not be recoverable. When indicators of potential impairment suggest that the carrying value of real estate investments may not be recoverable, the Company assesses the recoverability by estimating whether the Company will recover the carrying value of its real estate investments through the undiscounted future cash flows and the eventual disposition of the investment. The undiscounted future cash flows used to assess recoverability are based on several assumptions and are probability-weighted based on the Company’s best estimates as of the date of evaluation. These assumptions include, among others, market rent, revenue and expense growth rates, absorption period, stabilized occupancy, holding period, market capitalization rates, and estimated market values based on analysis of letters of intent, purchase and sale agreements and recent sales data for comparable properties. If, based on this analysis, the Company does not believe that it will be able to recover the carrying value of its real estate investments, the Company would record an impairment loss to the extent that the carrying value exceeds the estimated fair value of its real estate investments.
The principal considerations for our determination that performing procedures relating to the impairment assessments of real estate investments is a critical audit matter are (i) the significant judgment by management in (a) identifying events and changes in circumstances that are indicators of impairment related to the performance of the investment and market conditions and (b) developing the undiscounted future cash flows utilized in the recoverability assessment of real estate investments with potential impairment and (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating audit evidence related to (a) management’s identification of events or changes in circumstances related to the performance of the investment and market conditions and (b) management’s probability weightings and assumptions used in the undiscounted future cash flows related to market rent, revenue and expense growth rates, absorption period, stabilized occupancy, holding period and market capitalization rates (collectively referred to as the “significant assumptions”).
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management’s impairment assessments of investments in real estate properties, including controls over management’s (a) identification of events and changes in circumstances indicating that the carrying amounts of the real estate investments may not be recoverable and (b) recoverability assessment of real estate investments with potential impairment. These procedures also included, among others, (i) testing management's process for (a) identifying events and changes in circumstances that are indicators of impairment and (b) assessing the recoverability of the real estate investments with potential impairments, (ii) evaluating the appropriateness of the undiscounted cash flow models and probability weightings used in the recoverability assessment process, (iii) testing the completeness, accuracy, relevance and reliability of the underlying data used in the undiscounted cash flow models, (iv) evaluating the reasonableness of management’s assessment of events and changes in circumstances that are indicators of impairment related to performance of the investment and general market conditions indicating that the carrying amounts of its real estate investments may not be recoverable by considering the consistency with the current and past performance of the real estate investment and the consistency with external market and industry data, and (v) evaluating the reasonableness of the significant assumptions used in the undiscounted future cash flows of real estate investments with potential impairment by considering the consistency of the significant assumptions with the current and past performance of the real estate investments, the consistency with external market and industry data, and whether these significant assumptions were consistent with evidence obtained in other areas of the audit.

/s/ PricewaterhouseCoopers LLP
Irvine, California
February 27, 2024
 
We have served as the Company’s auditor since 2010.
F-3


SABRA HEALTH CARE REIT, INC.
CONSOLIDATED BALANCE SHEETS
(dollars in thousands, except per share data)
 
December 31,
20232022
Assets
Real estate investments, net of accumulated depreciation of $1,021,086 and $913,345 as of December 31, 2023 and 2022, respectively
$4,617,261 $4,959,343 
Loans receivable and other investments, net420,624 411,396 
Investment in unconsolidated joint ventures136,843 134,962 
Cash and cash equivalents41,285 49,308 
Restricted cash5,434 4,624 
Lease intangible assets, net30,897 40,131 
Accounts receivable, prepaid expenses and other assets, net133,806 147,908 
Total assets$5,386,150 $5,747,672 
Liabilities
Secured debt, net$47,301 $49,232 
Revolving credit facility94,429 196,982 
Term loans, net537,120 526,129 
Senior unsecured notes, net1,735,253 1,734,431 
Accounts payable and accrued liabilities136,981 142,259 
Lease intangible liabilities, net32,532 42,244 
Total liabilities2,583,616 2,691,277 
Commitments and contingencies (Note 15)
Equity
Preferred stock, $0.01 par value; 10,000,000 shares authorized, zero shares issued and outstanding as of December 31, 2023 and 2022
  
Common stock, $0.01 par value; 500,000,000 shares authorized, 231,266,020 and 231,009,295 shares issued and outstanding as of December 31, 2023 and 2022, respectively
2,313 2,310 
Additional paid-in capital4,494,755 4,486,967 
Cumulative distributions in excess of net income(1,718,279)(1,451,945)
Accumulated other comprehensive income23,745 19,063 
Total equity2,802,534 3,056,395 
Total liabilities and equity$5,386,150 $5,747,672 
See accompanying notes to consolidated financial statements.
F-4


SABRA HEALTH CARE REIT, INC.
CONSOLIDATED STATEMENTS OF INCOME (LOSS)
(dollars in thousands, except per share data)
 
Year Ended December 31,
 202320222021
Revenues:
Rental and related revenues (Note 4)$376,266 $400,586 $396,716 
Resident fees and services236,153 186,672 155,512 
Interest and other income35,095 37,553 17,317 
Total revenues647,514 624,811 569,545 
 
Expenses:
Depreciation and amortization183,087 187,782 178,991 
Interest112,964 105,471 98,632 
Triple-net portfolio operating expenses17,932 19,623 20,221 
Senior housing - managed portfolio operating expenses177,313 142,990 120,980 
General and administrative47,472 39,574 34,669 
Provision for loan losses and other reserves191 141 3,935 
Impairment of real estate14,332 94,042 9,499 
Total expenses553,291 589,623 466,927 
   
Other (expense) income:
Loss on extinguishment of debt(1,541)(411)(34,622)
Other income (expense)2,598 (1,097)373 
Net (loss) gain on sales of real estate(76,625)(12,011)12,301 
Total other expense(75,568)(13,519)(21,948)
Income before loss from unconsolidated joint ventures and income tax expense18,655 21,669 80,670 
Loss from unconsolidated joint ventures(2,897)(98,032)(192,081)
Income tax expense(2,002)(1,242)(1,845)
Net income (loss)$13,756 $(77,605)$(113,256)
Net income (loss), per:
Basic common share$0.06 $(0.34)$(0.52)
Diluted common share$0.06 $(0.34)$(0.52)
Weighted average number of common shares outstanding, basic231,203,391 230,947,895 219,073,027 
Weighted average number of common shares outstanding, diluted232,792,778 230,947,895 219,073,027 
See accompanying notes to consolidated financial statements.
F-5


SABRA HEALTH CARE REIT, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(in thousands, except footnote data)

Year Ended December 31,
 202320222021
Net income (loss)$13,756 $(77,605)$(113,256)
Other comprehensive income (loss):
Unrealized gain (loss), net of tax:
Foreign currency translation (loss) gain(205)3,141 (142)
Unrealized gain on cash flow hedges (1)
4,887 25,943 30,032 
Total other comprehensive income4,682 29,084 29,890 
Comprehensive income (loss)$18,438 $(48,521)$(83,366)
(1)    Amounts are net of income tax benefit of $17,000 and $0.1 million for the years ended December 31, 2022 and 2021, respectively. No such income tax benefit was recognized during the year ended December 31, 2023.
See accompanying notes to consolidated financial statements.

F-6


SABRA HEALTH CARE REIT, INC.
CONSOLIDATED STATEMENTS OF EQUITY
(dollars in thousands, except per share data)
 Common StockAdditional
Paid-in Capital
Cumulative Distributions in Excess of Net IncomeAccumulated Other Comprehensive (Loss) IncomeTotal Equity
 SharesAmounts
Balance, December 31, 2020210,560,815 $2,106 $4,163,228 $(716,195)$(39,911)$3,409,228 
Net loss— — — (113,256)— (113,256)
Other comprehensive income— — — — 29,890 29,890 
Amortization of stock-based compensation— — 10,748 — — 10,748 
Common stock issuance, net19,837,840 198 308,475 — — 308,673 
Common dividends ($1.20 per share)
— — — (265,753)— (265,753)
Balance, December 31, 2021230,398,655 2,304 4,482,451 (1,095,204)(10,021)3,379,530 
Net loss— — — (77,605)— (77,605)
Other comprehensive income— — — — 29,084 29,084 
Amortization of stock-based compensation— — 9,433 — — 9,433 
Common stock issuance, net610,640 6 (4,917)— — (4,911)
Common dividends ($1.20 per share)
— — — (279,136)— (279,136)
Balance, December 31, 2022231,009,295 2,310 4,486,967 (1,451,945)19,063 3,056,395 
Net income— — — 13,756 — 13,756 
Other comprehensive income— — — — 4,682 4,682 
Amortization of stock-based compensation— — 10,559 — — 10,559 
Common stock issuance, net256,725 3 (2,771)— — (2,768)
Common dividends ($1.20 per share)
— — — (280,090)— (280,090)
Balance, December 31, 2023231,266,020 $2,313 $4,494,755 $(1,718,279)$23,745 $2,802,534 
See accompanying notes to consolidated financial statements.
F-7


SABRA HEALTH CARE REIT, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
Year Ended December 31,
 202320222021
Cash flows from operating activities:
Net income (loss)$13,756 $(77,605)$(113,256)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization183,087 187,782 178,991 
Non-cash rental and related revenues(8,699)2,183 25,823 
Non-cash interest income(372)(2,285)(1,988)
Non-cash interest expense12,265 11,094 8,368 
Stock-based compensation expense7,917 7,453 7,914 
Loss on extinguishment of debt1,541 411 34,622 
Provision for loan losses and other reserves191 141 3,935 
Net loss (gain) on sales of real estate76,625 12,011 (12,301)
Impairment of real estate14,332 94,042 9,499 
Other-than-temporary impairment of unconsolidated joint ventures 57,778 164,126 
Loss from unconsolidated joint ventures2,897 40,254 27,955 
Distributions of earnings from unconsolidated joint ventures3,469   
Other non-cash items(3,704)2,167  
Changes in operating assets and liabilities:
Accounts receivable, prepaid expenses and other assets, net(11,078)(6,443)8,223 
Accounts payable and accrued liabilities8,344 (13,250)14,479 
Net cash provided by operating activities300,571 315,733 356,390 
Cash flows from investing activities:
Acquisition of real estate(78,530)(92,204)(99,448)
Origination and fundings of loans receivable(11,418)(23,812)(290,000)
Origination and fundings of preferred equity investments(11,023)(8,021)(9,061)
Additions to real estate(84,855)(54,473)(42,651)
Escrow deposits for potential investments (780) 
Repayments of loans receivable9,274 5,272 2,949 
Repayments of preferred equity investments5,460 5,376 1,292 
Investment in unconsolidated joint ventures(5,235)(142,910) 
Net proceeds from the sales of real estate247,622 87,304 100,723 
Deposits for potential sale of real estate 8,000  
Net proceeds from sales-type lease25,490   
Insurance proceeds5,801   
Distributions in excess of earnings from unconsolidated joint ventures544   
Net cash provided by (used in) investing activities103,130 (216,248)(336,196)
Cash flows from financing activities:
Net (repayments of) borrowings from revolving credit facility(104,338)204,046  
Proceeds from term loans12,188   
Proceeds from issuance of senior unsecured notes  791,520 
Principal payments on senior unsecured notes  (300,000)
Principal payments on term loans (63,750)(455,000)
Principal payments on secured debt(1,979)(17,516)(12,661)
Payments of deferred financing costs(18,142)(20)(9,317)
Payments related to extinguishment of debt  (30,196)
Payment of contingent consideration(17,900)(2,500) 
Issuance of common stock, net(2,682)(4,810)308,713 
Dividends paid on common stock(277,447)(277,157)(262,919)
Net cash (used in) provided by financing activities(410,300)(161,707)30,140 
Net (decrease) increase in cash, cash equivalents and restricted cash(6,599)(62,222)50,334 
Effect of foreign currency translation on cash, cash equivalents and restricted cash(614)268 29 
Cash, cash equivalents and restricted cash, beginning of period53,932 115,886 65,523 
Cash, cash equivalents and restricted cash, end of period$46,719 $53,932 $115,886 
See accompanying notes to consolidated financial statements.
F-8


SABRA HEALTH CARE REIT, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)
(in thousands)
Year Ended December 31,
 202320222021
Supplemental disclosure of cash flow information:
Interest paid$102,409 $97,723 $85,464 
Income taxes paid$1,670 $1,657 $1,839 
Supplemental disclosure of non-cash investing activities:
Decrease in loans receivable and other investments due to acquisition of real estate$4,644 $14,311 $ 
See accompanying notes to consolidated financial statements.

F-9


SABRA HEALTH CARE REIT, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 
1.BUSINESS
Overview
Sabra Health Care REIT, Inc. (“Sabra” or the “Company”) was incorporated on May 10, 2010 as a wholly owned subsidiary of Sun Healthcare Group, Inc. (“Sun”) and commenced operations on November 15, 2010 following Sabra’s separation from Sun. Sabra elected to be treated as a real estate investment trust (“REIT”) with the filing of its United States (“U.S.”) federal income tax return for the taxable year beginning January 1, 2011. Sabra believes that it has been organized and operated, and it intends to continue to operate, in a manner to qualify as a REIT. Sabra’s primary business consists of acquiring, financing and owning real estate property to be leased to third-party tenants in the healthcare sector. Sabra primarily generates revenues by leasing properties to tenants throughout the U.S. and Canada. Sabra owns substantially all of its assets and properties and conducts its operations through Sabra Health Care Limited Partnership, a Delaware limited partnership (the “Operating Partnership”), of which Sabra is the sole general partner and a wholly owned subsidiary of Sabra is currently the only limited partner, or by subsidiaries of the Operating Partnership. The Company’s investment portfolio is primarily comprised of skilled nursing/transitional care facilities, senior housing communities (“Senior Housing - Leased”), behavioral health facilities and specialty hospitals and other facilities, in each case leased to tenants who are responsible for the operations of these facilities; senior housing communities operated by third-party property managers pursuant to property management agreements (“Senior Housing - Managed”); investments in joint ventures; investments in loans receivable; and preferred equity investments.
2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Principles of Consolidation and Basis of Presentation
The accompanying consolidated financial statements include the accounts of Sabra and its wholly owned subsidiaries as of December 31, 2023 and 2022 and for the years ended December 31, 2023, 2022 and 2021. All significant intercompany transactions and balances have been eliminated in consolidation. The consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”).
GAAP requires the Company to identify entities for which control is achieved through voting rights or other means and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). A VIE is broadly defined as an entity with one or more of the following characteristics: (a) the total equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (b) as a group, the holders of the equity investment at risk lack (i) the ability to make decisions about the entity’s activities through voting or similar rights, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity; or (c) the equity investors have voting rights that are not proportional to their economic interests, and substantially all of the entity’s activities either involve, or are conducted on behalf of, an investor that has disproportionately few voting rights. If the Company were determined to be the primary beneficiary of the VIE, the Company would consolidate investments in the VIE. The Company may change its original assessment of a VIE due to events such as modifications of contractual arrangements that affect the characteristics or adequacy of the entity’s equity investments at risk and the disposal of all or a portion of an interest held by the primary beneficiary.
The Company identifies the primary beneficiary of a VIE as the enterprise that has both: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. The Company performs this analysis on an ongoing basis. As of December 31, 2023, the Company determined that it was not the primary beneficiary of any VIEs.
As it relates to investments in loans, in addition to the Company’s assessment of VIEs and whether the Company is the primary beneficiary of those VIEs, the Company evaluates the loan terms and other pertinent facts to determine whether the loan investment should be accounted for as a loan or as a real estate joint venture. If an investment has the characteristics of a real estate joint venture, including if the Company participates in the majority of the borrower’s expected residual profit, the Company would account for the investment as an investment in a real estate joint venture and not as a loan investment. Expected residual profit is defined as the amount of profit, whether called interest or another name, such as an equity kicker, above a reasonable amount of interest and fees expected to be earned by a lender. At December 31, 2023 and 2022, none of the Company’s investments in loans were accounted for as real estate joint ventures.
F-10


As it relates to investments in joint ventures, the Company assesses any partners’ rights and their impact on the presumption of control of the partnership by any single partner. The Company also applies this guidance to managing member interests in limited liability companies. The Company reassesses its determination of which entity controls the joint venture if: there is a change to the terms or in the exercisability of the rights of any partners or members, the general partner or managing member increases or decreases its ownership interests, or there is an increase or decrease in the number of outstanding ownership interests. As of December 31, 2023, the Company’s determination of which entity controls its investments in joint ventures has not changed as a result of any reassessment.
Use of Estimates
The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.
Real Estate Investments and Rental Revenue Recognition
Real Estate Acquisition Valuation
All assets acquired and liabilities assumed in an acquisition of real estate accounted for as a business combination are measured at their acquisition date fair values. For acquisitions of real estate accounted for as an asset acquisition, the fair value of consideration transferred by the Company (including transaction costs) is allocated to all assets acquired and liabilities assumed on a relative fair value basis. The acquisition value of land, building and improvements are included in real estate investments on the accompanying consolidated balance sheets. The acquisition value of above market lease, tenant origination and absorption costs and tenant relationship intangible assets is included in lease intangible assets, net on the accompanying consolidated balance sheets. The acquisition value of below market lease intangible liabilities is included in lease intangible liabilities, net on the accompanying consolidated balance sheets. Acquisition costs associated with real estate acquisitions deemed asset acquisitions are capitalized, and costs associated with real estate acquisitions deemed business combinations are expensed as incurred. Restructuring costs that do not meet the definition of a liability at the acquisition date are expensed in periods subsequent to the acquisition date.
Estimates of the fair values of the tangible assets, identifiable intangibles and assumed liabilities require the Company to make significant assumptions to estimate market lease rates, property operating expenses, carrying costs during lease-up periods, discount rates, market absorption periods, and the number of years the property will be held for investment. The Company makes its best estimate based on the Company’s evaluation of the specific characteristics of each tenant’s lease. The use of inappropriate assumptions would result in an incorrect valuation of the Company’s acquired tangible assets, identifiable intangibles and assumed liabilities, which would impact the amount of the Company’s net income.
Depreciation and Amortization
Real estate costs related to the acquisition and improvement of properties are capitalized and amortized on a straight-line basis over the lesser of the expected useful life of the asset and the remaining lease term of any property subject to a ground lease. Tenant improvements are capitalized and amortized on a straight-line basis over the lesser of the expected useful life of the asset and the remaining lease term. Depreciation is discontinued when a property is identified as held for sale. Repair and maintenance costs are charged to expense as incurred and significant replacements and betterments are capitalized. Repair and maintenance costs include all costs that do not extend the useful life of the real estate asset. The Company considers the period of future benefit of an asset to determine its appropriate useful life. Depreciation of real estate assets and amortization of tenant origination and absorption costs and tenant relationship lease intangibles are included in depreciation and amortization on the accompanying consolidated statements of income (loss). Amortization of above and below market lease intangibles is included in rental income on the accompanying consolidated statements of income (loss). The Company anticipates the estimated useful lives of its assets by class to be generally as follows: land improvements, 15 to 20 years; buildings and building improvements, five to 45 years; and furniture and equipment, three to 10 years. Intangibles are generally amortized over the remaining noncancellable lease terms, with tenant relationship intangible amortization periods including extension periods.
Impairment of Real Estate Investments
The Company regularly monitors events and changes in circumstances, including investment operating performance and general market conditions, that could indicate that the carrying amounts of its real estate investments may not be recoverable. When indicators of potential impairment suggest that the carrying value of real estate investments may not be recoverable, the Company assesses the recoverability by estimating whether the Company will recover the carrying value of its real estate investments through the undiscounted future cash flows and the eventual disposition of the investment. In some instances, there may be various potential outcomes for an investment and its potential undiscounted future cash flows. In these instances, the
F-11


undiscounted future cash flows models used to assess recoverability are based on several assumptions and are probability-weighted based on the Company’s best estimates as of the date of evaluation. These assumptions include, among others, market rent, revenue and expense growth rates, absorption period, stabilized occupancy, holding period, market capitalization rates, and estimated market values based on analysis of letters of intent, purchase and sale agreements and recent sales data for comparable properties. When discounted cash flow is used to determine fair value, a discount rate assumption is also used. The assumptions are generally based on management’s experience in its local real estate markets, and the effects of current market conditions, which are subject to economic and market uncertainties. If, based on this analysis, the Company does not believe that it will be able to recover the carrying value of its real estate investments, the Company would record an impairment loss to the extent that the carrying value exceeds the estimated fair value of its real estate investments. The Company determines estimated fair value based primarily upon (i) estimated sale prices from signed contracts or letters of intent from third-party offers, (ii) discounted cash flow models of the investment over its remaining hold period, (iii) third-party appraisals and (iv) recent sales data for comparable properties.
Revenue Recognition
The Company recognizes rental revenue from tenants, including rental abatements, lease incentives and contractual fixed increases attributable to operating leases, on a straight-line basis over the term of the related leases when it is probable that substantially all rents over the life of a lease are collectible. Certain of the Company’s leases provide for contingent rents equal to a percentage of the facility’s revenue in excess of specified base amounts or other thresholds. Such revenue is recognized when actual results reported by the tenant, or estimates of tenant results, exceed the applicable base amount or other threshold.
The Company assesses the collectability of rents on a lease-by-lease basis, and in doing so, considers such things as historical bad debts, tenant creditworthiness, current economic trends, facility operating performance, lease structure, credit enhancements (including guarantees), current developments relevant to a tenant’s business specifically and to its business category generally, and changes in tenants’ payment patterns. The Company’s assessment includes an estimation of a tenant’s ability to fulfill all of its rental obligations over the remaining lease term. In addition, with respect to tenants in bankruptcy, management makes estimates of the expected recovery of pre-petition and post-petition claims in assessing the estimated collectability of the related receivable. If at any time the Company cannot determine that it is probable that substantially all rents over the life of a lease are collectible, rental revenue will be recognized only to the extent of payments received, and all receivables associated with the lease will be written off irrespective of amounts expected to be collectible. Any recoveries of these amounts will be recorded in future periods upon receipt of payment. Write-offs of receivables and any recoveries of previously written-off receivables are recorded as adjustments to rental revenue.
Revenue from resident fees and services is recorded monthly as services are provided and includes resident room and care charges, ancillary services charges and other resident charges.
Government Grants
By analogy to International Accounting Standards 20, Accounting for Government Grants and Disclosure of Government Assistance, government assistance provided to the Company in the form of an income grant, which is not related to long-lived assets and is not required to be repaid, is recognized as grant income when there is reasonable assurance that the grant will be received and the Company will comply with any conditions associated with the grant. Additionally, grants are recognized over the periods in which the Company recognizes the qualifying expenses and/or lost income for which the grants are intended to compensate. As of December 31, 2023, 2022 and 2021, the amount of qualifying expenditures exceeded amounts recognized under The Coronavirus Aid Relief and Economic Security Act and other programs, and the Company had complied with all grant conditions. Accordingly, during the years ended December 31, 2023, 2022 and 2021, the Company recognized $0.1 million, $0.1 million and $0.5 million, respectively, of grants in resident fees and services, and during the year ended December 31, 2022, the Company recognized $3.6 million of grants in loss from unconsolidated joint ventures in the accompanying consolidated statements of income (loss).
Casualty Gains and Losses
Income resulting from insurance recoveries of property damage or business interruption losses is recognized when proceeds are received or contingencies related to the insurance recoveries are resolved.
A vacant facility owned by the Company suffered damages as a result of vandalism and theft. The Company received $6.2 million of insurance proceeds and recorded a $3.7 million gain related to the property damage during the year ended December 31, 2023 which is included in other income (expense) on the accompanying consolidated statements of income (loss).
F-12


A fire occurred at one of the Company’s Senior Housing - Managed communities. The Company received $1.1 million of insurance proceeds and recorded $0.5 million of business interruption insurance income during the year ended December 31, 2023 which is included in other income (expense) on the accompanying consolidated statements of income (loss). The remaining proceeds were recorded as expense reimbursements in Senior Housing - Managed portfolio operating expenses on the accompanying consolidated statements of income (loss).
Assets Held for Sale, Dispositions and Discontinued Operations
The Company generally considers real estate to be “held for sale” when the following criteria are met: (i) management commits to a plan to sell the property, (ii) the property is available for sale immediately, (iii) the property is actively being marketed for sale at a price that is reasonable in relation to its current fair value, (iv) the sale of the property within one year is considered probable and (v) significant changes to the plan to sell are not expected. Real estate that is held for sale and its related assets are classified as assets held for sale and are included in accounts receivable, prepaid expenses and other assets, net on the accompanying consolidated balance sheets. Secured indebtedness and other liabilities related to real estate held for sale are classified as liabilities related to assets held for sale and are included in accounts payable and accrued liabilities on the accompanying consolidated balance sheets. Real estate classified as held for sale is no longer depreciated and is reported at the lower of its carrying value or its estimated fair value less estimated costs to sell. As of December 31, 2023 and 2022, the Company did not have any assets held for sale.
For sales of real estate where the Company has collected the consideration to which it is entitled in exchange for transferring the real estate, the related assets and liabilities are removed from the balance sheet and the resultant gain or loss is recorded in the period in which the transaction closes. Any post-sale involvement is accounted for as separate performance obligations, and when the separate performance obligations are satisfied, the portion of the sales price allocated to each such obligation is recognized.
Additionally, the Company records the operating results related to real estate that has been disposed of or classified as held for sale as discontinued operations for all periods presented if it represents a strategic shift that has or will have a major effect on the Company’s operations and financial results.
Investment in Unconsolidated Joint Ventures
The Company reports investments in unconsolidated entities over whose operating and financial policies it has the ability to exercise significant influence under the equity method of accounting. Under this method of accounting, the Company’s share of the investee’s earnings or losses is included in the Company’s consolidated statements of income (loss). The initial carrying value of the investment is based on the amount paid to purchase the joint venture interest. Differences between the Company’s cost basis and the basis reflected at the joint venture level are generally amortized over the lives of the related assets and liabilities, and such amortization is included in the Company’s share of earnings of the joint venture. In addition, distributions received from unconsolidated entities are classified based on the nature of the activity or activities that generated the distribution.
The Company regularly monitors events and changes in circumstances, including investment operating performance, changes in anticipated holding period and general market conditions, that could indicate that the carrying amounts of its equity method investments may be impaired. An equity method investment's value is impaired when the fair value of the investment is less than its carrying value and the Company determines the decline in value is other-than-temporary. The fair value is estimated based on discounted cash flows models that include all estimated cash inflows and outflows and any estimated debt premiums or discounts. The discounted cash flows are based on several assumptions, including management fee, absorption period, terminal capitalization rates, revenue and expense per bed, revenue and expense growth percentage, replacement reserve per unit, stabilized occupancy, stabilized operating margin, price per bed and discount rates. The assumptions are generally based on management’s experience in its local real estate markets, and the effects of current market conditions, which are subject to economic and market uncertainties. If the Company believes that there is an other-than-temporary decline in the value of an equity method investment, the Company would record an impairment loss to the extent that the carrying value exceeds the estimated fair value of such equity method investment.
Loans Receivable and Credit Losses
Loans Receivable
The Company’s loans receivable are reflected at amortized cost on the accompanying consolidated balance sheets. The amortized cost of a loan receivable is the outstanding unpaid principal balance, net of unamortized discounts, costs and fees directly associated with the origination of the loan.
F-13


Loans acquired in connection with a business combination are recorded at their acquisition date fair value. The Company determines the fair value of loans receivable based on estimates of expected discounted cash flows, collateral, credit risk and other factors. The Company does not establish a valuation allowance at the acquisition date, as the amount of estimated future cash flows reflects its judgment regarding their uncertainty. The Company recognizes the difference between the acquisition date fair value and the total expected cash flows as interest income using the effective interest method over the life of the applicable loan. The Company immediately recognizes in income any unamortized balances if the loan is repaid before its contractual maturity.
Interest income on the Company’s loans receivable is recognized on an accrual basis over the life of the investment using the interest method. Direct loan origination costs are amortized over the term of the loan as an adjustment to interest income. When concerns exist as to the ultimate collection of principal or interest due under a loan, the loan is placed on nonaccrual status, and the Company will not recognize interest income until the cash is received, or the loan returns to accrual status. If the Company determines that the collection of interest according to the contractual terms of the loan or through the receipts of assets in satisfaction of contractual amounts due is probable, the Company will resume the accrual of interest. In instances where borrowers are in default under the terms of their loans, the Company may continue recognizing interest income provided that all amounts owed under the contractual terms of the loan, including accrued and unpaid interest, do not exceed the estimated fair value of the collateral, less costs to sell.
On a quarterly basis, the Company evaluates the collectability of its interest income receivable and establishes a reserve for amounts not expected to be collected. The Company’s evaluation includes reviewing credit quality indicators such as payment status, changes affecting the operations of the facilities securing the loans, and national and regional economic factors. The reserve is a valuation allowance that reflects management’s estimate of losses inherent in the interest income receivable balance as of the balance sheet date. The reserve is adjusted through provision for loan losses and other reserves on the Company’s consolidated statements of income (loss) and is decreased by charge-offs to specific receivables.
Credit Losses
On a quarterly basis, the Company evaluates the collectability of its loan portfolio, including the portion of unfunded loan commitments expected to be funded, and establishes an allowance for credit losses. The allowance for credit losses is calculated using the related amortization schedules, payment histories and loan-to-value ratios. The following rates are applied to determine the aggregate expected losses, which is recorded as the allowance for credit losses: (i) a default rate, (ii) a liquidation cost rate and (iii) a distressed property reduction rate. If no loan-to-value ratio is available, a loss severity rate is applied in place of the liquidation cost rate and the distressed property reduction rate. The default rate is based on average charge-off and delinquency rates from the Federal Reserve, and the other rates are based on industry research and historical performance of a similar portfolio of financial assets. The allowance for credit losses is a valuation allowance that reflects management’s estimate of losses inherent in the loan portfolio as of the balance sheet date. The reserve is adjusted through provision for loan losses and other reserves on the Company’s consolidated statements of income (loss) and is decreased by charge-offs to specific loans.
Preferred Equity Investments and Preferred Return
Preferred equity investments are accounted for at unreturned capital contributions, plus accrued and unpaid preferred returns. The Company recognizes preferred return income on a monthly basis based on the outstanding investment including any previously accrued and unpaid return. As a preferred member of the preferred equity joint ventures in which the Company participates, the Company is not entitled to share in the joint venture’s earnings or losses. Rather, the Company is entitled to receive a preferred return, which is deferred if the cash flow of the joint venture is insufficient to currently pay the accrued preferred return.
The Company regularly monitors events and changes in circumstances that could indicate that the carrying amounts of its preferred equity investments may not be recoverable or realized. On a quarterly basis, the Company evaluates its preferred equity investments for impairment based on a comparison of the fair value of the investment to its carrying value. The fair value is estimated based on discounted cash flows that include all estimated cash inflows and outflows over a specified holding period. If, based on this analysis, the Company does not believe that it will be able to recover the carrying value of its preferred equity investment, the Company would record an impairment loss to the extent that the carrying value exceeds the estimated fair value of its preferred equity investment.
Cash and Cash Equivalents
The Company considers all short-term (with an original maturity of three months or less), highly-liquid investments utilized as part of the Company’s cash-management activities to be cash equivalents. Cash equivalents may include cash and short-term investments. Short-term investments are stated at cost, which approximates fair value.
F-14


The Company’s cash and cash equivalents balance exceeded federally insurable limits as of December 31, 2023. To date, the Company has experienced no loss or lack of access to cash in its operating accounts. The Company has a corporate banking relationship with Bank of America, N.A. in which it deposits the majority of its cash.
Restricted Cash
Restricted cash primarily consists of amounts held by an exchange accommodation titleholder or by secured debt lenders to provide for future real estate tax expenditures, tenant improvements and capital expenditures. Pursuant to the terms of the Company’s leases with certain tenants, the Company has assigned its interests in certain of these restricted cash accounts with secured debt lenders to the tenants, and this amount is included in accounts payable and accrued liabilities on the Company’s consolidated balance sheets. As of December 31, 2023 and 2022, restricted cash totaled $5.4 million and $4.6 million, respectively, and restricted cash obligations totaled $1.4 million and $3.9 million, respectively.
Lessee Accounting
For operating leases greater than 12 months for which the Company is the lessee, such as corporate office leases and ground leases, the Company recognizes a right-of-use (“ROU”) asset and related lease liability on its consolidated balance sheets at inception of the lease. ROU assets represent the Company’s right to use underlying assets for the lease term, and lease liabilities are determined based on the estimated present value of the Company’s minimum lease payments under the agreements. The discount rate used to determine the lease liabilities is based on the estimated incremental borrowing rate on a lease-by-lease basis. Certain of the Company’s lease agreements have options to extend or terminate the contract terms upon meeting certain criteria. The lease term utilized in the calculation of the lease liability includes these options if exercise is considered reasonably certain. As of December 31, 2023 and 2022, the Company had $11.6 million and $8.5 million of ROU assets included in accounts receivable, prepaid expenses and other assets, net, and $12.5 million and $9.2 million of lease liabilities included in accounts payable and accrued liabilities, respectively, on its consolidated balance sheets.
During the years ended December 31, 2023, 2022 and 2021, the Company incurred lease expense of $1.4 million, $1.2 million and $1.2 million, respectively. As of December 31, 2023, the weighted average remaining lease term and discount rate were 17 years and 8%, respectively, and the future minimum lease payments under the operating leases included in the Company’s lease liability were as follows (in thousands):
2024$1,310 
20251,802 
20261,324 
20271,347 
20281,330 
Thereafter18,104 
Undiscounted minimum lease payments included in the lease liability25,217 
Less: imputed interest(12,729)
Present value of lease liability$12,488 
Stock-Based Compensation
Stock-based compensation expense for stock-based awards granted to Sabra’s employees (teammates) and its non-employee directors is recognized in the statements of income (loss) based on the estimated grant date fair value, as adjusted. Compensation expense for awards with graded vesting schedules is generally recognized ratably over the period from the grant date to the date when the award is no longer contingent on the recipient providing additional services. Compensation expense for awards with performance-based vesting conditions is recognized based on the Company’s estimate of the ultimate value of such award after considering the Company’s expectations of future performance. Forfeitures of stock-based awards are recognized as they occur.
Deferred Financing Costs
Deferred financing costs representing fees paid to third parties are amortized over the terms of the respective financing agreements using the interest method. Deferred financing costs related to secured debt, term loans and senior unsecured notes are recorded as a reduction of the related debt liability, and deferred financing costs related to the revolving credit facility are recorded in accounts receivable, prepaid expenses and other assets, net. Unamortized deferred financing costs are generally expensed when the associated debt is refinanced or repaid before maturity. Costs incurred in seeking financings that do not close are expensed in the period in which it is determined that the financing will not close.
F-15


Income Taxes
The Company elected to be treated as a REIT with the filing of its U.S. federal income tax return for the taxable year beginning January 1, 2011. The Company believes that it has been organized and operated, and it intends to continue to operate, in a manner to qualify as a REIT. To qualify as a REIT, the Company must meet certain organizational and operational requirements, including a requirement to distribute at least 90% of the Company’s annual REIT taxable income to stockholders (which is computed without regard to the dividends-paid deduction or net capital gains and which does not necessarily equal net income as calculated in accordance with GAAP). As a REIT, the Company generally will not be subject to federal income tax on income that it distributes as dividends to its stockholders. If the Company fails to qualify as a REIT in any taxable year, it will be subject to U.S. federal income tax on its taxable income at regular corporate income tax rates and generally will not be permitted to qualify for treatment as a REIT for federal income tax purposes for the four taxable years following the year during which qualification is lost, unless the Internal Revenue Service grants the Company relief under certain statutory provisions. Such an event could materially and adversely affect the Company’s net income and net cash available for distribution to stockholders. However, the Company believes that it is organized and operates in such a manner as to qualify for treatment as a REIT.
As a result of certain investments, the Company now records income tax expense or benefit with respect to certain of its entities that are taxed as taxable REIT subsidiaries under provisions similar to those applicable to regular corporations and not under the REIT provisions.
The Company accounts for deferred income taxes using the asset and liability method and recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company’s financial statements or tax returns. Under this method, the Company determines deferred tax assets and liabilities based on the differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Any increase or decrease in the deferred tax liability that results from a change in circumstances, and that causes a change in the Company’s judgment about expected future tax consequences of events, is included in the tax provision when such changes occur. Deferred income taxes also reflect the impact of operating loss and tax credit carryforwards. A valuation allowance is provided if the Company believes it is more likely than not that all or some portion of the deferred tax asset will not be realized. Any increase or decrease in the valuation allowance that results from a change in circumstances, and that causes a change in the Company’s judgment about the realizability of the related deferred tax asset, is included in the tax provision when such changes occur. 
The Company evaluates its tax positions using a two-step approach: step one (recognition) occurs when the Company concludes that a tax position, based solely on its technical merits, is more likely than not to be sustained upon examination, and step two (measurement) is only addressed if step one has been satisfied (i.e., the position is more likely than not to be sustained). Under step two, the tax benefit is measured as the largest amount of benefit (determined on a cumulative probability basis) that is more likely than not to be realized upon ultimate settlement. The Company will recognize tax penalties relating to unrecognized tax benefits as additional tax expense.
Foreign Currency
Certain of the Company’s subsidiaries’ functional currencies are the local currencies of their respective foreign jurisdictions. The Company translates the results of operations of its foreign subsidiaries into U.S. dollars using average rates of exchange in effect during the period presented, and it translates balance sheet accounts using exchange rates in effect at the end of the period presented. The Company records resulting currency translation adjustments in accumulated other comprehensive loss, a component of stockholders’ equity, on its consolidated balance sheets, and it records foreign currency transaction gains and losses as a component of other (expense) income on its consolidated statements of income (loss).
Derivative Instruments
The Company uses certain types of derivative instruments for the purpose of managing interest rate and currency risk. To qualify for hedge accounting, derivative instruments used for risk management purposes must effectively reduce the risk exposure that they are designed to hedge. In addition, at inception, the Company must make an assessment that the transaction that the Company intends to hedge is probable of occurring, and this assessment must be updated each reporting period.
The Company recognizes all derivative instruments as assets or liabilities on the consolidated balance sheets at their fair value. For derivatives designated and qualified as a hedge, the change in fair value of the effective portion of the derivatives is recognized in accumulated other comprehensive loss. Changes in the fair value of derivative instruments that are not designated in hedging relationships or that do not meet the criteria for hedge accounting would be recognized in earnings. In addition, the Company classifies cash flows from qualifying cash flow hedging relationships in the same category as the cash flows from the hedged items.
F-16


The Company formally documents all relationships between hedging instruments and hedged items, as well as its risk-management objectives and strategy for undertaking various hedge transactions. This process includes designating all derivatives that are part of a hedging relationship to specific transactions, as well as recognizing obligations or assets on the consolidated balance sheets. The Company also assesses and documents, both at inception of the hedging relationship and on a quarterly basis thereafter, whether the derivatives are highly effective in offsetting the designated risks associated with the respective hedged items. If it is determined that a derivative ceases to be highly effective as a hedge, or that it is probable the underlying transaction will not occur, the Company would discontinue hedge accounting prospectively and record the appropriate adjustment to earnings based on the then-current fair value of the derivative.
Fair Value Measurements
Under GAAP, the Company is required to measure certain financial instruments at fair value on a recurring basis. In addition, the Company is required to measure other financial instruments and balances at fair value on a non-recurring basis (e.g., carrying value of impaired loans receivable and long-lived assets). Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The GAAP fair value framework uses a three-tiered approach. Fair value measurements are classified and disclosed in one of the following three categories:
Level 1: unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities;
Level 2: quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which significant inputs and significant value drivers are observable in active markets; and
Level 3: prices or valuation techniques where little or no market data is available that requires inputs that are both significant to the fair value measurement and unobservable.
When available, the Company utilizes quoted market prices from an independent third-party source to determine fair value and classifies such items as Level 1 or Level 2. In instances where the market for a financial instrument is not active, regardless of the availability of a nonbinding quoted market price, observable inputs might not be relevant and could require the Company to make a significant adjustment to derive a fair value measurement. Additionally, in an inactive market, a market price quoted from an independent third party may rely more on models with inputs based on information available only to that independent third party. When the Company determines the market for a financial instrument owned by the Company to be illiquid or when market transactions for similar instruments do not appear orderly, the Company may use several valuation sources (including internal valuations, discounted cash flow analysis and quoted market prices) to establish a fair value. If more than one valuation source is used, the Company will assign weights to the various valuation sources. Additionally, when determining the fair value of liabilities in circumstances in which a quoted price in an active market for an identical liability is not available, the Company measures fair value using (i) a valuation technique that uses the quoted price of the identical liability when traded as an asset or quoted prices for similar liabilities or similar liabilities when traded as assets or (ii) another valuation technique that is consistent with the principles of fair value measurement, such as the income approach or the market approach.
Changes in assumptions or estimation methodologies can have a material effect on these estimated fair values. In this regard, the derived fair value estimates cannot be substantiated by comparison to independent markets and, in many cases, may not be realized in an immediate settlement of the instrument.
The Company considers the following factors to be indicators of an inactive market: (i) there are few recent transactions, (ii) price quotations are not based on current information, (iii) price quotations vary substantially either over time or among market makers (for example, some brokered markets), (iv) indexes that previously were highly correlated with the fair values of the asset or liability are demonstrably uncorrelated with recent indications of fair value for that asset or liability, (v) there is a significant increase in implied liquidity risk premiums, yields, or performance indicators (such as delinquency rates or loss severities) for observed transactions or quoted prices when compared with the Company’s estimate of expected cash flows, considering all available market data about credit and other nonperformance risk for the asset or liability, (vi) there is a wide bid-ask spread or significant increase in the bid-ask spread, (vii) there is a significant decline or absence of a market for new issuances (that is, a primary market) for the asset or liability or similar assets or liabilities, and (viii) little information is released publicly (for example, a principal-to-principal market).
The Company considers the following factors to be indicators of non-orderly transactions: (i) there was not adequate exposure to the market for a period before the measurement date to allow for marketing activities that are usual and customary for transactions involving such assets or liabilities under current market conditions, (ii) there was a usual and customary marketing period, but the seller marketed the asset or liability to a single market participant, (iii) the seller is in or near
F-17


bankruptcy or receivership (that is, distressed), or the seller was required to sell to meet regulatory or legal requirements (that is, forced), and (iv) the transaction price is an outlier when compared with other recent transactions for the same or similar assets or liabilities.
Per Share Data
Basic earnings per common share is computed by dividing net income applicable to common stockholders by the weighted average number of shares of common stock and common equivalents outstanding during the period. Diluted earnings per common share is calculated by including the effect of dilutive securities, such as the impact of forward equity sales agreements using the treasury stock method and common shares issuable from certain performance restricted stock units and unvested restricted stock units. See Note 14, “Earnings Per Common Share.”
Industry Segments
The Company has one reportable segment consisting of investments in healthcare-related real estate properties.
Beds, Units and Other Measures
The number of beds, units and other measures used to describe the Company’s real estate investments included in the Notes to Consolidated Financial Statements are presented on an unaudited basis.
Recently Issued Accounting Standards Update
Issued but Not Yet Adopted
In March 2020, the Financial Accounting Standards Board (“FASB”) issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”). ASU 2020-04 provides temporary optional guidance that provides transition relief for reference rate reform, including optional expedients and exceptions for applying GAAP to contract modifications, hedging relationships and other transactions that reference the London Interbank Offered Rate (“LIBOR”) or a reference rate that is expected to be discontinued as a result of reference rate reform if certain criteria are met. ASU 2020-04 is effective upon issuance, and the provisions generally can be applied prospectively as of January 1, 2020 through December 31, 2024. During the first quarter of 2020, the Company elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. As of July 1, 2023, the Company had converted all of its LIBOR-indexed debt and derivatives to Secured Overnight Financing Rate (“SOFR”)-based indexes (effective with the respective instrument’s next reset date for certain instruments). For all derivatives in hedge accounting relationships, the Company utilized the effective relief in Topic 848 that allows for the continuation of hedge accounting throughout the transition process. Application of these expedients preserves the presentation of derivatives consistent with past presentation. In January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848): Scope, which refines the scope of Topic 848 and clarifies some of its guidance. In December 2022, the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848, which defers the sunset date of Topic 848 from December 31, 2022 to December 31, 2024. The Company continues to evaluate the impact of the guidance as it relates to hedging relationships and other transactions that reference the Canadian Dollar Offered Rate (“CDOR”) which is expected to be discontinued in 2024 and may apply other elections as applicable as additional changes in the market occur.

F-18


3.RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED)
    During the year ended December 31, 2023, the Company acquired two skilled nursing/transitional care facilities, one Senior Housing - Leased community and one Senior Housing - Managed community. During the year ended December 31, 2022, the Company acquired three Senior Housing - Managed communities and one behavioral health facility. The Senior Housing - Managed community acquired during the year ended December 31, 2023 and two of the Senior Housing - Managed communities acquired during the year ended December 31, 2022 were part of the Company’s proprietary development pipeline and were previously reflected as preferred equity investments which had a book value of $4.6 million and $14.3 million, respectively, at the time of acquisition. The consideration was allocated as follows (in thousands):
Year Ended December 31,
20232022
Land$6,796 $11,767 
Building and improvements79,830 89,646 
Tenant origination and absorption costs intangible assets3,492 5,061 
Tenant relationship intangible assets255 41 
Total consideration$90,373 $106,515 
The tenant origination and absorption costs intangible assets and tenant relationship intangible assets had weighted-average amortization periods as of the respective dates of acquisition of four years and 22 years, respectively, for acquisitions completed during the year ended December 31, 2023. The tenant origination and absorption costs intangible assets and tenant relationship intangible assets had weighted-average amortization periods as of the respective dates of acquisition of two years and 25 years, respectively, for acquisitions completed during the year ended December 31, 2022.
For the year ended December 31, 2023, the Company recognized $10.4 million and $0.7 million of total revenues and net income, respectively, from the facilities acquired during the year ended December 31, 2023. For the year ended December 31, 2022, the Company recognized $11.1 million and $1.6 million of total revenues and net loss, respectively, from the facilities acquired during the year ended December 31, 2022.
During the three months ended June 30, 2023, the Company, in accordance with the terms of the agreements pursuant to which it purchased the facilities, paid $17.9 million in additional consideration related to two Senior Housing - Managed communities that achieved certain performance metrics. This amount is included in real estate investments, net of accumulated depreciation on the accompanying consolidated balance sheets.

4.INVESTMENT IN REAL ESTATE PROPERTIES
The Company’s real estate properties held for investment consisted of the following (dollars in thousands):
As of December 31, 2023  
Property TypeNumber of
Properties
Number of
Beds/Units
Total
Real Estate
at Cost
Accumulated
Depreciation
Total
Real Estate
Investments, Net
Skilled Nursing/Transitional Care241 26,769 $3,050,861 $(535,653)$2,515,208 
Senior Housing - Leased43 3,473 573,274 (109,601)463,673 
Senior Housing - Managed61 6,041 1,289,485 (255,803)1,033,682 
Behavioral Health18 1,159 496,737 (71,943)424,794 
Specialty Hospitals and Other15 392 225,443 (47,454)177,989 
378 37,834 5,635,800 (1,020,454)4,615,346 
Corporate Level2,547 (632)1,915 
$5,638,347 $(1,021,086)$4,617,261 
F-19


As of December 31, 2022
Property TypeNumber of
Properties
Number of
Beds/Units
Total
Real Estate
at Cost
Accumulated
Depreciation
Total
Real Estate
Investments, Net
Skilled Nursing/Transitional Care264 29,136 $3,385,221 $(492,495)$2,892,726 
Senior Housing - Leased47 3,550 590,694 (97,716)492,978 
Senior Housing - Managed59 5,942 1,205,283 (222,089)983,194 
Behavioral Health17 965 465,143 (58,481)406,662 
Specialty Hospitals and Other15 392 225,443 (42,038)183,405 
402 39,985 5,871,784 (912,819)4,958,965 
Corporate Level904 (526)378 
$5,872,688 $(913,345)$4,959,343 
As of December 31,
20232022
Building and improvements$4,843,258 $5,034,470 
Furniture and equipment238,185 262,644 
Land improvements10,306 7,085 
Land546,598 568,489 
Total real estate at cost5,638,347 5,872,688 
Accumulated depreciation(1,021,086)(913,345)
Total real estate investments, net$4,617,261 $4,959,343 
Operating Leases
As of December 31, 2023, the substantial majority of the Company’s real estate properties (excluding 61 Senior Housing - Managed communities) were leased under triple-net operating leases with expirations ranging from one year to 19 years. As of December 31, 2023, the leases had a weighted-average remaining term of eight years. The leases generally include provisions to extend the lease terms and other negotiated terms and conditions. The Company, through its subsidiaries, retains substantially all of the risks and benefits of ownership of the real estate assets leased to the tenants. The Company may receive additional security under these operating leases in the form of letters of credit and security deposits from the lessee or guarantees from the parent of the lessee. Security deposits received in cash related to tenant leases are included in accounts payable and accrued liabilities on the accompanying consolidated balance sheets and totaled $16.4 million and $13.0 million as of December 31, 2023 and 2022, respectively, and letters of credit deposited with the Company totaled approximately $56 million and $57 million as of December 31, 2023 and 2022, respectively. In addition, the Company’s tenants have deposited with the Company $12.4 million and $13.3 million as of December 31, 2023 and 2022, respectively, for future real estate taxes, insurance expenditures and tenant improvements related to the Company’s properties and their operations, and these amounts are included in accounts payable and accrued liabilities on the accompanying consolidated balance sheets.
Lessor costs that are paid by the lessor and reimbursed by the lessee are included in the measurement of variable lease revenue and the associated expense. As a result, the Company recognized variable lease revenue and the associated expense of $15.3 million, $17.7 million and $18.0 million during the years ended December 31, 2023, 2022 and 2021, respectively.
The Company monitors the creditworthiness of its tenants by evaluating the ability of the tenants to meet their lease obligations to the Company based on the tenants’ financial performance, including, as applicable and appropriate, the evaluation of any parent guarantees (or the guarantees of other related parties) of such lease obligations. The primary basis for the Company’s evaluation of the credit quality of its tenants (and more specifically the tenant’s ability to pay their rent obligations to the Company) is the tenant’s lease coverage ratio as supplemented by the parent’s fixed charge coverage ratio for those entities with a parent guarantee. These coverage ratios include earnings before interest, taxes, depreciation, amortization and rent (“EBITDAR”) to rent and earnings before interest, taxes, depreciation, amortization, rent and management fees (“EBITDARM”) to rent at the lease level and consolidated EBITDAR to total fixed charges at the parent guarantor level when such a guarantee exists. The Company obtains various financial and operational information from the majority of its tenants each month and reviews this information in conjunction with the above-described coverage metrics to identify financial and operational trends, evaluate the impact of the industry’s operational and financial environment (including the impact of government reimbursement), and evaluate the management of the tenant’s operations. These metrics help the Company identify
F-20


potential areas of concern relative to its tenants’ credit quality and ultimately the tenant’s ability to generate sufficient liquidity to meet its obligations, including its obligation to continue to pay the rent due to the Company.
In 2021, the Company concluded that its lease with the Avamere Family of Companies (“Avamere”) should no longer be accounted for on an accrual basis and wrote off $25.2 million of straight-line rent receivable balances, and in 2022, Avamere’s lease was amended to, among other things, reduce Avamere’s annual base rent to $30.7 million from $44.1 million, effective February 1, 2022.
In 2022, the Company concluded that its leases with North American Health Care, Inc. (“North American”) should no longer be accounted for on an accrual basis and wrote off $15.6 million of straight-line rent receivable balances related to these leases. The facilities were transitioned to the Ensign Group or Avamere, as applicable, effective February 1, 2023.
For the year ended December 31, 2023, no tenant relationship represented 10% or more of the Company’s total revenues.
As of December 31, 2023, the future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases were as follows and may materially differ from actual future rental payments received (in thousands):
2024$377,721 
2025372,911 
2026357,434 
2027334,489 
2028310,963 
Thereafter1,289,067 
$3,042,585 
Senior Housing - Managed Communities
The Company’s Senior Housing - Managed communities offer residents certain ancillary services that are not contemplated in the lease with each resident (i.e., housekeeping, laundry, guest meals, etc.). These services are provided and paid for in addition to the standard services included in each resident lease (i.e., room and board, standard meals, etc.). The Company bills residents for ancillary services one month in arrears and recognizes revenue as the services are provided, as the Company has no continuing performance obligation related to those services. Resident fees and services includes ancillary service revenue of $2.0 million, $1.5 million and $1.3 million for the years ended December 31, 2023, 2022 and 2021, respectively.
Capital and Other Expenditures
As of December 31, 2023, the Company’s aggregate commitment for future capital and other expenditures associated with facilities leased under triple-net operating leases was approximately $27 million. These commitments are principally for improvements to its facilities.
Investment in Unconsolidated Joint Ventures
The following is a summary of the Company’s investment in unconsolidated joint ventures (dollars in thousands):
Property Type
Number of
Properties as of
December 31, 2023
Ownership as of
December 31, 2023 (1)
Book Value as of December 31,
20232022
Sienna Joint VentureSenior Housing - Managed12 50 %$119,724 $120,269 
Marlin Spring Joint VentureSenior Housing - Managed4 85 %17,119 14,693 
$136,843 $134,962 
(1)    These investments are not consolidated because the Company does not control, through voting rights or other means, the joint ventures.
The Company formed a joint venture with Marlin Spring (the “Marlin Spring Joint Venture”) that completed the acquisition of one and three senior housing communities that are being managed by third-party operators during 2023 and 2022, respectively. The gross investment, excluding acquisition costs, by the Marlin Spring Joint Venture totaled CAD $30.0 million and CAD $82.5 million during 2023 and 2022, respectively. In addition, the Marlin Spring Joint Venture assumed and financed
F-21


an aggregate CAD $23.6 million and CAD $65.0 million of debt during 2023 and 2022, respectively. The Company’s equity investment was CAD $6.1 million and CAD $16.6 million during 2023 and 2022, respectively.
During 2022, the Company formed a joint venture with Sienna Senior Living (the “Sienna Joint Venture”), and the Sienna Joint Venture completed the acquisition of 12 senior housing communities that are being managed by Sienna Senior Living. The gross investment by the Sienna Joint Venture totaled CAD $379.0 million, excluding acquisition costs, and in addition, the Sienna Joint Venture assumed CAD $53.4 million of debt. The Company’s equity investment was CAD $161.8 million.
During the second quarter of 2021, the Company determined that it intended to eventually exit its 49% stake in the real estate platform of TPG (the “Enlivant Joint Venture”) and concluded that the carrying value exceeded the estimated fair value of the investment and deemed the decline to be other-than-temporary. This resulted in the Company recording an impairment charge totaling $164.1 million during the three months ended June 30, 2021 which is included in loss from unconsolidated joint ventures on the accompanying consolidated statements of income (loss).
During the fourth quarter of 2022, due to the confluence of labor shortages, increased labor costs, elevated interest rates and a slower than anticipated recovery in the operating performance of the underlying facilities, the Company concluded that the estimated fair value of its investment in the Enlivant Joint Venture had further declined to zero based on updated future cash flow analyses. This decline was deemed to be other-than-temporary, and the Company recorded an impairment charge totaling $57.8 million during the three months ended December 31, 2022 which is included in loss from unconsolidated joint ventures on the accompanying consolidated statements of income (loss).
Effective January 1, 2023, the Company discontinued applying the equity method of accounting to the Enlivant Joint Venture. Effective May 1, 2023, the Company withdrew and resigned its membership in the Enlivant Joint Venture and accordingly, no longer has an equity interest in the Enlivant Joint Venture as of such date.
Summarized Financial Information
The following tables present summarized financial information for the Company’s investments in unconsolidated joint ventures (in thousands).
As of December 31,
20232022
Total assets$353,779 $754,220 
Total liabilities106,490 894,969 
Member’s equity (deficit)247,289 (140,749)
Year Ended December 31,
202320222021
Total revenues$64,446 $351,073 $274,693 
Operating expenses (1)
47,811 324,462 265,194 
Net loss(9,823)(66,171)(35,276)
Company’s share of net loss$(2,897)$(32,581)$(17,184)
Basis adjustments 7,673 10,771 
Other-than-temporary impairment 57,778 164,126 
Loss from unconsolidated joint venture$(2,897)$(98,032)$(192,081)
(1)    During the years ended December 31, 2022 and 2021, TPG caused the Enlivant Joint Venture to fund $25.0 million and $20.0 million, respectively, of payments to Enlivant beyond amounts contractually required under the management agreement. These payments were to support the operations of Enlivant and are reflected as operating expenses. Funding for the support payments did not require capital contributions from Sabra but rather were funded with proceeds received by the Enlivant Joint Venture from TPG for the issuance of senior preferred interests or with cash on hand at the Enlivant Joint Venture.
Certain amounts in the financial information have been reclassified to conform to Sabra’s presentation. For the Enlivant Joint Venture, except for basis adjustments, other-than-temporary impairment and loss from unconsolidated joint venture, the financial information reflects the historical cost basis of the assets which pre-dated the Company’s investment in the Enlivant Joint Venture. In addition, the Company’s share of net loss in the Enlivant Joint Venture excludes certain equity-like compensation expense and the related income tax impact as such expense is not the responsibility of the Company under the terms of the joint venture agreement.
F-22


Net Investment in Sales-Type Lease
As of December 31, 2022, the Company had a $25.5 million net investment in one skilled nursing/transitional care facility leased to a tenant under a sales-type lease, as the tenant is obligated to purchase the property at the end of the lease term. During the three months ended March 31, 2023, the tenant purchased the skilled nursing/transitional care facility for net proceeds of $25.5 million as obligated under terms of the lease.

5.IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS
Impairment of Real Estate
During the years ended December 31, 2023, 2022 and 2021, the Company recognized real estate impairments of $14.3 million, $94.0 million and $9.5 million, respectively, related to three, 10 and three facilities, respectively. These facilities have either been sold or are closed.
To estimate the fair value of the impaired facilities, the Company utilized a market approach which considered binding sale agreements, non-binding offers from unrelated third parties or model-derived valuations with significant unobservable inputs (Level 3 measurements), as applicable.
The Company continues to evaluate additional assets for sale as part of its initiative to recycle capital and further improve its portfolio quality. This could lead to a shorter hold period and could result in the determination that the full amount of the Company’s investment is not recoverable, resulting in an impairment charge which could be material.
Dispositions
The following table summarizes the Company’s dispositions for the periods presented (dollars in millions):
Year Ended December 31,
202320222021
Number of facilities281816
Consideration, net of closing costs$255.6 $87.3 $103.4 
Net carrying value332.2 99.3 92.1 
Net (loss) gain on sale$(76.6)$(12.0)$11.3 
The Company recognized net loss of $80.9 million and $94.8 million during the years ended December 31, 2023 and 2022, respectively, and net income of $21.5 million during the year ended December 31, 2021, which includes impairment of real estate of $7.1 million, $94.0 million and $9.5 million for the years ended December 31, 2023, 2022 and 2021, respectively, and net (loss) gain on sale from these facilities.
The sale of the disposition facilities does not represent a strategic shift that has or will have a major effect on the Company’s operations and financial results, and therefore the results of operations attributable to these facilities have remained in continuing operations.

F-23


6.INTANGIBLE ASSETS AND LIABILITIES
The following table summarizes the Company’s intangible assets and liabilities as of December 31, 2023 and 2022 (in thousands):
As of December 31,
20232022
Lease Intangible Assets:
Above market leases$7,496 $7,496 
Tenant origination and absorption costs43,071 58,578 
Tenant relationship16,983 20,119 
Gross lease intangible assets67,550 86,193 
Accumulated amortization(36,653)(46,062)
Lease intangible assets, net$30,897 $40,131 
Lease Intangible Liabilities:
Below market leases$68,573 $80,208 
Accumulated amortization(36,041)(37,964)
Lease intangible liabilities, net$32,532 $42,244 
The following is a summary of real estate intangible amortization income (expense) for the years ended December 31, 2023, 2022 and 2021 (in thousands): 
Year Ended December 31,
202320222021
Increase (decrease) to rental income related to above/below market leases, net (1)
$5,821 $6,624 $(13,512)
Depreciation and amortization related to tenant origination and absorption costs and tenant relationship(11,616)(17,591)(8,694)
(1)    Balance for the year ended December 31, 2021 includes $18.6 million of accelerated amortization related to the above market lease intangible associated with the Company’s lease with Avamere. See Note 4, “Investment in Real Estate Properties,” for further discussion.
The remaining unamortized balance for these outstanding intangible assets and liabilities as of December 31, 2023 will be amortized for the years ending December 31 as follows (dollars in thousands):
Lease Intangible
Assets
 Lease Intangible
Liabilities
2024$5,523 $5,690 
20254,612 5,139 
20264,411 4,884 
20273,115 4,442 
20282,662 4,296 
Thereafter10,574 8,081 
$30,897 $32,532 
  
Weighted-average remaining amortization period8.8 years6.5 years

F-24


7.LOANS RECEIVABLE AND OTHER INVESTMENTS
    As of December 31, 2023 and 2022, the Company’s loans receivable and other investments consisted of the following (dollars in thousands):
As of December 31, 2023
Investment
Quantity
as of
December 31, 2023
Property Type
Principal Balance as of December 31, 2023 (1)
Book Value
as of
December 31, 2023
Book Value
as of
December 31, 2022
Weighted Average Contractual Interest Rate / Rate of ReturnWeighted Average Annualized Effective Interest Rate / Rate of Return
Maturity Date
as of
December 31, 2023
Loans Receivable:
Mortgage2 Behavioral Health$319,000 $319,000 $319,000 7.6 %7.6 %11/01/26 - 01/31/27
Other12 Multiple53,873 50,440 47,936 7.7 %7.4 %10/01/23 - 05/01/29
14 372,873 369,440 366,936 7.7 %7.6 %
Allowance for loan losses— (6,665)(6,611)
$372,873 $362,775 $360,325 
Other Investments:
Preferred Equity5 Skilled Nursing / Senior Housing57,681 57,849 51,071 11.0 %11.0 %N/A
Total19 $430,554 $420,624 $411,396 8.1 %8.1 %
(1)    Principal balance includes amounts funded and accrued but unpaid interest / preferred return and excludes capitalizable fees.
As of December 31, 2023, the Company has committed to provide up to $0.5 million of future funding related to one loan receivable investment.
Additional information regarding the Company’s loans receivable is as follows (dollars in thousands):
Year Ended December 31,
202320222021
Allowance for loan losses:
Balance at the beginning of the year$6,611 $6,344 $2,458 
Provision for loan losses192 267 3,886 
Write-off of uncollectible balances(138)  
Balance at the end of the year$6,665 $6,611 $6,344 
As of December 31,
20232022
Deteriorated credit quality:
Number of loans receivable investments1 1 
Principal balance$1,214 $1,214 
Book value  
Nonaccrual status:
Number of loans receivable investments3 3 
Book value$ $ 
As of December 31, 2023 and 2022, the Company did not consider any preferred equity investments to be impaired, and no preferred equity investments were on nonaccrual status.

F-25


8.DEBT
Secured Indebtedness
The Company’s secured debt consists of the following (dollars in thousands):
Principal Balance as of December 31, (1)
As of December 31, 2023
Weighted Average Interest Rate
Weighted Average Effective Interest Rate (2)
Interest Rate Type
2023
2022
Maturity Date
Fixed Rate$48,143 $50,123 2.85 %3.34 %May 2031 - 
August 2051
(1)    Principal balance does not include deferred financing costs, net of $0.8 million and $0.9 million as of December 31, 2023 and 2022, respectively.
(2)    Weighted average effective interest rate includes private mortgage insurance.
During the year ended December 31, 2022, the Company repaid $15.4 million of debt secured by three facilities.
During the year ended December 31, 2021, the Company sold two facilities and repaid $9.8 million of debt secured by the facilities which resulted in a $0.1 million loss on extinguishment of debt related to write-offs of deferred financing costs.
Senior Unsecured Notes
The Company’s senior unsecured notes consist of the following (dollars in thousands):
Principal Balance as of December 31, (1)
TitleMaturity Date
2023
2022
5.125% senior unsecured notes due 2026
August 15, 2026$500,000 $500,000 
5.88% senior unsecured notes due 2027
May 17, 2027100,000 100,000 
3.90% senior unsecured notes due 2029
October 15, 2029350,000 350,000 
3.20% senior unsecured notes due 2031
December 1, 2031800,000 800,000 
$1,750,000 $1,750,000 
(1)    Principal balance does not include discount, net of $4.3 million and deferred financing costs, net of $10.5 million as of December 31, 2023 and does not include discount, net of $3.5 million and deferred financing costs, net of $12.0 million as of December 31, 2022. In addition, the weighted average effective interest rate as of December 31, 2023 was 4.01%.
4.80% Notes Due 2024. On May 29, 2019, the Operating Partnership and Sabra Capital Corporation, wholly owned subsidiaries of the Company (the “Issuers”), completed an underwritten public offering of $300.0 million aggregate principal amount of 4.80% senior unsecured notes due 2024 (the “2024 Notes”). The net proceeds were $295.3 million after deducting underwriting discounts and other offering expenses.
On October 7, 2021, the Issuers redeemed all $300.0 million aggregate principal amount outstanding of the 2024 Notes at a cash redemption price of 110.045% of the principal amount being redeemed, plus accrued and unpaid interest. The redemption resulted in $32.7 million of redemption related costs and write-offs for the year ended December 31, 2021, consisting of $30.2 million in payments made to noteholders and legal fees for early redemption and $2.5 million of write-offs associated with unamortized discount and deferred financing costs.
5.125% Notes Due 2026. In connection with the Company’s merger with Care Capital Properties (“CCP”), on August 17, 2017, the Operating Partnership assumed $500.0 million aggregate principal amount of 5.125% senior unsecured notes due 2026 (the “2026 Notes”) issued by Care Capital Properties, LP in July 2016. The 2026 Notes accrue interest at a rate of 5.125% per annum payable semiannually on February 15 and August 15 of each year.
The Operating Partnership may, at its option, redeem the 2026 Notes at any time in whole or from time to time in part prior to their stated maturity. The redemption price for 2026 Notes that are redeemed will be equal to (i) 100% of their principal amount, together with accrued and unpaid interest thereon, if any, to (but excluding) the date of redemption, plus, (ii) if redeemed prior to May 15, 2026, a make-whole premium. Assuming the 2026 Notes are not redeemed, the 2026 Notes mature on August 15, 2026.
5.88% Notes Due 2027. In connection with the Company’s merger with CCP, on August 17, 2017, the Operating Partnership assumed $100.0 million aggregate principal amount of unregistered senior unsecured notes due 2027 (the “2027 Notes”) issued by Care Capital Properties, LP in May 2016. The 2027 Notes accrue interest at a rate of 5.88% per annum payable semiannually on May 17 and November 17 of each year.
F-26


The Operating Partnership may prepay the 2027 Notes, in whole at any time or in part from time to time, at 100% of the principal amount to be prepaid plus a make-whole premium. Assuming the 2027 Notes are not redeemed, the 2027 Notes mature on May 17, 2027.
3.90% Notes Due 2029. On October 7, 2019, the Issuers completed an underwritten public offering of $350.0 million aggregate principal amount of 3.90% senior unsecured notes due 2029 (the “2029 Notes”). The net proceeds were $340.5 million after deducting underwriting discounts and other offering expenses. A portion of the net proceeds was used to redeem all $200.0 million of 5.375% unsecured senior notes due 2023 (the “2023 Notes”), and the remaining net proceeds were used to repay borrowings outstanding on the Prior Revolving Credit Facility (as defined below). The 2029 Notes accrue interest at a rate of 3.90% per annum payable semiannually on April 15 and October 15 of each year. In 2019, Sabra Capital Corporation’s obligations as a co-issuer under the 2029 Notes were automatically released and discharged upon the redemption of the 2023 Notes.
The 2029 Notes are redeemable at the option of the Operating Partnership, in whole or in part at any time and from time to time, prior to July 15, 2029, at a price equal to 100% of the principal amount, together with any accrued and unpaid interest to, but not including, the redemption date, plus a make-whole premium. The Operating Partnership may also redeem the 2029 Notes on or after July 15, 2029, at a price equal to 100% of the principal amount, together with any accrued and unpaid interest to, but not including, the redemption date. Assuming the 2029 Notes are not redeemed, the 2029 Notes mature on October 15, 2029.
3.20% Notes Due 2031. On September 30, 2021, the Operating Partnership completed an underwritten public offering of $800.0 million aggregate principal amount of 3.20% senior unsecured notes due 2031 (the “2031 Notes”). The net proceeds were $782.2 million after deducting underwriting discounts and other offering expenses. The net proceeds were used to repay $345.0 million of the Company’s U.S. dollar Prior Term Loans (as defined below), redeem all of the 2024 Notes, as discussed above, and to fund a portion of one of the Company’s mortgage loans. The 2031 Notes accrue interest at a rate of 3.20% per annum payable semiannually on June 1 and December 1 of each year, commencing on June 1, 2022.
The 2031 Notes are redeemable at the option of the Operating Partnership, in whole or in part at any time and from time to time, prior to September 1, 2031, at a price equal to 100% of the principal amount, together with any accrued and unpaid interest to the redemption date, plus a “make-whole” premium. The Operating Partnership may also redeem the 2031 Notes on or after September 1, 2031, at a price equal to 100% of the principal amount, together with any accrued and unpaid interest to the redemption date. Assuming the 2031 Notes are not redeemed, the 2031 Notes mature on December 1, 2031.
The obligations under the 2027 Notes are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by Sabra and one of its non-operating subsidiaries, subject to release under certain customary circumstances. The obligations under the 2026 Notes, 2029 Notes and 2031 Notes are fully and unconditionally guaranteed, on an unsecured basis, by Sabra; provided, however, that such guarantee is subject to release under certain customary circumstances.
The indenture governing the 2026 Notes contains certain covenants that, among other things, limits the ability of Sabra, the Issuers and their subsidiaries to: (i) consummate a merger, consolidate or sell all or substantially all of our consolidated assets and (ii) incur secured or unsecured indebtedness. In addition, Sabra, the Operating Partnership and their subsidiaries are required to maintain at all times consolidated unencumbered total asset value in an amount not less than 150% of the aggregate outstanding principal amount of the Company’s consolidated unsecured debt.
The agreement governing the 2027 Notes provides for customary events of default, including, but not limited to, the failure to make payments of interest or premium, if any, on, or principal of, the 2027 Notes, the failure to comply with certain covenants and agreements specified in the agreement governing the 2027 Notes for a period of time after notice has been provided, the acceleration of other indebtedness resulting from the failure to pay principal on such other indebtedness prior to its maturity, and certain events of insolvency. In addition, certain change of control events constitute an event of default under the agreement governing the 2027 Notes. If any event of default occurs, the principal of, premium, if any, and accrued interest on all the then-outstanding 2027 Notes may become due and payable immediately.
The indenture governing the 2029 Notes and 2031 Notes contains restrictive covenants that, among other things, restrict the ability of Sabra, the Issuers and their subsidiaries to: (i) incur or guarantee additional indebtedness; (ii) incur or guarantee secured indebtedness; and (iii) merge or consolidate or sell all or substantially all of their assets. The indenture governing the 2029 Notes and 2031 Notes also provides for customary events of default, including, but not limited to, the failure to make payments of interest or premium, if any, on, or principal of, the 2029 Notes and 2031 Notes, the failure to comply with certain covenants and agreements specified in the indenture for a period of time after notice has been provided, the acceleration of other indebtedness resulting from the failure to pay principal on such other indebtedness prior to its maturity, and certain events of insolvency. If any event of default occurs, the principal of, premium, if any, and accrued interest on all the then-outstanding 2029 Notes and 2031 Notes may become due and payable immediately. The indenture governing the 2029 Notes and 2031
F-27


Notes requires Sabra, the Issuers and their subsidiaries to maintain Total Unencumbered Assets (as defined in the indentures) of at least 150% of the Company’s unsecured indebtedness.
The Company was in compliance with all applicable financial covenants under the indentures and agreements (the “Senior Notes Indentures”) governing the 2026 Notes, 2027 Notes, 2029 Notes and 2031 Notes (collectively, the “Senior Notes”) outstanding as of December 31, 2023.
Credit Agreement
On September 9, 2019, the Operating Partnership and Sabra Canadian Holdings, LLC (together, the “Borrowers”), Sabra and the other parties thereto entered into a fifth amended and restated unsecured credit agreement (the “Prior Credit Agreement”).
The Prior Credit Agreement included a $1.0 billion revolving credit facility (the “Prior Revolving Credit Facility”), a $436.3 million U.S. dollar term loan and a CAD $125.0 million Canadian dollar term loan (collectively, the “Prior Term Loans”). Further, up to $175.0 million of the Prior Revolving Credit Facility could be used for borrowings in certain foreign currencies. The Prior Credit Agreement also contained an accordion feature that allowed for an increase in the total available borrowings to $2.75 billion, subject to terms and conditions.
During the years ended December 31, 2022 and 2021, the Company recognized $0.4 million and $1.8 million, respectively, of loss on extinguishment of debt related to write-offs of deferred financing costs in connection with the partial pay down of the U.S. dollar Prior Term Loan.
Borrowings under the Prior Revolving Credit Facility bore interest on the outstanding principal amount at a rate equal to a ratings-based applicable interest margin plus, CDOR for Canadian dollar borrowings, or at the Operating Partnership’s option for U.S. dollar borrowings, either (a) LIBOR or (b) a base rate determined as the greater of (i) the federal funds rate plus 0.5%, (ii) the prime rate, and (iii) one-month LIBOR plus 1.0% (the “Prior Base Rate”). The ratings-based applicable interest margin for borrowings varied based on the Debt Ratings, as defined in the Prior Credit Agreement, and ranged from 0.775% to 1.45% per annum for CDOR or LIBOR based borrowings and 0.00% to 0.45% per annum for borrowings at the Prior Base Rate. In addition, the Operating Partnership paid a facility fee ranging between 0.125% and 0.300% per annum based on the aggregate amount of commitments under the Prior Revolving Credit Facility regardless of amounts outstanding thereunder.
The U.S. dollar Prior Term Loan bore interest on the outstanding principal amount at a rate equal to a ratings-based applicable interest margin plus, at the Operating Partnership’s option, either (a) LIBOR or (b) the Prior Base Rate. The ratings-based applicable interest margin for borrowings varied based on the Debt Ratings and ranged from 0.85% to 1.65% per annum for LIBOR based borrowings and 0.00% to 0.65% per annum for borrowings at the Prior Base Rate. The Canadian dollar Prior Term Loan bore interest on the outstanding principal amount at a rate equal to CDOR plus an interest margin ranged from 0.85% to 1.65% depending on the Debt Ratings.
On January 4, 2023, the Borrowers, and the other parties thereto entered into a sixth amended and restated unsecured credit agreement (the “Credit Agreement”). During the year ended December 31, 2023, the Company recorded $18.1 million of deferred financing costs related to the Credit Agreement and recognized $1.5 million of loss on extinguishment of debt related to write-offs of deferred financing costs in connection with amending and restating the Prior Credit Agreement.
The Credit Agreement includes a $1.0 billion revolving credit facility (the “Revolving Credit Facility”), a $430.0 million U.S. dollar term loan and a CAD $150.0 million Canadian dollar term loan (collectively, the “Term Loans”). Further, up to $350.0 million of the Revolving Credit Facility may be used for borrowings in certain foreign currencies. The Credit Agreement also contains an accordion feature that can increase the total available borrowings to $2.75 billion, subject to terms and conditions.
The Revolving Credit Facility has a maturity date of January 4, 2027, and includes two six-month extension options. The Term Loans have a maturity date of January 4, 2028.
As of December 31, 2023, there was $94.4 million (including CAD $44.3 million) outstanding under the Revolving Credit Facility and $905.6 million available for borrowing.
Borrowings under the Revolving Credit Facility bear interest on the outstanding principal amount at a rate equal to a ratings-based applicable interest margin plus, CDOR for Canadian dollar borrowings, or at the Operating Partnership’s option for U.S. dollar borrowings, either (a) Daily Simple SOFR, as defined in the Credit Agreement, or (b) a base rate determined as the greater of (i) the federal funds rate plus 0.5%, (ii) the prime rate, (iii) Term SOFR, as defined in the Credit Agreement, plus 1.0% (the “Base Rate”), and (iv) 1.00%. The ratings-based applicable interest margin for borrowings will vary based on the Debt Ratings, as defined in the Credit Agreement, and will range from 0.775% to 1.450% per annum for Daily Simple SOFR
F-28


based borrowings and 0.00% to 0.450% per annum for borrowings at the Base Rate. As of December 31, 2023, the weighted average interest rate on the Revolving Credit Facility was 6.57%. In addition, the Operating Partnership pays a facility fee ranging between 0.125% and 0.300% per annum based on the aggregate amount of commitments under the Revolving Credit Facility regardless of amounts outstanding thereunder.
The U.S. dollar Term Loan bears interest on the outstanding principal amount at a ratings-based applicable interest margin plus, at the Operating Partnership’s option, either (a) Term SOFR or (b) the Base Rate. The ratings-based applicable interest margin for borrowings will vary based on the Debt Ratings and will range from 0.850% to 1.650% per annum for Term SOFR based borrowings and 0.00% to 0.650% per annum for borrowings at the Base Rate. As of December 31, 2023, the interest rate on the U.S. dollar Term Loan was 6.73%. The Canadian dollar Term Loan bears interest on the outstanding principal amount at a rate equal CDOR plus an interest margin that will range from 0.850% to 1.650% depending on the Debt Ratings. As of December 31, 2023, the interest rate on the Canadian dollar Term Loan was 6.71%.
The Company has interest rate swaps and interest rate collars that fix and set a cap and floor, respectively, for the SOFR portion of the interest rate for $430.0 million of SOFR-based borrowings under its U.S. dollar Term Loan at a weighted average rate of 2.69% and interest rate swaps that fix the CDOR portion of the interest rate for CAD $150.0 million of CDOR-based borrowings under its Canadian dollar Term Loan at a rate of 1.63%. As of December 31, 2023, the effective interest rate on the U.S. dollar and Canadian dollar Term Loans was 3.94% and 2.88%, respectively. In addition, the Canadian dollar Term Loan and the CAD $44.3 million outstanding under the Revolving Credit Facility as of December 31, 2023 are designated as net investment hedges. See Note 9, “Derivative and Hedging Instruments,” for further information.
The obligations of the Borrowers under the Credit Agreement are guaranteed by the Company and certain of its subsidiaries.
The Credit Agreement contains customary covenants that include restrictions or limitations on the ability to pay dividends, incur additional indebtedness, engage in non-healthcare related business activities, enter into transactions with affiliates and sell or otherwise transfer certain assets as well as customary events of default. The Credit Agreement also requires Sabra, through the Operating Partnership, to comply with specified financial covenants, which include a maximum total leverage ratio, a maximum secured debt leverage ratio, a minimum fixed charge coverage ratio, a maximum unsecured leverage ratio, a minimum tangible net worth requirement and a minimum unsecured interest coverage ratio. As of December 31, 2023, the Company was in compliance with all applicable financial covenants under the Credit Agreement.
Interest Expense
During the years ended December 31, 2023, 2022 and 2021, the Company incurred interest expense of $113.0 million, $105.5 million and $98.6 million, respectively. Interest expense includes non-cash interest expense of $12.3 million, $11.1 million and $8.4 million for the years ended December 31, 2023, 2022 and 2021, respectively. As of December 31, 2023 and 2022, the Company had $16.5 million and $18.2 million, respectively, of accrued interest included in accounts payable and accrued liabilities on the accompanying consolidated balance sheets.
Maturities
The following is a schedule of maturities for the Company’s outstanding debt as of December 31, 2023 (in thousands):
Secured
Indebtedness
Revolving
Credit Facility (1)
Term LoansSenior NotesTotal
2024$2,033 $ $ $ $2,033 
20252,089    2,089 
20262,147   500,000 502,147 
20272,206 94,429  100,000 196,635 
20282,266  543,190  545,456 
Thereafter37,402   1,150,000 1,187,402 
Total Debt48,143 94,429 543,190 1,750,000 2,435,762 
Discount, net   (4,258)(4,258)
Deferred financing costs, net(842) (6,070)(10,489)(17,401)
Total Debt, Net$47,301 $94,429 $537,120 $1,735,253 $2,414,103 
(1)    Revolving Credit Facility is subject to two six-month extension options.

F-29


9.DERIVATIVE AND HEDGING INSTRUMENTS
The Company is exposed to various market risks, including the potential loss arising from adverse changes in interest rates and foreign exchange rates. The Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates and foreign exchange rates. The Company’s derivative financial instruments are used to manage differences in the amount of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s investments and borrowings.
Certain of the Company’s foreign operations expose the Company to fluctuations of foreign interest rates and exchange rates. These fluctuations may impact the value in the Company’s functional currency, the U.S. dollar, of the Company’s investment in foreign operations, the cash receipts and payments related to these foreign operations and payments of interest and principal under Canadian dollar denominated debt. The Company enters into derivative financial instruments to protect the value of its foreign investments and fix a portion of the interest payments for certain debt obligations. The Company does not enter into derivatives for speculative purposes.
Cash Flow Hedges
The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish these objectives, the Company primarily uses interest rate swaps and collars as part of its interest rate risk management strategy. As of December 31, 2023, approximately $6.9 million of gains, which are included in accumulated other comprehensive income, are expected to be reclassified into earnings in the next 12 months.
Net Investment Hedges
The Company is exposed to fluctuations in foreign exchange rates on investments it holds in Canada. The Company uses cross currency interest rate swaps to hedge its exposure to changes in foreign exchange rates on these foreign investments.
The following presents the notional amount of derivative instruments as of the dates indicated (in thousands):  
As of December 31,
20232022
Derivatives designated as cash flow hedges:
Denominated in U.S. Dollars (1)
$753,750 $436,250 
Denominated in Canadian Dollars (2)
$300,000 $125,000 
Derivatives designated as net investment hedges:
Denominated in Canadian Dollars$55,335 $55,991 
Financial instrument designated as net investment hedge:
Denominated in Canadian Dollars$194,300 $329,500 
Derivatives not designated as net investment hedges:
Denominated in Canadian Dollars$965 $309 
(1) Balance as of December 31, 2023 includes two forward starting interest rate swaps with an effective date of August 2024 and an aggregate notional amount of $323.8 million.
(2)    Balance as of December 31, 2023 includes two forward starting interest rate swaps with an effective date of September 2024 and an aggregate notional amount of CAD $150.0 million.
F-30


Derivative and Financial Instruments Designated as Hedging Instruments
The following is a summary of the derivative and financial instruments designated as hedging instruments held by the Company at December 31, 2023 and 2022 (dollars in thousands):    
Count as of December 31, 2023
Maturity Dates
Fair Value as of December 31,
TypeDesignation20232022Balance Sheet Location
Assets:
Interest rate swapsCash flow5 $6,002 $11,004 2024 - 2028Accounts receivable, prepaid expenses and other assets, net
Interest rate collarsCash flow2 3,216 6,622 2024Accounts receivable, prepaid expenses and other assets, net
Forward starting interest rate swapsCash flow4 6,736  2028Accounts receivable, prepaid expenses and other assets, net
Cross currency interest rate swapsNet investment2 2,964 3,851 2025Accounts receivable, prepaid expenses and other assets, net
$18,918 $21,477 
Liabilities:
CAD borrowings under Revolving Credit FacilityNet investment1 33,429 150,982 2027Revolving credit facility
CAD Term LoanNet investment1 113,190 92,288 2028Term loans, net
$146,619 $243,270 
The following presents the effect of the Company’s derivative and financial instruments designated as hedging instruments on the consolidated statements of income (loss) and the consolidated statements of equity for the years ended December 31, 2023, 2022 and 2021 (in thousands):
Gain (Loss) Recognized in Other Comprehensive Income (Loss)Gain (Loss) Reclassified from Accumulated Other Comprehensive Income (Loss)
Into Income
Income Statement Location
For the year ended December 31,
202320222021202320222021
Cash Flow Hedges:
Interest rate products$13,116 $22,032 $17,408 $8,332 $(4,179)$(12,774)Interest expense
Net Investment Hedges:
Foreign currency products(664)2,233 (272)   N/A
CAD borrowings under Revolving Credit Facility(3,456)9,454     N/A
CAD Term Loan(2,465)6,150 (338)   N/A
$6,531 $39,869 $16,798 $8,332 $(4,179)$(12,774)
During the years ended December 31, 2023, 2022 and 2021, no cash flow hedges were determined to be ineffective.
Derivatives Not Designated as Hedging Instruments
As of December 31, 2023, the Company had no material balances related to derivatives not designated as hedging instruments. During the years ended December 31, 2023, 2022 and 2021, the Company recorded $18,000, $0.1 million and $22,000 of other expense, respectively, related to the portion of derivatives not designated as hedging instruments.
F-31


Offsetting Derivatives
The Company enters into master netting arrangements, which reduce credit risk by permitting net settlement of transactions with the same counterparty. The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of December 31, 2023 and 2022 (in thousands):
As of December 31, 2023
Gross Amounts of Recognized Assets / LiabilitiesGross Amounts Offset in the Balance SheetNet Amounts of Assets / Liabilities presented in the Balance SheetGross Amounts Not Offset in the Balance Sheet
Financial InstrumentsCash Collateral ReceivedNet Amount
Offsetting Assets:
Derivatives$18,918 $ $18,918 $ $ $18,918 
Offsetting Liabilities:
Derivatives$ $ $ $ $ $ 
As of December 31, 2022
Gross Amounts of Recognized Assets / LiabilitiesGross Amounts Offset in the Balance SheetNet Amounts of Assets / Liabilities presented in the Balance SheetGross Amounts Not Offset in the Balance Sheet
Financial InstrumentsCash Collateral ReceivedNet Amount
Offsetting Assets:
Derivatives$21,477 $ $21,477 $ $ $21,477 
Offsetting Liabilities:
Derivatives$ $ $ $ $ $ 
Credit Risk-related Contingent Features
The Company has agreements with each of its derivative counterparties that contain a provision pursuant to which the Company could be declared in default on the derivative obligation if the Company defaults on any of its indebtedness, including a default where repayment of the indebtedness has not been accelerated by the lender. As of December 31, 2023, the Company had no derivatives in a net liability position related to these agreements.

10.FAIR VALUE DISCLOSURES
Financial Instruments
The fair value for certain financial instruments is derived using a combination of market quotes, pricing models and other valuation techniques that involve significant management judgment. The price transparency of financial instruments is a key determinant of the degree of judgment involved in determining the fair value of the Company’s financial instruments.
Financial instruments for which actively quoted prices or pricing parameters are available and whose markets contain orderly transactions will generally have a higher degree of price transparency than financial instruments whose markets are inactive or consist of non-orderly trades. The Company evaluates several factors when determining if a market is inactive or when market transactions are not orderly. The carrying values of cash and cash equivalents, restricted cash, accounts payable, accrued liabilities and the Credit Agreement are reasonable estimates of fair value because of the short-term maturities of these instruments. Fair values for other financial instruments are derived as follows:
Loans receivable: These instruments are presented on the accompanying consolidated balance sheets at their amortized cost and not at fair value. The fair values of the loans receivable were estimated using an internal valuation model that considered the expected cash flows for the loans receivable, as well as the underlying collateral value and other credit enhancements as applicable. The Company utilized discount rates ranging from 6% to 15% with a weighted average rate of 6% in its fair value calculation. As such, the Company classifies these instruments as Level 3.
Preferred equity investments: These instruments are presented on the accompanying consolidated balance sheets at their cost and not at fair value. The fair values of the preferred equity investments were estimated using an internal valuation model that considered the expected future cash flows for the preferred equity investments, the underlying collateral value and other credit enhancements. The Company utilized discount rates ranging from 10% to 15% with a weighted average rate of 11% in its fair value calculation. As such, the Company classifies these instruments as Level 3.
F-32


Derivative instruments: The Company’s derivative instruments are presented at fair value on the accompanying consolidated balance sheets. The Company estimates the fair value of derivative instruments, including its interest rate swaps, interest rate collars and cross currency swaps, using the assistance of a third party using inputs that are observable in the market, which include forward yield curves and other relevant information. Although the Company has determined that the majority of the inputs used to value its derivative financial instruments fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivative financial instruments utilize Level 3 inputs, such as estimates of current credit spreads, to evaluate the likelihood of default by itself and its counterparties. The Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of its derivative financial instruments. As a result, the Company has determined that its derivative financial instruments valuations in their entirety are classified in Level 2 of the fair value hierarchy.
Senior Notes: These instruments are presented on the accompanying consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Senior Notes were determined using third-party market quotes derived from orderly trades. As such, the Company classifies these instruments as Level 2.
Secured indebtedness: These instruments are presented on the accompanying consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Company’s secured debt were estimated using a discounted cash flow analysis based on management’s estimates of current market interest rates for instruments with similar characteristics, including remaining loan term, loan-to-value ratio, type of collateral and other credit enhancements. The Company utilized a rate of 6% in its fair value calculation. As such, the Company classifies these instruments as Level 3.
The following are the face values, carrying amounts and fair values of the Company’s financial instruments as of December 31, 2023 and 2022 whose carrying amounts do not approximate their fair value (in thousands):
 As of December 31, 2023As of December 31, 2022
 
Face
Value
(1)
Carrying
Amount
(2)
Fair
Value
Face
Value
(1)
Carrying
Amount
(2)
Fair
Value
Financial assets:
Loans receivable$372,873 $362,775 $383,141 $370,364 $360,325 $370,188 
Preferred equity investments57,681 57,849 59,526 50,902 51,071 51,995 
Financial liabilities:
Senior Notes1,750,000 1,735,253 1,567,428 1,750,000 1,734,431 1,463,041 
Secured indebtedness48,143 47,301 36,279 50,123 49,232 38,149 
(1)    Face value represents amounts contractually due under the terms of the respective agreements.
(2)    Carrying amount represents the book value of financial instruments, including unamortized premiums/discounts and deferred financing costs.
The Company determined the fair value of financial instruments as of December 31, 2023 whose carrying amounts do not approximate their fair value with valuation methods utilizing the following types of inputs (in thousands):
Fair Value Measurements Using
TotalQuoted Prices in
Active Markets for
Identical Assets
(Level 1)
Significant Other
Observable Inputs
(Level 2)
Significant
Unobservable Inputs
(Level 3)
Financial assets:
Loans receivable$383,141 $ $ $383,141 
Preferred equity investments59,526   59,526 
Financial liabilities:
Senior Notes1,567,428  1,567,428  
Secured indebtedness36,279   36,279 
Disclosure of the fair value of financial instruments is based on pertinent information available to the Company at the applicable dates and requires a significant amount of judgment. Transaction volume for certain of the Company’s financial instruments remains relatively low, which has made the estimation of fair values difficult. Therefore, both the actual results and the Company’s estimate of fair value at a future date could be materially different.
F-33


Items Measured at Fair Value on a Recurring Basis
During the year ended December 31, 2023, the Company recorded the following amounts measured at fair value (in thousands):
Fair Value Measurements Using
TotalQuoted Prices in
Active Markets for
Identical Assets
(Level 1)
Significant Other
Observable Inputs
(Level 2)
Significant
Unobservable Inputs
(Level 3)
Recurring Basis:
Financial assets:
Interest rate swaps$6,002 $ $6,002 $ 
Interest rate collars3,216  3,216  
Forward starting interest rate swaps6,736  6,736  
Cross currency interest rate swaps2,964  2,964  

11.EQUITY
Common Stock
On December 11, 2019, the Company established an at-the-market equity offering program (the “2019 ATM Program”) pursuant to which shares of its common stock having an aggregate gross sales price of up to $400.0 million may be sold from time to time (i) by the Company through a consortium of banks acting as sales agents or directly to the banks acting as principals or (ii) by a consortium of banks acting as forward sellers on behalf of any forward purchasers pursuant to a forward sale agreement. On August 6, 2021, the Company terminated the 2019 ATM Program pursuant to its termination rights.
During the year ended December 31, 2021, the Company sold 2.2 million shares under the 2019 ATM Program at an average price of $17.78 per share, generating gross proceeds of $38.8 million (before $0.6 million of commissions), excluding sales utilizing the forward feature of the 2019 ATM Program, as described below.
Additionally, during the year ended December 31, 2021, the Company utilized the forward feature of the 2019 ATM Program to allow for the sale of up to 6.8 million shares of the Company’s common stock at an initial weighted average price of $17.49 per share, net of commissions. During the year ended December 31, 2021, the Company settled 7.9 million (inclusive of the 6.8 million shares referenced in the immediately preceding sentence, and constituting all of the open forward positions under the 2019 ATM Program) at a weighted average net price of $17.36 per share, after commissions and fees, resulting in net proceeds of $137.0 million.
On August 6, 2021, the Company established a new at-the-market equity offering program (the “Prior ATM Program”) pursuant to which shares of its common stock having an aggregate gross sales price of up to $500.0 million may be sold from time to time (i) by the Company through a consortium of banks acting as sales agents or directly to the banks acting as principals or (ii) by a consortium of banks acting as forward sellers on behalf of any forward purchasers pursuant to a forward sale agreement. On November 9, 2022, the Company terminated the Prior ATM Program.
During the year ended December 31, 2021, the Company utilized the forward feature of the Prior ATM Program to allow for the sale of up to 1.7 million shares of the Company’s common stock at an initial weighted average price of $14.56 per share, net of commissions, and settled all of the open forward positions under the Prior ATM Program by issuing 1.7 million shares at a weighted average net price of $14.23 per share, after commissions and fees, resulting in net proceeds of $24.2 million. No other shares were sold under the Prior ATM Program during the year ended December 31, 2021. No shares were sold under the Prior ATM Program and the Company did not utilize the forward feature of the Prior ATM Program during the period from January 1, 2022 to November 9, 2022.
On October 15, 2021, the Company completed an underwritten public offering of 7.8 million newly issued shares of its common stock pursuant to an effective registration statement. The Company received net proceeds, before expenses, of $112.6 million from the offering at a price of $14.40 per share. These proceeds were used to fund a portion of one of the Company’s mortgage loan investments.
On February 23, 2023, the Company established an at-the-market equity offering program (the “ATM Program”) pursuant to which shares of its common stock having an aggregate gross sales price of up to $500.0 million may be sold from time to time (i) by the Company through a consortium of banks acting as sales agents or directly to the banks acting as
F-34


principals or (ii) by a consortium of banks acting as forward sellers on behalf of any forward purchasers pursuant to a forward sale agreement. The use of a forward sale agreement would allow the Company to lock in a share price on the sale of shares at the time the agreement is effective, but defer receiving the proceeds from the sale of the shares until a later date. The Company may also elect to cash settle or net share settle all or a portion of its obligations under any forward sale agreement. The forward sale agreements have a one year term during which time the Company may settle the forward sales by delivery of physical shares of common stock to the forward purchasers or, at the Company’s election, in cash or net shares. The forward sale price that the Company expects to receive upon settlement will be the initial forward price established upon the effective date, subject to adjustments for (i) the forward purchasers’ stock borrowing costs and (ii) certain fixed price reductions during the term of the agreement.
During the year ended December 31, 2023, no shares were sold under the ATM Program and the Company did not utilize the forward feature of the ATM Program. As of December 31, 2023, the Company had $500.0 million available under the ATM Program.
During the years ended December 31, 2023, 2022 and 2021, the Company issued 0.3 million, 0.6 million and 0.2 million shares, respectively, of common stock as a result of restricted stock unit vestings.
Upon any payment of shares to teammates as a result of restricted stock unit vestings, the teammates’ related tax withholding obligation will generally be satisfied by the Company, reducing the number of shares to be delivered by a number of shares necessary to satisfy the related applicable tax withholding obligation. During the years ended December 31, 2023, 2022 and 2021, the Company incurred $1.8 million, $3.3 million and $2.1 million, respectively, in tax withholding obligations on behalf of its teammates that were satisfied through a reduction in the number of shares delivered to those participants.
Accumulated Other Comprehensive Income
The following is a summary of the Company’s accumulated other comprehensive income (in thousands):
As of December 31,
20232022
Foreign currency translation gain$963 $1,168 
Unrealized gain on cash flow hedges22,782 17,895 
Total accumulated other comprehensive income$23,745 $19,063 

12.STOCK-BASED COMPENSATION
All stock-based awards are subject to the terms of the 2009 Performance Incentive Plan, which was assumed by the Company effective as of November 15, 2010 in connection with the Company’s separation from Sun and was most recently amended and restated in April 2017. The 2009 Performance Incentive Plan provides for the granting of stock-based compensation, including stock options, time-based stock units, funds from operations-based stock units (“FFO Units”), relative total stockholder return-based stock units (“TSR Units”) and performance-based restricted stock units to directors, officers and other teammates in connection with their employment with or services provided to the Company.
Restricted Stock Units and Performance-Based Restricted Stock Units
Under the 2009 Performance Incentive Plan, restricted stock units and performance-based restricted stock units generally have a contractual life or vest over a three- to five-year period. The vesting of certain restricted stock units may accelerate, as defined in the grant, upon retirement, a change in control and other events. When vested (and subject to any applicable deferral or holdback period), each performance-based restricted stock unit is convertible into one share of common stock, subject to any deferrals in issuance pursuant to the grant. The restricted stock units are valued on the grant date based on the market price of the Company’s common stock on that date. Generally, the Company recognizes the fair value of the awards over the applicable vesting period as compensation expense. In addition, since the shares to be issued may vary based on the performance of the Company, the Company must make assumptions regarding the projected performance criteria and the shares that will ultimately be issued. The amount of FFO Units that will ultimately vest is dependent on the amount by which the Company’s funds from operations as adjusted (“FFO”) differs from a target FFO amount for a period specified in each grant and will range from 0% to 200% of the FFO Units initially granted. Similarly, the amount of TSR Units that will ultimately vest is dependent on the amount by which the total shareholder return (“TSR”) of the Company’s common stock differs from a predefined peer group for a period specified in each grant and will range from 0% to 200% of the TSR Units initially granted. Upon any payment of shares as a result of restricted stock unit vestings, the related tax withholding obligation will generally be satisfied by the Company, reducing the number of shares to be delivered by a number of shares necessary to satisfy the related applicable tax
F-35


withholding obligation. The value of the shares withheld is dependent on the closing price of the Company’s common stock on the date the relevant transaction occurs.
The following table summarizes additional information concerning restricted stock units at December 31, 2023:
Restricted Stock UnitsWeighted Average Grant Date Fair Value Per Unit
Unvested as of December 31, 20222,147,784 $15.07 
Granted832,308 14.73 
Vested(591,745)15.34 
Dividends reinvested237,195 14.96 
Cancelled/forfeited(156,275)19.51 
Unvested as of December 31, 20232,469,267 $14.61 
As of December 31, 2023, the weighted average remaining vesting period of restricted stock units was 2.7 years. The weighted average fair value per share at the date of grant for restricted stock units for the years ended December 31, 2023, 2022 and 2021 was $14.73, $12.78 and $15.55, respectively. The total fair value of units vested during the years ended December 31, 2023, 2022 and 2021 was $9.1 million, $5.7 million and $15.9 million, respectively.
The fair value of the TSR Units is estimated on the date of grant using a Monte Carlo valuation model that uses the assumptions noted in the table below. The risk-free rate is based on the U.S. Treasury yield curve in effect at the grant date for the expected performance period. Expected volatility is based on historical volatility for the most recent 3-year period ending on the grant date for the Company and the selected peer companies, and is calculated on a daily basis. The following are the key assumptions used in this valuation:
202320222021
Risk free interest rate
3.98% - 4.13%
0.99% - 4.13%
0.17% - 0.99%
Expected stock price volatility
30.17% - 56.11%
53.60% - 56.11%
53.17% - 53.60%
Expected service period
3.0 years
3.0 years
3.0 years
Expected dividend yield (assuming full reinvestment) % % %
During the years ended December 31, 2023, 2022 and 2021, the Company recognized $7.9 million, $7.5 million and $7.9 million, respectively, of stock-based compensation expense included in general and administrative expense in the consolidated statements of income (loss). As of December 31, 2023, there was $25.7 million of total unrecognized stock-based compensation expense related to unvested awards, which is expected to be recognized over a weighted average period of 2.7 years.
Employee Benefit Plan
The Company maintains a 401(k) plan that allows for eligible participants to defer compensation, subject to certain limitations imposed by the Internal Revenue Code of 1986, as amended (the “Code”). The Company provides a discretionary matching contribution of up to 4% of each participant’s eligible compensation. During each of the years ended December 31, 2023, 2022 and 2021, the Company’s matching contributions were $0.3 million.

13.INCOME TAXES
The Company elected to be treated as a REIT with the filing of its U.S. federal income tax return for the taxable year beginning January 1, 2011. To qualify as a REIT, the Company must meet a number of organizational and operational requirements, including a requirement to distribute at least 90% of its taxable ordinary income. In addition, the Company is required to meet certain asset and income tests. As a REIT, the Company generally will not be subject to corporate level federal income tax on taxable income that it distributes to its stockholders. The Company also elected to treat certain of its consolidated subsidiaries as taxable REIT subsidiaries, which are subject to federal, state and foreign income taxes. In addition, as a result of our investments in Canada, the Company is subject to income taxes under the laws of Canada.
F-36


The following is a summary of the Company’s provision for income taxes and deferred taxes (in thousands):
Year Ended December 31,
202320222021
Provision for federal, state and local income taxes$2,002 $1,234 $2,263 
Provision (benefit) for foreign income taxes 8 (418)
Income tax expense$2,002 $1,242 $1,845 
As of December 31,
20232022
Deferred tax assets:
Federal$9,553 $6,390 
Valuation allowance on federal(9,553)(6,390)
Foreign12,211 8,455 
Valuation allowance on foreign(12,169)(8,430)
Deferred tax (liabilities):
Foreign(42)(25)
$ $ 
The Company classifies interest and penalties from significant uncertain tax positions as interest expense and operating expenses, respectively, in its consolidated financial statements. During the years ended December 31, 2023, 2022 and 2021, the Company did not incur any such interest or penalties. With certain exceptions, the tax years 2020 and thereafter remain open to examination by the major taxing jurisdictions with which the Company files tax returns.

14.EARNINGS PER COMMON SHARE
The following table illustrates the computation of basic and diluted earnings per share (in thousands, except share and per share amounts):
Year Ended December 31,
202320222021
Numerator
Net income (loss)$13,756 $(77,605)$(113,256)
Denominator
Basic weighted average common shares and common equivalents231,203,391 230,947,895 219,073,027 
Dilutive restricted stock units1,589,387   
Diluted weighted average common shares232,792,778 230,947,895 219,073,027 
Net income (loss), per:
Basic common share$0.06 $(0.34)$(0.52)
Diluted common share$0.06 $(0.34)$(0.52)
During the years ended December 31, 2023, 2022 and 2021, approximately 500, 0.9 million and 1.0 million restricted stock units, respectively, and during the year ended December 31, 2021, approximately 25,000 shares related to forward equity sale agreements, were not included in computing diluted earnings per share because they were considered anti-dilutive.

15.COMMITMENTS AND CONTINGENCIES
Environmental
As an owner of real estate, the Company is subject to various environmental laws of federal, state and local governments. The Company is not aware of any environmental liability that could have a material adverse effect on its financial condition or results of operations. However, changes in applicable environmental laws and regulations, the uses and conditions of properties in the vicinity of the Company’s properties, the activities of its tenants and other environmental conditions of which the Company is unaware with respect to the properties could result in future environmental liabilities. As of December 31, 2023,
F-37


the Company does not expect that compliance with existing environmental laws will have a material adverse effect on the Company’s financial condition and results of operations.
Legal Matters
From time to time, the Company and its subsidiaries are party to legal proceedings that arise in the ordinary course of its business. Management is not aware of any legal proceedings where the likelihood of a loss contingency is reasonably possible and the amount or range of reasonably possible losses is material to the Company’s results of operations, financial condition or cash flows.

16.SUBSEQUENT EVENTS
The Company evaluates subsequent events up until the date the consolidated financial statements are issued.
Dividend Declaration
On February 1, 2024, the Company’s board of directors declared a quarterly cash dividend of $0.30 per share of common stock. The dividend will be paid on February 29, 2024 to common stockholders of record as of the close of business on February 13, 2024.
F-38



SCHEDULE III
REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION
As of December 31, 2023
(dollars in thousands)
Initial Cost to CompanyCost Capitalized Subsequent to AcquisitionGross Amount at which Carried at Close of PeriodLife on Which Depreciation in Latest Income Statement is Computed
 DescriptionOwnership Percentage
Encum- brances(1)
Land 
Building and Improve- ments(2)(3)
Total 
Land 
Building and Improve- ments(2)(3)
Total Accumulated Depreciation and AmortizationOriginal Date of Construction/ Renovation 
Date Acquired
Skilled Nursing/Transitional Care Facilities         
Bedford, NH100%$5,006 $1,911 $12,245 $14,156 $ $1,911 $10,546 $12,457 $(5,272)1992/2010, 201911/15/1036
Milford, NH100% 312 1,679 1,991  312 1,168 1,480 (986)1890/200511/15/1020
North Conway, NH100%10,337 417 5,352 5,769  417 4,374 4,791 (2,006)1988/200911/15/1043
Wolfeboro, NH100%8,708 454 4,531 4,985  454 3,747 4,201 (1,669)1984/1986, 1987, 200911/15/1041
Middletown, DE100% 1,650 21,730 23,380  1,650 21,730 23,380 (7,574)200508/01/1140
Dover, DE100% 4,940 15,500 20,440  4,940 15,500 20,440 (5,676)1996/201608/01/1140
Wilmington, DE100% 2,460 25,240 27,700 12,436 2,460 37,676 40,136 (9,841)2009/202208/01/1140
Millsboro, DE100% 1,640 22,620 24,260  1,632 22,620 24,252 (8,095)200808/01/1140
Warrington, PA100% 2,617 11,662 14,279 395 2,617 288 2,905  1958/2009/ 201603/30/1240
Duffield, VA100% 509 5,018 5,527 1,333 509 5,964 6,473 (2,388)1981/201305/10/1240
Arlington, TX100% 3,783 14,219 18,002  3,783 13,702 17,485 (3,956)2003/201211/30/1240
Rockport, TX100% 1,005 6,628 7,633  1,005 6,212 7,217 (1,824)2002/2012, 201811/30/1240
Lincoln, NE100% 6,368 29,919 36,287  6,368 29,919 36,287 (8,351)1962/1996, 201302/14/1440
Fremont, NE100% 615 16,176 16,791  615 16,176 16,791 (4,953)200802/14/1440
Fremont, NE100% 615 2,943 3,558  615 2,943 3,558 (1,069)1970/1979, 1983, 199402/14/1440
Bartlesville, OK100% 1,332 6,904 8,236 986 1,332 7,890 9,222 (2,190)1989/201910/29/1440
Oklahoma City, OK100% 2,189 23,567 25,756 2,534 2,189 25,749 27,938 (6,639)1963/1984, 2018, 201910/29/1440
Norman, OK100% 869 5,236 6,105 785 869 6,021 6,890 (1,847)2001/2013, 201910/29/1440
Minneapolis, MN100% 2,931 6,943 9,874 1,190 2,931 7,999 10,930 (1,800)1941/2014, 201908/17/1740
Eugene, OR100% 2,205 28,700 30,905 2,252 2,205 30,952 33,157 (5,883)1988/201608/17/1740
Lebanon, OR100% 958 14,176 15,134  958 14,176 15,134 (2,427)197408/17/1740
Portland, OR100% 1,791 12,833 14,624 2,761 1,791 15,594 17,385 (3,466)1964/201608/17/1740
F-39


Initial Cost to CompanyCost Capitalized Subsequent to AcquisitionGross Amount at which Carried at Close of PeriodLife on Which Depreciation in Latest Income Statement is Computed
 DescriptionOwnership Percentage
Encum- brances(1)
Land 
Building and Improve- ments(2)(3)
Total 
Land 
Building and Improve- ments(2)(3)
Total Accumulated Depreciation and AmortizationOriginal Date of Construction/ Renovation 
Date Acquired
Tigard, OR100% 2,011 11,667 13,678  2,011 11,667 13,678 (2,064)197508/17/1740
Hillsboro, OR100% 1,387 14,028 15,415  1,387 14,028 15,415 (2,399)197308/17/1740
Junction City, OR100% 584 7,901 8,485  584 7,901 8,485 (1,403)1966/201508/17/1740
Eugene, OR100% 1,380 14,921 16,301 1,791 1,380 16,712 18,092 (3,421)1966/201608/17/1740
Coos Bay, OR100% 829 8,518 9,347  829 8,518 9,347 (1,569)196808/17/1740
Gladstone, OR100% 792 5,000 5,792  792 5,000 5,792 (907)196108/17/1740
Newport, OR100% 406 5,001 5,407  406 5,001 5,407 (866)1973/201408/17/1740
Oregon City, OR100% 1,496 12,142 13,638  1,496 12,142 13,638 (2,076)197408/17/1740
Tacoma, WA100% 1,771 11,595 13,366 15 1,771 11,610 13,381 (2,313)201708/17/1740
Shoreline, WA100% 4,703 14,444 19,147  4,703 14,444 19,147 (2,559)1993/201408/17/1740
Bellingham, WA100%  15,330 15,330   15,330 15,330 (2,740)1984/201508/17/1740
Sequim, WA100% 427 4,450 4,877  427 4,450 4,877 (954)197408/17/1740
Tacoma, WA100% 1,705 4,952 6,657  1,705 4,952 6,657 (925)196808/17/1740
Tacoma, WA100% 2,195 1,956 4,151  2,195 1,956 4,151 (484)1972/201408/17/1740
Vancouver, WA100% 1,782 15,116 16,898  1,782 15,116 16,898 (2,798)199108/17/1740
Lake Oswego, OR100% 5,947 13,401 19,348  5,947 13,401 19,348 (2,395)2005/201608/17/1740
Medford, OR100% 2,043 38,485 40,528 2,960 2,043 41,445 43,488 (7,773)1974/201608/17/1740
Seattle, WA100% 2,508 6,401 8,909  2,508 6,401 8,909 (1,158)197008/17/1740
Boise, ID100% 681 9,348 10,029 627 681 9,975 10,656 (1,774)197908/17/1740
Salem, OR100% 2,114 15,651 17,765  2,114 15,651 17,765 (2,758)198108/17/1740
Medford, OR100% 1,375 23,808 25,183  1,375 23,808 25,183 (4,231)1961/201608/17/1740
Northglenn, CO100% 1,662 26,014 27,676 3,258 1,662 29,272 30,934 (5,916)1972/201608/17/1740
Brighton, CO100% 1,933 11,624 13,557 200 1,933 11,824 13,757 (2,166)197108/17/1740
Santa Ana, CA100% 1,889 11,682 13,571  1,889 11,682 13,571 (1,947)200808/17/1740
La Mesa, CA100% 1,276 8,177 9,453  1,276 8,177 9,453 (1,416)201208/17/1740
Westminster, MD100% 2,128 6,614 8,742 487 2,128 6,978 9,106 (1,618)1973/2010, 201908/17/1740
F-40


Initial Cost to CompanyCost Capitalized Subsequent to AcquisitionGross Amount at which Carried at Close of PeriodLife on Which Depreciation in Latest Income Statement is Computed
 DescriptionOwnership Percentage
Encum- brances(1)
Land 
Building and Improve- ments(2)(3)
Total 
Land 
Building and Improve- ments(2)(3)
Total Accumulated Depreciation and AmortizationOriginal Date of Construction/ Renovation 
Date Acquired
Kansas City, MO100% 1,985 2,714 4,699 303 1,714  1,714  198308/17/1740
Parkersburg, WV100% 697 10,688 11,385 285 697 10,911 11,608 (2,428)1974/1999, 201908/17/1740
Cincinnati, OH100% 2,686 10,062 12,748 295 2,686 10,357 13,043 (2,058)1989/201508/17/1740
Charlottesville, VA100% 2,840 8,450 11,290 1,176 2,840 9,523 12,363 (2,334)1964/2009, 201908/17/1740
Annandale, VA100% 7,241 17,727 24,968 3,218 7,241 20,864 28,105 (4,579)1963/2013, 201908/17/1740
Petersburg, VA100% 988 8,416 9,404 146 988 8,478 9,466 (1,672)1970/200908/17/1740
Petersburg, VA100% 1,174 8,858 10,032 151 1,174 8,942 10,116 (1,749)1976/201008/17/1740
Hagerstown, MD100% 1,393 13,438 14,831 150 1,393 13,477 14,870 (2,501)1971/201008/17/1740
Cumberland, MD100% 800 16,973 17,773 457 800 17,305 18,105 (3,237)196808/17/1740
Gilroy, CA100% 662 23,775 24,437  662 23,775 24,437 (4,022)1968/202108/17/1740
Mount Pleasant, SC100% 2,689 3,942 6,631 205 2,689 4,147 6,836 (831)1977/201508/17/1740
Harrogate, TN100% 1,811 4,963 6,774  1,811 4,963 6,774 (1,054)1990/200508/17/1740
Conway, SC100% 1,408 10,784 12,192 295 1,408 11,079 12,487 (2,075)197508/17/1740
Baytown, TX100% 426 3,236 3,662 173 426 3,251 3,677 (683)1975/201908/17/1740
Huntsville, TX100% 302 3,153 3,455 75 302 3,168 3,470 (644)1968/201908/17/1740
Center, TX100% 231 1,335 1,566 312 231 1,477 1,708 (398)1972/201908/17/1740
Humble, TX100% 2,114 1,643 3,757 596 2,114 1,953 4,067 (571)1972/201908/17/1740
Houston, TX100% 1,019 5,734 6,753 318 1,019 5,807 6,826 (1,124)1982/201908/17/1740
Linden, TX100% 112 256 368 133 112 280 392 (98)1968/201908/17/1740
Sherman, TX100% 469 6,310 6,779 255 469 6,338 6,807 (1,188)1971/201908/17/1740
Mount Pleasant, TX100% 250 6,913 7,163 345 250 7,160 7,410 (1,372)1970/201908/17/1740
Waxahachie, TX100% 416 7,259 7,675 976 416 8,106 8,522 (1,618)1976/201908/17/1740
Gilmer, TX100% 707 4,552 5,259 93 707 4,562 5,269 (910)1990/201908/17/1740
Sparks, NV100% 1,986 9,004 10,990  1,986 9,004 10,990 (1,714)198808/17/1740
Richmond, IN100% 259 9,819 10,078 131 259 9,950 10,209 (1,856)1975/200508/17/1740
Petersburg, IN100% 581 5,367 5,948 23 581 5,390 5,971 (1,054)1970/200908/17/1740
Maryville, MO100% 114 5,955 6,069  150 5,955 6,105 (1,187)197208/17/1740
F-41


Initial Cost to CompanyCost Capitalized Subsequent to AcquisitionGross Amount at which Carried at Close of PeriodLife on Which Depreciation in Latest Income Statement is Computed
 DescriptionOwnership Percentage
Encum- brances(1)
Land 
Building and Improve- ments(2)(3)
Total 
Land 
Building and Improve- ments(2)(3)
Total Accumulated Depreciation and AmortizationOriginal Date of Construction/ Renovation 
Date Acquired
Ashland, MO100% 765 2,669 3,434  229 628 857  199308/17/1740
St. Louis, MO100% 2,071 5,739 7,810  375 818 1,193  1988/199108/17/1740
Doniphan, MO100% 657 8,251 8,908  657 8,251 8,908 (1,551)199108/17/1740
Dixon, MO100% 521 3,358 3,879  521 3,358 3,879 (684)1989/201108/17/1740
Forsyth, MO100% 594 8,549 9,143  594 8,549 9,143 (1,631)1993/200708/17/1740
Seymour, MO100% 658 901 1,559  658 901 1,559 (240)199008/17/1740
Silex, MO100% 807 4,990 5,797  807 4,990 5,797 (965)199108/17/1740
Columbia, MO100% 2,322 6,547 8,869  2,322 6,547 8,869 (1,287)199408/17/1740
Strafford, MO100% 1,634 6,518 8,152  1,634 6,518 8,152 (1,253)199508/17/1740
Windsor, MO100% 471 6,819 7,290  471 6,819 7,290 (1,188)199608/17/1740
Conroe, TX100% 1,222 19,099 20,321  1,222 19,099 20,321 (3,251)200108/17/1740
Houston, TX100% 1,334 11,615 12,949  1,334 11,615 12,949 (2,060)2003/201308/17/1740
Humble, TX100% 1,541 12,332 13,873 645 1,541 12,977 14,518 (2,611)2003/201908/17/1740
Missouri City, TX100% 1,825 9,681 11,506  1,825 9,681 11,506 (1,784)200508/17/1740
Houston, TX100% 2,676 7,396 10,072  2,676 7,396 10,072 (1,394)200508/17/1740
Houston, TX100% 1,732 12,921 14,653  1,732 12,921 14,653 (2,274)199908/17/1740
Topeka, KS100% 176 2,340 2,516  176 2,340 2,516 (474)1973/201308/17/1740
Salina, KS100% 301 4,201 4,502  301 4,201 4,502 (814)198108/17/1740
Terre Haute, IN100% 1,067 7,061 8,128  1,067 7,061 8,128 (1,286)1965/198408/17/1740
Gas City, IN100% 345 8,852 9,197  345 8,852 9,197 (1,536)1974/202208/17/1740
Winchester, IN100% 711 5,554 6,265  711 5,554 6,265 (1,016)1986/1998, 202108/17/1740
Columbus, IN100% 1,290 10,714 12,004  1,290 10,714 12,004 (1,868)1988/2004, 202208/17/1740
Portland, IN100% 315 9,848 10,163  315 9,848 10,163 (1,743)1964/202208/17/1740
Clinton, IN100% 884 9,839 10,723  884 9,839 10,723 (1,829)1971/202108/17/1740
Las Vegas, NV100% 509 18,216 18,725  509 18,216 18,725 (3,036)196408/17/1740
Las Vegas, NV100% 3,169 7,863 11,032  3,169 7,863 11,032 (1,477)1972/199708/17/1740
Alameda, CA100% 3,078 22,328 25,406  3,078 22,328 25,406 (3,806)1967/202108/17/1740
Dover, NH100% 522 5,839 6,361  522 5,839 6,361 (1,385)1969/1992, 201708/17/1740
F-42


Initial Cost to CompanyCost Capitalized Subsequent to AcquisitionGross Amount at which Carried at Close of PeriodLife on Which Depreciation in Latest Income Statement is Computed
 DescriptionOwnership Percentage
Encum- brances(1)
Land 
Building and Improve- ments(2)(3)
Total 
Land 
Building and Improve- ments(2)(3)
Total Accumulated Depreciation and AmortizationOriginal Date of Construction/ Renovation Date Acquired
Augusta, ME100% 135 6,470 6,605  135 6,470 6,605 (1,206)196708/17/1740
Bangor, ME100% 302 1,811 2,113 2,211 302 4,021 4,323 (1,019)1967/1993, 201908/17/1740
Bath, ME100% 250 1,934 2,184  250 1,934 2,184 (402)197408/17/1740
Brewer, ME100% 177 14,497 14,674 2,520 177 17,017 17,194 (3,371)1974/1990, 201908/17/1740
Kennebunk, ME100% 198 6,822 7,020 2,005 198 8,827 9,025 (1,634)1977/202208/17/1740
Norway, ME100% 791 3,680 4,471  791 3,680 4,471 (729)197608/17/1740
Yarmouth, ME100% 134 2,072 2,206  134 2,072 2,206 (442)195208/17/1740
Marlborough, MA100% 942 1,541 2,483 8,727 942 10,268 11,210 (3,468)1973/201808/17/1740
Bangor, ME100% 229 7,171 7,400 511 229 7,682 7,911 (1,446)1969/1993, 202208/17/1740
Orange, CA100% 4,163 14,755 18,918  4,163 14,755 18,918 (2,640)1987/202008/17/1740
Lancaster, TX100% 548 5,794 6,342  548 5,794 6,342 (1,140)200808/17/1740
Garland, TX100% 1,118 7,490 8,608  1,118 7,490 8,608 (1,403)200808/17/1740
Clarksville, TX100% 279 4,269 4,548 100 279 4,369 4,648 (970)1989/201908/17/1740
McKinney, TX100% 1,272 6,047 7,319  1,272 6,047 7,319 (1,217)200608/17/1740
Hopkins, MN100% 807 4,668 5,475 530 807 5,198 6,005 (1,418)1961/2008, 201908/17/1740
Florence, WI100% 291 3,778 4,069  291 3,778 4,069 (795)197008/17/1740
St. Francis, WI100% 166 1,887 2,053  166 1,887 2,053 (412)1960/199708/17/1740
Rochester, MN100% 645 7,067 7,712 178 645 7,245 7,890 (1,442)1967/2011, 201908/17/1740
Wisconsin Dells, WI100% 1,640 1,599 3,239  1,640 1,599 3,239 (453)1972/200608/17/1740
Sheboygan, WI100% 1,038 2,839 3,877  1,038 2,839 3,877 (681)1967/201208/17/1740
Hendersonville, NC100% 1,611 3,503 5,114  1,611 3,503 5,114 (774)197908/17/1740
Baytown, TX100% 579 22,317 22,896 103 579 22,419 22,998 (3,865)2000/201308/17/1740
Baytown, TX100% 589 20,475 21,064 362 589 20,837 21,426 (3,830)200808/17/1740
F-43


Initial Cost to CompanyCost Capitalized Subsequent to AcquisitionGross Amount at which Carried at Close of PeriodLife on Which Depreciation in Latest Income Statement is Computed
 DescriptionOwnership Percentage
Encum- brances(1)
Land 
Building and Improve- ments(2)(3)
Total 
Land 
Building and Improve- ments(2)(3)
Total Accumulated Depreciation and AmortizationOriginal Date of Construction/ Renovation Date Acquired
Houston, TX100% 1,300 13,353 14,653 31 1,300 13,384 14,684 (2,475)200608/17/1740
Pasadena, TX100% 1,148 23,579 24,727 47 1,148 23,626 24,774 (4,142)200408/17/1740
Webster, TX100% 904 10,315 11,219 24 904 10,338 11,242 (1,958)2000/200908/17/1740
Beaumont, TX100% 945 20,424 21,369 272 945 20,696 21,641 (3,634)200908/17/1740
Orange, TX100% 711 10,737 11,448 186 711 10,923 11,634 (2,014)200608/17/1740
Huntsville, AL100% 634 28,071 28,705 19 634 28,089 28,723 (4,713)1968/201208/17/1740
Terre Haute, IN100% 644 37,451 38,095 59 644 37,511 38,155 (7,069)1996/201308/17/1740
Madison, TN100% 902 3,850 4,752 23 902 3,873 4,775 (886)1969/201608/17/1740
Savannah, GA100% 1,235 3,765 5,000 18 1,235 3,783 5,018 (908)1970/201508/17/1740
Bowling Green, KY100% 280 13,975 14,255 32 280 14,007 14,287 (2,597)1970/201508/17/1740
Calvert City, KY100% 1,176 7,012 8,188 25 1,176 7,037 8,213 (1,385)1962/201508/17/1740
Winchester, KY100% 554 13,207 13,761 43 554 13,250 13,804 (2,507)1967/201508/17/1740
Calhoun, KY100% 613 7,643 8,256 30 613 7,673 8,286 (1,551)1963/201508/17/1740
Bremen, IN100% 173 7,393 7,566 38 173 7,431 7,604 (1,373)1982/201508/17/1740
Muncie, IN100% 374 27,429 27,803 38 374 27,467 27,841 (4,710)1980/201308/17/1740
Lebanon, IN100% 612 11,755 12,367 39 612 11,794 12,406 (2,141)1977/201208/17/1740
Marietta, GA100% 364 16,116 16,480 20 364 16,137 16,501 (3,004)1969/201508/17/1740
Danville, KY100% 790 9,356 10,146 32 790 9,388 10,178 (2,048)1962/201508/17/1740
Owensboro, KY100% 1,048 22,587 23,635 40 1,048 22,627 23,675 (4,031)1963/201108/17/1740
Memphis, TN100% 1,633 9,371 11,004 21 1,633 9,392 11,025 (1,832)1981/201508/17/1740
Norfolk, VA100% 705 16,451 17,156 33 705 16,485 17,190 (3,322)1969/201508/17/1740
Harrodsburg, KY100% 1,049 9,851 10,900 21 1,049 9,872 10,921 (2,050)1975/201608/17/1740
Cookeville, TN100% 1,034 15,555 16,589 32 1,034 15,586 16,620 (2,841)1979/201608/17/1740
Washington Court House, OH100% 405 4,839 5,244 20 405 4,859 5,264 (1,049)1984/201508/17/1740
Galion, OH100% 836 668 1,504 14 836 683 1,519 (237)1967/198508/17/1740
Roanoke Rapids, NC100% 373 10,308 10,681 25 373 10,334 10,707 (2,070)1967/201508/17/1740
Kinston, NC100% 954 7,987 8,941 73 954 8,059 9,013 (1,807)1960/201508/17/1740
Chapel Hill, NC100% 809 2,703 3,512 1,191 809 3,893 4,702 (964)1984/201508/17/1740
Chillicothe, OH100% 260 8,924 9,184 19 260 8,943 9,203 (1,850)1974/201508/17/1740
Coshocton, OH100% 374 2,530 2,904 37 374 2,567 2,941 (715)1974/201508/17/1740
Pine Knot, KY100% 208 7,665 7,873 23 208 7,689 7,897 (1,447)199008/17/1740
F-44


Initial Cost to CompanyCost Capitalized Subsequent to AcquisitionGross Amount at which Carried at Close of PeriodLife on Which Depreciation in Latest Income Statement is Computed
 DescriptionOwnership Percentage
Encum- brances(1)
Land 
Building and Improve- ments(2)(3)
Total 
Land 
Building and Improve- ments(2)(3)
Total Accumulated Depreciation and AmortizationOriginal Date of Construction/ Renovation Date Acquired
Bardstown, KY100% 634 4,094 4,728 16 634 4,110 4,744 (903)1968/201008/17/1740
Glasgow, KY100% 83 2,057 2,140 28 83 2,086 2,169 (552)196808/17/1740
Carrollton, KY100% 124 1,693 1,817 21 124 1,714 1,838 (476)1978/201608/17/1740
Horse Cave, KY100% 208 7,070 7,278 38 208 7,108 7,316 (1,460)199308/17/1740
Lawrenceburg, KY100% 635 9,861 10,496 17 635 9,879 10,514 (1,887)197308/17/1740
Annville, KY100% 479 6,078 6,557 17 479 6,095 6,574 (1,140)198908/17/1740
Louisville, KY100% 3,528 4,653 8,181 24 3,528 4,677 8,205 (1,095)1982/201208/17/1740
Louisville, KY100% 2,207 20,733 22,940 29 2,207 20,761 22,968 (3,667)1991/201008/17/1740
Tompkinsville, KY100% 333 9,556 9,889 26 333 9,582 9,915 (1,809)196908/17/1740
Radcliff, KY100% 1,815 7,470 9,285 34 1,815 7,504 9,319 (1,793)198608/17/1740
Hartford, KY100% 312 8,189 8,501 21 312 8,210 8,522 (1,583)196708/17/1740
Louisville, KY100% 427 6,003 6,430 21 427 6,023 6,450 (1,237)1975/200508/17/1740
Louisville, KY100% 1,134 9,166 10,300 28 1,134 9,194 10,328 (1,938)1979/201308/17/1740
Lexington, KY100% 2,558 4,311 6,869 51 2,558 4,361 6,919 (998)198908/17/1740
Columbia, KY100% 114 11,141 11,255 28 114 11,169 11,283 (2,063)196508/17/1740
Monticello, AR100% 206 3,179 3,385  206 3,179 3,385 (704)199508/17/1740
Benton, AR100% 1,336 7,386 8,722  1,336 7,386 8,722 (1,493)199208/17/1740
Wynne, AR100% 227 4,007 4,234  227 4,007 4,234 (818)199008/17/1740
Morrilton, AR100% 412 2,642 3,054 3,038 467 5,680 6,147 (936)1996/202208/17/1740
Bryant, AR100% 819 8,938 9,757  819 8,938 9,757 (1,609)1989/201508/17/1740
Savannah, GA100% 2,194 11,711 13,905  2,194 11,711 13,905 (2,080)197208/17/1740
F-45


Initial Cost to CompanyCost Capitalized Subsequent to AcquisitionGross Amount at which Carried at Close of PeriodLife on Which Depreciation in Latest Income Statement is Computed
 DescriptionOwnership Percentage
Encum- brances(1)
Land 
Building and Improve- ments(2)(3)
Total 
Land 
Building and Improve- ments(2)(3)
Total Accumulated Depreciation and AmortizationOriginal Date of Construction/ Renovation Date Acquired
Durham, NC100% 470 9,633 10,103  470 9,633 10,103 (1,695)1968/200608/17/1740
Raleigh, NC100% 1,155 11,749 12,904  1,155 11,749 12,904 (2,117)197108/17/1740
Raleigh, NC100% 926 17,649 18,575  926 17,649 18,575 (3,125)1967/200708/17/1740
Wilmington, NC100% 611 5,051 5,662  611 5,051 5,662 (1,015)1966/201308/17/1740
Winston-Salem, NC100% 879 3,283 4,162  879 3,283 4,162 (753)196508/17/1740
Lincolnton, NC100%  9,967 9,967   9,967 9,967 (1,803)197608/17/1740
Monroe, NC100% 166 5,906 6,072  166 5,906 6,072 (1,189)1963/200508/17/1740
Zebulon, NC100% 594 8,559 9,153  594 8,559 9,153 (1,486)1973/201008/17/1740
Rocky Mount, NC100%  18,314 18,314   18,314 18,314 (3,123)197508/17/1740
DeSoto, TX100% 942 6,033 6,975 320 942 6,353 7,295 (1,236)198708/17/1740
Trinity, TX100% 363 3,852 4,215  363 3,852 4,215 (822)1985/201908/17/1740
Kirbyville, TX100% 208 5,809 6,017  208 5,809 6,017 (1,186)198708/17/1740
Marshall, TX100% 732 4,288 5,020  732 4,288 5,020 (901)200808/17/1740
Warren, MI100% 2,052 25,539 27,591  2,052 25,539 27,591 (5,009)1961/200108/17/1740
Hamburg, NY100% 1,026 54,086 55,112  1,026 54,086 55,112 (9,273)1983/201408/17/1740
East Patchogue, NY100% 2,181 30,373 32,554  2,181 30,373 32,554 (5,478)1988/201108/17/1740
Williamsville, NY100% 1,122 46,413 47,535  1,122 46,413 47,535 (7,814)1992/200708/17/1740
Cheektowaga, NY100% 1,164 29,905 31,069  1,164 29,905 31,069 (5,335)1979/200608/17/1740
North Tonawanda, NY100% 830 29,488 30,318  830 29,488 30,318 (5,259)1982/200708/17/1740
West Seneca, NY100% 1,325 26,839 28,164  1,325 26,839 28,164 (4,698)1974/200808/17/1740
Beverly, MA100% 2,410 13,588 15,998  2,410 13,588 15,998 (3,199)1965/201508/17/1740

F-46


Initial Cost to CompanyCost Capitalized Subsequent to AcquisitionGross Amount at which Carried at Close of PeriodLife on Which Depreciation in Latest Income Statement is Computed
 DescriptionOwnership Percentage
Encum- brances(1)
Land 
Building and Improve- ments(2)(3)
Total 
Land 
Building and Improve- ments(2)(3)
Total Accumulated Depreciation and AmortizationOriginal Date of Construction/ Renovation Date Acquired
Lancaster, MA100% 343 7,733 8,076  343 7,733 8,076 (1,407)1970/200508/17/1740
New London, CT100% 505 2,248 2,753 48 505 2,296 2,801 (712)1967/201608/17/1740
Enfield, CT100% 437 16,461 16,898 231 437 16,693 17,130 (3,085)1968/201508/17/1740
Quincy, MA100% 894 904 1,798 129 894 1,033 1,927 (335)1965/200308/17/1740
Fishkill, NY100% 964 30,107 31,071 421 964 30,518 31,482 (5,495)199508/17/1740
Highland, NY100% 4,371 11,473 15,844 260 4,371 11,733 16,104 (2,252)199808/17/1740
Beacon, NY100%  25,400 25,400 267  25,666 25,666 (4,802)200208/17/1740
Springfield, MA100% 817 11,357 12,174 386 817 11,743 12,560 (2,094)198708/17/1740
Andover, MA100% 2,123 5,383 7,506 18 2,123 5,401 7,524 (1,131)199208/17/1740
Reading, MA100% 1,534 5,221 6,755 540 1,534 5,760 7,294 (1,216)198808/17/1740
Sudbury, MA100% 2,017 3,458 5,475 421 2,017 3,879 5,896 (922)1997/202108/17/1740
Lowell, MA100% 1,335 9,019 10,354 489 1,335 9,508 10,843 (1,847)1966/200708/17/1740
Worcester, MA100% 945 8,770 9,715 50 945 8,820 9,765 (1,693)1970/198808/17/1740
W. Springfield, MA100% 2,022 7,345 9,367  2,022 7,345 9,367 (1,556)1960/198508/17/1740
East Longmeadow, MA100% 2,968 8,957 11,925 790 2,968 9,748 12,716 (2,055)1985/200508/17/1740
Long Beach, CA100% 2,939 11,782 14,721  2,939 11,690 14,629 (2,246)1968/201109/19/1740
Anaheim, CA100% 2,044 14,167 16,211  2,044 14,167 16,211 (2,643)1968/201109/19/1740
Fairfield, CA100% 586 23,582 24,168  586 23,582 24,168 (4,095)1966/200609/19/1740
Baldwin Park, CA100% 2,270 17,063 19,333  2,270 17,063 19,333 (3,126)1970/201509/19/1740
Grand Terrace, CA100% 432 9,382 9,814  432 9,382 9,814 (1,732)1945/201709/19/1740
Pacifica, CA100% 1,510 27,397 28,907  1,510 27,397 28,907 (4,692)197509/19/1740
Burien, WA100% 823 17,431 18,254  826 17,431 18,257 (3,145)1965/201409/19/1740
Seattle, WA100% 4,802 7,927 12,729  4,802 7,927 12,729 (1,604)1963/201609/19/1740
Huntington Bch, CA100% 2,312 9,885 12,197  2,312 9,885 12,197 (1,817)1965/201009/19/1740
F-47


Initial Cost to CompanyCost Capitalized Subsequent to AcquisitionGross Amount at which Carried at Close of PeriodLife on Which Depreciation in Latest Income Statement is Computed
 DescriptionOwnership Percentage
Encum- brances(1)
Land 
Building and Improve- ments(2)(3)
Total 
Land 
Building and Improve- ments(2)(3)
Total Accumulated Depreciation and AmortizationOriginal Date of Construction/ Renovation Date Acquired
Chatsworth, CA100% 7,841 16,916 24,757  7,841 16,916 24,757 (3,239)197609/19/1740
Woodland, CA100% 504 7,369 7,873  504 7,369 7,873 (1,425)1975/201009/19/1740
Danville, CA100% 1,491 17,157 18,648  1,491 17,157 18,648 (3,074)196509/19/1740
Van Nuys, CA100% 2,456 16,462 18,918  2,456 16,462 18,918 (2,841)1958/201509/19/1740
Lomita, CA100% 2,743 14,734 17,477  2,743 14,734 17,477 (2,763)196909/19/1740
Sacramento, CA100% 2,846 17,962 20,808  2,846 17,962 20,808 (3,178)197209/19/1740
Issaquah, WA100% 10,125 7,771 17,896  10,125 7,771 17,896 (1,653)1975/201209/19/1740
Long Beach, CA100% 3,157 22,067 25,224  3,157 22,067 25,224 (4,001)1966/201409/19/1740
Long Beach, CA100% 2,857 5,878 8,735  2,857 5,878 8,735 (1,150)1952/201309/19/1740
Lodi, CA100% 812 21,059 21,871  812 21,059 21,871 (3,553)196509/19/1740
Riverside, CA100% 1,717 13,806 15,523  1,717 13,806 15,523 (2,725)196609/19/1740
Woodland, CA100% 278 16,729 17,007  278 16,729 17,007 (2,990)1930/200709/19/1740
Bee Cave, TX100% 2,107 10,413 12,520  2,107 10,413 12,520 (2,147)201412/15/1740
El Monte, CA100% 2,058 19,671 21,729  2,058 19,671 21,729 (3,401)196501/10/1840
Shoreline, WA100% 8,861 11,478 20,339 103 8,861 11,580 20,441 (2,368)1964/201201/19/1840
Elizabethtown, KY100% 729  729 19,329 729 19,329 20,058 (479)202105/27/2140
Crown Point, IN100% 1,522 14,951 16,473  1,522 14,951 16,473 (78)201511/01/2340
Dyer, IN100% 1,859 19,547 21,406  1,859 19,547 21,406 (100)201511/01/2340
24,051 328,000 2,663,453 2,991,453 91,777 325,583 2,725,278 3,050,861 (535,653)  
Senior Housing - Leased        
Exeter, NH100%1,880 571 7,183 7,754  571 5,912 6,483 (2,771)198711/15/1043
Nashua, NH100%4,457  5,654 5,654   4,566 4,566 (1,949)198911/15/1040
Keene, NH100%3,237 304 3,992 4,296  304 3,263 3,567 (1,650)199511/15/1046
Dover, NH100%2,335 801 10,036 10,837  801 8,584 9,385 (4,002)1987/2009, 201911/15/1042
Green Bay, WI100% 256 2,262 2,518 1,032 256 1,976 2,232 (767)2004/201111/22/1140
Rockport, TX100% 789 607 1,396  789 475 1,264 (183)1996/201811/30/1240
Cadillac, MI100% 217 3,000 3,217  217 2,920 3,137 (910)2001/2006, 202312/14/1240
F-48


Initial Cost to CompanyCost Capitalized Subsequent to AcquisitionGross Amount at which Carried at Close of PeriodLife on Which Depreciation in Latest Income Statement is Computed
 DescriptionOwnership Percentage
Encum- brances(1)
Land 
Building and Improve- ments(2)(3)
Total 
Land 
Building and Improve- ments(2)(3)
Total Accumulated Depreciation and AmortizationOriginal Date of Construction/ Renovation Date Acquired
Greenville, MI100% 684 5,832 6,516 249 684 5,841 6,525 (1,876)1999/2001, 2012, 2013, 201812/14/1240
Manistee, MI100% 952 2,578 3,530 2,547 952 5,076 6,028 (1,970)2002/201712/14/1240
Mason, MI100% 198 4,131 4,329  198 4,032 4,230 (1,323)2009/201212/14/1240
Alpena, MI100% 546 13,139 13,685  546 13,000 13,546 (3,763)2006/2008, 201012/14/1240
Fremont, NE100% 504 17,670 18,174  504 17,670 18,174 (5,020)1989/200202/14/1440
Norfolk, NE100% 217 9,906 10,123 4,680 217 14,586 14,803 (4,284)1989/1991, 1994, 2018, 201902/14/1440
Fort Wayne, IN100%12,183 2,300 21,115 23,415 2,747 2,300 23,846 26,146 (7,799)2011/2016, 201804/30/1440
Brandon, FL100% 1,283 8,424 9,707 483 1,283 8,722 10,005 (2,532)1999/201610/01/1440
Lecanto, FL100% 1,031 5,577 6,608 615 1,023 6,053 7,076 (2,026)1997/201610/01/1440
Zephyrhills, FL100% 1,688 9,098 10,786 360 1,688 9,343 11,031 (2,924)2008/201610/01/1440
Sun City West, AZ100% 930 9,170 10,100 248 930 9,418 10,348 (2,188)201207/01/1640
Fredericksburg, VA100% 1,379 21,209 22,588  1,379 21,209 22,588 (4,644)201607/14/1640
Round Rock, TX100% 679 13,642 14,321  679 13,642 14,321 (3,035)201608/01/1640
Santa Fe, NM100% 1,866 19,441 21,307  2,157 21,736 23,893 (4,587)200609/23/1640
Santa Fe, NM100% 670 7,743 8,413 430 670 8,571 9,241 (810)202009/23/1640
Franklin, NH100% 292 6,889 7,181 211 292 7,110 7,402 (1,700)198811/30/1640
Henderson, NV100% 1,430 21,850 23,280  1,430 21,862 23,292 (4,411)201612/01/1640
Brenham, TX100% 476 11,912 12,388  476 11,922 12,398 (2,753)199112/02/1640
Cedar Park, TX100% 1,035 13,127 14,162  1,035 13,127 14,162 (2,546)201706/01/1740
Keizer, OR100% 1,220 31,783 33,003  1,220 31,783 33,003 (5,435)1970/202108/17/1740
Lawrence, KS100% 584 4,431 5,015  584 4,431 5,015 (849)1995/201408/17/1740
Salina, KS100% 584 3,020 3,604  584 3,020 3,604 (575)1989/201408/17/1740
Topeka, KS100% 313 5,492 5,805  313 5,492 5,805 (967)1986/201408/17/1740
Lafayette, CO100% 1,085 19,243 20,328 9 1,883 19,205 21,088 (3,382)201612/15/1740
Winnebago, IL100% 263 3,743 4,006  263 3,743 4,006 (707)200701/31/1840
Pewaukee, WI100% 1,019 3,606 4,625  1,019 3,606 4,625 (635)201004/16/1840
Pewaukee, WI100% 661 5,680 6,341  661 5,680 6,341 (923)201504/16/1840
Sarasota, FL100% 1,440 22,541 23,981  1,440 22,541 23,981 (3,495)201805/18/1840
Knoxville, TN100% 1,603 9,219 10,822  1,603 9,219 10,822 (1,651)201708/31/1840
F-49


Initial Cost to CompanyCost Capitalized Subsequent to AcquisitionGross Amount at which Carried at Close of PeriodLife on Which Depreciation in Latest Income Statement is Computed
 DescriptionOwnership Percentage
Encum- brances(1)
Land 
Building and Improve- ments(2)(3)
Total 
Land 
Building and Improve- ments(2)(3)
Total Accumulated Depreciation and AmortizationOriginal Date of Construction/ Renovation Date Acquired
Shavano Park, TX100% 2,131 11,541 13,672  2,131 11,541 13,672 (1,890)201508/31/1840
Beavercreek, OH100% 1,622 24,215 25,837 7,561 1,622 31,773 33,395 (5,805)201611/01/1840
McCordsville, IN100% 1,587 31,315 32,902  1,587 31,315 32,902 (3,487)201701/07/2040
Louisville, KY100% 1,841 21,827 23,668  1,841 21,827 23,668 (2,359)201501/31/2040
Sellersburg, IN100% 1,060 28,702 29,762 5,504 1,060 34,206 35,266 (3,336)201504/01/2040
Jasper, IN100% 657 25,226 25,883  657 25,226 25,883 (1,614)201910/01/2140
Norman, OK100% 557 2,663 3,220 1,135 557 3,798 4,355 (68)199902/01/2340
24,092 39,325 509,434 548,759 27,811 40,406 532,868 573,274 (109,601)
Senior Housing - Managed
Frankenmuth, MI100% 5,027 20,929 25,956 637 5,027 21,170 26,197 (6,342)1982/200809/21/1240
Gaylord, MI100% 2,024 5,467 7,491 141 2,024 5,583 7,607 (2,060)200212/14/1240
East Tawas, MI100% 258 3,713 3,971 399 258 3,984 4,242 (1,551)200512/14/1240
Marshfield, WI100% 574 8,733 9,307 220 574 8,803 9,377 (2,623)201012/18/1240
Woodstock, VA100% 597 5,465 6,062 117 597 5,448 6,045 (1,538)1996/201506/28/1340
Allen, TX100% 2,190 45,767 47,957 948 2,190 50,510 52,700 (12,723)2004/201009/25/1440
Gainesville, FL100% 2,139 44,789 46,928 1,562 2,139 49,736 51,875 (13,797)1986/2013, 2015, 201909/25/1440
McKinney, TX100% 2,760 44,397 47,157 1,497 2,760 49,615 52,375 (12,854)2006/2010, 201909/25/1440
Raleigh, NC100% 2,344 37,506 39,850 1,749 2,344 43,072 45,416 (10,650)2002/2014, 202209/25/1440
San Luis Obispo, CA100% 4,992 30,909 35,901 1,117 4,992 35,062 40,054 (9,094)1987/2006, 2015, 202109/25/1440
Winston-Salem, NC100% 2,995 24,428 27,423 676 2,995 26,841 29,836 (7,132)200109/25/1440
Longview, TX100% 805 26,498 27,303 824 805 27,972 28,777 (7,930)1985/201009/25/1440
Kansas City, MO100% 1,325 20,510 21,835 923 1,325 25,844 27,169 (6,657)198309/25/1440
Yuma, AZ100% 530 21,775 22,305 484 530 22,678 23,208 (6,226)1996/201409/25/1440
Nashville, TN100% 1,996 19,368 21,364 1,227 1,996 21,607 23,603 (6,530)1986/200009/25/1440
Branford, CT100% 2,403 18,821 21,224 732 2,403 22,939 25,342 (5,668)198709/25/1440
Richmond, VA100% 1,080 19,545 20,625 1,602 1,080 23,606 24,686 (6,296)1989/2007, 202209/25/1440
Auburn, AL100% 3,209 17,326 20,535 516 3,209 18,482 21,691 (5,259)200109/25/1440
Menomonee Falls, WI100% 1,477 18,778 20,255 426 1,477 20,272 21,749 (5,690) 2005/2006, 2007/2011, 201909/25/1440
Glenville, NY100% 978 18,257 19,235 571 978 19,711 20,689 (5,564)2001/201409/25/1440
Eustis, FL100% 1,152 17,523 18,675 606 1,152 18,811 19,963 (5,669)1984/1988, 201309/25/1440

F-50


Initial Cost to CompanyCost Capitalized Subsequent to AcquisitionGross Amount at which Carried at Close of PeriodLife on Which Depreciation in Latest Income Statement is Computed
 DescriptionOwnership Percentage
Encum- brances(1)
Land 
Building and Improve- ments(2)(3)
Total 
Land 
Building and Improve- ments(2)(3)
Total Accumulated Depreciation and AmortizationOriginal Date of Construction/ Renovation Date Acquired
Phoenix, AZ100% 2,567 12,029 14,596 983 2,567 13,881 16,448 (4,425)198609/25/1440
Jonesboro, AR100% 1,782 11,244 13,026 373 1,782 12,326 14,108 (3,705)199909/25/1440
Ogden, UT100% 794 10,873 11,667 798 794 12,673 13,467 (3,764)1985/201609/25/1440
Olympia, WA100% 2,477 23,767 26,244 923 2,477 27,924 30,401 (7,326)1986/201610/07/1440
Windsor, ON100% 1,360 16,855 18,215 526 1,378 18,359 19,737 (4,576)199806/11/1540
London, ON100% 960 19,056 20,016 368 972 20,408 21,380 (4,954)1998/2015, 201906/11/1540
Kelowna, BC100% 2,321 8,308 10,629 626 2,352 9,846 12,198 (2,639)1990/2019, 202006/11/1540
Waterloo, ON100% 1,823 22,135 23,958 380 1,848 23,213 25,061 (5,546)2005/201506/11/1540
Sarnia, ON100% 1,187 20,346 21,533 740 1,203 22,905 24,108 (5,273)2000/201906/11/1540
Kamloops, BC100% 679 8,024 8,703 250 687 9,040 9,727 (2,332)1992/201406/11/1540
Vernon, BC100% 843 10,724 11,567 236 273 11,643 11,916 (2,829)1990/2008, 202106/11/1540
Penticton, BC100% 763 6,771 7,534 239 773 7,940 8,713 (2,058)1990/1991, 2014, 201906/11/1540
Calgary, AB100% 3,908 20,996 24,904 1,077 3,963 22,749 26,712 (5,259)201309/17/1540
Lake Stevens, WA100% 1,559 9,059 10,618 96 1,559 9,168 10,727 (2,349)1998/201209/17/1540
Eugene, OR100% 1,428 16,138 17,566 143 1,428 16,303 17,731 (3,690)1996/1997, 2011, 201909/17/1540
Tualatin, OR100% 527 14,659 15,186 138 527 14,852 15,379 (3,364)1995/1997, 201909/17/1540
Salem, OR100% 1,074 19,421 20,495 451 1,074 19,884 20,958 (4,774)1989/1995, 201809/17/1540
Ramsey, MN100% 1,182 13,280 14,462 208 1,182 13,783 14,965 (2,627)201510/06/1740
Marshfield, WI100% 500 4,134 4,634 89 500 4,263 4,763 (923)201410/06/1740
Dover, DE100% 2,797 23,054 25,851 456 2,797 23,422 26,219 (4,245)199901/02/1840
Charleston, WV100% 419 4,239 4,658 1,008 419 5,066 5,485 (1,302)196901/02/1840
Williamsport, PA100% 296 9,191 9,487 907 296 9,973 10,269 (2,001)1990/200901/02/1840
Reading, PA100% 684 12,950 13,634 276 684 13,201 13,885 (2,475)200401/02/1840
Scott Depot, WV100% 230 6,271 6,501 713 230 6,767 6,997 (1,444)199601/02/1840
Clarks Summit, PA100% 406 9,471 9,877 1,271 406 10,524 10,930 (2,264)199701/02/1840
Wyncote, PA100% 1,781 4,911 6,692 814 1,781 5,517 7,298 (1,345)190901/02/1840
Douglassville, PA100% 611 19,083 19,694 356 611 19,367 19,978 (3,418)200801/02/1840
Milford, DE100% 1,199 18,786 19,985 589 1,199 19,231 20,430 (3,476)199901/02/1840
Oak Hill, WV100% 609 2,636 3,245 1,157 609 3,703 4,312 (1,053)2001/201401/02/1840
Lewisburg, WV100% 355 5,055 5,410 677 355 5,449 5,804 (1,227)199501/02/1840
Strasburg, VA100% 666 5,551 6,217 22 666 5,573 6,239 (931)200104/30/1840
Richardson, TX100% 2,282 10,556 12,838 1,288 2,282 11,934 14,216 (1,673)1999/202011/01/1940
Poway, CA100% 3,693 14,467 18,160 1,072 3,693 15,688 19,381 (1,915)1987/2011, 202111/22/1940
F-51


Initial Cost to CompanyCost Capitalized Subsequent to AcquisitionGross Amount at which Carried at Close of PeriodLife on Which Depreciation in Latest Income Statement is Computed
 DescriptionOwnership Percentage
Encum- brances(1)
Land 
Building and Improve- ments(2)(3)
Total 
Land 
Building and Improve- ments(2)(3)
Total Accumulated Depreciation and AmortizationOriginal Date of Construction/ Renovation Date Acquired
New Braunfels, TX100% 1,312 23,108 24,420 360 1,312 23,664 24,976 (2,871)201501/15/2040
Augusta, GA100% 419 24,958 25,377 94 459 28,548 29,007 (2,343)201803/05/2140
Anchorage, AK100% 1,965 29,533 31,498 150 1,965 29,683 31,648 (2,304)201905/01/2140
Loveland, OH100% 3,691 21,168 24,859 41 3,691 21,269 24,960 (1,220)201702/01/2240
Indianapolis, IN100% 4,950 32,631 37,581 43 6,299 41,563 47,862 (1,674)201708/01/2240
Saginaw, MI100% 1,651 29,283 30,934 1,440 1,651 31,289 32,940 (1,247)2013/202308/01/2240
Madeira, OH100% 2,858 42,670 45,528 3 2,858 42,691 45,549 (1,109)201902/01/2340
 101,463 1,087,895 1,189,358 38,355 102,457 1,187,028 1,289,485 (255,803)
Behavioral Health
Aurora, CO100% 2,874 12,829 15,703 1,950 2,874 14,563 17,437 (3,931)2009/2018, 202109/20/1240
Colorado Springs, CO100% 430 13,703 14,133 1,033 430 14,736 15,166 (4,445)1985/2017, 201803/05/1440
Colorado Springs, CO100% 1,210 9,490 10,700 2,058 1,210 11,548 12,758 (2,326)2013/201911/16/1540
Bluffton, IN100% 254 5,105 5,359 1,486 254 6,591 6,845 (1,364)1970/2015, 202108/17/1740
Elizabethtown, KY100% 239 4,853 5,092 699 239 5,552 5,791 (971)196908/17/1740
Morrilton, AR100% 508  508 3,169 508 3,169 3,677 (98)1988/2019, 202308/17/1740
Glendale, AZ100% 1,501 67,046 68,547  1,501 67,046 68,547 (11,140)1996/201308/17/1740
Tempe, AZ100% 3,137 50,073 53,210  3,137 50,073 53,210 (8,505)2001/201608/17/1740
Covina, CA100% 23,472 71,542 95,014  23,472 71,542 95,014 (12,348)1974/201108/17/1740
Ventura, CA100% 8,089 43,645 51,734  8,089 43,645 51,734 (8,190)1984/201808/17/1740
San Diego, CA100% 8,403 55,015 63,418 7,599 8,403 62,614 71,017 (11,947)1988/201708/17/1740
New London, CT100% 356 152 508 3,665 356 3,817 4,173 (746)1967/2016, 202108/17/1740
Carmel, IN100% 963 4,347 5,310  963 4,347 5,310 (680)1996/201907/24/1940
Louisville, KY100% 1,078 8,305 9,383  1,078 8,305 9,383 (1,153)2002/201808/21/1940
Monroeville, PA100% 2,034 1,758 3,792 18,545 2,034 20,303 22,337 (2,869)1987/202012/18/1940
Gulf Breeze, FL100% 498 1,480 1,978 3,733 498 5,213 5,711 (139)2001/202103/15/2140
Greenville, SC100% 1,197 9,496 10,693 21,507 1,197 31,012 32,209 (574)1994/202212/16/2140
Raytown, MO100% 1,475 6,564 8,039 8,379 1,475 14,943 16,418 (517)1978/202210/27/2240
 57,718 365,403 423,121 73,823 57,718 439,019 496,737 (71,943)
F-52


Initial Cost to CompanyCost Capitalized Subsequent to AcquisitionGross Amount at which Carried at Close of PeriodLife on Which Depreciation in Latest Income Statement is Computed
 DescriptionOwnership Percentage
Encum- brances(1)
Land 
Building and Improve- ments(2)(3)
Total 
Land 
Building and Improve- ments(2)(3)
Total Accumulated Depreciation and AmortizationOriginal Date of Construction/ Renovation Date Acquired
Specialty Hospitals and Other
Sunnyvale, TX100% 4,020 57,620 61,640  4,020 57,620 61,640 (22,152)200905/03/1140
Arlington, TX100%  44,217 44,217   44,217 44,217 (7,195)2009/201608/17/1740
Conroe, TX100% 2,935 25,003 27,938  2,935 25,003 27,938 (4,600)199208/17/1740
Houston, TX100% 3,001 14,581 17,582  3,001 14,581 17,582 (2,416)1999/200908/17/1740
Spring, TX100% 1,319 15,153 16,472  1,319 15,153 16,472 (2,516)1995/199808/17/1740
Orange, CA100% 2,060 5,538 7,598 145 2,060 5,683 7,743 (986)200008/17/1740
Maxwell, TX100% 902 2,384 3,286 1 902 2,384 3,286 (458)199308/17/1740
Maxwell, TX100% 901 1,198 2,099  901 1,198 2,099 (278)1994/200908/17/1740
Maxwell, TX100% 456 2,632 3,088  456 2,632 3,088 (477)199208/17/1740
San Marcos, TX100% 51 359 410 62 51 359 410 (67)186908/17/1740
Seguin, TX100% 539 2,627 3,166  539 2,627 3,166 (605)198908/17/1740
Seguin, TX100% 228 3,407 3,635 79 228 3,486 3,714 (669)1985/199108/17/1740
Kingsbury, TX100% 104 2,788 2,892 27 104 2,814 2,918 (495)1990/201208/17/1740
Seguin, TX100% 52 805 857  52 805 857 (154)197008/17/1740
Florence, KY100% 3,866 26,447 30,313  3,866 26,447 30,313 (4,386)200008/17/1740
 20,434 204,759 225,193 314 20,434 205,009 225,443 (47,454)
  48,143 546,940 4,830,944 5,377,884 232,080 546,598 5,089,202 5,635,800 (1,020,454)  
    136 136 2,411  2,547 2,547 (632)  
  $48,143 $546,940 $4,831,080 $5,378,020 $234,491 $546,598 $5,091,749 $5,638,347 $(1,021,086)  
(1)    Encumbrances do not include deferred financing costs, net of $0.8 million as of December 31, 2023.
(2)    Building and building improvements include land improvements and furniture and equipment.
(3)    The aggregate cost of real estate for federal income tax purposes was $4.7 billion.

F-53


SCHEDULE III
REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION
(dollars in thousands)


Year Ended December 31,
202320222021
Real estate:
Balance at the beginning of the year$5,872,688 $5,994,208 $5,966,695 
Acquisitions86,626 101,413 96,157 
Improvements86,073 65,111 47,319 
Impairment(18,853)(160,550)(11,063)
Sale of real estate(379,272)(110,901)(102,575)
Foreign currency translation3,394 (10,247)524 
Other (1)
(12,309)(6,346)(2,849)
Balance at the end of the year$5,638,347 $5,872,688 $5,994,208 
  
Accumulated depreciation:
Balance at the beginning of the year$(913,345)$(831,324)$(681,657)
Depreciation expense(171,278)(170,159)(170,264)
Impairment4,432 66,603 1,666 
Sale of real estate49,585 13,217 16,097 
Foreign currency translation(747)1,972 (15)
Other (1)
10,267 6,346 2,849 
Balance at the end of the year$(1,021,086)$(913,345)$(831,324)
(1)    Primarily represents real estate and accumulated depreciation related to fully-depreciated assets and reductions to net real estate due to casualty events.
F-54


SCHEDULE IV
MORTGAGE LOANS ON REAL ESTATE
As of December 31, 2023
(dollars in thousands)

DescriptionContractual Interest RateMaturity DatePeriodic Payment TermsPrior LiensPrincipal Balance
Book Value (1)
Principal Amount of Loans Subject to Delinquent Principal or Interest
Mortgages:
River Vista10.0 %2027
(2)
$ $19,000 $19,000 N/A
Recovery Centers of America7.5 2026
(2)
 300,000 300,000 N/A
$ $319,000 $319,000 
(1)    The aggregate cost for federal income tax purposes was $321.2 million as of December 31, 2023.
(2)    Interest is due monthly, and principal is due at the maturity date.



Changes in mortgage loans are summarized as follows:
Year Ended December 31,
202320222021
Balance at the beginning of the year$319,000 $312,343 $22,343 
Additions during period:
Draws 10,000  
New mortgage loans  290,000 
Deductions during period:
Paydowns/repayments (3,343) 
Balance at the end of the year$319,000 $319,000 $312,343 


SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Tustin, State of California, on February 27, 2024.
 
SABRA HEALTH CARE REIT, INC.
By:
/S/    RICHARD K. MATROS         
 
Richard K. Matros
Chief Executive Officer, President and Chair

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:
 
Name
Title 
Date
/S/    RICHARD K. MATROSChief Executive Officer, President and Chair (Principal Executive Officer)February 27, 2024
Richard K. Matros
/S/    MICHAEL COSTAChief Financial Officer, Secretary and Executive Vice President (Principal Financial Officer)February 27, 2024
Michael Costa
/S/    JESSICA FLORESChief Accounting Officer, Executive Vice President (Principal Accounting Officer)February 27, 2024
Jessica Flores
/S/    CRAIG A. BARBAROSHDirectorFebruary 27, 2024
Craig A. Barbarosh
/S/    KATIE CUSACKDirectorFebruary 27, 2024
Katie Cusack
/S/    MICHAEL J. FOSTERDirectorFebruary 27, 2024
Michael J. Foster
/S/    LYNNE S. KATZMANNDirectorFebruary 27, 2024
Lynne S. Katzmann
/S/    ANN KONODirectorFebruary 27, 2024
Ann Kono
/S/    JEFFREY A. MALEHORNDirectorFebruary 27, 2024
Jeffrey A. Malehorn
/S/    CLIFTON J. PORTER IIDirectorFebruary 27, 2024
Clifton J. Porter II
EX-10.9 2 sbraex1092023q4.htm DIRECTORS COMPENSATION POLICY Document
EXHIBIT 10.9
SABRA HEALTH CARE REIT, INC. DIRECTORS’ COMPENSATION POLICY
(Effective March 21, 2023)

Directors of Sabra Health Care REIT, Inc., a Maryland corporation (the “Company”), who are not employed by the Company or one of its subsidiaries (“non-employee directors”) are entitled to the compensation set forth below for their service as a member of the Board of Directors (the “Board”) of the Company. The Board has the right to amend this policy from time to time.

Cash Compensation
Annual Retainer    $ 80,000
Additional Chair/Lead Independent Director Retainer    $ 30,000
Additional Committee Chair Retainers
Audit Committee Chair    $ 25,000
Compensation Committee Chair    $ 15,000
Nominating and Governance Committee Chair    $ 15,000
Committee Meeting Fee (per meeting)    $ 1,500

Equity Compensation
Annual Equity Award    $135,000

Cash Compensation
Each non-employee director will be entitled to an annual cash retainer while serving on the Board in the amount set forth above (the “Annual Retainer”). A non-employee director who serves as the Chair of the Board or the Company’s Lead Independent Director will be entitled to an additional annual cash retainer while serving in that position in the amount set forth above (the “Additional Chair/Lead Independent Director Retainer”). A non-employee director who serves as the Chair of the Audit Committee, the Compensation Committee or the Nominating and Governance Committee of the Board will be entitled to an additional annual cash retainer while serving in that position in the applicable amount set forth above (an “Additional Committee Chair Retainer”). A non-employee director who is a member of, and attends a meeting of, the Audit Committee, the Compensation Committee or the Nominating and Governance Committee of the Board (each, a “Committee Meeting”) will be entitled to a fee for attendance at the meeting in the amount set forth above (a “Committee Meeting Fee”); provided that the Committee Meeting Fee for a particular Committee Meeting will be reduced to $750 if the meeting is either (1) a telephonic meeting lasting for less than thirty minutes, or (2) a meeting that is held as an in-person meeting but the non-employee director attends the meeting other than in person.
The amounts of the Annual Retainer, Additional Chair/Lead Independent Director Retainer, and Additional Committee Chair Retainers reflected above are expressed as annualized amounts. These retainers will be paid on a quarterly basis, at the end of each quarter in arrears, and will be pro-rated if a non-employee director serves (or serves in the corresponding position, as the case may be) for only a portion of the quarter (with the proration based on the number of calendar days in the quarter that the director served as a non-employee director or held the particular position, as the case may be). Committee Meeting Fees for attendance at one or more meetings that occur in a particular quarter will be paid at the end of that quarter.

Equity Awards
Annual Equity Awards for Non-Employee Directors
On the date of each annual meeting of the Company’s stockholders, each non-employee director then in office will automatically be granted an award of restricted stock units (an “Annual RSU Award”) determined by dividing
(1) the Annual Equity Award grant value set forth above by (2) the per-share closing price of the Company’s common stock on the date of such annual meeting (rounded down to the nearest whole unit). Each Annual RSU Award will vest in equal monthly installments over the one-year period following the date of grant. Should the annual meeting of the Company’s stockholders in the year following the year in which the award was granted occur prior to the last vesting date of the award, the outstanding and unvested portion of the award will vest on the day prior to that annual meeting. In the event that more than one annual meeting of the Company’s stockholders occurs during a given fiscal year, Annual RSU Awards will be made only in connection with the first such meeting to occur in that year.
For each new non-employee director appointed or elected to the Board other than on the date of an annual meeting of the Company’s stockholders, on the date that the new non-employee director first becomes a member of
1


the Board, the new non-employee director will automatically be granted a pro-rata portion of the Annual RSU Award (a “Pro-Rata Annual RSU Award”) determined by dividing (1) a pro-rata portion of the Annual Equity Award grant value set forth above by (2) the per-share closing price of the Company’s common stock on the date the new non-employee director first became a member of the Board. The pro-rata portion of the Annual Equity Award grant value for purposes of a Pro-Rata Annual RSU Award will equal the Annual Equity Award grant value set forth above multiplied by a fraction (not greater than one), the numerator of which is 12 minus the number of whole months that as of the particular grant date had elapsed since the Company’s last annual meeting of stockholders at which Annual RSU Awards were granted by the Company to non-employee directors, and the denominator of which is 12, with the result to be rounded down to the nearest whole unit. Each Pro-Rata Annual RSU Award will vest in equal monthly installments based on the number of whole months remaining in the period beginning with the month following the month in which the Pro-Rata Annual RSU Award was granted and ending with the month in which the next scheduled annual meeting of the Company’s stockholders in which Annual RSU Awards will be granted.

Provisions Applicable to All Non-Employee Director Equity Awards
Each restricted stock unit award will be made under and subject to the terms and conditions of the Company’s 2009 Performance Incentive Plan (the “2009 Plan”) or any successor equity compensation plan approved by the Company’s stockholders and in effect at the time of grant, and will be evidenced by, and subject to the terms and conditions of, an award agreement in the form approved by the Board to evidence such type of grant pursuant to this policy (the “Form of Award Agreement”). To the extent then vested, restricted stock units will generally be paid in an equal number of shares of the Company’s common stock on the earlier to occur of (1) that date that is five years following the original grant date, (2) the date the non-employee director ceases to be a member of the Board, or (3) the occurrence of a “change in control.”

Restricted stock unit awards granted under the 2009 Plan are generally forfeited as to the unvested portion of the award upon the non-employee director’s termination of service as a director for any reason. However, vesting of a non-employee director’s outstanding and unvested restricted stock units will accelerate upon a change in control of the Company or should the director’s services terminate due to the director’s death or disability.
Non-employee directors are entitled to receive dividend equivalents with respect to outstanding and unpaid restricted stock units granted pursuant to this policy. Dividend equivalents, if any, are paid in the form of a credit of additional restricted stock units under the 2009 Plan and are subject to the same vesting, payment and other provisions as the underlying restricted stock units.
The definition of “change in control” and specific payment, termination and dividend equivalent provisions applicable to an award are set forth in the related Form of Award Agreement.

Elective Grants of Equity Awards
Non-employee directors may participate in the Company’s Non-Employee Directors Stock-For-Fees Program, pursuant to which they may elect that certain of their cash retainers be converted into the right to receive an award of stock units under the 2009 Plan.

Expense Reimbursement

All non-employee directors will be entitled to reimbursement from the Company for their reasonable travel (including airfare and ground transportation), lodging and meal expenses incident to meetings of the Board or committees thereof or in connection with other Board-related business. The Company will make reimbursement to a non-employee director within a reasonable amount of time following submission by the non-employee director of reasonable written substantiation for the expenses.
2
EX-21.1 3 sbraex2112023q4.htm LIST OF SUBSIDIARIES Document

Exhibit 21.1
Sabra Subsidiaries
Entity NameJurisdiction of Organization
1717 Senior Partners, LLC Indiana
2100 Benvoulin Court Holdings, Inc. British Columbia
2829-34th Street Holdings, Inc.British Columbia
317 Winnipeg St. Holdings Inc.British Columbia
870 Westminster Ave. Holdings, Inc. British Columbia
Arden Real Estate Holdings, LLCDelaware
Beaumont Senior Partners, LLC Indiana
Beavercreek Senior Partners, LLCIndiana
Bloomsburg Nominee LLCDelaware
Bloomsburg Nominee LPDelaware
C.H.W. Limited Liability CompanyNew Hampshire
CCP Arlington 1961 LLCDelaware
CCP Ashland 7250 LLCDelaware
CCP Aspen Grove 7382 LLCDelaware
CCP Augusta 0544 LLCDelaware
CCP Autumn View 7580 LLCDelaware
CCP Autumn Woods 7586 LLCDelaware
CCP Avalon 5010 LPDelaware
CCP Bay View 0738 LPDelaware
CCP Bayview 7176 LLCDelaware
CCP Bear Creek 3764 LLCDelaware
CCP Bellefontaine Gardens 7251 LLCDelaware
CCP Belleville 7343 LLCDelaware
CCP Bellingham 0158 LLCDelaware
CCP Bellingham 1501 LLCDelaware
CCP Blueberry Hill 0581 LLCDelaware
CCP Boise 0216 LLCDelaware
CCP Bolton Manor 0529 LLCDelaware
CCP Bremen 0290 LLCDelaware
CCP Brentwood 0555 LLCDelaware
CCP Brewer 0547 LLCDelaware
CCP Brighton 0873 LLCDelaware
CCP Brookhaven 7581 LLCDelaware
CCP Burlington House 2702 LPDelaware
CCP Camelot 0563 LLCDelaware
CCP Cascade Park 7360 LLCDelaware
CCP Chapel Hill 0806 LPDelaware
CCP Cherry Hills 1159 LLCDelaware
CCP Cheyenne 0441 LLCDelaware
CCP Chillicothe 0569 LPDelaware
CCP Clackamas 1513 LLCDelaware
1


CCP Colony House 0582 LLCDelaware
CCP Conway 7175 LLCDelaware
CCP Coos Bay 1510 LLCDelaware
CCP Coshocton 0635 LPDelaware
CCP Country Manor 0507 LLCDelaware
CCP Covina 4003 LPDelaware
CCP Crestview 1505 LLCDelaware
CCP Current River 7252 LLCDelaware
CCP Cypress Pointe 0188 LPDelaware
CCP Danville Centre 0782 LLCDelaware
CCP Den-Mar 0542 LLCDelaware
CCP Dixon 7253 LLCDelaware
CCP Dover 0591 LLCDelaware
CCP Driftwood 7140 LPDelaware
CCP Dundee 7170 LLCDelaware
CCP Dutchess 1741 LLCDelaware
CCP Eastside 0545 LLCDelaware
CCP Eliot 0526 LLCDelaware
CCP Elizabethtown 0787 LLCDelaware
CCP Eugene 1509 LLCDelaware
CCP Evergreen North Cascades 7201 LLCDelaware
CCP Fayette County 7452 LPDelaware
CCP Finance I LLCDelaware
CCP Finance II LLCDelaware
CCP Firesteel 7380 LLCDelaware
CCP Florence Villa 3781 LLCDelaware
CCP Forsyth 7254 LLCDelaware
CCP Fountain Circle 0280 LLCDelaware
CCP Fountain Springs 7381 LLCDelaware
CCP Galion 7451 LPDelaware
CCP Garden Gate 7583 LLCDelaware
CCP Garden Valley 1155 LLCDelaware
CCP Glendale 4001 LLCDelaware
CCP Glenwood 7255 LLCDelaware
CCP Golden/7470 LLCDelaware
CCP Gravios 2227 LLCDelaware
CCP Guardian Roanoke 0704 LPDelaware
CCP Guardian Rocky Mount 0723 LPDelaware
CCP Guardian Zebulon 0713 LPDelaware
CCP Harbour Point 0826 LLCDelaware
CCP Harris Hill 7582 LLCDelaware
CCP Harrodsburg 0864 LLCDelaware
CCP Healthbridge 7403 LPDelaware
CCP Hillcrest 0785 LLCDelaware
CCP Hillsboro 1507 LLCDelaware
2


CCP Holdings GP1 LLCDelaware
CCP Hopkins 3784 LLCDelaware
CCP Junction City 1508 LLCDelaware
CCP Kachina Point 0853 LLCDelaware
CCP Kansas II LLCDelaware
CCP Keizer 1526 LLCDelaware
CCP Kennebunk 0549 LLCDelaware
CCP King City 1506 LLCDelaware
CCP Kinston 0711 LPDelaware
CCP La Mesa 1910 LLCDelaware
CCP Lakeshore 4000 LLCDelaware
CCP Las Vegas 0640 LLCDelaware
CCP Lebanon 1504 LLCDelaware
CCP Lincoln 0307 LPDelaware
CCP Madison 0132 LLCDelaware
CCP Malley 0859 LLCDelaware
CCP Marietta 0645 LLCDelaware
CCP Maryville 3785 LLCDelaware
CCP Masters 0884 LLCDelaware
CCP McKinney 1677 LLCDelaware
CCP Meadowvale 0269 LLCDelaware
CCP Medford 0453 LLCDelaware
CCP MG Manor 7387 LLCDelaware
CCP Millbrook 1678 LLCDelaware
CCP Minneapolis 7005 LLCDelaware
CCP Monroe 0707 LPDelaware
CCP Mountain View 1529 LLCDelaware
CCP Mountain View 2228 LLCDelaware
CCP Mt. Pleasant 7171 LLCDelaware
CCP Muncie 0406 LLCDelaware
CCP Newport 1528 LLCDelaware
CCP Newton Wellesley 0539 LLCDelaware
CCP North Gate 7584 LLCDelaware
CCP Northern Nevada 2226 LLCDelaware
CCP Norway 0550 LLCDelaware
CCP Nutmeg Pavilion 0567 LLCDelaware
CCP Oakridge 3766 LLCDelaware
CCP Oakview 0278 LLCDelaware
CCP Olympic 1503 LLCDelaware
CCP Orange Hills 7390 LPDelaware
CCP Palisade 7383 LLCDelaware
CCP Parkway Pavilion 0568 LLCDelaware
CCP Parkwood 0407 LLCDelaware
CCP Pearl Kruse 1527 LLCDelaware
CCP Petersburg 3767 LLCDelaware
3


CCP Pettigrew 0116 LPDelaware
CCP Phoenix 1930 LLCDelaware
CCP Pleasant Valley 1679 LLCDelaware
CCP Prairie View 7385 LLCDelaware
CCP Primacy 0822 LLCDelaware
CCP Properties Business TrustMassachusetts
CCP Queen Anne 0462 LLCDelaware
CCP Quincy 0537 LLCDelaware
CCP Raleigh 0143 LPDelaware
CCP Rawlins 0481 LLCDelaware
CCP Regency 1676 LLCDelaware
CCP Regency Manor 2701 LPDelaware
CCP Richmond Beach 1500 LLCDelaware
CCP River Terrace 0587 LLCDelaware
CCP Riverpark 1502 LLCDelaware
CCP Riverside 0281 LLCDelaware
CCP Riverview 7384 LLCDelaware
CCP Rosewood 0277 LLCDelaware
CCP Royal Oaks 0112 LLCDelaware
CCP Sachem 0514 LLCDelaware
CCP Sage View 0483 LLCDelaware
CCP San Diego 4005 LPDelaware
CCP Savannah Rehab 0155 LLCDelaware
CCP Savannah Specialty 0660 LLCDelaware
CCP Seneca 7585 LLCDelaware
CCP Senior Indiana LLCDelaware
CCP Shepherd 7386 LLCDelaware
CCP Silas Creek 0191 LPDelaware
CCP Silex 7256 LLCDelaware
CCP Smoky Hill 7350 LLCDelaware
CCP South Hampton 7257 LLCDelaware
CCP South Shore Manor 3782 LLCDelaware
CCP Springfield Business TrustMassachusetts
CCP St. Francis 1742 LLCDelaware
CCP Strafford 7258 LLCDelaware
CCP Sunnybrook 0137 LPDelaware
CCP Sunnyside 0452 LLCDelaware
CCP Tacoma 1512 LLCDelaware
CCP Tacoma 1515 LLCDelaware
CCP Tacoma Pearl 1532 LLCDelaware
CCP Tempe 4002 LLCDelaware
CCP Three Fountains 1525 LLCDelaware
CCP Torrey Pines 0641 LLCDelaware
CCP Tri-State 7172 LLCDelaware
CCP Ulster 1743 LLCDelaware
4


CCP Ventura 4004 LPDelaware
CCP Villa Campana 0851 LLCDelaware
CCP Village 1931 LLCDelaware
CCP Warren 7453 LPDelaware
CCP Western Village 3780 LLCDelaware
CCP Westgate Manor 0554 LLCDelaware
CCP Westminster 3775 LLCDelaware
CCP Westwood Manor 7348 LLCDelaware
CCP WH Holdings LLCDelaware
CCP Wheatcrest 7388 LLCDelaware
CCP Whitesburg 0791 LLCDelaware
CCP Wind River 0482 LLCDelaware
CCP Windsor 7259 LLCDelaware
CCP Winship Green 0546 LLCDelaware
CCP Worthington 1160 LLCDelaware
CCP Wyomissing 1237 LLCDelaware
Charleston AID II OpCo LLCDelaware
Charleston AID II PropCo LLCDelaware
Chesterfield Holdings, LLC (Joint Venture)Delaware
Chesterfield TRS, LLC (Subsidiary of Joint Venture)Delaware
Clarks Summit AID II OpCo LLCDelaware
Clarks Summit AID II PropCo LLCDelaware
Clarksville Senior Partners, LLC Indiana
Deerfield Senior Partners, LLC Indiana
Douglassville AID II OpCo LLCDelaware
Douglassville AID II PropCo LLCDelaware
Dover AID II OpCo LLCDelaware
Dover AID II PropCo LLCDelaware
DSBR LLC (Joint Venture)Delaware
Gainesville Holding, LLC (Joint Venture)Delaware
Gainesville Propco, LLC (Subsidiary of Joint Venture)Delaware
HEB Health Care Partners, LLC (Joint Venture)Delaware
HEB SNF RE GenPar, LLCTexas
HEB SNF RE, L.P.Texas
L.P.E. New Hampshire
Langdon Place of Dover, a general partnershipNew Hampshire
Langdon Place of Keene Limited PartnershipNew Hampshire
LBG 1717 JV, LLC (Joint Venture)Indiana
Lewisburg AID II OpCo LLCDelaware
Lewisburg AID II PropCo LLCDelaware
Madeira Senior Partners, LLC (Subsidiary of Joint Venture)Indiana
Master Aid II PROPCO LLCDelaware
Master Aid II-B PROPCO LLCDelaware
Master Tenant (FNMA) AID II Opco LLCDelaware
Master Tenant (UNEN) AID II Opco LLCDelaware
5


McCordsville Senior Partners, LLC Indiana
Milford AID II OpCo LLCDelaware
Milford AID II PropCo LLCDelaware
MLD Properties, LLCDelaware
MLD Shelton Investors Partnership California
New Hampshire Holdings, LLCDelaware
Oak Hill AID II OpCo LLCDelaware
Oak Hill AID II PropCo LLCDelaware
Parent AID II Opco TRS LLCDelaware
Park Place AL, LLCIndiana
Reading AID II OpCo LLCDelaware
Reading AID II PropCo LLCDelaware
Sabra 1717 Preferred Equity, LLC Delaware
Sabra AL Holdings, LLCDelaware
Sabra AL Operations, LLCDelaware
Sabra Alamitos, LPDelaware
Sabra Beachside, LPDelaware
Sabra Beaumont Preferred Equity, LLCDelaware
Sabra Beavercreek Preferred Equity, LLCDelaware
Sabra Bedford Hills, LLCDelaware
Sabra Broadway, LPDelaware
Sabra Burien, LLCDelaware
Sabra CA Holdco, Inc.British Columbia
Sabra CA Holdings, LPDelaware
Sabra California GP, LLCDelaware
Sabra Canadian GP I, Inc. British Columbia
Sabra Canadian GP II, Inc. British Columbia
Sabra Canadian GP III, Inc. British Columbia
Sabra Canadian GP IV, Inc. British Columbia
Sabra Canadian Holdings, LLCDelaware
Sabra Canadian Properties I, Limited Partnership British Columbia
Sabra Canadian Properties II, Limited Partnership British Columbia
Sabra Canadian Properties III, Limited Partnership British Columbia
Sabra Canadian Properties IV, Limited Partnership British Columbia
Sabra Capital CorporationDelaware
Sabra Chatsworth, LPDelaware
Sabra Chesterfield Preferred Equity, LLCDelaware
Sabra Clarksville Preferred Equity, LLCDelaware
Sabra Colorado, LLCNevada
Sabra Colorado II, LLCNevada
Sabra Cottonwood, LPDelaware
Sabra Coventry, LPDelaware
Sabra Danville, LPDelaware
Sabra Deer Lodge, LLCDelaware
Sabra Deerfield Operations, LLC Delaware
6


Sabra Deerfield Preferred Equity, LLC Delaware
Sabra East Coast Operations I, LLCDelaware
Sabra East Coast Operations II, LLCDelaware
Sabra Edgewater, LPDelaware
Sabra Fairfield, LPDelaware
Sabra Fairmont, LPDelaware
Sabra FHAPT, LLCDelaware
Sabra Forest Hills, LLCDelaware
Sabra Garden View, LPDelaware
Sabra Grand Terrace, LPDelaware
Sabra Hagerstown, LLCDelaware
Sabra Health Care AL, LLCDelaware
Sabra Health Care Delaware, LLCDelaware
Sabra Health Care Frankenmuth, LLCDelaware
Sabra Health Care Holdings I, LLCDelaware
Sabra Health Care Holdings II, LLCDelaware
Sabra Health Care Holdings III, LLCDelaware
Sabra Health Care Holdings IV, LLCDelaware
Sabra Health Care Holdings V, LLCDelaware
Sabra Health Care Holdings VI, LLCDelaware
Sabra Health Care Investments, LPDelaware
Sabra Health Care Limited PartnershipDelaware
Sabra Health Care Northeast, LLCDelaware
Sabra Health Care Pennsylvania, LLCDelaware
Sabra Health Care Virginia II, LLCDelaware
Sabra Health Care Virginia, LLCDelaware
Sabra Health Care, L.L.C.Delaware
Sabra IL California GP, LLCDelaware
Sabra IL California, L.P.Delaware
Sabra IL Holdings, LLCDelaware
Sabra IL Operations, LLCDelaware
Sabra IL Texas GP, LLCTexas
Sabra IL Texas, L.P.Texas
Sabra Issaquah, LLCDelaware
Sabra Lake Balboa, LPDelaware
Sabra Lake Drive, LLCDelaware
Sabra LBG Madeira, LLC (Joint Venture)Delaware
Sabra Lomita, LPDelaware
Sabra Madiera Preferred Equity, LLCDelaware
Sabra Marshfield II RP, LLCDelaware
Sabra Marshfield II TRS, LLCDelaware
Sabra McCordsville Preferred Equity, LLCDelaware
Sabra Michigan, LLCDelaware
Sabra Midwest Operations I, LLCDelaware
Sabra Midwest Operations II, LLCDelaware
7


Sabra Midwest Operations III, LLCDelaware
Sabra Midwest Operations IV, LLCDelaware
Sabra Midwest Operations V, LLCDelaware
Sabra Midwest Operations VI, LLCDelaware
Sabra Missouri River, LLCDelaware
Sabra Nashua, LLCNew Hampshire
Sabra New Braunfels Preferred Equity, LLC Delaware
Sabra New Mexico II, LLCDelaware
Sabra North Carolina GP, LLCDelaware
Sabra North Carolina, L.P.Delaware
Sabra North Conway, L.L.C.New Hampshire
Sabra Opco AL, LLCDelaware
Sabra Pacifica, LPDelaware
Sabra Palm Terrace, LPDelaware
Sabra Park Ridge, LLCDelaware
Sabra Park West, LLCDelaware
Sabra Phoenix Holding, LLC Delaware
Sabra Phoenix Marshfield, LLC Delaware
Sabra Phoenix TRS Venture II, LLC Delaware
Sabra Phoenix TRS Venture, LLCDelaware
Sabra Phoenix Wisconsin, LLCDelaware
Sabra Propco AL, LLCDelaware
Sabra Ramona, LPDelaware
Sabra Ramsey, LLCDelaware
Sabra Ramsey TRS, LLCDelaware
Sabra Southern Operations I, LLCDelaware
Sabra Southern Operations II, LLCDelaware
Sabra Southern Operations III, LLCDelaware
Sabra Southern Operations IV, LLCDelaware
Sabra Southern Operations V, LLCDelaware
Sabra Texas GP, LLCTexas
Sabra Texas Holdings GP, LLCTexas
Sabra Texas Holdings, LPTexas
Sabra Texas Holdings II, L.P.Texas
Sabra Texas Properties LPTexas
Sabra Texas Properties II, L.P.Texas
Sabra Texas Properties III, L.P.Texas
Sabra Texas Properties IV, L.P.Texas
Sabra Texas Properties VI, L.P.Texas
Sabra TRS Holdings, LLCDelaware
Sabra University, LPDelaware
Sabra Virginia III, LLCDelaware
Sabra Wellmore Preferred Equity, LLCDelaware
Sabra West Coast Operations I, LLCDelaware
Sabra West Coast Operations II, LLCDelaware
8


Sabra West Coast Operations III, LLCDelaware
Sabra West Coast Operations IV, LLCDelaware
Sabra West Coast Operations V, LLCDelaware
Sabra West Lake Operations, LLCDelaware
Sabra Wisconsin, LLCDelaware
Sabra Wisconsin II, LLCDelaware
Sabra Woodland, LPDelaware
Sabra-Sundara Master Developer, LLC (Joint Venture)Delaware
SbraREIT Assisted Living I, ULCNova Scotia
SbraREIT Canadian GP V Inc.Nova Scotia
SbraREIT Canadian Properties V, Limited PartnershipAlberta
SbraREIT Independent Living I, ULCBritish Columbia
SbraREIT Independent Living II, ULCBritish Columbia
Scott Depot AID II OpCo LLCDelaware
Scott Depot AID II PropCo LLCDelaware
SHDG Chesterfield, LLC (Subsidiary of Joint Venture)Delaware
SHDG Missouri, LLC (Subsidiary of Joint Venture)Delaware
Sundara Prop-1, LLC (Subsidiary of Joint Venture)Texas
United Rehab Realty Holding, LLCDelaware
Wellmore of Daniel Island JV, LLC (Joint Venture)Delaware
Wellmore of Daniel Island Propco, LLC (Subsidiary of Joint Venture)Delaware
Williamsport AID II OpCo LLCDelaware
Williamsport AID II PropCo LLCDelaware
Wyncote AID II OpCo LLCDelaware
Wyncote AID II PropCo LLCDelaware
Sienna Sabra GP Corp (Joint Venture) Ontario
Sienna Sabra LP (Subsidiary of Joint Venture)Ontario
Sienna Sabra ON Corp (Subsidiary of Joint Venture)Ontario
Sienna Sabra SK Corp (Subsidiary of Joint Venture)Ontario
Joliette Residences GP Inc (Joint Venture)Ontario
Joliette Residences Limited Partnership (Subsidiary of Joint Venture)Ontario
PCF Residences GP Inc. (Joint Venture)Ontario
PCF Residences Limited Partnership (Subsidiary of Joint Venture)Ontario
VD Residences GP Inc (Joint Venture)Ontario
VD Residences Limited Partnership (Subsidiary of Joint Venture)Ontario
VD Residences Limited (Subsidiary of Joint Venture)Ontario
Sabra CA LoanCo, Inc.British Columbia

9
EX-23.1 4 sbraex2312023q4.htm CONSENT OF PRICEWATERHOUSECOOPERS LLP Document

Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-268285) and Form S-8 (Nos. 333-220055 and 333-239427) of Sabra Health Care REIT, Inc. of our report dated February 27, 2024 relating to the financial statements, financial statement schedules, and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.

/s/ PricewaterhouseCoopers LLP
Irvine, California
February 27, 2024


EX-31.1 5 sbraex3112023q4.htm SECTION 302 CEO CERTIFICATION Document

Exhibit 31.1
Certification of Chief Executive Officer pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
I, Richard K. Matros, certify that:

1.I have reviewed this annual report on Form 10-K of Sabra Health Care REIT, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 27, 2024
 
/S/    RICHARD K. MATROS
Richard K. Matros
Chief Executive Officer, President and Chair



EX-31.2 6 sbraex3122023q4.htm SECTION 302 CFO CERTIFICATION Document

Exhibit 31.2
Certification of Chief Financial Officer pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
I, Michael Costa, certify that:

1.I have reviewed this annual report on Form 10-K of Sabra Health Care REIT, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: 
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 27, 2024
 
/S/    MICHAEL COSTA
Michael Costa
Chief Financial Officer, Secretary and Executive Vice President


EX-32.1 7 sbraex3212023q4.htm SECTION 906 CEO CERTIFICATION Document

Exhibit 32.1
Certification pursuant to 18 U.S.C. Section 1350,
as Adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002
In connection with the Annual Report on Form 10-K of Sabra Health Care REIT, Inc. (the “Registrant”) for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Richard K. Matros, as Chief Executive Officer, President and Chair of the Registrant, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

Date: February 27, 2024
 
/S/    RICHARD K. MATROS
Richard K. Matros
Chief Executive Officer, President and Chair


EX-32.2 8 sbraex3222023q4.htm SECTION 906 CFO CERTIFICATION Document

Exhibit 32.2
Certification pursuant to 18 U.S.C. Section 1350,
as Adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002
In connection with the Annual Report on Form 10-K of Sabra Health Care REIT, Inc. (the “Registrant”) for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Michael Costa, as Chief Financial Officer, Secretary and Executive Vice President of the Registrant, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.
 

Date: February 27, 2024
 
/S/    MICHAEL COSTA
Michael Costa
Chief Financial Officer, Secretary and Executive Vice President



EX-97.1 9 sbraex9712023q4.htm INCENTIVE COMPENSATION RECOUPMENT POLICY Document

EXHIBIT 97.1
Incentive Compensation Recoupment Policy

As Amended and Restated by
the Board of Directors on September 20, 2023

In the event Sabra Health Care REIT, Inc. (the “Company”) is required to prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws (including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period), the Company shall recover reasonably promptly the amount of any erroneously awarded Incentive-Based Compensation from each Covered Individual unless an exception (set forth below) applies.

Incentive-Based Compensation shall be considered “erroneously awarded” under this policy to the extent such Incentive-Based Compensation (1) is received by the Covered Individual on or after October 2, 2023 (the effective date of Rule 5608 of The Nasdaq Stock Market LLC (“Nasdaq”) listing rules) and while the Company has a class of securities listed on a national securities exchange or a national securities association,
(2) is received by the Covered Individual during the three completed fiscal years immediately preceding the date that the Company is required to prepare the accounting restatement (and any transition period applicable to a change in the Company’s fiscal year as required by Nasdaq listing rules), and (3) the amount of such received Incentive- Based Compensation exceeds the amount of the Incentive-Based Compensation that would have been received by the Covered Individual had it been determined based on the restated financial results (with such Incentive-Based Compensation computed in each case without regard to any taxes paid). For purposes of this policy, the date that the Company is required to prepare the accounting restatement is the earlier to occur of
(A) the date the Company’s Board of Directors (the “Board”), or a committee of the Board, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare such accounting restatement, or (B) the date a court, regulator, or other legally authorized body directs the Company to prepare such accounting restatement.
For purposes of this policy, Incentive-Based Compensation is considered “received” by a Covered Individual in the Company’s fiscal period during which the Financial Reporting Measure applicable to the Incentive-Based Compensation is attained, even if the payment or grant of the Incentive-Based Compensation occurs after the end of that fiscal period. For Incentive-Based Compensation based on stock price or total shareholder return, where the amount of erroneously awarded compensation is not subject to mathematical recalculation directly from the information in an accounting restatement, the amount of erroneously awarded compensation will be determined by the Compensation Committee of the Board (the “Committee”) based on a reasonable estimate of the effect of the accounting restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was received. The Company must maintain documentation of the determination of that reasonable estimate and provide such documentation to Nasdaq as required by Nasdaq listing rules. If the erroneously awarded Incentive-Based Compensation consists of shares (including share- denominated equity awards) or options that are still held by the Covered Individual at the time of recovery, the recoverable amount is the number of shares or options received in excess of the number of shares or options that would have
1




been received based on the accounting restatement (or the value of that excess number). If the options have been exercised but the underlying shares have not been sold, the recoverable amount is the number of shares underlying the excess options based on the restatement (or the value thereof). If the shares have been sold, the recoverable amount is the proceeds that were received in connection with the sale of the excess number of shares. Amounts credited under plans (other than tax-qualified plans for which the exception set forth below applies) based on erroneously awarded Incentive-Based Compensation and any accrued earnings thereon are also recoverable under this policy.

The Company shall not be required under this policy to recover erroneously awarded Incentive-Based Compensation if the Committee has made a determination that recovery would be impracticable and either of the following conditions are met: (1) after making a reasonable attempt to recover such erroneously awarded Incentive-Based Compensation, the Committee determines that the direct expense paid to a third party to assist in enforcing this policy would exceed the amount to be recovered (documentation evidencing the reasonable attempt to recover the erroneously awarded Incentive-Based Compensation must be maintained and provided to Nasdaq as required by Nasdaq listing rules), or (2) the recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Internal Revenue Code Section 401(a)(13) or Internal Revenue Code Section 411(a) and the regulations thereunder.
For purposes of this policy, the following definitions will apply:
Covered Individual” means any current or former officer of the Company who is or was subject to Section 16 of the Securities Exchange Act of 1934, as amended, at any time during the applicable performance period for the relevant Incentive-Based Compensation, regardless of whether such individual continues to hold such position or continues to be employed by the Company or any of its subsidiaries.
Incentive-Based Compensation” means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure.
Financial Reporting Measures” means measures that are determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, and any measures that are derived wholly or in part from such measures (including, for purposes of this policy, stock price and total shareholder return). A Financial Reporting Measure need not be presented within the Company’s financial statements or included in a filing with the Securities and Exchange Commission.

This policy is intended to comply with the requirements of Rule 10D-1 promulgated by the Securities and Exchange Commission and the related listing rules of Nasdaq, and the terms hereof shall be construed consistent with that intent. This policy does not limit any other remedies the Company may have available to it in the circumstances, which may include, without limitation, dismissing an employee or initiating other disciplinary procedures. The provisions of this policy are in addition to (and not in lieu of) any rights to repayment the Company may have under Section 304 of the Sarbanes-Oxley Act of 2002 (applicable to the Chief Executive Officer and Chief Financial Officer only) and other applicable laws. The Company shall not indemnify any
2




Covered Individual against the loss of erroneously-awarded Incentive-Based Compensation that is recovered by the Company pursuant to this policy.

The Committee shall have the sole authority to construe and interpret this policy and to make all determinations required to be made pursuant to this policy. Any such construction, interpretation or determination by the Committee shall be final and binding.
The Committee may revise this policy from time to time.
3

EX-101.SCH 10 sbra-20231231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONSOLIDATED STATEMENTS OF INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - CONSOLIDATED STATEMENTS OF EQUITY link:presentationLink link:calculationLink link:definitionLink 0000009 - Statement - CONSOLIDATED STATEMENTS OF EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000010 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - BUSINESS link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - INTANGIBLE ASSETS AND LIABILITIES link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - LOANS RECEIVABLE AND OTHER INVESTMENTS link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - FAIR VALUE DISCLOSURES link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - EQUITY link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - EARNINGS PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - SCHEDULE IV - MORTGAGE LOANS ON REAL ESTATE link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - INTANGIBLE ASSETS AND LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - LOANS RECEIVABLE AND OTHER INVESTMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - FAIR VALUE DISCLOSURES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - EARNINGS PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED)- Purchase Price Allocation for Recent Real Estate Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Real Estate Properties Held for Investment (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Operating Leases Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Future Minimum Rental Payments from Non-Cancelable Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Senior Housing - Managed Communities Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Capital and Other Expenditures Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Schedule of Investment in Joint Ventures (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Investment in Unconsolidated Joint Venture Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Summarized Financial Information for Enlivant Joint Venture (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Net Investment in Sales-Type Lease Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS - Dispositions (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - INTANGIBLE ASSETS AND LIABILITIES - Intangible Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - INTANGIBLE ASSETS AND LIABILITIES - Real Estate Intangible Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - INTANGIBLE ASSETS AND LIABILITIES - Remaining Unamortized Balance for Outstanding Intangible Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - LOANS RECEIVABLE AND OTHER INVESTMENTS - Composition of Loans Receivable and Other Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - LOANS RECEIVABLE AND OTHER INVESTMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - LOANS RECEIVABLE AND OTHER INVESTMENTS - Schedule of Additional Information Regarding the Company's Loans Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - DEBT - Secured Indebtedness (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - DEBT - Secured Indebtedness Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - DEBT - Senior Unsecured Notes (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - DEBT - Senior Unsecured Notes Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - DEBT - Credit Agreement Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - DEBT - Interest Expense Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - DEBT - Schedule of Maturities for Outstanding Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS - Notional Amounts of Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS - Summary of Derivative and Financial Instruments Designated as Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS - Effect of Derivative Financial Instruments on the Condensed Consolidated Statements of Income and Condensed Consolidated Statements of Equity (Details) link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS - Gross Presentation, Effects of Offsetting, and a Net Presentation of Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 9954518 - Disclosure - FAIR VALUE DISCLOSURES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954519 - Disclosure - FAIR VALUE DISCLOSURES - Face Values, Carrying Amounts and Fair Values of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954520 - Disclosure - FAIR VALUE DISCLOSURES - Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954521 - Disclosure - FAIR VALUE DISCLOSURES - Items Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9954522 - Disclosure - EQUITY - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954523 - Disclosure - EQUITY - Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 9954524 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954525 - Disclosure - STOCK-BASED COMPENSATION - Restricted Stock Units Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954526 - Disclosure - STOCK-BASED COMPENSATION - Assumptions Used in Total Stockholder Return-Based Stock Units Valuation (Details) link:presentationLink link:calculationLink link:definitionLink 9954527 - Disclosure - INCOME TAXES - Provision for Income Tax Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954528 - Disclosure - INCOME TAXES - Deferred Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954529 - Disclosure - INCOME TAXES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954530 - Disclosure - EARNINGS PER COMMON SHARE - Computation of Basic and Diluted Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954531 - Disclosure - EARNINGS PER COMMON SHARE - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954532 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink 9954533 - Disclosure - SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION - Summary of Real Estate Properties (Details) link:presentationLink link:calculationLink link:definitionLink 9954534 - Disclosure - SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION - Rollforward of Real Estate and Accumulated Depreciation (Details) link:presentationLink link:calculationLink link:definitionLink 9954535 - Disclosure - SCHEDULE IV - MORTGAGE LOANS ON REAL ESTATE (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 sbra-20231231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 12 sbra-20231231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 13 sbra-20231231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Net income (loss), per: Net Income Loss Attributable To Common Stockholders [Abstract] Net Income Loss Attributable To Common Stockholders Book Value SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Deferred Financing Costs Deferred Charges, Policy [Policy Text Block] Financing Receivable, Allowance for Credit Loss [Roll Forward] Financing Receivable, Allowance for Credit Loss [Roll Forward] Prior ATM Program Prior ATM Program [Member] Prior ATM Program [Member] Medford, OR 1 Medford, OR 1 [Member] Medford, OR 1 Millsboro, DE Millsboro, DE [Member] Millsboro, DE Borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Frankenmuth, MI Frankenmuth, MI [Member] Frankenmuth, MI Loss reclassified accumulated other comprehensive income (loss) into income, net investment hedges Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Investment, Name [Domain] Investment, Name [Domain] Lincolnton, NC Lincolnton, NC [Member] Lincolnton, NC Interest rate Line of Credit Facility, Interest Rate at Period End Schedule of Purchase Price Allocation Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Clarksville, TX Clarksville, TX [Member] Clarksville, TX Boise, ID Boise, ID [Member] Boise, ID Real Estate Investments, Inventory Inventory, Real Estate, Policy [Policy Text Block] Orange, CA Orange, CA [Member] Orange, CA Bee Cave, TX Bee Cave, TX [Member] Bee Cave, TX Knoxville, TN Knoxville, TN [Member] Knoxville, TN Impairment upon disposal Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down Letters of credit deposited Letters Of Credit Deposits Letters Of Credit Deposits Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Five Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Conway, SC Conway, SC [Member] Conway, SC Behavioral health facility Behavioral Health Behavioral Health [Member] Behavioral Health EQUITY Equity [Text Block] Lawrenceburg, KY Lawrenceburg, KY [Member] Lawrenceburg, KY Number of shares of common stock convertible upon each performance-based restricted stock unit vesting (in shares) Conversion Of Stock, Shares Issuable Upon Conversion Conversion Of Stock, Shares Issuable Upon Conversion 2023 Below Market Lease, Amortization Income, Year One Financial assets: Financial Assets [Abstract] Financial Assets Total Quantity Number Of Investments Number Of Investments Expected dividend yield (assuming full reinvestment) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Life on Which Depreciation in Latest Income Statement is Computed SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Life Used for Depreciation 2025 Below Market Lease, Amortization Income, Year Three Land  SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Land, Amount Maxwell, TX 1 Maxwell, TX 1 [Member] Maxwell, TX 1 Bowling Green, KY Bowling Green, KY [Member] Bowling Green, KY Preferred stock, $0.01 par value; 10,000,000 shares authorized, zero shares issued and outstanding as of December 31, 2023 and 2022 Preferred Stock, Value, Issued Subsequent Event Type [Domain] Subsequent Event Type [Domain] Origination and fundings of loans receivable Payments to Acquire Notes Receivable Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Diluted common share (in dollars per share) Earnings Per Share, Diluted Receivable [Domain] Receivable [Domain] Number of properties sold securing debt Number Of Properties Sold Securing Debt Number Of Properties Sold Securing Debt Other Other [Member] Other [Member] Skilled nursing transitional care facility Skilled Nursing/Transitional Care Skilled Nursing Transitional Care Facilities [Member] Skilled Nursing Transitional Care Facilities [Member] LIBOR London Interbank Offered Rate (LIBOR) 1 [Member] London Interbank Offered Rate (LIBOR) 1 Line of Credit Line of Credit [Member] Alpena, MI Alpena, MI [Member] Alpena, MI Shoreline, WA Shoreline, WA [Member] Shoreline, WA Lease Intangible Liabilities: Below Market Lease, Net [Abstract] Las Vegas, NV 1 Las Vegas, NV 1 [Member] Las Vegas, NV 1 Prior ATM Program - Forward Feature Prior ATM Program - Forward Feature [Member] Prior ATM Program - Forward Feature Derivative asset, statement of financial position Derivative Asset, Statement of Financial Position [Extensible Enumeration] Trading Symbol Trading Symbol Madeira, OH Madeira, OH [Member] Madeira, OH Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Five Proceeds of insurance Unusual or Infrequent Item, or Both, Insurance Proceeds Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Carmel, IN Carmel, IN [Member] Carmel, IN Oklahoma City, OK Oklahoma City, OK [Member] Oklahoma City, OK 2019 ATM Program - Forward Feature 2019 ATM Program - Forward Feature [Member] 2019 ATM Program - Forward Feature Yarmouth, ME Yarmouth, ME [Member] Yarmouth, ME 2026 Below Market Lease, Amortization Income, Year Four Total Lessor, Operating Lease, Payment to be Received Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] SOFR Secured Overnight Financing Rate (SOFR) [Member] Secured Overnight Financing Rate (SOFR) Equity Equity, Attributable to Parent [Abstract] Computation of Basic and Diluted Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Derivative liability, statement of financial position Derivative Liability, Statement of Financial Position [Extensible Enumeration] Pasadena, TX Pasadena, TX [Member] Pasadena, TX Executive Category: Executive Category [Axis] Accumulated amortization Below Market Lease, Accumulated Amortization 2027 Lessor, Operating Lease, Payment to be Received, Year Four Restricted Stock Units Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Financial liabilities: Financial Liabilities Fair Value Disclosure [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Quoted Prices in Active Markets for Identical Assets (Level 1) Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Furniture and equipment Fixtures and Equipment, Gross Warrington, PA Warrington, PA [Member] Warrington, PA Carrying Amount Reported Value Measurement [Member] Senior housing facilities - managed communities, proprietary development pipeline Senior Housing Facilities - Managed Communities, Proprietary Development Pipeline [Member] Senior Housing Facilities - Managed Communities, Proprietary Development Pipeline Equity Components [Axis] Equity Components [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items] SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items] Credit Losses Credit Loss, Financial Instrument [Policy Text Block] Terre Haute, IN 1 Terre Haute, IN 1 [Member] Terre Haute, IN 1 Hedging Relationship [Domain] Hedging Relationship [Domain] Draws SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Period Increase (Decrease) Ashland, MO Ashland, MO [Member] Ashland, MO 4.80% senior unsecured notes due 2024 4.80% Senior Unsecured Notes Due 2024 [Member] 4.80% Senior Unsecured Notes Due 2024 [Member] 2025 Long-Term Debt, Maturity, Year Two Enlivant Joint Venture Enlivant Joint Venture [Member] Enlivant Joint Venture [Member] Entity Small Business Entity Small Business Seguin, TX 1 Seguin, TX 1 [Member] Seguin, TX 1 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Four Local Phone Number Local Phone Number Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Fremont, NE 2 Fremont, NE 2 [Member] Fremont, NE 2 Notional amount Derivative, Notional Amount Forward starting interest rate swaps Forward Starting Interest Rate Swaps [Member] Forward Starting Interest Rate Swaps [Member] Improvements SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Improvements Measurement Frequency [Axis] Measurement Frequency [Axis] Huntsville, TX Huntsville, TX [Member] Huntsville, TX Bath, ME Bath, ME [Member] Bath, ME Arlington, TX Arlington, TX [Member] Arlington, TX Restricted Stock Units Restricted Stock Units Restricted Stock Units (RSUs) [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Real estate: SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate [Roll Forward] Gainesville, FL Gainesville, FL [Member] Gainesville, FL Poway, CA Poway, CA [Member] Poway, CA Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Schedule of Debt Schedule of Long-Term Debt Instruments [Table Text Block] Penticton, BC Penticton, BC [Member] Penticton, BC Write-off of non-cash rent receivable Write-Off Of Non-Cash Rent Receivable And Intangibles Write-Off Of Non-Cash Rent Receivable And Intangibles Principal payments on term loans Repayment of term loans Repayments of Medium-term Notes Schedule of Investment in Joint Ventures Equity Method Investments [Table Text Block] Mortgages Mortgages [Member] Shares issued (in shares) Sale of Stock, Number of Shares Issued in Transaction Variable Interest Entities Consolidation, Variable Interest Entity, Policy [Policy Text Block] Total revenues Total revenues Revenues Seattle, WA Seattle, WA [Member] Seattle, WA Debt covenant, consolidated unencumbered total asset value to aggregate principal of unsecured debt Debt Covenant, Unencumbered Assets To Unsecured Debt Ratio, Minimum Debt Covenant, Unencumbered Assets To Unsecured Debt Ratio, Minimum Pewaukee, WI 1 Pewaukee, WI 1 [Member] Pewaukee, WI 1 Tompkinsville, KY Tompkinsville, KY [Member] Tompkinsville, KY Interest Interest expense Interest Expense, Debt Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Common Stock Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Impairment SEC Schedule III, Real Estate Accumulated Depreciation, Impairment SEC Schedule III, Real Estate Accumulated Depreciation, Impairment Williamsport, PA Williamsport, PA [Member] Williamsport, PA Crown Point, IN Crown Point, IN [Member] Crown Point, IN Anti-dilutive securities not included in computation of diluted earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Net investment in sales type lease Sales-Type Lease, Net Investment in Lease, before Allowance for Credit Loss Accounts receivable, prepaid expenses and other assets, net Accounts Receivable, Prepaid Expenses Deferred Financing Costs And Other Assets, Net Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs. Also, includes the sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization. Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Number of acquired properties Business Acquisition, Number of Acquired Properties Business Acquisition, Number of Acquired Properties Common dividends Dividends, Common Stock Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Hedging Designation [Axis] Hedging Designation [Axis] Variable lease revenue Variable Lease, Income Gain (loss) recognized in other comprehensive income (loss), net investment hedges Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax San Diego, CA San Diego, CA [Member] San Diego, CA Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Avamere Avamere Family Of Companies [Member] Avamere Family Of Companies PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Income Taxes [Line Items] Valuation Allowance [Line Items] Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Schedule of Provision for Income Tax Expense Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Jonesboro, AR Jonesboro, AR [Member] Jonesboro, AR Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Mount Pleasant, TX Mount Pleasant, TX [Member] Mount Pleasant, TX Real Estate and Accumulated Depreciation, by Property [Table] SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, by Property [Table] Offsetting Liabilities: Offsetting Derivative Liabilities [Abstract] Average price per share (in dollars per share) Sale Of Stock, Average Price Per Share Sale Of Stock, Average Price Per Share Hopkins, MN Hopkins, MN [Member] Hopkins, MN Houston, TX 1 Houston, TX 1 [Member] Houston, TX 1 Weighted Average Contractual Interest Rate / Rate of Return Financing Receivable, Fixed Interest Rate Financing Fixed Interest Rate Real Estate [Domain] Real Estate [Domain] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Maryville, MO Maryville, MO [Member] Maryville, MO Recently Issued Accounting Standards Update New Accounting Pronouncements, Policy [Policy Text Block] Lease intangible assets, net Lease intangible assets, net Finite-Lived Intangible Assets, Net Winston-Salem, NC Winston-Salem, NC [Member] Winston-Salem, NC Gross Presentation, Effects of Offsetting, and a Net Presentation of Derivatives, Liabilities Offsetting Liabilities [Table Text Block] Center, TX Center, TX [Member] Center, TX Counterparty Name [Domain] Counterparty Name [Domain] Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Gain of unusual amount Gain on Business Interruption Insurance Recovery Colorado Springs, CO 1 Colorado Springs, CO 1 [Member] Colorado Springs, CO 1 Financial liabilities Debt Instrument, Fair Value Disclosure Business Acquisition, By Type [Domain] Business Acquisition, By Type [Domain] [Domain] for Business Acquisition, By Type [Axis] Price per share (in dollars per share) Sale of Stock, Price Per Share Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Initial Cost to Company SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Initial Cost [Abstract] Annual base rent Lessor, Annual Base Rent Lessor, Annual Base Rent Security Exchange Name Security Exchange Name Springfield, MA Springfield, MA [Member] Springfield, MA Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Aggregate cost of real estate for federal income tax purposes Real Estate and Accumulated Depreciation, Initial Cost, Tax Basis Real Estate and Accumulated Depreciation, Initial Cost, Tax Basis Nonaccrual status Nonperforming Financial Instruments [Member] Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Bedford, NH Bedford, NH [Member] Bedford, NH Employee Stock Option Employee Stock Option [Member] DERIVATIVE AND HEDGING INSTRUMENTS Derivative Instruments and Hedging Activities Disclosure [Text Block] Hartford, KY Hartford, KY [Member] Hartford, KY Aggregate gross proceeds possible from sales of common stock under equity offering program Sale Of Stock, Maximum Proceeds From Common Stock Issuances Sale Of Stock, Maximum Proceeds From Common Stock Issuances Vandalism And Theft Vandalism And Theft [Member] Vandalism And Theft Tualatin, OR Tualatin, OR [Member] Tualatin, OR Properties in sales-type Lessor, Sales-Type Lease, Number of Properties Lessor, Sales-Type Lease, Number of Properties Aggregate principal amount redeemed Debt Instrument, Repurchased Face Amount Maximum Maximum [Member] Total unrecognized stock-based compensation expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Document Type Document Type Hillsboro, OR Hillsboro, OR [Member] Hillsboro, OR Tabular List, Table Tabular List [Table Text Block] Currency Swap Currency Swap [Member] McCordsville, IN McCordsville, IN [Member] McCordsville, IN Thereafter Long-Term Debt, Maturity, after Year Five Raytown, MO Raytown, MO [Member] Raytown, MO Principal Balance Preferred equity investments Preferred Equity Investment, Face Value Preferred Equity Investment, Face Value Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Senior housing - leased portfolio Senior Housing - Leased Senior Housing Facilities - Leased [Member] Senior Housing Facilities - Leased [Member] STOCK-BASED COMPENSATION Share-Based Payment Arrangement [Text Block] Principles of Consolidation and Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Non-cash interest income Other Noncash Income (Expense) Book Value Preferred Equity Investment, Carrying Amount Preferred Equity Investment, Carrying Amount Business Acquisition [Axis] Business Acquisition [Axis] Impairment SEC Schedule III, Real Estate, Impairments SEC Schedule III, Real Estate, Impairments Reading, PA Reading, PA [Member] Reading, PA Rochester, MN Rochester, MN [Member] Rochester, MN Total Principal Balance Investment Owned, Balance, Principal Amount Derivative [Table] Derivative [Table] Variable Rate [Axis] Variable Rate [Axis] Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Net (loss) gain on sales of real estate Net loss (gain) on sales of real estate Gains (Losses) on Sales of Investment Real Estate Indianapolis, IN Indianapolis, IN [Member] Indianapolis, IN 2024 Lessor, Operating Lease, Payment to be Received, Year One Savannah, GA 2 Savannah, GA 2 [Member] Savannah, GA 2 Title of 12(b) Security Title of 12(b) Security Forsyth, MO Forsyth, MO [Member] Forsyth, MO Marshfield, WI Marshfield, WI [Member] Marshfield, WI Net income (loss) Disposal Group, Including Discontinued Operation, Operating Income (Loss) Andover, MA Andover, MA [Member] Andover, MA Williamsville, NY Williamsville, NY [Member] Williamsville, NY RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) Business Combination Disclosure [Text Block] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Operating Segments Operating Segments [Member] Unvested, beginning (in dollars per share) Unvested, ending (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Eugene, OR 2 Eugene, OR 2 [Member] Eugene, OR 2 5.375% senior unsecured notes due 2023 5.375% Senior Unsecured Notes Due 2023 [Member] 5.375% Senior Unsecured Notes Due 2023 [Member] Payments to acquire buildings Payments to Acquire Buildings Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Proceeds from term loans Proceeds from Issuance of Medium-term Notes Lexington, KY Lexington, KY [Member] Lexington, KY Fixed interest rate under swap Derivative, Fixed Interest Rate Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Revenue Recognition Revenue Recognition, Leases [Policy Text Block] Schedule of Loans Receivable and Other Investments Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Accumulated depreciation Accumulated Depreciation Real Estate Investment Property, Accumulated Depreciation Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Term loans, net Loans Payable to Bank Entity Tax Identification Number Entity Tax Identification Number Manistee, MI Manistee, MI [Member] Manistee, MI SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation Disclosure [Text Block] Statistical Measurement [Axis] Statistical Measurement [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Impairment of real estate Impairment of real estate Impairment of Real Estate Cookeville, TN Cookeville, TN [Member] Cookeville, TN Rockport, TX Rockport, TX [Member] Rockport, TX 2024 Below Market Lease, Amortization Income, Year Two Operating lease expiration period Lessor, Operating Lease, Term of Contract Loss from unconsolidated joint ventures Loss from unconsolidated joint venture Income (Loss) From Equity Method Investments And Other Than Temporary Impairment Income (Loss) From Equity Method Investments And Other Than Temporary Impairment Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Waxahachie, TX Waxahachie, TX [Member] Waxahachie, TX North Conway, NH North Conway, NH [Member] North Conway, NH Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Gas City, IN Gas City, IN [Member] Gas City, IN Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Harrodsburg, KY Harrodsburg, KY [Member] Harrodsburg, KY Glenville, NY Glenville, NY [Member] Glenville, NY Schedule of Deferred Taxes Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Beavercreek, OH Beavercreek, OH [Member] Beavercreek, OH Buildings and Improvements SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Initial Cost of Building and Improvements Derivative Instruments Derivatives, Policy [Policy Text Block] Augusta, GA Augusta, GA [Member] Augusta, GA Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] 2023 Finite-Lived Intangible Asset, Expected Amortization, Year One Shares outstanding (in shares) Common Stock, Shares, Outstanding Long Beach, CA 3 Long Beach, CA 3 [Member] Long Beach, CA 3 Oak Hill, WV Oak Hill, WV [Member] Oak Hill, WV New mortgage loans SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, New Mortgage Loan Other (expense) income: Other Income and Expenses [Abstract] PEO PEO [Member] Humble, TX 2 Humble, TX 2 [Member] Humble, TX 2 Escrow deposits for potential investments Payments For Escrow Deposits For Potential Investments Payments For Escrow Deposits For Potential Investments Schedule of Future Minimum Rental Payments from Non-Cancelable Operating Leases Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block] Auditor Location Auditor Location Sarasota, FL Sarasota, FL [Member] Sarasota, FL Other non-cash items Other Operating Activities, Cash Flow Statement Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Keizer, OR Keizer, OR [Member] Keizer, OR Par value (in dollars per share) Common Stock, Par or Stated Value Per Share Sale of Stock [Axis] Sale of Stock [Axis] Wynne, AR Wynne, AR [Member] Wynne, AR Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Below market leases Below Market Lease, Gross Loss reclassified accumulated other comprehensive income (loss) into income, cash flow hedge Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Interest rate swaps Interest rate swaps Interest Rate Swap [Member] Business Interruption Loss [Domain] Business Interruption Loss [Domain] Debt Instrument [Axis] Debt Instrument [Axis] Total revenues Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount W. Springfield, MA W. Springfield, MA [Member] W. Springfield, MA Measurement Input Type [Domain] Measurement Input Type [Domain] Credit Facility [Axis] Credit Facility [Axis] Spring, TX Spring, TX [Member] Spring, TX ATM Program ATM Program [Member] ATM Program [Member] Financial Instruments Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Security Not Offset Income tax benefit on unrealized gains (losses) on cash flow hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax Schedule of Maturities for Outstanding Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Total liabilities Total liabilities Liabilities Nashua, NH Nashua, NH [Member] Nashua, NH Marshall, TX Marshall, TX [Member] Marshall, TX Orange, TX Orange, TX [Member] Orange, TX Measurement Frequency [Domain] Measurement Frequency [Domain] Bangor, ME 1 Bangor, ME 1 [Member] Bangor, ME 1 Houston, TX 2 Houston, TX 2 [Member] Houston, TX 2 Corporate Level Corporate Segment [Member] 2026 Lessor, Operating Lease, Payment to be Received, Year Three Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Lafayette, CO Lafayette, CO [Member] Lafayette, CO Accounting Policies [Line Items] Accounting Policies [Line Items] Accounting Policies Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Number of real estate properties impaired Number Of Real Estate Properties Impaired Number Of Real Estate Properties Impaired Sold Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Franklin, NH Franklin, NH [Member] Franklin, NH Specialty Hospitals and Other Specialty Hospitals and Other Specialty Hospitals And Other [Member] Specialty Hospitals And Other [Member] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Subsequent Event Subsequent Event [Line Items] Building and Improvements SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Building and Improvements, Amount Shares allowed for forward feature of ATM Program (in shares) Forward Contract Indexed to Issuer's Equity, Shares Historical volatility rate period Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Historical Volatility Rate Period Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Historical Volatility Rate Period Quantity Financing Receivable, Number Of Loans Financing Receivable, Number Of Loans General and administrative General and Administrative Expense Interest and other income Interest and Fee Income, Loans and Leases Conroe, TX Conroe, TX [Member] Conroe, TX Ineffectiveness on cash flow hedges Derivatives, Net Hedge Ineffectiveness Gain (Loss) Derivatives, Net Hedge Ineffectiveness Gain (Loss) SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Abstract] SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Abstract] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Middletown, DE Middletown, DE [Member] Middletown, DE Louisville, KY Louisville, KY [Member] Louisville, KY Industry Segments Segment Reporting, Policy [Policy Text Block] Number of variable interest entities Variable Interest Entity, Number Of Entities Variable Interest Entity, Number Of Entities Green Bay, WI Green Bay, WI [Member] Green Bay, WI Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Warren, MI Warren, MI [Member] Warren, MI Extension period Line Of Credit Facility, Optional Extension Period Line Of Credit Facility, Optional Extension Period Allowance for loan losses Balance at the beginning of the year Balance at the end of the year Financing Receivable, Allowance for Credit Loss Total expenses Operating And Interest Expense Operating And Interest Expense Other Investments: Preferred Equity, Net [Abstract] Preferred Equity, Net [Abstract] Per Share Data Earnings Per Share, Policy [Policy Text Block] Lecanto, FL Lecanto, FL [Member] Lecanto, FL London, ON London, ON [Member] London, ON Huntington Bch, CA Huntington Bch, CA [Member] Huntington Bch, CA Issuance of common stock, net Proceeds (Payments) From Issuance Of Stock, Net Of Taxes Paid On Behalf Of Employees Proceeds (Payments) From Issuance Of Stock, Net Of Taxes Paid On Behalf Of Employees Insurance proceeds Proceeds from Insurance Settlement, Investing Activities Encumbrances SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Amount of Encumbrances Schedule of Accumulated Other Comprehensive Income Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Hagerstown, MD Hagerstown, MD [Member] Hagerstown, MD Monroeville, PA Monroeville, PA [Member] Monroeville, PA Weighted average fair value per share at grant date (in dollars per share) Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Five Linden, TX Linden, TX [Member] Linden, TX Gain (loss) recognized in other comprehensive income (loss) Other Comprehensive Income (Loss), Cash Flow And Net Investment Hedge, Gain (Loss), Before Reclassification And Tax Other Comprehensive Income (Loss), Cash Flow And Net Investment Hedge, Gain (Loss), Before Reclassification And Tax Clarks Summit, PA Clarks Summit, PA [Member] Clarks Summit, PA Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Pine Knot, KY Pine Knot, KY [Member] Pine Knot, KY Schedule of Remaining Unamortized Balance for Outstanding Intangible Assets Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Senior unsecured notes, net Unsecured Debt Kinston, NC Kinston, NC [Member] Kinston, NC Unrealized gain (loss), net of tax: Other Comprehensive Income (Loss), Unrealized Gain (Loss), Net of Tax [Abstract] Other Comprehensive Income (Loss), Unrealized Gain (Loss), Net of Tax [Abstract] Depreciation and amortization Depreciation and amortization Depreciation, Depletion and Amortization Other income (expense) Other Operating Income (Expense), Net Marlin Spring Joint Venture Marlin Spring Joint Venture [Member] Marlin Spring Joint Venture Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Business Combination and Asset Acquisition [Abstract] Book Value Book value Financing Receivable, after Allowance for Credit Loss Anchorage, AK Anchorage, AK [Member] Anchorage, AK Consolidation Items [Axis] Consolidation Items [Axis] Kennebunk, ME Kennebunk, ME [Member] Kennebunk, ME Available borrowing capacity Line of Credit Facility, Capacity Available for Trade Purchases Valuation allowance Deferred Tax Assets, Valuation Allowance Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Interest and penalties from significant uncertain tax positions Income Tax Examination, Penalties and Interest Expense Seymour, MO Seymour, MO [Member] Seymour, MO Fifth Amended and Restated Credit Agreement Credit Agreement [Member] Fifth Amended and Restated Credit Agreement [Member] Restricted cash Restricted Cash and Cash Equivalents Foreign currency translation (loss) gain Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Unrealized gain on cash flow hedges Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Beacon, NY Beacon, NY [Member] Beacon, NY Sudbury, MA Sudbury, MA [Member] Sudbury, MA Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Shares issued (in shares) Preferred Stock, Shares Issued Assumptions used in valuation Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract] Strasburg, VA Strasburg, VA [Member] Strasburg, VA Entity Emerging Growth Company Entity Emerging Growth Company Provision for loan losses Financing Receivable, Allowance for Credit Loss, Period Increase (Decrease) Deferred financing costs Deferred financing costs, net Deferred financing costs, net Debt Issuance Costs, Net 3.20% senior unsecured notes due 2031 3.20% Senior Unsecured Notes Due 2031 [Member] 3.20% Senior Unsecured Notes Due 2031 Deferred tax assets Deferred Tax Assets, Gross Petersburg, VA 1 Petersburg, VA 1 [Member] Petersburg, VA 1 Harrogate, TN Harrogate, TN [Member] Harrogate, TN Tenant intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Baytown, TX 2 Baytown, TX 2 [Member] Baytown, TX 2 Assets Held for Sale, Dispositions and Discontinued Operations Real Estate Held for Development and Sale, Policy [Policy Text Block] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] East Patchogue, NY East Patchogue, NY [Member] East Patchogue, NY Antidilutive Securities [Axis] Antidilutive Securities [Axis] SCHEDULE IV - MORTGAGE LOANS ON REAL ESTATE SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Text Block] Calgary, AB Calgary, AB [Member] Calgary, AB Title Trading Arrangement, Individual Title Number of preferred equity investments for funding commitment Commitment For Funding, Preferred Equity Investment, Number Commitment For Funding, Preferred Equity Investment, Number Sequim, WA Sequim, WA [Member] Sequim, WA Nashville, TN Nashville, TN [Member] Nashville, TN Common Stock Common Stock [Member] Furniture and equipment Furniture and Equipment [Member] Furniture and Equipment [Member] Individual: Individual [Axis] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Worcester, MA Worcester, MA [Member] Worcester, MA Income Statement Location [Domain] Income Statement Location [Domain] Baytown, TX Baytown, TX [Member] Baytown, TX Discount, net Discount, net Debt Instrument, Unamortized Discount (Premium), Net Waterloo, ON Waterloo, ON [Member] Waterloo, ON U.S. dollar Term Loans U.S. Dollar Term Loan [Member] U.S. Dollar Term Loan [Member] Principal payments on secured debt Repayments of fixed rate secured debt Repayments of Secured Debt Schedule of Fair Value of Financial Instruments Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] SEC Schedule, 12-29, Real Estate Companies, Investment in Movement in Mortgage Loans on Real Estate [Roll Forward] SEC Schedule, 12-29, Real Estate Companies, Investment in Movement in Mortgage Loans on Real Estate [Roll Forward] Weighted average interest rate (percent) Debt, Weighted Average Interest Rate Member’s equity (deficit) Equity, Including Portion Attributable to Noncontrolling Interest Kansas City, MO Kansas City, MO [Member] Kansas City, MO Minimum Minimum [Member] Credit risk-related contingent features Credit Risk Contract [Member] Zephyrhills, FL Zephyrhills, FL [Member] Zephyrhills, FL Fremont, NE Fremont, NE [Member] Fremont, NE Bartlesville, OK Bartlesville, OK [Member] Bartlesville, OK Eugene, OR Eugene, OR [Member] Eugene, OR Distributions of earnings from unconsolidated joint ventures Proceeds from Equity Method Investment, Distribution Van Nuys, CA Van Nuys, CA [Member] Van Nuys, CA Company’s share of net loss Income (Loss) From Equity Method Investments, Before Basis Adjustments Income (Loss) From Equity Method Investments, Before Basis Adjustments Number of properties Number of Properties Number of Real Estate Properties Total other comprehensive income Other comprehensive income Other Comprehensive Income (Loss), Net of Tax Owensboro, KY Owensboro, KY [Member] Owensboro, KY Gains included in accumulated other comprehensive income expected to be reclassified into retained earnings in the next 12 months Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months Disposal Group Classification [Axis] Disposal Group Classification [Axis] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Tax withholding obligations incurred on behalf of employees Payment, Tax Withholding, Share-Based Payment Arrangement Liabilities Liabilities [Abstract] Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Las Vegas, NV 2 Las Vegas, NV 2 [Member] Las Vegas, NV 2 COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Wolfeboro, NH Wolfeboro, NH [Member] Wolfeboro, NH Windsor, MO Windsor, MO [Member] Windsor, MO Fairfield, CA Fairfield, CA [Member] Fairfield, CA Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Portland, OR Portland, OR [Member] Portland, OR Lebanon, OR Lebanon, OR [Member] Lebanon, OR TSR Units Total Shareholder Return Units [Member] Total Shareholder Return Units [Member] Unrealized gain (loss) on cash flow hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Basic common share (in dollars per share) Earnings Per Share, Basic Accumulated depreciation: SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Accumulated Depreciation [Roll Forward] Accounting Policies [Abstract] Accounting Policies [Abstract] Sale of Stock [Domain] Sale of Stock [Domain] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Sherman, TX Sherman, TX [Member] Sherman, TX Deferred taxes, net Deferred Tax Assets, Net Repayments of preferred equity investments Repayments Of Preferred Equity Investments Repayments Of Preferred Equity Investments Greenville, MI Greenville, MI [Member] Greenville, MI Income taxes paid Income Taxes Paid Marshfield, WI 1 Marshfield, WI 1 [Member] Marshfield, WI 1 Real Estate and Accumulated Depreciation SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items] Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Real estate investments, net of accumulated depreciation of $1,021,086 and $913,345 as of December 31, 2023 and 2022, respectively Total Real Estate Investments, Net Real Estate Investment Property, Net Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Foreign currency translation SEC Schedule III, Real Estate Accumulated Depreciation, Foreign Currency Translation SEC Schedule III, Real Estate Accumulated Depreciation, Foreign Currency Translation Fremont, NE 1 Fremont, NE 1 [Member] Fremont, NE 1 Repayments of loans receivable Proceeds from Collection of Notes Receivable Entity Public Float Entity Public Float Kelowna, BC Kelowna, BC [Member] Kelowna, BC Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Land improvements Land Improvements Derivative Instrument [Axis] Derivative Instrument [Axis] Total Debt Long-Term Debt, Gross Security deposit liability Security Deposit Liability All Trading Arrangements All Trading Arrangements [Member] Net (loss) gain on sale Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Forward sale agreement term Sale Of Stock, Agreement Term Sale Of Stock, Agreement Term All Adjustments to Compensation All Adjustments to Compensation [Member] Principal Balance Balance at the beginning of the year Balance at the end of the year SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Face Amount of Mortgages Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Compensation Amount Outstanding Recovery Compensation Amount Woodland, CA 2 Woodland, CA 2 [Member] Woodland, CA 2 Equity Method Investment, Nonconsolidated Investee [Axis] Equity Method Investment, Nonconsolidated Investee [Axis] Foreign currency translation SEC Schedule III, Real Estate, Foreign Currency Translation SEC Schedule III, Real Estate, Foreign Currency Translation Provision for loan losses and other reserves Provision for loan losses and other reserves Accounts Receivable, Credit Loss Expense (Reversal) Pacifica, CA Pacifica, CA [Member] Pacifica, CA Fair Value Net Amounts of Assets presented in the Balance Sheet Financial assets Derivative Asset Cancelled/forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Preferred equity investments, measurement input Preferred Equity Investments, Measurement Input Preferred Equity Investments, Measurement Input Subsequent Event Type [Axis] Subsequent Event Type [Axis] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Norfolk, VA Norfolk, VA [Member] Norfolk, VA Loans Receivable: Financing Receivable, after Allowance for Credit Loss [Abstract] Seguin, TX 3 Seguin, TX 3 [Member] Seguin, TX 3 Schedule of Derivative and Financial Instruments Designated as Hedging Instruments Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block] Glasgow, KY Glasgow, KY [Member] Glasgow, KY Hendersonville, NC Hendersonville, NC [Member] Hendersonville, NC 5.125% senior unsecured notes due 2026 5.125% Senior Unsecured Notes Due 2026 [Member] 5.125% Senior Unsecured Notes Due 2026 [Member] Document Financial Statement Error Correction [Flag] Document Financial Statement Error Correction [Flag] Cancelled/forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Number of loans receivable investments Financing Receivable, Number Of Loans, Impaired Financing Receivable, Number Of Loans, Impaired Basis adjustments Income (Loss) From Equity Method Investments, Basis Adjustments Income (Loss) From Equity Method Investments, Basis Adjustments Investment in Unconsolidated Joint Ventures and Preferred Equity Investments and Preferred Return Equity Method Investments [Policy Text Block] Schedule of Real Estate Properties Held for Investment Schedule of Real Estate Properties [Table Text Block] Distributions in excess of earnings from unconsolidated joint ventures Proceeds from Equity Method Investment, Distribution, Return of Capital Term loans, net Loans Payable To Bank [Member] Loans Payable To Bank [Member] Revenue, type, extensible enumeration Revenue, Product and Service [Extensible Enumeration] 2024 Long-Term Debt, Maturity, Year One Operating lease, liability, statement of financial position Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration] Winchester, IN Winchester, IN [Member] Winchester, IN Redemption Period One Debt Instrument, Redemption, Period One [Member] Hamburg, NY Hamburg, NY [Member] Hamburg, NY Newport, OR Newport, OR [Member] Newport, OR Non-cash rent receivable Noncash Rent Receivable [Member] Noncash Rent Receivable Dilutive restricted stock units (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Eustis, FL Eustis, FL [Member] Eustis, FL Memphis, TN Memphis, TN [Member] Memphis, TN Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Document Period End Date Document Period End Date Adoption Date Trading Arrangement Adoption Date Cost Capitalized Subsequent to Acquisition SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Cost Capitalized Subsequent to Acquisition, Cost St. Louis, MO St. Louis, MO [Member] St. Louis, MO Numerator Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Income tax expense Income tax expense Income Tax Expense (Benefit) Weighted average remaining vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Designated as Hedging Instrument Designated as Hedging Instrument [Member] New Braunfels, TX New Braunfels, TX [Member] New Braunfels, TX Windsor, ON Windsor, ON [Member] Windsor, ON Write-off of uncollectible balances Financing Receivable, Allowance for Credit Loss, Writeoff FAIR VALUE DISCLOSURES Fair Value Disclosures [Text Block] Depreciation expense SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Accumulated Depreciation, Depreciation Expense Chatsworth, CA Chatsworth, CA [Member] Chatsworth, CA Gain on business interruption insurance recovery, statement of income or comprehensive income Gain on Business Interruption Insurance Recovery, Statement of Income or Comprehensive Income [Extensible Enumeration] Operating expenses Operating Costs and Expenses Write-offs associated with unamortized discount and deferred financing costs Deferred Debt Issuance Cost, Writeoff INTANGIBLE ASSETS AND LIABILITIES Intangible Assets And Intangible Liabilities Disclosure [Text Block] Intangible Assets And Intangible Liabilities Disclosure Non-cash rental and related revenues Non-Cash Rental And Related Revenues Adjustments Non-Cash Rental And Related Revenues Adjustments Sale of real estate SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Cost of Investment in Real Estate Sold Assets held for sale Real Estate, Held-for-Sale Equity [Abstract] Equity [Abstract] Weighted-average remaining term of operating leases Operating Lease, Weighted Average Remaining Lease Term Roanoke Rapids, NC Roanoke Rapids, NC [Member] Roanoke Rapids, NC Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Lake Stevens, WA Lake Stevens, WA [Member] Lake Stevens, WA Seguin, TX 2 Seguin, TX 2 [Member] Seguin, TX 2 2025 Lessor, Operating Lease, Payment to be Received, Year Two Shavano Park, TX Shavano Park, TX [Member] Shavano Park, TX Financial Instrument Performance Status [Axis] Financial Instrument Performance Status [Axis] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Clinton, IN Clinton, IN [Member] Clinton, IN Net carrying value Disposal Group, Including Discontinued Operation, Assets And Liabilities, Net Disposal Group, Including Discontinued Operation, Assets And Liabilities, Net Tacoma, WA 3 Tacoma, WA 3 [Member] Tacoma, WA 3 Credit Facility [Domain] Credit Facility [Domain] Santa Fe, NM 1 Santa Fe, NM 1 [Member] Santa Fe, NM 1 Interest rate collars Interest rate collars Interest Rate Collar [Member] Interest Rate Collar Florence, WI Florence, WI [Member] Florence, WI Number of facilities Disposal Group, Including Discontinued Operations, Number Of Properties Disposal Group, Including Discontinued Operations, Number Of Properties Net Amount Derivative Asset, Including Not Subject to Master Netting Arrangement, after Offset and Deduction Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Estimated useful lives of assets Property, Plant and Equipment, Useful Life Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Dyer, IN Dyer, IN [Member] Dyer, IN Cincinnati, OH Cincinnati, OH [Member] Cincinnati, OH Accounting Policies [Table] Accounting Policies [Table] Accounting Policies [Table] Number of derivative instruments held Derivative, Number of Instruments Held Proceeds from issuance of senior unsecured notes Proceeds from Issuance of Unsecured Debt Cash and Cash Equivalents Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block] Charlottesville, VA Charlottesville, VA [Member] Charlottesville, VA Interest rate products Interest Rate Contract [Member] Lomita, CA Lomita, CA [Member] Lomita, CA Count Derivative Asset, Number of Instruments Held Future funding commitment Other Commitment Medford, OR 2 Medford, OR 2 [Member] Medford, OR 2 Brenham, TX Brenham, TX [Member] Brenham, TX Additional Paid-in Capital Additional Paid-in Capital [Member] Document Annual Report Document Annual Report Balance Sheet Location [Axis] Balance Sheet Location [Axis] Principal payments on senior unsecured notes Repayments of Unsecured Debt Loss from unconsolidated joint ventures Income (Loss) from Equity Method Investments Triple-net portfolio Triple-Net Portfolio [Member] Triple-Net Portfolio [Member] Cover [Abstract] Weighted-average remaining amortization period Below Market Lease, Remaining Amortization Period Below Market Lease, Remaining Amortization Period SUBSEQUENT EVENTS Subsequent Events [Text Block] LOANS RECEIVABLE AND OTHER INVESTMENTS Loans, Notes, Trade and Other Receivables Disclosure [Text Block] Debt, measurement input Debt Instrument, Measurement Input Woodland, CA 1 Woodland, CA 1 [Member] Woodland, CA 1 Recurring Fair Value, Recurring [Member] Zebulon, NC Zebulon, NC [Member] Zebulon, NC Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Dividends paid on common stock Payments of Dividends Monticello, AR Monticello, AR [Member] Monticello, AR Richmond, IN Richmond, IN [Member] Richmond, IN Undiscounted minimum lease payments included in the lease liability Lessee, Operating Lease, Liability, to be Paid Riverside, CA Riverside, CA [Member] Riverside, CA Credit Loss Status [Axis] Credit Loss Status [Axis] Cash Flow Hedges Cash flow Cash Flow Hedging [Member] Audit Information [Abstract] Audit Information [Abstract] Audit Information Weighted Average Annualized Effective Interest Rate / Rate of Return Financing Receivable, Effective Interest Rate Financing Receivable, Effective Interest Rate Secured Debt Secured Indebtedness Secured Debt [Member] Equity Component [Domain] Equity Component [Domain] Gross Presentation, Effects of Offsetting, and a Net Presentation of Derivatives, Assets Offsetting Assets [Table Text Block] Wyncote, PA Wyncote, PA [Member] Wyncote, PA Sacramento, CA Sacramento, CA [Member] Sacramento, CA Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Tacoma, WA 1 Tacoma, WA 1 [Member] Tacoma, WA 1 Entity Current Reporting Status Entity Current Reporting Status Longview, TX Longview, TX [Member] Longview, TX Oregon City, OR Oregon City, OR [Member] Oregon City, OR Brandon, FL Brandon, FL [Member] Brandon, FL 2027 Below Market Lease, Amortization Income, Year Five Deferred tax (liabilities) Deferred Tax Liabilities, Gross Consolidated Entities [Domain] Consolidated Entities [Domain] Funding payments beyond contractual requirements Funding Payments, Beyond Contractual Requirement Funding Payments, Beyond Contractual Requirement Keene, NH Keene, NH [Member] Keene, NH Tacoma, WA 2 Tacoma, WA 2 [Member] Tacoma, WA 2 Enfield, CT Enfield, CT [Member] Enfield, CT Segments [Axis] Segments [Axis] Lancaster, TX Lancaster, TX [Member] Lancaster, TX Additions to real estate Payments to Acquire Furniture and Fixtures Fair Value Estimate of Fair Value Measurement [Member] Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Calhoun, KY Calhoun, KY [Member] Calhoun, KY Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Revolving credit facility Long-Term Line of Credit Real Estate Properties [Line Items] Real Estate Properties [Line Items] Business Interruption Loss [Axis] Business Interruption Loss [Axis] Cheektowaga, NY Cheektowaga, NY [Member] Cheektowaga, NY Real Estate, Type of Property [Axis] Real Estate, Type of Property [Axis] Winnebago, IL Winnebago, IL [Member] Winnebago, IL Consolidated Entities [Axis] Consolidated Entities [Axis] Variable Rate [Domain] Variable Rate [Domain] Pay vs Performance Disclosure [Line Items] Entity Voluntary Filers Entity Voluntary Filers Brewer, ME Brewer, ME [Member] Brewer, ME Mason, MI Mason, MI [Member] Mason, MI Statistical Measurement [Domain] Statistical Measurement [Domain] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Auburn, AL Auburn, AL [Member] Auburn, AL Houston, TX 4 Houston, TX 4 [Member] Houston, TX 4 Unvested, beginning (in shares) Unvested, ending (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number DEBT Debt Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Interest rate Debt Instrument, Interest Rate At Period End Debt Instrument, Interest Rate At Period End Trinity, TX Trinity, TX [Member] Trinity, TX Matching contributions Defined Contribution Plan, Employer Discretionary Contribution Amount Cross currency interest rate swaps Cross currency interest rate swaps Cross Currency Interest Rate Contract [Member] Revolving Credit Facility Revolving Credit Facility [Member] Primary beneficiary Variable Interest Entity, Primary Beneficiary [Member] Effect of foreign currency translation on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Marlborough, MA Marlborough, MA [Member] Marlborough, MA Credit Loss Status [Domain] Credit Loss Status [Domain] Sienna Joint Venture Sienna Joint Venture [Member] Sienna Joint Venture MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Covina, CA Covina, CA [Member] Covina, CA Tempe, AZ Tempe, AZ [Member] Tempe, AZ Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations and Disposal Groups [Abstract] Net income (loss) Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual Restatement Determination Date: Restatement Determination Date [Axis] Investment, Name [Axis] Investment, Name [Axis] Number of Beds/Units Number of Units in Real Estate Property Commitments and contingencies (Note 15) Commitments and Contingencies Notional amount Derivative, Amount of Hedged Item Deductions during period: Mortgage Loans On Real Estate, Deductions [Abstract] Mortgage Loans On Real Estate, Deductions [Abstract] Dividends reinvested (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Dividends Reinvested In Period Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Dividends Reinvested In Period Weighted Average Contractual Interest Rate / Rate of Return Preferred Equity Investment, Weighted Average Contractual Rate Preferred Equity Investment, Weighted Average Contractual Rate Initial weighted average price (in dollars per share) Sale Of Stock, Forward Agreement, Initial Weighted Average Price, Forward Feature Sale Of Stock, Forward Agreement, Initial Weighted Average Price, Forward Feature Proceeds from issuance of common stock Proceeds from Issuance of Common Stock East Tawas, MI East Tawas, MI [Member] East Tawas, MI Geographical [Axis] Geographical [Axis] Total Real Estate at Cost Real Estate Investment Property, at Cost INCOME TAXES Income Tax Disclosure [Text Block] Net (repayments of) borrowings from revolving credit facility Proceeds from (Repayments of) Lines of Credit Shoreline, WA 1 Shoreline, WA 1 [Member] Shoreline, WA 1 Carrollton, KY Carrollton, KY [Member] Carrollton, KY Muncie, IN Muncie, IN [Member] Muncie, IN Future funding on investment Future Funding On Investment [Member] Future Funding On Investment Lessee Accounting Lessee, Leases [Policy Text Block] Origination and fundings of preferred equity investments Payments For Preferred Equity Investments Payments For Preferred Equity Investments Mortgage Mortgage Loans Receivable [Member] Mortgage Loans Receivable [Member] Par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Business Acquisition [Line Items] Business Acquisition [Line Items] Weighted Average Grant Date Fair Value Per Unit Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Senior Housing - Managed Senior Housing Facilities [Member] Senior Housing Facilities [Member] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Payment of contingent consideration Payment for contingent consideration Payment for Contingent Consideration Liability, Financing Activities Gross Amounts of Recognized Liabilities Derivative Liability, Subject to Master Netting Arrangement, before Offset PEO Total Compensation Amount PEO Total Compensation Amount Secured debt, net Secured Debt Hedging Relationship [Axis] Hedging Relationship [Axis] Future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases: Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Abstract] Land Land Loss reclassified accumulated other comprehensive income (loss) into income Other Comprehensive Income (Loss), Cash Flow And Net Investment Hedge, Gain (Loss), Reclassification, Before Tax Other Comprehensive Income (Loss), Cash Flow And Net Investment Hedge, Gain (Loss), Reclassification, Before Tax Schedule of Remaining Unamortized Balance for Outstanding Intangible Liabilities Below Market Lease, Future Amortization Income [Table Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Florence, KY Florence, KY [Member] Florence, KY Santa Fe, NM 2 Santa Fe, NM 2 [Member] Santa Fe, NM 2 Beaumont, TX Beaumont, TX [Member] Beaumont, TX Interest Rate Swap Two Interest Rate Swap Two [Member] Interest Rate Swap Two Buildings and building improvements Building and Building Improvements [Member] Loveland, OH Loveland, OH [Member] Loveland, OH Aggregate cost for federal income tax purposes SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Federal Income Tax Basis Sunnyvale, TX Sunnyvale, TX [Member] Sunnyvale, TX Number of investments in loans accounted for as real estate joint ventures Real Estate Investments, Joint Ventures, Number Real Estate Investments, Joint Ventures, Number Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Missouri City, TX Missouri City, TX [Member] Missouri City, TX Net income (loss) Net income (loss) Net income (loss) Net Income (Loss) Derivative Contract [Domain] Derivative Contract [Domain] Schedule of Notional Amount of Derivatives Instruments Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Menomonee Falls, WI Menomonee Falls, WI [Member] Menomonee Falls, WI Disposal group, not discontinued operations, gain (loss) on disposal, statement of income Disposal Group, Not Discontinued Operation, Gain (Loss) On Disposal, Statement Of Income, Extensible List, Not Disclosed Flag Disposal Group, Not Discontinued Operation, Gain (Loss) On Disposal, Statement Of Income, Extensible List, Not Disclosed Flag Bryant, AR Bryant, AR [Member] Bryant, AR Finite-Lived Intangible Assets Finite-Lived Intangible Assets [Line Items] SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Loan Category [Domain] SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Loan Category [Domain] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Ogden, UT Ogden, UT [Member] Ogden, UT Gain (loss) recognized in other comprehensive income (loss), cash flow hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Maxwell, TX 3 Maxwell, TX 3 [Member] Maxwell, TX 3 Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Weighted-average amortization period of intangible assets Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Foreign currency products Foreign Exchange Contract [Member] Raleigh, NC 2 Raleigh, NC 2 [Member] Raleigh, NC 2 SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation Disclosure [Abstract] SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation Disclosure [Abstract] Name Measure Name Name Forgone Recovery, Individual Name Gladstone, OR Gladstone, OR [Member] Gladstone, OR Parkersburg, WV Parkersburg, WV [Member] Parkersburg, WV Financial Instrument Performance Status [Domain] Financial Instrument Performance Status [Domain] Building and improvements Buildings and Improvements, Gross Valuation Allowance [Table] Valuation Allowance [Table] Allen, TX Allen, TX [Member] Allen, TX Measurement Basis [Axis] Measurement Basis [Axis] Underlying Securities Award Underlying Securities Amount Petersburg, VA 2 Petersburg, VA 2 [Member] Petersburg, VA 2 Norfolk, NE Norfolk, NE [Member] Norfolk, NE Durham, NC Durham, NC [Member] Durham, NC Grants recognized Grant Income Grant Income Fair Value Measurement [Domain] Fair Value Measurement [Domain] Gilmer, TX Gilmer, TX [Member] Gilmer, TX Total weighted average contractual interest rate / rate of return Investments, Weighted Average Contractual Rate Investments, Weighted Average Contractual Rate Business Acquisition, By Type [Axis] Business Acquisition, By Type [Axis] Business Acquisition, By Type [Axis] Common dividends (in dollars per share) Quarterly cash dividend declared on common stock (in dollars per share) Common Stock, Dividends, Per Share, Declared Net proceeds from the sales of real estate Proceeds from Sale of Other Productive Assets Book value Financing Receivable, Nonaccrual Payments for stock issuance commissions Payments of Stock Issuance Costs Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] 5.88% senior unsecured notes due 2027 5.88% Senior Unsecured Notes Due 2027 [Member] 5.88% Senior Unsecured Notes Due 2027 Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Total  Real Estate and Accumulated Depreciation, Initial Cost Real Estate and Accumulated Depreciation, Initial Cost Acquisition of real estate Payments to Acquire Real Estate Income Statement Location [Axis] Income Statement Location [Axis] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Petersburg, IN Petersburg, IN [Member] Petersburg, IN Schedule of Real Estate Properties Held for Investment [Table] Schedule of Real Estate Properties [Table] Schedule of Future Minimum Lease Payments Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Debt assumed Business Acquisition Debt Assumed Business Acquisition Debt Assumed Schedule of Face Values, Carrying Amounts and Fair Values of Financial Instruments Fair Value, by Balance Sheet Grouping [Table Text Block] Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Tenant origination and absorption costs Tenant origination and absorption costs intangible assets Tenant Origination and Absorption Costs [Member] Tenant Origination and Absorption Costs [Member] Cash Collateral Received Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Grand Terrace, CA Grand Terrace, CA [Member] Grand Terrace, CA Real Estate Investments Real Estate, Policy [Policy Text Block] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Number of extension options Line Of Credit Facility, Number Of Extension Options Line Of Credit Facility, Number Of Extension Options Payments related to extinguishment of debt Payments made to noteholders and legal fees for early redemption Payment for Debt Extinguishment or Debt Prepayment Cost Future capital expenditures Capital Expenditures Incurred but Not yet Paid Additions during period: Mortgage Loans On Real Estate, Additions [Abstract] Mortgage Loans On Real Estate, Additions [Abstract] Sparks, NV Sparks, NV [Member] Sparks, NV Loss on extinguishment of debt Loss on extinguishment of debt Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Fishkill, NY Fishkill, NY [Member] Fishkill, NY Loans Receivable Financing Receivable [Policy Text Block] Trading Arrangement: Trading Arrangement [Axis] Accelerated amortization Amortization, Accelerated, Lease Intangible Amortization, Accelerated, Lease Intangible Use of Estimates Use of Estimates, Policy [Policy Text Block] San Luis Obispo, CA San Luis Obispo, CA [Member] San Luis Obispo, CA Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Fredericksburg, VA Fredericksburg, VA [Member] Fredericksburg, VA Vancouver, WA Vancouver, WA [Member] Vancouver, WA Discount Rate Measurement Input, Discount Rate [Member] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Summary of Additional Information Concerning Restricted Stock Units Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] 2026 Long-Term Debt, Maturity, Year Three Sarnia, ON Sarnia, ON [Member] Sarnia, ON El Monte, CA El Monte, CA [Member] El Monte, CA Deposits for potential sale of real estate Proceeds from Deposits on Real Estate Sales Phoenix, AZ Phoenix, AZ [Member] Phoenix, AZ Real Estate [Abstract] Auditor Firm ID Auditor Firm ID Depreciation and amortization related to tenant origination and absorption costs and tenant relationship Amortization of Intangible Assets Entity Shell Company Entity Shell Company East Longmeadow, MA East Longmeadow, MA [Member] East Longmeadow, MA Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Risk free interest rate, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Restatement Determination Date Restatement Determination Date Loans receivable and other investments, net Total Book Value Financing Receivable And Other Investments, Net Amount after allowance and deduction of deferred interest and fees, unamortized costs and premiums and discounts from face amounts, of loans and other investments held in portfolio, including but not limited to, commercial and consumer loans. Includes loans held for sale. Excludes loans and leases covered under loss sharing agreements. Wilmington, DE Wilmington, DE [Member] Wilmington, DE Senior housing - managed portfolio Senior Housing - Managed Senior Housing Facilities - Managed Portfolio [Member] Senior Housing Facilities - Managed Portfolio [Member] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Long Beach, CA 2 Long Beach, CA 2 [Member] Long Beach, CA 2 Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Washington Court House, OH Washington Court House, OH [Member] Washington Court House, OH Equity interest, investment basis amount Equity Method Investment, Estimated Fair Value Investment Basis Amount Equity Method Investment, Estimated Fair Value Investment Basis Amount Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities Aurora, CO Aurora, CO [Member] Aurora, CO River Vista River Vista [Member] River Vista Term Loans Loans Payable [Member] Denominator Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Shares issued (in shares) Common Stock, Shares, Issued Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Cumulative Distributions in Excess of Net Income Accumulated Distributions in Excess of Net Income [Member] Net income (loss), per: Earnings Per Share, Basic And Diluted EPS [Abstract] Earnings Per Share, Basic And Diluted EPS Weighted Average Annualized Effective Interest Rate / Rate of Return Preferred Equity Investment, Weighted Average Effective Rate Preferred Equity Investment, Weighted Average Effective Rate Total Debt, Net Long-Term Debt 2027 Long-Term Debt, Maturity, Year Four Foreign currency translation gain Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Tenant deposits for future real estate taxes, insurance expenditures, and tenant improvements Property Taxes, Insurance, And Tenant Improvement Deposit Liability Property Taxes, Insurance, And Tenant Improvement Deposit Liability Weighted average period for recognition of stock-based compensation expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Salem, OR Salem, OR [Member] Salem, OR Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Dixon, MO Dixon, MO [Member] Dixon, MO Coos Bay, OR Coos Bay, OR [Member] Coos Bay, OR Federal Domestic Tax Authority [Member] Entity Address, Address Line One Entity Address, Address Line One Receivable Type [Axis] Receivable Type [Axis] Fixed Rate Fixed Rate Mortgages [Member] Fixed Rate Mortgages [Member] Subsequent Event [Table] Subsequent Event [Table] Net (decrease) increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Duffield, VA Duffield, VA [Member] Duffield, VA Sienna Senior Living Sienna Senior Living [Member] Sienna Senior Living Gulf Breeze, FL Gulf Breeze, FL [Member] Gulf Breeze, FL Schedule of Real Estate Intangible Amortization Income (Expense) Schedule Of Real Estate Intangibles Amortization Income And Expense [Table Text Block] Schedule Of Real Estate Intangibles Amortization Income And Expense Wisconsin Dells, WI Wisconsin Dells, WI [Member] Wisconsin Dells, WI Subsequent event Subsequent Event [Member] Baldwin Park, CA Baldwin Park, CA [Member] Baldwin Park, CA Schedule of Intangible Assets and Liabilities Schedule of Finite-Lived Intangible Assets [Table Text Block] Preferred Stock Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract] Income Statement [Abstract] Income Statement Amounts Income Statement [Abstract] Douglassville, PA Douglassville, PA [Member] Douglassville, PA Common stock issuance, net (in shares) Stock Issued During Period, Shares, New Issues Other SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Accumulated Depreciation, Other Deduction Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Baytown, TX 1 Baytown, TX 1 [Member] Baytown, TX 1 Fair value of derivatives in a net liability position Fair value Net Amounts of Liabilities presented in the Balance Sheet Derivative Liability Government Grants Government Grants, Policy [Policy Text Block] Government Grants, Policy Greenville, SC Greenville, SC [Member] Greenville, SC Class of Stock [Line Items] Class of Stock [Line Items] Scott Depot, WV Scott Depot, WV [Member] Scott Depot, WV Real estate intangible amortization income (expense) Real Estate Intangible Amortization Income (Expense) [Abstract] Real Estate Intangible Amortization Income (Expense) Deteriorated credit quality Financial Asset Acquired with Credit Deterioration [Member] Other Commitments [Domain] Other Commitments [Domain] Investment in unconsolidated joint ventures Book value Equity Method Investments Saginaw, MI Saginaw, MI [Member] Saginaw, MI Lease intangible liabilities, net Lease intangible liabilities, net Below Market Lease, Net Woodstock, VA Woodstock, VA [Member] Woodstock, VA DeSoto, TX DeSoto, TX [Member] DeSoto, TX INVESTMENT IN REAL ESTATE PROPERTIES Real Estate Disclosure [Text Block] Ramsey, MN Ramsey, MN [Member] Ramsey, MN IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Savannah, GA 1 Savannah, GA 1 [Member] Savannah, GA 1 Total Shareholder Return Amount Total Shareholder Return Amount Milford, DE Milford, DE [Member] Milford, DE Vesting percentage Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Percentage Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Percentage Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Sellersburg, IN Sellersburg, IN [Member] Sellersburg, IN Supplemental disclosure of non-cash investing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Long Beach, CA 1 Long Beach, CA 1 [Member] Long Beach, CA 1 Segments [Domain] Segments [Domain] Lake Oswego, OR Lake Oswego, OR [Member] Lake Oswego, OR Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Milford, NH Milford, NH [Member] Milford, NH Consolidation Items [Domain] Consolidation Items [Domain] Schedule of Additional Information Regarding the Company's Loans Receivable Schedule Of Additional Information, Loans And Financing Receivable [Table Text Block] Schedule Of Additional Information, Loans And Financing Receivable Aggregate principal amount Financial liabilities Debt Instrument, Face Amount Bellingham, WA Bellingham, WA [Member] Bellingham, WA Cumberland, MD Cumberland, MD [Member] Cumberland, MD Deferred tax (liabilities): Deferred Tax Liabilities, Net [Abstract] Colorado Springs, CO 2 Colorado Springs, CO 2 [Member] Colorado Springs, CO 2 Equity Method Investment, Nonconsolidated Investee [Domain] Equity Method Investment, Nonconsolidated Investee [Domain] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Houston, TX 3 Houston, TX 3 [Member] Houston, TX 3 Disposal Group Name [Domain] Disposal Group Name [Domain] Cumulative distributions in excess of net income Accumulated Distributions in Excess of Net Income Chillicothe, OH Chillicothe, OH [Member] Chillicothe, OH Recent Real Estate Acquisitions Series of Individually Immaterial Business Acquisitions [Member] Principal balance Principal balance Loans receivable Financing Receivable, Principal Amount Financing Receivable, Principal Amount Morrilton, AR Morrilton, AR [Member] Morrilton, AR Net proceeds from sales-type lease Proceeds from Lease Payment, Sales-Type and Direct Financing Leases, Investing Activity Net loss Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Quantity Preferred Equity Investments, Number Preferred Equity Investments, Number of Investments Gross Amounts of Recognized Assets Derivative Asset, Subject to Master Netting Arrangement, before Offset Discretionary matching contribution (percent) Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent Richardson, TX Richardson, TX [Member] Richardson, TX Humble, TX 1 Humble, TX 1 [Member] Humble, TX 1 Rocky Mount, NC Rocky Mount, NC [Member] Rocky Mount, NC Name of Property [Domain] Name of Property [Domain] Building and improvements Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Buildings Operating lease liability Present value of lease liability Operating Lease, Liability Wilmington, NC Wilmington, NC [Member] Wilmington, NC BUSINESS Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Elizabethtown, KY Elizabethtown, KY [Member] Elizabethtown, KY Consideration, net of closing costs Disposal Group, Including Discontinued Operation, Consideration Portland, IN Portland, IN [Member] Portland, IN Accounts receivable, prepaid expenses and other assets, net Increase (Decrease) in Prepaid Expense and Other Assets Accumulated Other Comprehensive (Loss) Income Total accumulated other comprehensive income AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount New London, CT New London, CT [Member] New London, CT Lebanon, IN Lebanon, IN [Member] Lebanon, IN All Executive Categories All Executive Categories [Member] Bremen, IN Bremen, IN [Member] Bremen, IN Danville, CA Danville, CA [Member] Danville, CA Net Amount Derivative Liability, Including Not Subject to Master Netting Arrangement, after Offset and Deduction Henderson, NV Henderson, NV [Member] Henderson, NV Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Coshocton, OH Coshocton, OH [Member] Coshocton, OH Debt Disclosure [Abstract] Debt Disclosure [Abstract] Financial Instruments Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Security Not Offset Number of reportable segments Number of Reportable Segments Earnings Per Share [Abstract] Earnings Per Share [Abstract] St. Francis, WI St. Francis, WI [Member] St. Francis, WI Common stock, $0.01 par value; 500,000,000 shares authorized, 231,266,020 and 231,009,295 shares issued and outstanding as of December 31, 2023 and 2022, respectively Common Stock, Value, Issued Redemption price (percent) Debt Instrument, Redemption Price, Percentage Acquisitions SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Other Acquisition Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Louisville, KY 3 Louisville, KY 3 [Member] Louisville, KY 3 Ventura, CA Ventura, CA [Member] Ventura, CA Round Rock, TX Round Rock, TX [Member] Round Rock, TX Vernon, BC Vernon, BC [Member] Vernon, BC Senior Notes Senior Notes [Member] Pewaukee, WI 2 Pewaukee, WI 2 [Member] Pewaukee, WI 2 Canadian dollar Term Loan Canadian Dollar Term Loan [Member] Canadian Dollar Term Loan [Member] Radcliff, KY Radcliff, KY [Member] Radcliff, KY Minneapolis, MN Minneapolis, MN [Member] Minneapolis, MN Accrued interest Interest Payable 2028 Lessor, Operating Lease, Payment to be Received, Year Five All Individuals All Individuals [Member] Lancaster, MA Lancaster, MA [Member] Lancaster, MA Total other expense Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category FFO Units Funds From Operations Units [Member] Funds From Operations Units [Member] Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Norman, OK Norman, OK [Member] Norman, OK Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Doniphan, MO Doniphan, MO [Member] Doniphan, MO Income Tax Authority [Axis] Income Tax Authority [Axis] PEO Name PEO Name Expected stock price volatility, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Shares authorized (in shares) Preferred Stock, Shares Authorized Base Rate Base Rate [Member] Madison, TN Madison, TN [Member] Madison, TN Shares outstanding (in shares) Preferred Stock, Shares Outstanding Deferred tax assets: Deferred Tax Assets, Net of Valuation Allowance [Abstract] Danville, KY Danville, KY [Member] Danville, KY Northglenn, CO Northglenn, CO [Member] Northglenn, CO Junction City, OR Junction City, OR [Member] Junction City, OR Forward Equity Sale Agreements Forward Equity Sale Agreement Shares [Member] Forward Equity Sale Agreement Shares Bangor, ME 2 Bangor, ME 2 [Member] Bangor, ME 2 Corporate Assets Corporate, Non-Segment [Member] Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Interest rate Debt Instrument, Interest Rate, Stated Percentage La Mesa, CA La Mesa, CA [Member] La Mesa, CA Statement of Financial Position [Abstract] Balance Sheet Amounts Statement of Financial Position [Abstract] Total equity Beginning balance Ending balance Accumulated other comprehensive income (loss) Equity, Attributable to Parent Loans receivable, measurement input Financing Receivable, Measurement Input Financing Receivable, Measurement Input McKinney, TX McKinney, TX [Member] McKinney, TX Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] North Tonawanda, NY North Tonawanda, NY [Member] North Tonawanda, NY Annandale, VA Annandale, VA [Member] Annandale, VA Jasper, IN Jasper, IN [Member] Jasper, IN Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Benton, AR Benton, AR [Member] Benton, AR Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Expected service period Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Subsequent Events [Abstract] Subsequent Events [Abstract] Maxwell, TX 2 Maxwell, TX 2 [Member] Maxwell, TX 2 Principal balance Long-Term Debt, Percentage Bearing Fixed Interest, Amount Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Richmond, VA Richmond, VA [Member] Richmond, VA Hedging Designation [Domain] Hedging Designation [Domain] Reading, MA Reading, MA [Member] Reading, MA Significant Other Observable Inputs (Level 2) Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Resident fee and services Revenue From Contract With Customer, Excluding Assessed Tax [Member] Revenue From Contract With Customer, Excluding Assessed Tax Net Investment Hedges Net investment Net Investment Hedging [Member] Quincy, MA Quincy, MA [Member] Quincy, MA Fire Fire [Member] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Recovery Centers of America Recovery Centers Of America [Member] Recovery Centers Of America Dover, NH Dover, NH [Member] Dover, NH Weighted average effective interest rate (percent) Debt Instrument, Interest Rate, Effective Percentage Total consideration Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Effect of Derivatives and Financial Instruments Designated as Hedging Instruments on Income and Equity Derivative Instruments, Gain (Loss) [Table Text Block] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Topeka, KS Topeka, KS [Member] Topeka, KS CDOR Canadian Dollar Offer Rate (CDOR) [Member] Canadian Dollar Offer Rate (CDOR) [Member] Document Fiscal Period Focus Document Fiscal Period Focus Facilities Facilities [Member] Facilities 2027 Lessee, Operating Lease, Liability, to be Paid, Year Four Operating lease, expense Operating Lease, Expense Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Weighted Average Weighted Average [Member] 2019 ATM Program 2019 ATM Program [Member] 2019 ATM Program Houston, TX Houston, TX [Member] Houston, TX Foreign Foreign Tax Authority [Member] Terre Haute, IN Terre Haute, IN [Member] Terre Haute, IN City Area Code City Area Code EARNINGS PER COMMON SHARE Earnings Per Share [Text Block] Product and Service [Axis] Product and Service [Axis] Branford, CT Branford, CT [Member] Branford, CT Huntsville, AL Huntsville, AL [Member] Huntsville, AL Seattle, WA 1 Seattle, WA 1 [Member] Seattle, WA 1 Fort Wayne, IN Fort Wayne, IN [Member] Fort Wayne, IN Ownership Equity interest in joint venture Equity Method Investment, Ownership Percentage Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Sheboygan, WI Sheboygan, WI [Member] Sheboygan, WI Summary of Assumptions Used in Total Stockholder Return-Based Stock Units Valuation Schedule Of Share-Based Payment Award, Restricted Stock Units, Valuation Assumptions [Table Text Block] Schedule of Share-based Payment Award, Restricted Stock Units, Valuation Assumptions [Table Text Block] 3.90% senior unsecured notes due 2029 3.90% Senior Unsecured Notes Due 2029 [Member] Senior Unsecured Notes Due 2029 [Member] Webster, TX Webster, TX [Member] Webster, TX Other SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Other Deduction Total  Balance at the beginning of the year Balance at the end of the year SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Gross Receivables [Abstract] Receivables [Abstract] Salina, KS Salina, KS [Member] Salina, KS Land improvements Land Improvements [Member] Exercise Price Award Exercise Price Amount available for issuance Sale Of Stock, Remaining Amount Available For Issuance Sale Of Stock, Remaining Amount Available For Issuance Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Investment in unconsolidated joint ventures Payments to Acquire Interest in Joint Venture Other expense related to derivatives Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Bluffton, IN Bluffton, IN [Member] Bluffton, IN Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Loan Category [Axis] SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Loan Category [Axis] Land Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land Eugene, OR 1 Eugene, OR 1 [Member] Eugene, OR 1 Liabilities: Derivative Liability [Abstract] Deferred financing costs Debt Issuance Costs, Gross Operating lease, right-of-use asset, statement of financial position Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Contractual Interest Rate SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Interest Rate Thereafter Lessor, Operating Lease, Payment to be Received, after Year Five Loss from unconsolidated joint venture Income (Loss) From Equity Method Investments [Member] Income (Loss) From Equity Method Investments Total liabilities and equity Liabilities and Equity West Seneca, NY West Seneca, NY [Member] West Seneca, NY Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Restricted cash obligations Accrued Obligations Associated With Restricted Cash Accrued Obligations Associated With Restricted Cash Weighted-average remaining amortization period Finite-Lived Intangible Assets, Remaining Amortization Period Operating lease right-of-use asset Operating Lease, Right-of-Use Asset Tenant relationships Tenant relationship intangible assets Tenant relationship Tenant Relationship [Member] Tenant Relationship [Member] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Risk free interest rate, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Provision (benefit) for foreign income taxes Current Foreign Tax Expense (Benefit) Expected stock price volatility, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Norway, ME Norway, ME [Member] Norway, ME Lodi, CA Lodi, CA [Member] Lodi, CA Number of loans receivable investments Financing Receivable, Number Of Loans, Nonaccrual Status Financing Receivable, Number Of Loans, Nonaccrual Status Annville, KY Annville, KY [Member] Annville, KY Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Burien, WA Burien, WA [Member] Burien, WA Interest Rate Swap One Interest Rate Swap One [Member] Interest Rate Swap One Preferred equity investment book value at acquisition Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value Columbus, IN Columbus, IN [Member] Columbus, IN Beverly, MA Beverly, MA [Member] Beverly, MA Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Termination Date Trading Arrangement Termination Date Land  SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Initial Cost of Land Provision for federal, state and local income taxes Current Federal, State and Local, Tax Expense (Benefit) Shares authorized (in shares) Common Stock, Shares Authorized Glendale, AZ Glendale, AZ [Member] Glendale, AZ Mount Pleasant, SC Mount Pleasant, SC [Member] Mount Pleasant, SC Borrowing capacity in certain foreign currencies Line Of Credit Facility, Maximum Borrowing Capacity, Foreign Currency Line Of Credit Facility, Maximum Borrowing Capacity, Foreign Currency SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate Schedule [Table] SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate Schedule [Table] Total weighted average annualized effective interest rate / rate of return Investments, Weighted Average Effective Rate Investments, Weighted Average Effective Rate Anaheim, CA Anaheim, CA [Member] Anaheim, CA Gross Amount at which Carried at Close of Period SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Gross [Abstract] Cadillac, MI Cadillac, MI [Member] Cadillac, MI Adjustments to reconcile net income (loss) to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Measurement Input Type [Axis] Measurement Input Type [Axis] Kamloops, BC Kamloops, BC [Member] Kamloops, BC Derivative [Line Items] Derivative [Line Items] Award Timing Disclosures [Line Items] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Thereafter Below Market Lease, Amortization Income, after Year Five Total fair value of units vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Cash Collateral Received Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset Other Commitments [Axis] Other Commitments [Axis] Additional paid-in capital Additional Paid in Capital Loans receivable Loans Receivable, Fair Value Disclosure Columbia, MO Columbia, MO [Member] Columbia, MO Alameda, CA Alameda, CA [Member] Alameda, CA Income Taxes Income Tax, Policy [Policy Text Block] Revolving credit facility Long-Term Line Of Credit [Member] Long-Term Line Of Credit 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Three Book Value Financing Receivable, before Allowance for Credit Loss Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Tigard, OR Tigard, OR [Member] Tigard, OR Insider Trading Arrangements [Line Items] Galion, OH Galion, OH [Member] Galion, OH Shares issued upon vesting (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Underwritten Public Offering Underwritten Public Offering [Member] Underwritten Public Offering Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Augusta, ME Augusta, ME [Member] Augusta, ME 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Two Yuma, AZ Yuma, AZ [Member] Yuma, AZ Adjustment to Compensation, Amount Adjustment to Compensation Amount Auditor Name Auditor Name Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Louisville, KY 1 Louisville, KY 1 [Member] Louisville, KY 1 Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Disposal Group Name [Axis] Disposal Group Name [Axis] Schedule of Items Measured at Fair Value on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Raleigh, NC 1 Raleigh, NC 1 [Member] Raleigh, NC 1 Entity Central Index Key Entity Central Index Key Non-cash interest expense Amortization of Debt Issuance Costs and Discounts Sun City West, AZ Sun City West, AZ [Member] Sun City West, AZ Dispositions: Disposal Group, Not Discontinued Operation, Disposal Disclosures [Abstract] Highland, NY Highland, NY [Member] Highland, NY Lease Intangible Liabilities Below Market Lease, Net, Amortization Income, Fiscal Year Maturity [Abstract] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Gross lease intangible assets Finite-Lived Intangible Assets, Gross Income Tax Authority [Domain] Income Tax Authority [Domain] Dividends reinvested (in dollars per share) Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Dividends Reinvested In Period, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Dividends Reinvested In Period, Weighted Average Grant Date Fair Value Other-than-temporary impairment of unconsolidated joint ventures Other-than-temporary impairment Equity Method Investment, Other than Temporary Impairment Payments of deferred financing costs Payments of Financing Costs Name Trading Arrangement, Individual Name Common stock issuance, net Stock Issued During Period, Value, New Issues Ancillary services Health Care, Resident Service, Ancillary Service [Member] Health Care, Resident Service, Ancillary Service [Member] North American Health Care, Inc North American Health Care, Inc [Member] North American Health Care, Inc Accumulated Depreciation and Amortization Balance at the beginning of the year Balance at the end of the year SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Accumulated Depreciation Resident fees and services Revenue from Contract with Customer, Excluding Assessed Tax Entity [Domain] Entity [Domain] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Dover, DE Dover, DE [Member] Dover, DE Lease Intangible Assets: Finite-Lived Intangible Assets, Net [Abstract] Legal Entity [Axis] Legal Entity [Axis] Gross Amounts Offset in the Balance Sheet Derivative Liability, Subject to Master Netting Arrangement, Asset Offset Principal balance Senior Notes Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Silex, MO Silex, MO [Member] Silex, MO Raleigh, NC Raleigh, NC [Member] Raleigh, NC Gilroy, CA Gilroy, CA [Member] Gilroy, CA Weighted-average number of common shares outstanding, diluted (in shares) Diluted weighted average common shares (in shares) Weighted Average Number of Shares Outstanding, Diluted Columbia, KY Columbia, KY [Member] Columbia, KY Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Assets: Derivative Asset [Abstract] Increase (decrease) to rental income related to above/below market leases, net Amortization of above and below Market Leases Schedule of Dispositions Disposal Groups, Including Discontinued Operations [Table Text Block] Expenses: Operating Expenses [Abstract] Offsetting Assets: Offsetting Derivative Assets [Abstract] Company Selected Measure Amount Company Selected Measure Amount Louisville, KY 2 Louisville, KY 2 [Member] Louisville, KY 2 Strafford, MO Strafford, MO [Member] Strafford, MO Above market leases Above Market Leases [Member] Total assets Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Brighton, CO Brighton, CO [Member] Brighton, CO Decrease in loans receivable and other investments due to acquisition of real estate Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) Amortization of stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Kingsbury, TX Kingsbury, TX [Member] Kingsbury, TX 2028 Long-Term Debt, Maturity, Year Five Cedar Park, TX Cedar Park, TX [Member] Cedar Park, TX Lewisburg, WV Lewisburg, WV [Member] Lewisburg, WV Count Derivative Liability, Number of Instruments Held Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Non-NEOs Non-NEOs [Member] Garland, TX Garland, TX [Member] Garland, TX Prime Rate Prime Rate [Member] Lincoln, NE Lincoln, NE [Member] Lincoln, NE Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Income before loss from unconsolidated joint ventures and income tax expense Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Issaquah, WA Issaquah, WA [Member] Issaquah, WA Non-PEO NEO Non-PEO NEO [Member] Winchester, KY Winchester, KY [Member] Winchester, KY Adjustment to Compensation: Adjustment to Compensation [Axis] Lowell, MA Lowell, MA [Member] Lowell, MA Kirbyville, TX Kirbyville, TX [Member] Kirbyville, TX Olympia, WA Olympia, WA [Member] Olympia, WA Marietta, GA Marietta, GA [Member] Marietta, GA Gross Amounts Offset in the Balance Sheet Derivative Asset, Subject to Master Netting Arrangement, Liability Offset Debt Instrument [Line Items] Debt Instrument [Line Items] Weighted-average number of common shares outstanding, basic (in shares) Basic weighted average common shares and common equivalents (in shares) Weighted Average Number of Shares Outstanding, Basic San Marcos, TX San Marcos, TX [Member] San Marcos, TX Monroe, NC Monroe, NC [Member] Monroe, NC Charleston, WV Charleston, WV [Member] Charleston, WV Horse Cave, KY Horse Cave, KY [Member] Horse Cave, KY Redemption Period Two Debt Instrument, Redemption, Period Two [Member] Sale of real estate SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Accumulated Depreciation, Investment in Real Estate Sold Calvert City, KY Calvert City, KY [Member] Calvert City, KY Revenues: Revenues [Abstract] Prior Liens SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Prior Lien, Amount Lease Intangible Assets Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Louisville, KY 4 Louisville, KY 4 [Member] Louisville, KY 4 Changes in operating assets and liabilities: Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract] Number of acquired properties Number Of Real Estate Properties Acquired Number Of Real Estate Properties Acquired Rental and related revenues (Note 4) Operating Lease, Lease Income Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Annum percent unused borrowing fee Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Statement [Line Items] Statement [Line Items] Gaylord, MI Gaylord, MI [Member] Gaylord, MI Santa Ana, CA Santa Ana, CA [Member] Santa Ana, CA Exeter, NH Exeter, NH [Member] Exeter, NH Bardstown, KY Bardstown, KY [Member] Bardstown, KY Preferred equity investments Preferred Equity Investment, Fair Value Disclosure Preferred Equity Investment, Fair Value Disclosure Lawrence, KS Lawrence, KS [Member] Lawrence, KS Westminster, MD Westminster, MD [Member] Westminster, MD Name of Property [Axis] Name of Property [Axis] Chapel Hill, NC Chapel Hill, NC [Member] Chapel Hill, NC Paydowns/repayments SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Collections of Principal Health Care, Resident Service [Member] EX-101.PRE 14 sbra-20231231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 15 sbra-20231231_g1.jpg begin 644 sbra-20231231_g1.jpg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htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover - USD ($)
$ in Billions
12 Months Ended
Dec. 31, 2023
Feb. 20, 2024
Jun. 30, 2023
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2023    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 001-34950    
Entity Registrant Name SABRA HEALTH CARE REIT, INC.    
Entity Incorporation, State or Country Code MD    
Entity Tax Identification Number 27-2560479    
Entity Address, Address Line One 1781 Flight Way    
Entity Address, City or Town Tustin    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 92782    
City Area Code 888    
Local Phone Number 393-8248    
Title of 12(b) Security Common Stock, $0.01 par value    
Trading Symbol SBRA    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 2.7
Entity Common Stock, Shares Outstanding   231,476,751  
Documents Incorporated by Reference
Portions of the Proxy Statement for the registrant’s 2024 Annual Meeting of Stockholders, to be filed with the Securities and Exchange Commission not later than 120 days after December 31, 2023, are incorporated by reference in Part III herein.
   
Entity Central Index Key 0001492298    
Document Fiscal Year Focus 2023    
Document Fiscal Period Focus FY    
Amendment Flag false    
XML 17 R2.htm IDEA: XBRL DOCUMENT v3.24.0.1
Audit Information
12 Months Ended
Dec. 31, 2023
Audit Information [Abstract]  
Auditor Name PricewaterhouseCoopers LLP
Auditor Location Irvine, California
Auditor Firm ID 238
XML 18 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Assets    
Real estate investments, net of accumulated depreciation of $1,021,086 and $913,345 as of December 31, 2023 and 2022, respectively $ 4,617,261 $ 4,959,343
Loans receivable and other investments, net 420,624 411,396
Investment in unconsolidated joint ventures 136,843 134,962
Cash and cash equivalents 41,285 49,308
Restricted cash 5,434 4,624
Lease intangible assets, net 30,897 40,131
Accounts receivable, prepaid expenses and other assets, net 133,806 147,908
Total assets 5,386,150 5,747,672
Liabilities    
Secured debt, net 47,301 49,232
Revolving credit facility 94,429 196,982
Term loans, net 537,120 526,129
Senior unsecured notes, net 1,735,253 1,734,431
Accounts payable and accrued liabilities 136,981 142,259
Lease intangible liabilities, net 32,532 42,244
Total liabilities 2,583,616 2,691,277
Commitments and contingencies (Note 15)
Equity    
Preferred stock, $0.01 par value; 10,000,000 shares authorized, zero shares issued and outstanding as of December 31, 2023 and 2022 0 0
Common stock, $0.01 par value; 500,000,000 shares authorized, 231,266,020 and 231,009,295 shares issued and outstanding as of December 31, 2023 and 2022, respectively 2,313 2,310
Additional paid-in capital 4,494,755 4,486,967
Cumulative distributions in excess of net income (1,718,279) (1,451,945)
Accumulated other comprehensive income 23,745 19,063
Total equity 2,802,534 3,056,395
Total liabilities and equity $ 5,386,150 $ 5,747,672
XML 19 R4.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Assets    
Accumulated depreciation $ 1,021,086 $ 913,345
Preferred Stock    
Par value (in dollars per share) $ 0.01 $ 0.01
Shares authorized (in shares) 10,000,000 10,000,000
Shares issued (in shares) 0 0
Shares outstanding (in shares) 0 0
Common Stock    
Par value (in dollars per share) $ 0.01 $ 0.01
Shares authorized (in shares) 500,000,000 500,000,000
Shares issued (in shares) 231,266,020 231,009,295
Shares outstanding (in shares) 231,266,020 231,009,295
XML 20 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED STATEMENTS OF INCOME (LOSS) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenues:      
Rental and related revenues (Note 4) $ 376,266 $ 400,586 $ 396,716
Resident fees and services 236,153 186,672 155,512
Interest and other income 35,095 37,553 17,317
Total revenues 647,514 624,811 569,545
Expenses:      
Depreciation and amortization 183,087 187,782 178,991
Interest 112,964 105,471 98,632
General and administrative 47,472 39,574 34,669
Provision for loan losses and other reserves 191 141 3,935
Impairment of real estate 14,332 94,042 9,499
Total expenses 553,291 589,623 466,927
Other (expense) income:      
Loss on extinguishment of debt (1,541) (411) (34,622)
Other income (expense) 2,598 (1,097) 373
Net (loss) gain on sales of real estate (76,625) (12,011) 12,301
Total other expense (75,568) (13,519) (21,948)
Income before loss from unconsolidated joint ventures and income tax expense 18,655 21,669 80,670
Loss from unconsolidated joint ventures (2,897) (98,032) (192,081)
Income tax expense (2,002) (1,242) (1,845)
Net income (loss) $ 13,756 $ (77,605) $ (113,256)
Net income (loss), per:      
Basic common share (in dollars per share) $ 0.06 $ (0.34) $ (0.52)
Diluted common share (in dollars per share) $ 0.06 $ (0.34) $ (0.52)
Weighted-average number of common shares outstanding, basic (in shares) 231,203,391 230,947,895 219,073,027
Weighted-average number of common shares outstanding, diluted (in shares) 232,792,778 230,947,895 219,073,027
Revenue, type, extensible enumeration Health Care, Resident Service [Member] Health Care, Resident Service [Member] Health Care, Resident Service [Member]
Triple-net portfolio      
Expenses:      
Operating expenses $ 17,932 $ 19,623 $ 20,221
Senior housing - managed portfolio      
Expenses:      
Operating expenses $ 177,313 $ 142,990 $ 120,980
XML 21 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Statement of Comprehensive Income [Abstract]      
Net income (loss) $ 13,756 $ (77,605) $ (113,256)
Unrealized gain (loss), net of tax:      
Foreign currency translation (loss) gain (205) 3,141 (142)
Unrealized gain (loss) on cash flow hedges [1] 4,887 25,943 30,032
Total other comprehensive income 4,682 29,084 29,890
Comprehensive income (loss) $ 18,438 $ (48,521) $ (83,366)
[1] Amounts are net of income tax benefit of $17,000 and $0.1 million for the years ended December 31, 2022 and 2021, respectively. No such income tax benefit was recognized during the year ended December 31, 2023.
XML 22 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Statement of Comprehensive Income [Abstract]      
Income tax benefit on unrealized gains (losses) on cash flow hedges $ 0 $ 17 $ 100
XML 23 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED STATEMENTS OF EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Cumulative Distributions in Excess of Net Income
Accumulated Other Comprehensive (Loss) Income
Beginning balance (in shares) at Dec. 31, 2020   210,560,815      
Beginning balance at Dec. 31, 2020 $ 3,409,228 $ 2,106 $ 4,163,228 $ (716,195) $ (39,911)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income (loss) (113,256)     (113,256)  
Other comprehensive income 29,890       29,890
Amortization of stock-based compensation 10,748   10,748    
Common stock issuance, net (in shares)   19,837,840      
Common stock issuance, net 308,673 $ 198 308,475    
Common dividends (265,753)     (265,753)  
Ending balance (in shares) at Dec. 31, 2021   230,398,655      
Ending balance at Dec. 31, 2021 3,379,530 $ 2,304 4,482,451 (1,095,204) (10,021)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income (loss) (77,605)     (77,605)  
Other comprehensive income 29,084       29,084
Amortization of stock-based compensation 9,433   9,433    
Common stock issuance, net (in shares)   610,640      
Common stock issuance, net (4,911) $ 6 (4,917)    
Common dividends (279,136)     (279,136)  
Ending balance (in shares) at Dec. 31, 2022   231,009,295      
Ending balance at Dec. 31, 2022 3,056,395 $ 2,310 4,486,967 (1,451,945) 19,063
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income (loss) 13,756     13,756  
Other comprehensive income 4,682       4,682
Amortization of stock-based compensation 10,559   10,559    
Common stock issuance, net (in shares)   256,725      
Common stock issuance, net (2,768) $ 3 (2,771)    
Common dividends (280,090)     (280,090)  
Ending balance (in shares) at Dec. 31, 2023   231,266,020      
Ending balance at Dec. 31, 2023 $ 2,802,534 $ 2,313 $ 4,494,755 $ (1,718,279) $ 23,745
XML 24 R9.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED STATEMENTS OF EQUITY (Parenthetical) - $ / shares
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Statement of Stockholders' Equity [Abstract]      
Common dividends (in dollars per share) $ 1.20 $ 1.20 $ 1.20
XML 25 R10.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Cash flows from operating activities:      
Net income (loss) $ 13,756 $ (77,605) $ (113,256)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:      
Depreciation and amortization 183,087 187,782 178,991
Non-cash rental and related revenues (8,699) 2,183 25,823
Non-cash interest income (372) (2,285) (1,988)
Non-cash interest expense 12,265 11,094 8,368
Stock-based compensation expense 7,917 7,453 7,914
Loss on extinguishment of debt 1,541 411 34,622
Provision for loan losses and other reserves 191 141 3,935
Net loss (gain) on sales of real estate 76,625 12,011 (12,301)
Impairment of real estate 14,332 94,042 9,499
Other-than-temporary impairment of unconsolidated joint ventures 0 57,778 164,126
Loss from unconsolidated joint ventures 2,897 40,254 27,955
Distributions of earnings from unconsolidated joint ventures 3,469 0 0
Other non-cash items (3,704) 2,167 0
Changes in operating assets and liabilities:      
Accounts receivable, prepaid expenses and other assets, net (11,078) (6,443) 8,223
Accounts payable and accrued liabilities 8,344 (13,250) 14,479
Net cash provided by operating activities 300,571 315,733 356,390
Cash flows from investing activities:      
Acquisition of real estate (78,530) (92,204) (99,448)
Origination and fundings of loans receivable (11,418) (23,812) (290,000)
Origination and fundings of preferred equity investments (11,023) (8,021) (9,061)
Additions to real estate (84,855) (54,473) (42,651)
Escrow deposits for potential investments 0 (780) 0
Repayments of loans receivable 9,274 5,272 2,949
Repayments of preferred equity investments 5,460 5,376 1,292
Investment in unconsolidated joint ventures (5,235) (142,910) 0
Net proceeds from the sales of real estate 247,622 87,304 100,723
Deposits for potential sale of real estate 0 8,000 0
Net proceeds from sales-type lease 25,490 0 0
Insurance proceeds 5,801 0 0
Distributions in excess of earnings from unconsolidated joint ventures 544 0 0
Net cash provided by (used in) investing activities 103,130 (216,248) (336,196)
Cash flows from financing activities:      
Net (repayments of) borrowings from revolving credit facility (104,338) 204,046 0
Proceeds from term loans 12,188 0 0
Proceeds from issuance of senior unsecured notes 0 0 791,520
Principal payments on senior unsecured notes 0 0 (300,000)
Principal payments on term loans 0 (63,750) (455,000)
Principal payments on secured debt (1,979) (17,516) (12,661)
Payments of deferred financing costs (18,142) (20) (9,317)
Payments related to extinguishment of debt 0 0 (30,196)
Payment of contingent consideration (17,900) (2,500) 0
Issuance of common stock, net (2,682) (4,810) 308,713
Dividends paid on common stock (277,447) (277,157) (262,919)
Net cash (used in) provided by financing activities (410,300) (161,707) 30,140
Net (decrease) increase in cash, cash equivalents and restricted cash (6,599) (62,222) 50,334
Effect of foreign currency translation on cash, cash equivalents and restricted cash (614) 268 29
Cash, cash equivalents and restricted cash, beginning of period 53,932 115,886 65,523
Cash, cash equivalents and restricted cash, end of period 46,719 53,932 115,886
Supplemental disclosure of cash flow information:      
Interest paid 102,409 97,723 85,464
Income taxes paid 1,670 1,657 1,839
Supplemental disclosure of non-cash investing activities:      
Decrease in loans receivable and other investments due to acquisition of real estate $ 4,644 $ 14,311 $ 0
XML 26 R11.htm IDEA: XBRL DOCUMENT v3.24.0.1
BUSINESS
12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BUSINESS BUSINESS
Overview
Sabra Health Care REIT, Inc. (“Sabra” or the “Company”) was incorporated on May 10, 2010 as a wholly owned subsidiary of Sun Healthcare Group, Inc. (“Sun”) and commenced operations on November 15, 2010 following Sabra’s separation from Sun. Sabra elected to be treated as a real estate investment trust (“REIT”) with the filing of its United States (“U.S.”) federal income tax return for the taxable year beginning January 1, 2011. Sabra believes that it has been organized and operated, and it intends to continue to operate, in a manner to qualify as a REIT. Sabra’s primary business consists of acquiring, financing and owning real estate property to be leased to third-party tenants in the healthcare sector. Sabra primarily generates revenues by leasing properties to tenants throughout the U.S. and Canada. Sabra owns substantially all of its assets and properties and conducts its operations through Sabra Health Care Limited Partnership, a Delaware limited partnership (the “Operating Partnership”), of which Sabra is the sole general partner and a wholly owned subsidiary of Sabra is currently the only limited partner, or by subsidiaries of the Operating Partnership. The Company’s investment portfolio is primarily comprised of skilled nursing/transitional care facilities, senior housing communities (“Senior Housing - Leased”), behavioral health facilities and specialty hospitals and other facilities, in each case leased to tenants who are responsible for the operations of these facilities; senior housing communities operated by third-party property managers pursuant to property management agreements (“Senior Housing - Managed”); investments in joint ventures; investments in loans receivable; and preferred equity investments.
XML 27 R12.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Principles of Consolidation and Basis of Presentation
The accompanying consolidated financial statements include the accounts of Sabra and its wholly owned subsidiaries as of December 31, 2023 and 2022 and for the years ended December 31, 2023, 2022 and 2021. All significant intercompany transactions and balances have been eliminated in consolidation. The consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”).
GAAP requires the Company to identify entities for which control is achieved through voting rights or other means and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). A VIE is broadly defined as an entity with one or more of the following characteristics: (a) the total equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (b) as a group, the holders of the equity investment at risk lack (i) the ability to make decisions about the entity’s activities through voting or similar rights, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity; or (c) the equity investors have voting rights that are not proportional to their economic interests, and substantially all of the entity’s activities either involve, or are conducted on behalf of, an investor that has disproportionately few voting rights. If the Company were determined to be the primary beneficiary of the VIE, the Company would consolidate investments in the VIE. The Company may change its original assessment of a VIE due to events such as modifications of contractual arrangements that affect the characteristics or adequacy of the entity’s equity investments at risk and the disposal of all or a portion of an interest held by the primary beneficiary.
The Company identifies the primary beneficiary of a VIE as the enterprise that has both: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. The Company performs this analysis on an ongoing basis. As of December 31, 2023, the Company determined that it was not the primary beneficiary of any VIEs.
As it relates to investments in loans, in addition to the Company’s assessment of VIEs and whether the Company is the primary beneficiary of those VIEs, the Company evaluates the loan terms and other pertinent facts to determine whether the loan investment should be accounted for as a loan or as a real estate joint venture. If an investment has the characteristics of a real estate joint venture, including if the Company participates in the majority of the borrower’s expected residual profit, the Company would account for the investment as an investment in a real estate joint venture and not as a loan investment. Expected residual profit is defined as the amount of profit, whether called interest or another name, such as an equity kicker, above a reasonable amount of interest and fees expected to be earned by a lender. At December 31, 2023 and 2022, none of the Company’s investments in loans were accounted for as real estate joint ventures.
As it relates to investments in joint ventures, the Company assesses any partners’ rights and their impact on the presumption of control of the partnership by any single partner. The Company also applies this guidance to managing member interests in limited liability companies. The Company reassesses its determination of which entity controls the joint venture if: there is a change to the terms or in the exercisability of the rights of any partners or members, the general partner or managing member increases or decreases its ownership interests, or there is an increase or decrease in the number of outstanding ownership interests. As of December 31, 2023, the Company’s determination of which entity controls its investments in joint ventures has not changed as a result of any reassessment.
Use of Estimates
The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.
Real Estate Investments and Rental Revenue Recognition
Real Estate Acquisition Valuation
All assets acquired and liabilities assumed in an acquisition of real estate accounted for as a business combination are measured at their acquisition date fair values. For acquisitions of real estate accounted for as an asset acquisition, the fair value of consideration transferred by the Company (including transaction costs) is allocated to all assets acquired and liabilities assumed on a relative fair value basis. The acquisition value of land, building and improvements are included in real estate investments on the accompanying consolidated balance sheets. The acquisition value of above market lease, tenant origination and absorption costs and tenant relationship intangible assets is included in lease intangible assets, net on the accompanying consolidated balance sheets. The acquisition value of below market lease intangible liabilities is included in lease intangible liabilities, net on the accompanying consolidated balance sheets. Acquisition costs associated with real estate acquisitions deemed asset acquisitions are capitalized, and costs associated with real estate acquisitions deemed business combinations are expensed as incurred. Restructuring costs that do not meet the definition of a liability at the acquisition date are expensed in periods subsequent to the acquisition date.
Estimates of the fair values of the tangible assets, identifiable intangibles and assumed liabilities require the Company to make significant assumptions to estimate market lease rates, property operating expenses, carrying costs during lease-up periods, discount rates, market absorption periods, and the number of years the property will be held for investment. The Company makes its best estimate based on the Company’s evaluation of the specific characteristics of each tenant’s lease. The use of inappropriate assumptions would result in an incorrect valuation of the Company’s acquired tangible assets, identifiable intangibles and assumed liabilities, which would impact the amount of the Company’s net income.
Depreciation and Amortization
Real estate costs related to the acquisition and improvement of properties are capitalized and amortized on a straight-line basis over the lesser of the expected useful life of the asset and the remaining lease term of any property subject to a ground lease. Tenant improvements are capitalized and amortized on a straight-line basis over the lesser of the expected useful life of the asset and the remaining lease term. Depreciation is discontinued when a property is identified as held for sale. Repair and maintenance costs are charged to expense as incurred and significant replacements and betterments are capitalized. Repair and maintenance costs include all costs that do not extend the useful life of the real estate asset. The Company considers the period of future benefit of an asset to determine its appropriate useful life. Depreciation of real estate assets and amortization of tenant origination and absorption costs and tenant relationship lease intangibles are included in depreciation and amortization on the accompanying consolidated statements of income (loss). Amortization of above and below market lease intangibles is included in rental income on the accompanying consolidated statements of income (loss). The Company anticipates the estimated useful lives of its assets by class to be generally as follows: land improvements, 15 to 20 years; buildings and building improvements, five to 45 years; and furniture and equipment, three to 10 years. Intangibles are generally amortized over the remaining noncancellable lease terms, with tenant relationship intangible amortization periods including extension periods.
Impairment of Real Estate Investments
The Company regularly monitors events and changes in circumstances, including investment operating performance and general market conditions, that could indicate that the carrying amounts of its real estate investments may not be recoverable. When indicators of potential impairment suggest that the carrying value of real estate investments may not be recoverable, the Company assesses the recoverability by estimating whether the Company will recover the carrying value of its real estate investments through the undiscounted future cash flows and the eventual disposition of the investment. In some instances, there may be various potential outcomes for an investment and its potential undiscounted future cash flows. In these instances, the
undiscounted future cash flows models used to assess recoverability are based on several assumptions and are probability-weighted based on the Company’s best estimates as of the date of evaluation. These assumptions include, among others, market rent, revenue and expense growth rates, absorption period, stabilized occupancy, holding period, market capitalization rates, and estimated market values based on analysis of letters of intent, purchase and sale agreements and recent sales data for comparable properties. When discounted cash flow is used to determine fair value, a discount rate assumption is also used. The assumptions are generally based on management’s experience in its local real estate markets, and the effects of current market conditions, which are subject to economic and market uncertainties. If, based on this analysis, the Company does not believe that it will be able to recover the carrying value of its real estate investments, the Company would record an impairment loss to the extent that the carrying value exceeds the estimated fair value of its real estate investments. The Company determines estimated fair value based primarily upon (i) estimated sale prices from signed contracts or letters of intent from third-party offers, (ii) discounted cash flow models of the investment over its remaining hold period, (iii) third-party appraisals and (iv) recent sales data for comparable properties.
Revenue Recognition
The Company recognizes rental revenue from tenants, including rental abatements, lease incentives and contractual fixed increases attributable to operating leases, on a straight-line basis over the term of the related leases when it is probable that substantially all rents over the life of a lease are collectible. Certain of the Company’s leases provide for contingent rents equal to a percentage of the facility’s revenue in excess of specified base amounts or other thresholds. Such revenue is recognized when actual results reported by the tenant, or estimates of tenant results, exceed the applicable base amount or other threshold.
The Company assesses the collectability of rents on a lease-by-lease basis, and in doing so, considers such things as historical bad debts, tenant creditworthiness, current economic trends, facility operating performance, lease structure, credit enhancements (including guarantees), current developments relevant to a tenant’s business specifically and to its business category generally, and changes in tenants’ payment patterns. The Company’s assessment includes an estimation of a tenant’s ability to fulfill all of its rental obligations over the remaining lease term. In addition, with respect to tenants in bankruptcy, management makes estimates of the expected recovery of pre-petition and post-petition claims in assessing the estimated collectability of the related receivable. If at any time the Company cannot determine that it is probable that substantially all rents over the life of a lease are collectible, rental revenue will be recognized only to the extent of payments received, and all receivables associated with the lease will be written off irrespective of amounts expected to be collectible. Any recoveries of these amounts will be recorded in future periods upon receipt of payment. Write-offs of receivables and any recoveries of previously written-off receivables are recorded as adjustments to rental revenue.
Revenue from resident fees and services is recorded monthly as services are provided and includes resident room and care charges, ancillary services charges and other resident charges.
Government Grants
By analogy to International Accounting Standards 20, Accounting for Government Grants and Disclosure of Government Assistance, government assistance provided to the Company in the form of an income grant, which is not related to long-lived assets and is not required to be repaid, is recognized as grant income when there is reasonable assurance that the grant will be received and the Company will comply with any conditions associated with the grant. Additionally, grants are recognized over the periods in which the Company recognizes the qualifying expenses and/or lost income for which the grants are intended to compensate. As of December 31, 2023, 2022 and 2021, the amount of qualifying expenditures exceeded amounts recognized under The Coronavirus Aid Relief and Economic Security Act and other programs, and the Company had complied with all grant conditions. Accordingly, during the years ended December 31, 2023, 2022 and 2021, the Company recognized $0.1 million, $0.1 million and $0.5 million, respectively, of grants in resident fees and services, and during the year ended December 31, 2022, the Company recognized $3.6 million of grants in loss from unconsolidated joint ventures in the accompanying consolidated statements of income (loss).
Casualty Gains and Losses
Income resulting from insurance recoveries of property damage or business interruption losses is recognized when proceeds are received or contingencies related to the insurance recoveries are resolved.
A vacant facility owned by the Company suffered damages as a result of vandalism and theft. The Company received $6.2 million of insurance proceeds and recorded a $3.7 million gain related to the property damage during the year ended December 31, 2023 which is included in other income (expense) on the accompanying consolidated statements of income (loss).
A fire occurred at one of the Company’s Senior Housing - Managed communities. The Company received $1.1 million of insurance proceeds and recorded $0.5 million of business interruption insurance income during the year ended December 31, 2023 which is included in other income (expense) on the accompanying consolidated statements of income (loss). The remaining proceeds were recorded as expense reimbursements in Senior Housing - Managed portfolio operating expenses on the accompanying consolidated statements of income (loss).
Assets Held for Sale, Dispositions and Discontinued Operations
The Company generally considers real estate to be “held for sale” when the following criteria are met: (i) management commits to a plan to sell the property, (ii) the property is available for sale immediately, (iii) the property is actively being marketed for sale at a price that is reasonable in relation to its current fair value, (iv) the sale of the property within one year is considered probable and (v) significant changes to the plan to sell are not expected. Real estate that is held for sale and its related assets are classified as assets held for sale and are included in accounts receivable, prepaid expenses and other assets, net on the accompanying consolidated balance sheets. Secured indebtedness and other liabilities related to real estate held for sale are classified as liabilities related to assets held for sale and are included in accounts payable and accrued liabilities on the accompanying consolidated balance sheets. Real estate classified as held for sale is no longer depreciated and is reported at the lower of its carrying value or its estimated fair value less estimated costs to sell. As of December 31, 2023 and 2022, the Company did not have any assets held for sale.
For sales of real estate where the Company has collected the consideration to which it is entitled in exchange for transferring the real estate, the related assets and liabilities are removed from the balance sheet and the resultant gain or loss is recorded in the period in which the transaction closes. Any post-sale involvement is accounted for as separate performance obligations, and when the separate performance obligations are satisfied, the portion of the sales price allocated to each such obligation is recognized.
Additionally, the Company records the operating results related to real estate that has been disposed of or classified as held for sale as discontinued operations for all periods presented if it represents a strategic shift that has or will have a major effect on the Company’s operations and financial results.
Investment in Unconsolidated Joint Ventures
The Company reports investments in unconsolidated entities over whose operating and financial policies it has the ability to exercise significant influence under the equity method of accounting. Under this method of accounting, the Company’s share of the investee’s earnings or losses is included in the Company’s consolidated statements of income (loss). The initial carrying value of the investment is based on the amount paid to purchase the joint venture interest. Differences between the Company’s cost basis and the basis reflected at the joint venture level are generally amortized over the lives of the related assets and liabilities, and such amortization is included in the Company’s share of earnings of the joint venture. In addition, distributions received from unconsolidated entities are classified based on the nature of the activity or activities that generated the distribution.
The Company regularly monitors events and changes in circumstances, including investment operating performance, changes in anticipated holding period and general market conditions, that could indicate that the carrying amounts of its equity method investments may be impaired. An equity method investment's value is impaired when the fair value of the investment is less than its carrying value and the Company determines the decline in value is other-than-temporary. The fair value is estimated based on discounted cash flows models that include all estimated cash inflows and outflows and any estimated debt premiums or discounts. The discounted cash flows are based on several assumptions, including management fee, absorption period, terminal capitalization rates, revenue and expense per bed, revenue and expense growth percentage, replacement reserve per unit, stabilized occupancy, stabilized operating margin, price per bed and discount rates. The assumptions are generally based on management’s experience in its local real estate markets, and the effects of current market conditions, which are subject to economic and market uncertainties. If the Company believes that there is an other-than-temporary decline in the value of an equity method investment, the Company would record an impairment loss to the extent that the carrying value exceeds the estimated fair value of such equity method investment.
Loans Receivable and Credit Losses
Loans Receivable
The Company’s loans receivable are reflected at amortized cost on the accompanying consolidated balance sheets. The amortized cost of a loan receivable is the outstanding unpaid principal balance, net of unamortized discounts, costs and fees directly associated with the origination of the loan.
Loans acquired in connection with a business combination are recorded at their acquisition date fair value. The Company determines the fair value of loans receivable based on estimates of expected discounted cash flows, collateral, credit risk and other factors. The Company does not establish a valuation allowance at the acquisition date, as the amount of estimated future cash flows reflects its judgment regarding their uncertainty. The Company recognizes the difference between the acquisition date fair value and the total expected cash flows as interest income using the effective interest method over the life of the applicable loan. The Company immediately recognizes in income any unamortized balances if the loan is repaid before its contractual maturity.
Interest income on the Company’s loans receivable is recognized on an accrual basis over the life of the investment using the interest method. Direct loan origination costs are amortized over the term of the loan as an adjustment to interest income. When concerns exist as to the ultimate collection of principal or interest due under a loan, the loan is placed on nonaccrual status, and the Company will not recognize interest income until the cash is received, or the loan returns to accrual status. If the Company determines that the collection of interest according to the contractual terms of the loan or through the receipts of assets in satisfaction of contractual amounts due is probable, the Company will resume the accrual of interest. In instances where borrowers are in default under the terms of their loans, the Company may continue recognizing interest income provided that all amounts owed under the contractual terms of the loan, including accrued and unpaid interest, do not exceed the estimated fair value of the collateral, less costs to sell.
On a quarterly basis, the Company evaluates the collectability of its interest income receivable and establishes a reserve for amounts not expected to be collected. The Company’s evaluation includes reviewing credit quality indicators such as payment status, changes affecting the operations of the facilities securing the loans, and national and regional economic factors. The reserve is a valuation allowance that reflects management’s estimate of losses inherent in the interest income receivable balance as of the balance sheet date. The reserve is adjusted through provision for loan losses and other reserves on the Company’s consolidated statements of income (loss) and is decreased by charge-offs to specific receivables.
Credit Losses
On a quarterly basis, the Company evaluates the collectability of its loan portfolio, including the portion of unfunded loan commitments expected to be funded, and establishes an allowance for credit losses. The allowance for credit losses is calculated using the related amortization schedules, payment histories and loan-to-value ratios. The following rates are applied to determine the aggregate expected losses, which is recorded as the allowance for credit losses: (i) a default rate, (ii) a liquidation cost rate and (iii) a distressed property reduction rate. If no loan-to-value ratio is available, a loss severity rate is applied in place of the liquidation cost rate and the distressed property reduction rate. The default rate is based on average charge-off and delinquency rates from the Federal Reserve, and the other rates are based on industry research and historical performance of a similar portfolio of financial assets. The allowance for credit losses is a valuation allowance that reflects management’s estimate of losses inherent in the loan portfolio as of the balance sheet date. The reserve is adjusted through provision for loan losses and other reserves on the Company’s consolidated statements of income (loss) and is decreased by charge-offs to specific loans.
Preferred Equity Investments and Preferred Return
Preferred equity investments are accounted for at unreturned capital contributions, plus accrued and unpaid preferred returns. The Company recognizes preferred return income on a monthly basis based on the outstanding investment including any previously accrued and unpaid return. As a preferred member of the preferred equity joint ventures in which the Company participates, the Company is not entitled to share in the joint venture’s earnings or losses. Rather, the Company is entitled to receive a preferred return, which is deferred if the cash flow of the joint venture is insufficient to currently pay the accrued preferred return.
The Company regularly monitors events and changes in circumstances that could indicate that the carrying amounts of its preferred equity investments may not be recoverable or realized. On a quarterly basis, the Company evaluates its preferred equity investments for impairment based on a comparison of the fair value of the investment to its carrying value. The fair value is estimated based on discounted cash flows that include all estimated cash inflows and outflows over a specified holding period. If, based on this analysis, the Company does not believe that it will be able to recover the carrying value of its preferred equity investment, the Company would record an impairment loss to the extent that the carrying value exceeds the estimated fair value of its preferred equity investment.
Cash and Cash Equivalents
The Company considers all short-term (with an original maturity of three months or less), highly-liquid investments utilized as part of the Company’s cash-management activities to be cash equivalents. Cash equivalents may include cash and short-term investments. Short-term investments are stated at cost, which approximates fair value.
The Company’s cash and cash equivalents balance exceeded federally insurable limits as of December 31, 2023. To date, the Company has experienced no loss or lack of access to cash in its operating accounts. The Company has a corporate banking relationship with Bank of America, N.A. in which it deposits the majority of its cash.
Restricted Cash
Restricted cash primarily consists of amounts held by an exchange accommodation titleholder or by secured debt lenders to provide for future real estate tax expenditures, tenant improvements and capital expenditures. Pursuant to the terms of the Company’s leases with certain tenants, the Company has assigned its interests in certain of these restricted cash accounts with secured debt lenders to the tenants, and this amount is included in accounts payable and accrued liabilities on the Company’s consolidated balance sheets. As of December 31, 2023 and 2022, restricted cash totaled $5.4 million and $4.6 million, respectively, and restricted cash obligations totaled $1.4 million and $3.9 million, respectively.
Lessee Accounting
For operating leases greater than 12 months for which the Company is the lessee, such as corporate office leases and ground leases, the Company recognizes a right-of-use (“ROU”) asset and related lease liability on its consolidated balance sheets at inception of the lease. ROU assets represent the Company’s right to use underlying assets for the lease term, and lease liabilities are determined based on the estimated present value of the Company’s minimum lease payments under the agreements. The discount rate used to determine the lease liabilities is based on the estimated incremental borrowing rate on a lease-by-lease basis. Certain of the Company’s lease agreements have options to extend or terminate the contract terms upon meeting certain criteria. The lease term utilized in the calculation of the lease liability includes these options if exercise is considered reasonably certain. As of December 31, 2023 and 2022, the Company had $11.6 million and $8.5 million of ROU assets included in accounts receivable, prepaid expenses and other assets, net, and $12.5 million and $9.2 million of lease liabilities included in accounts payable and accrued liabilities, respectively, on its consolidated balance sheets.
During the years ended December 31, 2023, 2022 and 2021, the Company incurred lease expense of $1.4 million, $1.2 million and $1.2 million, respectively. As of December 31, 2023, the weighted average remaining lease term and discount rate were 17 years and 8%, respectively, and the future minimum lease payments under the operating leases included in the Company’s lease liability were as follows (in thousands):
2024$1,310 
20251,802 
20261,324 
20271,347 
20281,330 
Thereafter18,104 
Undiscounted minimum lease payments included in the lease liability25,217 
Less: imputed interest(12,729)
Present value of lease liability$12,488 
Stock-Based Compensation
Stock-based compensation expense for stock-based awards granted to Sabra’s employees (teammates) and its non-employee directors is recognized in the statements of income (loss) based on the estimated grant date fair value, as adjusted. Compensation expense for awards with graded vesting schedules is generally recognized ratably over the period from the grant date to the date when the award is no longer contingent on the recipient providing additional services. Compensation expense for awards with performance-based vesting conditions is recognized based on the Company’s estimate of the ultimate value of such award after considering the Company’s expectations of future performance. Forfeitures of stock-based awards are recognized as they occur.
Deferred Financing Costs
Deferred financing costs representing fees paid to third parties are amortized over the terms of the respective financing agreements using the interest method. Deferred financing costs related to secured debt, term loans and senior unsecured notes are recorded as a reduction of the related debt liability, and deferred financing costs related to the revolving credit facility are recorded in accounts receivable, prepaid expenses and other assets, net. Unamortized deferred financing costs are generally expensed when the associated debt is refinanced or repaid before maturity. Costs incurred in seeking financings that do not close are expensed in the period in which it is determined that the financing will not close.
Income Taxes
The Company elected to be treated as a REIT with the filing of its U.S. federal income tax return for the taxable year beginning January 1, 2011. The Company believes that it has been organized and operated, and it intends to continue to operate, in a manner to qualify as a REIT. To qualify as a REIT, the Company must meet certain organizational and operational requirements, including a requirement to distribute at least 90% of the Company’s annual REIT taxable income to stockholders (which is computed without regard to the dividends-paid deduction or net capital gains and which does not necessarily equal net income as calculated in accordance with GAAP). As a REIT, the Company generally will not be subject to federal income tax on income that it distributes as dividends to its stockholders. If the Company fails to qualify as a REIT in any taxable year, it will be subject to U.S. federal income tax on its taxable income at regular corporate income tax rates and generally will not be permitted to qualify for treatment as a REIT for federal income tax purposes for the four taxable years following the year during which qualification is lost, unless the Internal Revenue Service grants the Company relief under certain statutory provisions. Such an event could materially and adversely affect the Company’s net income and net cash available for distribution to stockholders. However, the Company believes that it is organized and operates in such a manner as to qualify for treatment as a REIT.
As a result of certain investments, the Company now records income tax expense or benefit with respect to certain of its entities that are taxed as taxable REIT subsidiaries under provisions similar to those applicable to regular corporations and not under the REIT provisions.
The Company accounts for deferred income taxes using the asset and liability method and recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company’s financial statements or tax returns. Under this method, the Company determines deferred tax assets and liabilities based on the differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Any increase or decrease in the deferred tax liability that results from a change in circumstances, and that causes a change in the Company’s judgment about expected future tax consequences of events, is included in the tax provision when such changes occur. Deferred income taxes also reflect the impact of operating loss and tax credit carryforwards. A valuation allowance is provided if the Company believes it is more likely than not that all or some portion of the deferred tax asset will not be realized. Any increase or decrease in the valuation allowance that results from a change in circumstances, and that causes a change in the Company’s judgment about the realizability of the related deferred tax asset, is included in the tax provision when such changes occur. 
The Company evaluates its tax positions using a two-step approach: step one (recognition) occurs when the Company concludes that a tax position, based solely on its technical merits, is more likely than not to be sustained upon examination, and step two (measurement) is only addressed if step one has been satisfied (i.e., the position is more likely than not to be sustained). Under step two, the tax benefit is measured as the largest amount of benefit (determined on a cumulative probability basis) that is more likely than not to be realized upon ultimate settlement. The Company will recognize tax penalties relating to unrecognized tax benefits as additional tax expense.
Foreign Currency
Certain of the Company’s subsidiaries’ functional currencies are the local currencies of their respective foreign jurisdictions. The Company translates the results of operations of its foreign subsidiaries into U.S. dollars using average rates of exchange in effect during the period presented, and it translates balance sheet accounts using exchange rates in effect at the end of the period presented. The Company records resulting currency translation adjustments in accumulated other comprehensive loss, a component of stockholders’ equity, on its consolidated balance sheets, and it records foreign currency transaction gains and losses as a component of other (expense) income on its consolidated statements of income (loss).
Derivative Instruments
The Company uses certain types of derivative instruments for the purpose of managing interest rate and currency risk. To qualify for hedge accounting, derivative instruments used for risk management purposes must effectively reduce the risk exposure that they are designed to hedge. In addition, at inception, the Company must make an assessment that the transaction that the Company intends to hedge is probable of occurring, and this assessment must be updated each reporting period.
The Company recognizes all derivative instruments as assets or liabilities on the consolidated balance sheets at their fair value. For derivatives designated and qualified as a hedge, the change in fair value of the effective portion of the derivatives is recognized in accumulated other comprehensive loss. Changes in the fair value of derivative instruments that are not designated in hedging relationships or that do not meet the criteria for hedge accounting would be recognized in earnings. In addition, the Company classifies cash flows from qualifying cash flow hedging relationships in the same category as the cash flows from the hedged items.
The Company formally documents all relationships between hedging instruments and hedged items, as well as its risk-management objectives and strategy for undertaking various hedge transactions. This process includes designating all derivatives that are part of a hedging relationship to specific transactions, as well as recognizing obligations or assets on the consolidated balance sheets. The Company also assesses and documents, both at inception of the hedging relationship and on a quarterly basis thereafter, whether the derivatives are highly effective in offsetting the designated risks associated with the respective hedged items. If it is determined that a derivative ceases to be highly effective as a hedge, or that it is probable the underlying transaction will not occur, the Company would discontinue hedge accounting prospectively and record the appropriate adjustment to earnings based on the then-current fair value of the derivative.
Fair Value Measurements
Under GAAP, the Company is required to measure certain financial instruments at fair value on a recurring basis. In addition, the Company is required to measure other financial instruments and balances at fair value on a non-recurring basis (e.g., carrying value of impaired loans receivable and long-lived assets). Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The GAAP fair value framework uses a three-tiered approach. Fair value measurements are classified and disclosed in one of the following three categories:
Level 1: unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities;
Level 2: quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which significant inputs and significant value drivers are observable in active markets; and
Level 3: prices or valuation techniques where little or no market data is available that requires inputs that are both significant to the fair value measurement and unobservable.
When available, the Company utilizes quoted market prices from an independent third-party source to determine fair value and classifies such items as Level 1 or Level 2. In instances where the market for a financial instrument is not active, regardless of the availability of a nonbinding quoted market price, observable inputs might not be relevant and could require the Company to make a significant adjustment to derive a fair value measurement. Additionally, in an inactive market, a market price quoted from an independent third party may rely more on models with inputs based on information available only to that independent third party. When the Company determines the market for a financial instrument owned by the Company to be illiquid or when market transactions for similar instruments do not appear orderly, the Company may use several valuation sources (including internal valuations, discounted cash flow analysis and quoted market prices) to establish a fair value. If more than one valuation source is used, the Company will assign weights to the various valuation sources. Additionally, when determining the fair value of liabilities in circumstances in which a quoted price in an active market for an identical liability is not available, the Company measures fair value using (i) a valuation technique that uses the quoted price of the identical liability when traded as an asset or quoted prices for similar liabilities or similar liabilities when traded as assets or (ii) another valuation technique that is consistent with the principles of fair value measurement, such as the income approach or the market approach.
Changes in assumptions or estimation methodologies can have a material effect on these estimated fair values. In this regard, the derived fair value estimates cannot be substantiated by comparison to independent markets and, in many cases, may not be realized in an immediate settlement of the instrument.
The Company considers the following factors to be indicators of an inactive market: (i) there are few recent transactions, (ii) price quotations are not based on current information, (iii) price quotations vary substantially either over time or among market makers (for example, some brokered markets), (iv) indexes that previously were highly correlated with the fair values of the asset or liability are demonstrably uncorrelated with recent indications of fair value for that asset or liability, (v) there is a significant increase in implied liquidity risk premiums, yields, or performance indicators (such as delinquency rates or loss severities) for observed transactions or quoted prices when compared with the Company’s estimate of expected cash flows, considering all available market data about credit and other nonperformance risk for the asset or liability, (vi) there is a wide bid-ask spread or significant increase in the bid-ask spread, (vii) there is a significant decline or absence of a market for new issuances (that is, a primary market) for the asset or liability or similar assets or liabilities, and (viii) little information is released publicly (for example, a principal-to-principal market).
The Company considers the following factors to be indicators of non-orderly transactions: (i) there was not adequate exposure to the market for a period before the measurement date to allow for marketing activities that are usual and customary for transactions involving such assets or liabilities under current market conditions, (ii) there was a usual and customary marketing period, but the seller marketed the asset or liability to a single market participant, (iii) the seller is in or near
bankruptcy or receivership (that is, distressed), or the seller was required to sell to meet regulatory or legal requirements (that is, forced), and (iv) the transaction price is an outlier when compared with other recent transactions for the same or similar assets or liabilities.
Per Share Data
Basic earnings per common share is computed by dividing net income applicable to common stockholders by the weighted average number of shares of common stock and common equivalents outstanding during the period. Diluted earnings per common share is calculated by including the effect of dilutive securities, such as the impact of forward equity sales agreements using the treasury stock method and common shares issuable from certain performance restricted stock units and unvested restricted stock units. See Note 14, “Earnings Per Common Share.”
Industry Segments
The Company has one reportable segment consisting of investments in healthcare-related real estate properties.
Beds, Units and Other Measures
The number of beds, units and other measures used to describe the Company’s real estate investments included in the Notes to Consolidated Financial Statements are presented on an unaudited basis.
Recently Issued Accounting Standards Update
Issued but Not Yet Adopted
In March 2020, the Financial Accounting Standards Board (“FASB”) issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”). ASU 2020-04 provides temporary optional guidance that provides transition relief for reference rate reform, including optional expedients and exceptions for applying GAAP to contract modifications, hedging relationships and other transactions that reference the London Interbank Offered Rate (“LIBOR”) or a reference rate that is expected to be discontinued as a result of reference rate reform if certain criteria are met. ASU 2020-04 is effective upon issuance, and the provisions generally can be applied prospectively as of January 1, 2020 through December 31, 2024. During the first quarter of 2020, the Company elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. As of July 1, 2023, the Company had converted all of its LIBOR-indexed debt and derivatives to Secured Overnight Financing Rate (“SOFR”)-based indexes (effective with the respective instrument’s next reset date for certain instruments). For all derivatives in hedge accounting relationships, the Company utilized the effective relief in Topic 848 that allows for the continuation of hedge accounting throughout the transition process. Application of these expedients preserves the presentation of derivatives consistent with past presentation. In January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848): Scope, which refines the scope of Topic 848 and clarifies some of its guidance. In December 2022, the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848, which defers the sunset date of Topic 848 from December 31, 2022 to December 31, 2024. The Company continues to evaluate the impact of the guidance as it relates to hedging relationships and other transactions that reference the Canadian Dollar Offered Rate (“CDOR”) which is expected to be discontinued in 2024 and may apply other elections as applicable as additional changes in the market occur.
XML 28 R13.htm IDEA: XBRL DOCUMENT v3.24.0.1
RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED)
12 Months Ended
Dec. 31, 2023
Business Combination and Asset Acquisition [Abstract]  
RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED)
    During the year ended December 31, 2023, the Company acquired two skilled nursing/transitional care facilities, one Senior Housing - Leased community and one Senior Housing - Managed community. During the year ended December 31, 2022, the Company acquired three Senior Housing - Managed communities and one behavioral health facility. The Senior Housing - Managed community acquired during the year ended December 31, 2023 and two of the Senior Housing - Managed communities acquired during the year ended December 31, 2022 were part of the Company’s proprietary development pipeline and were previously reflected as preferred equity investments which had a book value of $4.6 million and $14.3 million, respectively, at the time of acquisition. The consideration was allocated as follows (in thousands):
Year Ended December 31,
20232022
Land$6,796 $11,767 
Building and improvements79,830 89,646 
Tenant origination and absorption costs intangible assets3,492 5,061 
Tenant relationship intangible assets255 41 
Total consideration$90,373 $106,515 
The tenant origination and absorption costs intangible assets and tenant relationship intangible assets had weighted-average amortization periods as of the respective dates of acquisition of four years and 22 years, respectively, for acquisitions completed during the year ended December 31, 2023. The tenant origination and absorption costs intangible assets and tenant relationship intangible assets had weighted-average amortization periods as of the respective dates of acquisition of two years and 25 years, respectively, for acquisitions completed during the year ended December 31, 2022.
For the year ended December 31, 2023, the Company recognized $10.4 million and $0.7 million of total revenues and net income, respectively, from the facilities acquired during the year ended December 31, 2023. For the year ended December 31, 2022, the Company recognized $11.1 million and $1.6 million of total revenues and net loss, respectively, from the facilities acquired during the year ended December 31, 2022.
During the three months ended June 30, 2023, the Company, in accordance with the terms of the agreements pursuant to which it purchased the facilities, paid $17.9 million in additional consideration related to two Senior Housing - Managed communities that achieved certain performance metrics. This amount is included in real estate investments, net of accumulated depreciation on the accompanying consolidated balance sheets.
XML 29 R14.htm IDEA: XBRL DOCUMENT v3.24.0.1
INVESTMENT IN REAL ESTATE PROPERTIES
12 Months Ended
Dec. 31, 2023
Real Estate [Abstract]  
INVESTMENT IN REAL ESTATE PROPERTIES INVESTMENT IN REAL ESTATE PROPERTIES
The Company’s real estate properties held for investment consisted of the following (dollars in thousands):
As of December 31, 2023  
Property TypeNumber of
Properties
Number of
Beds/Units
Total
Real Estate
at Cost
Accumulated
Depreciation
Total
Real Estate
Investments, Net
Skilled Nursing/Transitional Care241 26,769 $3,050,861 $(535,653)$2,515,208 
Senior Housing - Leased43 3,473 573,274 (109,601)463,673 
Senior Housing - Managed61 6,041 1,289,485 (255,803)1,033,682 
Behavioral Health18 1,159 496,737 (71,943)424,794 
Specialty Hospitals and Other15 392 225,443 (47,454)177,989 
378 37,834 5,635,800 (1,020,454)4,615,346 
Corporate Level2,547 (632)1,915 
$5,638,347 $(1,021,086)$4,617,261 
As of December 31, 2022
Property TypeNumber of
Properties
Number of
Beds/Units
Total
Real Estate
at Cost
Accumulated
Depreciation
Total
Real Estate
Investments, Net
Skilled Nursing/Transitional Care264 29,136 $3,385,221 $(492,495)$2,892,726 
Senior Housing - Leased47 3,550 590,694 (97,716)492,978 
Senior Housing - Managed59 5,942 1,205,283 (222,089)983,194 
Behavioral Health17 965 465,143 (58,481)406,662 
Specialty Hospitals and Other15 392 225,443 (42,038)183,405 
402 39,985 5,871,784 (912,819)4,958,965 
Corporate Level904 (526)378 
$5,872,688 $(913,345)$4,959,343 
As of December 31,
20232022
Building and improvements$4,843,258 $5,034,470 
Furniture and equipment238,185 262,644 
Land improvements10,306 7,085 
Land546,598 568,489 
Total real estate at cost5,638,347 5,872,688 
Accumulated depreciation(1,021,086)(913,345)
Total real estate investments, net$4,617,261 $4,959,343 
Operating Leases
As of December 31, 2023, the substantial majority of the Company’s real estate properties (excluding 61 Senior Housing - Managed communities) were leased under triple-net operating leases with expirations ranging from one year to 19 years. As of December 31, 2023, the leases had a weighted-average remaining term of eight years. The leases generally include provisions to extend the lease terms and other negotiated terms and conditions. The Company, through its subsidiaries, retains substantially all of the risks and benefits of ownership of the real estate assets leased to the tenants. The Company may receive additional security under these operating leases in the form of letters of credit and security deposits from the lessee or guarantees from the parent of the lessee. Security deposits received in cash related to tenant leases are included in accounts payable and accrued liabilities on the accompanying consolidated balance sheets and totaled $16.4 million and $13.0 million as of December 31, 2023 and 2022, respectively, and letters of credit deposited with the Company totaled approximately $56 million and $57 million as of December 31, 2023 and 2022, respectively. In addition, the Company’s tenants have deposited with the Company $12.4 million and $13.3 million as of December 31, 2023 and 2022, respectively, for future real estate taxes, insurance expenditures and tenant improvements related to the Company’s properties and their operations, and these amounts are included in accounts payable and accrued liabilities on the accompanying consolidated balance sheets.
Lessor costs that are paid by the lessor and reimbursed by the lessee are included in the measurement of variable lease revenue and the associated expense. As a result, the Company recognized variable lease revenue and the associated expense of $15.3 million, $17.7 million and $18.0 million during the years ended December 31, 2023, 2022 and 2021, respectively.
The Company monitors the creditworthiness of its tenants by evaluating the ability of the tenants to meet their lease obligations to the Company based on the tenants’ financial performance, including, as applicable and appropriate, the evaluation of any parent guarantees (or the guarantees of other related parties) of such lease obligations. The primary basis for the Company’s evaluation of the credit quality of its tenants (and more specifically the tenant’s ability to pay their rent obligations to the Company) is the tenant’s lease coverage ratio as supplemented by the parent’s fixed charge coverage ratio for those entities with a parent guarantee. These coverage ratios include earnings before interest, taxes, depreciation, amortization and rent (“EBITDAR”) to rent and earnings before interest, taxes, depreciation, amortization, rent and management fees (“EBITDARM”) to rent at the lease level and consolidated EBITDAR to total fixed charges at the parent guarantor level when such a guarantee exists. The Company obtains various financial and operational information from the majority of its tenants each month and reviews this information in conjunction with the above-described coverage metrics to identify financial and operational trends, evaluate the impact of the industry’s operational and financial environment (including the impact of government reimbursement), and evaluate the management of the tenant’s operations. These metrics help the Company identify
potential areas of concern relative to its tenants’ credit quality and ultimately the tenant’s ability to generate sufficient liquidity to meet its obligations, including its obligation to continue to pay the rent due to the Company.
In 2021, the Company concluded that its lease with the Avamere Family of Companies (“Avamere”) should no longer be accounted for on an accrual basis and wrote off $25.2 million of straight-line rent receivable balances, and in 2022, Avamere’s lease was amended to, among other things, reduce Avamere’s annual base rent to $30.7 million from $44.1 million, effective February 1, 2022.
In 2022, the Company concluded that its leases with North American Health Care, Inc. (“North American”) should no longer be accounted for on an accrual basis and wrote off $15.6 million of straight-line rent receivable balances related to these leases. The facilities were transitioned to the Ensign Group or Avamere, as applicable, effective February 1, 2023.
For the year ended December 31, 2023, no tenant relationship represented 10% or more of the Company’s total revenues.
As of December 31, 2023, the future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases were as follows and may materially differ from actual future rental payments received (in thousands):
2024$377,721 
2025372,911 
2026357,434 
2027334,489 
2028310,963 
Thereafter1,289,067 
$3,042,585 
Senior Housing - Managed Communities
The Company’s Senior Housing - Managed communities offer residents certain ancillary services that are not contemplated in the lease with each resident (i.e., housekeeping, laundry, guest meals, etc.). These services are provided and paid for in addition to the standard services included in each resident lease (i.e., room and board, standard meals, etc.). The Company bills residents for ancillary services one month in arrears and recognizes revenue as the services are provided, as the Company has no continuing performance obligation related to those services. Resident fees and services includes ancillary service revenue of $2.0 million, $1.5 million and $1.3 million for the years ended December 31, 2023, 2022 and 2021, respectively.
Capital and Other Expenditures
As of December 31, 2023, the Company’s aggregate commitment for future capital and other expenditures associated with facilities leased under triple-net operating leases was approximately $27 million. These commitments are principally for improvements to its facilities.
Investment in Unconsolidated Joint Ventures
The following is a summary of the Company’s investment in unconsolidated joint ventures (dollars in thousands):
Property Type
Number of
Properties as of
December 31, 2023
Ownership as of
December 31, 2023 (1)
Book Value as of December 31,
20232022
Sienna Joint VentureSenior Housing - Managed12 50 %$119,724 $120,269 
Marlin Spring Joint VentureSenior Housing - Managed85 %17,119 14,693 
$136,843 $134,962 
(1)    These investments are not consolidated because the Company does not control, through voting rights or other means, the joint ventures.
The Company formed a joint venture with Marlin Spring (the “Marlin Spring Joint Venture”) that completed the acquisition of one and three senior housing communities that are being managed by third-party operators during 2023 and 2022, respectively. The gross investment, excluding acquisition costs, by the Marlin Spring Joint Venture totaled CAD $30.0 million and CAD $82.5 million during 2023 and 2022, respectively. In addition, the Marlin Spring Joint Venture assumed and financed
an aggregate CAD $23.6 million and CAD $65.0 million of debt during 2023 and 2022, respectively. The Company’s equity investment was CAD $6.1 million and CAD $16.6 million during 2023 and 2022, respectively.
During 2022, the Company formed a joint venture with Sienna Senior Living (the “Sienna Joint Venture”), and the Sienna Joint Venture completed the acquisition of 12 senior housing communities that are being managed by Sienna Senior Living. The gross investment by the Sienna Joint Venture totaled CAD $379.0 million, excluding acquisition costs, and in addition, the Sienna Joint Venture assumed CAD $53.4 million of debt. The Company’s equity investment was CAD $161.8 million.
During the second quarter of 2021, the Company determined that it intended to eventually exit its 49% stake in the real estate platform of TPG (the “Enlivant Joint Venture”) and concluded that the carrying value exceeded the estimated fair value of the investment and deemed the decline to be other-than-temporary. This resulted in the Company recording an impairment charge totaling $164.1 million during the three months ended June 30, 2021 which is included in loss from unconsolidated joint ventures on the accompanying consolidated statements of income (loss).
During the fourth quarter of 2022, due to the confluence of labor shortages, increased labor costs, elevated interest rates and a slower than anticipated recovery in the operating performance of the underlying facilities, the Company concluded that the estimated fair value of its investment in the Enlivant Joint Venture had further declined to zero based on updated future cash flow analyses. This decline was deemed to be other-than-temporary, and the Company recorded an impairment charge totaling $57.8 million during the three months ended December 31, 2022 which is included in loss from unconsolidated joint ventures on the accompanying consolidated statements of income (loss).
Effective January 1, 2023, the Company discontinued applying the equity method of accounting to the Enlivant Joint Venture. Effective May 1, 2023, the Company withdrew and resigned its membership in the Enlivant Joint Venture and accordingly, no longer has an equity interest in the Enlivant Joint Venture as of such date.
Summarized Financial Information
The following tables present summarized financial information for the Company’s investments in unconsolidated joint ventures (in thousands).
As of December 31,
20232022
Total assets$353,779 $754,220 
Total liabilities106,490 894,969 
Member’s equity (deficit)247,289 (140,749)
Year Ended December 31,
202320222021
Total revenues$64,446 $351,073 $274,693 
Operating expenses (1)
47,811 324,462 265,194 
Net loss(9,823)(66,171)(35,276)
Company’s share of net loss$(2,897)$(32,581)$(17,184)
Basis adjustments— 7,673 10,771 
Other-than-temporary impairment— 57,778 164,126 
Loss from unconsolidated joint venture$(2,897)$(98,032)$(192,081)
(1)    During the years ended December 31, 2022 and 2021, TPG caused the Enlivant Joint Venture to fund $25.0 million and $20.0 million, respectively, of payments to Enlivant beyond amounts contractually required under the management agreement. These payments were to support the operations of Enlivant and are reflected as operating expenses. Funding for the support payments did not require capital contributions from Sabra but rather were funded with proceeds received by the Enlivant Joint Venture from TPG for the issuance of senior preferred interests or with cash on hand at the Enlivant Joint Venture.
Certain amounts in the financial information have been reclassified to conform to Sabra’s presentation. For the Enlivant Joint Venture, except for basis adjustments, other-than-temporary impairment and loss from unconsolidated joint venture, the financial information reflects the historical cost basis of the assets which pre-dated the Company’s investment in the Enlivant Joint Venture. In addition, the Company’s share of net loss in the Enlivant Joint Venture excludes certain equity-like compensation expense and the related income tax impact as such expense is not the responsibility of the Company under the terms of the joint venture agreement.
Net Investment in Sales-Type Lease
As of December 31, 2022, the Company had a $25.5 million net investment in one skilled nursing/transitional care facility leased to a tenant under a sales-type lease, as the tenant is obligated to purchase the property at the end of the lease term. During the three months ended March 31, 2023, the tenant purchased the skilled nursing/transitional care facility for net proceeds of $25.5 million as obligated under terms of the lease.
XML 30 R15.htm IDEA: XBRL DOCUMENT v3.24.0.1
IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS
12 Months Ended
Dec. 31, 2023
Discontinued Operations and Disposal Groups [Abstract]  
IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS
Impairment of Real Estate
During the years ended December 31, 2023, 2022 and 2021, the Company recognized real estate impairments of $14.3 million, $94.0 million and $9.5 million, respectively, related to three, 10 and three facilities, respectively. These facilities have either been sold or are closed.
To estimate the fair value of the impaired facilities, the Company utilized a market approach which considered binding sale agreements, non-binding offers from unrelated third parties or model-derived valuations with significant unobservable inputs (Level 3 measurements), as applicable.
The Company continues to evaluate additional assets for sale as part of its initiative to recycle capital and further improve its portfolio quality. This could lead to a shorter hold period and could result in the determination that the full amount of the Company’s investment is not recoverable, resulting in an impairment charge which could be material.
Dispositions
The following table summarizes the Company’s dispositions for the periods presented (dollars in millions):
Year Ended December 31,
202320222021
Number of facilities281816
Consideration, net of closing costs$255.6 $87.3 $103.4 
Net carrying value332.2 99.3 92.1 
Net (loss) gain on sale$(76.6)$(12.0)$11.3 
The Company recognized net loss of $80.9 million and $94.8 million during the years ended December 31, 2023 and 2022, respectively, and net income of $21.5 million during the year ended December 31, 2021, which includes impairment of real estate of $7.1 million, $94.0 million and $9.5 million for the years ended December 31, 2023, 2022 and 2021, respectively, and net (loss) gain on sale from these facilities.
The sale of the disposition facilities does not represent a strategic shift that has or will have a major effect on the Company’s operations and financial results, and therefore the results of operations attributable to these facilities have remained in continuing operations.
XML 31 R16.htm IDEA: XBRL DOCUMENT v3.24.0.1
INTANGIBLE ASSETS AND LIABILITIES
12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLE ASSETS AND LIABILITIES INTANGIBLE ASSETS AND LIABILITIES
The following table summarizes the Company’s intangible assets and liabilities as of December 31, 2023 and 2022 (in thousands):
As of December 31,
20232022
Lease Intangible Assets:
Above market leases$7,496 $7,496 
Tenant origination and absorption costs43,071 58,578 
Tenant relationship16,983 20,119 
Gross lease intangible assets67,550 86,193 
Accumulated amortization(36,653)(46,062)
Lease intangible assets, net$30,897 $40,131 
Lease Intangible Liabilities:
Below market leases$68,573 $80,208 
Accumulated amortization(36,041)(37,964)
Lease intangible liabilities, net$32,532 $42,244 
The following is a summary of real estate intangible amortization income (expense) for the years ended December 31, 2023, 2022 and 2021 (in thousands): 
Year Ended December 31,
202320222021
Increase (decrease) to rental income related to above/below market leases, net (1)
$5,821 $6,624 $(13,512)
Depreciation and amortization related to tenant origination and absorption costs and tenant relationship(11,616)(17,591)(8,694)
(1)    Balance for the year ended December 31, 2021 includes $18.6 million of accelerated amortization related to the above market lease intangible associated with the Company’s lease with Avamere. See Note 4, “Investment in Real Estate Properties,” for further discussion.
The remaining unamortized balance for these outstanding intangible assets and liabilities as of December 31, 2023 will be amortized for the years ending December 31 as follows (dollars in thousands):
Lease Intangible
Assets
 Lease Intangible
Liabilities
2024$5,523 $5,690 
20254,612 5,139 
20264,411 4,884 
20273,115 4,442 
20282,662 4,296 
Thereafter10,574 8,081 
$30,897 $32,532 
  
Weighted-average remaining amortization period8.8 years6.5 years
XML 32 R17.htm IDEA: XBRL DOCUMENT v3.24.0.1
LOANS RECEIVABLE AND OTHER INVESTMENTS
12 Months Ended
Dec. 31, 2023
Receivables [Abstract]  
LOANS RECEIVABLE AND OTHER INVESTMENTS LOANS RECEIVABLE AND OTHER INVESTMENTS
    As of December 31, 2023 and 2022, the Company’s loans receivable and other investments consisted of the following (dollars in thousands):
As of December 31, 2023
Investment
Quantity
as of
December 31, 2023
Property Type
Principal Balance as of December 31, 2023 (1)
Book Value
as of
December 31, 2023
Book Value
as of
December 31, 2022
Weighted Average Contractual Interest Rate / Rate of ReturnWeighted Average Annualized Effective Interest Rate / Rate of Return
Maturity Date
as of
December 31, 2023
Loans Receivable:
MortgageBehavioral Health$319,000 $319,000 $319,000 7.6 %7.6 %11/01/26 - 01/31/27
Other12 Multiple53,873 50,440 47,936 7.7 %7.4 %10/01/23 - 05/01/29
14 372,873 369,440 366,936 7.7 %7.6 %
Allowance for loan losses— (6,665)(6,611)
$372,873 $362,775 $360,325 
Other Investments:
Preferred EquitySkilled Nursing / Senior Housing57,681 57,849 51,071 11.0 %11.0 %N/A
Total19 $430,554 $420,624 $411,396 8.1 %8.1 %
(1)    Principal balance includes amounts funded and accrued but unpaid interest / preferred return and excludes capitalizable fees.
As of December 31, 2023, the Company has committed to provide up to $0.5 million of future funding related to one loan receivable investment.
Additional information regarding the Company’s loans receivable is as follows (dollars in thousands):
Year Ended December 31,
202320222021
Allowance for loan losses:
Balance at the beginning of the year$6,611 $6,344 $2,458 
Provision for loan losses192 267 3,886 
Write-off of uncollectible balances(138)— — 
Balance at the end of the year$6,665 $6,611 $6,344 
As of December 31,
20232022
Deteriorated credit quality:
Number of loans receivable investments
Principal balance$1,214 $1,214 
Book value— — 
Nonaccrual status:
Number of loans receivable investments
Book value$— $— 
As of December 31, 2023 and 2022, the Company did not consider any preferred equity investments to be impaired, and no preferred equity investments were on nonaccrual status.
XML 33 R18.htm IDEA: XBRL DOCUMENT v3.24.0.1
DEBT
12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
DEBT DEBT
Secured Indebtedness
The Company’s secured debt consists of the following (dollars in thousands):
Principal Balance as of December 31, (1)
As of December 31, 2023
Weighted Average Interest Rate
Weighted Average Effective Interest Rate (2)
Interest Rate Type
2023
2022
Maturity Date
Fixed Rate$48,143 $50,123 2.85 %3.34 %May 2031 - 
August 2051
(1)    Principal balance does not include deferred financing costs, net of $0.8 million and $0.9 million as of December 31, 2023 and 2022, respectively.
(2)    Weighted average effective interest rate includes private mortgage insurance.
During the year ended December 31, 2022, the Company repaid $15.4 million of debt secured by three facilities.
During the year ended December 31, 2021, the Company sold two facilities and repaid $9.8 million of debt secured by the facilities which resulted in a $0.1 million loss on extinguishment of debt related to write-offs of deferred financing costs.
Senior Unsecured Notes
The Company’s senior unsecured notes consist of the following (dollars in thousands):
Principal Balance as of December 31, (1)
TitleMaturity Date
2023
2022
5.125% senior unsecured notes due 2026
August 15, 2026$500,000 $500,000 
5.88% senior unsecured notes due 2027
May 17, 2027100,000 100,000 
3.90% senior unsecured notes due 2029
October 15, 2029350,000 350,000 
3.20% senior unsecured notes due 2031
December 1, 2031800,000 800,000 
$1,750,000 $1,750,000 
(1)    Principal balance does not include discount, net of $4.3 million and deferred financing costs, net of $10.5 million as of December 31, 2023 and does not include discount, net of $3.5 million and deferred financing costs, net of $12.0 million as of December 31, 2022. In addition, the weighted average effective interest rate as of December 31, 2023 was 4.01%.
4.80% Notes Due 2024. On May 29, 2019, the Operating Partnership and Sabra Capital Corporation, wholly owned subsidiaries of the Company (the “Issuers”), completed an underwritten public offering of $300.0 million aggregate principal amount of 4.80% senior unsecured notes due 2024 (the “2024 Notes”). The net proceeds were $295.3 million after deducting underwriting discounts and other offering expenses.
On October 7, 2021, the Issuers redeemed all $300.0 million aggregate principal amount outstanding of the 2024 Notes at a cash redemption price of 110.045% of the principal amount being redeemed, plus accrued and unpaid interest. The redemption resulted in $32.7 million of redemption related costs and write-offs for the year ended December 31, 2021, consisting of $30.2 million in payments made to noteholders and legal fees for early redemption and $2.5 million of write-offs associated with unamortized discount and deferred financing costs.
5.125% Notes Due 2026. In connection with the Company’s merger with Care Capital Properties (“CCP”), on August 17, 2017, the Operating Partnership assumed $500.0 million aggregate principal amount of 5.125% senior unsecured notes due 2026 (the “2026 Notes”) issued by Care Capital Properties, LP in July 2016. The 2026 Notes accrue interest at a rate of 5.125% per annum payable semiannually on February 15 and August 15 of each year.
The Operating Partnership may, at its option, redeem the 2026 Notes at any time in whole or from time to time in part prior to their stated maturity. The redemption price for 2026 Notes that are redeemed will be equal to (i) 100% of their principal amount, together with accrued and unpaid interest thereon, if any, to (but excluding) the date of redemption, plus, (ii) if redeemed prior to May 15, 2026, a make-whole premium. Assuming the 2026 Notes are not redeemed, the 2026 Notes mature on August 15, 2026.
5.88% Notes Due 2027. In connection with the Company’s merger with CCP, on August 17, 2017, the Operating Partnership assumed $100.0 million aggregate principal amount of unregistered senior unsecured notes due 2027 (the “2027 Notes”) issued by Care Capital Properties, LP in May 2016. The 2027 Notes accrue interest at a rate of 5.88% per annum payable semiannually on May 17 and November 17 of each year.
The Operating Partnership may prepay the 2027 Notes, in whole at any time or in part from time to time, at 100% of the principal amount to be prepaid plus a make-whole premium. Assuming the 2027 Notes are not redeemed, the 2027 Notes mature on May 17, 2027.
3.90% Notes Due 2029. On October 7, 2019, the Issuers completed an underwritten public offering of $350.0 million aggregate principal amount of 3.90% senior unsecured notes due 2029 (the “2029 Notes”). The net proceeds were $340.5 million after deducting underwriting discounts and other offering expenses. A portion of the net proceeds was used to redeem all $200.0 million of 5.375% unsecured senior notes due 2023 (the “2023 Notes”), and the remaining net proceeds were used to repay borrowings outstanding on the Prior Revolving Credit Facility (as defined below). The 2029 Notes accrue interest at a rate of 3.90% per annum payable semiannually on April 15 and October 15 of each year. In 2019, Sabra Capital Corporation’s obligations as a co-issuer under the 2029 Notes were automatically released and discharged upon the redemption of the 2023 Notes.
The 2029 Notes are redeemable at the option of the Operating Partnership, in whole or in part at any time and from time to time, prior to July 15, 2029, at a price equal to 100% of the principal amount, together with any accrued and unpaid interest to, but not including, the redemption date, plus a make-whole premium. The Operating Partnership may also redeem the 2029 Notes on or after July 15, 2029, at a price equal to 100% of the principal amount, together with any accrued and unpaid interest to, but not including, the redemption date. Assuming the 2029 Notes are not redeemed, the 2029 Notes mature on October 15, 2029.
3.20% Notes Due 2031. On September 30, 2021, the Operating Partnership completed an underwritten public offering of $800.0 million aggregate principal amount of 3.20% senior unsecured notes due 2031 (the “2031 Notes”). The net proceeds were $782.2 million after deducting underwriting discounts and other offering expenses. The net proceeds were used to repay $345.0 million of the Company’s U.S. dollar Prior Term Loans (as defined below), redeem all of the 2024 Notes, as discussed above, and to fund a portion of one of the Company’s mortgage loans. The 2031 Notes accrue interest at a rate of 3.20% per annum payable semiannually on June 1 and December 1 of each year, commencing on June 1, 2022.
The 2031 Notes are redeemable at the option of the Operating Partnership, in whole or in part at any time and from time to time, prior to September 1, 2031, at a price equal to 100% of the principal amount, together with any accrued and unpaid interest to the redemption date, plus a “make-whole” premium. The Operating Partnership may also redeem the 2031 Notes on or after September 1, 2031, at a price equal to 100% of the principal amount, together with any accrued and unpaid interest to the redemption date. Assuming the 2031 Notes are not redeemed, the 2031 Notes mature on December 1, 2031.
The obligations under the 2027 Notes are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by Sabra and one of its non-operating subsidiaries, subject to release under certain customary circumstances. The obligations under the 2026 Notes, 2029 Notes and 2031 Notes are fully and unconditionally guaranteed, on an unsecured basis, by Sabra; provided, however, that such guarantee is subject to release under certain customary circumstances.
The indenture governing the 2026 Notes contains certain covenants that, among other things, limits the ability of Sabra, the Issuers and their subsidiaries to: (i) consummate a merger, consolidate or sell all or substantially all of our consolidated assets and (ii) incur secured or unsecured indebtedness. In addition, Sabra, the Operating Partnership and their subsidiaries are required to maintain at all times consolidated unencumbered total asset value in an amount not less than 150% of the aggregate outstanding principal amount of the Company’s consolidated unsecured debt.
The agreement governing the 2027 Notes provides for customary events of default, including, but not limited to, the failure to make payments of interest or premium, if any, on, or principal of, the 2027 Notes, the failure to comply with certain covenants and agreements specified in the agreement governing the 2027 Notes for a period of time after notice has been provided, the acceleration of other indebtedness resulting from the failure to pay principal on such other indebtedness prior to its maturity, and certain events of insolvency. In addition, certain change of control events constitute an event of default under the agreement governing the 2027 Notes. If any event of default occurs, the principal of, premium, if any, and accrued interest on all the then-outstanding 2027 Notes may become due and payable immediately.
The indenture governing the 2029 Notes and 2031 Notes contains restrictive covenants that, among other things, restrict the ability of Sabra, the Issuers and their subsidiaries to: (i) incur or guarantee additional indebtedness; (ii) incur or guarantee secured indebtedness; and (iii) merge or consolidate or sell all or substantially all of their assets. The indenture governing the 2029 Notes and 2031 Notes also provides for customary events of default, including, but not limited to, the failure to make payments of interest or premium, if any, on, or principal of, the 2029 Notes and 2031 Notes, the failure to comply with certain covenants and agreements specified in the indenture for a period of time after notice has been provided, the acceleration of other indebtedness resulting from the failure to pay principal on such other indebtedness prior to its maturity, and certain events of insolvency. If any event of default occurs, the principal of, premium, if any, and accrued interest on all the then-outstanding 2029 Notes and 2031 Notes may become due and payable immediately. The indenture governing the 2029 Notes and 2031
Notes requires Sabra, the Issuers and their subsidiaries to maintain Total Unencumbered Assets (as defined in the indentures) of at least 150% of the Company’s unsecured indebtedness.
The Company was in compliance with all applicable financial covenants under the indentures and agreements (the “Senior Notes Indentures”) governing the 2026 Notes, 2027 Notes, 2029 Notes and 2031 Notes (collectively, the “Senior Notes”) outstanding as of December 31, 2023.
Credit Agreement
On September 9, 2019, the Operating Partnership and Sabra Canadian Holdings, LLC (together, the “Borrowers”), Sabra and the other parties thereto entered into a fifth amended and restated unsecured credit agreement (the “Prior Credit Agreement”).
The Prior Credit Agreement included a $1.0 billion revolving credit facility (the “Prior Revolving Credit Facility”), a $436.3 million U.S. dollar term loan and a CAD $125.0 million Canadian dollar term loan (collectively, the “Prior Term Loans”). Further, up to $175.0 million of the Prior Revolving Credit Facility could be used for borrowings in certain foreign currencies. The Prior Credit Agreement also contained an accordion feature that allowed for an increase in the total available borrowings to $2.75 billion, subject to terms and conditions.
During the years ended December 31, 2022 and 2021, the Company recognized $0.4 million and $1.8 million, respectively, of loss on extinguishment of debt related to write-offs of deferred financing costs in connection with the partial pay down of the U.S. dollar Prior Term Loan.
Borrowings under the Prior Revolving Credit Facility bore interest on the outstanding principal amount at a rate equal to a ratings-based applicable interest margin plus, CDOR for Canadian dollar borrowings, or at the Operating Partnership’s option for U.S. dollar borrowings, either (a) LIBOR or (b) a base rate determined as the greater of (i) the federal funds rate plus 0.5%, (ii) the prime rate, and (iii) one-month LIBOR plus 1.0% (the “Prior Base Rate”). The ratings-based applicable interest margin for borrowings varied based on the Debt Ratings, as defined in the Prior Credit Agreement, and ranged from 0.775% to 1.45% per annum for CDOR or LIBOR based borrowings and 0.00% to 0.45% per annum for borrowings at the Prior Base Rate. In addition, the Operating Partnership paid a facility fee ranging between 0.125% and 0.300% per annum based on the aggregate amount of commitments under the Prior Revolving Credit Facility regardless of amounts outstanding thereunder.
The U.S. dollar Prior Term Loan bore interest on the outstanding principal amount at a rate equal to a ratings-based applicable interest margin plus, at the Operating Partnership’s option, either (a) LIBOR or (b) the Prior Base Rate. The ratings-based applicable interest margin for borrowings varied based on the Debt Ratings and ranged from 0.85% to 1.65% per annum for LIBOR based borrowings and 0.00% to 0.65% per annum for borrowings at the Prior Base Rate. The Canadian dollar Prior Term Loan bore interest on the outstanding principal amount at a rate equal to CDOR plus an interest margin ranged from 0.85% to 1.65% depending on the Debt Ratings.
On January 4, 2023, the Borrowers, and the other parties thereto entered into a sixth amended and restated unsecured credit agreement (the “Credit Agreement”). During the year ended December 31, 2023, the Company recorded $18.1 million of deferred financing costs related to the Credit Agreement and recognized $1.5 million of loss on extinguishment of debt related to write-offs of deferred financing costs in connection with amending and restating the Prior Credit Agreement.
The Credit Agreement includes a $1.0 billion revolving credit facility (the “Revolving Credit Facility”), a $430.0 million U.S. dollar term loan and a CAD $150.0 million Canadian dollar term loan (collectively, the “Term Loans”). Further, up to $350.0 million of the Revolving Credit Facility may be used for borrowings in certain foreign currencies. The Credit Agreement also contains an accordion feature that can increase the total available borrowings to $2.75 billion, subject to terms and conditions.
The Revolving Credit Facility has a maturity date of January 4, 2027, and includes two six-month extension options. The Term Loans have a maturity date of January 4, 2028.
As of December 31, 2023, there was $94.4 million (including CAD $44.3 million) outstanding under the Revolving Credit Facility and $905.6 million available for borrowing.
Borrowings under the Revolving Credit Facility bear interest on the outstanding principal amount at a rate equal to a ratings-based applicable interest margin plus, CDOR for Canadian dollar borrowings, or at the Operating Partnership’s option for U.S. dollar borrowings, either (a) Daily Simple SOFR, as defined in the Credit Agreement, or (b) a base rate determined as the greater of (i) the federal funds rate plus 0.5%, (ii) the prime rate, (iii) Term SOFR, as defined in the Credit Agreement, plus 1.0% (the “Base Rate”), and (iv) 1.00%. The ratings-based applicable interest margin for borrowings will vary based on the Debt Ratings, as defined in the Credit Agreement, and will range from 0.775% to 1.450% per annum for Daily Simple SOFR
based borrowings and 0.00% to 0.450% per annum for borrowings at the Base Rate. As of December 31, 2023, the weighted average interest rate on the Revolving Credit Facility was 6.57%. In addition, the Operating Partnership pays a facility fee ranging between 0.125% and 0.300% per annum based on the aggregate amount of commitments under the Revolving Credit Facility regardless of amounts outstanding thereunder.
The U.S. dollar Term Loan bears interest on the outstanding principal amount at a ratings-based applicable interest margin plus, at the Operating Partnership’s option, either (a) Term SOFR or (b) the Base Rate. The ratings-based applicable interest margin for borrowings will vary based on the Debt Ratings and will range from 0.850% to 1.650% per annum for Term SOFR based borrowings and 0.00% to 0.650% per annum for borrowings at the Base Rate. As of December 31, 2023, the interest rate on the U.S. dollar Term Loan was 6.73%. The Canadian dollar Term Loan bears interest on the outstanding principal amount at a rate equal CDOR plus an interest margin that will range from 0.850% to 1.650% depending on the Debt Ratings. As of December 31, 2023, the interest rate on the Canadian dollar Term Loan was 6.71%.
The Company has interest rate swaps and interest rate collars that fix and set a cap and floor, respectively, for the SOFR portion of the interest rate for $430.0 million of SOFR-based borrowings under its U.S. dollar Term Loan at a weighted average rate of 2.69% and interest rate swaps that fix the CDOR portion of the interest rate for CAD $150.0 million of CDOR-based borrowings under its Canadian dollar Term Loan at a rate of 1.63%. As of December 31, 2023, the effective interest rate on the U.S. dollar and Canadian dollar Term Loans was 3.94% and 2.88%, respectively. In addition, the Canadian dollar Term Loan and the CAD $44.3 million outstanding under the Revolving Credit Facility as of December 31, 2023 are designated as net investment hedges. See Note 9, “Derivative and Hedging Instruments,” for further information.
The obligations of the Borrowers under the Credit Agreement are guaranteed by the Company and certain of its subsidiaries.
The Credit Agreement contains customary covenants that include restrictions or limitations on the ability to pay dividends, incur additional indebtedness, engage in non-healthcare related business activities, enter into transactions with affiliates and sell or otherwise transfer certain assets as well as customary events of default. The Credit Agreement also requires Sabra, through the Operating Partnership, to comply with specified financial covenants, which include a maximum total leverage ratio, a maximum secured debt leverage ratio, a minimum fixed charge coverage ratio, a maximum unsecured leverage ratio, a minimum tangible net worth requirement and a minimum unsecured interest coverage ratio. As of December 31, 2023, the Company was in compliance with all applicable financial covenants under the Credit Agreement.
Interest Expense
During the years ended December 31, 2023, 2022 and 2021, the Company incurred interest expense of $113.0 million, $105.5 million and $98.6 million, respectively. Interest expense includes non-cash interest expense of $12.3 million, $11.1 million and $8.4 million for the years ended December 31, 2023, 2022 and 2021, respectively. As of December 31, 2023 and 2022, the Company had $16.5 million and $18.2 million, respectively, of accrued interest included in accounts payable and accrued liabilities on the accompanying consolidated balance sheets.
Maturities
The following is a schedule of maturities for the Company’s outstanding debt as of December 31, 2023 (in thousands):
Secured
Indebtedness
Revolving
Credit Facility (1)
Term LoansSenior NotesTotal
2024$2,033 $— $— $— $2,033 
20252,089 — — — 2,089 
20262,147 — — 500,000 502,147 
20272,206 94,429 — 100,000 196,635 
20282,266 — 543,190 — 545,456 
Thereafter37,402 — — 1,150,000 1,187,402 
Total Debt48,143 94,429 543,190 1,750,000 2,435,762 
Discount, net— — — (4,258)(4,258)
Deferred financing costs, net(842)— (6,070)(10,489)(17,401)
Total Debt, Net$47,301 $94,429 $537,120 $1,735,253 $2,414,103 
(1)    Revolving Credit Facility is subject to two six-month extension options.
XML 34 R19.htm IDEA: XBRL DOCUMENT v3.24.0.1
DERIVATIVE AND HEDGING INSTRUMENTS
12 Months Ended
Dec. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
DERIVATIVE AND HEDGING INSTRUMENTS DERIVATIVE AND HEDGING INSTRUMENTS
The Company is exposed to various market risks, including the potential loss arising from adverse changes in interest rates and foreign exchange rates. The Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates and foreign exchange rates. The Company’s derivative financial instruments are used to manage differences in the amount of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s investments and borrowings.
Certain of the Company’s foreign operations expose the Company to fluctuations of foreign interest rates and exchange rates. These fluctuations may impact the value in the Company’s functional currency, the U.S. dollar, of the Company’s investment in foreign operations, the cash receipts and payments related to these foreign operations and payments of interest and principal under Canadian dollar denominated debt. The Company enters into derivative financial instruments to protect the value of its foreign investments and fix a portion of the interest payments for certain debt obligations. The Company does not enter into derivatives for speculative purposes.
Cash Flow Hedges
The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish these objectives, the Company primarily uses interest rate swaps and collars as part of its interest rate risk management strategy. As of December 31, 2023, approximately $6.9 million of gains, which are included in accumulated other comprehensive income, are expected to be reclassified into earnings in the next 12 months.
Net Investment Hedges
The Company is exposed to fluctuations in foreign exchange rates on investments it holds in Canada. The Company uses cross currency interest rate swaps to hedge its exposure to changes in foreign exchange rates on these foreign investments.
The following presents the notional amount of derivative instruments as of the dates indicated (in thousands):  
As of December 31,
20232022
Derivatives designated as cash flow hedges:
Denominated in U.S. Dollars (1)
$753,750 $436,250 
Denominated in Canadian Dollars (2)
$300,000 $125,000 
Derivatives designated as net investment hedges:
Denominated in Canadian Dollars$55,335 $55,991 
Financial instrument designated as net investment hedge:
Denominated in Canadian Dollars$194,300 $329,500 
Derivatives not designated as net investment hedges:
Denominated in Canadian Dollars$965 $309 
(1) Balance as of December 31, 2023 includes two forward starting interest rate swaps with an effective date of August 2024 and an aggregate notional amount of $323.8 million.
(2)    Balance as of December 31, 2023 includes two forward starting interest rate swaps with an effective date of September 2024 and an aggregate notional amount of CAD $150.0 million.
Derivative and Financial Instruments Designated as Hedging Instruments
The following is a summary of the derivative and financial instruments designated as hedging instruments held by the Company at December 31, 2023 and 2022 (dollars in thousands):    
Count as of December 31, 2023
Maturity Dates
Fair Value as of December 31,
TypeDesignation20232022Balance Sheet Location
Assets:
Interest rate swapsCash flow$6,002 $11,004 2024 - 2028Accounts receivable, prepaid expenses and other assets, net
Interest rate collarsCash flow3,216 6,622 2024Accounts receivable, prepaid expenses and other assets, net
Forward starting interest rate swapsCash flow6,736 — 2028Accounts receivable, prepaid expenses and other assets, net
Cross currency interest rate swapsNet investment2,964 3,851 2025Accounts receivable, prepaid expenses and other assets, net
$18,918 $21,477 
Liabilities:
CAD borrowings under Revolving Credit FacilityNet investment33,429 150,982 2027Revolving credit facility
CAD Term LoanNet investment113,190 92,288 2028Term loans, net
$146,619 $243,270 
The following presents the effect of the Company’s derivative and financial instruments designated as hedging instruments on the consolidated statements of income (loss) and the consolidated statements of equity for the years ended December 31, 2023, 2022 and 2021 (in thousands):
Gain (Loss) Recognized in Other Comprehensive Income (Loss)Gain (Loss) Reclassified from Accumulated Other Comprehensive Income (Loss)
Into Income
Income Statement Location
For the year ended December 31,
202320222021202320222021
Cash Flow Hedges:
Interest rate products$13,116 $22,032 $17,408 $8,332 $(4,179)$(12,774)Interest expense
Net Investment Hedges:
Foreign currency products(664)2,233 (272)— — — N/A
CAD borrowings under Revolving Credit Facility(3,456)9,454 — — — — N/A
CAD Term Loan(2,465)6,150 (338)— — — N/A
$6,531 $39,869 $16,798 $8,332 $(4,179)$(12,774)
During the years ended December 31, 2023, 2022 and 2021, no cash flow hedges were determined to be ineffective.
Derivatives Not Designated as Hedging Instruments
As of December 31, 2023, the Company had no material balances related to derivatives not designated as hedging instruments. During the years ended December 31, 2023, 2022 and 2021, the Company recorded $18,000, $0.1 million and $22,000 of other expense, respectively, related to the portion of derivatives not designated as hedging instruments.
Offsetting Derivatives
The Company enters into master netting arrangements, which reduce credit risk by permitting net settlement of transactions with the same counterparty. The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of December 31, 2023 and 2022 (in thousands):
As of December 31, 2023
Gross Amounts of Recognized Assets / LiabilitiesGross Amounts Offset in the Balance SheetNet Amounts of Assets / Liabilities presented in the Balance SheetGross Amounts Not Offset in the Balance Sheet
Financial InstrumentsCash Collateral ReceivedNet Amount
Offsetting Assets:
Derivatives$18,918 $— $18,918 $— $— $18,918 
Offsetting Liabilities:
Derivatives$— $— $— $— $— $— 
As of December 31, 2022
Gross Amounts of Recognized Assets / LiabilitiesGross Amounts Offset in the Balance SheetNet Amounts of Assets / Liabilities presented in the Balance SheetGross Amounts Not Offset in the Balance Sheet
Financial InstrumentsCash Collateral ReceivedNet Amount
Offsetting Assets:
Derivatives$21,477 $— $21,477 $— $— $21,477 
Offsetting Liabilities:
Derivatives$— $— $— $— $— $— 
Credit Risk-related Contingent Features
The Company has agreements with each of its derivative counterparties that contain a provision pursuant to which the Company could be declared in default on the derivative obligation if the Company defaults on any of its indebtedness, including a default where repayment of the indebtedness has not been accelerated by the lender. As of December 31, 2023, the Company had no derivatives in a net liability position related to these agreements.
XML 35 R20.htm IDEA: XBRL DOCUMENT v3.24.0.1
FAIR VALUE DISCLOSURES
12 Months Ended
Dec. 31, 2023
Fair Value Disclosures [Abstract]  
FAIR VALUE DISCLOSURES FAIR VALUE DISCLOSURES
Financial Instruments
The fair value for certain financial instruments is derived using a combination of market quotes, pricing models and other valuation techniques that involve significant management judgment. The price transparency of financial instruments is a key determinant of the degree of judgment involved in determining the fair value of the Company’s financial instruments.
Financial instruments for which actively quoted prices or pricing parameters are available and whose markets contain orderly transactions will generally have a higher degree of price transparency than financial instruments whose markets are inactive or consist of non-orderly trades. The Company evaluates several factors when determining if a market is inactive or when market transactions are not orderly. The carrying values of cash and cash equivalents, restricted cash, accounts payable, accrued liabilities and the Credit Agreement are reasonable estimates of fair value because of the short-term maturities of these instruments. Fair values for other financial instruments are derived as follows:
Loans receivable: These instruments are presented on the accompanying consolidated balance sheets at their amortized cost and not at fair value. The fair values of the loans receivable were estimated using an internal valuation model that considered the expected cash flows for the loans receivable, as well as the underlying collateral value and other credit enhancements as applicable. The Company utilized discount rates ranging from 6% to 15% with a weighted average rate of 6% in its fair value calculation. As such, the Company classifies these instruments as Level 3.
Preferred equity investments: These instruments are presented on the accompanying consolidated balance sheets at their cost and not at fair value. The fair values of the preferred equity investments were estimated using an internal valuation model that considered the expected future cash flows for the preferred equity investments, the underlying collateral value and other credit enhancements. The Company utilized discount rates ranging from 10% to 15% with a weighted average rate of 11% in its fair value calculation. As such, the Company classifies these instruments as Level 3.
Derivative instruments: The Company’s derivative instruments are presented at fair value on the accompanying consolidated balance sheets. The Company estimates the fair value of derivative instruments, including its interest rate swaps, interest rate collars and cross currency swaps, using the assistance of a third party using inputs that are observable in the market, which include forward yield curves and other relevant information. Although the Company has determined that the majority of the inputs used to value its derivative financial instruments fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivative financial instruments utilize Level 3 inputs, such as estimates of current credit spreads, to evaluate the likelihood of default by itself and its counterparties. The Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of its derivative financial instruments. As a result, the Company has determined that its derivative financial instruments valuations in their entirety are classified in Level 2 of the fair value hierarchy.
Senior Notes: These instruments are presented on the accompanying consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Senior Notes were determined using third-party market quotes derived from orderly trades. As such, the Company classifies these instruments as Level 2.
Secured indebtedness: These instruments are presented on the accompanying consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Company’s secured debt were estimated using a discounted cash flow analysis based on management’s estimates of current market interest rates for instruments with similar characteristics, including remaining loan term, loan-to-value ratio, type of collateral and other credit enhancements. The Company utilized a rate of 6% in its fair value calculation. As such, the Company classifies these instruments as Level 3.
The following are the face values, carrying amounts and fair values of the Company’s financial instruments as of December 31, 2023 and 2022 whose carrying amounts do not approximate their fair value (in thousands):
 As of December 31, 2023As of December 31, 2022
 
Face
Value
(1)
Carrying
Amount
(2)
Fair
Value
Face
Value
(1)
Carrying
Amount
(2)
Fair
Value
Financial assets:
Loans receivable$372,873 $362,775 $383,141 $370,364 $360,325 $370,188 
Preferred equity investments57,681 57,849 59,526 50,902 51,071 51,995 
Financial liabilities:
Senior Notes1,750,000 1,735,253 1,567,428 1,750,000 1,734,431 1,463,041 
Secured indebtedness48,143 47,301 36,279 50,123 49,232 38,149 
(1)    Face value represents amounts contractually due under the terms of the respective agreements.
(2)    Carrying amount represents the book value of financial instruments, including unamortized premiums/discounts and deferred financing costs.
The Company determined the fair value of financial instruments as of December 31, 2023 whose carrying amounts do not approximate their fair value with valuation methods utilizing the following types of inputs (in thousands):
Fair Value Measurements Using
TotalQuoted Prices in
Active Markets for
Identical Assets
(Level 1)
Significant Other
Observable Inputs
(Level 2)
Significant
Unobservable Inputs
(Level 3)
Financial assets:
Loans receivable$383,141 $— $— $383,141 
Preferred equity investments59,526 — — 59,526 
Financial liabilities:
Senior Notes1,567,428 — 1,567,428 — 
Secured indebtedness36,279 — — 36,279 
Disclosure of the fair value of financial instruments is based on pertinent information available to the Company at the applicable dates and requires a significant amount of judgment. Transaction volume for certain of the Company’s financial instruments remains relatively low, which has made the estimation of fair values difficult. Therefore, both the actual results and the Company’s estimate of fair value at a future date could be materially different.
Items Measured at Fair Value on a Recurring Basis
During the year ended December 31, 2023, the Company recorded the following amounts measured at fair value (in thousands):
Fair Value Measurements Using
TotalQuoted Prices in
Active Markets for
Identical Assets
(Level 1)
Significant Other
Observable Inputs
(Level 2)
Significant
Unobservable Inputs
(Level 3)
Recurring Basis:
Financial assets:
Interest rate swaps$6,002 $— $6,002 $— 
Interest rate collars3,216 — 3,216 — 
Forward starting interest rate swaps6,736 — 6,736 — 
Cross currency interest rate swaps2,964 — 2,964 — 
XML 36 R21.htm IDEA: XBRL DOCUMENT v3.24.0.1
EQUITY
12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
EQUITY EQUITY
Common Stock
On December 11, 2019, the Company established an at-the-market equity offering program (the “2019 ATM Program”) pursuant to which shares of its common stock having an aggregate gross sales price of up to $400.0 million may be sold from time to time (i) by the Company through a consortium of banks acting as sales agents or directly to the banks acting as principals or (ii) by a consortium of banks acting as forward sellers on behalf of any forward purchasers pursuant to a forward sale agreement. On August 6, 2021, the Company terminated the 2019 ATM Program pursuant to its termination rights.
During the year ended December 31, 2021, the Company sold 2.2 million shares under the 2019 ATM Program at an average price of $17.78 per share, generating gross proceeds of $38.8 million (before $0.6 million of commissions), excluding sales utilizing the forward feature of the 2019 ATM Program, as described below.
Additionally, during the year ended December 31, 2021, the Company utilized the forward feature of the 2019 ATM Program to allow for the sale of up to 6.8 million shares of the Company’s common stock at an initial weighted average price of $17.49 per share, net of commissions. During the year ended December 31, 2021, the Company settled 7.9 million (inclusive of the 6.8 million shares referenced in the immediately preceding sentence, and constituting all of the open forward positions under the 2019 ATM Program) at a weighted average net price of $17.36 per share, after commissions and fees, resulting in net proceeds of $137.0 million.
On August 6, 2021, the Company established a new at-the-market equity offering program (the “Prior ATM Program”) pursuant to which shares of its common stock having an aggregate gross sales price of up to $500.0 million may be sold from time to time (i) by the Company through a consortium of banks acting as sales agents or directly to the banks acting as principals or (ii) by a consortium of banks acting as forward sellers on behalf of any forward purchasers pursuant to a forward sale agreement. On November 9, 2022, the Company terminated the Prior ATM Program.
During the year ended December 31, 2021, the Company utilized the forward feature of the Prior ATM Program to allow for the sale of up to 1.7 million shares of the Company’s common stock at an initial weighted average price of $14.56 per share, net of commissions, and settled all of the open forward positions under the Prior ATM Program by issuing 1.7 million shares at a weighted average net price of $14.23 per share, after commissions and fees, resulting in net proceeds of $24.2 million. No other shares were sold under the Prior ATM Program during the year ended December 31, 2021. No shares were sold under the Prior ATM Program and the Company did not utilize the forward feature of the Prior ATM Program during the period from January 1, 2022 to November 9, 2022.
On October 15, 2021, the Company completed an underwritten public offering of 7.8 million newly issued shares of its common stock pursuant to an effective registration statement. The Company received net proceeds, before expenses, of $112.6 million from the offering at a price of $14.40 per share. These proceeds were used to fund a portion of one of the Company’s mortgage loan investments.
On February 23, 2023, the Company established an at-the-market equity offering program (the “ATM Program”) pursuant to which shares of its common stock having an aggregate gross sales price of up to $500.0 million may be sold from time to time (i) by the Company through a consortium of banks acting as sales agents or directly to the banks acting as
principals or (ii) by a consortium of banks acting as forward sellers on behalf of any forward purchasers pursuant to a forward sale agreement. The use of a forward sale agreement would allow the Company to lock in a share price on the sale of shares at the time the agreement is effective, but defer receiving the proceeds from the sale of the shares until a later date. The Company may also elect to cash settle or net share settle all or a portion of its obligations under any forward sale agreement. The forward sale agreements have a one year term during which time the Company may settle the forward sales by delivery of physical shares of common stock to the forward purchasers or, at the Company’s election, in cash or net shares. The forward sale price that the Company expects to receive upon settlement will be the initial forward price established upon the effective date, subject to adjustments for (i) the forward purchasers’ stock borrowing costs and (ii) certain fixed price reductions during the term of the agreement.
During the year ended December 31, 2023, no shares were sold under the ATM Program and the Company did not utilize the forward feature of the ATM Program. As of December 31, 2023, the Company had $500.0 million available under the ATM Program.
During the years ended December 31, 2023, 2022 and 2021, the Company issued 0.3 million, 0.6 million and 0.2 million shares, respectively, of common stock as a result of restricted stock unit vestings.
Upon any payment of shares to teammates as a result of restricted stock unit vestings, the teammates’ related tax withholding obligation will generally be satisfied by the Company, reducing the number of shares to be delivered by a number of shares necessary to satisfy the related applicable tax withholding obligation. During the years ended December 31, 2023, 2022 and 2021, the Company incurred $1.8 million, $3.3 million and $2.1 million, respectively, in tax withholding obligations on behalf of its teammates that were satisfied through a reduction in the number of shares delivered to those participants.
Accumulated Other Comprehensive Income
The following is a summary of the Company’s accumulated other comprehensive income (in thousands):
As of December 31,
20232022
Foreign currency translation gain$963 $1,168 
Unrealized gain on cash flow hedges22,782 17,895 
Total accumulated other comprehensive income$23,745 $19,063 
XML 37 R22.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCK-BASED COMPENSATION
12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION
All stock-based awards are subject to the terms of the 2009 Performance Incentive Plan, which was assumed by the Company effective as of November 15, 2010 in connection with the Company’s separation from Sun and was most recently amended and restated in April 2017. The 2009 Performance Incentive Plan provides for the granting of stock-based compensation, including stock options, time-based stock units, funds from operations-based stock units (“FFO Units”), relative total stockholder return-based stock units (“TSR Units”) and performance-based restricted stock units to directors, officers and other teammates in connection with their employment with or services provided to the Company.
Restricted Stock Units and Performance-Based Restricted Stock Units
Under the 2009 Performance Incentive Plan, restricted stock units and performance-based restricted stock units generally have a contractual life or vest over a three- to five-year period. The vesting of certain restricted stock units may accelerate, as defined in the grant, upon retirement, a change in control and other events. When vested (and subject to any applicable deferral or holdback period), each performance-based restricted stock unit is convertible into one share of common stock, subject to any deferrals in issuance pursuant to the grant. The restricted stock units are valued on the grant date based on the market price of the Company’s common stock on that date. Generally, the Company recognizes the fair value of the awards over the applicable vesting period as compensation expense. In addition, since the shares to be issued may vary based on the performance of the Company, the Company must make assumptions regarding the projected performance criteria and the shares that will ultimately be issued. The amount of FFO Units that will ultimately vest is dependent on the amount by which the Company’s funds from operations as adjusted (“FFO”) differs from a target FFO amount for a period specified in each grant and will range from 0% to 200% of the FFO Units initially granted. Similarly, the amount of TSR Units that will ultimately vest is dependent on the amount by which the total shareholder return (“TSR”) of the Company’s common stock differs from a predefined peer group for a period specified in each grant and will range from 0% to 200% of the TSR Units initially granted. Upon any payment of shares as a result of restricted stock unit vestings, the related tax withholding obligation will generally be satisfied by the Company, reducing the number of shares to be delivered by a number of shares necessary to satisfy the related applicable tax
withholding obligation. The value of the shares withheld is dependent on the closing price of the Company’s common stock on the date the relevant transaction occurs.
The following table summarizes additional information concerning restricted stock units at December 31, 2023:
Restricted Stock UnitsWeighted Average Grant Date Fair Value Per Unit
Unvested as of December 31, 20222,147,784 $15.07 
Granted832,308 14.73 
Vested(591,745)15.34 
Dividends reinvested237,195 14.96 
Cancelled/forfeited(156,275)19.51 
Unvested as of December 31, 20232,469,267 $14.61 
As of December 31, 2023, the weighted average remaining vesting period of restricted stock units was 2.7 years. The weighted average fair value per share at the date of grant for restricted stock units for the years ended December 31, 2023, 2022 and 2021 was $14.73, $12.78 and $15.55, respectively. The total fair value of units vested during the years ended December 31, 2023, 2022 and 2021 was $9.1 million, $5.7 million and $15.9 million, respectively.
The fair value of the TSR Units is estimated on the date of grant using a Monte Carlo valuation model that uses the assumptions noted in the table below. The risk-free rate is based on the U.S. Treasury yield curve in effect at the grant date for the expected performance period. Expected volatility is based on historical volatility for the most recent 3-year period ending on the grant date for the Company and the selected peer companies, and is calculated on a daily basis. The following are the key assumptions used in this valuation:
202320222021
Risk free interest rate
3.98% - 4.13%
0.99% - 4.13%
0.17% - 0.99%
Expected stock price volatility
30.17% - 56.11%
53.60% - 56.11%
53.17% - 53.60%
Expected service period
3.0 years
3.0 years
3.0 years
Expected dividend yield (assuming full reinvestment)— %— %— %
During the years ended December 31, 2023, 2022 and 2021, the Company recognized $7.9 million, $7.5 million and $7.9 million, respectively, of stock-based compensation expense included in general and administrative expense in the consolidated statements of income (loss). As of December 31, 2023, there was $25.7 million of total unrecognized stock-based compensation expense related to unvested awards, which is expected to be recognized over a weighted average period of 2.7 years.
Employee Benefit Plan
The Company maintains a 401(k) plan that allows for eligible participants to defer compensation, subject to certain limitations imposed by the Internal Revenue Code of 1986, as amended (the “Code”). The Company provides a discretionary matching contribution of up to 4% of each participant’s eligible compensation. During each of the years ended December 31, 2023, 2022 and 2021, the Company’s matching contributions were $0.3 million.
XML 38 R23.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES
12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
The Company elected to be treated as a REIT with the filing of its U.S. federal income tax return for the taxable year beginning January 1, 2011. To qualify as a REIT, the Company must meet a number of organizational and operational requirements, including a requirement to distribute at least 90% of its taxable ordinary income. In addition, the Company is required to meet certain asset and income tests. As a REIT, the Company generally will not be subject to corporate level federal income tax on taxable income that it distributes to its stockholders. The Company also elected to treat certain of its consolidated subsidiaries as taxable REIT subsidiaries, which are subject to federal, state and foreign income taxes. In addition, as a result of our investments in Canada, the Company is subject to income taxes under the laws of Canada.
The following is a summary of the Company’s provision for income taxes and deferred taxes (in thousands):
Year Ended December 31,
202320222021
Provision for federal, state and local income taxes$2,002 $1,234 $2,263 
Provision (benefit) for foreign income taxes— (418)
Income tax expense$2,002 $1,242 $1,845 
As of December 31,
20232022
Deferred tax assets:
Federal$9,553 $6,390 
Valuation allowance on federal(9,553)(6,390)
Foreign12,211 8,455 
Valuation allowance on foreign(12,169)(8,430)
Deferred tax (liabilities):
Foreign(42)(25)
$— $— 
The Company classifies interest and penalties from significant uncertain tax positions as interest expense and operating expenses, respectively, in its consolidated financial statements. During the years ended December 31, 2023, 2022 and 2021, the Company did not incur any such interest or penalties. With certain exceptions, the tax years 2020 and thereafter remain open to examination by the major taxing jurisdictions with which the Company files tax returns.
XML 39 R24.htm IDEA: XBRL DOCUMENT v3.24.0.1
EARNINGS PER COMMON SHARE
12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
EARNINGS PER COMMON SHARE EARNINGS PER COMMON SHARE
The following table illustrates the computation of basic and diluted earnings per share (in thousands, except share and per share amounts):
Year Ended December 31,
202320222021
Numerator
Net income (loss)$13,756 $(77,605)$(113,256)
Denominator
Basic weighted average common shares and common equivalents231,203,391 230,947,895 219,073,027 
Dilutive restricted stock units1,589,387 — — 
Diluted weighted average common shares232,792,778 230,947,895 219,073,027 
Net income (loss), per:
Basic common share$0.06 $(0.34)$(0.52)
Diluted common share$0.06 $(0.34)$(0.52)
During the years ended December 31, 2023, 2022 and 2021, approximately 500, 0.9 million and 1.0 million restricted stock units, respectively, and during the year ended December 31, 2021, approximately 25,000 shares related to forward equity sale agreements, were not included in computing diluted earnings per share because they were considered anti-dilutive.
XML 40 R25.htm IDEA: XBRL DOCUMENT v3.24.0.1
COMMITMENTS AND CONTINGENCIES
12 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
Environmental
As an owner of real estate, the Company is subject to various environmental laws of federal, state and local governments. The Company is not aware of any environmental liability that could have a material adverse effect on its financial condition or results of operations. However, changes in applicable environmental laws and regulations, the uses and conditions of properties in the vicinity of the Company’s properties, the activities of its tenants and other environmental conditions of which the Company is unaware with respect to the properties could result in future environmental liabilities. As of December 31, 2023,
the Company does not expect that compliance with existing environmental laws will have a material adverse effect on the Company’s financial condition and results of operations.
Legal Matters
From time to time, the Company and its subsidiaries are party to legal proceedings that arise in the ordinary course of its business. Management is not aware of any legal proceedings where the likelihood of a loss contingency is reasonably possible and the amount or range of reasonably possible losses is material to the Company’s results of operations, financial condition or cash flows.
XML 41 R26.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUBSEQUENT EVENTS
12 Months Ended
Dec. 31, 2023
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS SUBSEQUENT EVENTS
The Company evaluates subsequent events up until the date the consolidated financial statements are issued.
Dividend Declaration
On February 1, 2024, the Company’s board of directors declared a quarterly cash dividend of $0.30 per share of common stock. The dividend will be paid on February 29, 2024 to common stockholders of record as of the close of business on February 13, 2024.
XML 42 R27.htm IDEA: XBRL DOCUMENT v3.24.0.1
SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION
12 Months Ended
Dec. 31, 2023
SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation Disclosure [Abstract]  
SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION
SCHEDULE III
REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION
As of December 31, 2023
(dollars in thousands)
Initial Cost to CompanyCost Capitalized Subsequent to AcquisitionGross Amount at which Carried at Close of PeriodLife on Which Depreciation in Latest Income Statement is Computed
 DescriptionOwnership Percentage
Encum- brances(1)
Land 
Building and Improve- ments(2)(3)
Total 
Land 
Building and Improve- ments(2)(3)
Total Accumulated Depreciation and AmortizationOriginal Date of Construction/ Renovation 
Date Acquired
Skilled Nursing/Transitional Care Facilities         
Bedford, NH100%$5,006 $1,911 $12,245 $14,156 $— $1,911 $10,546 $12,457 $(5,272)1992/2010, 201911/15/1036
Milford, NH100%— 312 1,679 1,991 — 312 1,168 1,480 (986)1890/200511/15/1020
North Conway, NH100%10,337 417 5,352 5,769 — 417 4,374 4,791 (2,006)1988/200911/15/1043
Wolfeboro, NH100%8,708 454 4,531 4,985 — 454 3,747 4,201 (1,669)1984/1986, 1987, 200911/15/1041
Middletown, DE100%— 1,650 21,730 23,380 — 1,650 21,730 23,380 (7,574)200508/01/1140
Dover, DE100%— 4,940 15,500 20,440 — 4,940 15,500 20,440 (5,676)1996/201608/01/1140
Wilmington, DE100%— 2,460 25,240 27,700 12,436 2,460 37,676 40,136 (9,841)2009/202208/01/1140
Millsboro, DE100%— 1,640 22,620 24,260 — 1,632 22,620 24,252 (8,095)200808/01/1140
Warrington, PA100%— 2,617 11,662 14,279 395 2,617 288 2,905 — 1958/2009/ 201603/30/1240
Duffield, VA100%— 509 5,018 5,527 1,333 509 5,964 6,473 (2,388)1981/201305/10/1240
Arlington, TX100%— 3,783 14,219 18,002 — 3,783 13,702 17,485 (3,956)2003/201211/30/1240
Rockport, TX100%— 1,005 6,628 7,633 — 1,005 6,212 7,217 (1,824)2002/2012, 201811/30/1240
Lincoln, NE100%— 6,368 29,919 36,287 — 6,368 29,919 36,287 (8,351)1962/1996, 201302/14/1440
Fremont, NE100%— 615 16,176 16,791 — 615 16,176 16,791 (4,953)200802/14/1440
Fremont, NE100%— 615 2,943 3,558 — 615 2,943 3,558 (1,069)1970/1979, 1983, 199402/14/1440
Bartlesville, OK100%— 1,332 6,904 8,236 986 1,332 7,890 9,222 (2,190)1989/201910/29/1440
Oklahoma City, OK100%— 2,189 23,567 25,756 2,534 2,189 25,749 27,938 (6,639)1963/1984, 2018, 201910/29/1440
Norman, OK100%— 869 5,236 6,105 785 869 6,021 6,890 (1,847)2001/2013, 201910/29/1440
Minneapolis, MN100%— 2,931 6,943 9,874 1,190 2,931 7,999 10,930 (1,800)1941/2014, 201908/17/1740
Eugene, OR100%— 2,205 28,700 30,905 2,252 2,205 30,952 33,157 (5,883)1988/201608/17/1740
Lebanon, OR100%— 958 14,176 15,134 — 958 14,176 15,134 (2,427)197408/17/1740
Portland, OR100%— 1,791 12,833 14,624 2,761 1,791 15,594 17,385 (3,466)1964/201608/17/1740
Initial Cost to CompanyCost Capitalized Subsequent to AcquisitionGross Amount at which Carried at Close of PeriodLife on Which Depreciation in Latest Income Statement is Computed
 DescriptionOwnership Percentage
Encum- brances(1)
Land 
Building and Improve- ments(2)(3)
Total 
Land 
Building and Improve- ments(2)(3)
Total Accumulated Depreciation and AmortizationOriginal Date of Construction/ Renovation 
Date Acquired
Tigard, OR100%— 2,011 11,667 13,678 — 2,011 11,667 13,678 (2,064)197508/17/1740
Hillsboro, OR100%— 1,387 14,028 15,415 — 1,387 14,028 15,415 (2,399)197308/17/1740
Junction City, OR100%— 584 7,901 8,485 — 584 7,901 8,485 (1,403)1966/201508/17/1740
Eugene, OR100%— 1,380 14,921 16,301 1,791 1,380 16,712 18,092 (3,421)1966/201608/17/1740
Coos Bay, OR100%— 829 8,518 9,347 — 829 8,518 9,347 (1,569)196808/17/1740
Gladstone, OR100%— 792 5,000 5,792 — 792 5,000 5,792 (907)196108/17/1740
Newport, OR100%— 406 5,001 5,407 — 406 5,001 5,407 (866)1973/201408/17/1740
Oregon City, OR100%— 1,496 12,142 13,638 — 1,496 12,142 13,638 (2,076)197408/17/1740
Tacoma, WA100%— 1,771 11,595 13,366 15 1,771 11,610 13,381 (2,313)201708/17/1740
Shoreline, WA100%— 4,703 14,444 19,147 — 4,703 14,444 19,147 (2,559)1993/201408/17/1740
Bellingham, WA100%— — 15,330 15,330 — — 15,330 15,330 (2,740)1984/201508/17/1740
Sequim, WA100%— 427 4,450 4,877 — 427 4,450 4,877 (954)197408/17/1740
Tacoma, WA100%— 1,705 4,952 6,657 — 1,705 4,952 6,657 (925)196808/17/1740
Tacoma, WA100%— 2,195 1,956 4,151 — 2,195 1,956 4,151 (484)1972/201408/17/1740
Vancouver, WA100%— 1,782 15,116 16,898 — 1,782 15,116 16,898 (2,798)199108/17/1740
Lake Oswego, OR100%— 5,947 13,401 19,348 — 5,947 13,401 19,348 (2,395)2005/201608/17/1740
Medford, OR100%— 2,043 38,485 40,528 2,960 2,043 41,445 43,488 (7,773)1974/201608/17/1740
Seattle, WA100%— 2,508 6,401 8,909 — 2,508 6,401 8,909 (1,158)197008/17/1740
Boise, ID100%— 681 9,348 10,029 627 681 9,975 10,656 (1,774)197908/17/1740
Salem, OR100%— 2,114 15,651 17,765 — 2,114 15,651 17,765 (2,758)198108/17/1740
Medford, OR100%— 1,375 23,808 25,183 — 1,375 23,808 25,183 (4,231)1961/201608/17/1740
Northglenn, CO100%— 1,662 26,014 27,676 3,258 1,662 29,272 30,934 (5,916)1972/201608/17/1740
Brighton, CO100%— 1,933 11,624 13,557 200 1,933 11,824 13,757 (2,166)197108/17/1740
Santa Ana, CA100%— 1,889 11,682 13,571 — 1,889 11,682 13,571 (1,947)200808/17/1740
La Mesa, CA100%— 1,276 8,177 9,453 — 1,276 8,177 9,453 (1,416)201208/17/1740
Westminster, MD100%— 2,128 6,614 8,742 487 2,128 6,978 9,106 (1,618)1973/2010, 201908/17/1740
Initial Cost to CompanyCost Capitalized Subsequent to AcquisitionGross Amount at which Carried at Close of PeriodLife on Which Depreciation in Latest Income Statement is Computed
 DescriptionOwnership Percentage
Encum- brances(1)
Land 
Building and Improve- ments(2)(3)
Total 
Land 
Building and Improve- ments(2)(3)
Total Accumulated Depreciation and AmortizationOriginal Date of Construction/ Renovation 
Date Acquired
Kansas City, MO100%— 1,985 2,714 4,699 303 1,714 — 1,714 — 198308/17/1740
Parkersburg, WV100%— 697 10,688 11,385 285 697 10,911 11,608 (2,428)1974/1999, 201908/17/1740
Cincinnati, OH100%— 2,686 10,062 12,748 295 2,686 10,357 13,043 (2,058)1989/201508/17/1740
Charlottesville, VA100%— 2,840 8,450 11,290 1,176 2,840 9,523 12,363 (2,334)1964/2009, 201908/17/1740
Annandale, VA100%— 7,241 17,727 24,968 3,218 7,241 20,864 28,105 (4,579)1963/2013, 201908/17/1740
Petersburg, VA100%— 988 8,416 9,404 146 988 8,478 9,466 (1,672)1970/200908/17/1740
Petersburg, VA100%— 1,174 8,858 10,032 151 1,174 8,942 10,116 (1,749)1976/201008/17/1740
Hagerstown, MD100%— 1,393 13,438 14,831 150 1,393 13,477 14,870 (2,501)1971/201008/17/1740
Cumberland, MD100%— 800 16,973 17,773 457 800 17,305 18,105 (3,237)196808/17/1740
Gilroy, CA100%— 662 23,775 24,437 — 662 23,775 24,437 (4,022)1968/202108/17/1740
Mount Pleasant, SC100%— 2,689 3,942 6,631 205 2,689 4,147 6,836 (831)1977/201508/17/1740
Harrogate, TN100%— 1,811 4,963 6,774 — 1,811 4,963 6,774 (1,054)1990/200508/17/1740
Conway, SC100%— 1,408 10,784 12,192 295 1,408 11,079 12,487 (2,075)197508/17/1740
Baytown, TX100%— 426 3,236 3,662 173 426 3,251 3,677 (683)1975/201908/17/1740
Huntsville, TX100%— 302 3,153 3,455 75 302 3,168 3,470 (644)1968/201908/17/1740
Center, TX100%— 231 1,335 1,566 312 231 1,477 1,708 (398)1972/201908/17/1740
Humble, TX100%— 2,114 1,643 3,757 596 2,114 1,953 4,067 (571)1972/201908/17/1740
Houston, TX100%— 1,019 5,734 6,753 318 1,019 5,807 6,826 (1,124)1982/201908/17/1740
Linden, TX100%— 112 256 368 133 112 280 392 (98)1968/201908/17/1740
Sherman, TX100%— 469 6,310 6,779 255 469 6,338 6,807 (1,188)1971/201908/17/1740
Mount Pleasant, TX100%— 250 6,913 7,163 345 250 7,160 7,410 (1,372)1970/201908/17/1740
Waxahachie, TX100%— 416 7,259 7,675 976 416 8,106 8,522 (1,618)1976/201908/17/1740
Gilmer, TX100%— 707 4,552 5,259 93 707 4,562 5,269 (910)1990/201908/17/1740
Sparks, NV100%— 1,986 9,004 10,990 — 1,986 9,004 10,990 (1,714)198808/17/1740
Richmond, IN100%— 259 9,819 10,078 131 259 9,950 10,209 (1,856)1975/200508/17/1740
Petersburg, IN100%— 581 5,367 5,948 23 581 5,390 5,971 (1,054)1970/200908/17/1740
Maryville, MO100%— 114 5,955 6,069 — 150 5,955 6,105 (1,187)197208/17/1740
Initial Cost to CompanyCost Capitalized Subsequent to AcquisitionGross Amount at which Carried at Close of PeriodLife on Which Depreciation in Latest Income Statement is Computed
 DescriptionOwnership Percentage
Encum- brances(1)
Land 
Building and Improve- ments(2)(3)
Total 
Land 
Building and Improve- ments(2)(3)
Total Accumulated Depreciation and AmortizationOriginal Date of Construction/ Renovation 
Date Acquired
Ashland, MO100%— 765 2,669 3,434 — 229 628 857 — 199308/17/1740
St. Louis, MO100%— 2,071 5,739 7,810 — 375 818 1,193 — 1988/199108/17/1740
Doniphan, MO100%— 657 8,251 8,908 — 657 8,251 8,908 (1,551)199108/17/1740
Dixon, MO100%— 521 3,358 3,879 — 521 3,358 3,879 (684)1989/201108/17/1740
Forsyth, MO100%— 594 8,549 9,143 — 594 8,549 9,143 (1,631)1993/200708/17/1740
Seymour, MO100%— 658 901 1,559 — 658 901 1,559 (240)199008/17/1740
Silex, MO100%— 807 4,990 5,797 — 807 4,990 5,797 (965)199108/17/1740
Columbia, MO100%— 2,322 6,547 8,869 — 2,322 6,547 8,869 (1,287)199408/17/1740
Strafford, MO100%— 1,634 6,518 8,152 — 1,634 6,518 8,152 (1,253)199508/17/1740
Windsor, MO100%— 471 6,819 7,290 — 471 6,819 7,290 (1,188)199608/17/1740
Conroe, TX100%— 1,222 19,099 20,321 — 1,222 19,099 20,321 (3,251)200108/17/1740
Houston, TX100%— 1,334 11,615 12,949 — 1,334 11,615 12,949 (2,060)2003/201308/17/1740
Humble, TX100%— 1,541 12,332 13,873 645 1,541 12,977 14,518 (2,611)2003/201908/17/1740
Missouri City, TX100%— 1,825 9,681 11,506 — 1,825 9,681 11,506 (1,784)200508/17/1740
Houston, TX100%— 2,676 7,396 10,072 — 2,676 7,396 10,072 (1,394)200508/17/1740
Houston, TX100%— 1,732 12,921 14,653 — 1,732 12,921 14,653 (2,274)199908/17/1740
Topeka, KS100%— 176 2,340 2,516 — 176 2,340 2,516 (474)1973/201308/17/1740
Salina, KS100%— 301 4,201 4,502 — 301 4,201 4,502 (814)198108/17/1740
Terre Haute, IN100%— 1,067 7,061 8,128 — 1,067 7,061 8,128 (1,286)1965/198408/17/1740
Gas City, IN100%— 345 8,852 9,197 — 345 8,852 9,197 (1,536)1974/202208/17/1740
Winchester, IN100%— 711 5,554 6,265 — 711 5,554 6,265 (1,016)1986/1998, 202108/17/1740
Columbus, IN100%— 1,290 10,714 12,004 — 1,290 10,714 12,004 (1,868)1988/2004, 202208/17/1740
Portland, IN100%— 315 9,848 10,163 — 315 9,848 10,163 (1,743)1964/202208/17/1740
Clinton, IN100%— 884 9,839 10,723 — 884 9,839 10,723 (1,829)1971/202108/17/1740
Las Vegas, NV100%— 509 18,216 18,725 — 509 18,216 18,725 (3,036)196408/17/1740
Las Vegas, NV100%— 3,169 7,863 11,032 — 3,169 7,863 11,032 (1,477)1972/199708/17/1740
Alameda, CA100%— 3,078 22,328 25,406 — 3,078 22,328 25,406 (3,806)1967/202108/17/1740
Dover, NH100%— 522 5,839 6,361 — 522 5,839 6,361 (1,385)1969/1992, 201708/17/1740
Initial Cost to CompanyCost Capitalized Subsequent to AcquisitionGross Amount at which Carried at Close of PeriodLife on Which Depreciation in Latest Income Statement is Computed
 DescriptionOwnership Percentage
Encum- brances(1)
Land 
Building and Improve- ments(2)(3)
Total 
Land 
Building and Improve- ments(2)(3)
Total Accumulated Depreciation and AmortizationOriginal Date of Construction/ Renovation Date Acquired
Augusta, ME100%— 135 6,470 6,605 — 135 6,470 6,605 (1,206)196708/17/1740
Bangor, ME100%— 302 1,811 2,113 2,211 302 4,021 4,323 (1,019)1967/1993, 201908/17/1740
Bath, ME100%— 250 1,934 2,184 — 250 1,934 2,184 (402)197408/17/1740
Brewer, ME100%— 177 14,497 14,674 2,520 177 17,017 17,194 (3,371)1974/1990, 201908/17/1740
Kennebunk, ME100%— 198 6,822 7,020 2,005 198 8,827 9,025 (1,634)1977/202208/17/1740
Norway, ME100%— 791 3,680 4,471 — 791 3,680 4,471 (729)197608/17/1740
Yarmouth, ME100%— 134 2,072 2,206 — 134 2,072 2,206 (442)195208/17/1740
Marlborough, MA100%— 942 1,541 2,483 8,727 942 10,268 11,210 (3,468)1973/201808/17/1740
Bangor, ME100%— 229 7,171 7,400 511 229 7,682 7,911 (1,446)1969/1993, 202208/17/1740
Orange, CA100%— 4,163 14,755 18,918 — 4,163 14,755 18,918 (2,640)1987/202008/17/1740
Lancaster, TX100%— 548 5,794 6,342 — 548 5,794 6,342 (1,140)200808/17/1740
Garland, TX100%— 1,118 7,490 8,608 — 1,118 7,490 8,608 (1,403)200808/17/1740
Clarksville, TX100%— 279 4,269 4,548 100 279 4,369 4,648 (970)1989/201908/17/1740
McKinney, TX100%— 1,272 6,047 7,319 — 1,272 6,047 7,319 (1,217)200608/17/1740
Hopkins, MN100%— 807 4,668 5,475 530 807 5,198 6,005 (1,418)1961/2008, 201908/17/1740
Florence, WI100%— 291 3,778 4,069 — 291 3,778 4,069 (795)197008/17/1740
St. Francis, WI100%— 166 1,887 2,053 — 166 1,887 2,053 (412)1960/199708/17/1740
Rochester, MN100%— 645 7,067 7,712 178 645 7,245 7,890 (1,442)1967/2011, 201908/17/1740
Wisconsin Dells, WI100%— 1,640 1,599 3,239 — 1,640 1,599 3,239 (453)1972/200608/17/1740
Sheboygan, WI100%— 1,038 2,839 3,877 — 1,038 2,839 3,877 (681)1967/201208/17/1740
Hendersonville, NC100%— 1,611 3,503 5,114 — 1,611 3,503 5,114 (774)197908/17/1740
Baytown, TX100%— 579 22,317 22,896 103 579 22,419 22,998 (3,865)2000/201308/17/1740
Baytown, TX100%— 589 20,475 21,064 362 589 20,837 21,426 (3,830)200808/17/1740
Initial Cost to CompanyCost Capitalized Subsequent to AcquisitionGross Amount at which Carried at Close of PeriodLife on Which Depreciation in Latest Income Statement is Computed
 DescriptionOwnership Percentage
Encum- brances(1)
Land 
Building and Improve- ments(2)(3)
Total 
Land 
Building and Improve- ments(2)(3)
Total Accumulated Depreciation and AmortizationOriginal Date of Construction/ Renovation Date Acquired
Houston, TX100%— 1,300 13,353 14,653 31 1,300 13,384 14,684 (2,475)200608/17/1740
Pasadena, TX100%— 1,148 23,579 24,727 47 1,148 23,626 24,774 (4,142)200408/17/1740
Webster, TX100%— 904 10,315 11,219 24 904 10,338 11,242 (1,958)2000/200908/17/1740
Beaumont, TX100%— 945 20,424 21,369 272 945 20,696 21,641 (3,634)200908/17/1740
Orange, TX100%— 711 10,737 11,448 186 711 10,923 11,634 (2,014)200608/17/1740
Huntsville, AL100%— 634 28,071 28,705 19 634 28,089 28,723 (4,713)1968/201208/17/1740
Terre Haute, IN100%— 644 37,451 38,095 59 644 37,511 38,155 (7,069)1996/201308/17/1740
Madison, TN100%— 902 3,850 4,752 23 902 3,873 4,775 (886)1969/201608/17/1740
Savannah, GA100%— 1,235 3,765 5,000 18 1,235 3,783 5,018 (908)1970/201508/17/1740
Bowling Green, KY100%— 280 13,975 14,255 32 280 14,007 14,287 (2,597)1970/201508/17/1740
Calvert City, KY100%— 1,176 7,012 8,188 25 1,176 7,037 8,213 (1,385)1962/201508/17/1740
Winchester, KY100%— 554 13,207 13,761 43 554 13,250 13,804 (2,507)1967/201508/17/1740
Calhoun, KY100%— 613 7,643 8,256 30 613 7,673 8,286 (1,551)1963/201508/17/1740
Bremen, IN100%— 173 7,393 7,566 38 173 7,431 7,604 (1,373)1982/201508/17/1740
Muncie, IN100%— 374 27,429 27,803 38 374 27,467 27,841 (4,710)1980/201308/17/1740
Lebanon, IN100%— 612 11,755 12,367 39 612 11,794 12,406 (2,141)1977/201208/17/1740
Marietta, GA100%— 364 16,116 16,480 20 364 16,137 16,501 (3,004)1969/201508/17/1740
Danville, KY100%— 790 9,356 10,146 32 790 9,388 10,178 (2,048)1962/201508/17/1740
Owensboro, KY100%— 1,048 22,587 23,635 40 1,048 22,627 23,675 (4,031)1963/201108/17/1740
Memphis, TN100%— 1,633 9,371 11,004 21 1,633 9,392 11,025 (1,832)1981/201508/17/1740
Norfolk, VA100%— 705 16,451 17,156 33 705 16,485 17,190 (3,322)1969/201508/17/1740
Harrodsburg, KY100%— 1,049 9,851 10,900 21 1,049 9,872 10,921 (2,050)1975/201608/17/1740
Cookeville, TN100%— 1,034 15,555 16,589 32 1,034 15,586 16,620 (2,841)1979/201608/17/1740
Washington Court House, OH100%— 405 4,839 5,244 20 405 4,859 5,264 (1,049)1984/201508/17/1740
Galion, OH100%— 836 668 1,504 14 836 683 1,519 (237)1967/198508/17/1740
Roanoke Rapids, NC100%— 373 10,308 10,681 25 373 10,334 10,707 (2,070)1967/201508/17/1740
Kinston, NC100%— 954 7,987 8,941 73 954 8,059 9,013 (1,807)1960/201508/17/1740
Chapel Hill, NC100%— 809 2,703 3,512 1,191 809 3,893 4,702 (964)1984/201508/17/1740
Chillicothe, OH100%— 260 8,924 9,184 19 260 8,943 9,203 (1,850)1974/201508/17/1740
Coshocton, OH100%— 374 2,530 2,904 37 374 2,567 2,941 (715)1974/201508/17/1740
Pine Knot, KY100%— 208 7,665 7,873 23 208 7,689 7,897 (1,447)199008/17/1740
Initial Cost to CompanyCost Capitalized Subsequent to AcquisitionGross Amount at which Carried at Close of PeriodLife on Which Depreciation in Latest Income Statement is Computed
 DescriptionOwnership Percentage
Encum- brances(1)
Land 
Building and Improve- ments(2)(3)
Total 
Land 
Building and Improve- ments(2)(3)
Total Accumulated Depreciation and AmortizationOriginal Date of Construction/ Renovation Date Acquired
Bardstown, KY100%— 634 4,094 4,728 16 634 4,110 4,744 (903)1968/201008/17/1740
Glasgow, KY100%— 83 2,057 2,140 28 83 2,086 2,169 (552)196808/17/1740
Carrollton, KY100%— 124 1,693 1,817 21 124 1,714 1,838 (476)1978/201608/17/1740
Horse Cave, KY100%— 208 7,070 7,278 38 208 7,108 7,316 (1,460)199308/17/1740
Lawrenceburg, KY100%— 635 9,861 10,496 17 635 9,879 10,514 (1,887)197308/17/1740
Annville, KY100%— 479 6,078 6,557 17 479 6,095 6,574 (1,140)198908/17/1740
Louisville, KY100%— 3,528 4,653 8,181 24 3,528 4,677 8,205 (1,095)1982/201208/17/1740
Louisville, KY100%— 2,207 20,733 22,940 29 2,207 20,761 22,968 (3,667)1991/201008/17/1740
Tompkinsville, KY100%— 333 9,556 9,889 26 333 9,582 9,915 (1,809)196908/17/1740
Radcliff, KY100%— 1,815 7,470 9,285 34 1,815 7,504 9,319 (1,793)198608/17/1740
Hartford, KY100%— 312 8,189 8,501 21 312 8,210 8,522 (1,583)196708/17/1740
Louisville, KY100%— 427 6,003 6,430 21 427 6,023 6,450 (1,237)1975/200508/17/1740
Louisville, KY100%— 1,134 9,166 10,300 28 1,134 9,194 10,328 (1,938)1979/201308/17/1740
Lexington, KY100%— 2,558 4,311 6,869 51 2,558 4,361 6,919 (998)198908/17/1740
Columbia, KY100%— 114 11,141 11,255 28 114 11,169 11,283 (2,063)196508/17/1740
Monticello, AR100%— 206 3,179 3,385 — 206 3,179 3,385 (704)199508/17/1740
Benton, AR100%— 1,336 7,386 8,722 — 1,336 7,386 8,722 (1,493)199208/17/1740
Wynne, AR100%— 227 4,007 4,234 — 227 4,007 4,234 (818)199008/17/1740
Morrilton, AR100%— 412 2,642 3,054 3,038 467 5,680 6,147 (936)1996/202208/17/1740
Bryant, AR100%— 819 8,938 9,757 — 819 8,938 9,757 (1,609)1989/201508/17/1740
Savannah, GA100%— 2,194 11,711 13,905 — 2,194 11,711 13,905 (2,080)197208/17/1740
Initial Cost to CompanyCost Capitalized Subsequent to AcquisitionGross Amount at which Carried at Close of PeriodLife on Which Depreciation in Latest Income Statement is Computed
 DescriptionOwnership Percentage
Encum- brances(1)
Land 
Building and Improve- ments(2)(3)
Total 
Land 
Building and Improve- ments(2)(3)
Total Accumulated Depreciation and AmortizationOriginal Date of Construction/ Renovation Date Acquired
Durham, NC100%— 470 9,633 10,103 — 470 9,633 10,103 (1,695)1968/200608/17/1740
Raleigh, NC100%— 1,155 11,749 12,904 — 1,155 11,749 12,904 (2,117)197108/17/1740
Raleigh, NC100%— 926 17,649 18,575 — 926 17,649 18,575 (3,125)1967/200708/17/1740
Wilmington, NC100%— 611 5,051 5,662 — 611 5,051 5,662 (1,015)1966/201308/17/1740
Winston-Salem, NC100%— 879 3,283 4,162 — 879 3,283 4,162 (753)196508/17/1740
Lincolnton, NC100%— — 9,967 9,967 — — 9,967 9,967 (1,803)197608/17/1740
Monroe, NC100%— 166 5,906 6,072 — 166 5,906 6,072 (1,189)1963/200508/17/1740
Zebulon, NC100%— 594 8,559 9,153 — 594 8,559 9,153 (1,486)1973/201008/17/1740
Rocky Mount, NC100%— — 18,314 18,314 — — 18,314 18,314 (3,123)197508/17/1740
DeSoto, TX100%— 942 6,033 6,975 320 942 6,353 7,295 (1,236)198708/17/1740
Trinity, TX100%— 363 3,852 4,215 — 363 3,852 4,215 (822)1985/201908/17/1740
Kirbyville, TX100%— 208 5,809 6,017 — 208 5,809 6,017 (1,186)198708/17/1740
Marshall, TX100%— 732 4,288 5,020 — 732 4,288 5,020 (901)200808/17/1740
Warren, MI100%— 2,052 25,539 27,591 — 2,052 25,539 27,591 (5,009)1961/200108/17/1740
Hamburg, NY100%— 1,026 54,086 55,112 — 1,026 54,086 55,112 (9,273)1983/201408/17/1740
East Patchogue, NY100%— 2,181 30,373 32,554 — 2,181 30,373 32,554 (5,478)1988/201108/17/1740
Williamsville, NY100%— 1,122 46,413 47,535 — 1,122 46,413 47,535 (7,814)1992/200708/17/1740
Cheektowaga, NY100%— 1,164 29,905 31,069 — 1,164 29,905 31,069 (5,335)1979/200608/17/1740
North Tonawanda, NY100%— 830 29,488 30,318 — 830 29,488 30,318 (5,259)1982/200708/17/1740
West Seneca, NY100%— 1,325 26,839 28,164 — 1,325 26,839 28,164 (4,698)1974/200808/17/1740
Beverly, MA100%— 2,410 13,588 15,998 — 2,410 13,588 15,998 (3,199)1965/201508/17/1740
Initial Cost to CompanyCost Capitalized Subsequent to AcquisitionGross Amount at which Carried at Close of PeriodLife on Which Depreciation in Latest Income Statement is Computed
 DescriptionOwnership Percentage
Encum- brances(1)
Land 
Building and Improve- ments(2)(3)
Total 
Land 
Building and Improve- ments(2)(3)
Total Accumulated Depreciation and AmortizationOriginal Date of Construction/ Renovation Date Acquired
Lancaster, MA100%— 343 7,733 8,076 — 343 7,733 8,076 (1,407)1970/200508/17/1740
New London, CT100%— 505 2,248 2,753 48 505 2,296 2,801 (712)1967/201608/17/1740
Enfield, CT100%— 437 16,461 16,898 231 437 16,693 17,130 (3,085)1968/201508/17/1740
Quincy, MA100%— 894 904 1,798 129 894 1,033 1,927 (335)1965/200308/17/1740
Fishkill, NY100%— 964 30,107 31,071 421 964 30,518 31,482 (5,495)199508/17/1740
Highland, NY100%— 4,371 11,473 15,844 260 4,371 11,733 16,104 (2,252)199808/17/1740
Beacon, NY100%— — 25,400 25,400 267 — 25,666 25,666 (4,802)200208/17/1740
Springfield, MA100%— 817 11,357 12,174 386 817 11,743 12,560 (2,094)198708/17/1740
Andover, MA100%— 2,123 5,383 7,506 18 2,123 5,401 7,524 (1,131)199208/17/1740
Reading, MA100%— 1,534 5,221 6,755 540 1,534 5,760 7,294 (1,216)198808/17/1740
Sudbury, MA100%— 2,017 3,458 5,475 421 2,017 3,879 5,896 (922)1997/202108/17/1740
Lowell, MA100%— 1,335 9,019 10,354 489 1,335 9,508 10,843 (1,847)1966/200708/17/1740
Worcester, MA100%— 945 8,770 9,715 50 945 8,820 9,765 (1,693)1970/198808/17/1740
W. Springfield, MA100%— 2,022 7,345 9,367 — 2,022 7,345 9,367 (1,556)1960/198508/17/1740
East Longmeadow, MA100%— 2,968 8,957 11,925 790 2,968 9,748 12,716 (2,055)1985/200508/17/1740
Long Beach, CA100%— 2,939 11,782 14,721 — 2,939 11,690 14,629 (2,246)1968/201109/19/1740
Anaheim, CA100%— 2,044 14,167 16,211 — 2,044 14,167 16,211 (2,643)1968/201109/19/1740
Fairfield, CA100%— 586 23,582 24,168 — 586 23,582 24,168 (4,095)1966/200609/19/1740
Baldwin Park, CA100%— 2,270 17,063 19,333 — 2,270 17,063 19,333 (3,126)1970/201509/19/1740
Grand Terrace, CA100%— 432 9,382 9,814 — 432 9,382 9,814 (1,732)1945/201709/19/1740
Pacifica, CA100%— 1,510 27,397 28,907 — 1,510 27,397 28,907 (4,692)197509/19/1740
Burien, WA100%— 823 17,431 18,254 — 826 17,431 18,257 (3,145)1965/201409/19/1740
Seattle, WA100%— 4,802 7,927 12,729 — 4,802 7,927 12,729 (1,604)1963/201609/19/1740
Huntington Bch, CA100%— 2,312 9,885 12,197 — 2,312 9,885 12,197 (1,817)1965/201009/19/1740
Initial Cost to CompanyCost Capitalized Subsequent to AcquisitionGross Amount at which Carried at Close of PeriodLife on Which Depreciation in Latest Income Statement is Computed
 DescriptionOwnership Percentage
Encum- brances(1)
Land 
Building and Improve- ments(2)(3)
Total 
Land 
Building and Improve- ments(2)(3)
Total Accumulated Depreciation and AmortizationOriginal Date of Construction/ Renovation Date Acquired
Chatsworth, CA100%— 7,841 16,916 24,757 — 7,841 16,916 24,757 (3,239)197609/19/1740
Woodland, CA100%— 504 7,369 7,873 — 504 7,369 7,873 (1,425)1975/201009/19/1740
Danville, CA100%— 1,491 17,157 18,648 — 1,491 17,157 18,648 (3,074)196509/19/1740
Van Nuys, CA100%— 2,456 16,462 18,918 — 2,456 16,462 18,918 (2,841)1958/201509/19/1740
Lomita, CA100%— 2,743 14,734 17,477 — 2,743 14,734 17,477 (2,763)196909/19/1740
Sacramento, CA100%— 2,846 17,962 20,808 — 2,846 17,962 20,808 (3,178)197209/19/1740
Issaquah, WA100%— 10,125 7,771 17,896 — 10,125 7,771 17,896 (1,653)1975/201209/19/1740
Long Beach, CA100%— 3,157 22,067 25,224 — 3,157 22,067 25,224 (4,001)1966/201409/19/1740
Long Beach, CA100%— 2,857 5,878 8,735 — 2,857 5,878 8,735 (1,150)1952/201309/19/1740
Lodi, CA100%— 812 21,059 21,871 — 812 21,059 21,871 (3,553)196509/19/1740
Riverside, CA100%— 1,717 13,806 15,523 — 1,717 13,806 15,523 (2,725)196609/19/1740
Woodland, CA100%— 278 16,729 17,007 — 278 16,729 17,007 (2,990)1930/200709/19/1740
Bee Cave, TX100%— 2,107 10,413 12,520 — 2,107 10,413 12,520 (2,147)201412/15/1740
El Monte, CA100%— 2,058 19,671 21,729 — 2,058 19,671 21,729 (3,401)196501/10/1840
Shoreline, WA100%— 8,861 11,478 20,339 103 8,861 11,580 20,441 (2,368)1964/201201/19/1840
Elizabethtown, KY100%— 729 — 729 19,329 729 19,329 20,058 (479)202105/27/2140
Crown Point, IN100%— 1,522 14,951 16,473 — 1,522 14,951 16,473 (78)201511/01/2340
Dyer, IN100%— 1,859 19,547 21,406 — 1,859 19,547 21,406 (100)201511/01/2340
24,051 328,000 2,663,453 2,991,453 91,777 325,583 2,725,278 3,050,861 (535,653)  
Senior Housing - Leased        
Exeter, NH100%1,880 571 7,183 7,754 — 571 5,912 6,483 (2,771)198711/15/1043
Nashua, NH100%4,457 — 5,654 5,654 — — 4,566 4,566 (1,949)198911/15/1040
Keene, NH100%3,237 304 3,992 4,296 — 304 3,263 3,567 (1,650)199511/15/1046
Dover, NH100%2,335 801 10,036 10,837 — 801 8,584 9,385 (4,002)1987/2009, 201911/15/1042
Green Bay, WI100%— 256 2,262 2,518 1,032 256 1,976 2,232 (767)2004/201111/22/1140
Rockport, TX100%— 789 607 1,396 — 789 475 1,264 (183)1996/201811/30/1240
Cadillac, MI100%— 217 3,000 3,217 — 217 2,920 3,137 (910)2001/2006, 202312/14/1240
Initial Cost to CompanyCost Capitalized Subsequent to AcquisitionGross Amount at which Carried at Close of PeriodLife on Which Depreciation in Latest Income Statement is Computed
 DescriptionOwnership Percentage
Encum- brances(1)
Land 
Building and Improve- ments(2)(3)
Total 
Land 
Building and Improve- ments(2)(3)
Total Accumulated Depreciation and AmortizationOriginal Date of Construction/ Renovation Date Acquired
Greenville, MI100%— 684 5,832 6,516 249 684 5,841 6,525 (1,876)1999/2001, 2012, 2013, 201812/14/1240
Manistee, MI100%— 952 2,578 3,530 2,547 952 5,076 6,028 (1,970)2002/201712/14/1240
Mason, MI100%— 198 4,131 4,329 — 198 4,032 4,230 (1,323)2009/201212/14/1240
Alpena, MI100%— 546 13,139 13,685 — 546 13,000 13,546 (3,763)2006/2008, 201012/14/1240
Fremont, NE100%— 504 17,670 18,174 — 504 17,670 18,174 (5,020)1989/200202/14/1440
Norfolk, NE100%— 217 9,906 10,123 4,680 217 14,586 14,803 (4,284)1989/1991, 1994, 2018, 201902/14/1440
Fort Wayne, IN100%12,183 2,300 21,115 23,415 2,747 2,300 23,846 26,146 (7,799)2011/2016, 201804/30/1440
Brandon, FL100%— 1,283 8,424 9,707 483 1,283 8,722 10,005 (2,532)1999/201610/01/1440
Lecanto, FL100%— 1,031 5,577 6,608 615 1,023 6,053 7,076 (2,026)1997/201610/01/1440
Zephyrhills, FL100%— 1,688 9,098 10,786 360 1,688 9,343 11,031 (2,924)2008/201610/01/1440
Sun City West, AZ100%— 930 9,170 10,100 248 930 9,418 10,348 (2,188)201207/01/1640
Fredericksburg, VA100%— 1,379 21,209 22,588 — 1,379 21,209 22,588 (4,644)201607/14/1640
Round Rock, TX100%— 679 13,642 14,321 — 679 13,642 14,321 (3,035)201608/01/1640
Santa Fe, NM100%— 1,866 19,441 21,307 — 2,157 21,736 23,893 (4,587)200609/23/1640
Santa Fe, NM100%— 670 7,743 8,413 430 670 8,571 9,241 (810)202009/23/1640
Franklin, NH100%— 292 6,889 7,181 211 292 7,110 7,402 (1,700)198811/30/1640
Henderson, NV100%— 1,430 21,850 23,280 — 1,430 21,862 23,292 (4,411)201612/01/1640
Brenham, TX100%— 476 11,912 12,388 — 476 11,922 12,398 (2,753)199112/02/1640
Cedar Park, TX100%— 1,035 13,127 14,162 — 1,035 13,127 14,162 (2,546)201706/01/1740
Keizer, OR100%— 1,220 31,783 33,003 — 1,220 31,783 33,003 (5,435)1970/202108/17/1740
Lawrence, KS100%— 584 4,431 5,015 — 584 4,431 5,015 (849)1995/201408/17/1740
Salina, KS100%— 584 3,020 3,604 — 584 3,020 3,604 (575)1989/201408/17/1740
Topeka, KS100%— 313 5,492 5,805 — 313 5,492 5,805 (967)1986/201408/17/1740
Lafayette, CO100%— 1,085 19,243 20,328 1,883 19,205 21,088 (3,382)201612/15/1740
Winnebago, IL100%— 263 3,743 4,006 — 263 3,743 4,006 (707)200701/31/1840
Pewaukee, WI100%— 1,019 3,606 4,625 — 1,019 3,606 4,625 (635)201004/16/1840
Pewaukee, WI100%— 661 5,680 6,341 — 661 5,680 6,341 (923)201504/16/1840
Sarasota, FL100%— 1,440 22,541 23,981 — 1,440 22,541 23,981 (3,495)201805/18/1840
Knoxville, TN100%— 1,603 9,219 10,822 — 1,603 9,219 10,822 (1,651)201708/31/1840
Initial Cost to CompanyCost Capitalized Subsequent to AcquisitionGross Amount at which Carried at Close of PeriodLife on Which Depreciation in Latest Income Statement is Computed
 DescriptionOwnership Percentage
Encum- brances(1)
Land 
Building and Improve- ments(2)(3)
Total 
Land 
Building and Improve- ments(2)(3)
Total Accumulated Depreciation and AmortizationOriginal Date of Construction/ Renovation Date Acquired
Shavano Park, TX100%— 2,131 11,541 13,672 — 2,131 11,541 13,672 (1,890)201508/31/1840
Beavercreek, OH100%— 1,622 24,215 25,837 7,561 1,622 31,773 33,395 (5,805)201611/01/1840
McCordsville, IN100%— 1,587 31,315 32,902 — 1,587 31,315 32,902 (3,487)201701/07/2040
Louisville, KY100%— 1,841 21,827 23,668 — 1,841 21,827 23,668 (2,359)201501/31/2040
Sellersburg, IN100%— 1,060 28,702 29,762 5,504 1,060 34,206 35,266 (3,336)201504/01/2040
Jasper, IN100%— 657 25,226 25,883 — 657 25,226 25,883 (1,614)201910/01/2140
Norman, OK100%— 557 2,663 3,220 1,135 557 3,798 4,355 (68)199902/01/2340
24,092 39,325 509,434 548,759 27,811 40,406 532,868 573,274 (109,601)
Senior Housing - Managed
Frankenmuth, MI100%— 5,027 20,929 25,956 637 5,027 21,170 26,197 (6,342)1982/200809/21/1240
Gaylord, MI100%— 2,024 5,467 7,491 141 2,024 5,583 7,607 (2,060)200212/14/1240
East Tawas, MI100%— 258 3,713 3,971 399 258 3,984 4,242 (1,551)200512/14/1240
Marshfield, WI100%— 574 8,733 9,307 220 574 8,803 9,377 (2,623)201012/18/1240
Woodstock, VA100%— 597 5,465 6,062 117 597 5,448 6,045 (1,538)1996/201506/28/1340
Allen, TX100%— 2,190 45,767 47,957 948 2,190 50,510 52,700 (12,723)2004/201009/25/1440
Gainesville, FL100%— 2,139 44,789 46,928 1,562 2,139 49,736 51,875 (13,797)1986/2013, 2015, 201909/25/1440
McKinney, TX100%— 2,760 44,397 47,157 1,497 2,760 49,615 52,375 (12,854)2006/2010, 201909/25/1440
Raleigh, NC100%— 2,344 37,506 39,850 1,749 2,344 43,072 45,416 (10,650)2002/2014, 202209/25/1440
San Luis Obispo, CA100%— 4,992 30,909 35,901 1,117 4,992 35,062 40,054 (9,094)1987/2006, 2015, 202109/25/1440
Winston-Salem, NC100%— 2,995 24,428 27,423 676 2,995 26,841 29,836 (7,132)200109/25/1440
Longview, TX100%— 805 26,498 27,303 824 805 27,972 28,777 (7,930)1985/201009/25/1440
Kansas City, MO100%— 1,325 20,510 21,835 923 1,325 25,844 27,169 (6,657)198309/25/1440
Yuma, AZ100%— 530 21,775 22,305 484 530 22,678 23,208 (6,226)1996/201409/25/1440
Nashville, TN100%— 1,996 19,368 21,364 1,227 1,996 21,607 23,603 (6,530)1986/200009/25/1440
Branford, CT100%— 2,403 18,821 21,224 732 2,403 22,939 25,342 (5,668)198709/25/1440
Richmond, VA100%— 1,080 19,545 20,625 1,602 1,080 23,606 24,686 (6,296)1989/2007, 202209/25/1440
Auburn, AL100%— 3,209 17,326 20,535 516 3,209 18,482 21,691 (5,259)200109/25/1440
Menomonee Falls, WI100%— 1,477 18,778 20,255 426 1,477 20,272 21,749 (5,690) 2005/2006, 2007/2011, 201909/25/1440
Glenville, NY100%— 978 18,257 19,235 571 978 19,711 20,689 (5,564)2001/201409/25/1440
Eustis, FL100%— 1,152 17,523 18,675 606 1,152 18,811 19,963 (5,669)1984/1988, 201309/25/1440
Initial Cost to CompanyCost Capitalized Subsequent to AcquisitionGross Amount at which Carried at Close of PeriodLife on Which Depreciation in Latest Income Statement is Computed
 DescriptionOwnership Percentage
Encum- brances(1)
Land 
Building and Improve- ments(2)(3)
Total 
Land 
Building and Improve- ments(2)(3)
Total Accumulated Depreciation and AmortizationOriginal Date of Construction/ Renovation Date Acquired
Phoenix, AZ100%— 2,567 12,029 14,596 983 2,567 13,881 16,448 (4,425)198609/25/1440
Jonesboro, AR100%— 1,782 11,244 13,026 373 1,782 12,326 14,108 (3,705)199909/25/1440
Ogden, UT100%— 794 10,873 11,667 798 794 12,673 13,467 (3,764)1985/201609/25/1440
Olympia, WA100%— 2,477 23,767 26,244 923 2,477 27,924 30,401 (7,326)1986/201610/07/1440
Windsor, ON100%— 1,360 16,855 18,215 526 1,378 18,359 19,737 (4,576)199806/11/1540
London, ON100%— 960 19,056 20,016 368 972 20,408 21,380 (4,954)1998/2015, 201906/11/1540
Kelowna, BC100%— 2,321 8,308 10,629 626 2,352 9,846 12,198 (2,639)1990/2019, 202006/11/1540
Waterloo, ON100%— 1,823 22,135 23,958 380 1,848 23,213 25,061 (5,546)2005/201506/11/1540
Sarnia, ON100%— 1,187 20,346 21,533 740 1,203 22,905 24,108 (5,273)2000/201906/11/1540
Kamloops, BC100%— 679 8,024 8,703 250 687 9,040 9,727 (2,332)1992/201406/11/1540
Vernon, BC100%— 843 10,724 11,567 236 273 11,643 11,916 (2,829)1990/2008, 202106/11/1540
Penticton, BC100%— 763 6,771 7,534 239 773 7,940 8,713 (2,058)1990/1991, 2014, 201906/11/1540
Calgary, AB100%— 3,908 20,996 24,904 1,077 3,963 22,749 26,712 (5,259)201309/17/1540
Lake Stevens, WA100%— 1,559 9,059 10,618 96 1,559 9,168 10,727 (2,349)1998/201209/17/1540
Eugene, OR100%— 1,428 16,138 17,566 143 1,428 16,303 17,731 (3,690)1996/1997, 2011, 201909/17/1540
Tualatin, OR100%— 527 14,659 15,186 138 527 14,852 15,379 (3,364)1995/1997, 201909/17/1540
Salem, OR100%— 1,074 19,421 20,495 451 1,074 19,884 20,958 (4,774)1989/1995, 201809/17/1540
Ramsey, MN100%— 1,182 13,280 14,462 208 1,182 13,783 14,965 (2,627)201510/06/1740
Marshfield, WI100%— 500 4,134 4,634 89 500 4,263 4,763 (923)201410/06/1740
Dover, DE100%— 2,797 23,054 25,851 456 2,797 23,422 26,219 (4,245)199901/02/1840
Charleston, WV100%— 419 4,239 4,658 1,008 419 5,066 5,485 (1,302)196901/02/1840
Williamsport, PA100%— 296 9,191 9,487 907 296 9,973 10,269 (2,001)1990/200901/02/1840
Reading, PA100%— 684 12,950 13,634 276 684 13,201 13,885 (2,475)200401/02/1840
Scott Depot, WV100%— 230 6,271 6,501 713 230 6,767 6,997 (1,444)199601/02/1840
Clarks Summit, PA100%— 406 9,471 9,877 1,271 406 10,524 10,930 (2,264)199701/02/1840
Wyncote, PA100%— 1,781 4,911 6,692 814 1,781 5,517 7,298 (1,345)190901/02/1840
Douglassville, PA100%— 611 19,083 19,694 356 611 19,367 19,978 (3,418)200801/02/1840
Milford, DE100%— 1,199 18,786 19,985 589 1,199 19,231 20,430 (3,476)199901/02/1840
Oak Hill, WV100%— 609 2,636 3,245 1,157 609 3,703 4,312 (1,053)2001/201401/02/1840
Lewisburg, WV100%— 355 5,055 5,410 677 355 5,449 5,804 (1,227)199501/02/1840
Strasburg, VA100%— 666 5,551 6,217 22 666 5,573 6,239 (931)200104/30/1840
Richardson, TX100%— 2,282 10,556 12,838 1,288 2,282 11,934 14,216 (1,673)1999/202011/01/1940
Poway, CA100%— 3,693 14,467 18,160 1,072 3,693 15,688 19,381 (1,915)1987/2011, 202111/22/1940
Initial Cost to CompanyCost Capitalized Subsequent to AcquisitionGross Amount at which Carried at Close of PeriodLife on Which Depreciation in Latest Income Statement is Computed
 DescriptionOwnership Percentage
Encum- brances(1)
Land 
Building and Improve- ments(2)(3)
Total 
Land 
Building and Improve- ments(2)(3)
Total Accumulated Depreciation and AmortizationOriginal Date of Construction/ Renovation Date Acquired
New Braunfels, TX100%— 1,312 23,108 24,420 360 1,312 23,664 24,976 (2,871)201501/15/2040
Augusta, GA100%— 419 24,958 25,377 94 459 28,548 29,007 (2,343)201803/05/2140
Anchorage, AK100%— 1,965 29,533 31,498 150 1,965 29,683 31,648 (2,304)201905/01/2140
Loveland, OH100%— 3,691 21,168 24,859 41 3,691 21,269 24,960 (1,220)201702/01/2240
Indianapolis, IN100%— 4,950 32,631 37,581 43 6,299 41,563 47,862 (1,674)201708/01/2240
Saginaw, MI100%— 1,651 29,283 30,934 1,440 1,651 31,289 32,940 (1,247)2013/202308/01/2240
Madeira, OH100%— 2,858 42,670 45,528 2,858 42,691 45,549 (1,109)201902/01/2340
— 101,463 1,087,895 1,189,358 38,355 102,457 1,187,028 1,289,485 (255,803)
Behavioral Health
Aurora, CO100%— 2,874 12,829 15,703 1,950 2,874 14,563 17,437 (3,931)2009/2018, 202109/20/1240
Colorado Springs, CO100%— 430 13,703 14,133 1,033 430 14,736 15,166 (4,445)1985/2017, 201803/05/1440
Colorado Springs, CO100%— 1,210 9,490 10,700 2,058 1,210 11,548 12,758 (2,326)2013/201911/16/1540
Bluffton, IN100%— 254 5,105 5,359 1,486 254 6,591 6,845 (1,364)1970/2015, 202108/17/1740
Elizabethtown, KY100%— 239 4,853 5,092 699 239 5,552 5,791 (971)196908/17/1740
Morrilton, AR100%— 508 — 508 3,169 508 3,169 3,677 (98)1988/2019, 202308/17/1740
Glendale, AZ100%— 1,501 67,046 68,547 — 1,501 67,046 68,547 (11,140)1996/201308/17/1740
Tempe, AZ100%— 3,137 50,073 53,210 — 3,137 50,073 53,210 (8,505)2001/201608/17/1740
Covina, CA100%— 23,472 71,542 95,014 — 23,472 71,542 95,014 (12,348)1974/201108/17/1740
Ventura, CA100%— 8,089 43,645 51,734 — 8,089 43,645 51,734 (8,190)1984/201808/17/1740
San Diego, CA100%— 8,403 55,015 63,418 7,599 8,403 62,614 71,017 (11,947)1988/201708/17/1740
New London, CT100%— 356 152 508 3,665 356 3,817 4,173 (746)1967/2016, 202108/17/1740
Carmel, IN100%— 963 4,347 5,310 — 963 4,347 5,310 (680)1996/201907/24/1940
Louisville, KY100%— 1,078 8,305 9,383 — 1,078 8,305 9,383 (1,153)2002/201808/21/1940
Monroeville, PA100%— 2,034 1,758 3,792 18,545 2,034 20,303 22,337 (2,869)1987/202012/18/1940
Gulf Breeze, FL100%— 498 1,480 1,978 3,733 498 5,213 5,711 (139)2001/202103/15/2140
Greenville, SC100%— 1,197 9,496 10,693 21,507 1,197 31,012 32,209 (574)1994/202212/16/2140
Raytown, MO100%— 1,475 6,564 8,039 8,379 1,475 14,943 16,418 (517)1978/202210/27/2240
— 57,718 365,403 423,121 73,823 57,718 439,019 496,737 (71,943)
Initial Cost to CompanyCost Capitalized Subsequent to AcquisitionGross Amount at which Carried at Close of PeriodLife on Which Depreciation in Latest Income Statement is Computed
 DescriptionOwnership Percentage
Encum- brances(1)
Land 
Building and Improve- ments(2)(3)
Total 
Land 
Building and Improve- ments(2)(3)
Total Accumulated Depreciation and AmortizationOriginal Date of Construction/ Renovation Date Acquired
Specialty Hospitals and Other
Sunnyvale, TX100%— 4,020 57,620 61,640 — 4,020 57,620 61,640 (22,152)200905/03/1140
Arlington, TX100%— — 44,217 44,217 — — 44,217 44,217 (7,195)2009/201608/17/1740
Conroe, TX100%— 2,935 25,003 27,938 — 2,935 25,003 27,938 (4,600)199208/17/1740
Houston, TX100%— 3,001 14,581 17,582 — 3,001 14,581 17,582 (2,416)1999/200908/17/1740
Spring, TX100%— 1,319 15,153 16,472 — 1,319 15,153 16,472 (2,516)1995/199808/17/1740
Orange, CA100%— 2,060 5,538 7,598 145 2,060 5,683 7,743 (986)200008/17/1740
Maxwell, TX100%— 902 2,384 3,286 902 2,384 3,286 (458)199308/17/1740
Maxwell, TX100%— 901 1,198 2,099 — 901 1,198 2,099 (278)1994/200908/17/1740
Maxwell, TX100%— 456 2,632 3,088 — 456 2,632 3,088 (477)199208/17/1740
San Marcos, TX100%— 51 359 410 62 51 359 410 (67)186908/17/1740
Seguin, TX100%— 539 2,627 3,166 — 539 2,627 3,166 (605)198908/17/1740
Seguin, TX100%— 228 3,407 3,635 79 228 3,486 3,714 (669)1985/199108/17/1740
Kingsbury, TX100%— 104 2,788 2,892 27 104 2,814 2,918 (495)1990/201208/17/1740
Seguin, TX100%— 52 805 857 — 52 805 857 (154)197008/17/1740
Florence, KY100%— 3,866 26,447 30,313 — 3,866 26,447 30,313 (4,386)200008/17/1740
— 20,434 204,759 225,193 314 20,434 205,009 225,443 (47,454)
  48,143 546,940 4,830,944 5,377,884 232,080 546,598 5,089,202 5,635,800 (1,020,454)  
  — — 136 136 2,411 — 2,547 2,547 (632)  
  $48,143 $546,940 $4,831,080 $5,378,020 $234,491 $546,598 $5,091,749 $5,638,347 $(1,021,086)  
(1)    Encumbrances do not include deferred financing costs, net of $0.8 million as of December 31, 2023.
(2)    Building and building improvements include land improvements and furniture and equipment.
(3)    The aggregate cost of real estate for federal income tax purposes was $4.7 billion.
SCHEDULE III
REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION
(dollars in thousands)


Year Ended December 31,
202320222021
Real estate:
Balance at the beginning of the year$5,872,688 $5,994,208 $5,966,695 
Acquisitions86,626 101,413 96,157 
Improvements86,073 65,111 47,319 
Impairment(18,853)(160,550)(11,063)
Sale of real estate(379,272)(110,901)(102,575)
Foreign currency translation3,394 (10,247)524 
Other (1)
(12,309)(6,346)(2,849)
Balance at the end of the year$5,638,347 $5,872,688 $5,994,208 
  
Accumulated depreciation:
Balance at the beginning of the year$(913,345)$(831,324)$(681,657)
Depreciation expense(171,278)(170,159)(170,264)
Impairment4,432 66,603 1,666 
Sale of real estate49,585 13,217 16,097 
Foreign currency translation(747)1,972 (15)
Other (1)
10,267 6,346 2,849 
Balance at the end of the year$(1,021,086)$(913,345)$(831,324)
(1)    Primarily represents real estate and accumulated depreciation related to fully-depreciated assets and reductions to net real estate due to casualty events.
XML 43 R28.htm IDEA: XBRL DOCUMENT v3.24.0.1
SCHEDULE IV - MORTGAGE LOANS ON REAL ESTATE
12 Months Ended
Dec. 31, 2023
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Abstract]  
SCHEDULE IV - MORTGAGE LOANS ON REAL ESTATE
SCHEDULE IV
MORTGAGE LOANS ON REAL ESTATE
As of December 31, 2023
(dollars in thousands)

DescriptionContractual Interest RateMaturity DatePeriodic Payment TermsPrior LiensPrincipal Balance
Book Value (1)
Principal Amount of Loans Subject to Delinquent Principal or Interest
Mortgages:
River Vista10.0 %2027
(2)
$— $19,000 $19,000 N/A
Recovery Centers of America7.5 2026
(2)
— 300,000 300,000 N/A
$— $319,000 $319,000 
(1)    The aggregate cost for federal income tax purposes was $321.2 million as of December 31, 2023.
(2)    Interest is due monthly, and principal is due at the maturity date.



Changes in mortgage loans are summarized as follows:
Year Ended December 31,
202320222021
Balance at the beginning of the year$319,000 $312,343 $22,343 
Additions during period:
Draws— 10,000 — 
New mortgage loans— — 290,000 
Deductions during period:
Paydowns/repayments— (3,343)— 
Balance at the end of the year$319,000 $319,000 $312,343 
XML 44 R29.htm IDEA: XBRL DOCUMENT v3.24.0.1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Pay vs Performance Disclosure      
Net income (loss) $ 13,756 $ (77,605) $ (113,256)
XML 45 R30.htm IDEA: XBRL DOCUMENT v3.24.0.1
Insider Trading Arrangements
3 Months Ended
Dec. 31, 2023
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 46 R31.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Principles of Consolidation and Basis of Presentation The accompanying consolidated financial statements include the accounts of Sabra and its wholly owned subsidiaries as of December 31, 2023 and 2022 and for the years ended December 31, 2023, 2022 and 2021. All significant intercompany transactions and balances have been eliminated in consolidation. The consolidated financial statements are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”).
Variable Interest Entities
GAAP requires the Company to identify entities for which control is achieved through voting rights or other means and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). A VIE is broadly defined as an entity with one or more of the following characteristics: (a) the total equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (b) as a group, the holders of the equity investment at risk lack (i) the ability to make decisions about the entity’s activities through voting or similar rights, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity; or (c) the equity investors have voting rights that are not proportional to their economic interests, and substantially all of the entity’s activities either involve, or are conducted on behalf of, an investor that has disproportionately few voting rights. If the Company were determined to be the primary beneficiary of the VIE, the Company would consolidate investments in the VIE. The Company may change its original assessment of a VIE due to events such as modifications of contractual arrangements that affect the characteristics or adequacy of the entity’s equity investments at risk and the disposal of all or a portion of an interest held by the primary beneficiary.
The Company identifies the primary beneficiary of a VIE as the enterprise that has both: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. The Company performs this analysis on an ongoing basis. As of December 31, 2023, the Company determined that it was not the primary beneficiary of any VIEs.
As it relates to investments in loans, in addition to the Company’s assessment of VIEs and whether the Company is the primary beneficiary of those VIEs, the Company evaluates the loan terms and other pertinent facts to determine whether the loan investment should be accounted for as a loan or as a real estate joint venture. If an investment has the characteristics of a real estate joint venture, including if the Company participates in the majority of the borrower’s expected residual profit, the Company would account for the investment as an investment in a real estate joint venture and not as a loan investment. Expected residual profit is defined as the amount of profit, whether called interest or another name, such as an equity kicker, above a reasonable amount of interest and fees expected to be earned by a lender. At December 31, 2023 and 2022, none of the Company’s investments in loans were accounted for as real estate joint ventures.
As it relates to investments in joint ventures, the Company assesses any partners’ rights and their impact on the presumption of control of the partnership by any single partner. The Company also applies this guidance to managing member interests in limited liability companies. The Company reassesses its determination of which entity controls the joint venture if: there is a change to the terms or in the exercisability of the rights of any partners or members, the general partner or managing member increases or decreases its ownership interests, or there is an increase or decrease in the number of outstanding ownership interests. As of December 31, 2023, the Company’s determination of which entity controls its investments in joint ventures has not changed as a result of any reassessment.
Use of Estimates The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.
Real Estate Investments
Real Estate Acquisition Valuation
All assets acquired and liabilities assumed in an acquisition of real estate accounted for as a business combination are measured at their acquisition date fair values. For acquisitions of real estate accounted for as an asset acquisition, the fair value of consideration transferred by the Company (including transaction costs) is allocated to all assets acquired and liabilities assumed on a relative fair value basis. The acquisition value of land, building and improvements are included in real estate investments on the accompanying consolidated balance sheets. The acquisition value of above market lease, tenant origination and absorption costs and tenant relationship intangible assets is included in lease intangible assets, net on the accompanying consolidated balance sheets. The acquisition value of below market lease intangible liabilities is included in lease intangible liabilities, net on the accompanying consolidated balance sheets. Acquisition costs associated with real estate acquisitions deemed asset acquisitions are capitalized, and costs associated with real estate acquisitions deemed business combinations are expensed as incurred. Restructuring costs that do not meet the definition of a liability at the acquisition date are expensed in periods subsequent to the acquisition date.
Estimates of the fair values of the tangible assets, identifiable intangibles and assumed liabilities require the Company to make significant assumptions to estimate market lease rates, property operating expenses, carrying costs during lease-up periods, discount rates, market absorption periods, and the number of years the property will be held for investment. The Company makes its best estimate based on the Company’s evaluation of the specific characteristics of each tenant’s lease. The use of inappropriate assumptions would result in an incorrect valuation of the Company’s acquired tangible assets, identifiable intangibles and assumed liabilities, which would impact the amount of the Company’s net income.
Depreciation and Amortization
Real estate costs related to the acquisition and improvement of properties are capitalized and amortized on a straight-line basis over the lesser of the expected useful life of the asset and the remaining lease term of any property subject to a ground lease. Tenant improvements are capitalized and amortized on a straight-line basis over the lesser of the expected useful life of the asset and the remaining lease term. Depreciation is discontinued when a property is identified as held for sale. Repair and maintenance costs are charged to expense as incurred and significant replacements and betterments are capitalized. Repair and maintenance costs include all costs that do not extend the useful life of the real estate asset. The Company considers the period of future benefit of an asset to determine its appropriate useful life. Depreciation of real estate assets and amortization of tenant origination and absorption costs and tenant relationship lease intangibles are included in depreciation and amortization on the accompanying consolidated statements of income (loss). Amortization of above and below market lease intangibles is included in rental income on the accompanying consolidated statements of income (loss). The Company anticipates the estimated useful lives of its assets by class to be generally as follows: land improvements, 15 to 20 years; buildings and building improvements, five to 45 years; and furniture and equipment, three to 10 years. Intangibles are generally amortized over the remaining noncancellable lease terms, with tenant relationship intangible amortization periods including extension periods.
Impairment of Real Estate Investments
The Company regularly monitors events and changes in circumstances, including investment operating performance and general market conditions, that could indicate that the carrying amounts of its real estate investments may not be recoverable. When indicators of potential impairment suggest that the carrying value of real estate investments may not be recoverable, the Company assesses the recoverability by estimating whether the Company will recover the carrying value of its real estate investments through the undiscounted future cash flows and the eventual disposition of the investment. In some instances, there may be various potential outcomes for an investment and its potential undiscounted future cash flows. In these instances, the
undiscounted future cash flows models used to assess recoverability are based on several assumptions and are probability-weighted based on the Company’s best estimates as of the date of evaluation. These assumptions include, among others, market rent, revenue and expense growth rates, absorption period, stabilized occupancy, holding period, market capitalization rates, and estimated market values based on analysis of letters of intent, purchase and sale agreements and recent sales data for comparable properties. When discounted cash flow is used to determine fair value, a discount rate assumption is also used. The assumptions are generally based on management’s experience in its local real estate markets, and the effects of current market conditions, which are subject to economic and market uncertainties. If, based on this analysis, the Company does not believe that it will be able to recover the carrying value of its real estate investments, the Company would record an impairment loss to the extent that the carrying value exceeds the estimated fair value of its real estate investments. The Company determines estimated fair value based primarily upon (i) estimated sale prices from signed contracts or letters of intent from third-party offers, (ii) discounted cash flow models of the investment over its remaining hold period, (iii) third-party appraisals and (iv) recent sales data for comparable properties.
Real Estate Investments, Inventory
Real Estate Acquisition Valuation
All assets acquired and liabilities assumed in an acquisition of real estate accounted for as a business combination are measured at their acquisition date fair values. For acquisitions of real estate accounted for as an asset acquisition, the fair value of consideration transferred by the Company (including transaction costs) is allocated to all assets acquired and liabilities assumed on a relative fair value basis. The acquisition value of land, building and improvements are included in real estate investments on the accompanying consolidated balance sheets. The acquisition value of above market lease, tenant origination and absorption costs and tenant relationship intangible assets is included in lease intangible assets, net on the accompanying consolidated balance sheets. The acquisition value of below market lease intangible liabilities is included in lease intangible liabilities, net on the accompanying consolidated balance sheets. Acquisition costs associated with real estate acquisitions deemed asset acquisitions are capitalized, and costs associated with real estate acquisitions deemed business combinations are expensed as incurred. Restructuring costs that do not meet the definition of a liability at the acquisition date are expensed in periods subsequent to the acquisition date.
Estimates of the fair values of the tangible assets, identifiable intangibles and assumed liabilities require the Company to make significant assumptions to estimate market lease rates, property operating expenses, carrying costs during lease-up periods, discount rates, market absorption periods, and the number of years the property will be held for investment. The Company makes its best estimate based on the Company’s evaluation of the specific characteristics of each tenant’s lease. The use of inappropriate assumptions would result in an incorrect valuation of the Company’s acquired tangible assets, identifiable intangibles and assumed liabilities, which would impact the amount of the Company’s net income.
Depreciation and Amortization
Real estate costs related to the acquisition and improvement of properties are capitalized and amortized on a straight-line basis over the lesser of the expected useful life of the asset and the remaining lease term of any property subject to a ground lease. Tenant improvements are capitalized and amortized on a straight-line basis over the lesser of the expected useful life of the asset and the remaining lease term. Depreciation is discontinued when a property is identified as held for sale. Repair and maintenance costs are charged to expense as incurred and significant replacements and betterments are capitalized. Repair and maintenance costs include all costs that do not extend the useful life of the real estate asset. The Company considers the period of future benefit of an asset to determine its appropriate useful life. Depreciation of real estate assets and amortization of tenant origination and absorption costs and tenant relationship lease intangibles are included in depreciation and amortization on the accompanying consolidated statements of income (loss). Amortization of above and below market lease intangibles is included in rental income on the accompanying consolidated statements of income (loss). The Company anticipates the estimated useful lives of its assets by class to be generally as follows: land improvements, 15 to 20 years; buildings and building improvements, five to 45 years; and furniture and equipment, three to 10 years. Intangibles are generally amortized over the remaining noncancellable lease terms, with tenant relationship intangible amortization periods including extension periods.
Impairment of Real Estate Investments
The Company regularly monitors events and changes in circumstances, including investment operating performance and general market conditions, that could indicate that the carrying amounts of its real estate investments may not be recoverable. When indicators of potential impairment suggest that the carrying value of real estate investments may not be recoverable, the Company assesses the recoverability by estimating whether the Company will recover the carrying value of its real estate investments through the undiscounted future cash flows and the eventual disposition of the investment. In some instances, there may be various potential outcomes for an investment and its potential undiscounted future cash flows. In these instances, the
undiscounted future cash flows models used to assess recoverability are based on several assumptions and are probability-weighted based on the Company’s best estimates as of the date of evaluation. These assumptions include, among others, market rent, revenue and expense growth rates, absorption period, stabilized occupancy, holding period, market capitalization rates, and estimated market values based on analysis of letters of intent, purchase and sale agreements and recent sales data for comparable properties. When discounted cash flow is used to determine fair value, a discount rate assumption is also used. The assumptions are generally based on management’s experience in its local real estate markets, and the effects of current market conditions, which are subject to economic and market uncertainties. If, based on this analysis, the Company does not believe that it will be able to recover the carrying value of its real estate investments, the Company would record an impairment loss to the extent that the carrying value exceeds the estimated fair value of its real estate investments. The Company determines estimated fair value based primarily upon (i) estimated sale prices from signed contracts or letters of intent from third-party offers, (ii) discounted cash flow models of the investment over its remaining hold period, (iii) third-party appraisals and (iv) recent sales data for comparable properties.
Revenue Recognition
Revenue Recognition
The Company recognizes rental revenue from tenants, including rental abatements, lease incentives and contractual fixed increases attributable to operating leases, on a straight-line basis over the term of the related leases when it is probable that substantially all rents over the life of a lease are collectible. Certain of the Company’s leases provide for contingent rents equal to a percentage of the facility’s revenue in excess of specified base amounts or other thresholds. Such revenue is recognized when actual results reported by the tenant, or estimates of tenant results, exceed the applicable base amount or other threshold.
The Company assesses the collectability of rents on a lease-by-lease basis, and in doing so, considers such things as historical bad debts, tenant creditworthiness, current economic trends, facility operating performance, lease structure, credit enhancements (including guarantees), current developments relevant to a tenant’s business specifically and to its business category generally, and changes in tenants’ payment patterns. The Company’s assessment includes an estimation of a tenant’s ability to fulfill all of its rental obligations over the remaining lease term. In addition, with respect to tenants in bankruptcy, management makes estimates of the expected recovery of pre-petition and post-petition claims in assessing the estimated collectability of the related receivable. If at any time the Company cannot determine that it is probable that substantially all rents over the life of a lease are collectible, rental revenue will be recognized only to the extent of payments received, and all receivables associated with the lease will be written off irrespective of amounts expected to be collectible. Any recoveries of these amounts will be recorded in future periods upon receipt of payment. Write-offs of receivables and any recoveries of previously written-off receivables are recorded as adjustments to rental revenue.
Revenue from resident fees and services is recorded monthly as services are provided and includes resident room and care charges, ancillary services charges and other resident charges.
Government Grants By analogy to International Accounting Standards 20, Accounting for Government Grants and Disclosure of Government Assistance, government assistance provided to the Company in the form of an income grant, which is not related to long-lived assets and is not required to be repaid, is recognized as grant income when there is reasonable assurance that the grant will be received and the Company will comply with any conditions associated with the grant. Additionally, grants are recognized over the periods in which the Company recognizes the qualifying expenses and/or lost income for which the grants are intended to compensate.
Assets Held for Sale, Dispositions and Discontinued Operations
The Company generally considers real estate to be “held for sale” when the following criteria are met: (i) management commits to a plan to sell the property, (ii) the property is available for sale immediately, (iii) the property is actively being marketed for sale at a price that is reasonable in relation to its current fair value, (iv) the sale of the property within one year is considered probable and (v) significant changes to the plan to sell are not expected. Real estate that is held for sale and its related assets are classified as assets held for sale and are included in accounts receivable, prepaid expenses and other assets, net on the accompanying consolidated balance sheets. Secured indebtedness and other liabilities related to real estate held for sale are classified as liabilities related to assets held for sale and are included in accounts payable and accrued liabilities on the accompanying consolidated balance sheets. Real estate classified as held for sale is no longer depreciated and is reported at the lower of its carrying value or its estimated fair value less estimated costs to sell. As of December 31, 2023 and 2022, the Company did not have any assets held for sale.
For sales of real estate where the Company has collected the consideration to which it is entitled in exchange for transferring the real estate, the related assets and liabilities are removed from the balance sheet and the resultant gain or loss is recorded in the period in which the transaction closes. Any post-sale involvement is accounted for as separate performance obligations, and when the separate performance obligations are satisfied, the portion of the sales price allocated to each such obligation is recognized.
Additionally, the Company records the operating results related to real estate that has been disposed of or classified as held for sale as discontinued operations for all periods presented if it represents a strategic shift that has or will have a major effect on the Company’s operations and financial results.
Investment in Unconsolidated Joint Ventures and Preferred Equity Investments and Preferred Return
The Company reports investments in unconsolidated entities over whose operating and financial policies it has the ability to exercise significant influence under the equity method of accounting. Under this method of accounting, the Company’s share of the investee’s earnings or losses is included in the Company’s consolidated statements of income (loss). The initial carrying value of the investment is based on the amount paid to purchase the joint venture interest. Differences between the Company’s cost basis and the basis reflected at the joint venture level are generally amortized over the lives of the related assets and liabilities, and such amortization is included in the Company’s share of earnings of the joint venture. In addition, distributions received from unconsolidated entities are classified based on the nature of the activity or activities that generated the distribution.
The Company regularly monitors events and changes in circumstances, including investment operating performance, changes in anticipated holding period and general market conditions, that could indicate that the carrying amounts of its equity method investments may be impaired. An equity method investment's value is impaired when the fair value of the investment is less than its carrying value and the Company determines the decline in value is other-than-temporary. The fair value is estimated based on discounted cash flows models that include all estimated cash inflows and outflows and any estimated debt premiums or discounts. The discounted cash flows are based on several assumptions, including management fee, absorption period, terminal capitalization rates, revenue and expense per bed, revenue and expense growth percentage, replacement reserve per unit, stabilized occupancy, stabilized operating margin, price per bed and discount rates. The assumptions are generally based on management’s experience in its local real estate markets, and the effects of current market conditions, which are subject to economic and market uncertainties. If the Company believes that there is an other-than-temporary decline in the value of an equity method investment, the Company would record an impairment loss to the extent that the carrying value exceeds the estimated fair value of such equity method investment.
Preferred equity investments are accounted for at unreturned capital contributions, plus accrued and unpaid preferred returns. The Company recognizes preferred return income on a monthly basis based on the outstanding investment including any previously accrued and unpaid return. As a preferred member of the preferred equity joint ventures in which the Company participates, the Company is not entitled to share in the joint venture’s earnings or losses. Rather, the Company is entitled to receive a preferred return, which is deferred if the cash flow of the joint venture is insufficient to currently pay the accrued preferred return.
The Company regularly monitors events and changes in circumstances that could indicate that the carrying amounts of its preferred equity investments may not be recoverable or realized. On a quarterly basis, the Company evaluates its preferred equity investments for impairment based on a comparison of the fair value of the investment to its carrying value. The fair value is estimated based on discounted cash flows that include all estimated cash inflows and outflows over a specified holding period. If, based on this analysis, the Company does not believe that it will be able to recover the carrying value of its preferred equity investment, the Company would record an impairment loss to the extent that the carrying value exceeds the estimated fair value of its preferred equity investment.
Loans Receivable
Loans Receivable
The Company’s loans receivable are reflected at amortized cost on the accompanying consolidated balance sheets. The amortized cost of a loan receivable is the outstanding unpaid principal balance, net of unamortized discounts, costs and fees directly associated with the origination of the loan.
Loans acquired in connection with a business combination are recorded at their acquisition date fair value. The Company determines the fair value of loans receivable based on estimates of expected discounted cash flows, collateral, credit risk and other factors. The Company does not establish a valuation allowance at the acquisition date, as the amount of estimated future cash flows reflects its judgment regarding their uncertainty. The Company recognizes the difference between the acquisition date fair value and the total expected cash flows as interest income using the effective interest method over the life of the applicable loan. The Company immediately recognizes in income any unamortized balances if the loan is repaid before its contractual maturity.
Interest income on the Company’s loans receivable is recognized on an accrual basis over the life of the investment using the interest method. Direct loan origination costs are amortized over the term of the loan as an adjustment to interest income. When concerns exist as to the ultimate collection of principal or interest due under a loan, the loan is placed on nonaccrual status, and the Company will not recognize interest income until the cash is received, or the loan returns to accrual status. If the Company determines that the collection of interest according to the contractual terms of the loan or through the receipts of assets in satisfaction of contractual amounts due is probable, the Company will resume the accrual of interest. In instances where borrowers are in default under the terms of their loans, the Company may continue recognizing interest income provided that all amounts owed under the contractual terms of the loan, including accrued and unpaid interest, do not exceed the estimated fair value of the collateral, less costs to sell.
On a quarterly basis, the Company evaluates the collectability of its interest income receivable and establishes a reserve for amounts not expected to be collected. The Company’s evaluation includes reviewing credit quality indicators such as payment status, changes affecting the operations of the facilities securing the loans, and national and regional economic factors. The reserve is a valuation allowance that reflects management’s estimate of losses inherent in the interest income receivable balance as of the balance sheet date. The reserve is adjusted through provision for loan losses and other reserves on the Company’s consolidated statements of income (loss) and is decreased by charge-offs to specific receivables.
Credit Losses
Credit Losses
On a quarterly basis, the Company evaluates the collectability of its loan portfolio, including the portion of unfunded loan commitments expected to be funded, and establishes an allowance for credit losses. The allowance for credit losses is calculated using the related amortization schedules, payment histories and loan-to-value ratios. The following rates are applied to determine the aggregate expected losses, which is recorded as the allowance for credit losses: (i) a default rate, (ii) a liquidation cost rate and (iii) a distressed property reduction rate. If no loan-to-value ratio is available, a loss severity rate is applied in place of the liquidation cost rate and the distressed property reduction rate. The default rate is based on average charge-off and delinquency rates from the Federal Reserve, and the other rates are based on industry research and historical performance of a similar portfolio of financial assets. The allowance for credit losses is a valuation allowance that reflects management’s estimate of losses inherent in the loan portfolio as of the balance sheet date. The reserve is adjusted through provision for loan losses and other reserves on the Company’s consolidated statements of income (loss) and is decreased by charge-offs to specific loans.
Cash and Cash Equivalents
The Company considers all short-term (with an original maturity of three months or less), highly-liquid investments utilized as part of the Company’s cash-management activities to be cash equivalents. Cash equivalents may include cash and short-term investments. Short-term investments are stated at cost, which approximates fair value.
The Company’s cash and cash equivalents balance exceeded federally insurable limits as of December 31, 2023. To date, the Company has experienced no loss or lack of access to cash in its operating accounts. The Company has a corporate banking relationship with Bank of America, N.A. in which it deposits the majority of its cash.
Restricted Cash Restricted cash primarily consists of amounts held by an exchange accommodation titleholder or by secured debt lenders to provide for future real estate tax expenditures, tenant improvements and capital expenditures. Pursuant to the terms of the Company’s leases with certain tenants, the Company has assigned its interests in certain of these restricted cash accounts with secured debt lenders to the tenants, and this amount is included in accounts payable and accrued liabilities on the Company’s consolidated balance sheets.
Lessee Accounting
Lessee Accounting
For operating leases greater than 12 months for which the Company is the lessee, such as corporate office leases and ground leases, the Company recognizes a right-of-use (“ROU”) asset and related lease liability on its consolidated balance sheets at inception of the lease. ROU assets represent the Company’s right to use underlying assets for the lease term, and lease liabilities are determined based on the estimated present value of the Company’s minimum lease payments under the agreements. The discount rate used to determine the lease liabilities is based on the estimated incremental borrowing rate on a lease-by-lease basis. Certain of the Company’s lease agreements have options to extend or terminate the contract terms upon meeting certain criteria. The lease term utilized in the calculation of the lease liability includes these options if exercise is considered reasonably certain.
Stock-Based Compensation
Stock-based compensation expense for stock-based awards granted to Sabra’s employees (teammates) and its non-employee directors is recognized in the statements of income (loss) based on the estimated grant date fair value, as adjusted. Compensation expense for awards with graded vesting schedules is generally recognized ratably over the period from the grant date to the date when the award is no longer contingent on the recipient providing additional services. Compensation expense for awards with performance-based vesting conditions is recognized based on the Company’s estimate of the ultimate value of such award after considering the Company’s expectations of future performance. Forfeitures of stock-based awards are recognized as they occur.
Deferred Financing Costs
Deferred financing costs representing fees paid to third parties are amortized over the terms of the respective financing agreements using the interest method. Deferred financing costs related to secured debt, term loans and senior unsecured notes are recorded as a reduction of the related debt liability, and deferred financing costs related to the revolving credit facility are recorded in accounts receivable, prepaid expenses and other assets, net. Unamortized deferred financing costs are generally expensed when the associated debt is refinanced or repaid before maturity. Costs incurred in seeking financings that do not close are expensed in the period in which it is determined that the financing will not close.
Income Taxes
The Company elected to be treated as a REIT with the filing of its U.S. federal income tax return for the taxable year beginning January 1, 2011. The Company believes that it has been organized and operated, and it intends to continue to operate, in a manner to qualify as a REIT. To qualify as a REIT, the Company must meet certain organizational and operational requirements, including a requirement to distribute at least 90% of the Company’s annual REIT taxable income to stockholders (which is computed without regard to the dividends-paid deduction or net capital gains and which does not necessarily equal net income as calculated in accordance with GAAP). As a REIT, the Company generally will not be subject to federal income tax on income that it distributes as dividends to its stockholders. If the Company fails to qualify as a REIT in any taxable year, it will be subject to U.S. federal income tax on its taxable income at regular corporate income tax rates and generally will not be permitted to qualify for treatment as a REIT for federal income tax purposes for the four taxable years following the year during which qualification is lost, unless the Internal Revenue Service grants the Company relief under certain statutory provisions. Such an event could materially and adversely affect the Company’s net income and net cash available for distribution to stockholders. However, the Company believes that it is organized and operates in such a manner as to qualify for treatment as a REIT.
As a result of certain investments, the Company now records income tax expense or benefit with respect to certain of its entities that are taxed as taxable REIT subsidiaries under provisions similar to those applicable to regular corporations and not under the REIT provisions.
The Company accounts for deferred income taxes using the asset and liability method and recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company’s financial statements or tax returns. Under this method, the Company determines deferred tax assets and liabilities based on the differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Any increase or decrease in the deferred tax liability that results from a change in circumstances, and that causes a change in the Company’s judgment about expected future tax consequences of events, is included in the tax provision when such changes occur. Deferred income taxes also reflect the impact of operating loss and tax credit carryforwards. A valuation allowance is provided if the Company believes it is more likely than not that all or some portion of the deferred tax asset will not be realized. Any increase or decrease in the valuation allowance that results from a change in circumstances, and that causes a change in the Company’s judgment about the realizability of the related deferred tax asset, is included in the tax provision when such changes occur. 
The Company evaluates its tax positions using a two-step approach: step one (recognition) occurs when the Company concludes that a tax position, based solely on its technical merits, is more likely than not to be sustained upon examination, and step two (measurement) is only addressed if step one has been satisfied (i.e., the position is more likely than not to be sustained). Under step two, the tax benefit is measured as the largest amount of benefit (determined on a cumulative probability basis) that is more likely than not to be realized upon ultimate settlement. The Company will recognize tax penalties relating to unrecognized tax benefits as additional tax expense.
Foreign Currency
Certain of the Company’s subsidiaries’ functional currencies are the local currencies of their respective foreign jurisdictions. The Company translates the results of operations of its foreign subsidiaries into U.S. dollars using average rates of exchange in effect during the period presented, and it translates balance sheet accounts using exchange rates in effect at the end of the period presented. The Company records resulting currency translation adjustments in accumulated other comprehensive loss, a component of stockholders’ equity, on its consolidated balance sheets, and it records foreign currency transaction gains and losses as a component of other (expense) income on its consolidated statements of income (loss).
Derivative Instruments
The Company uses certain types of derivative instruments for the purpose of managing interest rate and currency risk. To qualify for hedge accounting, derivative instruments used for risk management purposes must effectively reduce the risk exposure that they are designed to hedge. In addition, at inception, the Company must make an assessment that the transaction that the Company intends to hedge is probable of occurring, and this assessment must be updated each reporting period.
The Company recognizes all derivative instruments as assets or liabilities on the consolidated balance sheets at their fair value. For derivatives designated and qualified as a hedge, the change in fair value of the effective portion of the derivatives is recognized in accumulated other comprehensive loss. Changes in the fair value of derivative instruments that are not designated in hedging relationships or that do not meet the criteria for hedge accounting would be recognized in earnings. In addition, the Company classifies cash flows from qualifying cash flow hedging relationships in the same category as the cash flows from the hedged items.
The Company formally documents all relationships between hedging instruments and hedged items, as well as its risk-management objectives and strategy for undertaking various hedge transactions. This process includes designating all derivatives that are part of a hedging relationship to specific transactions, as well as recognizing obligations or assets on the consolidated balance sheets. The Company also assesses and documents, both at inception of the hedging relationship and on a quarterly basis thereafter, whether the derivatives are highly effective in offsetting the designated risks associated with the respective hedged items. If it is determined that a derivative ceases to be highly effective as a hedge, or that it is probable the underlying transaction will not occur, the Company would discontinue hedge accounting prospectively and record the appropriate adjustment to earnings based on the then-current fair value of the derivative.
Fair Value Measurements
Under GAAP, the Company is required to measure certain financial instruments at fair value on a recurring basis. In addition, the Company is required to measure other financial instruments and balances at fair value on a non-recurring basis (e.g., carrying value of impaired loans receivable and long-lived assets). Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The GAAP fair value framework uses a three-tiered approach. Fair value measurements are classified and disclosed in one of the following three categories:
Level 1: unadjusted quoted prices in active markets that are accessible at the measurement date for identical assets or liabilities;
Level 2: quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which significant inputs and significant value drivers are observable in active markets; and
Level 3: prices or valuation techniques where little or no market data is available that requires inputs that are both significant to the fair value measurement and unobservable.
When available, the Company utilizes quoted market prices from an independent third-party source to determine fair value and classifies such items as Level 1 or Level 2. In instances where the market for a financial instrument is not active, regardless of the availability of a nonbinding quoted market price, observable inputs might not be relevant and could require the Company to make a significant adjustment to derive a fair value measurement. Additionally, in an inactive market, a market price quoted from an independent third party may rely more on models with inputs based on information available only to that independent third party. When the Company determines the market for a financial instrument owned by the Company to be illiquid or when market transactions for similar instruments do not appear orderly, the Company may use several valuation sources (including internal valuations, discounted cash flow analysis and quoted market prices) to establish a fair value. If more than one valuation source is used, the Company will assign weights to the various valuation sources. Additionally, when determining the fair value of liabilities in circumstances in which a quoted price in an active market for an identical liability is not available, the Company measures fair value using (i) a valuation technique that uses the quoted price of the identical liability when traded as an asset or quoted prices for similar liabilities or similar liabilities when traded as assets or (ii) another valuation technique that is consistent with the principles of fair value measurement, such as the income approach or the market approach.
Changes in assumptions or estimation methodologies can have a material effect on these estimated fair values. In this regard, the derived fair value estimates cannot be substantiated by comparison to independent markets and, in many cases, may not be realized in an immediate settlement of the instrument.
The Company considers the following factors to be indicators of an inactive market: (i) there are few recent transactions, (ii) price quotations are not based on current information, (iii) price quotations vary substantially either over time or among market makers (for example, some brokered markets), (iv) indexes that previously were highly correlated with the fair values of the asset or liability are demonstrably uncorrelated with recent indications of fair value for that asset or liability, (v) there is a significant increase in implied liquidity risk premiums, yields, or performance indicators (such as delinquency rates or loss severities) for observed transactions or quoted prices when compared with the Company’s estimate of expected cash flows, considering all available market data about credit and other nonperformance risk for the asset or liability, (vi) there is a wide bid-ask spread or significant increase in the bid-ask spread, (vii) there is a significant decline or absence of a market for new issuances (that is, a primary market) for the asset or liability or similar assets or liabilities, and (viii) little information is released publicly (for example, a principal-to-principal market).
The Company considers the following factors to be indicators of non-orderly transactions: (i) there was not adequate exposure to the market for a period before the measurement date to allow for marketing activities that are usual and customary for transactions involving such assets or liabilities under current market conditions, (ii) there was a usual and customary marketing period, but the seller marketed the asset or liability to a single market participant, (iii) the seller is in or near
bankruptcy or receivership (that is, distressed), or the seller was required to sell to meet regulatory or legal requirements (that is, forced), and (iv) the transaction price is an outlier when compared with other recent transactions for the same or similar assets or liabilities.
Per Share Data Basic earnings per common share is computed by dividing net income applicable to common stockholders by the weighted average number of shares of common stock and common equivalents outstanding during the period. Diluted earnings per common share is calculated by including the effect of dilutive securities, such as the impact of forward equity sales agreements using the treasury stock method and common shares issuable from certain performance restricted stock units and unvested restricted stock units.
Industry Segments The Company has one reportable segment consisting of investments in healthcare-related real estate properties.
Recently Issued Accounting Standards Update
Issued but Not Yet Adopted
In March 2020, the Financial Accounting Standards Board (“FASB”) issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”). ASU 2020-04 provides temporary optional guidance that provides transition relief for reference rate reform, including optional expedients and exceptions for applying GAAP to contract modifications, hedging relationships and other transactions that reference the London Interbank Offered Rate (“LIBOR”) or a reference rate that is expected to be discontinued as a result of reference rate reform if certain criteria are met. ASU 2020-04 is effective upon issuance, and the provisions generally can be applied prospectively as of January 1, 2020 through December 31, 2024. During the first quarter of 2020, the Company elected to apply the hedge accounting expedients related to probability and the assessments of effectiveness for future LIBOR-indexed cash flows to assume that the index upon which future hedged transactions will be based matches the index on the corresponding derivatives. As of July 1, 2023, the Company had converted all of its LIBOR-indexed debt and derivatives to Secured Overnight Financing Rate (“SOFR”)-based indexes (effective with the respective instrument’s next reset date for certain instruments). For all derivatives in hedge accounting relationships, the Company utilized the effective relief in Topic 848 that allows for the continuation of hedge accounting throughout the transition process. Application of these expedients preserves the presentation of derivatives consistent with past presentation. In January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848): Scope, which refines the scope of Topic 848 and clarifies some of its guidance. In December 2022, the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848, which defers the sunset date of Topic 848 from December 31, 2022 to December 31, 2024. The Company continues to evaluate the impact of the guidance as it relates to hedging relationships and other transactions that reference the Canadian Dollar Offered Rate (“CDOR”) which is expected to be discontinued in 2024 and may apply other elections as applicable as additional changes in the market occur.
Fair Value of Financial Instruments
The fair value for certain financial instruments is derived using a combination of market quotes, pricing models and other valuation techniques that involve significant management judgment. The price transparency of financial instruments is a key determinant of the degree of judgment involved in determining the fair value of the Company’s financial instruments.
Financial instruments for which actively quoted prices or pricing parameters are available and whose markets contain orderly transactions will generally have a higher degree of price transparency than financial instruments whose markets are inactive or consist of non-orderly trades. The Company evaluates several factors when determining if a market is inactive or when market transactions are not orderly. The carrying values of cash and cash equivalents, restricted cash, accounts payable, accrued liabilities and the Credit Agreement are reasonable estimates of fair value because of the short-term maturities of these instruments. Fair values for other financial instruments are derived as follows:
Loans receivable: These instruments are presented on the accompanying consolidated balance sheets at their amortized cost and not at fair value. The fair values of the loans receivable were estimated using an internal valuation model that considered the expected cash flows for the loans receivable, as well as the underlying collateral value and other credit enhancements as applicable. The Company utilized discount rates ranging from 6% to 15% with a weighted average rate of 6% in its fair value calculation. As such, the Company classifies these instruments as Level 3.
Preferred equity investments: These instruments are presented on the accompanying consolidated balance sheets at their cost and not at fair value. The fair values of the preferred equity investments were estimated using an internal valuation model that considered the expected future cash flows for the preferred equity investments, the underlying collateral value and other credit enhancements. The Company utilized discount rates ranging from 10% to 15% with a weighted average rate of 11% in its fair value calculation. As such, the Company classifies these instruments as Level 3.
Derivative instruments: The Company’s derivative instruments are presented at fair value on the accompanying consolidated balance sheets. The Company estimates the fair value of derivative instruments, including its interest rate swaps, interest rate collars and cross currency swaps, using the assistance of a third party using inputs that are observable in the market, which include forward yield curves and other relevant information. Although the Company has determined that the majority of the inputs used to value its derivative financial instruments fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivative financial instruments utilize Level 3 inputs, such as estimates of current credit spreads, to evaluate the likelihood of default by itself and its counterparties. The Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of its derivative financial instruments. As a result, the Company has determined that its derivative financial instruments valuations in their entirety are classified in Level 2 of the fair value hierarchy.
Senior Notes: These instruments are presented on the accompanying consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Senior Notes were determined using third-party market quotes derived from orderly trades. As such, the Company classifies these instruments as Level 2.
Secured indebtedness: These instruments are presented on the accompanying consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Company’s secured debt were estimated using a discounted cash flow analysis based on management’s estimates of current market interest rates for instruments with similar characteristics, including remaining loan term, loan-to-value ratio, type of collateral and other credit enhancements. The Company utilized a rate of 6% in its fair value calculation. As such, the Company classifies these instruments as Level 3.
XML 47 R32.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Schedule of Future Minimum Lease Payments As of December 31, 2023, the weighted average remaining lease term and discount rate were 17 years and 8%, respectively, and the future minimum lease payments under the operating leases included in the Company’s lease liability were as follows (in thousands):
2024$1,310 
20251,802 
20261,324 
20271,347 
20281,330 
Thereafter18,104 
Undiscounted minimum lease payments included in the lease liability25,217 
Less: imputed interest(12,729)
Present value of lease liability$12,488 
XML 48 R33.htm IDEA: XBRL DOCUMENT v3.24.0.1
RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) (Tables)
12 Months Ended
Dec. 31, 2023
Business Combination and Asset Acquisition [Abstract]  
Schedule of Purchase Price Allocation The consideration was allocated as follows (in thousands):
Year Ended December 31,
20232022
Land$6,796 $11,767 
Building and improvements79,830 89,646 
Tenant origination and absorption costs intangible assets3,492 5,061 
Tenant relationship intangible assets255 41 
Total consideration$90,373 $106,515 
XML 49 R34.htm IDEA: XBRL DOCUMENT v3.24.0.1
INVESTMENT IN REAL ESTATE PROPERTIES (Tables)
12 Months Ended
Dec. 31, 2023
Real Estate [Abstract]  
Schedule of Real Estate Properties Held for Investment
The Company’s real estate properties held for investment consisted of the following (dollars in thousands):
As of December 31, 2023  
Property TypeNumber of
Properties
Number of
Beds/Units
Total
Real Estate
at Cost
Accumulated
Depreciation
Total
Real Estate
Investments, Net
Skilled Nursing/Transitional Care241 26,769 $3,050,861 $(535,653)$2,515,208 
Senior Housing - Leased43 3,473 573,274 (109,601)463,673 
Senior Housing - Managed61 6,041 1,289,485 (255,803)1,033,682 
Behavioral Health18 1,159 496,737 (71,943)424,794 
Specialty Hospitals and Other15 392 225,443 (47,454)177,989 
378 37,834 5,635,800 (1,020,454)4,615,346 
Corporate Level2,547 (632)1,915 
$5,638,347 $(1,021,086)$4,617,261 
As of December 31, 2022
Property TypeNumber of
Properties
Number of
Beds/Units
Total
Real Estate
at Cost
Accumulated
Depreciation
Total
Real Estate
Investments, Net
Skilled Nursing/Transitional Care264 29,136 $3,385,221 $(492,495)$2,892,726 
Senior Housing - Leased47 3,550 590,694 (97,716)492,978 
Senior Housing - Managed59 5,942 1,205,283 (222,089)983,194 
Behavioral Health17 965 465,143 (58,481)406,662 
Specialty Hospitals and Other15 392 225,443 (42,038)183,405 
402 39,985 5,871,784 (912,819)4,958,965 
Corporate Level904 (526)378 
$5,872,688 $(913,345)$4,959,343 
As of December 31,
20232022
Building and improvements$4,843,258 $5,034,470 
Furniture and equipment238,185 262,644 
Land improvements10,306 7,085 
Land546,598 568,489 
Total real estate at cost5,638,347 5,872,688 
Accumulated depreciation(1,021,086)(913,345)
Total real estate investments, net$4,617,261 $4,959,343 
Schedule of Future Minimum Rental Payments from Non-Cancelable Operating Leases
As of December 31, 2023, the future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases were as follows and may materially differ from actual future rental payments received (in thousands):
2024$377,721 
2025372,911 
2026357,434 
2027334,489 
2028310,963 
Thereafter1,289,067 
$3,042,585 
Schedule of Investment in Joint Ventures
The following is a summary of the Company’s investment in unconsolidated joint ventures (dollars in thousands):
Property Type
Number of
Properties as of
December 31, 2023
Ownership as of
December 31, 2023 (1)
Book Value as of December 31,
20232022
Sienna Joint VentureSenior Housing - Managed12 50 %$119,724 $120,269 
Marlin Spring Joint VentureSenior Housing - Managed85 %17,119 14,693 
$136,843 $134,962 
(1)    These investments are not consolidated because the Company does not control, through voting rights or other means, the joint ventures.
The following tables present summarized financial information for the Company’s investments in unconsolidated joint ventures (in thousands).
As of December 31,
20232022
Total assets$353,779 $754,220 
Total liabilities106,490 894,969 
Member’s equity (deficit)247,289 (140,749)
Year Ended December 31,
202320222021
Total revenues$64,446 $351,073 $274,693 
Operating expenses (1)
47,811 324,462 265,194 
Net loss(9,823)(66,171)(35,276)
Company’s share of net loss$(2,897)$(32,581)$(17,184)
Basis adjustments— 7,673 10,771 
Other-than-temporary impairment— 57,778 164,126 
Loss from unconsolidated joint venture$(2,897)$(98,032)$(192,081)
(1)    During the years ended December 31, 2022 and 2021, TPG caused the Enlivant Joint Venture to fund $25.0 million and $20.0 million, respectively, of payments to Enlivant beyond amounts contractually required under the management agreement. These payments were to support the operations of Enlivant and are reflected as operating expenses. Funding for the support payments did not require capital contributions from Sabra but rather were funded with proceeds received by the Enlivant Joint Venture from TPG for the issuance of senior preferred interests or with cash on hand at the Enlivant Joint Venture.
XML 50 R35.htm IDEA: XBRL DOCUMENT v3.24.0.1
IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS (Tables)
12 Months Ended
Dec. 31, 2023
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of Dispositions
The following table summarizes the Company’s dispositions for the periods presented (dollars in millions):
Year Ended December 31,
202320222021
Number of facilities281816
Consideration, net of closing costs$255.6 $87.3 $103.4 
Net carrying value332.2 99.3 92.1 
Net (loss) gain on sale$(76.6)$(12.0)$11.3 
XML 51 R36.htm IDEA: XBRL DOCUMENT v3.24.0.1
INTANGIBLE ASSETS AND LIABILITIES (Tables)
12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets and Liabilities
The following table summarizes the Company’s intangible assets and liabilities as of December 31, 2023 and 2022 (in thousands):
As of December 31,
20232022
Lease Intangible Assets:
Above market leases$7,496 $7,496 
Tenant origination and absorption costs43,071 58,578 
Tenant relationship16,983 20,119 
Gross lease intangible assets67,550 86,193 
Accumulated amortization(36,653)(46,062)
Lease intangible assets, net$30,897 $40,131 
Lease Intangible Liabilities:
Below market leases$68,573 $80,208 
Accumulated amortization(36,041)(37,964)
Lease intangible liabilities, net$32,532 $42,244 
Schedule of Real Estate Intangible Amortization Income (Expense)
The following is a summary of real estate intangible amortization income (expense) for the years ended December 31, 2023, 2022 and 2021 (in thousands): 
Year Ended December 31,
202320222021
Increase (decrease) to rental income related to above/below market leases, net (1)
$5,821 $6,624 $(13,512)
Depreciation and amortization related to tenant origination and absorption costs and tenant relationship(11,616)(17,591)(8,694)
(1)    Balance for the year ended December 31, 2021 includes $18.6 million of accelerated amortization related to the above market lease intangible associated with the Company’s lease with Avamere. See Note 4, “Investment in Real Estate Properties,” for further discussion.
Schedule of Remaining Unamortized Balance for Outstanding Intangible Assets
The remaining unamortized balance for these outstanding intangible assets and liabilities as of December 31, 2023 will be amortized for the years ending December 31 as follows (dollars in thousands):
Lease Intangible
Assets
 Lease Intangible
Liabilities
2024$5,523 $5,690 
20254,612 5,139 
20264,411 4,884 
20273,115 4,442 
20282,662 4,296 
Thereafter10,574 8,081 
$30,897 $32,532 
  
Weighted-average remaining amortization period8.8 years6.5 years
Schedule of Remaining Unamortized Balance for Outstanding Intangible Liabilities
The remaining unamortized balance for these outstanding intangible assets and liabilities as of December 31, 2023 will be amortized for the years ending December 31 as follows (dollars in thousands):
Lease Intangible
Assets
 Lease Intangible
Liabilities
2024$5,523 $5,690 
20254,612 5,139 
20264,411 4,884 
20273,115 4,442 
20282,662 4,296 
Thereafter10,574 8,081 
$30,897 $32,532 
  
Weighted-average remaining amortization period8.8 years6.5 years
XML 52 R37.htm IDEA: XBRL DOCUMENT v3.24.0.1
LOANS RECEIVABLE AND OTHER INVESTMENTS (Tables)
12 Months Ended
Dec. 31, 2023
Receivables [Abstract]  
Schedule of Loans Receivable and Other Investments As of December 31, 2023 and 2022, the Company’s loans receivable and other investments consisted of the following (dollars in thousands):
As of December 31, 2023
Investment
Quantity
as of
December 31, 2023
Property Type
Principal Balance as of December 31, 2023 (1)
Book Value
as of
December 31, 2023
Book Value
as of
December 31, 2022
Weighted Average Contractual Interest Rate / Rate of ReturnWeighted Average Annualized Effective Interest Rate / Rate of Return
Maturity Date
as of
December 31, 2023
Loans Receivable:
MortgageBehavioral Health$319,000 $319,000 $319,000 7.6 %7.6 %11/01/26 - 01/31/27
Other12 Multiple53,873 50,440 47,936 7.7 %7.4 %10/01/23 - 05/01/29
14 372,873 369,440 366,936 7.7 %7.6 %
Allowance for loan losses— (6,665)(6,611)
$372,873 $362,775 $360,325 
Other Investments:
Preferred EquitySkilled Nursing / Senior Housing57,681 57,849 51,071 11.0 %11.0 %N/A
Total19 $430,554 $420,624 $411,396 8.1 %8.1 %
(1)    Principal balance includes amounts funded and accrued but unpaid interest / preferred return and excludes capitalizable fees.
Schedule of Additional Information Regarding the Company's Loans Receivable
Additional information regarding the Company’s loans receivable is as follows (dollars in thousands):
Year Ended December 31,
202320222021
Allowance for loan losses:
Balance at the beginning of the year$6,611 $6,344 $2,458 
Provision for loan losses192 267 3,886 
Write-off of uncollectible balances(138)— — 
Balance at the end of the year$6,665 $6,611 $6,344 
As of December 31,
20232022
Deteriorated credit quality:
Number of loans receivable investments
Principal balance$1,214 $1,214 
Book value— — 
Nonaccrual status:
Number of loans receivable investments
Book value$— $— 
XML 53 R38.htm IDEA: XBRL DOCUMENT v3.24.0.1
DEBT (Tables)
12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
Schedule of Debt
The Company’s secured debt consists of the following (dollars in thousands):
Principal Balance as of December 31, (1)
As of December 31, 2023
Weighted Average Interest Rate
Weighted Average Effective Interest Rate (2)
Interest Rate Type
2023
2022
Maturity Date
Fixed Rate$48,143 $50,123 2.85 %3.34 %May 2031 - 
August 2051
(1)    Principal balance does not include deferred financing costs, net of $0.8 million and $0.9 million as of December 31, 2023 and 2022, respectively.
(2)    Weighted average effective interest rate includes private mortgage insurance.
The Company’s senior unsecured notes consist of the following (dollars in thousands):
Principal Balance as of December 31, (1)
TitleMaturity Date
2023
2022
5.125% senior unsecured notes due 2026
August 15, 2026$500,000 $500,000 
5.88% senior unsecured notes due 2027
May 17, 2027100,000 100,000 
3.90% senior unsecured notes due 2029
October 15, 2029350,000 350,000 
3.20% senior unsecured notes due 2031
December 1, 2031800,000 800,000 
$1,750,000 $1,750,000 
(1)    Principal balance does not include discount, net of $4.3 million and deferred financing costs, net of $10.5 million as of December 31, 2023 and does not include discount, net of $3.5 million and deferred financing costs, net of $12.0 million as of December 31, 2022. In addition, the weighted average effective interest rate as of December 31, 2023 was 4.01%.
Schedule of Maturities for Outstanding Debt
The following is a schedule of maturities for the Company’s outstanding debt as of December 31, 2023 (in thousands):
Secured
Indebtedness
Revolving
Credit Facility (1)
Term LoansSenior NotesTotal
2024$2,033 $— $— $— $2,033 
20252,089 — — — 2,089 
20262,147 — — 500,000 502,147 
20272,206 94,429 — 100,000 196,635 
20282,266 — 543,190 — 545,456 
Thereafter37,402 — — 1,150,000 1,187,402 
Total Debt48,143 94,429 543,190 1,750,000 2,435,762 
Discount, net— — — (4,258)(4,258)
Deferred financing costs, net(842)— (6,070)(10,489)(17,401)
Total Debt, Net$47,301 $94,429 $537,120 $1,735,253 $2,414,103 
(1)    Revolving Credit Facility is subject to two six-month extension options.
XML 54 R39.htm IDEA: XBRL DOCUMENT v3.24.0.1
DERIVATIVE AND HEDGING INSTRUMENTS (Tables)
12 Months Ended
Dec. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Notional Amount of Derivatives Instruments
The following presents the notional amount of derivative instruments as of the dates indicated (in thousands):  
As of December 31,
20232022
Derivatives designated as cash flow hedges:
Denominated in U.S. Dollars (1)
$753,750 $436,250 
Denominated in Canadian Dollars (2)
$300,000 $125,000 
Derivatives designated as net investment hedges:
Denominated in Canadian Dollars$55,335 $55,991 
Financial instrument designated as net investment hedge:
Denominated in Canadian Dollars$194,300 $329,500 
Derivatives not designated as net investment hedges:
Denominated in Canadian Dollars$965 $309 
(1) Balance as of December 31, 2023 includes two forward starting interest rate swaps with an effective date of August 2024 and an aggregate notional amount of $323.8 million.
(2)    Balance as of December 31, 2023 includes two forward starting interest rate swaps with an effective date of September 2024 and an aggregate notional amount of CAD $150.0 million.
Schedule of Derivative and Financial Instruments Designated as Hedging Instruments
The following is a summary of the derivative and financial instruments designated as hedging instruments held by the Company at December 31, 2023 and 2022 (dollars in thousands):    
Count as of December 31, 2023
Maturity Dates
Fair Value as of December 31,
TypeDesignation20232022Balance Sheet Location
Assets:
Interest rate swapsCash flow$6,002 $11,004 2024 - 2028Accounts receivable, prepaid expenses and other assets, net
Interest rate collarsCash flow3,216 6,622 2024Accounts receivable, prepaid expenses and other assets, net
Forward starting interest rate swapsCash flow6,736 — 2028Accounts receivable, prepaid expenses and other assets, net
Cross currency interest rate swapsNet investment2,964 3,851 2025Accounts receivable, prepaid expenses and other assets, net
$18,918 $21,477 
Liabilities:
CAD borrowings under Revolving Credit FacilityNet investment33,429 150,982 2027Revolving credit facility
CAD Term LoanNet investment113,190 92,288 2028Term loans, net
$146,619 $243,270 
Effect of Derivatives and Financial Instruments Designated as Hedging Instruments on Income and Equity
The following presents the effect of the Company’s derivative and financial instruments designated as hedging instruments on the consolidated statements of income (loss) and the consolidated statements of equity for the years ended December 31, 2023, 2022 and 2021 (in thousands):
Gain (Loss) Recognized in Other Comprehensive Income (Loss)Gain (Loss) Reclassified from Accumulated Other Comprehensive Income (Loss)
Into Income
Income Statement Location
For the year ended December 31,
202320222021202320222021
Cash Flow Hedges:
Interest rate products$13,116 $22,032 $17,408 $8,332 $(4,179)$(12,774)Interest expense
Net Investment Hedges:
Foreign currency products(664)2,233 (272)— — — N/A
CAD borrowings under Revolving Credit Facility(3,456)9,454 — — — — N/A
CAD Term Loan(2,465)6,150 (338)— — — N/A
$6,531 $39,869 $16,798 $8,332 $(4,179)$(12,774)
Gross Presentation, Effects of Offsetting, and a Net Presentation of Derivatives, Assets The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of December 31, 2023 and 2022 (in thousands):
As of December 31, 2023
Gross Amounts of Recognized Assets / LiabilitiesGross Amounts Offset in the Balance SheetNet Amounts of Assets / Liabilities presented in the Balance SheetGross Amounts Not Offset in the Balance Sheet
Financial InstrumentsCash Collateral ReceivedNet Amount
Offsetting Assets:
Derivatives$18,918 $— $18,918 $— $— $18,918 
Offsetting Liabilities:
Derivatives$— $— $— $— $— $— 
As of December 31, 2022
Gross Amounts of Recognized Assets / LiabilitiesGross Amounts Offset in the Balance SheetNet Amounts of Assets / Liabilities presented in the Balance SheetGross Amounts Not Offset in the Balance Sheet
Financial InstrumentsCash Collateral ReceivedNet Amount
Offsetting Assets:
Derivatives$21,477 $— $21,477 $— $— $21,477 
Offsetting Liabilities:
Derivatives$— $— $— $— $— $— 
Gross Presentation, Effects of Offsetting, and a Net Presentation of Derivatives, Liabilities The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of December 31, 2023 and 2022 (in thousands):
As of December 31, 2023
Gross Amounts of Recognized Assets / LiabilitiesGross Amounts Offset in the Balance SheetNet Amounts of Assets / Liabilities presented in the Balance SheetGross Amounts Not Offset in the Balance Sheet
Financial InstrumentsCash Collateral ReceivedNet Amount
Offsetting Assets:
Derivatives$18,918 $— $18,918 $— $— $18,918 
Offsetting Liabilities:
Derivatives$— $— $— $— $— $— 
As of December 31, 2022
Gross Amounts of Recognized Assets / LiabilitiesGross Amounts Offset in the Balance SheetNet Amounts of Assets / Liabilities presented in the Balance SheetGross Amounts Not Offset in the Balance Sheet
Financial InstrumentsCash Collateral ReceivedNet Amount
Offsetting Assets:
Derivatives$21,477 $— $21,477 $— $— $21,477 
Offsetting Liabilities:
Derivatives$— $— $— $— $— $— 
XML 55 R40.htm IDEA: XBRL DOCUMENT v3.24.0.1
FAIR VALUE DISCLOSURES (Tables)
12 Months Ended
Dec. 31, 2023
Fair Value Disclosures [Abstract]  
Schedule of Face Values, Carrying Amounts and Fair Values of Financial Instruments
The following are the face values, carrying amounts and fair values of the Company’s financial instruments as of December 31, 2023 and 2022 whose carrying amounts do not approximate their fair value (in thousands):
 As of December 31, 2023As of December 31, 2022
 
Face
Value
(1)
Carrying
Amount
(2)
Fair
Value
Face
Value
(1)
Carrying
Amount
(2)
Fair
Value
Financial assets:
Loans receivable$372,873 $362,775 $383,141 $370,364 $360,325 $370,188 
Preferred equity investments57,681 57,849 59,526 50,902 51,071 51,995 
Financial liabilities:
Senior Notes1,750,000 1,735,253 1,567,428 1,750,000 1,734,431 1,463,041 
Secured indebtedness48,143 47,301 36,279 50,123 49,232 38,149 
(1)    Face value represents amounts contractually due under the terms of the respective agreements.
(2)    Carrying amount represents the book value of financial instruments, including unamortized premiums/discounts and deferred financing costs.
Schedule of Fair Value of Financial Instruments
The Company determined the fair value of financial instruments as of December 31, 2023 whose carrying amounts do not approximate their fair value with valuation methods utilizing the following types of inputs (in thousands):
Fair Value Measurements Using
TotalQuoted Prices in
Active Markets for
Identical Assets
(Level 1)
Significant Other
Observable Inputs
(Level 2)
Significant
Unobservable Inputs
(Level 3)
Financial assets:
Loans receivable$383,141 $— $— $383,141 
Preferred equity investments59,526 — — 59,526 
Financial liabilities:
Senior Notes1,567,428 — 1,567,428 — 
Secured indebtedness36,279 — — 36,279 
Schedule of Items Measured at Fair Value on a Recurring Basis
During the year ended December 31, 2023, the Company recorded the following amounts measured at fair value (in thousands):
Fair Value Measurements Using
TotalQuoted Prices in
Active Markets for
Identical Assets
(Level 1)
Significant Other
Observable Inputs
(Level 2)
Significant
Unobservable Inputs
(Level 3)
Recurring Basis:
Financial assets:
Interest rate swaps$6,002 $— $6,002 $— 
Interest rate collars3,216 — 3,216 — 
Forward starting interest rate swaps6,736 — 6,736 — 
Cross currency interest rate swaps2,964 — 2,964 — 
XML 56 R41.htm IDEA: XBRL DOCUMENT v3.24.0.1
EQUITY (Tables)
12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
Schedule of Accumulated Other Comprehensive Income
The following is a summary of the Company’s accumulated other comprehensive income (in thousands):
As of December 31,
20232022
Foreign currency translation gain$963 $1,168 
Unrealized gain on cash flow hedges22,782 17,895 
Total accumulated other comprehensive income$23,745 $19,063 
XML 57 R42.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCK-BASED COMPENSATION (Tables)
12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Summary of Additional Information Concerning Restricted Stock Units
The following table summarizes additional information concerning restricted stock units at December 31, 2023:
Restricted Stock UnitsWeighted Average Grant Date Fair Value Per Unit
Unvested as of December 31, 20222,147,784 $15.07 
Granted832,308 14.73 
Vested(591,745)15.34 
Dividends reinvested237,195 14.96 
Cancelled/forfeited(156,275)19.51 
Unvested as of December 31, 20232,469,267 $14.61 
Summary of Assumptions Used in Total Stockholder Return-Based Stock Units Valuation The following are the key assumptions used in this valuation:
202320222021
Risk free interest rate
3.98% - 4.13%
0.99% - 4.13%
0.17% - 0.99%
Expected stock price volatility
30.17% - 56.11%
53.60% - 56.11%
53.17% - 53.60%
Expected service period
3.0 years
3.0 years
3.0 years
Expected dividend yield (assuming full reinvestment)— %— %— %
XML 58 R43.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES (Tables)
12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Schedule of Provision for Income Tax Expense
The following is a summary of the Company’s provision for income taxes and deferred taxes (in thousands):
Year Ended December 31,
202320222021
Provision for federal, state and local income taxes$2,002 $1,234 $2,263 
Provision (benefit) for foreign income taxes— (418)
Income tax expense$2,002 $1,242 $1,845 
As of December 31,
20232022
Deferred tax assets:
Federal$9,553 $6,390 
Valuation allowance on federal(9,553)(6,390)
Foreign12,211 8,455 
Valuation allowance on foreign(12,169)(8,430)
Deferred tax (liabilities):
Foreign(42)(25)
$— $— 
Schedule of Deferred Taxes
The following is a summary of the Company’s provision for income taxes and deferred taxes (in thousands):
Year Ended December 31,
202320222021
Provision for federal, state and local income taxes$2,002 $1,234 $2,263 
Provision (benefit) for foreign income taxes— (418)
Income tax expense$2,002 $1,242 $1,845 
As of December 31,
20232022
Deferred tax assets:
Federal$9,553 $6,390 
Valuation allowance on federal(9,553)(6,390)
Foreign12,211 8,455 
Valuation allowance on foreign(12,169)(8,430)
Deferred tax (liabilities):
Foreign(42)(25)
$— $— 
XML 59 R44.htm IDEA: XBRL DOCUMENT v3.24.0.1
EARNINGS PER COMMON SHARE (Tables)
12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
Computation of Basic and Diluted Earnings Per Share
The following table illustrates the computation of basic and diluted earnings per share (in thousands, except share and per share amounts):
Year Ended December 31,
202320222021
Numerator
Net income (loss)$13,756 $(77,605)$(113,256)
Denominator
Basic weighted average common shares and common equivalents231,203,391 230,947,895 219,073,027 
Dilutive restricted stock units1,589,387 — — 
Diluted weighted average common shares232,792,778 230,947,895 219,073,027 
Net income (loss), per:
Basic common share$0.06 $(0.34)$(0.52)
Diluted common share$0.06 $(0.34)$(0.52)
XML 60 R45.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)
12 Months Ended
Dec. 31, 2023
USD ($)
segment
investment
variableInterestEntity
Dec. 31, 2022
USD ($)
investment
Dec. 31, 2021
USD ($)
Accounting Policies [Line Items]      
Number of investments in loans accounted for as real estate joint ventures | investment 0 0  
Gain on business interruption insurance recovery, statement of income or comprehensive income Other income (expense)    
Assets held for sale $ 0 $ 0  
Restricted cash 5,434,000 4,624,000  
Restricted cash obligations 1,400,000 3,900,000  
Operating lease right-of-use asset 11,600,000 8,500,000  
Operating lease liability $ 12,488,000 $ 9,200,000  
Operating lease, liability, statement of financial position Accounts payable and accrued liabilities Accounts payable and accrued liabilities  
Operating lease, right-of-use asset, statement of financial position Accounts receivable, prepaid expenses and other assets, net Accounts receivable, prepaid expenses and other assets, net  
Operating lease, expense $ 1,400,000 $ 1,200,000 $ 1,200,000
Weighted-average remaining term of operating leases 17 years    
Weighted average discount rate 8.00%    
Number of reportable segments | segment 1    
Vandalism And Theft      
Accounting Policies [Line Items]      
Proceeds of insurance $ 6,200,000    
Gain of unusual amount 3,700,000    
Fire      
Accounting Policies [Line Items]      
Proceeds of insurance 1,100,000    
Gain of unusual amount 500,000    
Resident fee and services      
Accounting Policies [Line Items]      
Grants recognized 100,000 $ 100,000 $ 500,000
Loss from unconsolidated joint venture      
Accounting Policies [Line Items]      
Grants recognized $ 3,600,000    
Minimum | Land improvements      
Accounting Policies [Line Items]      
Estimated useful lives of assets 15 years    
Minimum | Buildings and building improvements      
Accounting Policies [Line Items]      
Estimated useful lives of assets 5 years    
Minimum | Furniture and equipment      
Accounting Policies [Line Items]      
Estimated useful lives of assets 3 years    
Maximum | Land improvements      
Accounting Policies [Line Items]      
Estimated useful lives of assets 20 years    
Maximum | Buildings and building improvements      
Accounting Policies [Line Items]      
Estimated useful lives of assets 45 years    
Maximum | Furniture and equipment      
Accounting Policies [Line Items]      
Estimated useful lives of assets 10 years    
Primary beneficiary      
Accounting Policies [Line Items]      
Number of variable interest entities | variableInterestEntity 0    
XML 61 R46.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Accounting Policies [Abstract]    
2024 $ 1,310  
2025 1,802  
2026 1,324  
2027 1,347  
2028 1,330  
Thereafter 18,104  
Undiscounted minimum lease payments included in the lease liability 25,217  
Less: imputed interest (12,729)  
Present value of lease liability $ 12,488 $ 9,200
XML 62 R47.htm IDEA: XBRL DOCUMENT v3.24.0.1
RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) - Narrative (Details)
$ in Thousands
3 Months Ended 12 Months Ended
Jun. 30, 2023
USD ($)
property
Dec. 31, 2023
USD ($)
property
Dec. 31, 2022
USD ($)
property
Dec. 31, 2021
USD ($)
Business Acquisition [Line Items]        
Payment for contingent consideration | $   $ 17,900 $ 2,500 $ 0
Recent Real Estate Acquisitions        
Business Acquisition [Line Items]        
Total revenues | $   10,400 11,100  
Net income (loss) | $   $ 700 $ (1,600)  
Recent Real Estate Acquisitions | Tenant origination and absorption costs        
Business Acquisition [Line Items]        
Weighted-average amortization period of intangible assets   4 years 2 years  
Recent Real Estate Acquisitions | Tenant relationships        
Business Acquisition [Line Items]        
Weighted-average amortization period of intangible assets   22 years 25 years  
Recent Real Estate Acquisitions | Skilled nursing transitional care facility        
Business Acquisition [Line Items]        
Number of acquired properties   2    
Recent Real Estate Acquisitions | Senior housing - leased portfolio        
Business Acquisition [Line Items]        
Number of acquired properties   1    
Recent Real Estate Acquisitions | Senior housing - managed portfolio        
Business Acquisition [Line Items]        
Number of acquired properties   1 3  
Preferred equity investment book value at acquisition | $   $ 4,600 $ 14,300  
Payment for contingent consideration | $ $ 17,900      
Number of properties 2      
Recent Real Estate Acquisitions | Behavioral health facility        
Business Acquisition [Line Items]        
Number of acquired properties     1  
Recent Real Estate Acquisitions | Senior housing facilities - managed communities, proprietary development pipeline        
Business Acquisition [Line Items]        
Number of acquired properties     2  
XML 63 R48.htm IDEA: XBRL DOCUMENT v3.24.0.1
RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED)- Purchase Price Allocation for Recent Real Estate Acquisitions (Details) - Recent Real Estate Acquisitions - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Business Acquisition [Line Items]    
Land $ 6,796 $ 11,767
Building and improvements 79,830 89,646
Total consideration 90,373 106,515
Tenant origination and absorption costs intangible assets    
Business Acquisition [Line Items]    
Tenant intangible assets 3,492 5,061
Tenant relationship intangible assets    
Business Acquisition [Line Items]    
Tenant intangible assets $ 255 $ 41
XML 64 R49.htm IDEA: XBRL DOCUMENT v3.24.0.1
INVESTMENT IN REAL ESTATE PROPERTIES - Real Estate Properties Held for Investment (Details)
$ in Thousands
Dec. 31, 2023
USD ($)
bed
facility
Dec. 31, 2022
USD ($)
bed
facility
Real Estate Properties [Line Items]    
Building and improvements $ 4,843,258 $ 5,034,470
Furniture and equipment 238,185 262,644
Land improvements 10,306 7,085
Land 546,598 568,489
Total Real Estate at Cost 5,638,347 5,872,688
Accumulated Depreciation (1,021,086) (913,345)
Total Real Estate Investments, Net $ 4,617,261 $ 4,959,343
Operating Segments    
Real Estate Properties [Line Items]    
Number of Properties | facility 378 402
Number of Beds/Units | bed 37,834 39,985
Total Real Estate at Cost $ 5,635,800 $ 5,871,784
Accumulated Depreciation (1,020,454) (912,819)
Total Real Estate Investments, Net $ 4,615,346 $ 4,958,965
Operating Segments | Skilled Nursing/Transitional Care    
Real Estate Properties [Line Items]    
Number of Properties | facility 241 264
Number of Beds/Units | bed 26,769 29,136
Total Real Estate at Cost $ 3,050,861 $ 3,385,221
Accumulated Depreciation (535,653) (492,495)
Total Real Estate Investments, Net $ 2,515,208 $ 2,892,726
Operating Segments | Senior Housing - Leased    
Real Estate Properties [Line Items]    
Number of Properties | facility 43 47
Number of Beds/Units | bed 3,473 3,550
Total Real Estate at Cost $ 573,274 $ 590,694
Accumulated Depreciation (109,601) (97,716)
Total Real Estate Investments, Net $ 463,673 $ 492,978
Operating Segments | Senior Housing - Managed    
Real Estate Properties [Line Items]    
Number of Properties | facility 61 59
Number of Beds/Units | bed 6,041 5,942
Total Real Estate at Cost $ 1,289,485 $ 1,205,283
Accumulated Depreciation (255,803) (222,089)
Total Real Estate Investments, Net $ 1,033,682 $ 983,194
Operating Segments | Behavioral Health    
Real Estate Properties [Line Items]    
Number of Properties | facility 18 17
Number of Beds/Units | bed 1,159 965
Total Real Estate at Cost $ 496,737 $ 465,143
Accumulated Depreciation (71,943) (58,481)
Total Real Estate Investments, Net $ 424,794 $ 406,662
Operating Segments | Specialty Hospitals and Other    
Real Estate Properties [Line Items]    
Number of Properties | facility 15 15
Number of Beds/Units | bed 392 392
Total Real Estate at Cost $ 225,443 $ 225,443
Accumulated Depreciation (47,454) (42,038)
Total Real Estate Investments, Net 177,989 183,405
Corporate Level    
Real Estate Properties [Line Items]    
Total Real Estate at Cost 2,547 904
Accumulated Depreciation (632) (526)
Total Real Estate Investments, Net $ 1,915 $ 378
XML 65 R50.htm IDEA: XBRL DOCUMENT v3.24.0.1
INVESTMENT IN REAL ESTATE PROPERTIES - Operating Leases Narrative (Details)
$ in Millions
1 Months Ended 12 Months Ended
Feb. 01, 2022
USD ($)
Jan. 31, 2022
USD ($)
Dec. 31, 2023
USD ($)
facility
Dec. 31, 2022
USD ($)
facility
Dec. 31, 2021
USD ($)
Real Estate Properties [Line Items]          
Weighted-average remaining term of operating leases     17 years    
Security deposit liability     $ 16.4 $ 13.0  
Letters of credit deposited     56.0 57.0  
Tenant deposits for future real estate taxes, insurance expenditures, and tenant improvements     12.4 13.3  
Variable lease revenue     $ 15.3 17.7 $ 18.0
Avamere          
Real Estate Properties [Line Items]          
Annual base rent $ 30.7 $ 44.1      
Avamere | Non-cash rent receivable          
Real Estate Properties [Line Items]          
Write-off of non-cash rent receivable         $ 25.2
North American Health Care, Inc          
Real Estate Properties [Line Items]          
Write-off of non-cash rent receivable       $ 15.6  
Senior housing - managed portfolio          
Real Estate Properties [Line Items]          
Weighted-average remaining term of operating leases     8 years    
Senior housing - managed portfolio | Minimum          
Real Estate Properties [Line Items]          
Operating lease expiration period     1 year    
Senior housing - managed portfolio | Maximum          
Real Estate Properties [Line Items]          
Operating lease expiration period     19 years    
Operating Segments          
Real Estate Properties [Line Items]          
Number of properties | facility     378 402  
Operating Segments | Senior housing - managed portfolio          
Real Estate Properties [Line Items]          
Number of properties | facility     61 59  
XML 66 R51.htm IDEA: XBRL DOCUMENT v3.24.0.1
INVESTMENT IN REAL ESTATE PROPERTIES - Future Minimum Rental Payments from Non-Cancelable Operating Leases (Details)
$ in Thousands
Dec. 31, 2023
USD ($)
Future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases:  
2024 $ 377,721
2025 372,911
2026 357,434
2027 334,489
2028 310,963
Thereafter 1,289,067
Total $ 3,042,585
XML 67 R52.htm IDEA: XBRL DOCUMENT v3.24.0.1
INVESTMENT IN REAL ESTATE PROPERTIES - Senior Housing - Managed Communities Narrative (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disaggregation of Revenue [Line Items]      
Resident fees and services $ 236,153 $ 186,672 $ 155,512
Ancillary services      
Disaggregation of Revenue [Line Items]      
Resident fees and services $ 2,000 $ 1,500 $ 1,300
XML 68 R53.htm IDEA: XBRL DOCUMENT v3.24.0.1
INVESTMENT IN REAL ESTATE PROPERTIES - Capital and Other Expenditures Narrative (Details)
$ in Millions
12 Months Ended
Dec. 31, 2023
USD ($)
Real Estate [Abstract]  
Future capital expenditures $ 27
XML 69 R54.htm IDEA: XBRL DOCUMENT v3.24.0.1
INVESTMENT IN REAL ESTATE PROPERTIES - Schedule of Investment in Joint Ventures (Details)
$ in Thousands, $ in Millions
Dec. 31, 2023
USD ($)
property
Dec. 31, 2023
CAD ($)
property
Dec. 31, 2022
USD ($)
Dec. 31, 2022
CAD ($)
Schedule of Equity Method Investments [Line Items]        
Book value $ 136,843   $ 134,962  
Sienna Joint Venture        
Schedule of Equity Method Investments [Line Items]        
Ownership 50.00% 50.00%    
Book value $ 119,724   120,269  
Marlin Spring Joint Venture        
Schedule of Equity Method Investments [Line Items]        
Ownership 85.00% 85.00%    
Book value $ 17,119   $ 14,693  
Senior Housing - Managed | Sienna Joint Venture        
Schedule of Equity Method Investments [Line Items]        
Book value       $ 161.8
Senior Housing - Managed | Marlin Spring Joint Venture        
Schedule of Equity Method Investments [Line Items]        
Book value   $ 6.1   $ 16.6
Senior Housing - Managed | Sienna Joint Venture        
Schedule of Equity Method Investments [Line Items]        
Number of properties | property 12 12    
Senior Housing - Managed | Marlin Spring Joint Venture        
Schedule of Equity Method Investments [Line Items]        
Number of properties | property 4 4    
XML 70 R55.htm IDEA: XBRL DOCUMENT v3.24.0.1
INVESTMENT IN REAL ESTATE PROPERTIES - Investment in Unconsolidated Joint Venture Narrative (Details)
$ in Millions
3 Months Ended 12 Months Ended
Dec. 31, 2022
USD ($)
property
Jun. 30, 2021
USD ($)
Dec. 31, 2023
USD ($)
property
Dec. 31, 2023
CAD ($)
Dec. 31, 2022
USD ($)
property
Dec. 31, 2022
CAD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2023
CAD ($)
property
Dec. 31, 2022
CAD ($)
property
Schedule of Equity Method Investments [Line Items]                  
Investment in unconsolidated joint ventures $ 134,962,000   $ 136,843,000   $ 134,962,000        
Other-than-temporary impairment of unconsolidated joint ventures     0   57,778,000   $ 164,126,000    
Marlin Spring Joint Venture                  
Schedule of Equity Method Investments [Line Items]                  
Investment in unconsolidated joint ventures 14,693,000   $ 17,119,000   14,693,000        
Equity interest in joint venture     85.00%         85.00%  
Sienna Joint Venture                  
Schedule of Equity Method Investments [Line Items]                  
Investment in unconsolidated joint ventures 120,269,000   $ 119,724,000   120,269,000        
Equity interest in joint venture     50.00%         50.00%  
Enlivant Joint Venture                  
Schedule of Equity Method Investments [Line Items]                  
Equity interest in joint venture   49.00%              
Other-than-temporary impairment of unconsolidated joint ventures 57,800,000 $ 164,100,000 $ 0   $ 57,778,000   $ 164,126,000    
Equity interest, investment basis amount $ 0                
Senior Housing - Managed | Marlin Spring Joint Venture                  
Schedule of Equity Method Investments [Line Items]                  
Number of acquired properties | property 3   1   3     1 3
Payments to acquire buildings       $ 30.0   $ 82.5      
Investment in unconsolidated joint ventures               $ 6.1 $ 16.6
Senior Housing - Managed | Marlin Spring Joint Venture | Marlin Spring Joint Venture                  
Schedule of Equity Method Investments [Line Items]                  
Debt assumed               $ 23.6 $ 65.0
Senior Housing - Managed | Sienna Joint Venture                  
Schedule of Equity Method Investments [Line Items]                  
Number of acquired properties | property 12       12       12
Payments to acquire buildings           $ 379.0      
Investment in unconsolidated joint ventures                 $ 161.8
Senior Housing - Managed | Sienna Joint Venture | Sienna Senior Living                  
Schedule of Equity Method Investments [Line Items]                  
Debt assumed                 $ 53.4
XML 71 R56.htm IDEA: XBRL DOCUMENT v3.24.0.1
INVESTMENT IN REAL ESTATE PROPERTIES - Summarized Financial Information for Enlivant Joint Venture (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2022
Jun. 30, 2021
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Balance Sheet Amounts          
Total assets $ 5,747,672   $ 5,386,150 $ 5,747,672  
Total liabilities 2,691,277   2,583,616 2,691,277  
Income Statement Amounts          
Total revenues     647,514 624,811 $ 569,545
Other-than-temporary impairment     0 57,778 164,126
Loss from unconsolidated joint venture     (2,897) (98,032) (192,081)
Enlivant Joint Venture          
Income Statement Amounts          
Company’s share of net loss     (2,897) (32,581) (17,184)
Basis adjustments     0 7,673 10,771
Other-than-temporary impairment 57,800 $ 164,100 0 57,778 164,126
Loss from unconsolidated joint venture     (2,897) (98,032) (192,081)
Enlivant Joint Venture          
Balance Sheet Amounts          
Total assets 754,220   353,779 754,220  
Total liabilities 894,969   106,490 894,969  
Member’s equity (deficit) $ (140,749)   247,289 (140,749)  
Income Statement Amounts          
Total revenues     64,446 351,073 274,693
Operating expenses     47,811 324,462 265,194
Net loss     $ (9,823) (66,171) (35,276)
Funding payments beyond contractual requirements       $ 25,000 $ 20,000
XML 72 R57.htm IDEA: XBRL DOCUMENT v3.24.0.1
INVESTMENT IN REAL ESTATE PROPERTIES - Net Investment in Sales-Type Lease Narrative (Details)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
property
Dec. 31, 2021
USD ($)
Real Estate Properties [Line Items]        
Net proceeds from sales-type lease   $ 25,490 $ 0 $ 0
Skilled Nursing/Transitional Care        
Real Estate Properties [Line Items]        
Net investment in sales type lease     $ 25,500  
Properties in sales-type | property     1  
Net proceeds from sales-type lease $ 25,500      
XML 73 R58.htm IDEA: XBRL DOCUMENT v3.24.0.1
IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS - Narrative (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2023
USD ($)
facility
Dec. 31, 2022
USD ($)
facility
Dec. 31, 2021
USD ($)
facility
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Impairment of real estate | $ $ 14,332 $ 94,042 $ 9,499
Sold | Facilities      
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]      
Number of real estate properties impaired | facility 3 10 3
XML 74 R59.htm IDEA: XBRL DOCUMENT v3.24.0.1
IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS - Dispositions (Details)
$ in Millions
12 Months Ended
Dec. 31, 2023
USD ($)
facility
Dec. 31, 2022
USD ($)
facility
Dec. 31, 2021
USD ($)
facility
Dispositions:      
Number of facilities | facility 28 18 16
Consideration, net of closing costs $ 255.6 $ 87.3 $ 103.4
Net carrying value 332.2 99.3 92.1
Net (loss) gain on sale (76.6) (12.0) 11.3
Net income (loss) (80.9) (94.8) 21.5
Impairment upon disposal $ 7.1 $ 94.0 $ 9.5
Disposal group, not discontinued operations, gain (loss) on disposal, statement of income Net (loss) gain on sale    
XML 75 R60.htm IDEA: XBRL DOCUMENT v3.24.0.1
INTANGIBLE ASSETS AND LIABILITIES - Intangible Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Lease Intangible Assets:    
Gross lease intangible assets $ 67,550 $ 86,193
Accumulated amortization (36,653) (46,062)
Lease intangible assets, net 30,897 40,131
Lease Intangible Liabilities:    
Below market leases 68,573 80,208
Accumulated amortization (36,041) (37,964)
Lease intangible liabilities, net 32,532 42,244
Above market leases    
Lease Intangible Assets:    
Gross lease intangible assets 7,496 7,496
Tenant origination and absorption costs    
Lease Intangible Assets:    
Gross lease intangible assets 43,071 58,578
Tenant relationship    
Lease Intangible Assets:    
Gross lease intangible assets $ 16,983 $ 20,119
XML 76 R61.htm IDEA: XBRL DOCUMENT v3.24.0.1
INTANGIBLE ASSETS AND LIABILITIES - Real Estate Intangible Amortization (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Real estate intangible amortization income (expense)      
Increase (decrease) to rental income related to above/below market leases, net $ 5,821 $ 6,624 $ (13,512)
Depreciation and amortization related to tenant origination and absorption costs and tenant relationship $ (11,616) $ (17,591) (8,694)
Avamere | Above market leases      
Real estate intangible amortization income (expense)      
Accelerated amortization     $ 18,600
XML 77 R62.htm IDEA: XBRL DOCUMENT v3.24.0.1
INTANGIBLE ASSETS AND LIABILITIES - Remaining Unamortized Balance for Outstanding Intangible Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Lease Intangible Assets    
2023 $ 5,523  
2024 4,612  
2025 4,411  
2026 3,115  
2027 2,662  
Thereafter 10,574  
Lease intangible assets, net $ 30,897 $ 40,131
Weighted-average remaining amortization period 8 years 9 months 18 days  
Lease Intangible Liabilities    
2023 $ 5,690  
2024 5,139  
2025 4,884  
2026 4,442  
2027 4,296  
Thereafter 8,081  
Lease intangible liabilities, net $ 32,532 $ 42,244
Weighted-average remaining amortization period 6 years 6 months  
XML 78 R63.htm IDEA: XBRL DOCUMENT v3.24.0.1
LOANS RECEIVABLE AND OTHER INVESTMENTS - Composition of Loans Receivable and Other Investments (Details)
$ in Thousands
Dec. 31, 2023
USD ($)
investment
loan
preferredEquityInvestment
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Loans Receivable:        
Quantity | loan 14      
Principal balance $ 372,873 $ 370,364    
Book Value 369,440 366,936    
Allowance for loan losses (6,665) (6,611) $ (6,344) $ (2,458)
Book Value $ 362,775 360,325    
Weighted Average Contractual Interest Rate / Rate of Return 7.70%      
Weighted Average Annualized Effective Interest Rate / Rate of Return 7.60%      
Other Investments:        
Quantity | preferredEquityInvestment 5      
Principal Balance $ 57,681 50,902    
Book Value $ 57,849 51,071    
Weighted Average Contractual Interest Rate / Rate of Return 11.00%      
Weighted Average Annualized Effective Interest Rate / Rate of Return 11.00%      
Total Quantity | investment 19      
Total Principal Balance $ 430,554      
Total Book Value $ 420,624 411,396    
Total weighted average contractual interest rate / rate of return 8.10%      
Total weighted average annualized effective interest rate / rate of return 8.10%      
Mortgage        
Loans Receivable:        
Quantity | loan 2      
Principal balance $ 319,000      
Book Value $ 319,000 319,000    
Weighted Average Contractual Interest Rate / Rate of Return 7.60%      
Weighted Average Annualized Effective Interest Rate / Rate of Return 7.60%      
Other        
Loans Receivable:        
Quantity | loan 12      
Principal balance $ 53,873      
Book Value $ 50,440 $ 47,936    
Weighted Average Contractual Interest Rate / Rate of Return 7.70%      
Weighted Average Annualized Effective Interest Rate / Rate of Return 7.40%      
XML 79 R64.htm IDEA: XBRL DOCUMENT v3.24.0.1
LOANS RECEIVABLE AND OTHER INVESTMENTS - Narrative (Details) - Future funding on investment
$ in Millions
Dec. 31, 2023
USD ($)
investment
Accounts, Notes, Loans and Financing Receivable [Line Items]  
Future funding commitment | $ $ 0.5
Number of preferred equity investments for funding commitment | investment 1
XML 80 R65.htm IDEA: XBRL DOCUMENT v3.24.0.1
LOANS RECEIVABLE AND OTHER INVESTMENTS - Schedule of Additional Information Regarding the Company's Loans Receivable (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2023
USD ($)
loan
Dec. 31, 2022
USD ($)
loan
Dec. 31, 2021
USD ($)
Financing Receivable, Allowance for Credit Loss [Roll Forward]      
Balance at the beginning of the year $ 6,611 $ 6,344 $ 2,458
Provision for loan losses 192 267 3,886
Write-off of uncollectible balances (138) 0 0
Balance at the end of the year 6,665 6,611 $ 6,344
Accounts, Notes, Loans and Financing Receivable [Line Items]      
Principal balance 372,873 370,364  
Book value $ 362,775 $ 360,325  
Nonaccrual status      
Accounts, Notes, Loans and Financing Receivable [Line Items]      
Number of loans receivable investments | loan 3 3  
Book value $ 0 $ 0  
Deteriorated credit quality      
Accounts, Notes, Loans and Financing Receivable [Line Items]      
Number of loans receivable investments | loan 1 1  
Principal balance $ 1,214 $ 1,214  
Book value $ 0 $ 0  
XML 81 R66.htm IDEA: XBRL DOCUMENT v3.24.0.1
DEBT - Secured Indebtedness (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Debt Instrument [Line Items]    
Deferred financing costs $ 17,401  
Secured Debt    
Debt Instrument [Line Items]    
Deferred financing costs 842 $ 900
Secured Debt | Fixed Rate    
Debt Instrument [Line Items]    
Principal balance $ 48,143 $ 50,123
Weighted average interest rate (percent) 2.85%  
Weighted average effective interest rate (percent) 3.34%  
XML 82 R67.htm IDEA: XBRL DOCUMENT v3.24.0.1
DEBT - Secured Indebtedness Narrative (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
facility
Dec. 31, 2021
USD ($)
facility
Debt Instrument [Line Items]      
Repayments of fixed rate secured debt $ 1,979 $ 17,516 $ 12,661
Loss on extinguishment of debt $ 1,541 411 34,622
Secured Indebtedness      
Debt Instrument [Line Items]      
Repayments of fixed rate secured debt   $ 15,400 $ 9,800
Number of properties sold securing debt | facility   3 2
Loss on extinguishment of debt     $ 100
XML 83 R68.htm IDEA: XBRL DOCUMENT v3.24.0.1
DEBT - Senior Unsecured Notes (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Sep. 30, 2021
Oct. 07, 2019
Aug. 17, 2017
Debt Instrument [Line Items]          
Discount, net $ 4,258        
Deferred financing costs 17,401        
Senior Notes          
Debt Instrument [Line Items]          
Principal balance 1,750,000 $ 1,750,000      
Discount, net 4,258 3,500      
Deferred financing costs $ 10,489 12,000      
Weighted average effective interest rate (percent) 4.01%        
Senior Notes | 5.125% senior unsecured notes due 2026          
Debt Instrument [Line Items]          
Interest rate 5.125%       5.125%
Principal balance $ 500,000 500,000      
Senior Notes | 5.88% senior unsecured notes due 2027          
Debt Instrument [Line Items]          
Interest rate 5.88%       5.88%
Principal balance $ 100,000 100,000      
Senior Notes | 3.90% senior unsecured notes due 2029          
Debt Instrument [Line Items]          
Interest rate 3.90%     3.90%  
Principal balance $ 350,000 350,000      
Senior Notes | 3.20% senior unsecured notes due 2031          
Debt Instrument [Line Items]          
Interest rate 3.20%   3.20%    
Principal balance $ 800,000 $ 800,000      
XML 84 R69.htm IDEA: XBRL DOCUMENT v3.24.0.1
DEBT - Senior Unsecured Notes Narrative (Details) - USD ($)
12 Months Ended
Oct. 07, 2021
Sep. 30, 2021
Oct. 07, 2019
May 29, 2019
Aug. 17, 2017
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Debt Instrument [Line Items]                
Proceeds from issuance of senior unsecured notes           $ 0 $ 0 $ 791,520,000
Loss on extinguishment of debt           1,541,000 411,000 34,622,000
Payments made to noteholders and legal fees for early redemption           0 0 30,196,000
Repayment of term loans           0 63,750,000 $ 455,000,000
Senior Notes                
Debt Instrument [Line Items]                
Aggregate principal amount           $ 1,750,000,000 $ 1,750,000,000  
Senior Notes | 4.80% senior unsecured notes due 2024                
Debt Instrument [Line Items]                
Interest rate       4.80%        
Aggregate principal amount       $ 300,000,000        
Proceeds from issuance of senior unsecured notes       $ 295,300,000        
Aggregate principal amount redeemed $ 300,000,000              
Redemption price (percent) 110.045%              
Loss on extinguishment of debt $ 32,700,000              
Write-offs associated with unamortized discount and deferred financing costs 2,500,000              
Payments made to noteholders and legal fees for early redemption $ 30,200,000              
Senior Notes | 5.125% senior unsecured notes due 2026                
Debt Instrument [Line Items]                
Interest rate         5.125% 5.125%    
Aggregate principal amount         $ 500,000,000      
Redemption price (percent)         100.00%      
Debt covenant, consolidated unencumbered total asset value to aggregate principal of unsecured debt           150.00%    
Senior Notes | 5.88% senior unsecured notes due 2027                
Debt Instrument [Line Items]                
Interest rate         5.88% 5.88%    
Aggregate principal amount         $ 100,000,000      
Redemption price (percent)         100.00%      
Senior Notes | 3.90% senior unsecured notes due 2029                
Debt Instrument [Line Items]                
Interest rate     3.90%     3.90%    
Aggregate principal amount     $ 350,000,000          
Proceeds from issuance of senior unsecured notes     $ 340,500,000          
Debt covenant, consolidated unencumbered total asset value to aggregate principal of unsecured debt           150.00%    
Senior Notes | 3.90% senior unsecured notes due 2029 | Redemption Period One                
Debt Instrument [Line Items]                
Redemption price (percent)     100.00%          
Senior Notes | 3.90% senior unsecured notes due 2029 | Redemption Period Two                
Debt Instrument [Line Items]                
Redemption price (percent)     100.00%          
Senior Notes | 5.375% senior unsecured notes due 2023                
Debt Instrument [Line Items]                
Interest rate     5.375%          
Aggregate principal amount redeemed     $ 200,000,000          
Senior Notes | 3.20% senior unsecured notes due 2031                
Debt Instrument [Line Items]                
Interest rate   3.20%       3.20%    
Aggregate principal amount   $ 800,000,000            
Proceeds from issuance of senior unsecured notes   $ 782,200,000            
Debt covenant, consolidated unencumbered total asset value to aggregate principal of unsecured debt           150.00%    
Senior Notes | 3.20% senior unsecured notes due 2031 | Redemption Period One                
Debt Instrument [Line Items]                
Redemption price (percent)   100.00%            
Senior Notes | 3.20% senior unsecured notes due 2031 | Redemption Period Two                
Debt Instrument [Line Items]                
Redemption price (percent)   100.00%            
U.S. dollar Term Loans                
Debt Instrument [Line Items]                
Repayment of term loans   $ 345,000,000            
XML 85 R70.htm IDEA: XBRL DOCUMENT v3.24.0.1
DEBT - Credit Agreement Narrative (Details)
12 Months Ended
Jan. 04, 2023
USD ($)
extensionOption
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2023
CAD ($)
Jan. 04, 2023
CAD ($)
extensionOption
Sep. 09, 2019
USD ($)
Sep. 09, 2019
CAD ($)
Debt Instrument [Line Items]                
Loss on extinguishment of debt   $ 1,541,000 $ 411,000 $ 34,622,000        
Revolving credit facility   94,429,000 196,982,000          
Fifth Amended and Restated Credit Agreement                
Debt Instrument [Line Items]                
Deferred financing costs   18,100,000            
Fifth Amended and Restated Credit Agreement | U.S. dollar Term Loans                
Debt Instrument [Line Items]                
Loss on extinguishment of debt   $ 1,500,000 $ 400,000 $ 1,800,000        
Financial liabilities $ 430,000,000           $ 436,300,000  
Interest rate   6.73%     6.73%      
Weighted average effective interest rate (percent)   3.94%     3.94%      
Fifth Amended and Restated Credit Agreement | U.S. dollar Term Loans | Interest rate swaps                
Debt Instrument [Line Items]                
Financial liabilities   $ 430,000,000            
Fixed interest rate under swap   2.69%     2.69%      
Fifth Amended and Restated Credit Agreement | U.S. dollar Term Loans | Base Rate | Minimum                
Debt Instrument [Line Items]                
Basis spread on variable rate 0.00% 0.00%            
Fifth Amended and Restated Credit Agreement | U.S. dollar Term Loans | Base Rate | Maximum                
Debt Instrument [Line Items]                
Basis spread on variable rate 0.65% 0.65%            
Fifth Amended and Restated Credit Agreement | U.S. dollar Term Loans | LIBOR | Minimum                
Debt Instrument [Line Items]                
Basis spread on variable rate   0.85%            
Fifth Amended and Restated Credit Agreement | U.S. dollar Term Loans | LIBOR | Maximum                
Debt Instrument [Line Items]                
Basis spread on variable rate   1.65%            
Fifth Amended and Restated Credit Agreement | U.S. dollar Term Loans | SOFR | Minimum                
Debt Instrument [Line Items]                
Basis spread on variable rate 0.85%              
Fifth Amended and Restated Credit Agreement | U.S. dollar Term Loans | SOFR | Maximum                
Debt Instrument [Line Items]                
Basis spread on variable rate 1.65%              
Fifth Amended and Restated Credit Agreement | Canadian dollar Term Loan                
Debt Instrument [Line Items]                
Financial liabilities           $ 150,000,000   $ 125,000,000
Interest rate   6.71%     6.71%      
Weighted average effective interest rate (percent)   2.88%     2.88%      
Fifth Amended and Restated Credit Agreement | Canadian dollar Term Loan | Interest rate swaps                
Debt Instrument [Line Items]                
Financial liabilities         $ 150,000,000      
Fixed interest rate under swap   1.63%     1.63%      
Fifth Amended and Restated Credit Agreement | Canadian dollar Term Loan | CDOR | Minimum                
Debt Instrument [Line Items]                
Basis spread on variable rate 0.85% 0.85%            
Fifth Amended and Restated Credit Agreement | Canadian dollar Term Loan | CDOR | Maximum                
Debt Instrument [Line Items]                
Basis spread on variable rate 1.65% 1.65%            
Line of Credit | Fifth Amended and Restated Credit Agreement                
Debt Instrument [Line Items]                
Borrowing capacity $ 2,750,000,000           2,750,000,000  
Revolving Credit Facility | Fifth Amended and Restated Credit Agreement                
Debt Instrument [Line Items]                
Borrowing capacity $ 1,000,000,000           1,000,000,000  
Basis spread on variable rate 1.00%              
Borrowing capacity in certain foreign currencies $ 350,000,000           $ 175,000,000  
Number of extension options | extensionOption 2         2    
Extension period 6 months              
Revolving credit facility   $ 94,400,000     $ 44,300,000      
Available borrowing capacity   $ 905,600,000            
Interest rate   6.57%     6.57%      
Revolving Credit Facility | Fifth Amended and Restated Credit Agreement | Minimum                
Debt Instrument [Line Items]                
Annum percent unused borrowing fee 0.125% 0.125%            
Revolving Credit Facility | Fifth Amended and Restated Credit Agreement | Maximum                
Debt Instrument [Line Items]                
Annum percent unused borrowing fee 0.30% 0.30%            
Revolving Credit Facility | Fifth Amended and Restated Credit Agreement | Prime Rate                
Debt Instrument [Line Items]                
Basis spread on variable rate 0.50% 0.50%            
Revolving Credit Facility | Fifth Amended and Restated Credit Agreement | Base Rate                
Debt Instrument [Line Items]                
Basis spread on variable rate 1.00% 1.00%            
Revolving Credit Facility | Fifth Amended and Restated Credit Agreement | Base Rate | Minimum                
Debt Instrument [Line Items]                
Basis spread on variable rate 0.00% 0.00%            
Revolving Credit Facility | Fifth Amended and Restated Credit Agreement | Base Rate | Maximum                
Debt Instrument [Line Items]                
Basis spread on variable rate 0.45% 0.45%            
Revolving Credit Facility | Fifth Amended and Restated Credit Agreement | LIBOR | Minimum                
Debt Instrument [Line Items]                
Basis spread on variable rate   0.775%            
Revolving Credit Facility | Fifth Amended and Restated Credit Agreement | LIBOR | Maximum                
Debt Instrument [Line Items]                
Basis spread on variable rate   1.45%            
Revolving Credit Facility | Fifth Amended and Restated Credit Agreement | SOFR | Minimum                
Debt Instrument [Line Items]                
Basis spread on variable rate 0.775%              
Revolving Credit Facility | Fifth Amended and Restated Credit Agreement | SOFR | Maximum                
Debt Instrument [Line Items]                
Basis spread on variable rate 1.45%              
XML 86 R71.htm IDEA: XBRL DOCUMENT v3.24.0.1
DEBT - Interest Expense Narrative (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Debt Disclosure [Abstract]      
Interest expense $ 112,964 $ 105,471 $ 98,632
Non-cash interest expense 12,265 11,094 $ 8,368
Accrued interest $ 16,500 $ 18,200  
XML 87 R72.htm IDEA: XBRL DOCUMENT v3.24.0.1
DEBT - Schedule of Maturities for Outstanding Debt (Details)
$ in Thousands
Jan. 04, 2023
extensionOption
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Debt Instrument [Line Items]      
2024   $ 2,033  
2025   2,089  
2026   502,147  
2027   196,635  
2028   545,456  
Thereafter   1,187,402  
Total Debt   2,435,762  
Discount, net   (4,258)  
Deferred financing costs, net   (17,401)  
Total Debt, Net   2,414,103  
Revolving Credit Facility | Fifth Amended and Restated Credit Agreement      
Debt Instrument [Line Items]      
Number of extension options | extensionOption 2    
Extension period 6 months    
Secured Indebtedness      
Debt Instrument [Line Items]      
2024   2,033  
2025   2,089  
2026   2,147  
2027   2,206  
2028   2,266  
Thereafter   37,402  
Total Debt   48,143  
Discount, net   0  
Deferred financing costs, net   (842) $ (900)
Total Debt, Net   47,301  
Line of Credit      
Debt Instrument [Line Items]      
2024   0  
2025   0  
2026   0  
2027   94,429  
2028   0  
Thereafter   0  
Total Debt   94,429  
Discount, net   0  
Deferred financing costs, net   0  
Total Debt, Net   94,429  
Term Loans      
Debt Instrument [Line Items]      
2024   0  
2025   0  
2026   0  
2027   0  
2028   543,190  
Thereafter   0  
Total Debt   543,190  
Discount, net   0  
Deferred financing costs, net   (6,070)  
Total Debt, Net   537,120  
Senior Notes      
Debt Instrument [Line Items]      
2024   0  
2025   0  
2026   500,000  
2027   100,000  
2028   0  
Thereafter   1,150,000  
Total Debt   1,750,000  
Discount, net   (4,258) (3,500)
Deferred financing costs, net   (10,489) $ (12,000)
Total Debt, Net   $ 1,735,253  
XML 88 R73.htm IDEA: XBRL DOCUMENT v3.24.0.1
DERIVATIVE AND HEDGING INSTRUMENTS - Narrative (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Derivative [Line Items]      
Fair value of derivatives in a net liability position $ 0 $ 0  
Credit risk-related contingent features      
Derivative [Line Items]      
Fair value of derivatives in a net liability position 0    
Designated as Hedging Instrument      
Derivative [Line Items]      
Fair value of derivatives in a net liability position 146,619,000 243,270,000  
Not Designated as Hedging Instrument | Cross currency interest rate swaps      
Derivative [Line Items]      
Other expense related to derivatives 18,000 100,000 $ 22,000
Cash Flow Hedges | Interest rate swaps      
Derivative [Line Items]      
Ineffectiveness on cash flow hedges 0 $ 0 $ 0
Cash Flow Hedges | Designated as Hedging Instrument      
Derivative [Line Items]      
Gains included in accumulated other comprehensive income expected to be reclassified into retained earnings in the next 12 months $ 6,900,000    
XML 89 R74.htm IDEA: XBRL DOCUMENT v3.24.0.1
DERIVATIVE AND HEDGING INSTRUMENTS - Notional Amounts of Derivative Instruments (Details)
Dec. 31, 2023
USD ($)
derivative
Dec. 31, 2023
CAD ($)
derivative
Dec. 31, 2022
USD ($)
Dec. 31, 2022
CAD ($)
Cash Flow Hedges | Designated as Hedging Instrument | Cross currency interest rate swaps        
Derivative [Line Items]        
Notional amount $ 753,750,000 $ 300,000,000 $ 436,250,000 $ 125,000,000
Cash Flow Hedges | Designated as Hedging Instrument | Interest rate swaps        
Derivative [Line Items]        
Number of derivative instruments held | derivative 2 2    
Cash Flow Hedges | Designated as Hedging Instrument | Interest Rate Swap One        
Derivative [Line Items]        
Notional amount $ 323,800,000      
Cash Flow Hedges | Designated as Hedging Instrument | Interest Rate Swap Two        
Derivative [Line Items]        
Notional amount   $ 150,000,000    
Net Investment Hedges | Designated as Hedging Instrument        
Derivative [Line Items]        
Notional amount   194,300,000   329,500,000
Net Investment Hedges | Designated as Hedging Instrument | Cross currency interest rate swaps        
Derivative [Line Items]        
Notional amount   55,335,000   55,991,000
Net Investment Hedges | Not Designated as Hedging Instrument | Cross currency interest rate swaps        
Derivative [Line Items]        
Notional amount   $ 965,000   $ 309,000
XML 90 R75.htm IDEA: XBRL DOCUMENT v3.24.0.1
DERIVATIVE AND HEDGING INSTRUMENTS - Summary of Derivative and Financial Instruments Designated as Hedging Instruments (Details)
$ in Thousands
Dec. 31, 2023
USD ($)
instrument
Dec. 31, 2022
USD ($)
Assets:    
Fair Value $ 18,918 $ 21,477
Liabilities:    
Fair value $ 0 $ 0
Derivative liability, statement of financial position Revolving credit facility, Term loans, net Revolving credit facility, Term loans, net
Derivative asset, statement of financial position Accounts receivable, prepaid expenses and other assets, net Accounts receivable, prepaid expenses and other assets, net
Designated as Hedging Instrument    
Assets:    
Fair Value $ 18,918 $ 21,477
Liabilities:    
Fair value $ 146,619 243,270
Designated as Hedging Instrument | Interest rate swaps | Cash flow    
Assets:    
Count | instrument 5  
Fair Value $ 6,002 11,004
Designated as Hedging Instrument | Interest rate collars | Cash flow    
Assets:    
Count | instrument 2  
Fair Value   6,622
Designated as Hedging Instrument | Forward starting interest rate swaps | Cash flow    
Assets:    
Count | instrument 4  
Fair Value $ 6,736 0
Designated as Hedging Instrument | Cross currency interest rate swaps | Net investment    
Assets:    
Count | instrument 2  
Fair Value $ 2,964 3,851
Designated as Hedging Instrument | Currency Swap | Net investment | Revolving credit facility    
Liabilities:    
Count | instrument 1  
Fair value $ 33,429 150,982
Designated as Hedging Instrument | Currency Swap | Net investment | Term loans, net    
Liabilities:    
Count | instrument 1  
Fair value $ 113,190 $ 92,288
XML 91 R76.htm IDEA: XBRL DOCUMENT v3.24.0.1
DERIVATIVE AND HEDGING INSTRUMENTS - Effect of Derivative Financial Instruments on the Condensed Consolidated Statements of Income and Condensed Consolidated Statements of Equity (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Derivative Instruments, Gain (Loss) [Line Items]      
Gain (loss) recognized in other comprehensive income (loss) $ 6,531 $ 39,869 $ 16,798
Loss reclassified accumulated other comprehensive income (loss) into income 8,332 (4,179) (12,774)
Interest rate products      
Derivative Instruments, Gain (Loss) [Line Items]      
Gain (loss) recognized in other comprehensive income (loss), cash flow hedges 13,116 22,032 17,408
Loss reclassified accumulated other comprehensive income (loss) into income, cash flow hedge 8,332 (4,179) (12,774)
Foreign currency products      
Derivative Instruments, Gain (Loss) [Line Items]      
Gain (loss) recognized in other comprehensive income (loss), net investment hedges (664) 2,233 (272)
Loss reclassified accumulated other comprehensive income (loss) into income, net investment hedges 0 0 0
Currency Swap      
Derivative Instruments, Gain (Loss) [Line Items]      
Gain (loss) recognized in other comprehensive income (loss), net investment hedges (2,465) 6,150 (338)
Loss reclassified accumulated other comprehensive income (loss) into income, net investment hedges 0 0 0
Currency Swap | Revolving Credit Facility      
Derivative Instruments, Gain (Loss) [Line Items]      
Gain (loss) recognized in other comprehensive income (loss), net investment hedges (3,456) 9,454 0
Loss reclassified accumulated other comprehensive income (loss) into income, net investment hedges $ 0 $ 0 $ 0
XML 92 R77.htm IDEA: XBRL DOCUMENT v3.24.0.1
DERIVATIVE AND HEDGING INSTRUMENTS - Gross Presentation, Effects of Offsetting, and a Net Presentation of Derivatives (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Offsetting Assets:    
Gross Amounts of Recognized Assets $ 18,918 $ 21,477
Gross Amounts Offset in the Balance Sheet 0 0
Net Amounts of Assets presented in the Balance Sheet 18,918 21,477
Financial Instruments 0 0
Cash Collateral Received 0 0
Net Amount 18,918 21,477
Offsetting Liabilities:    
Gross Amounts of Recognized Liabilities 0 0
Gross Amounts Offset in the Balance Sheet 0 0
Net Amounts of Liabilities presented in the Balance Sheet 0 0
Financial Instruments 0 0
Cash Collateral Received 0 0
Net Amount $ 0 $ 0
XML 93 R78.htm IDEA: XBRL DOCUMENT v3.24.0.1
FAIR VALUE DISCLOSURES - Narrative (Details) - Discount Rate
Dec. 31, 2023
Minimum  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Loans receivable, measurement input 0.06
Preferred equity investments, measurement input 0.10
Maximum  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Loans receivable, measurement input 0.15
Preferred equity investments, measurement input 0.15
Weighted Average  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Loans receivable, measurement input 0.06
Preferred equity investments, measurement input 0.11
Secured Indebtedness | Weighted Average  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Debt, measurement input 0.06
XML 94 R79.htm IDEA: XBRL DOCUMENT v3.24.0.1
FAIR VALUE DISCLOSURES - Face Values, Carrying Amounts and Fair Values of Financial Instruments (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Financial assets:    
Loans receivable $ 372,873 $ 370,364
Preferred equity investments 57,681 50,902
Senior Notes    
Financial liabilities:    
Financial liabilities 1,750,000 1,750,000
Secured Indebtedness    
Financial liabilities:    
Financial liabilities 48,143 50,123
Carrying Amount    
Financial assets:    
Loans receivable 362,775 360,325
Preferred equity investments 57,849 51,071
Carrying Amount | Senior Notes    
Financial liabilities:    
Financial liabilities 1,735,253 1,734,431
Carrying Amount | Secured Indebtedness    
Financial liabilities:    
Financial liabilities 47,301 49,232
Fair Value    
Financial assets:    
Loans receivable 383,141 370,188
Preferred equity investments 59,526 51,995
Fair Value | Senior Notes    
Financial liabilities:    
Financial liabilities 1,567,428 1,463,041
Fair Value | Secured Indebtedness    
Financial liabilities:    
Financial liabilities $ 36,279 $ 38,149
XML 95 R80.htm IDEA: XBRL DOCUMENT v3.24.0.1
FAIR VALUE DISCLOSURES - Fair Value of Financial Instruments (Details) - Recurring
$ in Thousands
Dec. 31, 2023
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Loans receivable $ 383,141
Preferred equity investments 59,526
Senior Notes  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Financial liabilities 1,567,428
Secured Indebtedness  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Financial liabilities 36,279
Quoted Prices in Active Markets for Identical Assets (Level 1)  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Loans receivable 0
Preferred equity investments 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Senior Notes  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Financial liabilities 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Secured Indebtedness  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Financial liabilities 0
Significant Other Observable Inputs (Level 2)  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Loans receivable 0
Preferred equity investments 0
Significant Other Observable Inputs (Level 2) | Senior Notes  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Financial liabilities 1,567,428
Significant Other Observable Inputs (Level 2) | Secured Indebtedness  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Financial liabilities 0
Significant Unobservable Inputs (Level 3)  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Loans receivable 383,141
Preferred equity investments 59,526
Significant Unobservable Inputs (Level 3) | Senior Notes  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Financial liabilities 0
Significant Unobservable Inputs (Level 3) | Secured Indebtedness  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Financial liabilities $ 36,279
XML 96 R81.htm IDEA: XBRL DOCUMENT v3.24.0.1
FAIR VALUE DISCLOSURES - Items Measured at Fair Value on a Recurring Basis (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets $ 18,918 $ 21,477
Recurring | Interest rate swaps    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 6,002  
Recurring | Interest rate collars    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 3,216  
Recurring | Forward starting interest rate swaps    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 6,736  
Recurring | Cross currency interest rate swaps    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 2,964  
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Interest rate swaps    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 0  
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Interest rate collars    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 0  
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Forward starting interest rate swaps    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 0  
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Cross currency interest rate swaps    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 0  
Recurring | Significant Other Observable Inputs (Level 2) | Interest rate swaps    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 6,002  
Recurring | Significant Other Observable Inputs (Level 2) | Interest rate collars    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 3,216  
Recurring | Significant Other Observable Inputs (Level 2) | Forward starting interest rate swaps    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 6,736  
Recurring | Significant Other Observable Inputs (Level 2) | Cross currency interest rate swaps    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 2,964  
Recurring | Significant Unobservable Inputs (Level 3) | Interest rate swaps    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 0  
Recurring | Significant Unobservable Inputs (Level 3) | Interest rate collars    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 0  
Recurring | Significant Unobservable Inputs (Level 3) | Forward starting interest rate swaps    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 0  
Recurring | Significant Unobservable Inputs (Level 3) | Cross currency interest rate swaps    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets $ 0  
XML 97 R82.htm IDEA: XBRL DOCUMENT v3.24.0.1
EQUITY - Narrative (Details) - USD ($)
10 Months Ended 12 Months Ended
Feb. 23, 2023
Oct. 15, 2021
Aug. 06, 2021
Dec. 11, 2019
Nov. 09, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Class of Stock [Line Items]                
Tax withholding obligations incurred on behalf of employees           $ 1,800,000 $ 3,300,000 $ 2,100,000
Restricted Stock Units                
Class of Stock [Line Items]                
Shares issued upon vesting (in shares)           300,000 600,000 200,000
2019 ATM Program                
Class of Stock [Line Items]                
Aggregate gross proceeds possible from sales of common stock under equity offering program       $ 400,000,000        
Shares issued (in shares)               2,200,000
Average price per share (in dollars per share)               $ 17.78
Proceeds from issuance of common stock               $ 38,800,000
Payments for stock issuance commissions               $ 600,000
2019 ATM Program - Forward Feature                
Class of Stock [Line Items]                
Shares issued (in shares)               7,900,000
Proceeds from issuance of common stock               $ 137,000,000
Shares allowed for forward feature of ATM Program (in shares)               6,800,000
Initial weighted average price (in dollars per share)               $ 17.49
2019 ATM Program - Forward Feature | Weighted Average                
Class of Stock [Line Items]                
Average price per share (in dollars per share)               $ 17.36
Prior ATM Program                
Class of Stock [Line Items]                
Aggregate gross proceeds possible from sales of common stock under equity offering program     $ 500,000,000          
Shares issued (in shares)               0
Prior ATM Program - Forward Feature                
Class of Stock [Line Items]                
Shares issued (in shares)         0     1,700,000
Average price per share (in dollars per share)               $ 14.23
Proceeds from issuance of common stock               $ 24,200,000
Shares allowed for forward feature of ATM Program (in shares)               1,700,000
Initial weighted average price (in dollars per share)               $ 14.56
Underwritten Public Offering                
Class of Stock [Line Items]                
Shares issued (in shares)   7,800,000            
Proceeds from issuance of common stock   $ 112,600,000            
Price per share (in dollars per share)   $ 14.40            
ATM Program                
Class of Stock [Line Items]                
Aggregate gross proceeds possible from sales of common stock under equity offering program $ 500,000,000              
Shares issued (in shares)           0    
Forward sale agreement term 1 year              
Amount available for issuance           $ 500,000,000    
XML 98 R83.htm IDEA: XBRL DOCUMENT v3.24.0.1
EQUITY - Accumulated Other Comprehensive Income (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Accumulated other comprehensive income (loss) $ 2,802,534 $ 3,056,395 $ 3,379,530 $ 3,409,228
Total accumulated other comprehensive income        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Accumulated other comprehensive income (loss) 23,745 19,063 $ (10,021) $ (39,911)
Foreign currency translation gain        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Accumulated other comprehensive income (loss) 963 1,168    
Unrealized gain on cash flow hedges        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Accumulated other comprehensive income (loss) $ 22,782 $ 17,895    
XML 99 R84.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total fair value of units vested $ 9,100 $ 5,700 $ 15,900
Stock-based compensation expense 7,917 7,453 7,914
Total unrecognized stock-based compensation expense $ 25,700    
Weighted average period for recognition of stock-based compensation expense 2 years 8 months 12 days    
Discretionary matching contribution (percent) 4.00%    
Matching contributions $ 300 $ 300 $ 300
Restricted Stock Units      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of shares of common stock convertible upon each performance-based restricted stock unit vesting (in shares) 1    
Weighted average remaining vesting period 2 years 8 months 12 days    
Weighted average fair value per share at grant date (in dollars per share) $ 14.73 $ 12.78 $ 15.55
Restricted Stock Units | Minimum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period 3 years    
Restricted Stock Units | Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period 5 years    
FFO Units | Minimum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting percentage 0.00%    
FFO Units | Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting percentage 200.00%    
TSR Units      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Historical volatility rate period 3 years    
TSR Units | Minimum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting percentage 0.00%    
TSR Units | Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting percentage 200.00%    
XML 100 R85.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCK-BASED COMPENSATION - Restricted Stock Units Activity (Details) - Restricted Stock Units - $ / shares
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Restricted Stock Units      
Unvested, beginning (in shares) 2,147,784    
Granted (in shares) 832,308    
Vested (in shares) (591,745)    
Dividends reinvested (in shares) 237,195    
Cancelled/forfeited (in shares) (156,275)    
Unvested, ending (in shares) 2,469,267 2,147,784  
Weighted Average Grant Date Fair Value Per Unit      
Unvested, beginning (in dollars per share) $ 15.07    
Granted (in dollars per share) 14.73 $ 12.78 $ 15.55
Vested (in dollars per share) 15.34    
Dividends reinvested (in dollars per share) 14.96    
Cancelled/forfeited (in dollars per share) 19.51    
Unvested, ending (in dollars per share) $ 14.61 $ 15.07  
XML 101 R86.htm IDEA: XBRL DOCUMENT v3.24.0.1
STOCK-BASED COMPENSATION - Assumptions Used in Total Stockholder Return-Based Stock Units Valuation (Details) - TSR Units
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Assumptions used in valuation      
Risk free interest rate, minimum 3.98% 0.99% 0.17%
Risk free interest rate, maximum 4.13% 4.13% 0.99%
Expected stock price volatility, minimum 30.17% 53.60% 53.17%
Expected stock price volatility, maximum 56.11% 56.11% 53.60%
Expected service period 3 years    
Expected dividend yield (assuming full reinvestment) 0.00% 0.00% 0.00%
Maximum      
Assumptions used in valuation      
Expected service period   3 years 3 years
XML 102 R87.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES - Provision for Income Tax Expense (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]      
Provision for federal, state and local income taxes $ 2,002 $ 1,234 $ 2,263
Provision (benefit) for foreign income taxes 0 8 (418)
Income tax expense $ 2,002 $ 1,242 $ 1,845
XML 103 R88.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES - Deferred Taxes (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Deferred tax (liabilities):    
Deferred taxes, net $ 0 $ 0
Federal    
Deferred tax assets:    
Deferred tax assets 9,553 6,390
Valuation allowance (9,553) (6,390)
Foreign    
Deferred tax assets:    
Deferred tax assets 12,211 8,455
Valuation allowance (12,169) (8,430)
Deferred tax (liabilities):    
Deferred tax (liabilities) $ (42) $ (25)
XML 104 R89.htm IDEA: XBRL DOCUMENT v3.24.0.1
INCOME TAXES - Narrative (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]      
Interest and penalties from significant uncertain tax positions $ 0 $ 0 $ 0
XML 105 R90.htm IDEA: XBRL DOCUMENT v3.24.0.1
EARNINGS PER COMMON SHARE - Computation of Basic and Diluted Earnings Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Numerator      
Net income (loss) $ 13,756 $ (77,605) $ (113,256)
Denominator      
Basic weighted average common shares and common equivalents (in shares) 231,203,391 230,947,895 219,073,027
Dilutive restricted stock units (in shares) 1,589,387 0 0
Diluted weighted average common shares (in shares) 232,792,778 230,947,895 219,073,027
Net income (loss), per:      
Basic common share (in dollars per share) $ 0.06 $ (0.34) $ (0.52)
Diluted common share (in dollars per share) $ 0.06 $ (0.34) $ (0.52)
XML 106 R91.htm IDEA: XBRL DOCUMENT v3.24.0.1
EARNINGS PER COMMON SHARE - Narrative (Details) - shares
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Restricted Stock Units      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Anti-dilutive securities not included in computation of diluted earnings per share (in shares) 500 900,000 1,000,000
Forward Equity Sale Agreements      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Anti-dilutive securities not included in computation of diluted earnings per share (in shares)   25,000  
XML 107 R92.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUBSEQUENT EVENTS (Details) - $ / shares
12 Months Ended
Feb. 01, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Subsequent Event        
Quarterly cash dividend declared on common stock (in dollars per share)   $ 1.20 $ 1.20 $ 1.20
Subsequent event        
Subsequent Event        
Quarterly cash dividend declared on common stock (in dollars per share) $ 0.30      
XML 108 R93.htm IDEA: XBRL DOCUMENT v3.24.0.1
SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION - Summary of Real Estate Properties (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Real Estate and Accumulated Depreciation        
Encumbrances $ 48,143      
Initial Cost to Company        
Land  546,940      
Buildings and Improvements 4,831,080      
Total  5,378,020      
Cost Capitalized Subsequent to Acquisition 234,491      
Gross Amount at which Carried at Close of Period        
Land  546,598      
Building and Improvements 5,091,749      
Total  5,638,347 $ 5,872,688 $ 5,994,208 $ 5,966,695
Accumulated Depreciation and Amortization (1,021,086) (913,345) $ (831,324) $ (681,657)
Deferred financing costs, net 17,401      
Aggregate cost of real estate for federal income tax purposes 4,700,000      
Secured Debt        
Gross Amount at which Carried at Close of Period        
Deferred financing costs, net 842 $ 900    
Operating Segments        
Real Estate and Accumulated Depreciation        
Encumbrances 48,143      
Initial Cost to Company        
Land  546,940      
Buildings and Improvements 4,830,944      
Total  5,377,884      
Cost Capitalized Subsequent to Acquisition 232,080      
Gross Amount at which Carried at Close of Period        
Land  546,598      
Building and Improvements 5,089,202      
Total  5,635,800      
Accumulated Depreciation and Amortization (1,020,454)      
Corporate Assets        
Real Estate and Accumulated Depreciation        
Encumbrances 0      
Initial Cost to Company        
Land  0      
Buildings and Improvements 136      
Total  136      
Cost Capitalized Subsequent to Acquisition 2,411      
Gross Amount at which Carried at Close of Period        
Land  0      
Building and Improvements 2,547      
Total  2,547      
Accumulated Depreciation and Amortization (632)      
Skilled Nursing/Transitional Care        
Real Estate and Accumulated Depreciation        
Encumbrances 24,051      
Initial Cost to Company        
Land  328,000      
Buildings and Improvements 2,663,453      
Total  2,991,453      
Cost Capitalized Subsequent to Acquisition 91,777      
Gross Amount at which Carried at Close of Period        
Land  325,583      
Building and Improvements 2,725,278      
Total  3,050,861      
Accumulated Depreciation and Amortization (535,653)      
Skilled Nursing/Transitional Care | Bedford, NH        
Real Estate and Accumulated Depreciation        
Encumbrances 5,006      
Initial Cost to Company        
Land  1,911      
Buildings and Improvements 12,245      
Total  14,156      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,911      
Building and Improvements 10,546      
Total  12,457      
Accumulated Depreciation and Amortization $ (5,272)      
Life on Which Depreciation in Latest Income Statement is Computed 36 years      
Skilled Nursing/Transitional Care | Milford, NH        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  312      
Buildings and Improvements 1,679      
Total  1,991      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  312      
Building and Improvements 1,168      
Total  1,480      
Accumulated Depreciation and Amortization $ (986)      
Life on Which Depreciation in Latest Income Statement is Computed 20 years      
Skilled Nursing/Transitional Care | North Conway, NH        
Real Estate and Accumulated Depreciation        
Encumbrances $ 10,337      
Initial Cost to Company        
Land  417      
Buildings and Improvements 5,352      
Total  5,769      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  417      
Building and Improvements 4,374      
Total  4,791      
Accumulated Depreciation and Amortization $ (2,006)      
Life on Which Depreciation in Latest Income Statement is Computed 43 years      
Skilled Nursing/Transitional Care | Wolfeboro, NH        
Real Estate and Accumulated Depreciation        
Encumbrances $ 8,708      
Initial Cost to Company        
Land  454      
Buildings and Improvements 4,531      
Total  4,985      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  454      
Building and Improvements 3,747      
Total  4,201      
Accumulated Depreciation and Amortization $ (1,669)      
Life on Which Depreciation in Latest Income Statement is Computed 41 years      
Skilled Nursing/Transitional Care | Middletown, DE        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,650      
Buildings and Improvements 21,730      
Total  23,380      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,650      
Building and Improvements 21,730      
Total  23,380      
Accumulated Depreciation and Amortization $ (7,574)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Dover, DE        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  4,940      
Buildings and Improvements 15,500      
Total  20,440      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  4,940      
Building and Improvements 15,500      
Total  20,440      
Accumulated Depreciation and Amortization $ (5,676)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Wilmington, DE        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,460      
Buildings and Improvements 25,240      
Total  27,700      
Cost Capitalized Subsequent to Acquisition 12,436      
Gross Amount at which Carried at Close of Period        
Land  2,460      
Building and Improvements 37,676      
Total  40,136      
Accumulated Depreciation and Amortization $ (9,841)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Millsboro, DE        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,640      
Buildings and Improvements 22,620      
Total  24,260      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,632      
Building and Improvements 22,620      
Total  24,252      
Accumulated Depreciation and Amortization $ (8,095)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Warrington, PA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,617      
Buildings and Improvements 11,662      
Total  14,279      
Cost Capitalized Subsequent to Acquisition 395      
Gross Amount at which Carried at Close of Period        
Land  2,617      
Building and Improvements 288      
Total  2,905      
Accumulated Depreciation and Amortization $ 0      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Duffield, VA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  509      
Buildings and Improvements 5,018      
Total  5,527      
Cost Capitalized Subsequent to Acquisition 1,333      
Gross Amount at which Carried at Close of Period        
Land  509      
Building and Improvements 5,964      
Total  6,473      
Accumulated Depreciation and Amortization $ (2,388)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Arlington, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  3,783      
Buildings and Improvements 14,219      
Total  18,002      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  3,783      
Building and Improvements 13,702      
Total  17,485      
Accumulated Depreciation and Amortization $ (3,956)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Rockport, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,005      
Buildings and Improvements 6,628      
Total  7,633      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,005      
Building and Improvements 6,212      
Total  7,217      
Accumulated Depreciation and Amortization $ (1,824)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Lincoln, NE        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  6,368      
Buildings and Improvements 29,919      
Total  36,287      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  6,368      
Building and Improvements 29,919      
Total  36,287      
Accumulated Depreciation and Amortization $ (8,351)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Fremont, NE 1        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  615      
Buildings and Improvements 16,176      
Total  16,791      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  615      
Building and Improvements 16,176      
Total  16,791      
Accumulated Depreciation and Amortization $ (4,953)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Fremont, NE 2        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  615      
Buildings and Improvements 2,943      
Total  3,558      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  615      
Building and Improvements 2,943      
Total  3,558      
Accumulated Depreciation and Amortization $ (1,069)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Bartlesville, OK        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,332      
Buildings and Improvements 6,904      
Total  8,236      
Cost Capitalized Subsequent to Acquisition 986      
Gross Amount at which Carried at Close of Period        
Land  1,332      
Building and Improvements 7,890      
Total  9,222      
Accumulated Depreciation and Amortization $ (2,190)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Oklahoma City, OK        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,189      
Buildings and Improvements 23,567      
Total  25,756      
Cost Capitalized Subsequent to Acquisition 2,534      
Gross Amount at which Carried at Close of Period        
Land  2,189      
Building and Improvements 25,749      
Total  27,938      
Accumulated Depreciation and Amortization $ (6,639)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Norman, OK        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  869      
Buildings and Improvements 5,236      
Total  6,105      
Cost Capitalized Subsequent to Acquisition 785      
Gross Amount at which Carried at Close of Period        
Land  869      
Building and Improvements 6,021      
Total  6,890      
Accumulated Depreciation and Amortization $ (1,847)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Minneapolis, MN        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,931      
Buildings and Improvements 6,943      
Total  9,874      
Cost Capitalized Subsequent to Acquisition 1,190      
Gross Amount at which Carried at Close of Period        
Land  2,931      
Building and Improvements 7,999      
Total  10,930      
Accumulated Depreciation and Amortization $ (1,800)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Eugene, OR 1        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,205      
Buildings and Improvements 28,700      
Total  30,905      
Cost Capitalized Subsequent to Acquisition 2,252      
Gross Amount at which Carried at Close of Period        
Land  2,205      
Building and Improvements 30,952      
Total  33,157      
Accumulated Depreciation and Amortization $ (5,883)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Lebanon, OR        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  958      
Buildings and Improvements 14,176      
Total  15,134      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  958      
Building and Improvements 14,176      
Total  15,134      
Accumulated Depreciation and Amortization $ (2,427)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Portland, OR        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,791      
Buildings and Improvements 12,833      
Total  14,624      
Cost Capitalized Subsequent to Acquisition 2,761      
Gross Amount at which Carried at Close of Period        
Land  1,791      
Building and Improvements 15,594      
Total  17,385      
Accumulated Depreciation and Amortization $ (3,466)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Tigard, OR        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,011      
Buildings and Improvements 11,667      
Total  13,678      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  2,011      
Building and Improvements 11,667      
Total  13,678      
Accumulated Depreciation and Amortization $ (2,064)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Hillsboro, OR        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,387      
Buildings and Improvements 14,028      
Total  15,415      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,387      
Building and Improvements 14,028      
Total  15,415      
Accumulated Depreciation and Amortization $ (2,399)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Junction City, OR        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  584      
Buildings and Improvements 7,901      
Total  8,485      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  584      
Building and Improvements 7,901      
Total  8,485      
Accumulated Depreciation and Amortization $ (1,403)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Eugene, OR 2        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,380      
Buildings and Improvements 14,921      
Total  16,301      
Cost Capitalized Subsequent to Acquisition 1,791      
Gross Amount at which Carried at Close of Period        
Land  1,380      
Building and Improvements 16,712      
Total  18,092      
Accumulated Depreciation and Amortization $ (3,421)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Coos Bay, OR        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  829      
Buildings and Improvements 8,518      
Total  9,347      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  829      
Building and Improvements 8,518      
Total  9,347      
Accumulated Depreciation and Amortization $ (1,569)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Gladstone, OR        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  792      
Buildings and Improvements 5,000      
Total  5,792      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  792      
Building and Improvements 5,000      
Total  5,792      
Accumulated Depreciation and Amortization $ (907)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Newport, OR        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  406      
Buildings and Improvements 5,001      
Total  5,407      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  406      
Building and Improvements 5,001      
Total  5,407      
Accumulated Depreciation and Amortization $ (866)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Oregon City, OR        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,496      
Buildings and Improvements 12,142      
Total  13,638      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,496      
Building and Improvements 12,142      
Total  13,638      
Accumulated Depreciation and Amortization $ (2,076)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Tacoma, WA 1        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,771      
Buildings and Improvements 11,595      
Total  13,366      
Cost Capitalized Subsequent to Acquisition 15      
Gross Amount at which Carried at Close of Period        
Land  1,771      
Building and Improvements 11,610      
Total  13,381      
Accumulated Depreciation and Amortization $ (2,313)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Shoreline, WA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  4,703      
Buildings and Improvements 14,444      
Total  19,147      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  4,703      
Building and Improvements 14,444      
Total  19,147      
Accumulated Depreciation and Amortization $ (2,559)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Bellingham, WA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  0      
Buildings and Improvements 15,330      
Total  15,330      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  0      
Building and Improvements 15,330      
Total  15,330      
Accumulated Depreciation and Amortization $ (2,740)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Sequim, WA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  427      
Buildings and Improvements 4,450      
Total  4,877      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  427      
Building and Improvements 4,450      
Total  4,877      
Accumulated Depreciation and Amortization $ (954)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Tacoma, WA 2        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,705      
Buildings and Improvements 4,952      
Total  6,657      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,705      
Building and Improvements 4,952      
Total  6,657      
Accumulated Depreciation and Amortization $ (925)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Tacoma, WA 3        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,195      
Buildings and Improvements 1,956      
Total  4,151      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  2,195      
Building and Improvements 1,956      
Total  4,151      
Accumulated Depreciation and Amortization $ (484)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Vancouver, WA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,782      
Buildings and Improvements 15,116      
Total  16,898      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,782      
Building and Improvements 15,116      
Total  16,898      
Accumulated Depreciation and Amortization $ (2,798)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Lake Oswego, OR        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  5,947      
Buildings and Improvements 13,401      
Total  19,348      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  5,947      
Building and Improvements 13,401      
Total  19,348      
Accumulated Depreciation and Amortization $ (2,395)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Medford, OR 1        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,043      
Buildings and Improvements 38,485      
Total  40,528      
Cost Capitalized Subsequent to Acquisition 2,960      
Gross Amount at which Carried at Close of Period        
Land  2,043      
Building and Improvements 41,445      
Total  43,488      
Accumulated Depreciation and Amortization $ (7,773)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Seattle, WA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,508      
Buildings and Improvements 6,401      
Total  8,909      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  2,508      
Building and Improvements 6,401      
Total  8,909      
Accumulated Depreciation and Amortization $ (1,158)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Boise, ID        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  681      
Buildings and Improvements 9,348      
Total  10,029      
Cost Capitalized Subsequent to Acquisition 627      
Gross Amount at which Carried at Close of Period        
Land  681      
Building and Improvements 9,975      
Total  10,656      
Accumulated Depreciation and Amortization $ (1,774)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Salem, OR        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,114      
Buildings and Improvements 15,651      
Total  17,765      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  2,114      
Building and Improvements 15,651      
Total  17,765      
Accumulated Depreciation and Amortization $ (2,758)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Medford, OR 2        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,375      
Buildings and Improvements 23,808      
Total  25,183      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,375      
Building and Improvements 23,808      
Total  25,183      
Accumulated Depreciation and Amortization $ (4,231)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Northglenn, CO        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,662      
Buildings and Improvements 26,014      
Total  27,676      
Cost Capitalized Subsequent to Acquisition 3,258      
Gross Amount at which Carried at Close of Period        
Land  1,662      
Building and Improvements 29,272      
Total  30,934      
Accumulated Depreciation and Amortization $ (5,916)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Brighton, CO        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,933      
Buildings and Improvements 11,624      
Total  13,557      
Cost Capitalized Subsequent to Acquisition 200      
Gross Amount at which Carried at Close of Period        
Land  1,933      
Building and Improvements 11,824      
Total  13,757      
Accumulated Depreciation and Amortization $ (2,166)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Santa Ana, CA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,889      
Buildings and Improvements 11,682      
Total  13,571      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,889      
Building and Improvements 11,682      
Total  13,571      
Accumulated Depreciation and Amortization $ (1,947)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | La Mesa, CA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,276      
Buildings and Improvements 8,177      
Total  9,453      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,276      
Building and Improvements 8,177      
Total  9,453      
Accumulated Depreciation and Amortization $ (1,416)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Westminster, MD        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,128      
Buildings and Improvements 6,614      
Total  8,742      
Cost Capitalized Subsequent to Acquisition 487      
Gross Amount at which Carried at Close of Period        
Land  2,128      
Building and Improvements 6,978      
Total  9,106      
Accumulated Depreciation and Amortization $ (1,618)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Kansas City, MO        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,985      
Buildings and Improvements 2,714      
Total  4,699      
Cost Capitalized Subsequent to Acquisition 303      
Gross Amount at which Carried at Close of Period        
Land  1,714      
Building and Improvements 0      
Total  1,714      
Accumulated Depreciation and Amortization $ 0      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Parkersburg, WV        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  697      
Buildings and Improvements 10,688      
Total  11,385      
Cost Capitalized Subsequent to Acquisition 285      
Gross Amount at which Carried at Close of Period        
Land  697      
Building and Improvements 10,911      
Total  11,608      
Accumulated Depreciation and Amortization $ (2,428)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Cincinnati, OH        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,686      
Buildings and Improvements 10,062      
Total  12,748      
Cost Capitalized Subsequent to Acquisition 295      
Gross Amount at which Carried at Close of Period        
Land  2,686      
Building and Improvements 10,357      
Total  13,043      
Accumulated Depreciation and Amortization $ (2,058)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Charlottesville, VA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,840      
Buildings and Improvements 8,450      
Total  11,290      
Cost Capitalized Subsequent to Acquisition 1,176      
Gross Amount at which Carried at Close of Period        
Land  2,840      
Building and Improvements 9,523      
Total  12,363      
Accumulated Depreciation and Amortization $ (2,334)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Annandale, VA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  7,241      
Buildings and Improvements 17,727      
Total  24,968      
Cost Capitalized Subsequent to Acquisition 3,218      
Gross Amount at which Carried at Close of Period        
Land  7,241      
Building and Improvements 20,864      
Total  28,105      
Accumulated Depreciation and Amortization $ (4,579)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Petersburg, VA 1        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  988      
Buildings and Improvements 8,416      
Total  9,404      
Cost Capitalized Subsequent to Acquisition 146      
Gross Amount at which Carried at Close of Period        
Land  988      
Building and Improvements 8,478      
Total  9,466      
Accumulated Depreciation and Amortization $ (1,672)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Petersburg, VA 2        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,174      
Buildings and Improvements 8,858      
Total  10,032      
Cost Capitalized Subsequent to Acquisition 151      
Gross Amount at which Carried at Close of Period        
Land  1,174      
Building and Improvements 8,942      
Total  10,116      
Accumulated Depreciation and Amortization $ (1,749)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Hagerstown, MD        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,393      
Buildings and Improvements 13,438      
Total  14,831      
Cost Capitalized Subsequent to Acquisition 150      
Gross Amount at which Carried at Close of Period        
Land  1,393      
Building and Improvements 13,477      
Total  14,870      
Accumulated Depreciation and Amortization $ (2,501)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Cumberland, MD        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  800      
Buildings and Improvements 16,973      
Total  17,773      
Cost Capitalized Subsequent to Acquisition 457      
Gross Amount at which Carried at Close of Period        
Land  800      
Building and Improvements 17,305      
Total  18,105      
Accumulated Depreciation and Amortization $ (3,237)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Gilroy, CA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  662      
Buildings and Improvements 23,775      
Total  24,437      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  662      
Building and Improvements 23,775      
Total  24,437      
Accumulated Depreciation and Amortization $ (4,022)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Mount Pleasant, SC        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,689      
Buildings and Improvements 3,942      
Total  6,631      
Cost Capitalized Subsequent to Acquisition 205      
Gross Amount at which Carried at Close of Period        
Land  2,689      
Building and Improvements 4,147      
Total  6,836      
Accumulated Depreciation and Amortization $ (831)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Harrogate, TN        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,811      
Buildings and Improvements 4,963      
Total  6,774      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,811      
Building and Improvements 4,963      
Total  6,774      
Accumulated Depreciation and Amortization $ (1,054)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Conway, SC        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,408      
Buildings and Improvements 10,784      
Total  12,192      
Cost Capitalized Subsequent to Acquisition 295      
Gross Amount at which Carried at Close of Period        
Land  1,408      
Building and Improvements 11,079      
Total  12,487      
Accumulated Depreciation and Amortization $ (2,075)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Baytown, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  426      
Buildings and Improvements 3,236      
Total  3,662      
Cost Capitalized Subsequent to Acquisition 173      
Gross Amount at which Carried at Close of Period        
Land  426      
Building and Improvements 3,251      
Total  3,677      
Accumulated Depreciation and Amortization $ (683)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Huntsville, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  302      
Buildings and Improvements 3,153      
Total  3,455      
Cost Capitalized Subsequent to Acquisition 75      
Gross Amount at which Carried at Close of Period        
Land  302      
Building and Improvements 3,168      
Total  3,470      
Accumulated Depreciation and Amortization $ (644)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Center, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  231      
Buildings and Improvements 1,335      
Total  1,566      
Cost Capitalized Subsequent to Acquisition 312      
Gross Amount at which Carried at Close of Period        
Land  231      
Building and Improvements 1,477      
Total  1,708      
Accumulated Depreciation and Amortization $ (398)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Humble, TX 1        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,114      
Buildings and Improvements 1,643      
Total  3,757      
Cost Capitalized Subsequent to Acquisition 596      
Gross Amount at which Carried at Close of Period        
Land  2,114      
Building and Improvements 1,953      
Total  4,067      
Accumulated Depreciation and Amortization $ (571)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Houston, TX 1        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,019      
Buildings and Improvements 5,734      
Total  6,753      
Cost Capitalized Subsequent to Acquisition 318      
Gross Amount at which Carried at Close of Period        
Land  1,019      
Building and Improvements 5,807      
Total  6,826      
Accumulated Depreciation and Amortization $ (1,124)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Linden, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  112      
Buildings and Improvements 256      
Total  368      
Cost Capitalized Subsequent to Acquisition 133      
Gross Amount at which Carried at Close of Period        
Land  112      
Building and Improvements 280      
Total  392      
Accumulated Depreciation and Amortization $ (98)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Sherman, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  469      
Buildings and Improvements 6,310      
Total  6,779      
Cost Capitalized Subsequent to Acquisition 255      
Gross Amount at which Carried at Close of Period        
Land  469      
Building and Improvements 6,338      
Total  6,807      
Accumulated Depreciation and Amortization $ (1,188)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Mount Pleasant, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  250      
Buildings and Improvements 6,913      
Total  7,163      
Cost Capitalized Subsequent to Acquisition 345      
Gross Amount at which Carried at Close of Period        
Land  250      
Building and Improvements 7,160      
Total  7,410      
Accumulated Depreciation and Amortization $ (1,372)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Waxahachie, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  416      
Buildings and Improvements 7,259      
Total  7,675      
Cost Capitalized Subsequent to Acquisition 976      
Gross Amount at which Carried at Close of Period        
Land  416      
Building and Improvements 8,106      
Total  8,522      
Accumulated Depreciation and Amortization $ (1,618)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Gilmer, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  707      
Buildings and Improvements 4,552      
Total  5,259      
Cost Capitalized Subsequent to Acquisition 93      
Gross Amount at which Carried at Close of Period        
Land  707      
Building and Improvements 4,562      
Total  5,269      
Accumulated Depreciation and Amortization $ (910)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Sparks, NV        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,986      
Buildings and Improvements 9,004      
Total  10,990      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,986      
Building and Improvements 9,004      
Total  10,990      
Accumulated Depreciation and Amortization $ (1,714)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Richmond, IN        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  259      
Buildings and Improvements 9,819      
Total  10,078      
Cost Capitalized Subsequent to Acquisition 131      
Gross Amount at which Carried at Close of Period        
Land  259      
Building and Improvements 9,950      
Total  10,209      
Accumulated Depreciation and Amortization $ (1,856)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Petersburg, IN        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  581      
Buildings and Improvements 5,367      
Total  5,948      
Cost Capitalized Subsequent to Acquisition 23      
Gross Amount at which Carried at Close of Period        
Land  581      
Building and Improvements 5,390      
Total  5,971      
Accumulated Depreciation and Amortization $ (1,054)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Maryville, MO        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  114      
Buildings and Improvements 5,955      
Total  6,069      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  150      
Building and Improvements 5,955      
Total  6,105      
Accumulated Depreciation and Amortization $ (1,187)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Ashland, MO        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  765      
Buildings and Improvements 2,669      
Total  3,434      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  229      
Building and Improvements 628      
Total  857      
Accumulated Depreciation and Amortization $ 0      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | St. Louis, MO        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,071      
Buildings and Improvements 5,739      
Total  7,810      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  375      
Building and Improvements 818      
Total  1,193      
Accumulated Depreciation and Amortization $ 0      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Doniphan, MO        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  657      
Buildings and Improvements 8,251      
Total  8,908      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  657      
Building and Improvements 8,251      
Total  8,908      
Accumulated Depreciation and Amortization $ (1,551)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Dixon, MO        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  521      
Buildings and Improvements 3,358      
Total  3,879      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  521      
Building and Improvements 3,358      
Total  3,879      
Accumulated Depreciation and Amortization $ (684)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Forsyth, MO        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  594      
Buildings and Improvements 8,549      
Total  9,143      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  594      
Building and Improvements 8,549      
Total  9,143      
Accumulated Depreciation and Amortization $ (1,631)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Seymour, MO        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  658      
Buildings and Improvements 901      
Total  1,559      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  658      
Building and Improvements 901      
Total  1,559      
Accumulated Depreciation and Amortization $ (240)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Silex, MO        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  807      
Buildings and Improvements 4,990      
Total  5,797      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  807      
Building and Improvements 4,990      
Total  5,797      
Accumulated Depreciation and Amortization $ (965)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Columbia, MO        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,322      
Buildings and Improvements 6,547      
Total  8,869      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  2,322      
Building and Improvements 6,547      
Total  8,869      
Accumulated Depreciation and Amortization $ (1,287)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Strafford, MO        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,634      
Buildings and Improvements 6,518      
Total  8,152      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,634      
Building and Improvements 6,518      
Total  8,152      
Accumulated Depreciation and Amortization $ (1,253)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Windsor, MO        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  471      
Buildings and Improvements 6,819      
Total  7,290      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  471      
Building and Improvements 6,819      
Total  7,290      
Accumulated Depreciation and Amortization $ (1,188)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Conroe, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,222      
Buildings and Improvements 19,099      
Total  20,321      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,222      
Building and Improvements 19,099      
Total  20,321      
Accumulated Depreciation and Amortization $ (3,251)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Houston, TX 2        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,334      
Buildings and Improvements 11,615      
Total  12,949      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,334      
Building and Improvements 11,615      
Total  12,949      
Accumulated Depreciation and Amortization $ (2,060)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Humble, TX 2        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,541      
Buildings and Improvements 12,332      
Total  13,873      
Cost Capitalized Subsequent to Acquisition 645      
Gross Amount at which Carried at Close of Period        
Land  1,541      
Building and Improvements 12,977      
Total  14,518      
Accumulated Depreciation and Amortization $ (2,611)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Missouri City, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,825      
Buildings and Improvements 9,681      
Total  11,506      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,825      
Building and Improvements 9,681      
Total  11,506      
Accumulated Depreciation and Amortization $ (1,784)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Houston, TX 3        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,676      
Buildings and Improvements 7,396      
Total  10,072      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  2,676      
Building and Improvements 7,396      
Total  10,072      
Accumulated Depreciation and Amortization $ (1,394)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Houston, TX 4        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,732      
Buildings and Improvements 12,921      
Total  14,653      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,732      
Building and Improvements 12,921      
Total  14,653      
Accumulated Depreciation and Amortization $ (2,274)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Topeka, KS        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  176      
Buildings and Improvements 2,340      
Total  2,516      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  176      
Building and Improvements 2,340      
Total  2,516      
Accumulated Depreciation and Amortization $ (474)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Salina, KS        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  301      
Buildings and Improvements 4,201      
Total  4,502      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  301      
Building and Improvements 4,201      
Total  4,502      
Accumulated Depreciation and Amortization $ (814)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Terre Haute, IN        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,067      
Buildings and Improvements 7,061      
Total  8,128      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,067      
Building and Improvements 7,061      
Total  8,128      
Accumulated Depreciation and Amortization $ (1,286)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Gas City, IN        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  345      
Buildings and Improvements 8,852      
Total  9,197      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  345      
Building and Improvements 8,852      
Total  9,197      
Accumulated Depreciation and Amortization $ (1,536)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Winchester, IN        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  711      
Buildings and Improvements 5,554      
Total  6,265      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  711      
Building and Improvements 5,554      
Total  6,265      
Accumulated Depreciation and Amortization $ (1,016)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Columbus, IN        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,290      
Buildings and Improvements 10,714      
Total  12,004      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,290      
Building and Improvements 10,714      
Total  12,004      
Accumulated Depreciation and Amortization $ (1,868)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Portland, IN        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  315      
Buildings and Improvements 9,848      
Total  10,163      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  315      
Building and Improvements 9,848      
Total  10,163      
Accumulated Depreciation and Amortization $ (1,743)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Clinton, IN        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  884      
Buildings and Improvements 9,839      
Total  10,723      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  884      
Building and Improvements 9,839      
Total  10,723      
Accumulated Depreciation and Amortization $ (1,829)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Las Vegas, NV 1        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  509      
Buildings and Improvements 18,216      
Total  18,725      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  509      
Building and Improvements 18,216      
Total  18,725      
Accumulated Depreciation and Amortization $ (3,036)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Las Vegas, NV 2        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  3,169      
Buildings and Improvements 7,863      
Total  11,032      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  3,169      
Building and Improvements 7,863      
Total  11,032      
Accumulated Depreciation and Amortization $ (1,477)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Alameda, CA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  3,078      
Buildings and Improvements 22,328      
Total  25,406      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  3,078      
Building and Improvements 22,328      
Total  25,406      
Accumulated Depreciation and Amortization $ (3,806)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Dover, NH        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  522      
Buildings and Improvements 5,839      
Total  6,361      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  522      
Building and Improvements 5,839      
Total  6,361      
Accumulated Depreciation and Amortization $ (1,385)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Augusta, ME        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  135      
Buildings and Improvements 6,470      
Total  6,605      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  135      
Building and Improvements 6,470      
Total  6,605      
Accumulated Depreciation and Amortization $ (1,206)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Bangor, ME 1        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  302      
Buildings and Improvements 1,811      
Total  2,113      
Cost Capitalized Subsequent to Acquisition 2,211      
Gross Amount at which Carried at Close of Period        
Land  302      
Building and Improvements 4,021      
Total  4,323      
Accumulated Depreciation and Amortization $ (1,019)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Bath, ME        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  250      
Buildings and Improvements 1,934      
Total  2,184      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  250      
Building and Improvements 1,934      
Total  2,184      
Accumulated Depreciation and Amortization $ (402)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Brewer, ME        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  177      
Buildings and Improvements 14,497      
Total  14,674      
Cost Capitalized Subsequent to Acquisition 2,520      
Gross Amount at which Carried at Close of Period        
Land  177      
Building and Improvements 17,017      
Total  17,194      
Accumulated Depreciation and Amortization $ (3,371)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Kennebunk, ME        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  198      
Buildings and Improvements 6,822      
Total  7,020      
Cost Capitalized Subsequent to Acquisition 2,005      
Gross Amount at which Carried at Close of Period        
Land  198      
Building and Improvements 8,827      
Total  9,025      
Accumulated Depreciation and Amortization $ (1,634)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Norway, ME        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  791      
Buildings and Improvements 3,680      
Total  4,471      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  791      
Building and Improvements 3,680      
Total  4,471      
Accumulated Depreciation and Amortization $ (729)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Yarmouth, ME        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  134      
Buildings and Improvements 2,072      
Total  2,206      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  134      
Building and Improvements 2,072      
Total  2,206      
Accumulated Depreciation and Amortization $ (442)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Marlborough, MA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  942      
Buildings and Improvements 1,541      
Total  2,483      
Cost Capitalized Subsequent to Acquisition 8,727      
Gross Amount at which Carried at Close of Period        
Land  942      
Building and Improvements 10,268      
Total  11,210      
Accumulated Depreciation and Amortization $ (3,468)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Bangor, ME 2        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  229      
Buildings and Improvements 7,171      
Total  7,400      
Cost Capitalized Subsequent to Acquisition 511      
Gross Amount at which Carried at Close of Period        
Land  229      
Building and Improvements 7,682      
Total  7,911      
Accumulated Depreciation and Amortization $ (1,446)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Orange, CA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  4,163      
Buildings and Improvements 14,755      
Total  18,918      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  4,163      
Building and Improvements 14,755      
Total  18,918      
Accumulated Depreciation and Amortization $ (2,640)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Lancaster, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  548      
Buildings and Improvements 5,794      
Total  6,342      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  548      
Building and Improvements 5,794      
Total  6,342      
Accumulated Depreciation and Amortization $ (1,140)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Garland, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,118      
Buildings and Improvements 7,490      
Total  8,608      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,118      
Building and Improvements 7,490      
Total  8,608      
Accumulated Depreciation and Amortization $ (1,403)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Clarksville, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  279      
Buildings and Improvements 4,269      
Total  4,548      
Cost Capitalized Subsequent to Acquisition 100      
Gross Amount at which Carried at Close of Period        
Land  279      
Building and Improvements 4,369      
Total  4,648      
Accumulated Depreciation and Amortization $ (970)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | McKinney, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,272      
Buildings and Improvements 6,047      
Total  7,319      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,272      
Building and Improvements 6,047      
Total  7,319      
Accumulated Depreciation and Amortization $ (1,217)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Hopkins, MN        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  807      
Buildings and Improvements 4,668      
Total  5,475      
Cost Capitalized Subsequent to Acquisition 530      
Gross Amount at which Carried at Close of Period        
Land  807      
Building and Improvements 5,198      
Total  6,005      
Accumulated Depreciation and Amortization $ (1,418)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Florence, WI        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  291      
Buildings and Improvements 3,778      
Total  4,069      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  291      
Building and Improvements 3,778      
Total  4,069      
Accumulated Depreciation and Amortization $ (795)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | St. Francis, WI        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  166      
Buildings and Improvements 1,887      
Total  2,053      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  166      
Building and Improvements 1,887      
Total  2,053      
Accumulated Depreciation and Amortization $ (412)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Rochester, MN        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  645      
Buildings and Improvements 7,067      
Total  7,712      
Cost Capitalized Subsequent to Acquisition 178      
Gross Amount at which Carried at Close of Period        
Land  645      
Building and Improvements 7,245      
Total  7,890      
Accumulated Depreciation and Amortization $ (1,442)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Wisconsin Dells, WI        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,640      
Buildings and Improvements 1,599      
Total  3,239      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,640      
Building and Improvements 1,599      
Total  3,239      
Accumulated Depreciation and Amortization $ (453)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Sheboygan, WI        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,038      
Buildings and Improvements 2,839      
Total  3,877      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,038      
Building and Improvements 2,839      
Total  3,877      
Accumulated Depreciation and Amortization $ (681)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Hendersonville, NC        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,611      
Buildings and Improvements 3,503      
Total  5,114      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,611      
Building and Improvements 3,503      
Total  5,114      
Accumulated Depreciation and Amortization $ (774)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Baytown, TX 1        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  579      
Buildings and Improvements 22,317      
Total  22,896      
Cost Capitalized Subsequent to Acquisition 103      
Gross Amount at which Carried at Close of Period        
Land  579      
Building and Improvements 22,419      
Total  22,998      
Accumulated Depreciation and Amortization $ (3,865)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Baytown, TX 2        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  589      
Buildings and Improvements 20,475      
Total  21,064      
Cost Capitalized Subsequent to Acquisition 362      
Gross Amount at which Carried at Close of Period        
Land  589      
Building and Improvements 20,837      
Total  21,426      
Accumulated Depreciation and Amortization $ (3,830)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Houston, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,300      
Buildings and Improvements 13,353      
Total  14,653      
Cost Capitalized Subsequent to Acquisition 31      
Gross Amount at which Carried at Close of Period        
Land  1,300      
Building and Improvements 13,384      
Total  14,684      
Accumulated Depreciation and Amortization $ (2,475)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Pasadena, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,148      
Buildings and Improvements 23,579      
Total  24,727      
Cost Capitalized Subsequent to Acquisition 47      
Gross Amount at which Carried at Close of Period        
Land  1,148      
Building and Improvements 23,626      
Total  24,774      
Accumulated Depreciation and Amortization $ (4,142)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Webster, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  904      
Buildings and Improvements 10,315      
Total  11,219      
Cost Capitalized Subsequent to Acquisition 24      
Gross Amount at which Carried at Close of Period        
Land  904      
Building and Improvements 10,338      
Total  11,242      
Accumulated Depreciation and Amortization $ (1,958)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Beaumont, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  945      
Buildings and Improvements 20,424      
Total  21,369      
Cost Capitalized Subsequent to Acquisition 272      
Gross Amount at which Carried at Close of Period        
Land  945      
Building and Improvements 20,696      
Total  21,641      
Accumulated Depreciation and Amortization $ (3,634)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Orange, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  711      
Buildings and Improvements 10,737      
Total  11,448      
Cost Capitalized Subsequent to Acquisition 186      
Gross Amount at which Carried at Close of Period        
Land  711      
Building and Improvements 10,923      
Total  11,634      
Accumulated Depreciation and Amortization $ (2,014)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Huntsville, AL        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  634      
Buildings and Improvements 28,071      
Total  28,705      
Cost Capitalized Subsequent to Acquisition 19      
Gross Amount at which Carried at Close of Period        
Land  634      
Building and Improvements 28,089      
Total  28,723      
Accumulated Depreciation and Amortization $ (4,713)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Terre Haute, IN 1        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  644      
Buildings and Improvements 37,451      
Total  38,095      
Cost Capitalized Subsequent to Acquisition 59      
Gross Amount at which Carried at Close of Period        
Land  644      
Building and Improvements 37,511      
Total  38,155      
Accumulated Depreciation and Amortization $ (7,069)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Madison, TN        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  902      
Buildings and Improvements 3,850      
Total  4,752      
Cost Capitalized Subsequent to Acquisition 23      
Gross Amount at which Carried at Close of Period        
Land  902      
Building and Improvements 3,873      
Total  4,775      
Accumulated Depreciation and Amortization $ (886)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Savannah, GA 1        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,235      
Buildings and Improvements 3,765      
Total  5,000      
Cost Capitalized Subsequent to Acquisition 18      
Gross Amount at which Carried at Close of Period        
Land  1,235      
Building and Improvements 3,783      
Total  5,018      
Accumulated Depreciation and Amortization $ (908)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Bowling Green, KY        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  280      
Buildings and Improvements 13,975      
Total  14,255      
Cost Capitalized Subsequent to Acquisition 32      
Gross Amount at which Carried at Close of Period        
Land  280      
Building and Improvements 14,007      
Total  14,287      
Accumulated Depreciation and Amortization $ (2,597)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Calvert City, KY        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,176      
Buildings and Improvements 7,012      
Total  8,188      
Cost Capitalized Subsequent to Acquisition 25      
Gross Amount at which Carried at Close of Period        
Land  1,176      
Building and Improvements 7,037      
Total  8,213      
Accumulated Depreciation and Amortization $ (1,385)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Winchester, KY        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  554      
Buildings and Improvements 13,207      
Total  13,761      
Cost Capitalized Subsequent to Acquisition 43      
Gross Amount at which Carried at Close of Period        
Land  554      
Building and Improvements 13,250      
Total  13,804      
Accumulated Depreciation and Amortization $ (2,507)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Calhoun, KY        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  613      
Buildings and Improvements 7,643      
Total  8,256      
Cost Capitalized Subsequent to Acquisition 30      
Gross Amount at which Carried at Close of Period        
Land  613      
Building and Improvements 7,673      
Total  8,286      
Accumulated Depreciation and Amortization $ (1,551)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Bremen, IN        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  173      
Buildings and Improvements 7,393      
Total  7,566      
Cost Capitalized Subsequent to Acquisition 38      
Gross Amount at which Carried at Close of Period        
Land  173      
Building and Improvements 7,431      
Total  7,604      
Accumulated Depreciation and Amortization $ (1,373)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Muncie, IN        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  374      
Buildings and Improvements 27,429      
Total  27,803      
Cost Capitalized Subsequent to Acquisition 38      
Gross Amount at which Carried at Close of Period        
Land  374      
Building and Improvements 27,467      
Total  27,841      
Accumulated Depreciation and Amortization $ (4,710)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Lebanon, IN        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  612      
Buildings and Improvements 11,755      
Total  12,367      
Cost Capitalized Subsequent to Acquisition 39      
Gross Amount at which Carried at Close of Period        
Land  612      
Building and Improvements 11,794      
Total  12,406      
Accumulated Depreciation and Amortization $ (2,141)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Marietta, GA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  364      
Buildings and Improvements 16,116      
Total  16,480      
Cost Capitalized Subsequent to Acquisition 20      
Gross Amount at which Carried at Close of Period        
Land  364      
Building and Improvements 16,137      
Total  16,501      
Accumulated Depreciation and Amortization $ (3,004)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Danville, KY        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  790      
Buildings and Improvements 9,356      
Total  10,146      
Cost Capitalized Subsequent to Acquisition 32      
Gross Amount at which Carried at Close of Period        
Land  790      
Building and Improvements 9,388      
Total  10,178      
Accumulated Depreciation and Amortization $ (2,048)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Owensboro, KY        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,048      
Buildings and Improvements 22,587      
Total  23,635      
Cost Capitalized Subsequent to Acquisition 40      
Gross Amount at which Carried at Close of Period        
Land  1,048      
Building and Improvements 22,627      
Total  23,675      
Accumulated Depreciation and Amortization $ (4,031)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Memphis, TN        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,633      
Buildings and Improvements 9,371      
Total  11,004      
Cost Capitalized Subsequent to Acquisition 21      
Gross Amount at which Carried at Close of Period        
Land  1,633      
Building and Improvements 9,392      
Total  11,025      
Accumulated Depreciation and Amortization $ (1,832)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Norfolk, VA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  705      
Buildings and Improvements 16,451      
Total  17,156      
Cost Capitalized Subsequent to Acquisition 33      
Gross Amount at which Carried at Close of Period        
Land  705      
Building and Improvements 16,485      
Total  17,190      
Accumulated Depreciation and Amortization $ (3,322)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Harrodsburg, KY        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,049      
Buildings and Improvements 9,851      
Total  10,900      
Cost Capitalized Subsequent to Acquisition 21      
Gross Amount at which Carried at Close of Period        
Land  1,049      
Building and Improvements 9,872      
Total  10,921      
Accumulated Depreciation and Amortization $ (2,050)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Cookeville, TN        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,034      
Buildings and Improvements 15,555      
Total  16,589      
Cost Capitalized Subsequent to Acquisition 32      
Gross Amount at which Carried at Close of Period        
Land  1,034      
Building and Improvements 15,586      
Total  16,620      
Accumulated Depreciation and Amortization $ (2,841)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Washington Court House, OH        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  405      
Buildings and Improvements 4,839      
Total  5,244      
Cost Capitalized Subsequent to Acquisition 20      
Gross Amount at which Carried at Close of Period        
Land  405      
Building and Improvements 4,859      
Total  5,264      
Accumulated Depreciation and Amortization $ (1,049)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Galion, OH        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  836      
Buildings and Improvements 668      
Total  1,504      
Cost Capitalized Subsequent to Acquisition 14      
Gross Amount at which Carried at Close of Period        
Land  836      
Building and Improvements 683      
Total  1,519      
Accumulated Depreciation and Amortization $ (237)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Roanoke Rapids, NC        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  373      
Buildings and Improvements 10,308      
Total  10,681      
Cost Capitalized Subsequent to Acquisition 25      
Gross Amount at which Carried at Close of Period        
Land  373      
Building and Improvements 10,334      
Total  10,707      
Accumulated Depreciation and Amortization $ (2,070)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Kinston, NC        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  954      
Buildings and Improvements 7,987      
Total  8,941      
Cost Capitalized Subsequent to Acquisition 73      
Gross Amount at which Carried at Close of Period        
Land  954      
Building and Improvements 8,059      
Total  9,013      
Accumulated Depreciation and Amortization $ (1,807)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Chapel Hill, NC        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  809      
Buildings and Improvements 2,703      
Total  3,512      
Cost Capitalized Subsequent to Acquisition 1,191      
Gross Amount at which Carried at Close of Period        
Land  809      
Building and Improvements 3,893      
Total  4,702      
Accumulated Depreciation and Amortization $ (964)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Chillicothe, OH        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  260      
Buildings and Improvements 8,924      
Total  9,184      
Cost Capitalized Subsequent to Acquisition 19      
Gross Amount at which Carried at Close of Period        
Land  260      
Building and Improvements 8,943      
Total  9,203      
Accumulated Depreciation and Amortization $ (1,850)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Coshocton, OH        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  374      
Buildings and Improvements 2,530      
Total  2,904      
Cost Capitalized Subsequent to Acquisition 37      
Gross Amount at which Carried at Close of Period        
Land  374      
Building and Improvements 2,567      
Total  2,941      
Accumulated Depreciation and Amortization $ (715)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Pine Knot, KY        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  208      
Buildings and Improvements 7,665      
Total  7,873      
Cost Capitalized Subsequent to Acquisition 23      
Gross Amount at which Carried at Close of Period        
Land  208      
Building and Improvements 7,689      
Total  7,897      
Accumulated Depreciation and Amortization $ (1,447)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Bardstown, KY        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  634      
Buildings and Improvements 4,094      
Total  4,728      
Cost Capitalized Subsequent to Acquisition 16      
Gross Amount at which Carried at Close of Period        
Land  634      
Building and Improvements 4,110      
Total  4,744      
Accumulated Depreciation and Amortization $ (903)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Glasgow, KY        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  83      
Buildings and Improvements 2,057      
Total  2,140      
Cost Capitalized Subsequent to Acquisition 28      
Gross Amount at which Carried at Close of Period        
Land  83      
Building and Improvements 2,086      
Total  2,169      
Accumulated Depreciation and Amortization $ (552)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Carrollton, KY        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  124      
Buildings and Improvements 1,693      
Total  1,817      
Cost Capitalized Subsequent to Acquisition 21      
Gross Amount at which Carried at Close of Period        
Land  124      
Building and Improvements 1,714      
Total  1,838      
Accumulated Depreciation and Amortization $ (476)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Horse Cave, KY        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  208      
Buildings and Improvements 7,070      
Total  7,278      
Cost Capitalized Subsequent to Acquisition 38      
Gross Amount at which Carried at Close of Period        
Land  208      
Building and Improvements 7,108      
Total  7,316      
Accumulated Depreciation and Amortization $ (1,460)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Lawrenceburg, KY        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  635      
Buildings and Improvements 9,861      
Total  10,496      
Cost Capitalized Subsequent to Acquisition 17      
Gross Amount at which Carried at Close of Period        
Land  635      
Building and Improvements 9,879      
Total  10,514      
Accumulated Depreciation and Amortization $ (1,887)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Annville, KY        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  479      
Buildings and Improvements 6,078      
Total  6,557      
Cost Capitalized Subsequent to Acquisition 17      
Gross Amount at which Carried at Close of Period        
Land  479      
Building and Improvements 6,095      
Total  6,574      
Accumulated Depreciation and Amortization $ (1,140)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Louisville, KY 1        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  3,528      
Buildings and Improvements 4,653      
Total  8,181      
Cost Capitalized Subsequent to Acquisition 24      
Gross Amount at which Carried at Close of Period        
Land  3,528      
Building and Improvements 4,677      
Total  8,205      
Accumulated Depreciation and Amortization $ (1,095)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Louisville, KY 2        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,207      
Buildings and Improvements 20,733      
Total  22,940      
Cost Capitalized Subsequent to Acquisition 29      
Gross Amount at which Carried at Close of Period        
Land  2,207      
Building and Improvements 20,761      
Total  22,968      
Accumulated Depreciation and Amortization $ (3,667)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Tompkinsville, KY        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  333      
Buildings and Improvements 9,556      
Total  9,889      
Cost Capitalized Subsequent to Acquisition 26      
Gross Amount at which Carried at Close of Period        
Land  333      
Building and Improvements 9,582      
Total  9,915      
Accumulated Depreciation and Amortization $ (1,809)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Radcliff, KY        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,815      
Buildings and Improvements 7,470      
Total  9,285      
Cost Capitalized Subsequent to Acquisition 34      
Gross Amount at which Carried at Close of Period        
Land  1,815      
Building and Improvements 7,504      
Total  9,319      
Accumulated Depreciation and Amortization $ (1,793)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Hartford, KY        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  312      
Buildings and Improvements 8,189      
Total  8,501      
Cost Capitalized Subsequent to Acquisition 21      
Gross Amount at which Carried at Close of Period        
Land  312      
Building and Improvements 8,210      
Total  8,522      
Accumulated Depreciation and Amortization $ (1,583)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Louisville, KY 3        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  427      
Buildings and Improvements 6,003      
Total  6,430      
Cost Capitalized Subsequent to Acquisition 21      
Gross Amount at which Carried at Close of Period        
Land  427      
Building and Improvements 6,023      
Total  6,450      
Accumulated Depreciation and Amortization $ (1,237)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Louisville, KY 4        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,134      
Buildings and Improvements 9,166      
Total  10,300      
Cost Capitalized Subsequent to Acquisition 28      
Gross Amount at which Carried at Close of Period        
Land  1,134      
Building and Improvements 9,194      
Total  10,328      
Accumulated Depreciation and Amortization $ (1,938)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Lexington, KY        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,558      
Buildings and Improvements 4,311      
Total  6,869      
Cost Capitalized Subsequent to Acquisition 51      
Gross Amount at which Carried at Close of Period        
Land  2,558      
Building and Improvements 4,361      
Total  6,919      
Accumulated Depreciation and Amortization $ (998)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Columbia, KY        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  114      
Buildings and Improvements 11,141      
Total  11,255      
Cost Capitalized Subsequent to Acquisition 28      
Gross Amount at which Carried at Close of Period        
Land  114      
Building and Improvements 11,169      
Total  11,283      
Accumulated Depreciation and Amortization $ (2,063)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Monticello, AR        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  206      
Buildings and Improvements 3,179      
Total  3,385      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  206      
Building and Improvements 3,179      
Total  3,385      
Accumulated Depreciation and Amortization $ (704)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Benton, AR        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,336      
Buildings and Improvements 7,386      
Total  8,722      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,336      
Building and Improvements 7,386      
Total  8,722      
Accumulated Depreciation and Amortization $ (1,493)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Wynne, AR        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  227      
Buildings and Improvements 4,007      
Total  4,234      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  227      
Building and Improvements 4,007      
Total  4,234      
Accumulated Depreciation and Amortization $ (818)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Morrilton, AR        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  412      
Buildings and Improvements 2,642      
Total  3,054      
Cost Capitalized Subsequent to Acquisition 3,038      
Gross Amount at which Carried at Close of Period        
Land  467      
Building and Improvements 5,680      
Total  6,147      
Accumulated Depreciation and Amortization $ (936)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Bryant, AR        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  819      
Buildings and Improvements 8,938      
Total  9,757      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  819      
Building and Improvements 8,938      
Total  9,757      
Accumulated Depreciation and Amortization $ (1,609)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Savannah, GA 2        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,194      
Buildings and Improvements 11,711      
Total  13,905      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  2,194      
Building and Improvements 11,711      
Total  13,905      
Accumulated Depreciation and Amortization $ (2,080)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Durham, NC        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  470      
Buildings and Improvements 9,633      
Total  10,103      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  470      
Building and Improvements 9,633      
Total  10,103      
Accumulated Depreciation and Amortization $ (1,695)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Raleigh, NC 1        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,155      
Buildings and Improvements 11,749      
Total  12,904      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,155      
Building and Improvements 11,749      
Total  12,904      
Accumulated Depreciation and Amortization $ (2,117)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Raleigh, NC 2        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  926      
Buildings and Improvements 17,649      
Total  18,575      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  926      
Building and Improvements 17,649      
Total  18,575      
Accumulated Depreciation and Amortization $ (3,125)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Wilmington, NC        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  611      
Buildings and Improvements 5,051      
Total  5,662      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  611      
Building and Improvements 5,051      
Total  5,662      
Accumulated Depreciation and Amortization $ (1,015)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Winston-Salem, NC        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  879      
Buildings and Improvements 3,283      
Total  4,162      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  879      
Building and Improvements 3,283      
Total  4,162      
Accumulated Depreciation and Amortization $ (753)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Lincolnton, NC        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  0      
Buildings and Improvements 9,967      
Total  9,967      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  0      
Building and Improvements 9,967      
Total  9,967      
Accumulated Depreciation and Amortization $ (1,803)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Monroe, NC        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  166      
Buildings and Improvements 5,906      
Total  6,072      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  166      
Building and Improvements 5,906      
Total  6,072      
Accumulated Depreciation and Amortization $ (1,189)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Zebulon, NC        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  594      
Buildings and Improvements 8,559      
Total  9,153      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  594      
Building and Improvements 8,559      
Total  9,153      
Accumulated Depreciation and Amortization $ (1,486)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Rocky Mount, NC        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  0      
Buildings and Improvements 18,314      
Total  18,314      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  0      
Building and Improvements 18,314      
Total  18,314      
Accumulated Depreciation and Amortization $ (3,123)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | DeSoto, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  942      
Buildings and Improvements 6,033      
Total  6,975      
Cost Capitalized Subsequent to Acquisition 320      
Gross Amount at which Carried at Close of Period        
Land  942      
Building and Improvements 6,353      
Total  7,295      
Accumulated Depreciation and Amortization $ (1,236)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Trinity, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  363      
Buildings and Improvements 3,852      
Total  4,215      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  363      
Building and Improvements 3,852      
Total  4,215      
Accumulated Depreciation and Amortization $ (822)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Kirbyville, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  208      
Buildings and Improvements 5,809      
Total  6,017      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  208      
Building and Improvements 5,809      
Total  6,017      
Accumulated Depreciation and Amortization $ (1,186)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Marshall, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  732      
Buildings and Improvements 4,288      
Total  5,020      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  732      
Building and Improvements 4,288      
Total  5,020      
Accumulated Depreciation and Amortization $ (901)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Warren, MI        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,052      
Buildings and Improvements 25,539      
Total  27,591      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  2,052      
Building and Improvements 25,539      
Total  27,591      
Accumulated Depreciation and Amortization $ (5,009)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Hamburg, NY        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,026      
Buildings and Improvements 54,086      
Total  55,112      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,026      
Building and Improvements 54,086      
Total  55,112      
Accumulated Depreciation and Amortization $ (9,273)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | East Patchogue, NY        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,181      
Buildings and Improvements 30,373      
Total  32,554      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  2,181      
Building and Improvements 30,373      
Total  32,554      
Accumulated Depreciation and Amortization $ (5,478)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Williamsville, NY        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,122      
Buildings and Improvements 46,413      
Total  47,535      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,122      
Building and Improvements 46,413      
Total  47,535      
Accumulated Depreciation and Amortization $ (7,814)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Cheektowaga, NY        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,164      
Buildings and Improvements 29,905      
Total  31,069      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,164      
Building and Improvements 29,905      
Total  31,069      
Accumulated Depreciation and Amortization $ (5,335)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | North Tonawanda, NY        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  830      
Buildings and Improvements 29,488      
Total  30,318      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  830      
Building and Improvements 29,488      
Total  30,318      
Accumulated Depreciation and Amortization $ (5,259)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | West Seneca, NY        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,325      
Buildings and Improvements 26,839      
Total  28,164      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,325      
Building and Improvements 26,839      
Total  28,164      
Accumulated Depreciation and Amortization $ (4,698)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Beverly, MA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,410      
Buildings and Improvements 13,588      
Total  15,998      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  2,410      
Building and Improvements 13,588      
Total  15,998      
Accumulated Depreciation and Amortization $ (3,199)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Lancaster, MA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  343      
Buildings and Improvements 7,733      
Total  8,076      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  343      
Building and Improvements 7,733      
Total  8,076      
Accumulated Depreciation and Amortization $ (1,407)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | New London, CT        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  505      
Buildings and Improvements 2,248      
Total  2,753      
Cost Capitalized Subsequent to Acquisition 48      
Gross Amount at which Carried at Close of Period        
Land  505      
Building and Improvements 2,296      
Total  2,801      
Accumulated Depreciation and Amortization $ (712)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Enfield, CT        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  437      
Buildings and Improvements 16,461      
Total  16,898      
Cost Capitalized Subsequent to Acquisition 231      
Gross Amount at which Carried at Close of Period        
Land  437      
Building and Improvements 16,693      
Total  17,130      
Accumulated Depreciation and Amortization $ (3,085)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Quincy, MA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  894      
Buildings and Improvements 904      
Total  1,798      
Cost Capitalized Subsequent to Acquisition 129      
Gross Amount at which Carried at Close of Period        
Land  894      
Building and Improvements 1,033      
Total  1,927      
Accumulated Depreciation and Amortization $ (335)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Fishkill, NY        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  964      
Buildings and Improvements 30,107      
Total  31,071      
Cost Capitalized Subsequent to Acquisition 421      
Gross Amount at which Carried at Close of Period        
Land  964      
Building and Improvements 30,518      
Total  31,482      
Accumulated Depreciation and Amortization $ (5,495)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Highland, NY        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  4,371      
Buildings and Improvements 11,473      
Total  15,844      
Cost Capitalized Subsequent to Acquisition 260      
Gross Amount at which Carried at Close of Period        
Land  4,371      
Building and Improvements 11,733      
Total  16,104      
Accumulated Depreciation and Amortization $ (2,252)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Beacon, NY        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  0      
Buildings and Improvements 25,400      
Total  25,400      
Cost Capitalized Subsequent to Acquisition 267      
Gross Amount at which Carried at Close of Period        
Land  0      
Building and Improvements 25,666      
Total  25,666      
Accumulated Depreciation and Amortization $ (4,802)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Springfield, MA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  817      
Buildings and Improvements 11,357      
Total  12,174      
Cost Capitalized Subsequent to Acquisition 386      
Gross Amount at which Carried at Close of Period        
Land  817      
Building and Improvements 11,743      
Total  12,560      
Accumulated Depreciation and Amortization $ (2,094)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Andover, MA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,123      
Buildings and Improvements 5,383      
Total  7,506      
Cost Capitalized Subsequent to Acquisition 18      
Gross Amount at which Carried at Close of Period        
Land  2,123      
Building and Improvements 5,401      
Total  7,524      
Accumulated Depreciation and Amortization $ (1,131)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Reading, MA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,534      
Buildings and Improvements 5,221      
Total  6,755      
Cost Capitalized Subsequent to Acquisition 540      
Gross Amount at which Carried at Close of Period        
Land  1,534      
Building and Improvements 5,760      
Total  7,294      
Accumulated Depreciation and Amortization $ (1,216)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Sudbury, MA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,017      
Buildings and Improvements 3,458      
Total  5,475      
Cost Capitalized Subsequent to Acquisition 421      
Gross Amount at which Carried at Close of Period        
Land  2,017      
Building and Improvements 3,879      
Total  5,896      
Accumulated Depreciation and Amortization $ (922)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Lowell, MA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,335      
Buildings and Improvements 9,019      
Total  10,354      
Cost Capitalized Subsequent to Acquisition 489      
Gross Amount at which Carried at Close of Period        
Land  1,335      
Building and Improvements 9,508      
Total  10,843      
Accumulated Depreciation and Amortization $ (1,847)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Worcester, MA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  945      
Buildings and Improvements 8,770      
Total  9,715      
Cost Capitalized Subsequent to Acquisition 50      
Gross Amount at which Carried at Close of Period        
Land  945      
Building and Improvements 8,820      
Total  9,765      
Accumulated Depreciation and Amortization $ (1,693)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | W. Springfield, MA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,022      
Buildings and Improvements 7,345      
Total  9,367      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  2,022      
Building and Improvements 7,345      
Total  9,367      
Accumulated Depreciation and Amortization $ (1,556)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | East Longmeadow, MA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,968      
Buildings and Improvements 8,957      
Total  11,925      
Cost Capitalized Subsequent to Acquisition 790      
Gross Amount at which Carried at Close of Period        
Land  2,968      
Building and Improvements 9,748      
Total  12,716      
Accumulated Depreciation and Amortization $ (2,055)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Long Beach, CA 1        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,939      
Buildings and Improvements 11,782      
Total  14,721      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  2,939      
Building and Improvements 11,690      
Total  14,629      
Accumulated Depreciation and Amortization $ (2,246)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Anaheim, CA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,044      
Buildings and Improvements 14,167      
Total  16,211      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  2,044      
Building and Improvements 14,167      
Total  16,211      
Accumulated Depreciation and Amortization $ (2,643)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Fairfield, CA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  586      
Buildings and Improvements 23,582      
Total  24,168      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  586      
Building and Improvements 23,582      
Total  24,168      
Accumulated Depreciation and Amortization $ (4,095)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Baldwin Park, CA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,270      
Buildings and Improvements 17,063      
Total  19,333      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  2,270      
Building and Improvements 17,063      
Total  19,333      
Accumulated Depreciation and Amortization $ (3,126)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Grand Terrace, CA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  432      
Buildings and Improvements 9,382      
Total  9,814      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  432      
Building and Improvements 9,382      
Total  9,814      
Accumulated Depreciation and Amortization $ (1,732)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Pacifica, CA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,510      
Buildings and Improvements 27,397      
Total  28,907      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,510      
Building and Improvements 27,397      
Total  28,907      
Accumulated Depreciation and Amortization $ (4,692)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Burien, WA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  823      
Buildings and Improvements 17,431      
Total  18,254      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  826      
Building and Improvements 17,431      
Total  18,257      
Accumulated Depreciation and Amortization $ (3,145)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Seattle, WA 1        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  4,802      
Buildings and Improvements 7,927      
Total  12,729      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  4,802      
Building and Improvements 7,927      
Total  12,729      
Accumulated Depreciation and Amortization $ (1,604)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Huntington Bch, CA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,312      
Buildings and Improvements 9,885      
Total  12,197      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  2,312      
Building and Improvements 9,885      
Total  12,197      
Accumulated Depreciation and Amortization $ (1,817)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Chatsworth, CA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  7,841      
Buildings and Improvements 16,916      
Total  24,757      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  7,841      
Building and Improvements 16,916      
Total  24,757      
Accumulated Depreciation and Amortization $ (3,239)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Woodland, CA 1        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  504      
Buildings and Improvements 7,369      
Total  7,873      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  504      
Building and Improvements 7,369      
Total  7,873      
Accumulated Depreciation and Amortization $ (1,425)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Danville, CA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,491      
Buildings and Improvements 17,157      
Total  18,648      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,491      
Building and Improvements 17,157      
Total  18,648      
Accumulated Depreciation and Amortization $ (3,074)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Van Nuys, CA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,456      
Buildings and Improvements 16,462      
Total  18,918      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  2,456      
Building and Improvements 16,462      
Total  18,918      
Accumulated Depreciation and Amortization $ (2,841)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Lomita, CA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,743      
Buildings and Improvements 14,734      
Total  17,477      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  2,743      
Building and Improvements 14,734      
Total  17,477      
Accumulated Depreciation and Amortization $ (2,763)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Sacramento, CA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,846      
Buildings and Improvements 17,962      
Total  20,808      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  2,846      
Building and Improvements 17,962      
Total  20,808      
Accumulated Depreciation and Amortization $ (3,178)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Issaquah, WA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  10,125      
Buildings and Improvements 7,771      
Total  17,896      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  10,125      
Building and Improvements 7,771      
Total  17,896      
Accumulated Depreciation and Amortization $ (1,653)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Long Beach, CA 2        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  3,157      
Buildings and Improvements 22,067      
Total  25,224      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  3,157      
Building and Improvements 22,067      
Total  25,224      
Accumulated Depreciation and Amortization $ (4,001)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Long Beach, CA 3        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,857      
Buildings and Improvements 5,878      
Total  8,735      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  2,857      
Building and Improvements 5,878      
Total  8,735      
Accumulated Depreciation and Amortization $ (1,150)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Lodi, CA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  812      
Buildings and Improvements 21,059      
Total  21,871      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  812      
Building and Improvements 21,059      
Total  21,871      
Accumulated Depreciation and Amortization $ (3,553)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Riverside, CA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,717      
Buildings and Improvements 13,806      
Total  15,523      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,717      
Building and Improvements 13,806      
Total  15,523      
Accumulated Depreciation and Amortization $ (2,725)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Woodland, CA 2        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  278      
Buildings and Improvements 16,729      
Total  17,007      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  278      
Building and Improvements 16,729      
Total  17,007      
Accumulated Depreciation and Amortization $ (2,990)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Bee Cave, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,107      
Buildings and Improvements 10,413      
Total  12,520      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  2,107      
Building and Improvements 10,413      
Total  12,520      
Accumulated Depreciation and Amortization $ (2,147)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | El Monte, CA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,058      
Buildings and Improvements 19,671      
Total  21,729      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  2,058      
Building and Improvements 19,671      
Total  21,729      
Accumulated Depreciation and Amortization $ (3,401)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Shoreline, WA 1        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  8,861      
Buildings and Improvements 11,478      
Total  20,339      
Cost Capitalized Subsequent to Acquisition 103      
Gross Amount at which Carried at Close of Period        
Land  8,861      
Building and Improvements 11,580      
Total  20,441      
Accumulated Depreciation and Amortization $ (2,368)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Elizabethtown, KY        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  729      
Buildings and Improvements 0      
Total  729      
Cost Capitalized Subsequent to Acquisition 19,329      
Gross Amount at which Carried at Close of Period        
Land  729      
Building and Improvements 19,329      
Total  20,058      
Accumulated Depreciation and Amortization $ (479)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Crown Point, IN        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,522      
Buildings and Improvements 14,951      
Total  16,473      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,522      
Building and Improvements 14,951      
Total  16,473      
Accumulated Depreciation and Amortization $ (78)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Skilled Nursing/Transitional Care | Dyer, IN        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,859      
Buildings and Improvements 19,547      
Total  21,406      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,859      
Building and Improvements 19,547      
Total  21,406      
Accumulated Depreciation and Amortization $ (100)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased        
Real Estate and Accumulated Depreciation        
Encumbrances $ 24,092      
Initial Cost to Company        
Land  39,325      
Buildings and Improvements 509,434      
Total  548,759      
Cost Capitalized Subsequent to Acquisition 27,811      
Gross Amount at which Carried at Close of Period        
Land  40,406      
Building and Improvements 532,868      
Total  573,274      
Accumulated Depreciation and Amortization (109,601)      
Senior Housing - Leased | Rockport, TX        
Real Estate and Accumulated Depreciation        
Encumbrances 0      
Initial Cost to Company        
Land  789      
Buildings and Improvements 607      
Total  1,396      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  789      
Building and Improvements 475      
Total  1,264      
Accumulated Depreciation and Amortization $ (183)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Norman, OK        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  557      
Buildings and Improvements 2,663      
Total  3,220      
Cost Capitalized Subsequent to Acquisition 1,135      
Gross Amount at which Carried at Close of Period        
Land  557      
Building and Improvements 3,798      
Total  4,355      
Accumulated Depreciation and Amortization $ (68)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Topeka, KS        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  313      
Buildings and Improvements 5,492      
Total  5,805      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  313      
Building and Improvements 5,492      
Total  5,805      
Accumulated Depreciation and Amortization $ (967)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Salina, KS        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  584      
Buildings and Improvements 3,020      
Total  3,604      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  584      
Building and Improvements 3,020      
Total  3,604      
Accumulated Depreciation and Amortization $ (575)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Dover, NH        
Real Estate and Accumulated Depreciation        
Encumbrances $ 2,335      
Initial Cost to Company        
Land  801      
Buildings and Improvements 10,036      
Total  10,837      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  801      
Building and Improvements 8,584      
Total  9,385      
Accumulated Depreciation and Amortization $ (4,002)      
Life on Which Depreciation in Latest Income Statement is Computed 42 years      
Senior Housing - Leased | Exeter, NH        
Real Estate and Accumulated Depreciation        
Encumbrances $ 1,880      
Initial Cost to Company        
Land  571      
Buildings and Improvements 7,183      
Total  7,754      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  571      
Building and Improvements 5,912      
Total  6,483      
Accumulated Depreciation and Amortization $ (2,771)      
Life on Which Depreciation in Latest Income Statement is Computed 43 years      
Senior Housing - Leased | Nashua, NH        
Real Estate and Accumulated Depreciation        
Encumbrances $ 4,457      
Initial Cost to Company        
Land  0      
Buildings and Improvements 5,654      
Total  5,654      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  0      
Building and Improvements 4,566      
Total  4,566      
Accumulated Depreciation and Amortization $ (1,949)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Keene, NH        
Real Estate and Accumulated Depreciation        
Encumbrances $ 3,237      
Initial Cost to Company        
Land  304      
Buildings and Improvements 3,992      
Total  4,296      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  304      
Building and Improvements 3,263      
Total  3,567      
Accumulated Depreciation and Amortization $ (1,650)      
Life on Which Depreciation in Latest Income Statement is Computed 46 years      
Senior Housing - Leased | Green Bay, WI        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  256      
Buildings and Improvements 2,262      
Total  2,518      
Cost Capitalized Subsequent to Acquisition 1,032      
Gross Amount at which Carried at Close of Period        
Land  256      
Building and Improvements 1,976      
Total  2,232      
Accumulated Depreciation and Amortization $ (767)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Cadillac, MI        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  217      
Buildings and Improvements 3,000      
Total  3,217      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  217      
Building and Improvements 2,920      
Total  3,137      
Accumulated Depreciation and Amortization $ (910)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Greenville, MI        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  684      
Buildings and Improvements 5,832      
Total  6,516      
Cost Capitalized Subsequent to Acquisition 249      
Gross Amount at which Carried at Close of Period        
Land  684      
Building and Improvements 5,841      
Total  6,525      
Accumulated Depreciation and Amortization $ (1,876)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Manistee, MI        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  952      
Buildings and Improvements 2,578      
Total  3,530      
Cost Capitalized Subsequent to Acquisition 2,547      
Gross Amount at which Carried at Close of Period        
Land  952      
Building and Improvements 5,076      
Total  6,028      
Accumulated Depreciation and Amortization $ (1,970)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Mason, MI        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  198      
Buildings and Improvements 4,131      
Total  4,329      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  198      
Building and Improvements 4,032      
Total  4,230      
Accumulated Depreciation and Amortization $ (1,323)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Alpena, MI        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  546      
Buildings and Improvements 13,139      
Total  13,685      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  546      
Building and Improvements 13,000      
Total  13,546      
Accumulated Depreciation and Amortization $ (3,763)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Fremont, NE        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  504      
Buildings and Improvements 17,670      
Total  18,174      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  504      
Building and Improvements 17,670      
Total  18,174      
Accumulated Depreciation and Amortization $ (5,020)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Norfolk, NE        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  217      
Buildings and Improvements 9,906      
Total  10,123      
Cost Capitalized Subsequent to Acquisition 4,680      
Gross Amount at which Carried at Close of Period        
Land  217      
Building and Improvements 14,586      
Total  14,803      
Accumulated Depreciation and Amortization $ (4,284)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Fort Wayne, IN        
Real Estate and Accumulated Depreciation        
Encumbrances $ 12,183      
Initial Cost to Company        
Land  2,300      
Buildings and Improvements 21,115      
Total  23,415      
Cost Capitalized Subsequent to Acquisition 2,747      
Gross Amount at which Carried at Close of Period        
Land  2,300      
Building and Improvements 23,846      
Total  26,146      
Accumulated Depreciation and Amortization $ (7,799)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Brandon, FL        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,283      
Buildings and Improvements 8,424      
Total  9,707      
Cost Capitalized Subsequent to Acquisition 483      
Gross Amount at which Carried at Close of Period        
Land  1,283      
Building and Improvements 8,722      
Total  10,005      
Accumulated Depreciation and Amortization $ (2,532)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Lecanto, FL        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,031      
Buildings and Improvements 5,577      
Total  6,608      
Cost Capitalized Subsequent to Acquisition 615      
Gross Amount at which Carried at Close of Period        
Land  1,023      
Building and Improvements 6,053      
Total  7,076      
Accumulated Depreciation and Amortization $ (2,026)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Zephyrhills, FL        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,688      
Buildings and Improvements 9,098      
Total  10,786      
Cost Capitalized Subsequent to Acquisition 360      
Gross Amount at which Carried at Close of Period        
Land  1,688      
Building and Improvements 9,343      
Total  11,031      
Accumulated Depreciation and Amortization $ (2,924)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Sun City West, AZ        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  930      
Buildings and Improvements 9,170      
Total  10,100      
Cost Capitalized Subsequent to Acquisition 248      
Gross Amount at which Carried at Close of Period        
Land  930      
Building and Improvements 9,418      
Total  10,348      
Accumulated Depreciation and Amortization $ (2,188)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Fredericksburg, VA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,379      
Buildings and Improvements 21,209      
Total  22,588      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,379      
Building and Improvements 21,209      
Total  22,588      
Accumulated Depreciation and Amortization $ (4,644)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Round Rock, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  679      
Buildings and Improvements 13,642      
Total  14,321      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  679      
Building and Improvements 13,642      
Total  14,321      
Accumulated Depreciation and Amortization $ (3,035)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Santa Fe, NM 1        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,866      
Buildings and Improvements 19,441      
Total  21,307      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  2,157      
Building and Improvements 21,736      
Total  23,893      
Accumulated Depreciation and Amortization $ (4,587)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Santa Fe, NM 2        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  670      
Buildings and Improvements 7,743      
Total  8,413      
Cost Capitalized Subsequent to Acquisition 430      
Gross Amount at which Carried at Close of Period        
Land  670      
Building and Improvements 8,571      
Total  9,241      
Accumulated Depreciation and Amortization $ (810)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Franklin, NH        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  292      
Buildings and Improvements 6,889      
Total  7,181      
Cost Capitalized Subsequent to Acquisition 211      
Gross Amount at which Carried at Close of Period        
Land  292      
Building and Improvements 7,110      
Total  7,402      
Accumulated Depreciation and Amortization $ (1,700)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Henderson, NV        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,430      
Buildings and Improvements 21,850      
Total  23,280      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,430      
Building and Improvements 21,862      
Total  23,292      
Accumulated Depreciation and Amortization $ (4,411)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Brenham, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  476      
Buildings and Improvements 11,912      
Total  12,388      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  476      
Building and Improvements 11,922      
Total  12,398      
Accumulated Depreciation and Amortization $ (2,753)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Cedar Park, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,035      
Buildings and Improvements 13,127      
Total  14,162      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,035      
Building and Improvements 13,127      
Total  14,162      
Accumulated Depreciation and Amortization $ (2,546)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Keizer, OR        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,220      
Buildings and Improvements 31,783      
Total  33,003      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,220      
Building and Improvements 31,783      
Total  33,003      
Accumulated Depreciation and Amortization $ (5,435)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Lawrence, KS        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  584      
Buildings and Improvements 4,431      
Total  5,015      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  584      
Building and Improvements 4,431      
Total  5,015      
Accumulated Depreciation and Amortization $ (849)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Lafayette, CO        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,085      
Buildings and Improvements 19,243      
Total  20,328      
Cost Capitalized Subsequent to Acquisition 9      
Gross Amount at which Carried at Close of Period        
Land  1,883      
Building and Improvements 19,205      
Total  21,088      
Accumulated Depreciation and Amortization $ (3,382)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Winnebago, IL        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  263      
Buildings and Improvements 3,743      
Total  4,006      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  263      
Building and Improvements 3,743      
Total  4,006      
Accumulated Depreciation and Amortization $ (707)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Pewaukee, WI 1        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,019      
Buildings and Improvements 3,606      
Total  4,625      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,019      
Building and Improvements 3,606      
Total  4,625      
Accumulated Depreciation and Amortization $ (635)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Pewaukee, WI 2        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  661      
Buildings and Improvements 5,680      
Total  6,341      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  661      
Building and Improvements 5,680      
Total  6,341      
Accumulated Depreciation and Amortization $ (923)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Sarasota, FL        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,440      
Buildings and Improvements 22,541      
Total  23,981      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,440      
Building and Improvements 22,541      
Total  23,981      
Accumulated Depreciation and Amortization $ (3,495)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Knoxville, TN        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,603      
Buildings and Improvements 9,219      
Total  10,822      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,603      
Building and Improvements 9,219      
Total  10,822      
Accumulated Depreciation and Amortization $ (1,651)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Shavano Park, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,131      
Buildings and Improvements 11,541      
Total  13,672      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  2,131      
Building and Improvements 11,541      
Total  13,672      
Accumulated Depreciation and Amortization $ (1,890)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Beavercreek, OH        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,622      
Buildings and Improvements 24,215      
Total  25,837      
Cost Capitalized Subsequent to Acquisition 7,561      
Gross Amount at which Carried at Close of Period        
Land  1,622      
Building and Improvements 31,773      
Total  33,395      
Accumulated Depreciation and Amortization $ (5,805)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | McCordsville, IN        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,587      
Buildings and Improvements 31,315      
Total  32,902      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,587      
Building and Improvements 31,315      
Total  32,902      
Accumulated Depreciation and Amortization $ (3,487)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Louisville, KY        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,841      
Buildings and Improvements 21,827      
Total  23,668      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,841      
Building and Improvements 21,827      
Total  23,668      
Accumulated Depreciation and Amortization $ (2,359)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Sellersburg, IN        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,060      
Buildings and Improvements 28,702      
Total  29,762      
Cost Capitalized Subsequent to Acquisition 5,504      
Gross Amount at which Carried at Close of Period        
Land  1,060      
Building and Improvements 34,206      
Total  35,266      
Accumulated Depreciation and Amortization $ (3,336)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior Housing - Leased | Jasper, IN        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  657      
Buildings and Improvements 25,226      
Total  25,883      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  657      
Building and Improvements 25,226      
Total  25,883      
Accumulated Depreciation and Amortization $ (1,614)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  101,463      
Buildings and Improvements 1,087,895      
Total  1,189,358      
Cost Capitalized Subsequent to Acquisition 38,355      
Gross Amount at which Carried at Close of Period        
Land  102,457      
Building and Improvements 1,187,028      
Total  1,289,485      
Accumulated Depreciation and Amortization (255,803)      
Senior housing - managed portfolio | Dover, DE        
Real Estate and Accumulated Depreciation        
Encumbrances 0      
Initial Cost to Company        
Land  2,797      
Buildings and Improvements 23,054      
Total  25,851      
Cost Capitalized Subsequent to Acquisition 456      
Gross Amount at which Carried at Close of Period        
Land  2,797      
Building and Improvements 23,422      
Total  26,219      
Accumulated Depreciation and Amortization $ (4,245)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Salem, OR        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,074      
Buildings and Improvements 19,421      
Total  20,495      
Cost Capitalized Subsequent to Acquisition 451      
Gross Amount at which Carried at Close of Period        
Land  1,074      
Building and Improvements 19,884      
Total  20,958      
Accumulated Depreciation and Amortization $ (4,774)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Kansas City, MO        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,325      
Buildings and Improvements 20,510      
Total  21,835      
Cost Capitalized Subsequent to Acquisition 923      
Gross Amount at which Carried at Close of Period        
Land  1,325      
Building and Improvements 25,844      
Total  27,169      
Accumulated Depreciation and Amortization $ (6,657)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | McKinney, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,760      
Buildings and Improvements 44,397      
Total  47,157      
Cost Capitalized Subsequent to Acquisition 1,497      
Gross Amount at which Carried at Close of Period        
Land  2,760      
Building and Improvements 49,615      
Total  52,375      
Accumulated Depreciation and Amortization $ (12,854)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Winston-Salem, NC        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,995      
Buildings and Improvements 24,428      
Total  27,423      
Cost Capitalized Subsequent to Acquisition 676      
Gross Amount at which Carried at Close of Period        
Land  2,995      
Building and Improvements 26,841      
Total  29,836      
Accumulated Depreciation and Amortization $ (7,132)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Frankenmuth, MI        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  5,027      
Buildings and Improvements 20,929      
Total  25,956      
Cost Capitalized Subsequent to Acquisition 637      
Gross Amount at which Carried at Close of Period        
Land  5,027      
Building and Improvements 21,170      
Total  26,197      
Accumulated Depreciation and Amortization $ (6,342)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Gaylord, MI        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,024      
Buildings and Improvements 5,467      
Total  7,491      
Cost Capitalized Subsequent to Acquisition 141      
Gross Amount at which Carried at Close of Period        
Land  2,024      
Building and Improvements 5,583      
Total  7,607      
Accumulated Depreciation and Amortization $ (2,060)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | East Tawas, MI        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  258      
Buildings and Improvements 3,713      
Total  3,971      
Cost Capitalized Subsequent to Acquisition 399      
Gross Amount at which Carried at Close of Period        
Land  258      
Building and Improvements 3,984      
Total  4,242      
Accumulated Depreciation and Amortization $ (1,551)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Marshfield, WI        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  574      
Buildings and Improvements 8,733      
Total  9,307      
Cost Capitalized Subsequent to Acquisition 220      
Gross Amount at which Carried at Close of Period        
Land  574      
Building and Improvements 8,803      
Total  9,377      
Accumulated Depreciation and Amortization $ (2,623)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Woodstock, VA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  597      
Buildings and Improvements 5,465      
Total  6,062      
Cost Capitalized Subsequent to Acquisition 117      
Gross Amount at which Carried at Close of Period        
Land  597      
Building and Improvements 5,448      
Total  6,045      
Accumulated Depreciation and Amortization $ (1,538)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Allen, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,190      
Buildings and Improvements 45,767      
Total  47,957      
Cost Capitalized Subsequent to Acquisition 948      
Gross Amount at which Carried at Close of Period        
Land  2,190      
Building and Improvements 50,510      
Total  52,700      
Accumulated Depreciation and Amortization $ (12,723)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Gainesville, FL        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,139      
Buildings and Improvements 44,789      
Total  46,928      
Cost Capitalized Subsequent to Acquisition 1,562      
Gross Amount at which Carried at Close of Period        
Land  2,139      
Building and Improvements 49,736      
Total  51,875      
Accumulated Depreciation and Amortization $ (13,797)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Raleigh, NC        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,344      
Buildings and Improvements 37,506      
Total  39,850      
Cost Capitalized Subsequent to Acquisition 1,749      
Gross Amount at which Carried at Close of Period        
Land  2,344      
Building and Improvements 43,072      
Total  45,416      
Accumulated Depreciation and Amortization $ (10,650)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | San Luis Obispo, CA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  4,992      
Buildings and Improvements 30,909      
Total  35,901      
Cost Capitalized Subsequent to Acquisition 1,117      
Gross Amount at which Carried at Close of Period        
Land  4,992      
Building and Improvements 35,062      
Total  40,054      
Accumulated Depreciation and Amortization $ (9,094)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Longview, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  805      
Buildings and Improvements 26,498      
Total  27,303      
Cost Capitalized Subsequent to Acquisition 824      
Gross Amount at which Carried at Close of Period        
Land  805      
Building and Improvements 27,972      
Total  28,777      
Accumulated Depreciation and Amortization $ (7,930)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Yuma, AZ        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  530      
Buildings and Improvements 21,775      
Total  22,305      
Cost Capitalized Subsequent to Acquisition 484      
Gross Amount at which Carried at Close of Period        
Land  530      
Building and Improvements 22,678      
Total  23,208      
Accumulated Depreciation and Amortization $ (6,226)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Nashville, TN        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,996      
Buildings and Improvements 19,368      
Total  21,364      
Cost Capitalized Subsequent to Acquisition 1,227      
Gross Amount at which Carried at Close of Period        
Land  1,996      
Building and Improvements 21,607      
Total  23,603      
Accumulated Depreciation and Amortization $ (6,530)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Branford, CT        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,403      
Buildings and Improvements 18,821      
Total  21,224      
Cost Capitalized Subsequent to Acquisition 732      
Gross Amount at which Carried at Close of Period        
Land  2,403      
Building and Improvements 22,939      
Total  25,342      
Accumulated Depreciation and Amortization $ (5,668)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Richmond, VA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,080      
Buildings and Improvements 19,545      
Total  20,625      
Cost Capitalized Subsequent to Acquisition 1,602      
Gross Amount at which Carried at Close of Period        
Land  1,080      
Building and Improvements 23,606      
Total  24,686      
Accumulated Depreciation and Amortization $ (6,296)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Auburn, AL        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  3,209      
Buildings and Improvements 17,326      
Total  20,535      
Cost Capitalized Subsequent to Acquisition 516      
Gross Amount at which Carried at Close of Period        
Land  3,209      
Building and Improvements 18,482      
Total  21,691      
Accumulated Depreciation and Amortization $ (5,259)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Menomonee Falls, WI        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,477      
Buildings and Improvements 18,778      
Total  20,255      
Cost Capitalized Subsequent to Acquisition 426      
Gross Amount at which Carried at Close of Period        
Land  1,477      
Building and Improvements 20,272      
Total  21,749      
Accumulated Depreciation and Amortization $ (5,690)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Glenville, NY        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  978      
Buildings and Improvements 18,257      
Total  19,235      
Cost Capitalized Subsequent to Acquisition 571      
Gross Amount at which Carried at Close of Period        
Land  978      
Building and Improvements 19,711      
Total  20,689      
Accumulated Depreciation and Amortization $ (5,564)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Eustis, FL        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,152      
Buildings and Improvements 17,523      
Total  18,675      
Cost Capitalized Subsequent to Acquisition 606      
Gross Amount at which Carried at Close of Period        
Land  1,152      
Building and Improvements 18,811      
Total  19,963      
Accumulated Depreciation and Amortization $ (5,669)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Phoenix, AZ        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,567      
Buildings and Improvements 12,029      
Total  14,596      
Cost Capitalized Subsequent to Acquisition 983      
Gross Amount at which Carried at Close of Period        
Land  2,567      
Building and Improvements 13,881      
Total  16,448      
Accumulated Depreciation and Amortization $ (4,425)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Jonesboro, AR        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,782      
Buildings and Improvements 11,244      
Total  13,026      
Cost Capitalized Subsequent to Acquisition 373      
Gross Amount at which Carried at Close of Period        
Land  1,782      
Building and Improvements 12,326      
Total  14,108      
Accumulated Depreciation and Amortization $ (3,705)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Ogden, UT        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  794      
Buildings and Improvements 10,873      
Total  11,667      
Cost Capitalized Subsequent to Acquisition 798      
Gross Amount at which Carried at Close of Period        
Land  794      
Building and Improvements 12,673      
Total  13,467      
Accumulated Depreciation and Amortization $ (3,764)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Olympia, WA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,477      
Buildings and Improvements 23,767      
Total  26,244      
Cost Capitalized Subsequent to Acquisition 923      
Gross Amount at which Carried at Close of Period        
Land  2,477      
Building and Improvements 27,924      
Total  30,401      
Accumulated Depreciation and Amortization $ (7,326)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Windsor, ON        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,360      
Buildings and Improvements 16,855      
Total  18,215      
Cost Capitalized Subsequent to Acquisition 526      
Gross Amount at which Carried at Close of Period        
Land  1,378      
Building and Improvements 18,359      
Total  19,737      
Accumulated Depreciation and Amortization $ (4,576)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | London, ON        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  960      
Buildings and Improvements 19,056      
Total  20,016      
Cost Capitalized Subsequent to Acquisition 368      
Gross Amount at which Carried at Close of Period        
Land  972      
Building and Improvements 20,408      
Total  21,380      
Accumulated Depreciation and Amortization $ (4,954)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Kelowna, BC        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,321      
Buildings and Improvements 8,308      
Total  10,629      
Cost Capitalized Subsequent to Acquisition 626      
Gross Amount at which Carried at Close of Period        
Land  2,352      
Building and Improvements 9,846      
Total  12,198      
Accumulated Depreciation and Amortization $ (2,639)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Waterloo, ON        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,823      
Buildings and Improvements 22,135      
Total  23,958      
Cost Capitalized Subsequent to Acquisition 380      
Gross Amount at which Carried at Close of Period        
Land  1,848      
Building and Improvements 23,213      
Total  25,061      
Accumulated Depreciation and Amortization $ (5,546)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Sarnia, ON        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,187      
Buildings and Improvements 20,346      
Total  21,533      
Cost Capitalized Subsequent to Acquisition 740      
Gross Amount at which Carried at Close of Period        
Land  1,203      
Building and Improvements 22,905      
Total  24,108      
Accumulated Depreciation and Amortization $ (5,273)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Kamloops, BC        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  679      
Buildings and Improvements 8,024      
Total  8,703      
Cost Capitalized Subsequent to Acquisition 250      
Gross Amount at which Carried at Close of Period        
Land  687      
Building and Improvements 9,040      
Total  9,727      
Accumulated Depreciation and Amortization $ (2,332)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Vernon, BC        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  843      
Buildings and Improvements 10,724      
Total  11,567      
Cost Capitalized Subsequent to Acquisition 236      
Gross Amount at which Carried at Close of Period        
Land  273      
Building and Improvements 11,643      
Total  11,916      
Accumulated Depreciation and Amortization $ (2,829)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Penticton, BC        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  763      
Buildings and Improvements 6,771      
Total  7,534      
Cost Capitalized Subsequent to Acquisition 239      
Gross Amount at which Carried at Close of Period        
Land  773      
Building and Improvements 7,940      
Total  8,713      
Accumulated Depreciation and Amortization $ (2,058)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Calgary, AB        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  3,908      
Buildings and Improvements 20,996      
Total  24,904      
Cost Capitalized Subsequent to Acquisition 1,077      
Gross Amount at which Carried at Close of Period        
Land  3,963      
Building and Improvements 22,749      
Total  26,712      
Accumulated Depreciation and Amortization $ (5,259)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Lake Stevens, WA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,559      
Buildings and Improvements 9,059      
Total  10,618      
Cost Capitalized Subsequent to Acquisition 96      
Gross Amount at which Carried at Close of Period        
Land  1,559      
Building and Improvements 9,168      
Total  10,727      
Accumulated Depreciation and Amortization $ (2,349)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Eugene, OR        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,428      
Buildings and Improvements 16,138      
Total  17,566      
Cost Capitalized Subsequent to Acquisition 143      
Gross Amount at which Carried at Close of Period        
Land  1,428      
Building and Improvements 16,303      
Total  17,731      
Accumulated Depreciation and Amortization $ (3,690)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Tualatin, OR        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  527      
Buildings and Improvements 14,659      
Total  15,186      
Cost Capitalized Subsequent to Acquisition 138      
Gross Amount at which Carried at Close of Period        
Land  527      
Building and Improvements 14,852      
Total  15,379      
Accumulated Depreciation and Amortization $ (3,364)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Ramsey, MN        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,182      
Buildings and Improvements 13,280      
Total  14,462      
Cost Capitalized Subsequent to Acquisition 208      
Gross Amount at which Carried at Close of Period        
Land  1,182      
Building and Improvements 13,783      
Total  14,965      
Accumulated Depreciation and Amortization $ (2,627)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Marshfield, WI 1        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  500      
Buildings and Improvements 4,134      
Total  4,634      
Cost Capitalized Subsequent to Acquisition 89      
Gross Amount at which Carried at Close of Period        
Land  500      
Building and Improvements 4,263      
Total  4,763      
Accumulated Depreciation and Amortization $ (923)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Charleston, WV        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  419      
Buildings and Improvements 4,239      
Total  4,658      
Cost Capitalized Subsequent to Acquisition 1,008      
Gross Amount at which Carried at Close of Period        
Land  419      
Building and Improvements 5,066      
Total  5,485      
Accumulated Depreciation and Amortization $ (1,302)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Williamsport, PA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  296      
Buildings and Improvements 9,191      
Total  9,487      
Cost Capitalized Subsequent to Acquisition 907      
Gross Amount at which Carried at Close of Period        
Land  296      
Building and Improvements 9,973      
Total  10,269      
Accumulated Depreciation and Amortization $ (2,001)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Reading, PA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  684      
Buildings and Improvements 12,950      
Total  13,634      
Cost Capitalized Subsequent to Acquisition 276      
Gross Amount at which Carried at Close of Period        
Land  684      
Building and Improvements 13,201      
Total  13,885      
Accumulated Depreciation and Amortization $ (2,475)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Scott Depot, WV        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  230      
Buildings and Improvements 6,271      
Total  6,501      
Cost Capitalized Subsequent to Acquisition 713      
Gross Amount at which Carried at Close of Period        
Land  230      
Building and Improvements 6,767      
Total  6,997      
Accumulated Depreciation and Amortization $ (1,444)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Clarks Summit, PA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  406      
Buildings and Improvements 9,471      
Total  9,877      
Cost Capitalized Subsequent to Acquisition 1,271      
Gross Amount at which Carried at Close of Period        
Land  406      
Building and Improvements 10,524      
Total  10,930      
Accumulated Depreciation and Amortization $ (2,264)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Wyncote, PA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,781      
Buildings and Improvements 4,911      
Total  6,692      
Cost Capitalized Subsequent to Acquisition 814      
Gross Amount at which Carried at Close of Period        
Land  1,781      
Building and Improvements 5,517      
Total  7,298      
Accumulated Depreciation and Amortization $ (1,345)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Douglassville, PA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  611      
Buildings and Improvements 19,083      
Total  19,694      
Cost Capitalized Subsequent to Acquisition 356      
Gross Amount at which Carried at Close of Period        
Land  611      
Building and Improvements 19,367      
Total  19,978      
Accumulated Depreciation and Amortization $ (3,418)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Milford, DE        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,199      
Buildings and Improvements 18,786      
Total  19,985      
Cost Capitalized Subsequent to Acquisition 589      
Gross Amount at which Carried at Close of Period        
Land  1,199      
Building and Improvements 19,231      
Total  20,430      
Accumulated Depreciation and Amortization $ (3,476)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Oak Hill, WV        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  609      
Buildings and Improvements 2,636      
Total  3,245      
Cost Capitalized Subsequent to Acquisition 1,157      
Gross Amount at which Carried at Close of Period        
Land  609      
Building and Improvements 3,703      
Total  4,312      
Accumulated Depreciation and Amortization $ (1,053)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Lewisburg, WV        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  355      
Buildings and Improvements 5,055      
Total  5,410      
Cost Capitalized Subsequent to Acquisition 677      
Gross Amount at which Carried at Close of Period        
Land  355      
Building and Improvements 5,449      
Total  5,804      
Accumulated Depreciation and Amortization $ (1,227)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Strasburg, VA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  666      
Buildings and Improvements 5,551      
Total  6,217      
Cost Capitalized Subsequent to Acquisition 22      
Gross Amount at which Carried at Close of Period        
Land  666      
Building and Improvements 5,573      
Total  6,239      
Accumulated Depreciation and Amortization $ (931)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Richardson, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,282      
Buildings and Improvements 10,556      
Total  12,838      
Cost Capitalized Subsequent to Acquisition 1,288      
Gross Amount at which Carried at Close of Period        
Land  2,282      
Building and Improvements 11,934      
Total  14,216      
Accumulated Depreciation and Amortization $ (1,673)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Poway, CA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  3,693      
Buildings and Improvements 14,467      
Total  18,160      
Cost Capitalized Subsequent to Acquisition 1,072      
Gross Amount at which Carried at Close of Period        
Land  3,693      
Building and Improvements 15,688      
Total  19,381      
Accumulated Depreciation and Amortization $ (1,915)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | New Braunfels, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,312      
Buildings and Improvements 23,108      
Total  24,420      
Cost Capitalized Subsequent to Acquisition 360      
Gross Amount at which Carried at Close of Period        
Land  1,312      
Building and Improvements 23,664      
Total  24,976      
Accumulated Depreciation and Amortization $ (2,871)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Augusta, GA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  419      
Buildings and Improvements 24,958      
Total  25,377      
Cost Capitalized Subsequent to Acquisition 94      
Gross Amount at which Carried at Close of Period        
Land  459      
Building and Improvements 28,548      
Total  29,007      
Accumulated Depreciation and Amortization $ (2,343)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Anchorage, AK        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,965      
Buildings and Improvements 29,533      
Total  31,498      
Cost Capitalized Subsequent to Acquisition 150      
Gross Amount at which Carried at Close of Period        
Land  1,965      
Building and Improvements 29,683      
Total  31,648      
Accumulated Depreciation and Amortization $ (2,304)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Loveland, OH        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  3,691      
Buildings and Improvements 21,168      
Total  24,859      
Cost Capitalized Subsequent to Acquisition 41      
Gross Amount at which Carried at Close of Period        
Land  3,691      
Building and Improvements 21,269      
Total  24,960      
Accumulated Depreciation and Amortization $ (1,220)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Indianapolis, IN        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  4,950      
Buildings and Improvements 32,631      
Total  37,581      
Cost Capitalized Subsequent to Acquisition 43      
Gross Amount at which Carried at Close of Period        
Land  6,299      
Building and Improvements 41,563      
Total  47,862      
Accumulated Depreciation and Amortization $ (1,674)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Saginaw, MI        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,651      
Buildings and Improvements 29,283      
Total  30,934      
Cost Capitalized Subsequent to Acquisition 1,440      
Gross Amount at which Carried at Close of Period        
Land  1,651      
Building and Improvements 31,289      
Total  32,940      
Accumulated Depreciation and Amortization $ (1,247)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Senior housing - managed portfolio | Madeira, OH        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,858      
Buildings and Improvements 42,670      
Total  45,528      
Cost Capitalized Subsequent to Acquisition 3      
Gross Amount at which Carried at Close of Period        
Land  2,858      
Building and Improvements 42,691      
Total  45,549      
Accumulated Depreciation and Amortization $ (1,109)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Behavioral Health        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  57,718      
Buildings and Improvements 365,403      
Total  423,121      
Cost Capitalized Subsequent to Acquisition 73,823      
Gross Amount at which Carried at Close of Period        
Land  57,718      
Building and Improvements 439,019      
Total  496,737      
Accumulated Depreciation and Amortization (71,943)      
Behavioral Health | Morrilton, AR        
Real Estate and Accumulated Depreciation        
Encumbrances 0      
Initial Cost to Company        
Land  508      
Buildings and Improvements 0      
Total  508      
Cost Capitalized Subsequent to Acquisition 3,169      
Gross Amount at which Carried at Close of Period        
Land  508      
Building and Improvements 3,169      
Total  3,677      
Accumulated Depreciation and Amortization $ (98)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Behavioral Health | New London, CT        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  356      
Buildings and Improvements 152      
Total  508      
Cost Capitalized Subsequent to Acquisition 3,665      
Gross Amount at which Carried at Close of Period        
Land  356      
Building and Improvements 3,817      
Total  4,173      
Accumulated Depreciation and Amortization $ (746)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Behavioral Health | Elizabethtown, KY        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  239      
Buildings and Improvements 4,853      
Total  5,092      
Cost Capitalized Subsequent to Acquisition 699      
Gross Amount at which Carried at Close of Period        
Land  239      
Building and Improvements 5,552      
Total  5,791      
Accumulated Depreciation and Amortization $ (971)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Behavioral Health | Louisville, KY        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,078      
Buildings and Improvements 8,305      
Total  9,383      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,078      
Building and Improvements 8,305      
Total  9,383      
Accumulated Depreciation and Amortization $ (1,153)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Behavioral Health | Aurora, CO        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,874      
Buildings and Improvements 12,829      
Total  15,703      
Cost Capitalized Subsequent to Acquisition 1,950      
Gross Amount at which Carried at Close of Period        
Land  2,874      
Building and Improvements 14,563      
Total  17,437      
Accumulated Depreciation and Amortization $ (3,931)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Behavioral Health | Colorado Springs, CO 1        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  430      
Buildings and Improvements 13,703      
Total  14,133      
Cost Capitalized Subsequent to Acquisition 1,033      
Gross Amount at which Carried at Close of Period        
Land  430      
Building and Improvements 14,736      
Total  15,166      
Accumulated Depreciation and Amortization $ (4,445)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Behavioral Health | Colorado Springs, CO 2        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,210      
Buildings and Improvements 9,490      
Total  10,700      
Cost Capitalized Subsequent to Acquisition 2,058      
Gross Amount at which Carried at Close of Period        
Land  1,210      
Building and Improvements 11,548      
Total  12,758      
Accumulated Depreciation and Amortization $ (2,326)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Behavioral Health | Bluffton, IN        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  254      
Buildings and Improvements 5,105      
Total  5,359      
Cost Capitalized Subsequent to Acquisition 1,486      
Gross Amount at which Carried at Close of Period        
Land  254      
Building and Improvements 6,591      
Total  6,845      
Accumulated Depreciation and Amortization $ (1,364)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Behavioral Health | Glendale, AZ        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,501      
Buildings and Improvements 67,046      
Total  68,547      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,501      
Building and Improvements 67,046      
Total  68,547      
Accumulated Depreciation and Amortization $ (11,140)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Behavioral Health | Tempe, AZ        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  3,137      
Buildings and Improvements 50,073      
Total  53,210      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  3,137      
Building and Improvements 50,073      
Total  53,210      
Accumulated Depreciation and Amortization $ (8,505)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Behavioral Health | Covina, CA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  23,472      
Buildings and Improvements 71,542      
Total  95,014      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  23,472      
Building and Improvements 71,542      
Total  95,014      
Accumulated Depreciation and Amortization $ (12,348)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Behavioral Health | Ventura, CA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  8,089      
Buildings and Improvements 43,645      
Total  51,734      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  8,089      
Building and Improvements 43,645      
Total  51,734      
Accumulated Depreciation and Amortization $ (8,190)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Behavioral Health | San Diego, CA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  8,403      
Buildings and Improvements 55,015      
Total  63,418      
Cost Capitalized Subsequent to Acquisition 7,599      
Gross Amount at which Carried at Close of Period        
Land  8,403      
Building and Improvements 62,614      
Total  71,017      
Accumulated Depreciation and Amortization $ (11,947)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Behavioral Health | Carmel, IN        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  963      
Buildings and Improvements 4,347      
Total  5,310      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  963      
Building and Improvements 4,347      
Total  5,310      
Accumulated Depreciation and Amortization $ (680)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Behavioral Health | Monroeville, PA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,034      
Buildings and Improvements 1,758      
Total  3,792      
Cost Capitalized Subsequent to Acquisition 18,545      
Gross Amount at which Carried at Close of Period        
Land  2,034      
Building and Improvements 20,303      
Total  22,337      
Accumulated Depreciation and Amortization $ (2,869)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Behavioral Health | Gulf Breeze, FL        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  498      
Buildings and Improvements 1,480      
Total  1,978      
Cost Capitalized Subsequent to Acquisition 3,733      
Gross Amount at which Carried at Close of Period        
Land  498      
Building and Improvements 5,213      
Total  5,711      
Accumulated Depreciation and Amortization $ (139)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Behavioral Health | Greenville, SC        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,197      
Buildings and Improvements 9,496      
Total  10,693      
Cost Capitalized Subsequent to Acquisition 21,507      
Gross Amount at which Carried at Close of Period        
Land  1,197      
Building and Improvements 31,012      
Total  32,209      
Accumulated Depreciation and Amortization $ (574)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Behavioral Health | Raytown, MO        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,475      
Buildings and Improvements 6,564      
Total  8,039      
Cost Capitalized Subsequent to Acquisition 8,379      
Gross Amount at which Carried at Close of Period        
Land  1,475      
Building and Improvements 14,943      
Total  16,418      
Accumulated Depreciation and Amortization $ (517)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Specialty Hospitals and Other        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  20,434      
Buildings and Improvements 204,759      
Total  225,193      
Cost Capitalized Subsequent to Acquisition 314      
Gross Amount at which Carried at Close of Period        
Land  20,434      
Building and Improvements 205,009      
Total  225,443      
Accumulated Depreciation and Amortization (47,454)      
Specialty Hospitals and Other | Arlington, TX        
Real Estate and Accumulated Depreciation        
Encumbrances 0      
Initial Cost to Company        
Land  0      
Buildings and Improvements 44,217      
Total  44,217      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  0      
Building and Improvements 44,217      
Total  44,217      
Accumulated Depreciation and Amortization $ (7,195)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Specialty Hospitals and Other | Conroe, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,935      
Buildings and Improvements 25,003      
Total  27,938      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  2,935      
Building and Improvements 25,003      
Total  27,938      
Accumulated Depreciation and Amortization $ (4,600)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Specialty Hospitals and Other | Orange, CA        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  2,060      
Buildings and Improvements 5,538      
Total  7,598      
Cost Capitalized Subsequent to Acquisition 145      
Gross Amount at which Carried at Close of Period        
Land  2,060      
Building and Improvements 5,683      
Total  7,743      
Accumulated Depreciation and Amortization $ (986)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Specialty Hospitals and Other | Houston, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  3,001      
Buildings and Improvements 14,581      
Total  17,582      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  3,001      
Building and Improvements 14,581      
Total  17,582      
Accumulated Depreciation and Amortization $ (2,416)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Specialty Hospitals and Other | Sunnyvale, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  4,020      
Buildings and Improvements 57,620      
Total  61,640      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  4,020      
Building and Improvements 57,620      
Total  61,640      
Accumulated Depreciation and Amortization $ (22,152)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Specialty Hospitals and Other | Spring, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  1,319      
Buildings and Improvements 15,153      
Total  16,472      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  1,319      
Building and Improvements 15,153      
Total  16,472      
Accumulated Depreciation and Amortization $ (2,516)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Specialty Hospitals and Other | Maxwell, TX 1        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  902      
Buildings and Improvements 2,384      
Total  3,286      
Cost Capitalized Subsequent to Acquisition 1      
Gross Amount at which Carried at Close of Period        
Land  902      
Building and Improvements 2,384      
Total  3,286      
Accumulated Depreciation and Amortization $ (458)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Specialty Hospitals and Other | Maxwell, TX 2        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  901      
Buildings and Improvements 1,198      
Total  2,099      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  901      
Building and Improvements 1,198      
Total  2,099      
Accumulated Depreciation and Amortization $ (278)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Specialty Hospitals and Other | Maxwell, TX 3        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  456      
Buildings and Improvements 2,632      
Total  3,088      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  456      
Building and Improvements 2,632      
Total  3,088      
Accumulated Depreciation and Amortization $ (477)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Specialty Hospitals and Other | San Marcos, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  51      
Buildings and Improvements 359      
Total  410      
Cost Capitalized Subsequent to Acquisition 62      
Gross Amount at which Carried at Close of Period        
Land  51      
Building and Improvements 359      
Total  410      
Accumulated Depreciation and Amortization $ (67)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Specialty Hospitals and Other | Seguin, TX 1        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  539      
Buildings and Improvements 2,627      
Total  3,166      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  539      
Building and Improvements 2,627      
Total  3,166      
Accumulated Depreciation and Amortization $ (605)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Specialty Hospitals and Other | Seguin, TX 2        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  228      
Buildings and Improvements 3,407      
Total  3,635      
Cost Capitalized Subsequent to Acquisition 79      
Gross Amount at which Carried at Close of Period        
Land  228      
Building and Improvements 3,486      
Total  3,714      
Accumulated Depreciation and Amortization $ (669)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Specialty Hospitals and Other | Kingsbury, TX        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  104      
Buildings and Improvements 2,788      
Total  2,892      
Cost Capitalized Subsequent to Acquisition 27      
Gross Amount at which Carried at Close of Period        
Land  104      
Building and Improvements 2,814      
Total  2,918      
Accumulated Depreciation and Amortization $ (495)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Specialty Hospitals and Other | Seguin, TX 3        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  52      
Buildings and Improvements 805      
Total  857      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  52      
Building and Improvements 805      
Total  857      
Accumulated Depreciation and Amortization $ (154)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
Specialty Hospitals and Other | Florence, KY        
Real Estate and Accumulated Depreciation        
Encumbrances $ 0      
Initial Cost to Company        
Land  3,866      
Buildings and Improvements 26,447      
Total  30,313      
Cost Capitalized Subsequent to Acquisition 0      
Gross Amount at which Carried at Close of Period        
Land  3,866      
Building and Improvements 26,447      
Total  30,313      
Accumulated Depreciation and Amortization $ (4,386)      
Life on Which Depreciation in Latest Income Statement is Computed 40 years      
XML 109 R94.htm IDEA: XBRL DOCUMENT v3.24.0.1
SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION - Rollforward of Real Estate and Accumulated Depreciation (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Real estate:      
Balance at the beginning of the year $ 5,872,688 $ 5,994,208 $ 5,966,695
Acquisitions 86,626 101,413 96,157
Improvements 86,073 65,111 47,319
Impairment (18,853) (160,550) (11,063)
Sale of real estate (379,272) (110,901) (102,575)
Foreign currency translation 3,394 (10,247) 524
Other (12,309) (6,346) (2,849)
Balance at the end of the year 5,638,347 5,872,688 5,994,208
Accumulated depreciation:      
Balance at the beginning of the year (913,345) (831,324) (681,657)
Depreciation expense (171,278) (170,159) (170,264)
Impairment 4,432 66,603 1,666
Sale of real estate 49,585 13,217 16,097
Foreign currency translation (747) 1,972 (15)
Other 10,267 6,346 2,849
Balance at the end of the year $ (1,021,086) $ (913,345) $ (831,324)
XML 110 R95.htm IDEA: XBRL DOCUMENT v3.24.0.1
SCHEDULE IV - MORTGAGE LOANS ON REAL ESTATE (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]      
Principal Balance $ 319,000 $ 319,000 $ 312,343
Aggregate cost for federal income tax purposes 321,200    
SEC Schedule, 12-29, Real Estate Companies, Investment in Movement in Mortgage Loans on Real Estate [Roll Forward]      
Balance at the beginning of the year 319,000 312,343 22,343
Additions during period:      
Draws 0 10,000 0
New mortgage loans 0 0 290,000
Deductions during period:      
Paydowns/repayments 0 (3,343) 0
Balance at the end of the year 319,000 $ 319,000 $ 312,343
Mortgages      
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]      
Prior Liens 0    
Principal Balance 319,000    
Book Value 319,000    
Deductions during period:      
Balance at the end of the year $ 319,000    
Mortgages | River Vista      
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]      
Contractual Interest Rate 10.00%    
Prior Liens $ 0    
Principal Balance 19,000    
Book Value 19,000    
Deductions during period:      
Balance at the end of the year $ 19,000    
Mortgages | Recovery Centers of America      
SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]      
Contractual Interest Rate 7.50%    
Prior Liens $ 0    
Principal Balance 300,000    
Book Value 300,000    
Deductions during period:      
Balance at the end of the year $ 300,000    
EXCEL 112 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 113 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 114 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 116 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 751 486 1 true 484 0 false 16 false false R1.htm 0000001 - Document - Cover Sheet http://www.sabrahealth.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Document - Audit Information Sheet http://www.sabrahealth.com/role/AuditInformation Audit Information Cover 2 false false R3.htm 0000003 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS Statements 3 false false R4.htm 0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 4 false false R5.htm 0000005 - Statement - CONSOLIDATED STATEMENTS OF INCOME (LOSS) Sheet http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS CONSOLIDATED STATEMENTS OF INCOME (LOSS) Statements 5 false false R6.htm 0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Sheet http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Statements 6 false false R7.htm 0000007 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) Sheet http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) Statements 7 false false R8.htm 0000008 - Statement - CONSOLIDATED STATEMENTS OF EQUITY Sheet http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY CONSOLIDATED STATEMENTS OF EQUITY Statements 8 false false R9.htm 0000009 - Statement - CONSOLIDATED STATEMENTS OF EQUITY (Parenthetical) Sheet http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYParenthetical CONSOLIDATED STATEMENTS OF EQUITY (Parenthetical) Statements 9 false false R10.htm 0000010 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 10 false false R11.htm 0000011 - Disclosure - BUSINESS Sheet http://www.sabrahealth.com/role/BUSINESS BUSINESS Notes 11 false false R12.htm 0000012 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 12 false false R13.htm 0000013 - Disclosure - RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) Sheet http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATED RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) Notes 13 false false R14.htm 0000014 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES Sheet http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIES INVESTMENT IN REAL ESTATE PROPERTIES Notes 14 false false R15.htm 0000015 - Disclosure - IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS Sheet http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONS IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS Notes 15 false false R16.htm 0000016 - Disclosure - INTANGIBLE ASSETS AND LIABILITIES Sheet http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIES INTANGIBLE ASSETS AND LIABILITIES Notes 16 false false R17.htm 0000017 - Disclosure - LOANS RECEIVABLE AND OTHER INVESTMENTS Sheet http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTS LOANS RECEIVABLE AND OTHER INVESTMENTS Notes 17 false false R18.htm 0000018 - Disclosure - DEBT Sheet http://www.sabrahealth.com/role/DEBT DEBT Notes 18 false false R19.htm 0000019 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS Sheet http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTS DERIVATIVE AND HEDGING INSTRUMENTS Notes 19 false false R20.htm 0000020 - Disclosure - FAIR VALUE DISCLOSURES Sheet http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURES FAIR VALUE DISCLOSURES Notes 20 false false R21.htm 0000021 - Disclosure - EQUITY Sheet http://www.sabrahealth.com/role/EQUITY EQUITY Notes 21 false false R22.htm 0000022 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATION STOCK-BASED COMPENSATION Notes 22 false false R23.htm 0000023 - Disclosure - INCOME TAXES Sheet http://www.sabrahealth.com/role/INCOMETAXES INCOME TAXES Notes 23 false false R24.htm 0000024 - Disclosure - EARNINGS PER COMMON SHARE Sheet http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHARE EARNINGS PER COMMON SHARE Notes 24 false false R25.htm 0000025 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.sabrahealth.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 25 false false R26.htm 0000026 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.sabrahealth.com/role/SUBSEQUENTEVENTS SUBSEQUENT EVENTS Notes 26 false false R27.htm 0000027 - Disclosure - SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION Sheet http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATION SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION Notes 27 false false R28.htm 0000028 - Disclosure - SCHEDULE IV - MORTGAGE LOANS ON REAL ESTATE Sheet http://www.sabrahealth.com/role/SCHEDULEIVMORTGAGELOANSONREALESTATE SCHEDULE IV - MORTGAGE LOANS ON REAL ESTATE Notes 28 false false R29.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 29 false false R30.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 30 false false R31.htm 9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 31 false false R32.htm 9954472 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES 32 false false R33.htm 9954473 - Disclosure - RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) (Tables) Sheet http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDTables RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) (Tables) Tables http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATED 33 false false R34.htm 9954474 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES (Tables) Sheet http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESTables INVESTMENT IN REAL ESTATE PROPERTIES (Tables) Tables http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIES 34 false false R35.htm 9954475 - Disclosure - IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS (Tables) Sheet http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSTables IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS (Tables) Tables http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONS 35 false false R36.htm 9954476 - Disclosure - INTANGIBLE ASSETS AND LIABILITIES (Tables) Sheet http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESTables INTANGIBLE ASSETS AND LIABILITIES (Tables) Tables http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIES 36 false false R37.htm 9954477 - Disclosure - LOANS RECEIVABLE AND OTHER INVESTMENTS (Tables) Sheet http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSTables LOANS RECEIVABLE AND OTHER INVESTMENTS (Tables) Tables http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTS 37 false false R38.htm 9954478 - Disclosure - DEBT (Tables) Sheet http://www.sabrahealth.com/role/DEBTTables DEBT (Tables) Tables http://www.sabrahealth.com/role/DEBT 38 false false R39.htm 9954479 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS (Tables) Sheet http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSTables DERIVATIVE AND HEDGING INSTRUMENTS (Tables) Tables http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTS 39 false false R40.htm 9954480 - Disclosure - FAIR VALUE DISCLOSURES (Tables) Sheet http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESTables FAIR VALUE DISCLOSURES (Tables) Tables http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURES 40 false false R41.htm 9954481 - Disclosure - EQUITY (Tables) Sheet http://www.sabrahealth.com/role/EQUITYTables EQUITY (Tables) Tables http://www.sabrahealth.com/role/EQUITY 41 false false R42.htm 9954482 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONTables STOCK-BASED COMPENSATION (Tables) Tables http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATION 42 false false R43.htm 9954483 - Disclosure - INCOME TAXES (Tables) Sheet http://www.sabrahealth.com/role/INCOMETAXESTables INCOME TAXES (Tables) Tables http://www.sabrahealth.com/role/INCOMETAXES 43 false false R44.htm 9954484 - Disclosure - EARNINGS PER COMMON SHARE (Tables) Sheet http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHARETables EARNINGS PER COMMON SHARE (Tables) Tables http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHARE 44 false false R45.htm 9954485 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) Sheet http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) Details 45 false false R46.htm 9954486 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule (Details) Sheet http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule (Details) Details 46 false false R47.htm 9954487 - Disclosure - RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) - Narrative (Details) Sheet http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) - Narrative (Details) Details http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDTables 47 false false R48.htm 9954488 - Disclosure - RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED)- Purchase Price Allocation for Recent Real Estate Acquisitions (Details) Sheet http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED)- Purchase Price Allocation for Recent Real Estate Acquisitions (Details) Details http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDTables 48 false false R49.htm 9954489 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Real Estate Properties Held for Investment (Details) Sheet http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails INVESTMENT IN REAL ESTATE PROPERTIES - Real Estate Properties Held for Investment (Details) Details 49 false false R50.htm 9954490 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Operating Leases Narrative (Details) Sheet http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails INVESTMENT IN REAL ESTATE PROPERTIES - Operating Leases Narrative (Details) Details 50 false false R51.htm 9954491 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Future Minimum Rental Payments from Non-Cancelable Operating Leases (Details) Sheet http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESFutureMinimumRentalPaymentsfromNonCancelableOperatingLeasesDetails INVESTMENT IN REAL ESTATE PROPERTIES - Future Minimum Rental Payments from Non-Cancelable Operating Leases (Details) Details 51 false false R52.htm 9954492 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Senior Housing - Managed Communities Narrative (Details) Sheet http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSeniorHousingManagedCommunitiesNarrativeDetails INVESTMENT IN REAL ESTATE PROPERTIES - Senior Housing - Managed Communities Narrative (Details) Details 52 false false R53.htm 9954493 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Capital and Other Expenditures Narrative (Details) Sheet http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESCapitalandOtherExpendituresNarrativeDetails INVESTMENT IN REAL ESTATE PROPERTIES - Capital and Other Expenditures Narrative (Details) Details 53 false false R54.htm 9954494 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Schedule of Investment in Joint Ventures (Details) Sheet http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESScheduleofInvestmentinJointVenturesDetails INVESTMENT IN REAL ESTATE PROPERTIES - Schedule of Investment in Joint Ventures (Details) Details 54 false false R55.htm 9954495 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Investment in Unconsolidated Joint Venture Narrative (Details) Sheet http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails INVESTMENT IN REAL ESTATE PROPERTIES - Investment in Unconsolidated Joint Venture Narrative (Details) Details 55 false false R56.htm 9954496 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Summarized Financial Information for Enlivant Joint Venture (Details) Sheet http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialInformationforEnlivantJointVentureDetails INVESTMENT IN REAL ESTATE PROPERTIES - Summarized Financial Information for Enlivant Joint Venture (Details) Details 56 false false R57.htm 9954497 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Net Investment in Sales-Type Lease Narrative (Details) Sheet http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESNetInvestmentinSalesTypeLeaseNarrativeDetails INVESTMENT IN REAL ESTATE PROPERTIES - Net Investment in Sales-Type Lease Narrative (Details) Details 57 false false R58.htm 9954498 - Disclosure - IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS - Narrative (Details) Sheet http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSNarrativeDetails IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS - Narrative (Details) Details 58 false false R59.htm 9954499 - Disclosure - IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS - Dispositions (Details) Sheet http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSDispositionsDetails IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS - Dispositions (Details) Details 59 false false R60.htm 9954500 - Disclosure - INTANGIBLE ASSETS AND LIABILITIES - Intangible Assets and Liabilities (Details) Sheet http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESIntangibleAssetsandLiabilitiesDetails INTANGIBLE ASSETS AND LIABILITIES - Intangible Assets and Liabilities (Details) Details 60 false false R61.htm 9954501 - Disclosure - INTANGIBLE ASSETS AND LIABILITIES - Real Estate Intangible Amortization (Details) Sheet http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRealEstateIntangibleAmortizationDetails INTANGIBLE ASSETS AND LIABILITIES - Real Estate Intangible Amortization (Details) Details 61 false false R62.htm 9954502 - Disclosure - INTANGIBLE ASSETS AND LIABILITIES - Remaining Unamortized Balance for Outstanding Intangible Assets and Liabilities (Details) Sheet http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRemainingUnamortizedBalanceforOutstandingIntangibleAssetsandLiabilitiesDetails INTANGIBLE ASSETS AND LIABILITIES - Remaining Unamortized Balance for Outstanding Intangible Assets and Liabilities (Details) Details 62 false false R63.htm 9954503 - Disclosure - LOANS RECEIVABLE AND OTHER INVESTMENTS - Composition of Loans Receivable and Other Investments (Details) Sheet http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails LOANS RECEIVABLE AND OTHER INVESTMENTS - Composition of Loans Receivable and Other Investments (Details) Details 63 false false R64.htm 9954504 - Disclosure - LOANS RECEIVABLE AND OTHER INVESTMENTS - Narrative (Details) Sheet http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSNarrativeDetails LOANS RECEIVABLE AND OTHER INVESTMENTS - Narrative (Details) Details 64 false false R65.htm 9954505 - Disclosure - LOANS RECEIVABLE AND OTHER INVESTMENTS - Schedule of Additional Information Regarding the Company's Loans Receivable (Details) Sheet http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails LOANS RECEIVABLE AND OTHER INVESTMENTS - Schedule of Additional Information Regarding the Company's Loans Receivable (Details) Details 65 false false R66.htm 9954506 - Disclosure - DEBT - Secured Indebtedness (Details) Sheet http://www.sabrahealth.com/role/DEBTSecuredIndebtednessDetails DEBT - Secured Indebtedness (Details) Details 66 false false R67.htm 9954507 - Disclosure - DEBT - Secured Indebtedness Narrative (Details) Sheet http://www.sabrahealth.com/role/DEBTSecuredIndebtednessNarrativeDetails DEBT - Secured Indebtedness Narrative (Details) Details 67 false false R68.htm 9954508 - Disclosure - DEBT - Senior Unsecured Notes (Details) Notes http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails DEBT - Senior Unsecured Notes (Details) Details 68 false false R69.htm 9954509 - Disclosure - DEBT - Senior Unsecured Notes Narrative (Details) Notes http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails DEBT - Senior Unsecured Notes Narrative (Details) Details 69 false false R70.htm 9954510 - Disclosure - DEBT - Credit Agreement Narrative (Details) Sheet http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails DEBT - Credit Agreement Narrative (Details) Details 70 false false R71.htm 9954511 - Disclosure - DEBT - Interest Expense Narrative (Details) Sheet http://www.sabrahealth.com/role/DEBTInterestExpenseNarrativeDetails DEBT - Interest Expense Narrative (Details) Details 71 false false R72.htm 9954512 - Disclosure - DEBT - Schedule of Maturities for Outstanding Debt (Details) Sheet http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails DEBT - Schedule of Maturities for Outstanding Debt (Details) Details 72 false false R73.htm 9954513 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS - Narrative (Details) Sheet http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails DERIVATIVE AND HEDGING INSTRUMENTS - Narrative (Details) Details 73 false false R74.htm 9954514 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS - Notional Amounts of Derivative Instruments (Details) Sheet http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountsofDerivativeInstrumentsDetails DERIVATIVE AND HEDGING INSTRUMENTS - Notional Amounts of Derivative Instruments (Details) Details 74 false false R75.htm 9954515 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS - Summary of Derivative and Financial Instruments Designated as Hedging Instruments (Details) Sheet http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSSummaryofDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails DERIVATIVE AND HEDGING INSTRUMENTS - Summary of Derivative and Financial Instruments Designated as Hedging Instruments (Details) Details 75 false false R76.htm 9954516 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS - Effect of Derivative Financial Instruments on the Condensed Consolidated Statements of Income and Condensed Consolidated Statements of Equity (Details) Sheet http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofIncomeandCondensedConsolidatedStatementsofEquityDetails DERIVATIVE AND HEDGING INSTRUMENTS - Effect of Derivative Financial Instruments on the Condensed Consolidated Statements of Income and Condensed Consolidated Statements of Equity (Details) Details 76 false false R77.htm 9954517 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS - Gross Presentation, Effects of Offsetting, and a Net Presentation of Derivatives (Details) Sheet http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandaNetPresentationofDerivativesDetails DERIVATIVE AND HEDGING INSTRUMENTS - Gross Presentation, Effects of Offsetting, and a Net Presentation of Derivatives (Details) Details 77 false false R78.htm 9954518 - Disclosure - FAIR VALUE DISCLOSURES - Narrative (Details) Sheet http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails FAIR VALUE DISCLOSURES - Narrative (Details) Details 78 false false R79.htm 9954519 - Disclosure - FAIR VALUE DISCLOSURES - Face Values, Carrying Amounts and Fair Values of Financial Instruments (Details) Sheet http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails FAIR VALUE DISCLOSURES - Face Values, Carrying Amounts and Fair Values of Financial Instruments (Details) Details 79 false false R80.htm 9954520 - Disclosure - FAIR VALUE DISCLOSURES - Fair Value of Financial Instruments (Details) Sheet http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails FAIR VALUE DISCLOSURES - Fair Value of Financial Instruments (Details) Details 80 false false R81.htm 9954521 - Disclosure - FAIR VALUE DISCLOSURES - Items Measured at Fair Value on a Recurring Basis (Details) Sheet http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails FAIR VALUE DISCLOSURES - Items Measured at Fair Value on a Recurring Basis (Details) Details 81 false false R82.htm 9954522 - Disclosure - EQUITY - Narrative (Details) Sheet http://www.sabrahealth.com/role/EQUITYNarrativeDetails EQUITY - Narrative (Details) Details 82 false false R83.htm 9954523 - Disclosure - EQUITY - Accumulated Other Comprehensive Income (Details) Sheet http://www.sabrahealth.com/role/EQUITYAccumulatedOtherComprehensiveIncomeDetails EQUITY - Accumulated Other Comprehensive Income (Details) Details 83 false false R84.htm 9954524 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) Sheet http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails STOCK-BASED COMPENSATION - Narrative (Details) Details 84 false false R85.htm 9954525 - Disclosure - STOCK-BASED COMPENSATION - Restricted Stock Units Activity (Details) Sheet http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsActivityDetails STOCK-BASED COMPENSATION - Restricted Stock Units Activity (Details) Details 85 false false R86.htm 9954526 - Disclosure - STOCK-BASED COMPENSATION - Assumptions Used in Total Stockholder Return-Based Stock Units Valuation (Details) Sheet http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedinTotalStockholderReturnBasedStockUnitsValuationDetails STOCK-BASED COMPENSATION - Assumptions Used in Total Stockholder Return-Based Stock Units Valuation (Details) Details 86 false false R87.htm 9954527 - Disclosure - INCOME TAXES - Provision for Income Tax Expense (Details) Sheet http://www.sabrahealth.com/role/INCOMETAXESProvisionforIncomeTaxExpenseDetails INCOME TAXES - Provision for Income Tax Expense (Details) Details 87 false false R88.htm 9954528 - Disclosure - INCOME TAXES - Deferred Taxes (Details) Sheet http://www.sabrahealth.com/role/INCOMETAXESDeferredTaxesDetails INCOME TAXES - Deferred Taxes (Details) Details 88 false false R89.htm 9954529 - Disclosure - INCOME TAXES - Narrative (Details) Sheet http://www.sabrahealth.com/role/INCOMETAXESNarrativeDetails INCOME TAXES - Narrative (Details) Details 89 false false R90.htm 9954530 - Disclosure - EARNINGS PER COMMON SHARE - Computation of Basic and Diluted Earnings Per Share (Details) Sheet http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHAREComputationofBasicandDilutedEarningsPerShareDetails EARNINGS PER COMMON SHARE - Computation of Basic and Diluted Earnings Per Share (Details) Details 90 false false R91.htm 9954531 - Disclosure - EARNINGS PER COMMON SHARE - Narrative (Details) Sheet http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHARENarrativeDetails EARNINGS PER COMMON SHARE - Narrative (Details) Details 91 false false R92.htm 9954532 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://www.sabrahealth.com/role/SUBSEQUENTEVENTSDetails SUBSEQUENT EVENTS (Details) Details http://www.sabrahealth.com/role/SUBSEQUENTEVENTS 92 false false R93.htm 9954533 - Disclosure - SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION - Summary of Real Estate Properties (Details) Sheet http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION - Summary of Real Estate Properties (Details) Details 93 false false R94.htm 9954534 - Disclosure - SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION - Rollforward of Real Estate and Accumulated Depreciation (Details) Sheet http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONRollforwardofRealEstateandAccumulatedDepreciationDetails SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION - Rollforward of Real Estate and Accumulated Depreciation (Details) Details 94 false false R95.htm 9954535 - Disclosure - SCHEDULE IV - MORTGAGE LOANS ON REAL ESTATE (Details) Sheet http://www.sabrahealth.com/role/SCHEDULEIVMORTGAGELOANSONREALESTATEDetails SCHEDULE IV - MORTGAGE LOANS ON REAL ESTATE (Details) Details http://www.sabrahealth.com/role/SCHEDULEIVMORTGAGELOANSONREALESTATE 95 false false All Reports Book All Reports sbra-20231231.htm sbra-20231231.xsd sbra-20231231_cal.xml sbra-20231231_def.xml sbra-20231231_lab.xml sbra-20231231_pre.xml sbra-20231231_g1.jpg http://fasb.org/srt/2023 http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 119 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "sbra-20231231.htm": { "nsprefix": "sbra", "nsuri": "http://www.sabrahealth.com/20231231", "dts": { "inline": { "local": [ "sbra-20231231.htm" ] }, "schema": { "local": [ "sbra-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "sbra-20231231_cal.xml" ] }, "definitionLink": { "local": [ "sbra-20231231_def.xml" ] }, "labelLink": { "local": [ "sbra-20231231_lab.xml" ] }, "presentationLink": { "local": [ "sbra-20231231_pre.xml" ] } }, "keyStandard": 407, "keyCustom": 79, "axisStandard": 43, "axisCustom": 1, "memberStandard": 52, "memberCustom": 416, "hidden": { "total": 19, "http://fasb.org/us-gaap/2023": 15, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 751, "entityCount": 1, "segmentCount": 484, "elementCount": 1250, "unitCount": 16, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 4250, "http://fasb.org/srt/2023": 406, "http://xbrl.sec.gov/dei/2023": 38, "http://xbrl.sec.gov/ecd/2023": 4 }, "report": { "R1": { "role": "http://www.sabrahealth.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.sabrahealth.com/role/AuditInformation", "longName": "0000002 - Document - Audit Information", "shortName": "Audit Information", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS", "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RealEstateInvestmentPropertyNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "unique": true } }, "R4": { "role": "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RealEstateInvestmentPropertyAccumulatedDepreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "unique": true } }, "R5": { "role": "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS", "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF INCOME (LOSS)", "shortName": "CONSOLIDATED STATEMENTS OF INCOME (LOSS)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseLeaseIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseLeaseIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "unique": true } }, "R7": { "role": "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical", "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical)", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "link:footnote", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "link:footnote", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY", "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS OF EQUITY", "shortName": "CONSOLIDATED STATEMENTS OF EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:SharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-15", "name": "us-gaap:SharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYParenthetical", "longName": "0000009 - Statement - CONSOLIDATED STATEMENTS OF EQUITY (Parenthetical)", "shortName": "CONSOLIDATED STATEMENTS OF EQUITY (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true }, "uniqueAnchor": null }, "R10": { "role": "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "0000010 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "sbra:NonCashRentalAndRelatedRevenuesAdjustments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "unique": true } }, "R11": { "role": "http://www.sabrahealth.com/role/BUSINESS", "longName": "0000011 - Disclosure - BUSINESS", "shortName": "BUSINESS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "longName": "0000012 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATED", "longName": "0000013 - Disclosure - RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED)", "shortName": "RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIES", "longName": "0000014 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES", "shortName": "INVESTMENT IN REAL ESTATE PROPERTIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RealEstateDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RealEstateDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONS", "longName": "0000015 - Disclosure - IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS", "shortName": "IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIES", "longName": "0000016 - Disclosure - INTANGIBLE ASSETS AND LIABILITIES", "shortName": "INTANGIBLE ASSETS AND LIABILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "sbra:IntangibleAssetsAndIntangibleLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "sbra:IntangibleAssetsAndIntangibleLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTS", "longName": "0000017 - Disclosure - LOANS RECEIVABLE AND OTHER INVESTMENTS", "shortName": "LOANS RECEIVABLE AND OTHER INVESTMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.sabrahealth.com/role/DEBT", "longName": "0000018 - Disclosure - DEBT", "shortName": "DEBT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTS", "longName": "0000019 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS", "shortName": "DERIVATIVE AND HEDGING INSTRUMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURES", "longName": "0000020 - Disclosure - FAIR VALUE DISCLOSURES", "shortName": "FAIR VALUE DISCLOSURES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.sabrahealth.com/role/EQUITY", "longName": "0000021 - Disclosure - EQUITY", "shortName": "EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATION", "longName": "0000022 - Disclosure - STOCK-BASED COMPENSATION", "shortName": "STOCK-BASED COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.sabrahealth.com/role/INCOMETAXES", "longName": "0000023 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHARE", "longName": "0000024 - Disclosure - EARNINGS PER COMMON SHARE", "shortName": "EARNINGS PER COMMON SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.sabrahealth.com/role/COMMITMENTSANDCONTINGENCIES", "longName": "0000025 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.sabrahealth.com/role/SUBSEQUENTEVENTS", "longName": "0000026 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATION", "longName": "0000027 - Disclosure - SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION", "shortName": "SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "srt:RealEstateAndAccumulatedDepreciationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "srt:RealEstateAndAccumulatedDepreciationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.sabrahealth.com/role/SCHEDULEIVMORTGAGELOANSONREALESTATE", "longName": "0000028 - Disclosure - SCHEDULE IV - MORTGAGE LOANS ON REAL ESTATE", "shortName": "SCHEDULE IV - MORTGAGE LOANS ON REAL ESTATE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "srt:MortgageLoansOnRealEstateByLoanDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "srt:MortgageLoansOnRealEstateByLoanDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R29": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true }, "uniqueAnchor": null }, "R30": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "c-4", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrAdoptedFlag", "ecd:Rule10b51ArrTrmntdFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrAdoptedFlag", "ecd:Rule10b51ArrTrmntdFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "longName": "9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables", "longName": "9954472 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDTables", "longName": "9954473 - Disclosure - RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) (Tables)", "shortName": "RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESTables", "longName": "9954474 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES (Tables)", "shortName": "INVESTMENT IN REAL ESTATE PROPERTIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSTables", "longName": "9954475 - Disclosure - IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS (Tables)", "shortName": "IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESTables", "longName": "9954476 - Disclosure - INTANGIBLE ASSETS AND LIABILITIES (Tables)", "shortName": "INTANGIBLE ASSETS AND LIABILITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSTables", "longName": "9954477 - Disclosure - LOANS RECEIVABLE AND OTHER INVESTMENTS (Tables)", "shortName": "LOANS RECEIVABLE AND OTHER INVESTMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.sabrahealth.com/role/DEBTTables", "longName": "9954478 - Disclosure - DEBT (Tables)", "shortName": "DEBT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSTables", "longName": "9954479 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS (Tables)", "shortName": "DERIVATIVE AND HEDGING INSTRUMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESTables", "longName": "9954480 - Disclosure - FAIR VALUE DISCLOSURES (Tables)", "shortName": "FAIR VALUE DISCLOSURES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.sabrahealth.com/role/EQUITYTables", "longName": "9954481 - Disclosure - EQUITY (Tables)", "shortName": "EQUITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONTables", "longName": "9954482 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "shortName": "STOCK-BASED COMPENSATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.sabrahealth.com/role/INCOMETAXESTables", "longName": "9954483 - Disclosure - INCOME TAXES (Tables)", "shortName": "INCOME TAXES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHARETables", "longName": "9954484 - Disclosure - EARNINGS PER COMMON SHARE (Tables)", "shortName": "EARNINGS PER COMMON SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "longName": "9954485 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-5", "name": "sbra:RealEstateInvestmentsJointVenturesNumber", "unitRef": "investment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "sbra:RealEstateInvestmentsJointVenturesNumber", "span", "div", "us-gaap:ConsolidationVariableInterestEntityPolicy", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "sbra:RealEstateInvestmentsJointVenturesNumber", "unitRef": "investment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "sbra:RealEstateInvestmentsJointVenturesNumber", "span", "div", "us-gaap:ConsolidationVariableInterestEntityPolicy", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleDetails", "longName": "9954486 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails", "longName": "9954487 - Disclosure - RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) - Narrative (Details)", "shortName": "RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED) - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-74", "name": "us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "unique": true } }, "R48": { "role": "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails", "longName": "9954488 - Disclosure - RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED)- Purchase Price Allocation for Recent Real Estate Acquisitions (Details)", "shortName": "RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED)- Purchase Price Allocation for Recent Real Estate Acquisitions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-64", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLand", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-64", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLand", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails", "longName": "9954489 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Real Estate Properties Held for Investment (Details)", "shortName": "INVESTMENT IN REAL ESTATE PROPERTIES - Real Estate Properties Held for Investment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:BuildingsAndImprovementsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:BuildingsAndImprovementsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails", "longName": "9954490 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Operating Leases Narrative (Details)", "shortName": "INVESTMENT IN REAL ESTATE PROPERTIES - Operating Leases Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:SecurityDepositLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "unique": true } }, "R51": { "role": "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESFutureMinimumRentalPaymentsfromNonCancelableOperatingLeasesDetails", "longName": "9954491 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Future Minimum Rental Payments from Non-Cancelable Operating Leases (Details)", "shortName": "INVESTMENT IN REAL ESTATE PROPERTIES - Future Minimum Rental Payments from Non-Cancelable Operating Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSeniorHousingManagedCommunitiesNarrativeDetails", "longName": "9954492 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Senior Housing - Managed Communities Narrative (Details)", "shortName": "INVESTMENT IN REAL ESTATE PROPERTIES - Senior Housing - Managed Communities Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-99", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "unique": true } }, "R53": { "role": "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESCapitalandOtherExpendituresNarrativeDetails", "longName": "9954493 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Capital and Other Expenditures Narrative (Details)", "shortName": "INVESTMENT IN REAL ESTATE PROPERTIES - Capital and Other Expenditures Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CapitalExpendituresIncurredButNotYetPaid", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CapitalExpendituresIncurredButNotYetPaid", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESScheduleofInvestmentinJointVenturesDetails", "longName": "9954494 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Schedule of Investment in Joint Ventures (Details)", "shortName": "INVESTMENT IN REAL ESTATE PROPERTIES - Schedule of Investment in Joint Ventures (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:EquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:EquityMethodInvestmentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true }, "uniqueAnchor": null }, "R55": { "role": "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails", "longName": "9954495 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Investment in Unconsolidated Joint Venture Narrative (Details)", "shortName": "INVESTMENT IN REAL ESTATE PROPERTIES - Investment in Unconsolidated Joint Venture Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:EquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:EquityMethodInvestmentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-117", "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "unique": true } }, "R56": { "role": "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialInformationforEnlivantJointVentureDetails", "longName": "9954496 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Summarized Financial Information for Enlivant Joint Venture (Details)", "shortName": "INVESTMENT IN REAL ESTATE PROPERTIES - Summarized Financial Information for Enlivant Joint Venture (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:Assets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-125", "name": "sbra:IncomeLossFromEquityMethodInvestmentsBeforeBasisAdjustments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "unique": true } }, "R57": { "role": "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESNetInvestmentinSalesTypeLeaseNarrativeDetails", "longName": "9954497 - Disclosure - INVESTMENT IN REAL ESTATE PROPERTIES - Net Investment in Sales-Type Lease Narrative (Details)", "shortName": "INVESTMENT IN REAL ESTATE PROPERTIES - Net Investment in Sales-Type Lease Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-128", "name": "us-gaap:SalesTypeLeaseNetInvestmentInLease", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "unique": true } }, "R58": { "role": "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSNarrativeDetails", "longName": "9954498 - Disclosure - IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS - Narrative (Details)", "shortName": "IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ImpairmentOfRealEstate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-130", "name": "sbra:NumberOfRealEstatePropertiesImpaired", "unitRef": "facility", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "unique": true } }, "R59": { "role": "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSDispositionsDetails", "longName": "9954499 - Disclosure - IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS - Dispositions (Details)", "shortName": "IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS - Dispositions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-1", "name": "sbra:DisposalGroupIncludingDiscontinuedOperationsNumberOfProperties", "unitRef": "facility", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "sbra:DisposalGroupIncludingDiscontinuedOperationsNumberOfProperties", "unitRef": "facility", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESIntangibleAssetsandLiabilitiesDetails", "longName": "9954500 - Disclosure - INTANGIBLE ASSETS AND LIABILITIES - Intangible Assets and Liabilities (Details)", "shortName": "INTANGIBLE ASSETS AND LIABILITIES - Intangible Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRealEstateIntangibleAmortizationDetails", "longName": "9954501 - Disclosure - INTANGIBLE ASSETS AND LIABILITIES - Real Estate Intangible Amortization (Details)", "shortName": "INTANGIBLE ASSETS AND LIABILITIES - Real Estate Intangible Amortization (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfAboveAndBelowMarketLeases", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "sbra:ScheduleOfRealEstateIntangiblesAmortizationIncomeAndExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfAboveAndBelowMarketLeases", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "sbra:ScheduleOfRealEstateIntangiblesAmortizationIncomeAndExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRemainingUnamortizedBalanceforOutstandingIntangibleAssetsandLiabilitiesDetails", "longName": "9954502 - Disclosure - INTANGIBLE ASSETS AND LIABILITIES - Remaining Unamortized Balance for Outstanding Intangible Assets and Liabilities (Details)", "shortName": "INTANGIBLE ASSETS AND LIABILITIES - Remaining Unamortized Balance for Outstanding Intangible Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:BelowMarketLeaseFutureAmortizationIncomeTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:BelowMarketLeaseFutureAmortizationIncomeTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails", "longName": "9954503 - Disclosure - LOANS RECEIVABLE AND OTHER INVESTMENTS - Composition of Loans Receivable and Other Investments (Details)", "shortName": "LOANS RECEIVABLE AND OTHER INVESTMENTS - Composition of Loans Receivable and Other Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-5", "name": "sbra:FinancingReceivableNumberOfLoans", "unitRef": "loan", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "sbra:FinancingReceivableNumberOfLoans", "unitRef": "loan", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSNarrativeDetails", "longName": "9954504 - Disclosure - LOANS RECEIVABLE AND OTHER INVESTMENTS - Narrative (Details)", "shortName": "LOANS RECEIVABLE AND OTHER INVESTMENTS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-144", "name": "us-gaap:OtherCommitment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-144", "name": "us-gaap:OtherCommitment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails", "longName": "9954505 - Disclosure - LOANS RECEIVABLE AND OTHER INVESTMENTS - Schedule of Additional Information Regarding the Company's Loans Receivable (Details)", "shortName": "LOANS RECEIVABLE AND OTHER INVESTMENTS - Schedule of Additional Information Regarding the Company's Loans Receivable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:FinancingReceivableAllowanceForCreditLosses", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "sbra:ScheduleOfAdditionalInformationLoansAndFinancingReceivableTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FinancingReceivableAllowanceForCreditLossesPeriodIncreaseDecrease", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "sbra:ScheduleOfAdditionalInformationLoansAndFinancingReceivableTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "unique": true } }, "R66": { "role": "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessDetails", "longName": "9954506 - Disclosure - DEBT - Secured Indebtedness (Details)", "shortName": "DEBT - Secured Indebtedness (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:DeferredFinanceCostsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-149", "name": "us-gaap:LongtermDebtPercentageBearingFixedInterestAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "unique": true } }, "R67": { "role": "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessNarrativeDetails", "longName": "9954507 - Disclosure - DEBT - Secured Indebtedness Narrative (Details)", "shortName": "DEBT - Secured Indebtedness Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RepaymentsOfSecuredDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-153", "name": "us-gaap:RepaymentsOfSecuredDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "unique": true } }, "R68": { "role": "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails", "longName": "9954508 - Disclosure - DEBT - Senior Unsecured Notes (Details)", "shortName": "DEBT - Senior Unsecured Notes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-163", "name": "us-gaap:SeniorNotes", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "unique": true } }, "R69": { "role": "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails", "longName": "9954509 - Disclosure - DEBT - Senior Unsecured Notes Narrative (Details)", "shortName": "DEBT - Senior Unsecured Notes Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProceedsFromIssuanceOfUnsecuredDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-165", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "unique": true } }, "R70": { "role": "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "longName": "9954510 - Disclosure - DEBT - Credit Agreement Narrative (Details)", "shortName": "DEBT - Credit Agreement Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-206", "name": "us-gaap:DeferredFinanceCostsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "unique": true } }, "R71": { "role": "http://www.sabrahealth.com/role/DEBTInterestExpenseNarrativeDetails", "longName": "9954511 - Disclosure - DEBT - Interest Expense Narrative (Details)", "shortName": "DEBT - Interest Expense Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InterestExpenseDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:InterestPayableCurrentAndNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "unique": true } }, "R72": { "role": "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails", "longName": "9954512 - Disclosure - DEBT - Schedule of Maturities for Outstanding Debt (Details)", "shortName": "DEBT - Schedule of Maturities for Outstanding Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails", "longName": "9954513 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS - Narrative (Details)", "shortName": "DERIVATIVE AND HEDGING INSTRUMENTS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:DerivativeLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-276", "name": "us-gaap:DerivativeLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "unique": true } }, "R74": { "role": "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountsofDerivativeInstrumentsDetails", "longName": "9954514 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS - Notional Amounts of Derivative Instruments (Details)", "shortName": "DERIVATIVE AND HEDGING INSTRUMENTS - Notional Amounts of Derivative Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-235", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-235", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSSummaryofDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails", "longName": "9954515 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS - Summary of Derivative and Financial Instruments Designated as Hedging Instruments (Details)", "shortName": "DERIVATIVE AND HEDGING INSTRUMENTS - Summary of Derivative and Financial Instruments Designated as Hedging Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:DerivativeAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-252", "name": "us-gaap:DerivativeAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "unique": true } }, "R76": { "role": "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofIncomeandCondensedConsolidatedStatementsofEquityDetails", "longName": "9954516 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS - Effect of Derivative Financial Instruments on the Condensed Consolidated Statements of Income and Condensed Consolidated Statements of Equity (Details)", "shortName": "DERIVATIVE AND HEDGING INSTRUMENTS - Effect of Derivative Financial Instruments on the Condensed Consolidated Statements of Income and Condensed Consolidated Statements of Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-1", "name": "sbra:OtherComprehensiveIncomeLossCashFlowAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "sbra:OtherComprehensiveIncomeLossCashFlowAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandaNetPresentationofDerivativesDetails", "longName": "9954517 - Disclosure - DERIVATIVE AND HEDGING INSTRUMENTS - Gross Presentation, Effects of Offsetting, and a Net Presentation of Derivatives (Details)", "shortName": "DERIVATIVE AND HEDGING INSTRUMENTS - Gross Presentation, Effects of Offsetting, and a Net Presentation of Derivatives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails", "longName": "9954518 - Disclosure - FAIR VALUE DISCLOSURES - Narrative (Details)", "shortName": "FAIR VALUE DISCLOSURES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-277", "name": "sbra:FinancingReceivableMeasurementInput", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-277", "name": "sbra:FinancingReceivableMeasurementInput", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R79": { "role": "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails", "longName": "9954519 - Disclosure - FAIR VALUE DISCLOSURES - Face Values, Carrying Amounts and Fair Values of Financial Instruments (Details)", "shortName": "FAIR VALUE DISCLOSURES - Face Values, Carrying Amounts and Fair Values of Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-5", "name": "sbra:FinancingReceivablePrincipalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-151", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "unique": true } }, "R80": { "role": "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails", "longName": "9954520 - Disclosure - FAIR VALUE DISCLOSURES - Fair Value of Financial Instruments (Details)", "shortName": "FAIR VALUE DISCLOSURES - Fair Value of Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-293", "name": "us-gaap:LoansReceivableFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-293", "name": "us-gaap:LoansReceivableFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R81": { "role": "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails", "longName": "9954521 - Disclosure - FAIR VALUE DISCLOSURES - Items Measured at Fair Value on a Recurring Basis (Details)", "shortName": "FAIR VALUE DISCLOSURES - Items Measured at Fair Value on a Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:DerivativeAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-305", "name": "us-gaap:DerivativeAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "unique": true } }, "R82": { "role": "http://www.sabrahealth.com/role/EQUITYNarrativeDetails", "longName": "9954522 - Disclosure - EQUITY - Narrative (Details)", "shortName": "EQUITY - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R83": { "role": "http://www.sabrahealth.com/role/EQUITYAccumulatedOtherComprehensiveIncomeDetails", "longName": "9954523 - Disclosure - EQUITY - Accumulated Other Comprehensive Income (Details)", "shortName": "EQUITY - Accumulated Other Comprehensive Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-336", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "unique": true } }, "R84": { "role": "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "longName": "9954524 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)", "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R85": { "role": "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsActivityDetails", "longName": "9954525 - Disclosure - STOCK-BASED COMPENSATION - Restricted Stock Units Activity (Details)", "shortName": "STOCK-BASED COMPENSATION - Restricted Stock Units Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "c-346", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-333", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "unique": true } }, "R86": { "role": "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedinTotalStockholderReturnBasedStockUnitsValuationDetails", "longName": "9954526 - Disclosure - STOCK-BASED COMPENSATION - Assumptions Used in Total Stockholder Return-Based Stock Units Valuation (Details)", "shortName": "STOCK-BASED COMPENSATION - Assumptions Used in Total Stockholder Return-Based Stock Units Valuation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "c-348", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-348", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R87": { "role": "http://www.sabrahealth.com/role/INCOMETAXESProvisionforIncomeTaxExpenseDetails", "longName": "9954527 - Disclosure - INCOME TAXES - Provision for Income Tax Expense (Details)", "shortName": "INCOME TAXES - Provision for Income Tax Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R88": { "role": "http://www.sabrahealth.com/role/INCOMETAXESDeferredTaxesDetails", "longName": "9954528 - Disclosure - INCOME TAXES - Deferred Taxes (Details)", "shortName": "INCOME TAXES - Deferred Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:DeferredTaxAssetsLiabilitiesNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:DeferredTaxAssetsLiabilitiesNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R89": { "role": "http://www.sabrahealth.com/role/INCOMETAXESNarrativeDetails", "longName": "9954529 - Disclosure - INCOME TAXES - Narrative (Details)", "shortName": "INCOME TAXES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R90": { "role": "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHAREComputationofBasicandDilutedEarningsPerShareDetails", "longName": "9954530 - Disclosure - EARNINGS PER COMMON SHARE - Computation of Basic and Diluted Earnings Per Share (Details)", "shortName": "EARNINGS PER COMMON SHARE - Computation of Basic and Diluted Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "unique": true } }, "R91": { "role": "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHARENarrativeDetails", "longName": "9954531 - Disclosure - EARNINGS PER COMMON SHARE - Narrative (Details)", "shortName": "EARNINGS PER COMMON SHARE - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "c-357", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-357", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R92": { "role": "http://www.sabrahealth.com/role/SUBSEQUENTEVENTSDetails", "longName": "9954532 - Disclosure - SUBSEQUENT EVENTS (Details)", "shortName": "SUBSEQUENT EVENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-361", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "unique": true } }, "R93": { "role": "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails", "longName": "9954533 - Disclosure - SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION - Summary of Real Estate Properties (Details)", "shortName": "SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION - Summary of Real Estate Properties (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "c-5", "name": "srt:RealEstateAndAccumulatedDepreciationAmountOfEncumbrances", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "srt:RealEstateAndAccumulatedDepreciationAmountOfEncumbrances", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true, "unique": true } }, "R94": { "role": "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONRollforwardofRealEstateandAccumulatedDepreciationDetails", "longName": "9954534 - Disclosure - SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION - Rollforward of Real Estate and Accumulated Depreciation (Details)", "shortName": "SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION - Rollforward of Real Estate and Accumulated Depreciation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:RealEstateGrossAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RealEstateOtherAcquisitions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "unique": true } }, "R95": { "role": "http://www.sabrahealth.com/role/SCHEDULEIVMORTGAGELOANSONREALESTATEDetails", "longName": "9954535 - Disclosure - SCHEDULE IV - MORTGAGE LOANS ON REAL ESTATE (Details)", "shortName": "SCHEDULE IV - MORTGAGE LOANS ON REAL ESTATE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "c-5", "name": "srt:MortgageLoansOnRealEstateFaceAmountOfMortgages", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "srt:MortgageLoansOnRealEstateByLoanDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "srt:MortgageLoansOnRealEstateFederalIncomeTaxBasis1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "srt:MortgageLoansOnRealEstateByLoanDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sbra-20231231.htm", "unique": true } } }, "tag": { "sbra_A2019ATMProgramForwardFeatureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "A2019ATMProgramForwardFeatureMember", "presentation": [ "http://www.sabrahealth.com/role/EQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2019 ATM Program - Forward Feature", "label": "2019 ATM Program - Forward Feature [Member]", "documentation": "2019 ATM Program - Forward Feature" } } }, "auth_ref": [] }, "sbra_A2019ATMProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "A2019ATMProgramMember", "presentation": [ "http://www.sabrahealth.com/role/EQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2019 ATM Program", "label": "2019 ATM Program [Member]", "documentation": "2019 ATM Program" } } }, "auth_ref": [] }, "sbra_A3.90SeniorUnsecuredNotesDue2029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "A3.90SeniorUnsecuredNotesDue2029Member", "presentation": [ "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.90% senior unsecured notes due 2029", "label": "3.90% Senior Unsecured Notes Due 2029 [Member]", "documentation": "Senior Unsecured Notes Due 2029 [Member]" } } }, "auth_ref": [] }, "sbra_A320SeniorUnsecuredNotesDue2031Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "A320SeniorUnsecuredNotesDue2031Member", "presentation": [ "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.20% senior unsecured notes due 2031", "label": "3.20% Senior Unsecured Notes Due 2031 [Member]", "documentation": "3.20% Senior Unsecured Notes Due 2031" } } }, "auth_ref": [] }, "sbra_A4.80SeniorUnsecuredNotesDue2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "A4.80SeniorUnsecuredNotesDue2024Member", "presentation": [ "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.80% senior unsecured notes due 2024", "label": "4.80% Senior Unsecured Notes Due 2024 [Member]", "documentation": "4.80% Senior Unsecured Notes Due 2024 [Member]" } } }, "auth_ref": [] }, "sbra_A5.125SeniorUnsecuredNotesDue2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "A5.125SeniorUnsecuredNotesDue2026Member", "presentation": [ "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.125% senior unsecured notes due 2026", "label": "5.125% Senior Unsecured Notes Due 2026 [Member]", "documentation": "5.125% Senior Unsecured Notes Due 2026 [Member]" } } }, "auth_ref": [] }, "sbra_A5.375SeniorUnsecuredNotesDue2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "A5.375SeniorUnsecuredNotesDue2023Member", "presentation": [ "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.375% senior unsecured notes due 2023", "label": "5.375% Senior Unsecured Notes Due 2023 [Member]", "documentation": "5.375% Senior Unsecured Notes Due 2023 [Member]" } } }, "auth_ref": [] }, "sbra_A5.88SeniorUnsecuredNotesDue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "A5.88SeniorUnsecuredNotesDue2027Member", "presentation": [ "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.88% senior unsecured notes due 2027", "label": "5.88% Senior Unsecured Notes Due 2027 [Member]", "documentation": "5.88% Senior Unsecured Notes Due 2027" } } }, "auth_ref": [] }, "sbra_ATMProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ATMProgramMember", "presentation": [ "http://www.sabrahealth.com/role/EQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ATM Program", "label": "ATM Program [Member]", "documentation": "ATM Program [Member]" } } }, "auth_ref": [] }, "us-gaap_AboveMarketLeasesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AboveMarketLeasesMember", "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESIntangibleAssetsandLiabilitiesDetails", "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRealEstateIntangibleAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Above market leases", "label": "Above Market Leases [Member]", "documentation": "Leases acquired as part of a real property acquisition at above market lease rate." } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "sbra_AccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "AccountingPoliciesLineItems", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Line Items]", "label": "Accounting Policies [Line Items]", "documentation": "Accounting Policies" } } }, "auth_ref": [] }, "sbra_AccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "AccountingPoliciesTable", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Table]", "label": "Accounting Policies [Table]", "documentation": "Accounting Policies [Table]" } } }, "auth_ref": [] }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsNotesAndLoansReceivableLineItems", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails", "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSNarrativeDetails", "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails", "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receivable Type [Axis]", "label": "Receivable Type [Axis]", "documentation": "Information by type of receivable." } } }, "auth_ref": [ "r47" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued liabilities", "label": "Accounts Payable and Accrued Liabilities", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations." } } }, "auth_ref": [ "r145" ] }, "sbra_AccountsReceivablePrepaidExpensesDeferredFinancingCostsAndOtherAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "AccountsReceivablePrepaidExpensesDeferredFinancingCostsAndOtherAssetsNet", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, prepaid expenses and other assets, net", "label": "Accounts Receivable, Prepaid Expenses Deferred Financing Costs And Other Assets, Net", "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs. Also, includes the sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization." } } }, "auth_ref": [] }, "sbra_AccruedObligationsAssociatedWithRestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "AccruedObligationsAssociatedWithRestrictedCash", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash obligations", "label": "Accrued Obligations Associated With Restricted Cash", "documentation": "Accrued Obligations Associated With Restricted Cash" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDistributionsInExcessOfNetIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDistributionsInExcessOfNetIncome", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cumulative distributions in excess of net income", "label": "Accumulated Distributions in Excess of Net Income", "documentation": "The amount as of the balance sheet date by which cumulative distributions to shareholders (or partners) exceed retained earnings (or accumulated earnings)." } } }, "auth_ref": [ "r1069" ] }, "us-gaap_AccumulatedDistributionsInExcessOfNetIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDistributionsInExcessOfNetIncomeMember", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative Distributions in Excess of Net Income", "label": "Accumulated Distributions in Excess of Net Income [Member]", "documentation": "Cumulative distributions to shareholders (or partners) in excess of retained earnings (or accumulated earnings)." } } }, "auth_ref": [] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": [ "http://www.sabrahealth.com/role/EQUITYAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain on cash flow hedges", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r297", "r306", "r307", "r598", "r845", "r995" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.sabrahealth.com/role/EQUITYAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r305", "r306", "r633", "r635", "r636", "r637", "r638", "r639" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r48", "r49", "r174", "r287", "r680", "r711", "r712" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://www.sabrahealth.com/role/EQUITYAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r305", "r306", "r633", "r635", "r636", "r637", "r638", "r639" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY", "http://www.sabrahealth.com/role/EQUITYAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive (Loss) Income", "verboseLabel": "Total accumulated other comprehensive income", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r4", "r23", "r49", "r610", "r613", "r655", "r708", "r709", "r995", "r996", "r997", "r1008", "r1009", "r1010" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://www.sabrahealth.com/role/EQUITYAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation gain", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r6", "r23", "r49", "r306", "r307", "r635", "r636", "r637", "r638", "r639", "r995" ] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average amortization period of intangible assets", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r191" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r934" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r168", "r878", "r1072" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in\u00a0Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r567", "r568", "r569", "r723", "r1008", "r1009", "r1010", "r1046", "r1074" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r940" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r940" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r940" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r940" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r93", "r94", "r530" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r904", "r916", "r926", "r952" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r907", "r919", "r929", "r955" ] }, "sbra_AlamedaCAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "AlamedaCAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Alameda, CA", "label": "Alameda, CA [Member]", "documentation": "Alameda, CA" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r940" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r947" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r911", "r920", "r930", "r947", "r956", "r960", "r968" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r966" ] }, "sbra_AllenTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "AllenTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allen, TX", "label": "Allen, TX [Member]", "documentation": "Allen, TX" } } }, "auth_ref": [] }, "sbra_AlpenaMIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "AlpenaMIMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Alpena, MI", "label": "Alpena, MI [Member]", "documentation": "Alpena, MI" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "sbra_AmortizationAcceleratedLeaseIntangible": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "AmortizationAcceleratedLeaseIntangible", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRealEstateIntangibleAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accelerated amortization", "label": "Amortization, Accelerated, Lease Intangible", "documentation": "Amortization, Accelerated, Lease Intangible" } } }, "auth_ref": [] }, "us-gaap_AmortizationOfAboveAndBelowMarketLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfAboveAndBelowMarketLeases", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRealEstateIntangibleAmortizationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Increase (decrease) to rental income related to above/below market leases, net", "label": "Amortization of above and below Market Leases", "documentation": "Amount of non-cash amortization of intangible asset (liability) for above and below market leases." } } }, "auth_ref": [ "r1002" ] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.sabrahealth.com/role/DEBTInterestExpenseNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash interest expense", "label": "Amortization of Debt Issuance Costs and Discounts", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r492", "r641", "r858", "r859", "r1002" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRealEstateIntangibleAmortizationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Depreciation and amortization related to tenant origination and absorption costs and tenant relationship", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r14", "r78", "r81" ] }, "sbra_AnaheimCAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "AnaheimCAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Anaheim, CA", "label": "Anaheim, CA [Member]", "documentation": "Anaheim, CA" } } }, "auth_ref": [] }, "sbra_AnchorageAKMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "AnchorageAKMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Anchorage, AK", "label": "Anchorage, AK [Member]", "documentation": "Anchorage, AK" } } }, "auth_ref": [] }, "sbra_AndoverMAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "AndoverMAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Andover, MA", "label": "Andover, MA [Member]", "documentation": "Andover, MA" } } }, "auth_ref": [] }, "sbra_AnnandaleVAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "AnnandaleVAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annandale, VA", "label": "Annandale, VA [Member]", "documentation": "Annandale, VA" } } }, "auth_ref": [] }, "sbra_AnnvilleKYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "AnnvilleKYMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annville, KY", "label": "Annville, KY [Member]", "documentation": "Annville, KY" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHARENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Anti-dilutive securities not included in computation of diluted earnings per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r354" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHARENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r66" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHARENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHARENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r66" ] }, "sbra_ArlingtonTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ArlingtonTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Arlington, TX", "label": "Arlington, TX [Member]", "documentation": "Arlington, TX" } } }, "auth_ref": [] }, "sbra_AshlandMOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "AshlandMOMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ashland, MO", "label": "Ashland, MO [Member]", "documentation": "Ashland, MO" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialInformationforEnlivantJointVentureDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "verboseLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r214", "r282", "r324", "r362", "r382", "r388", "r404", "r457", "r458", "r460", "r461", "r462", "r464", "r466", "r468", "r469", "r596", "r599", "r630", "r675", "r757", "r878", "r893", "r1032", "r1033", "r1055" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "sbra_AuburnALMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "AuburnALMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Auburn, AL", "label": "Auburn, AL [Member]", "documentation": "Auburn, AL" } } }, "auth_ref": [] }, "sbra_AuditInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "AuditInformationAbstract", "lang": { "en-us": { "role": { "terseLabel": "Audit Information [Abstract]", "label": "Audit Information [Abstract]", "documentation": "Audit Information" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://www.sabrahealth.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r898", "r899", "r912" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://www.sabrahealth.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } }, "auth_ref": [ "r898", "r899", "r912" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://www.sabrahealth.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } }, "auth_ref": [ "r898", "r899", "r912" ] }, "sbra_AugustaGAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "AugustaGAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Augusta, GA", "label": "Augusta, GA [Member]", "documentation": "Augusta, GA" } } }, "auth_ref": [] }, "sbra_AugustaMEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "AugustaMEMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Augusta, ME", "label": "Augusta, ME [Member]", "documentation": "Augusta, ME" } } }, "auth_ref": [] }, "sbra_AuroraCOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "AuroraCOMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aurora, CO", "label": "Aurora, CO [Member]", "documentation": "Aurora, CO" } } }, "auth_ref": [] }, "sbra_AvamereFamilyOfCompaniesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "AvamereFamilyOfCompaniesMember", "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRealEstateIntangibleAmortizationDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Avamere", "label": "Avamere Family Of Companies [Member]", "documentation": "Avamere Family Of Companies" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r963" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r964" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r959" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r959" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r959" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r959" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r959" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r959" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.sabrahealth.com/role/EQUITYNarrativeDetails", "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedinTotalStockholderReturnBasedStockUnitsValuationDetails", "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r534", "r535", "r536", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r558", "r559", "r560", "r561", "r562" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r962" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r961" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r960" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r960" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSSummaryofDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSSummaryofDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r116", "r121" ] }, "sbra_BaldwinParkCAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "BaldwinParkCAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Baldwin Park, CA", "label": "Baldwin Park, CA [Member]", "documentation": "Baldwin Park, CA" } } }, "auth_ref": [] }, "sbra_BangorME1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "BangorME1Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bangor, ME 1", "label": "Bangor, ME 1 [Member]", "documentation": "Bangor, ME 1" } } }, "auth_ref": [] }, "sbra_BangorME2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "BangorME2Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bangor, ME 2", "label": "Bangor, ME 2 [Member]", "documentation": "Bangor, ME 2" } } }, "auth_ref": [] }, "sbra_BardstownKYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "BardstownKYMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bardstown, KY", "label": "Bardstown, KY [Member]", "documentation": "Bardstown, KY" } } }, "auth_ref": [] }, "sbra_BartlesvilleOKMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "BartlesvilleOKMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bartlesville, OK", "label": "Bartlesville, OK [Member]", "documentation": "Bartlesville, OK" } } }, "auth_ref": [] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BaseRateMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Base Rate", "label": "Base Rate [Member]", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation and Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "sbra_BathMEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "BathMEMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bath, ME", "label": "Bath, ME [Member]", "documentation": "Bath, ME" } } }, "auth_ref": [] }, "sbra_BaytownTX1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "BaytownTX1Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Baytown, TX 1", "label": "Baytown, TX 1 [Member]", "documentation": "Baytown, TX 1" } } }, "auth_ref": [] }, "sbra_BaytownTX2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "BaytownTX2Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Baytown, TX 2", "label": "Baytown, TX 2 [Member]", "documentation": "Baytown, TX 2" } } }, "auth_ref": [] }, "sbra_BaytownTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "BaytownTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Baytown, TX", "label": "Baytown, TX [Member]", "documentation": "Baytown, TX" } } }, "auth_ref": [] }, "sbra_BeaconNYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "BeaconNYMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Beacon, NY", "label": "Beacon, NY [Member]", "documentation": "Beacon, NY" } } }, "auth_ref": [] }, "sbra_BeaumontTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "BeaumontTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Beaumont, TX", "label": "Beaumont, TX [Member]", "documentation": "Beaumont, TX" } } }, "auth_ref": [] }, "sbra_BeavercreekOHMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "BeavercreekOHMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Beavercreek, OH", "label": "Beavercreek, OH [Member]", "documentation": "Beavercreek, OH" } } }, "auth_ref": [] }, "sbra_BedfordNHMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "BedfordNHMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bedford, NH", "label": "Bedford, NH [Member]", "documentation": "Bedford, NH" } } }, "auth_ref": [] }, "sbra_BeeCaveTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "BeeCaveTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bee Cave, TX", "label": "Bee Cave, TX [Member]", "documentation": "Bee Cave, TX" } } }, "auth_ref": [] }, "sbra_BehavioralHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "BehavioralHealthMember", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails", "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails", "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Behavioral health facility", "terseLabel": "Behavioral Health", "label": "Behavioral Health [Member]", "documentation": "Behavioral Health" } } }, "auth_ref": [] }, "sbra_BellinghamWAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "BellinghamWAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bellingham, WA", "label": "Bellingham, WA [Member]", "documentation": "Bellingham, WA" } } }, "auth_ref": [] }, "us-gaap_BelowMarketLeaseAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BelowMarketLeaseAccumulatedAmortization", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESIntangibleAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_BelowMarketLeaseNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESIntangibleAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated amortization", "label": "Below Market Lease, Accumulated Amortization", "documentation": "Amount of accumulated amortization of leases acquired as part of a real property acquisition at below market lease rate with a finite life." } } }, "auth_ref": [] }, "us-gaap_BelowMarketLeaseAmortizationIncomeAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BelowMarketLeaseAmortizationIncomeAfterYearFive", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRemainingUnamortizedBalanceforOutstandingIntangibleAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_BelowMarketLeaseNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRemainingUnamortizedBalanceforOutstandingIntangibleAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Below Market Lease, Amortization Income, after Year Five", "documentation": "Amount of amortization income for lease with finite life acquired as part of real property acquisition at below market lease rate expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_BelowMarketLeaseAmortizationIncomeNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BelowMarketLeaseAmortizationIncomeNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRemainingUnamortizedBalanceforOutstandingIntangibleAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_BelowMarketLeaseNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRemainingUnamortizedBalanceforOutstandingIntangibleAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023", "label": "Below Market Lease, Amortization Income, Year One", "documentation": "Amount of amortization income for lease with finite life acquired as part of real property acquisition at below market lease rate expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_BelowMarketLeaseAmortizationIncomeYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BelowMarketLeaseAmortizationIncomeYearFive", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRemainingUnamortizedBalanceforOutstandingIntangibleAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_BelowMarketLeaseNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRemainingUnamortizedBalanceforOutstandingIntangibleAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Below Market Lease, Amortization Income, Year Five", "documentation": "Amount of amortization income for lease with finite life acquired as part of real property acquisition at below market lease rate expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_BelowMarketLeaseAmortizationIncomeYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BelowMarketLeaseAmortizationIncomeYearFour", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRemainingUnamortizedBalanceforOutstandingIntangibleAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_BelowMarketLeaseNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRemainingUnamortizedBalanceforOutstandingIntangibleAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Below Market Lease, Amortization Income, Year Four", "documentation": "Amount of amortization income for lease with finite life acquired as part of real property acquisition at below market lease rate expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_BelowMarketLeaseAmortizationIncomeYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BelowMarketLeaseAmortizationIncomeYearThree", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRemainingUnamortizedBalanceforOutstandingIntangibleAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_BelowMarketLeaseNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRemainingUnamortizedBalanceforOutstandingIntangibleAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Below Market Lease, Amortization Income, Year Three", "documentation": "Amount of amortization income for lease with finite life acquired as part of real property acquisition at below market lease rate expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_BelowMarketLeaseAmortizationIncomeYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BelowMarketLeaseAmortizationIncomeYearTwo", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRemainingUnamortizedBalanceforOutstandingIntangibleAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_BelowMarketLeaseNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRemainingUnamortizedBalanceforOutstandingIntangibleAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Below Market Lease, Amortization Income, Year Two", "documentation": "Amount of amortization income for lease with finite life acquired as part of real property acquisition at below market lease rate expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_BelowMarketLeaseFutureAmortizationIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BelowMarketLeaseFutureAmortizationIncomeTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Remaining Unamortized Balance for Outstanding Intangible Liabilities", "label": "Below Market Lease, Future Amortization Income [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization income expected to be recorded in succeeding fiscal years for leases acquired as part of a real property acquisition at below market lease rate with a finite life." } } }, "auth_ref": [] }, "us-gaap_BelowMarketLeaseGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BelowMarketLeaseGross", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESIntangibleAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_BelowMarketLeaseNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESIntangibleAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Below market leases", "label": "Below Market Lease, Gross", "documentation": "Amount before amortization of leases acquired as part of a real property acquisition at below market lease rate with a finite life." } } }, "auth_ref": [] }, "us-gaap_BelowMarketLeaseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BelowMarketLeaseNet", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 6.0 }, "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESIntangibleAssetsandLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRemainingUnamortizedBalanceforOutstandingIntangibleAssetsandLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESIntangibleAssetsandLiabilitiesDetails", "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRemainingUnamortizedBalanceforOutstandingIntangibleAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease intangible liabilities, net", "totalLabel": "Lease intangible liabilities, net", "label": "Below Market Lease, Net", "documentation": "Amount after amortization of leases acquired as part of a real property acquisition at below market lease rate with a finite life." } } }, "auth_ref": [] }, "us-gaap_BelowMarketLeaseNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BelowMarketLeaseNetAbstract", "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESIntangibleAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Intangible Liabilities:", "label": "Below Market Lease, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BelowMarketLeaseNetAmortizationIncomeFiscalYearMaturityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BelowMarketLeaseNetAmortizationIncomeFiscalYearMaturityAbstract", "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRemainingUnamortizedBalanceforOutstandingIntangibleAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Intangible Liabilities", "label": "Below Market Lease, Net, Amortization Income, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "sbra_BelowMarketLeaseRemainingAmortizationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "BelowMarketLeaseRemainingAmortizationPeriod", "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRemainingUnamortizedBalanceforOutstandingIntangibleAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining amortization period", "label": "Below Market Lease, Remaining Amortization Period", "documentation": "Below Market Lease, Remaining Amortization Period" } } }, "auth_ref": [] }, "sbra_BentonARMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "BentonARMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Benton, AR", "label": "Benton, AR [Member]", "documentation": "Benton, AR" } } }, "auth_ref": [] }, "sbra_BeverlyMAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "BeverlyMAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Beverly, MA", "label": "Beverly, MA [Member]", "documentation": "Beverly, MA" } } }, "auth_ref": [] }, "sbra_BlufftonINMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "BlufftonINMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bluffton, IN", "label": "Bluffton, IN [Member]", "documentation": "Bluffton, IN" } } }, "auth_ref": [] }, "sbra_BoiseIDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "BoiseIDMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Boise, ID", "label": "Boise, ID [Member]", "documentation": "Boise, ID" } } }, "auth_ref": [] }, "sbra_BowlingGreenKYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "BowlingGreenKYMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bowling Green, KY", "label": "Bowling Green, KY [Member]", "documentation": "Bowling Green, KY" } } }, "auth_ref": [] }, "sbra_BrandonFLMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "BrandonFLMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Brandon, FL", "label": "Brandon, FL [Member]", "documentation": "Brandon, FL" } } }, "auth_ref": [] }, "sbra_BranfordCTMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "BranfordCTMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Branford, CT", "label": "Branford, CT [Member]", "documentation": "Branford, CT" } } }, "auth_ref": [] }, "sbra_BremenINMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "BremenINMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bremen, IN", "label": "Bremen, IN [Member]", "documentation": "Bremen, IN" } } }, "auth_ref": [] }, "sbra_BrenhamTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "BrenhamTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Brenham, TX", "label": "Brenham, TX [Member]", "documentation": "Brenham, TX" } } }, "auth_ref": [] }, "sbra_BrewerMEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "BrewerMEMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Brewer, ME", "label": "Brewer, ME [Member]", "documentation": "Brewer, ME" } } }, "auth_ref": [] }, "sbra_BrightonCOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "BrightonCOMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Brighton, CO", "label": "Brighton, CO [Member]", "documentation": "Brighton, CO" } } }, "auth_ref": [] }, "sbra_BryantARMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "BryantARMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bryant, AR", "label": "Bryant, AR [Member]", "documentation": "Bryant, AR" } } }, "auth_ref": [] }, "us-gaap_BuildingAndBuildingImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingAndBuildingImprovementsMember", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Buildings and building improvements", "label": "Building and Building Improvements [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing." } } }, "auth_ref": [] }, "us-gaap_BuildingsAndImprovementsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingsAndImprovementsGross", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails": { "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Building and improvements", "label": "Buildings and Improvements, Gross", "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing." } } }, "auth_ref": [ "r195" ] }, "sbra_BurienWAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "BurienWAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Burien, WA", "label": "Burien, WA [Member]", "documentation": "Burien, WA" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails", "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r594", "r871", "r872" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails", "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r96", "r98", "r594", "r871", "r872" ] }, "sbra_BusinessAcquisitionByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "BusinessAcquisitionByTypeAxis", "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, By Type [Axis]", "label": "Business Acquisition, By Type [Axis]", "documentation": "Business Acquisition, By Type [Axis]" } } }, "auth_ref": [] }, "sbra_BusinessAcquisitionByTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "BusinessAcquisitionByTypeDomain", "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, By Type [Domain]", "label": "Business Acquisition, By Type [Domain]", "documentation": "[Domain] for Business Acquisition, By Type [Axis]" } } }, "auth_ref": [] }, "sbra_BusinessAcquisitionDebtAssumed": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "BusinessAcquisitionDebtAssumed", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt assumed", "label": "Business Acquisition Debt Assumed", "documentation": "Business Acquisition Debt Assumed" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails", "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r594" ] }, "sbra_BusinessAcquisitionNumberOfAcquiredProperties": { "xbrltype": "integerItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "BusinessAcquisitionNumberOfAcquiredProperties", "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of acquired properties", "label": "Business Acquisition, Number of Acquired Properties", "documentation": "Business Acquisition, Number of Acquired Properties" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATED" ], "lang": { "en-us": { "role": { "terseLabel": "RECENT REAL ESTATE ACQUISITIONS (CONSOLIDATED)", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r207", "r595" ] }, "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss)", "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual", "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period." } } }, "auth_ref": [ "r97" ] }, "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total revenues", "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual", "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period." } } }, "auth_ref": [ "r97" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBuildings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedBuildings", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Building and improvements", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Buildings", "documentation": "Amount of facility held for productive use including, but not limited to, office, production, storage and distribution facilities, acquired at the acquisition date." } } }, "auth_ref": [ "r100" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tenant intangible assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": [ "r99", "r100" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLand": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLand", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land", "documentation": "Amount of real estate acquired, at the acquisition date." } } }, "auth_ref": [ "r100" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total consideration", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r99", "r100" ] }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred equity investment book value at acquisition", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value", "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages." } } }, "auth_ref": [ "r27" ] }, "us-gaap_BusinessInterruptionLossAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessInterruptionLossAxis", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Interruption Loss [Axis]", "label": "Business Interruption Loss [Axis]", "documentation": "Information by business interruption loss." } } }, "auth_ref": [ "r181" ] }, "us-gaap_BusinessInterruptionLossDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessInterruptionLossDomain", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Interruption Loss [Domain]", "label": "Business Interruption Loss [Domain]", "documentation": "Type or name of business interruption loss." } } }, "auth_ref": [ "r181" ] }, "sbra_CadillacMIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "CadillacMIMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cadillac, MI", "label": "Cadillac, MI [Member]", "documentation": "Cadillac, MI" } } }, "auth_ref": [] }, "sbra_CalgaryABMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "CalgaryABMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Calgary, AB", "label": "Calgary, AB [Member]", "documentation": "Calgary, AB" } } }, "auth_ref": [] }, "sbra_CalhounKYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "CalhounKYMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Calhoun, KY", "label": "Calhoun, KY [Member]", "documentation": "Calhoun, KY" } } }, "auth_ref": [] }, "sbra_CalvertCityKYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "CalvertCityKYMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Calvert City, KY", "label": "Calvert City, KY [Member]", "documentation": "Calvert City, KY" } } }, "auth_ref": [] }, "sbra_CanadianDollarOfferRateCDORMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "CanadianDollarOfferRateCDORMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CDOR", "label": "Canadian Dollar Offer Rate (CDOR) [Member]", "documentation": "Canadian Dollar Offer Rate (CDOR) [Member]" } } }, "auth_ref": [] }, "sbra_CanadianDollarTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "CanadianDollarTermLoanMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Canadian dollar Term Loan", "label": "Canadian Dollar Term Loan [Member]", "documentation": "Canadian Dollar Term Loan [Member]" } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESCapitalandOtherExpendituresNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future capital expenditures", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r63", "r64", "r65" ] }, "sbra_CarmelINMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "CarmelINMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carmel, IN", "label": "Carmel, IN [Member]", "documentation": "Carmel, IN" } } }, "auth_ref": [] }, "sbra_CarrolltonKYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "CarrolltonKYMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrollton, KY", "label": "Carrollton, KY [Member]", "documentation": "Carrollton, KY" } } }, "auth_ref": [] }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying Amount", "label": "Reported Value Measurement [Member]", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": [ "r136", "r137" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r60", "r279", "r840" ] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Cash", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": [ "r61", "r213" ] }, "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances." } } }, "auth_ref": [ "r61" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r60", "r185", "r320" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r3", "r185" ] }, "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gains included in accumulated other comprehensive income expected to be reclassified into retained earnings in the next 12 months", "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months", "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months." } } }, "auth_ref": [ "r132" ] }, "us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowHedgingMember", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountsofDerivativeInstrumentsDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSSummaryofDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flow Hedges", "verboseLabel": "Cash flow", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": [ "r112" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of non-cash investing activities:", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "sbra_CedarParkTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "CedarParkTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cedar Park, TX", "label": "Cedar Park, TX [Member]", "documentation": "Cedar Park, TX" } } }, "auth_ref": [] }, "sbra_CenterTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "CenterTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Center, TX", "label": "Center, TX [Member]", "documentation": "Center, TX" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r938" ] }, "sbra_ChapelHillNCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ChapelHillNCMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Chapel Hill, NC", "label": "Chapel Hill, NC [Member]", "documentation": "Chapel Hill, NC" } } }, "auth_ref": [] }, "sbra_CharlestonWVMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "CharlestonWVMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Charleston, WV", "label": "Charleston, WV [Member]", "documentation": "Charleston, WV" } } }, "auth_ref": [] }, "sbra_CharlottesvilleVAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "CharlottesvilleVAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Charlottesville, VA", "label": "Charlottesville, VA [Member]", "documentation": "Charlottesville, VA" } } }, "auth_ref": [] }, "sbra_ChatsworthCAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ChatsworthCAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Chatsworth, CA", "label": "Chatsworth, CA [Member]", "documentation": "Chatsworth, CA" } } }, "auth_ref": [] }, "sbra_CheektowagaNYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "CheektowagaNYMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cheektowaga, NY", "label": "Cheektowaga, NY [Member]", "documentation": "Cheektowaga, NY" } } }, "auth_ref": [] }, "sbra_ChillicotheOHMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ChillicotheOHMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Chillicothe, OH", "label": "Chillicothe, OH [Member]", "documentation": "Chillicothe, OH" } } }, "auth_ref": [] }, "sbra_CincinnatiOHMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "CincinnatiOHMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cincinnati, OH", "label": "Cincinnati, OH [Member]", "documentation": "Cincinnati, OH" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "sbra_ClarksSummitPAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ClarksSummitPAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clarks Summit, PA", "label": "Clarks Summit, PA [Member]", "documentation": "Clarks Summit, PA" } } }, "auth_ref": [] }, "sbra_ClarksvilleTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ClarksvilleTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clarksville, TX", "label": "Clarksville, TX [Member]", "documentation": "Clarksville, TX" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.sabrahealth.com/role/EQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r283", "r284", "r285", "r360", "r502", "r503", "r504", "r506", "r509", "r514", "r516", "r717", "r718", "r719", "r720", "r860", "r975", "r1003" ] }, "sbra_ClintonINMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ClintonINMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clinton, IN", "label": "Clinton, IN [Member]", "documentation": "Clinton, IN" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r939" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r939" ] }, "sbra_ColoradoSpringsCO1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ColoradoSpringsCO1Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Colorado Springs, CO 1", "label": "Colorado Springs, CO 1 [Member]", "documentation": "Colorado Springs, CO 1" } } }, "auth_ref": [] }, "sbra_ColoradoSpringsCO2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ColoradoSpringsCO2Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Colorado Springs, CO 2", "label": "Colorado Springs, CO 2 [Member]", "documentation": "Colorado Springs, CO 2" } } }, "auth_ref": [] }, "sbra_ColumbiaKYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ColumbiaKYMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Columbia, KY", "label": "Columbia, KY [Member]", "documentation": "Columbia, KY" } } }, "auth_ref": [] }, "sbra_ColumbiaMOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ColumbiaMOMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Columbia, MO", "label": "Columbia, MO [Member]", "documentation": "Columbia, MO" } } }, "auth_ref": [] }, "sbra_ColumbusINMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ColumbusINMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Columbus, IN", "label": "Columbus, IN [Member]", "documentation": "Columbus, IN" } } }, "auth_ref": [] }, "sbra_CommitmentForFundingPreferredEquityInvestmentNumber": { "xbrltype": "integerItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "CommitmentForFundingPreferredEquityInvestmentNumber", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of preferred equity investments for funding commitment", "label": "Commitment For Funding, Preferred Equity Investment, Number", "documentation": "Commitment For Funding, Preferred Equity Investment, Number" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 15)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r45", "r148", "r676", "r744" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.sabrahealth.com/role/COMMITMENTSANDCONTINGENCIES" ], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r198", "r451", "r452", "r822", "r1028" ] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITYParenthetical", "http://www.sabrahealth.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common dividends (in dollars per share)", "verboseLabel": "Quarterly cash dividend declared on common stock (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r203" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r881", "r882", "r883", "r885", "r886", "r887", "r890", "r1008", "r1009", "r1046", "r1070", "r1074" ] }, "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r167" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r167", "r745" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r167" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Shares outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r24", "r167", "r745", "r763", "r1074", "r1075" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, $0.01 par value; 500,000,000 shares authorized, 231,266,020 and 231,009,295 shares issued and outstanding as of December\u00a031, 2023 and 2022, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r167", "r679", "r878" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r944" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r943" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r945" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r942" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income (loss)", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r50", "r301", "r303", "r310", "r670", "r686" ] }, "sbra_ConroeTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ConroeTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conroe, TX", "label": "Conroe, TX [Member]", "documentation": "Conroe, TX" } } }, "auth_ref": [] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesAxis", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails", "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Axis]", "label": "Consolidated Entities [Axis]", "documentation": "Information by consolidated entity or group of entities." } } }, "auth_ref": [ "r245", "r329", "r596", "r597", "r599", "r600", "r657", "r832", "r988", "r991", "r992", "r1031", "r1034", "r1035" ] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesDomain", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails", "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Domain]", "label": "Consolidated Entities [Domain]", "documentation": "Entity or group of entities consolidated into reporting entity." } } }, "auth_ref": [ "r245", "r329", "r596", "r597", "r599", "r600", "r657", "r832", "r988", "r991", "r992", "r1031", "r1034", "r1035" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]", "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": [ "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r329", "r364", "r380", "r381", "r382", "r383", "r384", "r386", "r389", "r457", "r458", "r459", "r460", "r462", "r463", "r465", "r467", "r468", "r989", "r990", "r1032", "r1033" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]", "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": [ "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r329", "r364", "r380", "r381", "r382", "r383", "r384", "r386", "r389", "r457", "r458", "r459", "r460", "r462", "r463", "r465", "r467", "r468", "r989", "r990", "r1032", "r1033" ] }, "us-gaap_ConsolidationVariableInterestEntityPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationVariableInterestEntityPolicy", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entities", "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined)." } } }, "auth_ref": [ "r103", "r105", "r106" ] }, "sbra_ConversionOfStockSharesIssuableUponConversion": { "xbrltype": "sharesItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ConversionOfStockSharesIssuableUponConversion", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares of common stock convertible upon each performance-based restricted stock unit vesting (in shares)", "label": "Conversion Of Stock, Shares Issuable Upon Conversion", "documentation": "Conversion Of Stock, Shares Issuable Upon Conversion" } } }, "auth_ref": [] }, "sbra_ConwaySCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ConwaySCMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conway, SC", "label": "Conway, SC [Member]", "documentation": "Conway, SC" } } }, "auth_ref": [] }, "sbra_CookevilleTNMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "CookevilleTNMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cookeville, TN", "label": "Cookeville, TN [Member]", "documentation": "Cookeville, TN" } } }, "auth_ref": [] }, "sbra_CoosBayORMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "CoosBayORMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Coos Bay, OR", "label": "Coos Bay, OR [Member]", "documentation": "Coos Bay, OR" } } }, "auth_ref": [] }, "us-gaap_CorporateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateMember", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate Level", "label": "Corporate Segment [Member]", "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items." } } }, "auth_ref": [ "r1012" ] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateNonSegmentMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate Assets", "label": "Corporate, Non-Segment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": [ "r32", "r381", "r382", "r383", "r384", "r389", "r1014" ] }, "sbra_CoshoctonOHMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "CoshoctonOHMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Coshocton, OH", "label": "Coshocton, OH [Member]", "documentation": "Coshocton, OH" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRealEstateIntangibleAmortizationDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]", "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [ "r272", "r326", "r327", "r474", "r504", "r656", "r841", "r844" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "sbra_CovinaCAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "CovinaCAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Covina, CA", "label": "Covina, CA [Member]", "documentation": "Covina, CA" } } }, "auth_ref": [] }, "sbra_CreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "CreditAgreementMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fifth Amended and Restated Credit Agreement", "label": "Credit Agreement [Member]", "documentation": "Fifth Amended and Restated Credit Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofIncomeandCondensedConsolidatedStatementsofEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofIncomeandCondensedConsolidatedStatementsofEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditLossFinancialInstrumentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditLossFinancialInstrumentPolicyTextBlock", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Losses", "label": "Credit Loss, Financial Instrument [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status." } } }, "auth_ref": [ "r238", "r407", "r408", "r409", "r411", "r412", "r417", "r419", "r420", "r421", "r422", "r425", "r426", "r427", "r428", "r429", "r430", "r431" ] }, "us-gaap_CreditLossStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditLossStatusAxis", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Loss Status [Axis]", "label": "Credit Loss Status [Axis]", "documentation": "Information by credit loss status of financial asset." } } }, "auth_ref": [ "r1016", "r1020", "r1024" ] }, "us-gaap_CreditLossStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditLossStatusDomain", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Loss Status [Domain]", "label": "Credit Loss Status [Domain]", "documentation": "Credit loss status of financial asset." } } }, "auth_ref": [] }, "us-gaap_CreditRiskContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditRiskContractMember", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit risk-related contingent features", "label": "Credit Risk Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to the creditworthiness or the credit spread of an entity." } } }, "auth_ref": [ "r844", "r868", "r876" ] }, "us-gaap_CrossCurrencyInterestRateContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CrossCurrencyInterestRateContractMember", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountsofDerivativeInstrumentsDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSSummaryofDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Cross currency interest rate swaps", "terseLabel": "Cross currency interest rate swaps", "label": "Cross Currency Interest Rate Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates." } } }, "auth_ref": [ "r1040", "r1045" ] }, "sbra_CrownPointINMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "CrownPointINMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Crown Point, IN", "label": "Crown Point, IN [Member]", "documentation": "Crown Point, IN" } } }, "auth_ref": [] }, "sbra_CumberlandMDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "CumberlandMDMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumberland, MD", "label": "Cumberland, MD [Member]", "documentation": "Cumberland, MD" } } }, "auth_ref": [] }, "us-gaap_CurrencySwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrencySwapMember", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofIncomeandCondensedConsolidatedStatementsofEquityDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSSummaryofDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency Swap", "label": "Currency Swap [Member]", "documentation": "Swap involving the exchange of principal and interest in one currency for another currency." } } }, "auth_ref": [] }, "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentFederalStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INCOMETAXESProvisionforIncomeTaxExpenseDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INCOMETAXESProvisionforIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for federal, state and local income taxes", "label": "Current Federal, State and Local, Tax Expense (Benefit)", "documentation": "Amount of current federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r978" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentForeignTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INCOMETAXESProvisionforIncomeTaxExpenseDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INCOMETAXESProvisionforIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision (benefit) for foreign income taxes", "label": "Current Foreign Tax Expense (Benefit)", "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r978", "r1006" ] }, "sbra_DanvilleCAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "DanvilleCAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Danville, CA", "label": "Danville, CA [Member]", "documentation": "Danville, CA" } } }, "auth_ref": [] }, "sbra_DanvilleKYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "DanvilleKYMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Danville, KY", "label": "Danville, KY [Member]", "documentation": "Danville, KY" } } }, "auth_ref": [] }, "sbra_DeSotoTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "DeSotoTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "DeSoto, TX", "label": "DeSoto, TX [Member]", "documentation": "DeSoto, TX" } } }, "auth_ref": [] }, "sbra_DebtCovenantUnencumberedAssetsToUnsecuredDebtRatioMinimum": { "xbrltype": "percentItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "DebtCovenantUnencumberedAssetsToUnsecuredDebtRatioMinimum", "presentation": [ "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt covenant, consolidated unencumbered total asset value to aggregate principal of unsecured debt", "label": "Debt Covenant, Unencumbered Assets To Unsecured Debt Ratio, Minimum", "documentation": "Debt Covenant, Unencumbered Assets To Unsecured Debt Ratio, Minimum" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.sabrahealth.com/role/DEBT" ], "lang": { "en-us": { "role": { "terseLabel": "DEBT", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r199", "r322", "r470", "r476", "r477", "r478", "r479", "r480", "r481", "r486", "r493", "r494", "r496" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails", "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r39", "r162", "r163", "r215", "r217", "r329", "r471", "r472", "r473", "r474", "r475", "r477", "r482", "r483", "r484", "r485", "r487", "r488", "r489", "r490", "r491", "r492", "r642", "r855", "r856", "r857", "r858", "r859", "r1004" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basis spread on variable rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total Debt", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r39", "r217", "r497" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Aggregate principal amount", "terseLabel": "Financial liabilities", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r141", "r144", "r471", "r642", "r856", "r857" ] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": [ "r484", "r629", "r856", "r857" ] }, "sbra_DebtInstrumentInterestRateAtPeriodEnd": { "xbrltype": "percentItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "DebtInstrumentInterestRateAtPeriodEnd", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate", "label": "Debt Instrument, Interest Rate At Period End", "documentation": "Debt Instrument, Interest Rate At Period End" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average effective interest rate (percent)", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r43", "r141", "r499", "r642" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r43", "r472" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails", "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessDetails", "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessNarrativeDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r329", "r471", "r472", "r473", "r474", "r475", "r477", "r482", "r483", "r484", "r485", "r487", "r488", "r489", "r490", "r491", "r492", "r495", "r642", "r855", "r856", "r857", "r858", "r859", "r1004" ] }, "us-gaap_DebtInstrumentMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentMeasurementInput", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt, measurement input", "label": "Debt Instrument, Measurement Input", "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt." } } }, "auth_ref": [ "r625" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails", "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r44", "r329", "r471", "r472", "r473", "r474", "r475", "r477", "r482", "r483", "r484", "r485", "r487", "r488", "r489", "r490", "r491", "r492", "r642", "r855", "r856", "r857", "r858", "r859", "r1004" ] }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPeriodAxis", "presentation": [ "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Redemption, Period [Axis]", "label": "Debt Instrument, Redemption, Period [Axis]", "documentation": "Information about timing of debt redemption features under terms of the debt agreement." } } }, "auth_ref": [ "r31" ] }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPeriodDomain", "presentation": [ "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Redemption, Period [Domain]", "label": "Debt Instrument, Redemption, Period [Domain]", "documentation": "Period as defined under terms of the debt agreement for debt redemption features." } } }, "auth_ref": [ "r31" ] }, "us-gaap_DebtInstrumentRedemptionPeriodOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPeriodOneMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redemption Period One", "label": "Debt Instrument, Redemption, Period One [Member]", "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref": [ "r31" ] }, "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPeriodTwoMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redemption Period Two", "label": "Debt Instrument, Redemption, Period Two [Member]", "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement." } } }, "auth_ref": [ "r31" ] }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPricePercentage", "presentation": [ "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redemption price (percent)", "label": "Debt Instrument, Redemption Price, Percentage", "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer." } } }, "auth_ref": [ "r31" ] }, "us-gaap_DebtInstrumentRepurchasedFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRepurchasedFaceAmount", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate principal amount redeemed", "label": "Debt Instrument, Repurchased Face Amount", "documentation": "Face (par) amount of the original debt instrument that was repurchased." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails", "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessDetails", "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessNarrativeDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r44", "r88", "r91", "r140", "r141", "r144", "r149", "r201", "r202", "r329", "r471", "r472", "r473", "r474", "r475", "r477", "r482", "r483", "r484", "r485", "r487", "r488", "r489", "r490", "r491", "r492", "r495", "r642", "r855", "r856", "r857", "r858", "r859", "r1004" ] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount, net", "negatedTerseLabel": "Discount, net", "label": "Debt Instrument, Unamortized Discount (Premium), Net", "documentation": "Amount, after accumulated amortization, of debt discount (premium)." } } }, "auth_ref": [ "r140", "r141", "r142", "r143", "r144", "r1037" ] }, "us-gaap_DebtWeightedAverageInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtWeightedAverageInterestRate", "presentation": [ "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average interest rate (percent)", "label": "Debt, Weighted Average Interest Rate", "documentation": "Weighted average interest rate of debt outstanding." } } }, "auth_ref": [] }, "us-gaap_DeferredChargesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredChargesPolicyTextBlock", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Financing Costs", "label": "Deferred Charges, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges." } } }, "auth_ref": [ "r281" ] }, "us-gaap_DeferredFinanceCostsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsGross", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred financing costs", "label": "Debt Issuance Costs, Gross", "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r142" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails", "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails", "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred financing costs", "negatedTerseLabel": "Deferred financing costs, net", "verboseLabel": "Deferred financing costs, net", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r142", "r1037" ] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/INCOMETAXESDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INCOMETAXESDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Deferred tax (liabilities)", "label": "Deferred Tax Liabilities, Gross", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": [ "r164", "r165", "r216", "r581" ] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INCOMETAXESDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INCOMETAXESDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets", "label": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r582" ] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INCOMETAXESDeferredTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/INCOMETAXESDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred taxes, net", "label": "Deferred Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": [ "r1042" ] }, "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract", "presentation": [ "http://www.sabrahealth.com/role/INCOMETAXESDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets:", "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/INCOMETAXESDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INCOMETAXESDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r583" ] }, "us-gaap_DeferredTaxLiabilitiesNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesNetAbstract", "presentation": [ "http://www.sabrahealth.com/role/INCOMETAXESDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax (liabilities):", "label": "Deferred Tax Liabilities, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Matching contributions", "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discretionary matching contribution (percent)", "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent", "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": { "parentTag": "sbra_OperatingAndInterestExpense", "weight": 1.0, "order": 1.0 }, "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "verboseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r14", "r367" ] }, "us-gaap_DerivativeAmountOfHedgedItem": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAmountOfHedgedItem", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountsofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notional amount", "label": "Derivative, Amount of Hedged Item", "documentation": "Amount of hedged item in hedging relationship. Excludes hedged asset or liability." } } }, "auth_ref": [] }, "us-gaap_DerivativeAssetFairValueGrossLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetFairValueGrossLiability", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandaNetPresentationofDerivativesDetails": { "parentTag": "us-gaap_DerivativeAssets", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandaNetPresentationofDerivativesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross Amounts Offset in the Balance Sheet", "label": "Derivative Asset, Subject to Master Netting Arrangement, Liability Offset", "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r30", "r37", "r119", "r804", "r805" ] }, "us-gaap_DerivativeAssetNumberOfInstrumentsHeld": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetNumberOfInstrumentsHeld", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSSummaryofDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Count", "label": "Derivative Asset, Number of Instruments Held", "documentation": "The number of derivative instruments of a particular derivative asset or group of derivative assets held by the entity." } } }, "auth_ref": [ "r110", "r111" ] }, "us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSSummaryofDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative asset, statement of financial position", "label": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative asset." } } }, "auth_ref": [ "r601" ] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssets", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandaNetPresentationofDerivativesDetails": { "parentTag": "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandaNetPresentationofDerivativesDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSSummaryofDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair Value", "totalLabel": "Net Amounts of Assets presented in the Balance Sheet", "terseLabel": "Financial assets", "label": "Derivative Asset", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r290", "r293", "r629", "r725", "r726", "r727", "r728", "r729", "r731", "r732", "r733", "r735", "r736", "r750", "r751", "r797", "r802", "r803", "r804", "r806", "r807", "r844", "r883", "r1071" ] }, "us-gaap_DerivativeAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetsAbstract", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSSummaryofDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets:", "label": "Derivative Asset [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeCollateralObligationToReturnCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeCollateralObligationToReturnCash", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandaNetPresentationofDerivativesDetails": { "parentTag": "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandaNetPresentationofDerivativesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash Collateral Received", "label": "Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset", "documentation": "Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets." } } }, "auth_ref": [ "r35", "r129", "r291", "r842" ] }, "us-gaap_DerivativeCollateralObligationToReturnSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeCollateralObligationToReturnSecurities", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandaNetPresentationofDerivativesDetails": { "parentTag": "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandaNetPresentationofDerivativesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Financial Instruments", "label": "Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Security Not Offset", "documentation": "Amount of obligation to return securities collateral under master netting arrangements that have not been offset against derivative assets." } } }, "auth_ref": [ "r35", "r291", "r842" ] }, "us-gaap_DerivativeCollateralRightToReclaimCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeCollateralRightToReclaimCash", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandaNetPresentationofDerivativesDetails": { "parentTag": "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandaNetPresentationofDerivativesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash Collateral Received", "label": "Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset", "documentation": "Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities." } } }, "auth_ref": [ "r35", "r129", "r291", "r842" ] }, "us-gaap_DerivativeCollateralRightToReclaimSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeCollateralRightToReclaimSecurities", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandaNetPresentationofDerivativesDetails": { "parentTag": "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandaNetPresentationofDerivativesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Financial Instruments", "label": "Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Security Not Offset", "documentation": "Amount of right to receive securities collateral under master netting arrangements that have not been offset against derivative liabilities." } } }, "auth_ref": [ "r35", "r291", "r842" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofIncomeandCondensedConsolidatedStatementsofEquityDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountsofDerivativeInstrumentsDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSSummaryofDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r733", "r736", "r749", "r750", "r751", "r753", "r754", "r755", "r756", "r758", "r759", "r760", "r761", "r771", "r772", "r773", "r774", "r777", "r778", "r779", "r780", "r797", "r799", "r803", "r806", "r881", "r883" ] }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeAsset", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandaNetPresentationofDerivativesDetails": { "parentTag": "us-gaap_DerivativeAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandaNetPresentationofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Amounts of Recognized Assets", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement." } } }, "auth_ref": [ "r33", "r119", "r173", "r289", "r844" ] }, "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandaNetPresentationofDerivativesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandaNetPresentationofDerivativesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net Amount", "label": "Derivative Asset, Including Not Subject to Master Netting Arrangement, after Offset and Deduction", "documentation": "Fair value, after effect of master netting arrangement and deduction of obligation to return financial collateral not offset and financial instrument subject to master netting arrangement not offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset. Includes derivative not subject to master netting arrangement or similar agreement." } } }, "auth_ref": [ "r35", "r128" ] }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandaNetPresentationofDerivativesDetails": { "parentTag": "us-gaap_DerivativeLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandaNetPresentationofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Amounts of Recognized Liabilities", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": [ "r33", "r119", "r173", "r289", "r844" ] }, "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandaNetPresentationofDerivativesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandaNetPresentationofDerivativesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net Amount", "label": "Derivative Liability, Including Not Subject to Master Netting Arrangement, after Offset and Deduction", "documentation": "Fair value, after effect of master netting arrangement and deduction of obligation to return financial collateral not offset and financial instrument subject to master netting arrangement not offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset. Includes derivative not subject to master netting arrangement or similar agreement." } } }, "auth_ref": [ "r35", "r128" ] }, "us-gaap_DerivativeFixedInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFixedInterestRate", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed interest rate under swap", "label": "Derivative, Fixed Interest Rate", "documentation": "Fixed interest rate related to the interest rate derivative." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofIncomeandCondensedConsolidatedStatementsofEquityDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountsofDerivativeInstrumentsDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSSummaryofDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r117", "r120", "r122", "r124", "r733", "r736", "r749", "r750", "r751", "r753", "r754", "r755", "r756", "r758", "r759", "r760", "r761", "r771", "r772", "r773", "r774", "r777", "r778", "r779", "r780", "r797", "r799", "r803", "r806", "r844", "r881", "r883" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "DERIVATIVE AND HEDGING INSTRUMENTS", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": [ "r211", "r607", "r615" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountsofDerivativeInstrumentsDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSSummaryofDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [ "r25", "r117", "r122" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofIncomeandCondensedConsolidatedStatementsofEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Table]", "label": "Derivative Instruments, Gain (Loss) [Table]", "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r25", "r117", "r122", "r124", "r130", "r131", "r606" ] }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofIncomeandCondensedConsolidatedStatementsofEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r606" ] }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other expense related to derivatives", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments." } } }, "auth_ref": [ "r123", "r976" ] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilities", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandaNetPresentationofDerivativesDetails": { "parentTag": "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandaNetPresentationofDerivativesDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSSummaryofDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "netLabel": "Fair value of derivatives in a net liability position", "verboseLabel": "Fair value", "totalLabel": "Net Amounts of Liabilities presented in the Balance Sheet", "label": "Derivative Liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r290", "r293", "r629", "r725", "r726", "r727", "r728", "r731", "r732", "r733", "r735", "r736", "r758", "r760", "r761", "r799", "r800", "r802", "r803", "r804", "r806", "r807", "r844", "r1071" ] }, "us-gaap_DerivativeLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilitiesAbstract", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSSummaryofDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities:", "label": "Derivative Liability [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeLiabilityFairValueGrossAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityFairValueGrossAsset", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandaNetPresentationofDerivativesDetails": { "parentTag": "us-gaap_DerivativeLiabilities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandaNetPresentationofDerivativesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross Amounts Offset in the Balance Sheet", "label": "Derivative Liability, Subject to Master Netting Arrangement, Asset Offset", "documentation": "Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r30", "r37", "r119", "r804", "r805", "r842" ] }, "us-gaap_DerivativeLiabilityNumberOfInstrumentsHeld": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityNumberOfInstrumentsHeld", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSSummaryofDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Count", "label": "Derivative Liability, Number of Instruments Held", "documentation": "The number of derivative instruments of a particular derivative liability or group of derivative liabilities held by the entity." } } }, "auth_ref": [ "r110", "r111" ] }, "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSSummaryofDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative liability, statement of financial position", "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative liability." } } }, "auth_ref": [ "r601" ] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLineItems", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountsofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r615" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountsofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notional amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r1043", "r1044" ] }, "us-gaap_DerivativeNumberOfInstrumentsHeld": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNumberOfInstrumentsHeld", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountsofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of derivative instruments held", "label": "Derivative, Number of Instruments Held", "documentation": "The number of derivative instruments of a particular group held by the entity." } } }, "auth_ref": [ "r110", "r111", "r735", "r797", "r798", "r801", "r883" ] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeTable", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountsofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": [ "r25", "r108", "r109", "r111", "r114", "r118", "r122", "r125", "r127", "r131", "r615" ] }, "us-gaap_DerivativesFairValueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesFairValueLineItems", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSSummaryofDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives, Fair Value [Line Items]", "label": "Derivatives, Fair Value [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "sbra_DerivativesNetHedgeIneffectivenessGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "DerivativesNetHedgeIneffectivenessGainLoss", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ineffectiveness on cash flow hedges", "label": "Derivatives, Net Hedge Ineffectiveness Gain (Loss)", "documentation": "Derivatives, Net Hedge Ineffectiveness Gain (Loss)" } } }, "auth_ref": [] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesPolicyTextBlock", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments", "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": [ "r25", "r108", "r109", "r114", "r126", "r328" ] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountsofDerivativeInstrumentsDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSSummaryofDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Designated as Hedging Instrument", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r25" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSeniorHousingManagedCommunitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r519", "r861", "r862", "r863", "r864", "r865", "r866", "r867" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSeniorHousingManagedCommunitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r519", "r861", "r862", "r863", "r864", "r865", "r866", "r867" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATION" ], "lang": { "en-us": { "role": { "terseLabel": "STOCK-BASED COMPENSATION", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r528", "r533", "r563", "r564", "r566", "r874" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]", "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Axis]", "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r277" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Domain]", "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sold", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations." } } }, "auth_ref": [ "r15", "r29" ] }, "sbra_DisposalGroupIncludingDiscontinuedOperationAssetsAndLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsAndLiabilitiesNet", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSDispositionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net carrying value", "label": "Disposal Group, Including Discontinued Operation, Assets And Liabilities, Net", "documentation": "Disposal Group, Including Discontinued Operation, Assets And Liabilities, Net" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSDispositionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration, net of closing costs", "label": "Disposal Group, Including Discontinued Operation, Consideration", "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSDispositionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss)", "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)", "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r158" ] }, "sbra_DisposalGroupIncludingDiscontinuedOperationsNumberOfProperties": { "xbrltype": "integerItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "DisposalGroupIncludingDiscontinuedOperationsNumberOfProperties", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSDispositionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Number of facilities", "label": "Disposal Group, Including Discontinued Operations, Number Of Properties", "documentation": "Disposal Group, Including Discontinued Operations, Number Of Properties" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupNotDiscontinuedOperationDisposalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupNotDiscontinuedOperationDisposalDisclosuresAbstract", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSDispositionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dispositions:", "label": "Disposal Group, Not Discontinued Operation, Disposal Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSDispositionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net (loss) gain on sale", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations." } } }, "auth_ref": [ "r445", "r1002", "r1025" ] }, "sbra_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleListNotDisclosedFlag": { "xbrltype": "stringItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleListNotDisclosedFlag", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSDispositionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal group, not discontinued operations, gain (loss) on disposal, statement of income", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) On Disposal, Statement Of Income, Extensible List, Not Disclosed Flag", "documentation": "Disposal Group, Not Discontinued Operation, Gain (Loss) On Disposal, Statement Of Income, Extensible List, Not Disclosed Flag" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSDispositionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment upon disposal", "label": "Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down", "documentation": "Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations." } } }, "auth_ref": [ "r14", "r15", "r196" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONS" ], "lang": { "en-us": { "role": { "terseLabel": "IMPAIRMENT OF REAL ESTATE AND DISPOSITIONS", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r151", "r194" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Domain]", "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r871", "r872" ] }, "us-gaap_DividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsCommonStock", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Common dividends", "label": "Dividends, Common Stock", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)." } } }, "auth_ref": [ "r10", "r203" ] }, "sbra_DixonMOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "DixonMOMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dixon, MO", "label": "Dixon, MO [Member]", "documentation": "Dixon, MO" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r898", "r899", "r912" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Error Correction [Flag]", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r898", "r899", "r912", "r948" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r933" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Documents Incorporated by Reference", "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r896" ] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DomesticCountryMember", "presentation": [ "http://www.sabrahealth.com/role/INCOMETAXESDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Domestic Tax Authority [Member]", "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile." } } }, "auth_ref": [] }, "sbra_DoniphanMOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "DoniphanMOMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Doniphan, MO", "label": "Doniphan, MO [Member]", "documentation": "Doniphan, MO" } } }, "auth_ref": [] }, "sbra_DouglassvillePAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "DouglassvillePAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Douglassville, PA", "label": "Douglassville, PA [Member]", "documentation": "Douglassville, PA" } } }, "auth_ref": [] }, "sbra_DoverDEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "DoverDEMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dover, DE", "label": "Dover, DE [Member]", "documentation": "Dover, DE" } } }, "auth_ref": [] }, "sbra_DoverNHMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "DoverNHMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dover, NH", "label": "Dover, NH [Member]", "documentation": "Dover, NH" } } }, "auth_ref": [] }, "sbra_DuffieldVAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "DuffieldVAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Duffield, VA", "label": "Duffield, VA [Member]", "documentation": "Duffield, VA" } } }, "auth_ref": [] }, "sbra_DurhamNCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "DurhamNCMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Durham, NC", "label": "Durham, NC [Member]", "documentation": "Durham, NC" } } }, "auth_ref": [] }, "sbra_DyerINMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "DyerINMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dyer, IN", "label": "Dyer, IN [Member]", "documentation": "Dyer, IN" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS", "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHAREComputationofBasicandDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic common share (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r311", "r335", "r336", "r337", "r338", "r339", "r344", "r346", "r351", "r352", "r353", "r357", "r618", "r619", "r671", "r687", "r847" ] }, "sbra_EarningsPerShareBasicAndDilutedEPSAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "EarningsPerShareBasicAndDilutedEPSAbstract", "presentation": [ "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHAREComputationofBasicandDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss), per:", "label": "Earnings Per Share, Basic And Diluted EPS [Abstract]", "documentation": "Earnings Per Share, Basic And Diluted EPS" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS", "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHAREComputationofBasicandDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted common share (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r311", "r335", "r336", "r337", "r338", "r339", "r346", "r351", "r352", "r353", "r357", "r618", "r619", "r671", "r687", "r847" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Per Share Data", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r66", "r67" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHARE" ], "lang": { "en-us": { "role": { "terseLabel": "EARNINGS PER COMMON SHARE", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r343", "r354", "r355", "r356" ] }, "sbra_EastLongmeadowMAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "EastLongmeadowMAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "East Longmeadow, MA", "label": "East Longmeadow, MA [Member]", "documentation": "East Longmeadow, MA" } } }, "auth_ref": [] }, "sbra_EastPatchogueNYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "EastPatchogueNYMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "East Patchogue, NY", "label": "East Patchogue, NY [Member]", "documentation": "East Patchogue, NY" } } }, "auth_ref": [] }, "sbra_EastTawasMIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "EastTawasMIMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "East Tawas, MI", "label": "East Tawas, MI [Member]", "documentation": "East Tawas, MI" } } }, "auth_ref": [] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of foreign currency translation on cash, cash equivalents and restricted cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r632" ] }, "sbra_ElMonteCAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ElMonteCAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "El Monte, CA", "label": "El Monte, CA [Member]", "documentation": "El Monte, CA" } } }, "auth_ref": [] }, "sbra_ElizabethtownKYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ElizabethtownKYMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Elizabethtown, KY", "label": "Elizabethtown, KY [Member]", "documentation": "Elizabethtown, KY" } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total unrecognized stock-based compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r565" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average period for recognition of stock-based compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r565" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "sbra_EnfieldCTMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "EnfieldCTMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Enfield, CT", "label": "Enfield, CT [Member]", "documentation": "Enfield, CT" } } }, "auth_ref": [] }, "sbra_EnlivantJointVentureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "EnlivantJointVentureMember", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialInformationforEnlivantJointVentureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Enlivant Joint Venture", "label": "Enlivant Joint Venture [Member]", "documentation": "Enlivant Joint Venture [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r895" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESScheduleofInvestmentinJointVenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r895" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r895" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r973" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Public Float", "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r895" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r895" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r895" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r895" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r974" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY", "http://www.sabrahealth.com/role/EQUITYAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r24", "r274", "r305", "r306", "r307", "r330", "r331", "r332", "r334", "r340", "r342", "r359", "r405", "r406", "r517", "r567", "r568", "r569", "r587", "r588", "r609", "r610", "r611", "r612", "r613", "r614", "r617", "r633", "r635", "r636", "r637", "r638", "r639", "r655", "r708", "r709", "r710", "r723", "r783" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESScheduleofInvestmentinJointVenturesDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialInformationforEnlivantJointVentureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]", "documentation": "Name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": [ "r401", "r402", "r403" ] }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentDividendsOrDistributions", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Distributions of earnings from unconsolidated joint ventures", "label": "Proceeds from Equity Method Investment, Distribution", "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities." } } }, "auth_ref": [ "r12", "r14", "r175", "r682" ] }, "sbra_EquityMethodInvestmentEstimatedFairValueInvestmentBasisAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "EquityMethodInvestmentEstimatedFairValueInvestmentBasisAmount", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity interest, investment basis amount", "label": "Equity Method Investment, Estimated Fair Value Investment Basis Amount", "documentation": "Equity Method Investment, Estimated Fair Value Investment Basis Amount" } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialInformationforEnlivantJointVentureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]", "label": "Equity Method Investment, Nonconsolidated Investee [Axis]", "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity." } } }, "auth_ref": [ "r278", "r324", "r404", "r630" ] }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialInformationforEnlivantJointVentureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]", "label": "Equity Method Investment, Nonconsolidated Investee [Domain]", "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity." } } }, "auth_ref": [ "r278", "r324", "r404", "r630" ] }, "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialInformationforEnlivantJointVentureDetails": { "parentTag": "sbra_IncomeLossFromEquityMethodInvestmentsAndOtherThanTemporaryImpairment", "weight": -1.0, "order": 3.0 }, "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialInformationforEnlivantJointVentureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other-than-temporary impairment of unconsolidated joint ventures", "verboseLabel": "Other-than-temporary impairment", "label": "Equity Method Investment, Other than Temporary Impairment", "documentation": "This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment." } } }, "auth_ref": [ "r1017" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESScheduleofInvestmentinJointVenturesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Ownership", "terseLabel": "Equity interest in joint venture", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r401" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestments", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESScheduleofInvestmentinJointVenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in unconsolidated joint ventures", "verboseLabel": "Book value", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r372", "r399", "r993", "r1018" ] }, "us-gaap_EquityMethodInvestmentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsPolicy", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Investment in Unconsolidated Joint Ventures and Preferred Equity Investments and Preferred Return", "label": "Equity Method Investments [Policy Text Block]", "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received." } } }, "auth_ref": [ "r12", "r138", "r402" ] }, "us-gaap_EquityMethodInvestmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsTextBlock", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Investment in Joint Ventures", "label": "Equity Method Investments [Table Text Block]", "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information." } } }, "auth_ref": [ "r400" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r941" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r904", "r916", "r926", "r952" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r901", "r913", "r923", "r949" ] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": [ "r484", "r629", "r856", "r857" ] }, "sbra_EugeneOR1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "EugeneOR1Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Eugene, OR 1", "label": "Eugene, OR 1 [Member]", "documentation": "Eugene, OR 1" } } }, "auth_ref": [] }, "sbra_EugeneOR2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "EugeneOR2Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Eugene, OR 2", "label": "Eugene, OR 2 [Member]", "documentation": "Eugene, OR 2" } } }, "auth_ref": [] }, "sbra_EugeneORMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "EugeneORMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Eugene, OR", "label": "Eugene, OR [Member]", "documentation": "Eugene, OR" } } }, "auth_ref": [] }, "sbra_EustisFLMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "EustisFLMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Eustis, FL", "label": "Eustis, FL [Member]", "documentation": "Eustis, FL" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r947" ] }, "sbra_ExeterNHMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ExeterNHMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exeter, NH", "label": "Exeter, NH [Member]", "documentation": "Exeter, NH" } } }, "auth_ref": [] }, "sbra_FacilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "FacilitiesMember", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Facilities", "label": "Facilities [Member]", "documentation": "Facilities" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r621", "r622", "r626" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r621", "r622", "r626" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value of Financial Instruments", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances." } } }, "auth_ref": [ "r28", "r134", "r135", "r212" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r26" ] }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByBalanceSheetGroupingTextBlock", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Face Values, Carrying Amounts and Fair Values of Financial Instruments", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r134", "r136" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r484", "r521", "r522", "r523", "r524", "r525", "r526", "r622", "r661", "r662", "r663", "r856", "r857", "r868", "r869", "r870" ] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementBasisAxis", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Basis [Axis]", "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": [ "r34", "r134", "r484", "r856", "r857" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r621", "r622", "r624", "r625", "r627" ] }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosureItemAmountsDomain", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement [Domain]", "label": "Fair Value Measurement [Domain]", "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value." } } }, "auth_ref": [ "r484", "r856", "r857" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURES" ], "lang": { "en-us": { "role": { "terseLabel": "FAIR VALUE DISCLOSURES", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r620" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)", "verboseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r484", "r521", "r526", "r622", "r661", "r868", "r869", "r870" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Other Observable Inputs (Level 2)", "verboseLabel": "Significant Other Observable Inputs (Level 2)", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r484", "r521", "r526", "r622", "r662", "r856", "r857", "r868", "r869", "r870" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Unobservable Inputs (Level 3)", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r484", "r521", "r522", "r523", "r524", "r525", "r526", "r622", "r663", "r856", "r857", "r868", "r869", "r870" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r484", "r521", "r522", "r523", "r524", "r525", "r526", "r661", "r662", "r663", "r856", "r857", "r868", "r869", "r870" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r620", "r627" ] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Instruments", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r18", "r38" ] }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSSummaryofDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": [ "r116", "r118", "r130" ] }, "sbra_FairfieldCAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "FairfieldCAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fairfield, CA", "label": "Fairfield, CA [Member]", "documentation": "Fairfield, CA" } } }, "auth_ref": [] }, "us-gaap_FinanceLoansAndLeasesReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLoansAndLeasesReceivablePolicy", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Loans Receivable", "label": "Financing Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for financing receivable." } } }, "auth_ref": [ "r73", "r75", "r77", "r189", "r395", "r396", "r397", "r398" ] }, "us-gaap_FinancialAssetAcquiredWithCreditDeteriorationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialAssetAcquiredWithCreditDeteriorationMember", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deteriorated credit quality", "label": "Financial Asset Acquired with Credit Deterioration [Member]", "documentation": "Financial asset acquired with deteriorated credit quality." } } }, "auth_ref": [ "r1016" ] }, "sbra_FinancialAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "FinancialAssetsAbstract", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets:", "label": "Financial Assets [Abstract]", "documentation": "Financial Assets" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentPerformanceStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentPerformanceStatusAxis", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument Performance Status [Axis]", "label": "Financial Instrument Performance Status [Axis]", "documentation": "Information by category of performance or non-performance status of financial instruments." } } }, "auth_ref": [ "r1023" ] }, "us-gaap_FinancialInstrumentPerformanceStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentPerformanceStatusDomain", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument Performance Status [Domain]", "label": "Financial Instrument Performance Status [Domain]", "documentation": "Category of performance or non-performance status of financial instruments, including but not limited to, financing receivables, loans, debt, and investments." } } }, "auth_ref": [] }, "us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialLiabilitiesFairValueDisclosureAbstract", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities:", "label": "Financial Liabilities Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinancingReceivableAllowanceForCreditLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancingReceivableAllowanceForCreditLosses", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails": { "parentTag": "us-gaap_NotesReceivableNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails", "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Allowance for loan losses", "periodStartLabel": "Balance at the beginning of the year", "periodEndLabel": "Balance at the end of the year", "label": "Financing Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement." } } }, "auth_ref": [ "r20", "r240", "r242", "r243", "r288", "r410", "r413", "r416", "r1063" ] }, "us-gaap_FinancingReceivableAllowanceForCreditLossesPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancingReceivableAllowanceForCreditLossesPeriodIncreaseDecrease", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for loan losses", "label": "Financing Receivable, Allowance for Credit Loss, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) in allowance for credit loss on financing receivable." } } }, "auth_ref": [ "r72", "r1022" ] }, "us-gaap_FinancingReceivableAllowanceForCreditLossesRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancingReceivableAllowanceForCreditLossesRollForward", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing Receivable, Allowance for Credit Loss [Roll Forward]", "label": "Financing Receivable, Allowance for Credit Loss [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancingReceivableAllowanceForCreditLossesWriteOffs", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Write-off of uncollectible balances", "label": "Financing Receivable, Allowance for Credit Loss, Writeoff", "documentation": "Amount of writeoff of financing receivable, charged against allowance for credit loss." } } }, "auth_ref": [ "r21", "r415", "r424", "r852" ] }, "sbra_FinancingReceivableAndOtherInvestmentsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "FinancingReceivableAndOtherInvestmentsNet", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loans receivable and other investments, net", "totalLabel": "Total Book Value", "label": "Financing Receivable And Other Investments, Net", "documentation": "Amount after allowance and deduction of deferred interest and fees, unamortized costs and premiums and discounts from face amounts, of loans and other investments held in portfolio, including but not limited to, commercial and consumer loans. Includes loans held for sale. Excludes loans and leases covered under loss sharing agreements." } } }, "auth_ref": [] }, "sbra_FinancingReceivableEffectiveInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "FinancingReceivableEffectiveInterestRate", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Annualized Effective Interest Rate / Rate of Return", "label": "Financing Receivable, Effective Interest Rate", "documentation": "Financing Receivable, Effective Interest Rate" } } }, "auth_ref": [] }, "sbra_FinancingReceivableFixedInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "FinancingReceivableFixedInterestRate", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Contractual Interest Rate / Rate of Return", "label": "Financing Receivable, Fixed Interest Rate", "documentation": "Financing Fixed Interest Rate" } } }, "auth_ref": [] }, "sbra_FinancingReceivableMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "FinancingReceivableMeasurementInput", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loans receivable, measurement input", "label": "Financing Receivable, Measurement Input", "documentation": "Financing Receivable, Measurement Input" } } }, "auth_ref": [] }, "sbra_FinancingReceivableNumberOfLoans": { "xbrltype": "integerItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "FinancingReceivableNumberOfLoans", "calculation": { "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails": { "parentTag": "sbra_NumberOfInvestments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quantity", "label": "Financing Receivable, Number Of Loans", "documentation": "Financing Receivable, Number Of Loans" } } }, "auth_ref": [] }, "sbra_FinancingReceivableNumberOfLoansImpaired": { "xbrltype": "integerItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "FinancingReceivableNumberOfLoansImpaired", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of loans receivable investments", "label": "Financing Receivable, Number Of Loans, Impaired", "documentation": "Financing Receivable, Number Of Loans, Impaired" } } }, "auth_ref": [] }, "sbra_FinancingReceivableNumberOfLoansNonaccrualStatus": { "xbrltype": "integerItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "FinancingReceivableNumberOfLoansNonaccrualStatus", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of loans receivable investments", "label": "Financing Receivable, Number Of Loans, Nonaccrual Status", "documentation": "Financing Receivable, Number Of Loans, Nonaccrual Status" } } }, "auth_ref": [] }, "sbra_FinancingReceivablePrincipalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "FinancingReceivablePrincipalAmount", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails": { "parentTag": "us-gaap_InvestmentOwnedBalancePrincipalAmount", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails", "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Principal balance", "terseLabel": "Principal balance", "netLabel": "Loans receivable", "label": "Financing Receivable, Principal Amount", "documentation": "Financing Receivable, Principal Amount" } } }, "auth_ref": [] }, "us-gaap_FinancingReceivableRecordedInvestmentNonaccrualStatus": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancingReceivableRecordedInvestmentNonaccrualStatus", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Book value", "label": "Financing Receivable, Nonaccrual", "documentation": "Amortized cost of financing receivable on nonaccrual status. Excludes net investment in lease." } } }, "auth_ref": [ "r76", "r241", "r242", "r418" ] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESIntangibleAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESIntangibleAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r280", "r443" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRemainingUnamortizedBalanceforOutstandingIntangibleAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRemainingUnamortizedBalanceforOutstandingIntangibleAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRemainingUnamortizedBalanceforOutstandingIntangibleAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRemainingUnamortizedBalanceforOutstandingIntangibleAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r193" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRemainingUnamortizedBalanceforOutstandingIntangibleAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRemainingUnamortizedBalanceforOutstandingIntangibleAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r193" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRemainingUnamortizedBalanceforOutstandingIntangibleAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRemainingUnamortizedBalanceforOutstandingIntangibleAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r193" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRemainingUnamortizedBalanceforOutstandingIntangibleAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRemainingUnamortizedBalanceforOutstandingIntangibleAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r193" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRemainingUnamortizedBalanceforOutstandingIntangibleAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRemainingUnamortizedBalanceforOutstandingIntangibleAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r193" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESIntangibleAssetsandLiabilitiesDetails", "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRealEstateIntangibleAmortizationDetails", "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails", "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r441", "r442", "r443", "r444", "r667", "r668" ] }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRemainingUnamortizedBalanceforOutstandingIntangibleAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Intangible Assets", "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESIntangibleAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESIntangibleAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Gross lease intangible assets", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r192", "r668" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESIntangibleAssetsandLiabilitiesDetails", "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRealEstateIntangibleAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r667" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESIntangibleAssetsandLiabilitiesDetails", "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRealEstateIntangibleAmortizationDetails", "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails", "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r79", "r80" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 }, "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESIntangibleAssetsandLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRemainingUnamortizedBalanceforOutstandingIntangibleAssetsandLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESIntangibleAssetsandLiabilitiesDetails", "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRemainingUnamortizedBalanceforOutstandingIntangibleAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease intangible assets, net", "totalLabel": "Lease intangible assets, net", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r192", "r667" ] }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNetAbstract", "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESIntangibleAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Intangible Assets:", "label": "Finite-Lived Intangible Assets, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRemainingUnamortizedBalanceforOutstandingIntangibleAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining amortization period", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r667" ] }, "us-gaap_FireMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FireMember", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fire", "label": "Fire [Member]", "documentation": "Oxidation process that releases energy in the form of light and heat (flames) and often creates smoke." } } }, "auth_ref": [] }, "sbra_FishkillNYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "FishkillNYMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fishkill, NY", "label": "Fishkill, NY [Member]", "documentation": "Fishkill, NY" } } }, "auth_ref": [] }, "sbra_FixedRateMortgagesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "FixedRateMortgagesMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed Rate", "label": "Fixed Rate Mortgages [Member]", "documentation": "Fixed Rate Mortgages [Member]" } } }, "auth_ref": [] }, "us-gaap_FixturesAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FixturesAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails": { "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture and equipment", "label": "Fixtures and Equipment, Gross", "documentation": "Amount before accumulated depreciation of fixtures and equipment. Includes, but is not limited to, machinery, equipment, and engines." } } }, "auth_ref": [] }, "sbra_FlorenceKYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "FlorenceKYMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Florence, KY", "label": "Florence, KY [Member]", "documentation": "Florence, KY" } } }, "auth_ref": [] }, "sbra_FlorenceWIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "FlorenceWIMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Florence, WI", "label": "Florence, WI [Member]", "documentation": "Florence, WI" } } }, "auth_ref": [] }, "us-gaap_ForeignCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCountryMember", "presentation": [ "http://www.sabrahealth.com/role/INCOMETAXESDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign", "label": "Foreign Tax Authority [Member]", "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile." } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r631" ] }, "us-gaap_ForeignExchangeContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignExchangeContractMember", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofIncomeandCondensedConsolidatedStatementsofEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency products", "label": "Foreign Exchange Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates." } } }, "auth_ref": [ "r844", "r868", "r875" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r908", "r920", "r930", "r956" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r908", "r920", "r930", "r956" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r908", "r920", "r930", "r956" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r908", "r920", "r930", "r956" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r908", "r920", "r930", "r956" ] }, "sbra_ForsythMOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ForsythMOMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forsyth, MO", "label": "Forsyth, MO [Member]", "documentation": "Forsyth, MO" } } }, "auth_ref": [] }, "sbra_FortWayneINMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "FortWayneINMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fort Wayne, IN", "label": "Fort Wayne, IN [Member]", "documentation": "Fort Wayne, IN" } } }, "auth_ref": [] }, "us-gaap_ForwardContractIndexedToIssuersEquityShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForwardContractIndexedToIssuersEquityShares", "presentation": [ "http://www.sabrahealth.com/role/EQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares allowed for forward feature of ATM Program (in shares)", "label": "Forward Contract Indexed to Issuer's Equity, Shares", "documentation": "The maximum number of shares that could be issued to net share settle a contract, if applicable. If a contract does not have a fixed or determinable maximum number of shares that may be required to be issued, disclose the fact that a potentially infinite number of shares could be issued to settle the contract." } } }, "auth_ref": [ "r133" ] }, "sbra_ForwardEquitySaleAgreementSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ForwardEquitySaleAgreementSharesMember", "presentation": [ "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHARENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forward Equity Sale Agreements", "label": "Forward Equity Sale Agreement Shares [Member]", "documentation": "Forward Equity Sale Agreement Shares" } } }, "auth_ref": [] }, "sbra_ForwardStartingInterestRateSwapsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ForwardStartingInterestRateSwapsMember", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSSummaryofDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forward starting interest rate swaps", "label": "Forward Starting Interest Rate Swaps [Member]", "documentation": "Forward Starting Interest Rate Swaps [Member]" } } }, "auth_ref": [] }, "sbra_FrankenmuthMIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "FrankenmuthMIMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Frankenmuth, MI", "label": "Frankenmuth, MI [Member]", "documentation": "Frankenmuth, MI" } } }, "auth_ref": [] }, "sbra_FranklinNHMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "FranklinNHMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Franklin, NH", "label": "Franklin, NH [Member]", "documentation": "Franklin, NH" } } }, "auth_ref": [] }, "sbra_FredericksburgVAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "FredericksburgVAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fredericksburg, VA", "label": "Fredericksburg, VA [Member]", "documentation": "Fredericksburg, VA" } } }, "auth_ref": [] }, "sbra_FremontNE1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "FremontNE1Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fremont, NE 1", "label": "Fremont, NE 1 [Member]", "documentation": "Fremont, NE 1" } } }, "auth_ref": [] }, "sbra_FremontNE2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "FremontNE2Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fremont, NE 2", "label": "Fremont, NE 2 [Member]", "documentation": "Fremont, NE 2" } } }, "auth_ref": [] }, "sbra_FremontNEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "FremontNEMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fremont, NE", "label": "Fremont, NE [Member]", "documentation": "Fremont, NE" } } }, "auth_ref": [] }, "sbra_FundingPaymentsBeyondContractualRequirement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "FundingPaymentsBeyondContractualRequirement", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialInformationforEnlivantJointVentureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Funding payments beyond contractual requirements", "label": "Funding Payments, Beyond Contractual Requirement", "documentation": "Funding Payments, Beyond Contractual Requirement" } } }, "auth_ref": [] }, "sbra_FundsFromOperationsUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "FundsFromOperationsUnitsMember", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "FFO Units", "label": "Funds From Operations Units [Member]", "documentation": "Funds From Operations Units [Member]" } } }, "auth_ref": [] }, "sbra_FurnitureAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "FurnitureAndEquipmentMember", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture and equipment", "label": "Furniture and Equipment [Member]", "documentation": "Furniture and Equipment [Member]" } } }, "auth_ref": [] }, "sbra_FutureFundingOnInvestmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "FutureFundingOnInvestmentMember", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future funding on investment", "label": "Future Funding On Investment [Member]", "documentation": "Future Funding On Investment" } } }, "auth_ref": [] }, "us-gaap_GainOnBusinessInterruptionInsuranceRecovery": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainOnBusinessInterruptionInsuranceRecovery", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain of unusual amount", "label": "Gain on Business Interruption Insurance Recovery", "documentation": "The net amount (to the extent disclosed within this portion of the income statement) by which an insurance settlement exceeds incremental costs incurred from the event causing an interruption of business, plus the insurance award for earnings lost from the event, such as a natural catastrophe, explosion or fire." } } }, "auth_ref": [ "r182" ] }, "us-gaap_GainOnBusinessInterruptionInsuranceRecoveryStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainOnBusinessInterruptionInsuranceRecoveryStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on business interruption insurance recovery, statement of income or comprehensive income", "label": "Gain on Business Interruption Insurance Recovery, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes gain from business interruption insurance recovery." } } }, "auth_ref": [ "r313" ] }, "sbra_GainesvilleFLMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "GainesvilleFLMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gainesville, FL", "label": "Gainesville, FL [Member]", "documentation": "Gainesville, FL" } } }, "auth_ref": [] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 }, "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS", "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessNarrativeDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss on extinguishment of debt", "negatedTerseLabel": "Loss on extinguishment of debt", "negatedLabel": "Loss on extinguishment of debt", "label": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r14", "r83", "r84" ] }, "us-gaap_GainsLossesOnSalesOfInvestmentRealEstate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnSalesOfInvestmentRealEstate", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 }, "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Net (loss) gain on sales of real estate", "negatedLabel": "Net loss (gain) on sales of real estate", "label": "Gains (Losses) on Sales of Investment Real Estate", "documentation": "The net gain (loss) resulting from sales and other disposals of real estate owned for investment purposes." } } }, "auth_ref": [ "r228", "r230", "r231", "r998", "r999", "r1002", "r1064", "r1073" ] }, "sbra_GalionOHMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "GalionOHMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Galion, OH", "label": "Galion, OH [Member]", "documentation": "Galion, OH" } } }, "auth_ref": [] }, "sbra_GarlandTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "GarlandTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Garland, TX", "label": "Garland, TX [Member]", "documentation": "Garland, TX" } } }, "auth_ref": [] }, "sbra_GasCityINMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "GasCityINMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gas City, IN", "label": "Gas City, IN [Member]", "documentation": "Gas City, IN" } } }, "auth_ref": [] }, "sbra_GaylordMIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "GaylordMIMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gaylord, MI", "label": "Gaylord, MI [Member]", "documentation": "Gaylord, MI" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": { "parentTag": "sbra_OperatingAndInterestExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r177", "r767" ] }, "sbra_GilmerTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "GilmerTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gilmer, TX", "label": "Gilmer, TX [Member]", "documentation": "Gilmer, TX" } } }, "auth_ref": [] }, "sbra_GilroyCAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "GilroyCAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gilroy, CA", "label": "Gilroy, CA [Member]", "documentation": "Gilroy, CA" } } }, "auth_ref": [] }, "sbra_GladstoneORMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "GladstoneORMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gladstone, OR", "label": "Gladstone, OR [Member]", "documentation": "Gladstone, OR" } } }, "auth_ref": [] }, "sbra_GlasgowKYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "GlasgowKYMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Glasgow, KY", "label": "Glasgow, KY [Member]", "documentation": "Glasgow, KY" } } }, "auth_ref": [] }, "sbra_GlendaleAZMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "GlendaleAZMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Glendale, AZ", "label": "Glendale, AZ [Member]", "documentation": "Glendale, AZ" } } }, "auth_ref": [] }, "sbra_GlenvilleNYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "GlenvilleNYMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Glenville, NY", "label": "Glenville, NY [Member]", "documentation": "Glenville, NY" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "sbra_GovernmentGrantsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "GovernmentGrantsPolicyPolicyTextBlock", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Government Grants", "label": "Government Grants, Policy [Policy Text Block]", "documentation": "Government Grants, Policy" } } }, "auth_ref": [] }, "sbra_GrandTerraceCAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "GrandTerraceCAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Grand Terrace, CA", "label": "Grand Terrace, CA [Member]", "documentation": "Grand Terrace, CA" } } }, "auth_ref": [] }, "sbra_GrantIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "GrantIncome", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Grants recognized", "label": "Grant Income", "documentation": "Grant Income" } } }, "auth_ref": [] }, "sbra_GreenBayWIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "GreenBayWIMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Green Bay, WI", "label": "Green Bay, WI [Member]", "documentation": "Green Bay, WI" } } }, "auth_ref": [] }, "sbra_GreenvilleMIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "GreenvilleMIMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Greenville, MI", "label": "Greenville, MI [Member]", "documentation": "Greenville, MI" } } }, "auth_ref": [] }, "sbra_GreenvilleSCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "GreenvilleSCMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Greenville, SC", "label": "Greenville, SC [Member]", "documentation": "Greenville, SC" } } }, "auth_ref": [] }, "sbra_GulfBreezeFLMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "GulfBreezeFLMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gulf Breeze, FL", "label": "Gulf Breeze, FL [Member]", "documentation": "Gulf Breeze, FL" } } }, "auth_ref": [] }, "sbra_HagerstownMDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "HagerstownMDMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hagerstown, MD", "label": "Hagerstown, MD [Member]", "documentation": "Hagerstown, MD" } } }, "auth_ref": [] }, "sbra_HamburgNYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "HamburgNYMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hamburg, NY", "label": "Hamburg, NY [Member]", "documentation": "Hamburg, NY" } } }, "auth_ref": [] }, "sbra_HarrodsburgKYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "HarrodsburgKYMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Harrodsburg, KY", "label": "Harrodsburg, KY [Member]", "documentation": "Harrodsburg, KY" } } }, "auth_ref": [] }, "sbra_HarrogateTNMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "HarrogateTNMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Harrogate, TN", "label": "Harrogate, TN [Member]", "documentation": "Harrogate, TN" } } }, "auth_ref": [] }, "sbra_HartfordKYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "HartfordKYMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hartford, KY", "label": "Hartford, KY [Member]", "documentation": "Hartford, KY" } } }, "auth_ref": [] }, "sbra_HealthCareResidentServiceAncillaryServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "HealthCareResidentServiceAncillaryServiceMember", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSeniorHousingManagedCommunitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ancillary services", "label": "Health Care, Resident Service, Ancillary Service [Member]", "documentation": "Health Care, Resident Service, Ancillary Service [Member]" } } }, "auth_ref": [] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationAxis", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountsofDerivativeInstrumentsDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSSummaryofDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r25", "r606" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationDomain", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountsofDerivativeInstrumentsDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSSummaryofDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r25" ] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingRelationshipDomain", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountsofDerivativeInstrumentsDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSSummaryofDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": [ "r25" ] }, "sbra_HendersonNVMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "HendersonNVMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Henderson, NV", "label": "Henderson, NV [Member]", "documentation": "Henderson, NV" } } }, "auth_ref": [] }, "sbra_HendersonvilleNCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "HendersonvilleNCMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hendersonville, NC", "label": "Hendersonville, NC [Member]", "documentation": "Hendersonville, NC" } } }, "auth_ref": [] }, "sbra_HighlandNYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "HighlandNYMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Highland, NY", "label": "Highland, NY [Member]", "documentation": "Highland, NY" } } }, "auth_ref": [] }, "sbra_HillsboroORMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "HillsboroORMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hillsboro, OR", "label": "Hillsboro, OR [Member]", "documentation": "Hillsboro, OR" } } }, "auth_ref": [] }, "sbra_HopkinsMNMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "HopkinsMNMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hopkins, MN", "label": "Hopkins, MN [Member]", "documentation": "Hopkins, MN" } } }, "auth_ref": [] }, "sbra_HorseCaveKYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "HorseCaveKYMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Horse Cave, KY", "label": "Horse Cave, KY [Member]", "documentation": "Horse Cave, KY" } } }, "auth_ref": [] }, "sbra_HoustonTX1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "HoustonTX1Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Houston, TX 1", "label": "Houston, TX 1 [Member]", "documentation": "Houston, TX 1" } } }, "auth_ref": [] }, "sbra_HoustonTX2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "HoustonTX2Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Houston, TX 2", "label": "Houston, TX 2 [Member]", "documentation": "Houston, TX 2" } } }, "auth_ref": [] }, "sbra_HoustonTX3Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "HoustonTX3Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Houston, TX 3", "label": "Houston, TX 3 [Member]", "documentation": "Houston, TX 3" } } }, "auth_ref": [] }, "sbra_HoustonTX4Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "HoustonTX4Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Houston, TX 4", "label": "Houston, TX 4 [Member]", "documentation": "Houston, TX 4" } } }, "auth_ref": [] }, "sbra_HoustonTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "HoustonTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Houston, TX", "label": "Houston, TX [Member]", "documentation": "Houston, TX" } } }, "auth_ref": [] }, "sbra_HumbleTX1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "HumbleTX1Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Humble, TX 1", "label": "Humble, TX 1 [Member]", "documentation": "Humble, TX 1" } } }, "auth_ref": [] }, "sbra_HumbleTX2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "HumbleTX2Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Humble, TX 2", "label": "Humble, TX 2 [Member]", "documentation": "Humble, TX 2" } } }, "auth_ref": [] }, "sbra_HuntingtonBchCAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "HuntingtonBchCAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Huntington Bch, CA", "label": "Huntington Bch, CA [Member]", "documentation": "Huntington Bch, CA" } } }, "auth_ref": [] }, "sbra_HuntsvilleALMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "HuntsvilleALMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Huntsville, AL", "label": "Huntsville, AL [Member]", "documentation": "Huntsville, AL" } } }, "auth_ref": [] }, "sbra_HuntsvilleTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "HuntsvilleTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Huntsville, TX", "label": "Huntsville, TX [Member]", "documentation": "Huntsville, TX" } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r898", "r899", "r912" ] }, "us-gaap_ImpairmentOfRealEstate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfRealEstate", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": { "parentTag": "sbra_OperatingAndInterestExpense", "weight": 1.0, "order": 6.0 }, "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS", "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of real estate", "verboseLabel": "Impairment of real estate", "label": "Impairment of Real Estate", "documentation": "The charge against earnings in the period to reduce the carrying amount of real property to fair value." } } }, "auth_ref": [ "r1002", "r1026" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Income before loss from unconsolidated joint ventures and income tax expense", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments." } } }, "auth_ref": [ "r362", "r381", "r387", "r389", "r688", "r849" ] }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialInformationforEnlivantJointVentureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r210", "r324", "r333", "r362", "r381", "r387", "r389", "r404", "r457", "r458", "r460", "r461", "r462", "r464", "r466", "r468", "r469", "r619", "r630", "r683", "r849", "r1032" ] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss from unconsolidated joint ventures", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r14", "r175", "r219", "r369", "r399", "r682" ] }, "sbra_IncomeLossFromEquityMethodInvestmentsAndOtherThanTemporaryImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "IncomeLossFromEquityMethodInvestmentsAndOtherThanTemporaryImpairment", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 }, "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialInformationforEnlivantJointVentureDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialInformationforEnlivantJointVentureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss from unconsolidated joint ventures", "totalLabel": "Loss from unconsolidated joint venture", "label": "Income (Loss) From Equity Method Investments And Other Than Temporary Impairment", "documentation": "Income (Loss) From Equity Method Investments And Other Than Temporary Impairment" } } }, "auth_ref": [] }, "sbra_IncomeLossFromEquityMethodInvestmentsBasisAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "IncomeLossFromEquityMethodInvestmentsBasisAdjustments", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialInformationforEnlivantJointVentureDetails": { "parentTag": "sbra_IncomeLossFromEquityMethodInvestmentsAndOtherThanTemporaryImpairment", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialInformationforEnlivantJointVentureDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Basis adjustments", "label": "Income (Loss) From Equity Method Investments, Basis Adjustments", "documentation": "Income (Loss) From Equity Method Investments, Basis Adjustments" } } }, "auth_ref": [] }, "sbra_IncomeLossFromEquityMethodInvestmentsBeforeBasisAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "IncomeLossFromEquityMethodInvestmentsBeforeBasisAdjustments", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialInformationforEnlivantJointVentureDetails": { "parentTag": "sbra_IncomeLossFromEquityMethodInvestmentsAndOtherThanTemporaryImpairment", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialInformationforEnlivantJointVentureDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Company\u2019s share of net loss", "label": "Income (Loss) From Equity Method Investments, Before Basis Adjustments", "documentation": "Income (Loss) From Equity Method Investments, Before Basis Adjustments" } } }, "auth_ref": [] }, "sbra_IncomeLossFromEquityMethodInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "IncomeLossFromEquityMethodInvestmentsMember", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss from unconsolidated joint venture", "label": "Income (Loss) From Equity Method Investments [Member]", "documentation": "Income (Loss) From Equity Method Investments" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialInformationforEnlivantJointVentureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "verboseLabel": "Income Statement Amounts", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Axis]", "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r871", "r872" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]", "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r19", "r29", "r40", "r152", "r153", "r154", "r155", "r156", "r157", "r159", "r160", "r161", "r197" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r446", "r448", "r768" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r448", "r768" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.sabrahealth.com/role/INCOMETAXESDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority [Axis]", "label": "Income Tax Authority [Axis]", "documentation": "Information by tax jurisdiction." } } }, "auth_ref": [ "r22" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://www.sabrahealth.com/role/INCOMETAXESDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Authority [Domain]", "label": "Income Tax Authority [Domain]", "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.sabrahealth.com/role/INCOMETAXES" ], "lang": { "en-us": { "role": { "terseLabel": "INCOME TAXES", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r325", "r574", "r578", "r579", "r585", "r589", "r591", "r592", "r593", "r721" ] }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest and penalties from significant uncertain tax positions", "label": "Income Tax Examination, Penalties and Interest Expense", "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations." } } }, "auth_ref": [ "r1041" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 3.0 }, "http://www.sabrahealth.com/role/INCOMETAXESProvisionforIncomeTaxExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS", "http://www.sabrahealth.com/role/INCOMETAXESProvisionforIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income tax expense", "totalLabel": "Income tax expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r227", "r239", "r341", "r342", "r370", "r577", "r590", "r689" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r304", "r575", "r576", "r579", "r580", "r584", "r586", "r716" ] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes paid", "label": "Income Taxes Paid", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income." } } }, "auth_ref": [ "r59", "r62" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued liabilities", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r13" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accounts receivable, prepaid expenses and other assets, net", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r13" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHAREComputationofBasicandDilutedEarningsPerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHAREComputationofBasicandDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dilutive restricted stock units (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r347", "r348", "r349", "r353", "r532" ] }, "sbra_IndianapolisINMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "IndianapolisINMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indianapolis, IN", "label": "Indianapolis, IN [Member]", "documentation": "Indianapolis, IN" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r911", "r920", "r930", "r947", "r956", "r960", "r968" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r966" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r900", "r972" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r900", "r972" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r900", "r972" ] }, "sbra_IntangibleAssetsAndIntangibleLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "IntangibleAssetsAndIntangibleLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIES" ], "lang": { "en-us": { "role": { "terseLabel": "INTANGIBLE ASSETS AND LIABILITIES", "label": "Intangible Assets And Intangible Liabilities Disclosure [Text Block]", "documentation": "Intangible Assets And Intangible Liabilities Disclosure" } } }, "auth_ref": [] }, "us-gaap_InterestAndFeeIncomeLoansAndLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestAndFeeIncomeLoansAndLeases", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Interest and other income", "label": "Interest and Fee Income, Loans and Leases", "documentation": "The aggregate interest and fee income generated by: (1) loans the Entity has positive intent and ability to hold for the foreseeable future, or until maturity or payoff, including commercial and consumer loans, whether domestic or foreign, which may consist of: (a) industrial and agricultural; (b) real estate; and (c) real estate construction loans; (d) trade financing; (e) lease financing; (f) home equity lines-of-credit; (g) automobile and other vehicle loans; and (h) credit card and other revolving-type loans and (2) loans and leases held-for-sale which may include mortgage loans, direct financing, and sales-type leases." } } }, "auth_ref": [ "r221" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebt", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": { "parentTag": "sbra_OperatingAndInterestExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS", "http://www.sabrahealth.com/role/DEBTInterestExpenseNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest", "verboseLabel": "Interest expense", "label": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r178", "r490", "r500", "r858", "r859" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Interest paid", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r315", "r318", "r319" ] }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/DEBTInterestExpenseNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest", "label": "Interest Payable", "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables." } } }, "auth_ref": [ "r146", "r1066" ] }, "sbra_InterestRateCollarMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "InterestRateCollarMember", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSSummaryofDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate collars", "verboseLabel": "Interest rate collars", "label": "Interest Rate Collar [Member]", "documentation": "Interest Rate Collar" } } }, "auth_ref": [] }, "us-gaap_InterestRateContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateContractMember", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofIncomeandCondensedConsolidatedStatementsofEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate products", "label": "Interest Rate Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate." } } }, "auth_ref": [ "r837", "r844", "r868" ] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateSwapMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountsofDerivativeInstrumentsDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSSummaryofDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESItemsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate swaps", "verboseLabel": "Interest rate swaps", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": [ "r837", "r888", "r889" ] }, "sbra_InterestRateSwapOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "InterestRateSwapOneMember", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountsofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap One", "label": "Interest Rate Swap One [Member]", "documentation": "Interest Rate Swap One" } } }, "auth_ref": [] }, "sbra_InterestRateSwapTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "InterestRateSwapTwoMember", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountsofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swap Two", "label": "Interest Rate Swap Two [Member]", "documentation": "Interest Rate Swap Two" } } }, "auth_ref": [] }, "us-gaap_InventoryRealEstatePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRealEstatePolicy", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate Investments, Inventory", "label": "Inventory, Real Estate, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for capitalizing costs incurred as inventory, determining carrying values, recognizing impairment; and the timing of and methods used for charging inventory to cost of sales." } } }, "auth_ref": [ "r1" ] }, "us-gaap_InvestmentOwnedBalancePrincipalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentOwnedBalancePrincipalAmount", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total Principal Balance", "label": "Investment Owned, Balance, Principal Amount", "documentation": "Amount of principal of investment owned." } } }, "auth_ref": [ "r725", "r734", "r789", "r795", "r809", "r883" ] }, "sbra_InvestmentsWeightedAverageContractualRate": { "xbrltype": "percentItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "InvestmentsWeightedAverageContractualRate", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total weighted average contractual interest rate / rate of return", "label": "Investments, Weighted Average Contractual Rate", "documentation": "Investments, Weighted Average Contractual Rate" } } }, "auth_ref": [] }, "sbra_InvestmentsWeightedAverageEffectiveRate": { "xbrltype": "percentItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "InvestmentsWeightedAverageEffectiveRate", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total weighted average annualized effective interest rate / rate of return", "label": "Investments, Weighted Average Effective Rate", "documentation": "Investments, Weighted Average Effective Rate" } } }, "auth_ref": [] }, "sbra_IssaquahWAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "IssaquahWAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issaquah, WA", "label": "Issaquah, WA [Member]", "documentation": "Issaquah, WA" } } }, "auth_ref": [] }, "sbra_JasperINMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "JasperINMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Jasper, IN", "label": "Jasper, IN [Member]", "documentation": "Jasper, IN" } } }, "auth_ref": [] }, "sbra_JonesboroARMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "JonesboroARMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Jonesboro, AR", "label": "Jonesboro, AR [Member]", "documentation": "Jonesboro, AR" } } }, "auth_ref": [] }, "sbra_JunctionCityORMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "JunctionCityORMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Junction City, OR", "label": "Junction City, OR [Member]", "documentation": "Junction City, OR" } } }, "auth_ref": [] }, "sbra_KamloopsBCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "KamloopsBCMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kamloops, BC", "label": "Kamloops, BC [Member]", "documentation": "Kamloops, BC" } } }, "auth_ref": [] }, "sbra_KansasCityMOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "KansasCityMOMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kansas City, MO", "label": "Kansas City, MO [Member]", "documentation": "Kansas City, MO" } } }, "auth_ref": [] }, "sbra_KeeneNHMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "KeeneNHMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Keene, NH", "label": "Keene, NH [Member]", "documentation": "Keene, NH" } } }, "auth_ref": [] }, "sbra_KeizerORMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "KeizerORMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Keizer, OR", "label": "Keizer, OR [Member]", "documentation": "Keizer, OR" } } }, "auth_ref": [] }, "sbra_KelownaBCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "KelownaBCMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kelowna, BC", "label": "Kelowna, BC [Member]", "documentation": "Kelowna, BC" } } }, "auth_ref": [] }, "sbra_KennebunkMEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "KennebunkMEMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kennebunk, ME", "label": "Kennebunk, ME [Member]", "documentation": "Kennebunk, ME" } } }, "auth_ref": [] }, "sbra_KingsburyTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "KingsburyTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kingsbury, TX", "label": "Kingsbury, TX [Member]", "documentation": "Kingsbury, TX" } } }, "auth_ref": [] }, "sbra_KinstonNCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "KinstonNCMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kinston, NC", "label": "Kinston, NC [Member]", "documentation": "Kinston, NC" } } }, "auth_ref": [] }, "sbra_KirbyvilleTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "KirbyvilleTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Kirbyville, TX", "label": "Kirbyville, TX [Member]", "documentation": "Kirbyville, TX" } } }, "auth_ref": [] }, "sbra_KnoxvilleTNMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "KnoxvilleTNMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Knoxville, TN", "label": "Knoxville, TN [Member]", "documentation": "Knoxville, TN" } } }, "auth_ref": [] }, "sbra_LaMesaCAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LaMesaCAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "La Mesa, CA", "label": "La Mesa, CA [Member]", "documentation": "La Mesa, CA" } } }, "auth_ref": [] }, "sbra_LafayetteCOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LafayetteCOMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lafayette, CO", "label": "Lafayette, CO [Member]", "documentation": "Lafayette, CO" } } }, "auth_ref": [] }, "sbra_LakeOswegoORMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LakeOswegoORMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lake Oswego, OR", "label": "Lake Oswego, OR [Member]", "documentation": "Lake Oswego, OR" } } }, "auth_ref": [] }, "sbra_LakeStevensWAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LakeStevensWAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lake Stevens, WA", "label": "Lake Stevens, WA [Member]", "documentation": "Lake Stevens, WA" } } }, "auth_ref": [] }, "sbra_LancasterMAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LancasterMAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lancaster, MA", "label": "Lancaster, MA [Member]", "documentation": "Lancaster, MA" } } }, "auth_ref": [] }, "sbra_LancasterTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LancasterTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lancaster, TX", "label": "Lancaster, TX [Member]", "documentation": "Lancaster, TX" } } }, "auth_ref": [] }, "us-gaap_Land": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Land", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails": { "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land", "label": "Land", "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale." } } }, "auth_ref": [ "r994" ] }, "us-gaap_LandImprovements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LandImprovements", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails": { "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land improvements", "label": "Land Improvements", "documentation": "Amount before accumulated depreciation and depletion of additions or improvements to real estate held for productive use. Examples include, but are not limited to, walkways, driveways, fences, and parking lots." } } }, "auth_ref": [] }, "us-gaap_LandImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LandImprovementsMember", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land improvements", "label": "Land Improvements [Member]", "documentation": "Additions or improvements to real estate held." } } }, "auth_ref": [] }, "sbra_LasVegasNV1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LasVegasNV1Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Las Vegas, NV 1", "label": "Las Vegas, NV 1 [Member]", "documentation": "Las Vegas, NV 1" } } }, "auth_ref": [] }, "sbra_LasVegasNV2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LasVegasNV2Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Las Vegas, NV 2", "label": "Las Vegas, NV 2 [Member]", "documentation": "Las Vegas, NV 2" } } }, "auth_ref": [] }, "sbra_LawrenceKSMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LawrenceKSMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lawrence, KS", "label": "Lawrence, KS [Member]", "documentation": "Lawrence, KS" } } }, "auth_ref": [] }, "sbra_LawrenceburgKYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LawrenceburgKYMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lawrenceburg, KY", "label": "Lawrenceburg, KY [Member]", "documentation": "Lawrenceburg, KY" } } }, "auth_ref": [] }, "sbra_LebanonINMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LebanonINMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lebanon, IN", "label": "Lebanon, IN [Member]", "documentation": "Lebanon, IN" } } }, "auth_ref": [] }, "sbra_LebanonORMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LebanonORMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lebanon, OR", "label": "Lebanon, OR [Member]", "documentation": "Lebanon, OR" } } }, "auth_ref": [] }, "sbra_LecantoFLMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LecantoFLMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lecanto, FL", "label": "Lecanto, FL [Member]", "documentation": "Lecanto, FL" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESScheduleofInvestmentinJointVenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee Accounting", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r646" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Minimum Lease Payments", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1052" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Undiscounted minimum lease payments included in the lease liability", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r649" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r649" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r649" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r649" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r649" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r649" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r649" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r649" ] }, "sbra_LessorAnnualBaseRent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LessorAnnualBaseRent", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual base rent", "label": "Lessor, Annual Base Rent", "documentation": "Lessor, Annual Base Rent" } } }, "auth_ref": [] }, "us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsFiscalYearMaturityAbstract", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESFutureMinimumRentalPaymentsfromNonCancelableOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future minimum rental payments from the Company\u2019s properties held for investment under non-cancelable operating leases:", "label": "Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceived", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESFutureMinimumRentalPaymentsfromNonCancelableOperatingLeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESFutureMinimumRentalPaymentsfromNonCancelableOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Lessor, Operating Lease, Payment to be Received", "documentation": "Amount of lease payments to be received by lessor for operating lease." } } }, "auth_ref": [ "r651" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedFiveYears", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESFutureMinimumRentalPaymentsfromNonCancelableOperatingLeasesDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESFutureMinimumRentalPaymentsfromNonCancelableOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessor, Operating Lease, Payment to be Received, Year Five", "documentation": "Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r651" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESFutureMinimumRentalPaymentsfromNonCancelableOperatingLeasesDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESFutureMinimumRentalPaymentsfromNonCancelableOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessor, Operating Lease, Payment to be Received, Year Four", "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r651" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Minimum Rental Payments from Non-Cancelable Operating Leases", "label": "Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block]", "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease." } } }, "auth_ref": [ "r1053" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESFutureMinimumRentalPaymentsfromNonCancelableOperatingLeasesDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESFutureMinimumRentalPaymentsfromNonCancelableOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessor, Operating Lease, Payment to be Received, Year One", "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r651" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedThereafter", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESFutureMinimumRentalPaymentsfromNonCancelableOperatingLeasesDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESFutureMinimumRentalPaymentsfromNonCancelableOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessor, Operating Lease, Payment to be Received, after Year Five", "documentation": "Amount of lease payment to be received by lessor for operating lease after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r651" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESFutureMinimumRentalPaymentsfromNonCancelableOperatingLeasesDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESFutureMinimumRentalPaymentsfromNonCancelableOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessor, Operating Lease, Payment to be Received, Year Three", "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r651" ] }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESFutureMinimumRentalPaymentsfromNonCancelableOperatingLeasesDetails": { "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESFutureMinimumRentalPaymentsfromNonCancelableOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessor, Operating Lease, Payment to be Received, Year Two", "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r651" ] }, "us-gaap_LessorOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorOperatingLeaseTermOfContract", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease expiration period", "label": "Lessor, Operating Lease, Term of Contract", "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1054" ] }, "sbra_LessorSalesTypeLeaseNumberOfProperties": { "xbrltype": "integerItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LessorSalesTypeLeaseNumberOfProperties", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESNetInvestmentinSalesTypeLeaseNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Properties in sales-type", "label": "Lessor, Sales-Type Lease, Number of Properties", "documentation": "Lessor, Sales-Type Lease, Number of Properties" } } }, "auth_ref": [] }, "sbra_LettersOfCreditDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LettersOfCreditDeposits", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letters of credit deposited", "label": "Letters Of Credit Deposits", "documentation": "Letters Of Credit Deposits" } } }, "auth_ref": [] }, "sbra_LewisburgWVMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LewisburgWVMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lewisburg, WV", "label": "Lewisburg, WV [Member]", "documentation": "Lewisburg, WV" } } }, "auth_ref": [] }, "sbra_LexingtonKYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LexingtonKYMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lexington, KY", "label": "Lexington, KY [Member]", "documentation": "Lexington, KY" } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialInformationforEnlivantJointVentureDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "verboseLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r42", "r324", "r404", "r457", "r458", "r460", "r461", "r462", "r464", "r466", "r468", "r469", "r597", "r599", "r600", "r630", "r743", "r848", "r893", "r1032", "r1055", "r1056" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r171", "r218", "r681", "r878", "r1005", "r1019", "r1048" ] }, "sbra_LincolnNEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LincolnNEMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lincoln, NE", "label": "Lincoln, NE [Member]", "documentation": "Lincoln, NE" } } }, "auth_ref": [] }, "sbra_LincolntonNCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LincolntonNCMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lincolnton, NC", "label": "Lincolnton, NC [Member]", "documentation": "Lincolnton, NC" } } }, "auth_ref": [] }, "sbra_LindenTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LindenTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Linden, TX", "label": "Linden, TX [Member]", "documentation": "Linden, TX" } } }, "auth_ref": [] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCredit", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving credit facility", "label": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r39", "r217", "r1067" ] }, "us-gaap_LineOfCreditFacilityCapacityAvailableForTradePurchases": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityCapacityAvailableForTradePurchases", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available borrowing capacity", "label": "Line of Credit Facility, Capacity Available for Trade Purchases", "documentation": "The maximum amount of borrowing capacity under a line of credit that is available as of the balance sheet date for financing purchases of goods acquired for inventory or imminent delivery to a customer." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate", "label": "Line of Credit Facility, Interest Rate at Period End", "documentation": "The effective interest rate at the end of the reporting period." } } }, "auth_ref": [ "r41" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r41" ] }, "sbra_LineOfCreditFacilityMaximumBorrowingCapacityForeignCurrency": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LineOfCreditFacilityMaximumBorrowingCapacityForeignCurrency", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowing capacity in certain foreign currencies", "label": "Line Of Credit Facility, Maximum Borrowing Capacity, Foreign Currency", "documentation": "Line Of Credit Facility, Maximum Borrowing Capacity, Foreign Currency" } } }, "auth_ref": [] }, "sbra_LineOfCreditFacilityNumberOfExtensionOptions": { "xbrltype": "integerItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LineOfCreditFacilityNumberOfExtensionOptions", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of extension options", "label": "Line Of Credit Facility, Number Of Extension Options", "documentation": "Line Of Credit Facility, Number Of Extension Options" } } }, "auth_ref": [] }, "sbra_LineOfCreditFacilityOptionalExtensionPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LineOfCreditFacilityOptionalExtensionPeriod", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Extension period", "label": "Line Of Credit Facility, Optional Extension Period", "documentation": "Line Of Credit Facility, Optional Extension Period" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annum percent unused borrowing fee", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "LOANS RECEIVABLE AND OTHER INVESTMENTS", "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]", "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses." } } }, "auth_ref": [ "r1015" ] }, "us-gaap_LoansPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoansPayableMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loans", "label": "Loans Payable [Member]", "documentation": "Borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [] }, "us-gaap_LoansPayableToBank": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoansPayableToBank", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Term loans, net", "label": "Loans Payable to Bank", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of loans from a bank with maturities initially due after one year or beyond the normal operating cycle if longer." } } }, "auth_ref": [ "r39", "r217", "r1067" ] }, "sbra_LoansPayableToBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LoansPayableToBankMember", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSSummaryofDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term loans, net", "label": "Loans Payable To Bank [Member]", "documentation": "Loans Payable To Bank [Member]" } } }, "auth_ref": [] }, "us-gaap_LoansReceivableFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoansReceivableFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loans receivable", "label": "Loans Receivable, Fair Value Disclosure", "documentation": "Fair value portion of loan receivable, including, but not limited to, mortgage loans held for investment, finance receivables held for investment, policy loans on insurance contracts." } } }, "auth_ref": [ "r71" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "sbra_LodiCAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LodiCAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lodi, CA", "label": "Lodi, CA [Member]", "documentation": "Lodi, CA" } } }, "auth_ref": [] }, "sbra_LomitaCAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LomitaCAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lomita, CA", "label": "Lomita, CA [Member]", "documentation": "Lomita, CA" } } }, "auth_ref": [] }, "sbra_LondonInterbankOfferedRateLIBOR1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LondonInterbankOfferedRateLIBOR1Member", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "LIBOR", "label": "London Interbank Offered Rate (LIBOR) 1 [Member]", "documentation": "London Interbank Offered Rate (LIBOR) 1" } } }, "auth_ref": [] }, "sbra_LondonONMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LondonONMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "London, ON", "label": "London, ON [Member]", "documentation": "London, ON" } } }, "auth_ref": [] }, "sbra_LongBeachCA1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LongBeachCA1Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long Beach, CA 1", "label": "Long Beach, CA 1 [Member]", "documentation": "Long Beach, CA 1" } } }, "auth_ref": [] }, "sbra_LongBeachCA2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LongBeachCA2Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long Beach, CA 2", "label": "Long Beach, CA 2 [Member]", "documentation": "Long Beach, CA 2" } } }, "auth_ref": [] }, "sbra_LongBeachCA3Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LongBeachCA3Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long Beach, CA 3", "label": "Long Beach, CA 3 [Member]", "documentation": "Long Beach, CA 3" } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total Debt, Net", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r39", "r217", "r483", "r498", "r856", "r857", "r1067" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Long-Term Debt, Maturity, after Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r17", "r329", "r1038" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r17", "r329", "r488" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Long-Term Debt, Maturity, Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r17", "r329", "r488" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r17", "r329", "r488" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r17", "r329", "r488" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r17", "r329", "r488" ] }, "sbra_LongTermLineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LongTermLineOfCreditMember", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSSummaryofDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving credit facility", "label": "Long-Term Line Of Credit [Member]", "documentation": "Long-Term Line Of Credit" } } }, "auth_ref": [] }, "us-gaap_LongtermDebtPercentageBearingFixedInterestAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtPercentageBearingFixedInterestAmount", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal balance", "label": "Long-Term Debt, Percentage Bearing Fixed Interest, Amount", "documentation": "The portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate." } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails", "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessDetails", "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessNarrativeDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails", "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r44" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails", "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessDetails", "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessNarrativeDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails", "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r44", "r82" ] }, "sbra_LongviewTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LongviewTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Longview, TX", "label": "Longview, TX [Member]", "documentation": "Longview, TX" } } }, "auth_ref": [] }, "sbra_LouisvilleKY1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LouisvilleKY1Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Louisville, KY 1", "label": "Louisville, KY 1 [Member]", "documentation": "Louisville, KY 1" } } }, "auth_ref": [] }, "sbra_LouisvilleKY2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LouisvilleKY2Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Louisville, KY 2", "label": "Louisville, KY 2 [Member]", "documentation": "Louisville, KY 2" } } }, "auth_ref": [] }, "sbra_LouisvilleKY3Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LouisvilleKY3Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Louisville, KY 3", "label": "Louisville, KY 3 [Member]", "documentation": "Louisville, KY 3" } } }, "auth_ref": [] }, "sbra_LouisvilleKY4Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LouisvilleKY4Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Louisville, KY 4", "label": "Louisville, KY 4 [Member]", "documentation": "Louisville, KY 4" } } }, "auth_ref": [] }, "sbra_LouisvilleKYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LouisvilleKYMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Louisville, KY", "label": "Louisville, KY [Member]", "documentation": "Louisville, KY" } } }, "auth_ref": [] }, "sbra_LovelandOHMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LovelandOHMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loveland, OH", "label": "Loveland, OH [Member]", "documentation": "Loveland, OH" } } }, "auth_ref": [] }, "sbra_LowellMAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "LowellMAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lowell, MA", "label": "Lowell, MA [Member]", "documentation": "Lowell, MA" } } }, "auth_ref": [] }, "sbra_MadeiraOHMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "MadeiraOHMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Madeira, OH", "label": "Madeira, OH [Member]", "documentation": "Madeira, OH" } } }, "auth_ref": [] }, "sbra_MadisonTNMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "MadisonTNMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Madison, TN", "label": "Madison, TN [Member]", "documentation": "Madison, TN" } } }, "auth_ref": [] }, "sbra_ManisteeMIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ManisteeMIMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Manistee, MI", "label": "Manistee, MI [Member]", "documentation": "Manistee, MI" } } }, "auth_ref": [] }, "sbra_MariettaGAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "MariettaGAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marietta, GA", "label": "Marietta, GA [Member]", "documentation": "Marietta, GA" } } }, "auth_ref": [] }, "sbra_MarlboroughMAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "MarlboroughMAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marlborough, MA", "label": "Marlborough, MA [Member]", "documentation": "Marlborough, MA" } } }, "auth_ref": [] }, "sbra_MarlinSpringJointVentureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "MarlinSpringJointVentureMember", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESScheduleofInvestmentinJointVenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marlin Spring Joint Venture", "label": "Marlin Spring Joint Venture [Member]", "documentation": "Marlin Spring Joint Venture" } } }, "auth_ref": [] }, "sbra_MarshallTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "MarshallTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marshall, TX", "label": "Marshall, TX [Member]", "documentation": "Marshall, TX" } } }, "auth_ref": [] }, "sbra_MarshfieldWI1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "MarshfieldWI1Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marshfield, WI 1", "label": "Marshfield, WI 1 [Member]", "documentation": "Marshfield, WI 1" } } }, "auth_ref": [] }, "sbra_MarshfieldWIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "MarshfieldWIMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marshfield, WI", "label": "Marshfield, WI [Member]", "documentation": "Marshfield, WI" } } }, "auth_ref": [] }, "sbra_MaryvilleMOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "MaryvilleMOMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maryville, MO", "label": "Maryville, MO [Member]", "documentation": "Maryville, MO" } } }, "auth_ref": [] }, "sbra_MasonMIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "MasonMIMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mason, MI", "label": "Mason, MI [Member]", "documentation": "Mason, MI" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails", "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedinTotalStockholderReturnBasedStockUnitsValuationDetails", "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r453", "r454", "r455", "r456", "r527", "r665", "r707", "r735", "r736", "r788", "r791", "r793", "r794", "r808", "r835", "r836", "r851", "r860", "r873", "r880", "r1036", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062" ] }, "sbra_MaxwellTX1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "MaxwellTX1Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maxwell, TX 1", "label": "Maxwell, TX 1 [Member]", "documentation": "Maxwell, TX 1" } } }, "auth_ref": [] }, "sbra_MaxwellTX2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "MaxwellTX2Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maxwell, TX 2", "label": "Maxwell, TX 2 [Member]", "documentation": "Maxwell, TX 2" } } }, "auth_ref": [] }, "sbra_MaxwellTX3Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "MaxwellTX3Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maxwell, TX 3", "label": "Maxwell, TX 3 [Member]", "documentation": "Maxwell, TX 3" } } }, "auth_ref": [] }, "sbra_McCordsvilleINMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "McCordsvilleINMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "McCordsville, IN", "label": "McCordsville, IN [Member]", "documentation": "McCordsville, IN" } } }, "auth_ref": [] }, "sbra_McKinneyTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "McKinneyTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "McKinney, TX", "label": "McKinney, TX [Member]", "documentation": "McKinney, TX" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r939" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r939" ] }, "us-gaap_MeasurementInputDiscountRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputDiscountRateMember", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount Rate", "label": "Measurement Input, Discount Rate [Member]", "documentation": "Measurement input using interest rate to determine present value of future cash flows." } } }, "auth_ref": [ "r1047" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Axis]", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r623" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Domain]", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "sbra_MedfordOR1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "MedfordOR1Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medford, OR 1", "label": "Medford, OR 1 [Member]", "documentation": "Medford, OR 1" } } }, "auth_ref": [] }, "sbra_MedfordOR2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "MedfordOR2Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medford, OR 2", "label": "Medford, OR 2 [Member]", "documentation": "Medford, OR 2" } } }, "auth_ref": [] }, "sbra_MemphisTNMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "MemphisTNMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Memphis, TN", "label": "Memphis, TN [Member]", "documentation": "Memphis, TN" } } }, "auth_ref": [] }, "sbra_MenomoneeFallsWIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "MenomoneeFallsWIMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Menomonee Falls, WI", "label": "Menomonee Falls, WI [Member]", "documentation": "Menomonee Falls, WI" } } }, "auth_ref": [] }, "sbra_MiddletownDEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "MiddletownDEMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Middletown, DE", "label": "Middletown, DE [Member]", "documentation": "Middletown, DE" } } }, "auth_ref": [] }, "sbra_MilfordDEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "MilfordDEMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milford, DE", "label": "Milford, DE [Member]", "documentation": "Milford, DE" } } }, "auth_ref": [] }, "sbra_MilfordNHMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "MilfordNHMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milford, NH", "label": "Milford, NH [Member]", "documentation": "Milford, NH" } } }, "auth_ref": [] }, "sbra_MillsboroDEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "MillsboroDEMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Millsboro, DE", "label": "Millsboro, DE [Member]", "documentation": "Millsboro, DE" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails", "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedinTotalStockholderReturnBasedStockUnitsValuationDetails", "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r453", "r454", "r455", "r456", "r527", "r665", "r707", "r735", "r736", "r788", "r791", "r793", "r794", "r808", "r835", "r836", "r851", "r860", "r873", "r880", "r1036", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062" ] }, "sbra_MinneapolisMNMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "MinneapolisMNMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minneapolis, MN", "label": "Minneapolis, MN [Member]", "documentation": "Minneapolis, MN" } } }, "auth_ref": [] }, "sbra_MissouriCityTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "MissouriCityTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Missouri City, TX", "label": "Missouri City, TX [Member]", "documentation": "Missouri City, TX" } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r959" ] }, "sbra_MonroeNCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "MonroeNCMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Monroe, NC", "label": "Monroe, NC [Member]", "documentation": "Monroe, NC" } } }, "auth_ref": [] }, "sbra_MonroevillePAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "MonroevillePAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Monroeville, PA", "label": "Monroeville, PA [Member]", "documentation": "Monroeville, PA" } } }, "auth_ref": [] }, "sbra_MonticelloARMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "MonticelloARMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Monticello, AR", "label": "Monticello, AR [Member]", "documentation": "Monticello, AR" } } }, "auth_ref": [] }, "sbra_MorriltonARMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "MorriltonARMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Morrilton, AR", "label": "Morrilton, AR [Member]", "documentation": "Morrilton, AR" } } }, "auth_ref": [] }, "us-gaap_MortgageLoansOnRealEstate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MortgageLoansOnRealEstate", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIVMORTGAGELOANSONREALESTATEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Book Value", "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate", "documentation": "Amount of investment in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate." } } }, "auth_ref": [ "r817" ] }, "srt_MortgageLoansOnRealEstateAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MortgageLoansOnRealEstateAbstract", "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Abstract]", "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Abstract]" } } }, "auth_ref": [] }, "sbra_MortgageLoansOnRealEstateAdditionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "MortgageLoansOnRealEstateAdditionsAbstract", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIVMORTGAGELOANSONREALESTATEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions during period:", "label": "Mortgage Loans On Real Estate, Additions [Abstract]", "documentation": "Mortgage Loans On Real Estate, Additions [Abstract]" } } }, "auth_ref": [] }, "srt_MortgageLoansOnRealEstateByLoanDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MortgageLoansOnRealEstateByLoanDisclosureTextBlock", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIVMORTGAGELOANSONREALESTATE" ], "lang": { "en-us": { "role": { "terseLabel": "SCHEDULE IV - MORTGAGE LOANS ON REAL ESTATE", "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Text Block]", "documentation": "The entire disclosure for investment in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate. Includes, but is not limited to, information for each mortgage loan receivable equaling or exceeding 3 percent of carrying amount of mortgage." } } }, "auth_ref": [ "r262", "r821" ] }, "srt_MortgageLoansOnRealEstateCollectionsOfPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MortgageLoansOnRealEstateCollectionsOfPrincipal", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIVMORTGAGELOANSONREALESTATEDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Paydowns/repayments", "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Collections of Principal", "documentation": "Amount of decrease in investment in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate, from collection of principal." } } }, "auth_ref": [ "r257", "r819" ] }, "sbra_MortgageLoansOnRealEstateDeductionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "MortgageLoansOnRealEstateDeductionsAbstract", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIVMORTGAGELOANSONREALESTATEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deductions during period:", "label": "Mortgage Loans On Real Estate, Deductions [Abstract]", "documentation": "Mortgage Loans On Real Estate, Deductions [Abstract]" } } }, "auth_ref": [] }, "srt_MortgageLoansOnRealEstateDescriptionLoanCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MortgageLoansOnRealEstateDescriptionLoanCategoryAxis", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIVMORTGAGELOANSONREALESTATEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Loan Category [Axis]", "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Loan Category [Axis]", "documentation": "Information by loan category for investment in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate." } } }, "auth_ref": [ "r256", "r818" ] }, "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESNetInvestmentinSalesTypeLeaseNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESScheduleofInvestmentinJointVenturesDetails", "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate, Type of Property [Axis]", "label": "Real Estate, Type of Property [Axis]", "documentation": "Information by type of real estate property." } } }, "auth_ref": [ "r244", "r256", "r818", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831" ] }, "srt_MortgageLoansOnRealEstateFaceAmountOfMortgages": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MortgageLoansOnRealEstateFaceAmountOfMortgages", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIVMORTGAGELOANSONREALESTATEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal Balance", "periodStartLabel": "Balance at the beginning of the year", "periodEndLabel": "Balance at the end of the year", "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Face Amount of Mortgages", "documentation": "Amount of contractual principal due at origination of mortgage loan within investment in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate." } } }, "auth_ref": [ "r261", "r816" ] }, "srt_MortgageLoansOnRealEstateFederalIncomeTaxBasis1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MortgageLoansOnRealEstateFederalIncomeTaxBasis1", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIVMORTGAGELOANSONREALESTATEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate cost for federal income tax purposes", "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Federal Income Tax Basis", "documentation": "Amount of federal income tax basis of investment in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate." } } }, "auth_ref": [ "r258", "r820" ] }, "srt_MortgageLoansOnRealEstateInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MortgageLoansOnRealEstateInterestRate", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIVMORTGAGELOANSONREALESTATEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual Interest Rate", "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Interest Rate", "documentation": "Interest rate of mortgage loan within investment in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate." } } }, "auth_ref": [ "r259", "r814" ] }, "srt_MortgageLoansOnRealEstateLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MortgageLoansOnRealEstateLineItems", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIVMORTGAGELOANSONREALESTATEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]", "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r262", "r821" ] }, "srt_MortgageLoansOnRealEstateLoanCategoryDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MortgageLoansOnRealEstateLoanCategoryDomain", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIVMORTGAGELOANSONREALESTATEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Loan Category [Domain]", "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Loan Category [Domain]", "documentation": "Loan category for investment in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate." } } }, "auth_ref": [] }, "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESNetInvestmentinSalesTypeLeaseNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESScheduleofInvestmentinJointVenturesDetails", "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate [Domain]", "label": "Real Estate [Domain]", "documentation": "Land and any structures permanently fixed to it." } } }, "auth_ref": [ "r244", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831" ] }, "us-gaap_MortgageLoansOnRealEstateNewMortgageLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MortgageLoansOnRealEstateNewMortgageLoans", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIVMORTGAGELOANSONREALESTATEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New mortgage loans", "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, New Mortgage Loan", "documentation": "Amount of increase in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate, from new investment." } } }, "auth_ref": [ "r819" ] }, "us-gaap_MortgageLoansOnRealEstatePeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MortgageLoansOnRealEstatePeriodIncreaseDecrease", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIVMORTGAGELOANSONREALESTATEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Draws", "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) in investment in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate." } } }, "auth_ref": [ "r1076" ] }, "srt_MortgageLoansOnRealEstatePriorLiens1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MortgageLoansOnRealEstatePriorLiens1", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIVMORTGAGELOANSONREALESTATEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Liens", "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Prior Lien, Amount", "documentation": "Amount of prior lien on real estate securing mortgage loan within investment in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate." } } }, "auth_ref": [ "r260", "r815" ] }, "srt_MortgageLoansOnRealEstateScheduleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MortgageLoansOnRealEstateScheduleTable", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIVMORTGAGELOANSONREALESTATEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate Schedule [Table]", "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate Schedule [Table]", "documentation": "Disclosure of information about investment in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate." } } }, "auth_ref": [ "r262", "r821" ] }, "sbra_MortgageLoansReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "MortgageLoansReceivableMember", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mortgage", "label": "Mortgage Loans Receivable [Member]", "documentation": "Mortgage Loans Receivable [Member]" } } }, "auth_ref": [] }, "us-gaap_MortgagesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MortgagesMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIVMORTGAGELOANSONREALESTATEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mortgages", "label": "Mortgages [Member]", "documentation": "A loan to finance the purchase of real estate where the lender has a lien on the property as collateral for the loan." } } }, "auth_ref": [] }, "sbra_MountPleasantSCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "MountPleasantSCMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mount Pleasant, SC", "label": "Mount Pleasant, SC [Member]", "documentation": "Mount Pleasant, SC" } } }, "auth_ref": [] }, "sbra_MountPleasantTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "MountPleasantTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mount Pleasant, TX", "label": "Mount Pleasant, TX [Member]", "documentation": "Mount Pleasant, TX" } } }, "auth_ref": [] }, "us-gaap_MovementInMortgageLoansOnRealEstateRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MovementInMortgageLoansOnRealEstateRollForward", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIVMORTGAGELOANSONREALESTATEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-29, Real Estate Companies, Investment in Movement in Mortgage Loans on Real Estate [Roll Forward]", "label": "SEC Schedule, 12-29, Real Estate Companies, Investment in Movement in Mortgage Loans on Real Estate [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r967" ] }, "sbra_MuncieINMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "MuncieINMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Muncie, IN", "label": "Muncie, IN [Member]", "documentation": "Muncie, IN" } } }, "auth_ref": [] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r940" ] }, "sbra_NashuaNHMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "NashuaNHMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nashua, NH", "label": "Nashua, NH [Member]", "documentation": "Nashua, NH" } } }, "auth_ref": [] }, "sbra_NashvilleTNMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "NashvilleTNMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nashville, TN", "label": "Nashville, TN [Member]", "documentation": "Nashville, TN" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r317" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r317" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r185", "r186", "r187" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY", "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS", "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHAREComputationofBasicandDilutedEarningsPerShareDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)", "terseLabel": "Net income (loss)", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r176", "r187", "r220", "r278", "r299", "r302", "r307", "r324", "r333", "r335", "r336", "r337", "r338", "r341", "r342", "r350", "r362", "r381", "r387", "r389", "r404", "r457", "r458", "r460", "r461", "r462", "r464", "r466", "r468", "r469", "r619", "r630", "r684", "r765", "r781", "r782", "r849", "r891", "r1032" ] }, "sbra_NetIncomeLossAttributableToCommonStockholdersAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "NetIncomeLossAttributableToCommonStockholdersAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss), per:", "label": "Net Income Loss Attributable To Common Stockholders [Abstract]", "documentation": "Net Income Loss Attributable To Common Stockholders" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "presentation": [ "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHAREComputationofBasicandDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Numerator", "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetInvestmentHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetInvestmentHedgingMember", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountsofDerivativeInstrumentsDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSSummaryofDerivativeandFinancialInstrumentsDesignatedasHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Investment Hedges", "verboseLabel": "Net investment", "label": "Net Investment Hedging [Member]", "documentation": "Hedges of a net investment in a foreign operation." } } }, "auth_ref": [ "r113" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Issued Accounting Standards Update", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "sbra_NewBraunfelsTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "NewBraunfelsTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New Braunfels, TX", "label": "New Braunfels, TX [Member]", "documentation": "New Braunfels, TX" } } }, "auth_ref": [] }, "sbra_NewLondonCTMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "NewLondonCTMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New London, CT", "label": "New London, CT [Member]", "documentation": "New London, CT" } } }, "auth_ref": [] }, "sbra_NewportORMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "NewportORMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Newport, OR", "label": "Newport, OR [Member]", "documentation": "Newport, OR" } } }, "auth_ref": [] }, "sbra_NonCashRentalAndRelatedRevenuesAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "NonCashRentalAndRelatedRevenuesAdjustments", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash rental and related revenues", "label": "Non-Cash Rental And Related Revenues Adjustments", "documentation": "Non-Cash Rental And Related Revenues Adjustments" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r939" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r908", "r920", "r930", "r947", "r956" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r937" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r936" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r947" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r967" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r967" ] }, "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease in loans receivable and other investments due to acquisition of real estate", "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)", "documentation": "The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future." } } }, "auth_ref": [ "r63", "r64", "r65" ] }, "sbra_NoncashRentReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "NoncashRentReceivableMember", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash rent receivable", "label": "Noncash Rent Receivable [Member]", "documentation": "Noncash Rent Receivable" } } }, "auth_ref": [] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NondesignatedMember", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNarrativeDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSNotionalAmountsofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Not Designated as Hedging Instrument", "label": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r25" ] }, "us-gaap_NonperformingFinancingReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonperformingFinancingReceivableMember", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nonaccrual status", "label": "Nonperforming Financial Instruments [Member]", "documentation": "Category status of financial instruments in which payments are past due in accordance with the terms of the contract. Financial instruments include, but are not limited to, financing receivables, loans, debt, and investments." } } }, "auth_ref": [ "r74", "r1023" ] }, "sbra_NorfolkNEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "NorfolkNEMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Norfolk, NE", "label": "Norfolk, NE [Member]", "documentation": "Norfolk, NE" } } }, "auth_ref": [] }, "sbra_NorfolkVAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "NorfolkVAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Norfolk, VA", "label": "Norfolk, VA [Member]", "documentation": "Norfolk, VA" } } }, "auth_ref": [] }, "sbra_NormanOKMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "NormanOKMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Norman, OK", "label": "Norman, OK [Member]", "documentation": "Norman, OK" } } }, "auth_ref": [] }, "sbra_NorthAmericanHealthCareIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "NorthAmericanHealthCareIncMember", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "North American Health Care, Inc", "label": "North American Health Care, Inc [Member]", "documentation": "North American Health Care, Inc" } } }, "auth_ref": [] }, "sbra_NorthConwayNHMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "NorthConwayNHMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "North Conway, NH", "label": "North Conway, NH [Member]", "documentation": "North Conway, NH" } } }, "auth_ref": [] }, "sbra_NorthTonawandaNYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "NorthTonawandaNYMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "North Tonawanda, NY", "label": "North Tonawanda, NY [Member]", "documentation": "North Tonawanda, NY" } } }, "auth_ref": [] }, "sbra_NorthglennCOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "NorthglennCOMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Northglenn, CO", "label": "Northglenn, CO [Member]", "documentation": "Northglenn, CO" } } }, "auth_ref": [] }, "sbra_NorwayMEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "NorwayMEMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Norway, ME", "label": "Norway, ME [Member]", "documentation": "Norway, ME" } } }, "auth_ref": [] }, "us-gaap_NotesReceivableGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesReceivableGross", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails": { "parentTag": "us-gaap_NotesReceivableNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "netLabel": "Book Value", "label": "Financing Receivable, before Allowance for Credit Loss", "documentation": "Amortized cost, before allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease." } } }, "auth_ref": [ "r237", "r240", "r241", "r286", "r417", "r423", "r852", "r853", "r979", "r1021" ] }, "us-gaap_NotesReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesReceivableNet", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails": { "parentTag": "sbra_FinancingReceivableAndOtherInvestmentsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails", "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Book Value", "terseLabel": "Book value", "label": "Financing Receivable, after Allowance for Credit Loss", "documentation": "Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease." } } }, "auth_ref": [ "r394", "r423", "r752" ] }, "us-gaap_NotesReceivableNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesReceivableNetAbstract", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loans Receivable:", "label": "Financing Receivable, after Allowance for Credit Loss [Abstract]" } } }, "auth_ref": [] }, "sbra_NumberOfInvestments": { "xbrltype": "integerItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "NumberOfInvestments", "calculation": { "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total Quantity", "label": "Number Of Investments", "documentation": "Number Of Investments" } } }, "auth_ref": [] }, "sbra_NumberOfPropertiesSoldSecuringDebt": { "xbrltype": "integerItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "NumberOfPropertiesSoldSecuringDebt", "presentation": [ "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of properties sold securing debt", "label": "Number Of Properties Sold Securing Debt", "documentation": "Number Of Properties Sold Securing Debt" } } }, "auth_ref": [] }, "us-gaap_NumberOfRealEstateProperties": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfRealEstateProperties", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESScheduleofInvestmentinJointVenturesDetails", "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of properties", "verboseLabel": "Number\u00a0of Properties", "label": "Number of Real Estate Properties", "documentation": "The number of real estate properties owned as of the balance sheet date." } } }, "auth_ref": [] }, "sbra_NumberOfRealEstatePropertiesAcquired": { "xbrltype": "integerItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "NumberOfRealEstatePropertiesAcquired", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of acquired properties", "label": "Number Of Real Estate Properties Acquired", "documentation": "Number Of Real Estate Properties Acquired" } } }, "auth_ref": [] }, "sbra_NumberOfRealEstatePropertiesImpaired": { "xbrltype": "integerItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "NumberOfRealEstatePropertiesImpaired", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of real estate properties impaired", "label": "Number Of Real Estate Properties Impaired", "documentation": "Number Of Real Estate Properties Impaired" } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r1013" ] }, "us-gaap_NumberOfUnitsInRealEstateProperty": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfUnitsInRealEstateProperty", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number\u00a0of Beds/Units", "label": "Number of Units in Real Estate Property", "documentation": "The number of units in a real estate property owned as of the balance sheet date." } } }, "auth_ref": [] }, "sbra_OakHillWVMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "OakHillWVMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Oak Hill, WV", "label": "Oak Hill, WV [Member]", "documentation": "Oak Hill, WV" } } }, "auth_ref": [] }, "us-gaap_OffsettingAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OffsettingAssetsTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Presentation, Effects of Offsetting, and a Net Presentation of Derivatives, Assets", "label": "Offsetting Assets [Table Text Block]", "documentation": "Tabular disclosure of derivative and other financial assets that are subject to offsetting, including master netting arrangements." } } }, "auth_ref": [ "r172", "r292" ] }, "us-gaap_OffsettingDerivativeAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OffsettingDerivativeAssetsAbstract", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandaNetPresentationofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Offsetting Assets:", "label": "Offsetting Derivative Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OffsettingDerivativeLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OffsettingDerivativeLiabilitiesAbstract", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSGrossPresentationEffectsofOffsettingandaNetPresentationofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Offsetting Liabilities:", "label": "Offsetting Derivative Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OffsettingLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OffsettingLiabilitiesTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Presentation, Effects of Offsetting, and a Net Presentation of Derivatives, Liabilities", "label": "Offsetting Liabilities [Table Text Block]", "documentation": "Tabular disclosure of derivative and other financial liabilities that are subject to offsetting, including master netting arrangements." } } }, "auth_ref": [ "r172", "r292" ] }, "sbra_OgdenUTMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "OgdenUTMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ogden, UT", "label": "Ogden, UT [Member]", "documentation": "Ogden, UT" } } }, "auth_ref": [] }, "sbra_OklahomaCityOKMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "OklahomaCityOKMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Oklahoma City, OK", "label": "Oklahoma City, OK [Member]", "documentation": "Oklahoma City, OK" } } }, "auth_ref": [] }, "sbra_OlympiaWAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "OlympiaWAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Olympia, WA", "label": "Olympia, WA [Member]", "documentation": "Olympia, WA" } } }, "auth_ref": [] }, "sbra_OperatingAndInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "OperatingAndInterestExpense", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Total expenses", "label": "Operating And Interest Expense", "documentation": "Operating And Interest Expense" } } }, "auth_ref": [] }, "us-gaap_OperatingCostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingCostsAndExpenses", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": { "parentTag": "sbra_OperatingAndInterestExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialInformationforEnlivantJointVentureDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating expenses", "label": "Operating Costs and Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, expense", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r1051" ] }, "us-gaap_OperatingLeaseLeaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLeaseIncome", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Rental and related revenues (Note 4)", "label": "Operating Lease, Lease Income", "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable." } } }, "auth_ref": [ "r358", "r650", "r652" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails", "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability", "verboseLabel": "Present value of lease liability", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r644" ] }, "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, liability, statement of financial position", "label": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes operating lease liability." } } }, "auth_ref": [ "r645" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use asset", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r643" ] }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease, right-of-use asset, statement of financial position", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset." } } }, "auth_ref": [ "r645" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average discount rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r648", "r877" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails", "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining term of operating leases", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r647", "r877" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails", "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r380", "r381", "r382", "r383", "r384", "r389" ] }, "sbra_OrangeCAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "OrangeCAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Orange, CA", "label": "Orange, CA [Member]", "documentation": "Orange, CA" } } }, "auth_ref": [] }, "sbra_OrangeTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "OrangeTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Orange, TX", "label": "Orange, TX [Member]", "documentation": "Orange, TX" } } }, "auth_ref": [] }, "sbra_OregonCityORMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "OregonCityORMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Oregon City, OR", "label": "Oregon City, OR [Member]", "documentation": "Oregon City, OR" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.sabrahealth.com/role/BUSINESS" ], "lang": { "en-us": { "role": { "terseLabel": "BUSINESS", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r150", "r209", "r713", "r714" ] }, "us-gaap_OtherCommitment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitment", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Future funding commitment", "label": "Other Commitment", "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitmentsAxis", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Commitments [Axis]", "label": "Other Commitments [Axis]", "documentation": "Information by type of other commitment." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitmentsDomain", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Commitments [Domain]", "label": "Other Commitments [Domain]", "documentation": "Other future obligation." } } }, "auth_ref": [] }, "sbra_OtherComprehensiveIncomeLossCashFlowAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "OtherComprehensiveIncomeLossCashFlowAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofIncomeandCondensedConsolidatedStatementsofEquityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofIncomeandCondensedConsolidatedStatementsofEquityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Gain (loss) recognized in other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Cash Flow And Net Investment Hedge, Gain (Loss), Before Reclassification And Tax", "documentation": "Other Comprehensive Income (Loss), Cash Flow And Net Investment Hedge, Gain (Loss), Before Reclassification And Tax" } } }, "auth_ref": [] }, "sbra_OtherComprehensiveIncomeLossCashFlowAndNetInvestmentHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "OtherComprehensiveIncomeLossCashFlowAndNetInvestmentHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofIncomeandCondensedConsolidatedStatementsofEquityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofIncomeandCondensedConsolidatedStatementsofEquityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Loss reclassified accumulated other comprehensive income (loss) into income", "label": "Other Comprehensive Income (Loss), Cash Flow And Net Investment Hedge, Gain (Loss), Reclassification, Before Tax", "documentation": "Other Comprehensive Income (Loss), Cash Flow And Net Investment Hedge, Gain (Loss), Reclassification, Before Tax" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on cash flow hedges", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r294", "r295" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSSParenthetical" ], "lang": { "en-us": { "role": { "negatedLabel": "Income tax benefit on unrealized gains (losses) on cash flow hedges", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax", "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r296" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofIncomeandCondensedConsolidatedStatementsofEquityDetails": { "parentTag": "sbra_OtherComprehensiveIncomeLossCashFlowAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofIncomeandCondensedConsolidatedStatementsofEquityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Gain (loss) recognized in other comprehensive income (loss), cash flow hedges", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r294", "r295", "r602", "r603", "r608" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofIncomeandCondensedConsolidatedStatementsofEquityDetails": { "parentTag": "sbra_OtherComprehensiveIncomeLossCashFlowAndNetInvestmentHedgeGainLossReclassificationBeforeTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofIncomeandCondensedConsolidatedStatementsofEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss reclassified accumulated other comprehensive income (loss) into income, cash flow hedge", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r236", "r295", "r298" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation (loss) gain", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r5" ] }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofIncomeandCondensedConsolidatedStatementsofEquityDetails": { "parentTag": "sbra_OtherComprehensiveIncomeLossCashFlowAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofIncomeandCondensedConsolidatedStatementsofEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) recognized in other comprehensive income (loss), net investment hedges", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge." } } }, "auth_ref": [ "r604" ] }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofIncomeandCondensedConsolidatedStatementsofEquityDetails": { "parentTag": "sbra_OtherComprehensiveIncomeLossCashFlowAndNetInvestmentHedgeGainLossReclassificationBeforeTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofIncomeandCondensedConsolidatedStatementsofEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss reclassified accumulated other comprehensive income (loss) into income, net investment hedges", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge." } } }, "auth_ref": [ "r605" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive income", "verboseLabel": "Other comprehensive income", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r24", "r36", "r300", "r303", "r309", "r633", "r634", "r639", "r669", "r685", "r995", "r996" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss):", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "sbra_OtherComprehensiveIncomeLossUnrealizedGainLossNetofTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "OtherComprehensiveIncomeLossUnrealizedGainLossNetofTaxAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss), net of tax:", "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss), Net of Tax [Abstract]", "documentation": "Other Comprehensive Income (Loss), Unrealized Gain (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncomeAndExpensesAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Other (expense) income:", "label": "Other Income and Expenses [Abstract]" } } }, "auth_ref": [] }, "sbra_OtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "OtherMember", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other [Member]", "documentation": "Other [Member]" } } }, "auth_ref": [] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Non-cash interest income", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r187" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Total other expense", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r179" ] }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherOperatingActivitiesCashFlowStatement", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-cash items", "label": "Other Operating Activities, Cash Flow Statement", "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)." } } }, "auth_ref": [] }, "us-gaap_OtherOperatingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherOperatingIncomeExpenseNet", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense)", "label": "Other Operating Income (Expense), Net", "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r939" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r906", "r918", "r928", "r954" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r909", "r921", "r931", "r957" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r909", "r921", "r931", "r957" ] }, "sbra_OwensboroKYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "OwensboroKYMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Owensboro, KY", "label": "Owensboro, KY [Member]", "documentation": "Owensboro, KY" } } }, "auth_ref": [] }, "sbra_PacificaCAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "PacificaCAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pacifica, CA", "label": "Pacifica, CA [Member]", "documentation": "Pacifica, CA" } } }, "auth_ref": [] }, "sbra_ParkersburgWVMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ParkersburgWVMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Parkersburg, WV", "label": "Parkersburg, WV [Member]", "documentation": "Parkersburg, WV" } } }, "auth_ref": [] }, "sbra_PasadenaTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "PasadenaTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pasadena, TX", "label": "Pasadena, TX [Member]", "documentation": "Pasadena, TX" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r935" ] }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment of contingent consideration", "terseLabel": "Payment for contingent consideration", "label": "Payment for Contingent Consideration Liability, Financing Activities", "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date." } } }, "auth_ref": [ "r8" ] }, "sbra_PaymentsForEscrowDepositsForPotentialInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "PaymentsForEscrowDepositsForPotentialInvestments", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Escrow deposits for potential investments", "label": "Payments For Escrow Deposits For Potential Investments", "documentation": "Payments For Escrow Deposits For Potential Investments" } } }, "auth_ref": [] }, "sbra_PaymentsForPreferredEquityInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "PaymentsForPreferredEquityInvestments", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Origination and fundings of preferred equity investments", "label": "Payments For Preferred Equity Investments", "documentation": "Payments For Preferred Equity Investments" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDebtExtinguishmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDebtExtinguishmentCosts", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments related to extinguishment of debt", "terseLabel": "Payments made to noteholders and legal fees for early redemption", "label": "Payment for Debt Extinguishment or Debt Prepayment Cost", "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest." } } }, "auth_ref": [ "r9" ] }, "us-gaap_PaymentsOfDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDividends", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Dividends paid on common stock", "label": "Payments of Dividends", "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests." } } }, "auth_ref": [ "r57" ] }, "us-gaap_PaymentsOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfFinancingCosts", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments of deferred financing costs", "label": "Payments of Financing Costs", "documentation": "The cash outflow for loan and debt issuance costs." } } }, "auth_ref": [ "r56" ] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/EQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments for stock issuance commissions", "label": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r56" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/EQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax withholding obligations incurred on behalf of employees", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r314" ] }, "us-gaap_PaymentsToAcquireBuildings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBuildings", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments to acquire buildings", "label": "Payments to Acquire Buildings", "documentation": "The cash outflow for acquisition of buildings (properties) whether for investment or use." } } }, "auth_ref": [ "r184" ] }, "us-gaap_PaymentsToAcquireFurnitureAndFixtures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireFurnitureAndFixtures", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Additions to real estate", "label": "Payments to Acquire Furniture and Fixtures", "documentation": "The cash outflow for acquisition of furniture and fixtures." } } }, "auth_ref": [ "r184" ] }, "us-gaap_PaymentsToAcquireInterestInJointVenture": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireInterestInJointVenture", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Investment in unconsolidated joint ventures", "label": "Payments to Acquire Interest in Joint Venture", "documentation": "The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group." } } }, "auth_ref": [ "r54" ] }, "us-gaap_PaymentsToAcquireNotesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireNotesReceivable", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Origination and fundings of loans receivable", "label": "Payments to Acquire Notes Receivable", "documentation": "The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics." } } }, "auth_ref": [ "r53" ] }, "us-gaap_PaymentsToAcquireRealEstate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireRealEstate", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisition of real estate", "label": "Payments to Acquire Real Estate", "documentation": "The cash outflow from the acquisition of a piece of land, anything permanently fixed to it, including buildings, structures on it and so forth; includes real estate intended to generate income for the owner; excludes real estate acquired for use by the owner." } } }, "auth_ref": [ "r184" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r938" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r938" ] }, "sbra_PentictonBCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "PentictonBCMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Penticton, BC", "label": "Penticton, BC [Member]", "documentation": "Penticton, BC" } } }, "auth_ref": [] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r937" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r947" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r940" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r936" ] }, "sbra_PetersburgINMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "PetersburgINMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Petersburg, IN", "label": "Petersburg, IN [Member]", "documentation": "Petersburg, IN" } } }, "auth_ref": [] }, "sbra_PetersburgVA1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "PetersburgVA1Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Petersburg, VA 1", "label": "Petersburg, VA 1 [Member]", "documentation": "Petersburg, VA 1" } } }, "auth_ref": [] }, "sbra_PetersburgVA2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "PetersburgVA2Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Petersburg, VA 2", "label": "Petersburg, VA 2 [Member]", "documentation": "Petersburg, VA 2" } } }, "auth_ref": [] }, "sbra_PewaukeeWI1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "PewaukeeWI1Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pewaukee, WI 1", "label": "Pewaukee, WI 1 [Member]", "documentation": "Pewaukee, WI 1" } } }, "auth_ref": [] }, "sbra_PewaukeeWI2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "PewaukeeWI2Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pewaukee, WI 2", "label": "Pewaukee, WI 2 [Member]", "documentation": "Pewaukee, WI 2" } } }, "auth_ref": [] }, "sbra_PhoenixAZMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "PhoenixAZMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Phoenix, AZ", "label": "Phoenix, AZ [Member]", "documentation": "Phoenix, AZ" } } }, "auth_ref": [] }, "sbra_PineKnotKYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "PineKnotKYMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pine Knot, KY", "label": "Pine Knot, KY [Member]", "documentation": "Pine Knot, KY" } } }, "auth_ref": [] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Portion at Fair Value Measurement", "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": [ "r628" ] }, "sbra_PortlandINMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "PortlandINMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Portland, IN", "label": "Portland, IN [Member]", "documentation": "Portland, IN" } } }, "auth_ref": [] }, "sbra_PortlandORMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "PortlandORMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Portland, OR", "label": "Portland, OR [Member]", "documentation": "Portland, OR" } } }, "auth_ref": [] }, "sbra_PowayCAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "PowayCAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Poway, CA", "label": "Poway, CA [Member]", "documentation": "Poway, CA" } } }, "auth_ref": [] }, "sbra_PreferredEquityInvestmentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "PreferredEquityInvestmentCarryingAmount", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails": { "parentTag": "sbra_FinancingReceivableAndOtherInvestmentsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Book Value", "label": "Preferred Equity Investment, Carrying Amount", "documentation": "Preferred Equity Investment, Carrying Amount" } } }, "auth_ref": [] }, "sbra_PreferredEquityInvestmentFaceValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "PreferredEquityInvestmentFaceValue", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails": { "parentTag": "us-gaap_InvestmentOwnedBalancePrincipalAmount", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal Balance", "verboseLabel": "Preferred equity investments", "label": "Preferred Equity Investment, Face Value", "documentation": "Preferred Equity Investment, Face Value" } } }, "auth_ref": [] }, "sbra_PreferredEquityInvestmentFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "PreferredEquityInvestmentFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred equity investments", "label": "Preferred Equity Investment, Fair Value Disclosure", "documentation": "Preferred Equity Investment, Fair Value Disclosure" } } }, "auth_ref": [] }, "sbra_PreferredEquityInvestmentWeightedAverageContractualRate": { "xbrltype": "percentItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "PreferredEquityInvestmentWeightedAverageContractualRate", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Contractual Interest Rate / Rate of Return", "label": "Preferred Equity Investment, Weighted Average Contractual Rate", "documentation": "Preferred Equity Investment, Weighted Average Contractual Rate" } } }, "auth_ref": [] }, "sbra_PreferredEquityInvestmentWeightedAverageEffectiveRate": { "xbrltype": "percentItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "PreferredEquityInvestmentWeightedAverageEffectiveRate", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Annualized Effective Interest Rate / Rate of Return", "label": "Preferred Equity Investment, Weighted Average Effective Rate", "documentation": "Preferred Equity Investment, Weighted Average Effective Rate" } } }, "auth_ref": [] }, "sbra_PreferredEquityInvestmentsMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "PreferredEquityInvestmentsMeasurementInput", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred equity investments, measurement input", "label": "Preferred Equity Investments, Measurement Input", "documentation": "Preferred Equity Investments, Measurement Input" } } }, "auth_ref": [] }, "sbra_PreferredEquityInvestmentsNumber": { "xbrltype": "integerItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "PreferredEquityInvestmentsNumber", "calculation": { "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails": { "parentTag": "sbra_NumberOfInvestments", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quantity", "label": "Preferred Equity Investments, Number", "documentation": "Preferred Equity Investments, Number of Investments" } } }, "auth_ref": [] }, "sbra_PreferredEquityNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "PreferredEquityNetAbstract", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Investments:", "label": "Preferred Equity, Net [Abstract]", "documentation": "Preferred Equity, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock", "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r166", "r502" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r166", "r745" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r166", "r502" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r166", "r745", "r763", "r1074", "r1075" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Preferred stock, $0.01 par value; 10,000,000 shares authorized, zero shares issued and outstanding as of December\u00a031, 2023 and 2022", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r166", "r678", "r878" ] }, "us-gaap_PrimeRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrimeRateMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prime Rate", "label": "Prime Rate [Member]", "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers." } } }, "auth_ref": [] }, "sbra_PriorATMProgramForwardFeatureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "PriorATMProgramForwardFeatureMember", "presentation": [ "http://www.sabrahealth.com/role/EQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prior ATM Program - Forward Feature", "label": "Prior ATM Program - Forward Feature [Member]", "documentation": "Prior ATM Program - Forward Feature" } } }, "auth_ref": [] }, "sbra_PriorATMProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "PriorATMProgramMember", "presentation": [ "http://www.sabrahealth.com/role/EQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prior ATM Program", "label": "Prior ATM Program [Member]", "documentation": "Prior ATM Program [Member]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromCollectionOfNotesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromCollectionOfNotesReceivable", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Repayments of loans receivable", "label": "Proceeds from Collection of Notes Receivable", "documentation": "The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r52" ] }, "us-gaap_ProceedsFromDepositsOnRealEstateSales": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromDepositsOnRealEstateSales", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Deposits for potential sale of real estate", "label": "Proceeds from Deposits on Real Estate Sales", "documentation": "Cash inflow related to amounts received in advance from a potential buyer showing or confirming an intention to complete an acquisition of land, buildings, other structures, or any item classified as real estate." } } }, "auth_ref": [ "r1001" ] }, "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Distributions in excess of earnings from unconsolidated joint ventures", "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital", "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities." } } }, "auth_ref": [ "r316", "r1000" ] }, "us-gaap_ProceedsFromInsuranceSettlementInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromInsuranceSettlementInvestingActivities", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance proceeds", "label": "Proceeds from Insurance Settlement, Investing Activities", "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as investing activities. Excludes insurance settlement classified as operating activities." } } }, "auth_ref": [ "r11", "r51" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/EQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of common stock", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r7" ] }, "us-gaap_ProceedsFromIssuanceOfMediumTermNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfMediumTermNotes", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from term loans", "label": "Proceeds from Issuance of Medium-term Notes", "documentation": "The cash inflow from a debt funding received on a regular basis with maturities ranging from 5-10 years." } } }, "auth_ref": [ "r55" ] }, "us-gaap_ProceedsFromIssuanceOfUnsecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfUnsecuredDebt", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of senior unsecured notes", "label": "Proceeds from Issuance of Unsecured Debt", "documentation": "The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt." } } }, "auth_ref": [ "r55" ] }, "us-gaap_ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESNetInvestmentinSalesTypeLeaseNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from sales-type lease", "label": "Proceeds from Lease Payment, Sales-Type and Direct Financing Leases, Investing Activity", "documentation": "Amount of cash inflow from principal payment received from sales-type and direct financing leases classified as investing activity." } } }, "auth_ref": [ "r229" ] }, "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRepaymentsOfLinesOfCredit", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Net (repayments of) borrowings from revolving credit facility", "label": "Proceeds from (Repayments of) Lines of Credit", "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets)." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfOtherProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfOtherProductiveAssets", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from the sales of real estate", "label": "Proceeds from Sale of Other Productive Assets", "documentation": "Amount of cash inflow from the sale of tangible or intangible assets used to produce goods or deliver services, classified as other." } } }, "auth_ref": [ "r183" ] }, "sbra_ProceedsPaymentsFromIssuanceOfStockNetOfTaxesPaidOnBehalfOfEmployees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ProceedsPaymentsFromIssuanceOfStockNetOfTaxesPaidOnBehalfOfEmployees", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock, net", "label": "Proceeds (Payments) From Issuance Of Stock, Net Of Taxes Paid On Behalf Of Employees", "documentation": "Proceeds (Payments) From Issuance Of Stock, Net Of Taxes Paid On Behalf Of Employees" } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSeniorHousingManagedCommunitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r390", "r666", "r701", "r702", "r703", "r704", "r705", "r706", "r838", "r861", "r879", "r977", "r1029", "r1030", "r1039", "r1068" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSeniorHousingManagedCommunitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r390", "r666", "r701", "r702", "r703", "r704", "r705", "r706", "r838", "r861", "r879", "r977", "r1029", "r1030", "r1039", "r1068" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r16" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r195" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated useful lives of assets", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "sbra_PropertyTaxesInsuranceAndTenantImprovementDepositLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "PropertyTaxesInsuranceAndTenantImprovementDepositLiability", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tenant deposits for future real estate taxes, insurance expenditures, and tenant improvements", "label": "Property Taxes, Insurance, And Tenant Improvement Deposit Liability", "documentation": "Property Taxes, Insurance, And Tenant Improvement Deposit Liability" } } }, "auth_ref": [] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": { "parentTag": "sbra_OperatingAndInterestExpense", "weight": 1.0, "order": 5.0 }, "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for loan losses and other reserves", "verboseLabel": "Provision for loan losses and other reserves", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r312", "r414" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r935" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r935" ] }, "sbra_QuincyMAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "QuincyMAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quincy, MA", "label": "Quincy, MA [Member]", "documentation": "Quincy, MA" } } }, "auth_ref": [] }, "sbra_RadcliffKYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "RadcliffKYMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Radcliff, KY", "label": "Radcliff, KY [Member]", "documentation": "Radcliff, KY" } } }, "auth_ref": [] }, "sbra_RaleighNC1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "RaleighNC1Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raleigh, NC 1", "label": "Raleigh, NC 1 [Member]", "documentation": "Raleigh, NC 1" } } }, "auth_ref": [] }, "sbra_RaleighNC2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "RaleighNC2Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raleigh, NC 2", "label": "Raleigh, NC 2 [Member]", "documentation": "Raleigh, NC 2" } } }, "auth_ref": [] }, "sbra_RaleighNCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "RaleighNCMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raleigh, NC", "label": "Raleigh, NC [Member]", "documentation": "Raleigh, NC" } } }, "auth_ref": [] }, "sbra_RamseyMNMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "RamseyMNMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ramsey, MN", "label": "Ramsey, MN [Member]", "documentation": "Ramsey, MN" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/EQUITYNarrativeDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails", "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedinTotalStockholderReturnBasedStockUnitsValuationDetails", "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r453", "r454", "r455", "r456", "r520", "r527", "r559", "r560", "r561", "r664", "r665", "r707", "r735", "r736", "r788", "r791", "r793", "r794", "r808", "r835", "r836", "r851", "r860", "r873", "r880", "r883", "r1027", "r1036", "r1058", "r1059", "r1060", "r1061", "r1062" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/EQUITYNarrativeDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails", "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedinTotalStockholderReturnBasedStockUnitsValuationDetails", "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r453", "r454", "r455", "r456", "r520", "r527", "r559", "r560", "r561", "r664", "r665", "r707", "r735", "r736", "r788", "r791", "r793", "r794", "r808", "r835", "r836", "r851", "r860", "r873", "r880", "r883", "r1027", "r1036", "r1058", "r1059", "r1060", "r1061", "r1062" ] }, "sbra_RaytownMOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "RaytownMOMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raytown, MO", "label": "Raytown, MO [Member]", "documentation": "Raytown, MO" } } }, "auth_ref": [] }, "sbra_ReadingMAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ReadingMAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reading, MA", "label": "Reading, MA [Member]", "documentation": "Reading, MA" } } }, "auth_ref": [] }, "sbra_ReadingPAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ReadingPAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reading, PA", "label": "Reading, PA [Member]", "documentation": "Reading, PA" } } }, "auth_ref": [] }, "us-gaap_RealEstateAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateAbstract", "lang": { "en-us": { "role": { "label": "Real Estate [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RealEstateAccumulatedDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateAccumulatedDepreciation", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONRollforwardofRealEstateandAccumulatedDepreciationDetails", "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated Depreciation and Amortization", "negatedPeriodStartLabel": "Balance at the beginning of the year", "negatedPeriodEndLabel": "Balance at the end of the year", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Accumulated Depreciation", "documentation": "Amount of accumulated depreciation pertaining to real estate investments for entities with a substantial portion of business acquiring and holding investment real estate." } } }, "auth_ref": [ "r827" ] }, "us-gaap_RealEstateAccumulatedDepreciationOtherDeductions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateAccumulatedDepreciationOtherDeductions", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONRollforwardofRealEstateandAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Accumulated Depreciation, Other Deduction", "documentation": "Amount of other deductions to accumulated depreciation, excluding sales, for entities with a substantial portion of business acquiring and holding investment real estate." } } }, "auth_ref": [ "r832" ] }, "us-gaap_RealEstateAccumulatedDepreciationRealEstateSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateAccumulatedDepreciationRealEstateSold", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONRollforwardofRealEstateandAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of real estate", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Accumulated Depreciation, Investment in Real Estate Sold", "documentation": "Amount of decrease to accumulated depreciation for real estate investments sold for entities with a substantial portion of business acquiring and holding investment real estate." } } }, "auth_ref": [ "r832" ] }, "srt_RealEstateAndAccumulatedDepreciationAmountOfEncumbrances": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RealEstateAndAccumulatedDepreciationAmountOfEncumbrances", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Encumbrances", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Amount of Encumbrances", "documentation": "Amount of lien or mortgage outstanding on real estate investment properties for entities with a substantial portion of business acquiring and holding investment real estate." } } }, "auth_ref": [ "r247", "r823" ] }, "srt_RealEstateAndAccumulatedDepreciationByPropertyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RealEstateAndAccumulatedDepreciationByPropertyTable", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate and Accumulated Depreciation, by Property [Table]", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, by Property [Table]", "documentation": "Disclosure of information about real estate investments and accompanying accumulated depreciation for entities with a substantial portion of business acquiring and holding investment real estate." } } }, "auth_ref": [ "r244", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831" ] }, "us-gaap_RealEstateAndAccumulatedDepreciationCarryingAmountOfBuildingsAndImprovements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateAndAccumulatedDepreciationCarryingAmountOfBuildingsAndImprovements", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails": { "parentTag": "us-gaap_RealEstateGrossAtCarryingValue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Building and Improvements", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Building and Improvements, Amount", "documentation": "Amount before accumulated depreciation of buildings and improvements for entities with a substantial portion of business acquiring and holding investment real estate. Excludes real estate not held as an investment or interest." } } }, "auth_ref": [ "r826" ] }, "us-gaap_RealEstateAndAccumulatedDepreciationCarryingAmountOfLand": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateAndAccumulatedDepreciationCarryingAmountOfLand", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails": { "parentTag": "us-gaap_RealEstateGrossAtCarryingValue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Land, Amount", "documentation": "Amount of land for entities with a substantial portion of business acquiring and holding investment real estate. Excludes real estate not held as an investment or interest." } } }, "auth_ref": [ "r826" ] }, "us-gaap_RealEstateAndAccumulatedDepreciationCarryingAmountOfLandAndBuildingsAndImprovementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateAndAccumulatedDepreciationCarryingAmountOfLandAndBuildingsAndImprovementsAbstract", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Amount at which Carried at Close of Period", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Gross [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RealEstateAndAccumulatedDepreciationCostsCapitalizedSubsequentToAcquisitionCarryingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateAndAccumulatedDepreciationCostsCapitalizedSubsequentToAcquisitionCarryingCosts", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost Capitalized Subsequent to Acquisition", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Cost Capitalized Subsequent to Acquisition, Cost", "documentation": "Amount of cost capitalized subsequent to acquisition for real estate investment property, including, but not limited to, real estate tax and insurance, by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate. Excludes initial purchase price and improvement, and real estate not held as investment or interest." } } }, "auth_ref": [ "r825" ] }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIVMORTGAGELOANSONREALESTATEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Name of Property [Axis]", "label": "Name of Property [Axis]", "documentation": "Information by name of property." } } }, "auth_ref": [ "r246", "r273", "r833", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084" ] }, "srt_RealEstateAndAccumulatedDepreciationDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RealEstateAndAccumulatedDepreciationDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation Disclosure [Abstract]", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation Disclosure [Abstract]" } } }, "auth_ref": [] }, "srt_RealEstateAndAccumulatedDepreciationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RealEstateAndAccumulatedDepreciationDisclosureTextBlock", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATION" ], "lang": { "en-us": { "role": { "terseLabel": "SCHEDULE III - REAL ESTATE ASSETS AND ACCUMULATED DEPRECIATION", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation Disclosure [Text Block]", "documentation": "The entire disclosure of real estate investments and associated accumulated depreciation for entities with a significant portion of their business acquiring and holding investment real estate." } } }, "auth_ref": [ "r255", "r834" ] }, "sbra_RealEstateAndAccumulatedDepreciationInitialCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "RealEstateAndAccumulatedDepreciationInitialCost", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Real Estate and Accumulated Depreciation, Initial Cost", "documentation": "Real Estate and Accumulated Depreciation, Initial Cost" } } }, "auth_ref": [] }, "us-gaap_RealEstateAndAccumulatedDepreciationInitialCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateAndAccumulatedDepreciationInitialCostAbstract", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial Cost to Company", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Initial Cost [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RealEstateAndAccumulatedDepreciationInitialCostOfBuildingsAndImprovements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateAndAccumulatedDepreciationInitialCostOfBuildingsAndImprovements", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails": { "parentTag": "sbra_RealEstateAndAccumulatedDepreciationInitialCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Buildings and Improvements", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Initial Cost of Building and Improvements", "documentation": "Initial cost of buildings and improvements for entities with a substantial portion of business acquiring and holding investment real estate. Excludes real estate not held as an investment or interest." } } }, "auth_ref": [ "r824" ] }, "us-gaap_RealEstateAndAccumulatedDepreciationInitialCostOfLand": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateAndAccumulatedDepreciationInitialCostOfLand", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails": { "parentTag": "sbra_RealEstateAndAccumulatedDepreciationInitialCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Initial Cost of Land", "documentation": "Initial cost of land for entities with a substantial portion of business acquiring and holding investment real estate. Excludes real estate not held as an investment or interest." } } }, "auth_ref": [ "r824" ] }, "sbra_RealEstateAndAccumulatedDepreciationInitialCostTaxBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "RealEstateAndAccumulatedDepreciationInitialCostTaxBasis", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate cost of real estate for federal income tax purposes", "label": "Real Estate and Accumulated Depreciation, Initial Cost, Tax Basis", "documentation": "Real Estate and Accumulated Depreciation, Initial Cost, Tax Basis" } } }, "auth_ref": [] }, "us-gaap_RealEstateAndAccumulatedDepreciationLifeUsedForDepreciation1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateAndAccumulatedDepreciationLifeUsedForDepreciation1", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Life on Which Depreciation in Latest Income Statement is Computed", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation, Life Used for Depreciation", "documentation": "Useful life on which depreciation was computed for entities with a substantial portion of business acquiring and holding investment real estate, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r830" ] }, "srt_RealEstateAndAccumulatedDepreciationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RealEstateAndAccumulatedDepreciationLineItems", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate and Accumulated Depreciation", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate and Accumulated Depreciation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r244", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831" ] }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIVMORTGAGELOANSONREALESTATEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Name of Property [Domain]", "label": "Name of Property [Domain]", "documentation": "Name of the property, for example, but not limited to, ABC Shopping Center." } } }, "auth_ref": [ "r246", "r833", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r1077", "r1078", "r1079", "r1080", "r1081", "r1082", "r1083", "r1084" ] }, "us-gaap_RealEstateCostOfRealEstateSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateCostOfRealEstateSold", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONRollforwardofRealEstateandAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Sale of real estate", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Cost of Investment in Real Estate Sold", "documentation": "Amount of real estate investments sold for entities with a substantial portion of business acquiring and holding investment real estate." } } }, "auth_ref": [ "r832" ] }, "us-gaap_RealEstateDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateDisclosureTextBlock", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIES" ], "lang": { "en-us": { "role": { "terseLabel": "INVESTMENT IN REAL ESTATE PROPERTIES", "label": "Real Estate Disclosure [Text Block]", "documentation": "The entire disclosure for certain real estate investment financial statements, real estate investment trust operating support agreements, real estate owned, retail land sales, time share transactions, as well as other real estate related disclosures." } } }, "auth_ref": [ "r222", "r223", "r224", "r225", "r226" ] }, "us-gaap_RealEstateGrossAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateGrossAtCarryingValue", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONRollforwardofRealEstateandAccumulatedDepreciationDetails", "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "periodStartLabel": "Balance at the beginning of the year", "periodEndLabel": "Balance at the end of the year", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Gross", "documentation": "Amount, before accumulated depreciation, of real estate investment by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate. Excludes real estate not held as investment or interest." } } }, "auth_ref": [ "r826" ] }, "us-gaap_RealEstateHeldForDevelopmentAndSalePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateHeldForDevelopmentAndSalePolicy", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Assets Held for Sale, Dispositions and Discontinued Operations", "label": "Real Estate Held for Development and Sale, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for real estate held for development or sale." } } }, "auth_ref": [ "r2" ] }, "us-gaap_RealEstateHeldforsale": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateHeldforsale", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets held for sale", "label": "Real Estate, Held-for-Sale", "documentation": "Amount of investment in land and building held for sale. Excludes real estate considered inventory." } } }, "auth_ref": [ "r1065" ] }, "us-gaap_RealEstateImprovements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateImprovements", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONRollforwardofRealEstateandAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Improvements", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Improvements", "documentation": "Amount of increase in real estate investments related to improvements for entities with a substantial portion of business acquiring and holding investment real estate." } } }, "auth_ref": [ "r832" ] }, "sbra_RealEstateIntangibleAmortizationIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "RealEstateIntangibleAmortizationIncomeExpenseAbstract", "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRealEstateIntangibleAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real estate intangible amortization income (expense)", "label": "Real Estate Intangible Amortization Income (Expense) [Abstract]", "documentation": "Real Estate Intangible Amortization Income (Expense)" } } }, "auth_ref": [] }, "us-gaap_RealEstateInvestmentPropertyAccumulatedDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateInvestmentPropertyAccumulatedDepreciation", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails": { "parentTag": "us-gaap_RealEstateInvestmentPropertyNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated depreciation", "negatedLabel": "Accumulated Depreciation", "label": "Real Estate Investment Property, Accumulated Depreciation", "documentation": "The cumulative amount of depreciation for real estate property held for investment purposes." } } }, "auth_ref": [ "r673" ] }, "us-gaap_RealEstateInvestmentPropertyAtCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateInvestmentPropertyAtCost", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails": { "parentTag": "us-gaap_RealEstateInvestmentPropertyNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total Real Estate at\u00a0Cost", "label": "Real Estate Investment Property, at Cost", "documentation": "Amount of real estate investment property which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments." } } }, "auth_ref": [ "r674" ] }, "us-gaap_RealEstateInvestmentPropertyNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateInvestmentPropertyNet", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 }, "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Real estate investments, net of accumulated depreciation of $1,021,086 and $913,345 as of December\u00a031, 2023 and 2022, respectively", "totalLabel": "Total Real Estate Investments, Net", "label": "Real Estate Investment Property, Net", "documentation": "Amount of real estate investment property, net of accumulated depreciation, which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments." } } }, "auth_ref": [ "r1065" ] }, "sbra_RealEstateInvestmentsJointVenturesNumber": { "xbrltype": "integerItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "RealEstateInvestmentsJointVenturesNumber", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of investments in loans accounted for as real estate joint ventures", "label": "Real Estate Investments, Joint Ventures, Number", "documentation": "Real Estate Investments, Joint Ventures, Number" } } }, "auth_ref": [] }, "us-gaap_RealEstateOtherAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateOtherAcquisitions", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONRollforwardofRealEstateandAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Other Acquisition", "documentation": "Amount of increase in real estate investments from acquisitions other than through foreclosure for entities with a substantial portion of business acquiring and holding investment real estate." } } }, "auth_ref": [ "r832" ] }, "us-gaap_RealEstateOtherDeductions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateOtherDeductions", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONRollforwardofRealEstateandAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Other Deduction", "documentation": "Amount of other deductions to real estate investments, excluding sales, for entities with a substantial portion of business acquiring and holding investment real estate." } } }, "auth_ref": [ "r832" ] }, "us-gaap_RealEstatePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstatePolicyTextBlock", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate Investments", "label": "Real Estate, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for entities that primarily develop and then sell real property at retail or otherwise." } } }, "auth_ref": [ "r0", "r139" ] }, "us-gaap_RealEstatePropertiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstatePropertiesLineItems", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESNetInvestmentinSalesTypeLeaseNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate Properties [Line Items]", "label": "Real Estate Properties [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ReceivableTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivableTypeDomain", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails", "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receivable [Domain]", "label": "Receivable [Domain]", "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates." } } }, "auth_ref": [ "r47" ] }, "us-gaap_ReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Receivables [Abstract]", "label": "Receivables [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ReconciliationOfCarryingAmountOfRealEstateInvestmentsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfCarryingAmountOfRealEstateInvestmentsRollForward", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONRollforwardofRealEstateandAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real estate:", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ReconciliationOfRealEstateAccumulatedDepreciationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfRealEstateAccumulatedDepreciationRollForward", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONRollforwardofRealEstateandAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated depreciation:", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Accumulated Depreciation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "sbra_RecoveryCentersOfAmericaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "RecoveryCentersOfAmericaMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIVMORTGAGELOANSONREALESTATEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recovery Centers of America", "label": "Recovery Centers Of America [Member]", "documentation": "Recovery Centers Of America" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r901", "r913", "r923", "r949" ] }, "us-gaap_RepaymentsOfMediumTermNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfMediumTermNotes", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Principal payments on term loans", "terseLabel": "Repayment of term loans", "label": "Repayments of Medium-term Notes", "documentation": "The cash outflow to pay off borrowing used to receive debt funding on a regular basis with maturities ranging from 5-10 years." } } }, "auth_ref": [ "r58" ] }, "sbra_RepaymentsOfPreferredEquityInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "RepaymentsOfPreferredEquityInvestments", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayments of preferred equity investments", "label": "Repayments Of Preferred Equity Investments", "documentation": "Repayments Of Preferred Equity Investments" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfSecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfSecuredDebt", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Principal payments on secured debt", "terseLabel": "Repayments of fixed rate secured debt", "label": "Repayments of Secured Debt", "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt." } } }, "auth_ref": [ "r58" ] }, "us-gaap_RepaymentsOfUnsecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfUnsecuredDebt", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Principal payments on senior unsecured notes", "label": "Repayments of Unsecured Debt", "documentation": "The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt." } } }, "auth_ref": [ "r58" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRealEstateIntangibleAmortizationDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]", "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [ "r326", "r327", "r474", "r504", "r656", "r843", "r844" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r902", "r914", "r924", "r950" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r903", "r915", "r925", "r951" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r910", "r922", "r932", "r958" ] }, "us-gaap_RestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash and Cash Equivalents", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r60", "r213", "r279", "r320", "r677" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHARENarrativeDetails", "http://www.sabrahealth.com/role/EQUITYNarrativeDetails", "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units", "verboseLabel": "Restricted Stock Units", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSeniorHousingManagedCommunitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Resident fees and services", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r363", "r364", "r380", "r385", "r386", "r390", "r391", "r393", "r518", "r519", "r666" ] }, "sbra_RevenueFromContractWithCustomerExcludingAssessedTaxMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "RevenueFromContractWithCustomerExcludingAssessedTaxMember", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Resident fee and services", "label": "Revenue From Contract With Customer, Excluding Assessed Tax [Member]", "documentation": "Revenue From Contract With Customer, Excluding Assessed Tax" } } }, "auth_ref": [] }, "us-gaap_RevenueRecognitionLeases": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionLeases", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue Recognition, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue recognition for leases entered into by lessor." } } }, "auth_ref": [ "r846" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialInformationforEnlivantJointVentureDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total revenues", "verboseLabel": "Total revenues", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r308", "r324", "r363", "r364", "r380", "r385", "r386", "r390", "r391", "r393", "r404", "r457", "r458", "r460", "r461", "r462", "r464", "r466", "r468", "r469", "r630", "r672", "r1032" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues:", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails", "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSEffectofDerivativeFinancialInstrumentsontheCondensedConsolidatedStatementsofIncomeandCondensedConsolidatedStatementsofEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "sbra_RichardsonTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "RichardsonTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Richardson, TX", "label": "Richardson, TX [Member]", "documentation": "Richardson, TX" } } }, "auth_ref": [] }, "sbra_RichmondINMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "RichmondINMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Richmond, IN", "label": "Richmond, IN [Member]", "documentation": "Richmond, IN" } } }, "auth_ref": [] }, "sbra_RichmondVAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "RichmondVAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Richmond, VA", "label": "Richmond, VA [Member]", "documentation": "Richmond, VA" } } }, "auth_ref": [] }, "sbra_RiverVistaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "RiverVistaMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIVMORTGAGELOANSONREALESTATEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "River Vista", "label": "River Vista [Member]", "documentation": "River Vista" } } }, "auth_ref": [] }, "sbra_RiversideCAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "RiversideCAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Riverside, CA", "label": "Riverside, CA [Member]", "documentation": "Riverside, CA" } } }, "auth_ref": [] }, "sbra_RoanokeRapidsNCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "RoanokeRapidsNCMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Roanoke Rapids, NC", "label": "Roanoke Rapids, NC [Member]", "documentation": "Roanoke Rapids, NC" } } }, "auth_ref": [] }, "sbra_RochesterMNMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "RochesterMNMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rochester, MN", "label": "Rochester, MN [Member]", "documentation": "Rochester, MN" } } }, "auth_ref": [] }, "sbra_RockportTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "RockportTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rockport, TX", "label": "Rockport, TX [Member]", "documentation": "Rockport, TX" } } }, "auth_ref": [] }, "sbra_RockyMountNCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "RockyMountNCMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rocky Mount, NC", "label": "Rocky Mount, NC [Member]", "documentation": "Rocky Mount, NC" } } }, "auth_ref": [] }, "sbra_RoundRockTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "RoundRockTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Round Rock, TX", "label": "Round Rock, TX [Member]", "documentation": "Round Rock, TX" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r967" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r967" ] }, "us-gaap_SECScheduleIIIRealEstateAccumulatedDepreciationDepreciationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SECScheduleIIIRealEstateAccumulatedDepreciationDepreciationExpense", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONRollforwardofRealEstateandAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Depreciation expense", "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Accumulated Depreciation, Depreciation Expense", "documentation": "Amount of depreciation expense of real estate investments for entities with a substantial portion of business acquiring and holding investment real estate." } } }, "auth_ref": [ "r832" ] }, "sbra_SECScheduleIIIRealEstateAccumulatedDepreciationForeignCurrencyTranslation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SECScheduleIIIRealEstateAccumulatedDepreciationForeignCurrencyTranslation", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONRollforwardofRealEstateandAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Foreign currency translation", "label": "SEC Schedule III, Real Estate Accumulated Depreciation, Foreign Currency Translation", "documentation": "SEC Schedule III, Real Estate Accumulated Depreciation, Foreign Currency Translation" } } }, "auth_ref": [] }, "sbra_SECScheduleIIIRealEstateAccumulatedDepreciationImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SECScheduleIIIRealEstateAccumulatedDepreciationImpairment", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONRollforwardofRealEstateandAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment", "label": "SEC Schedule III, Real Estate Accumulated Depreciation, Impairment", "documentation": "SEC Schedule III, Real Estate Accumulated Depreciation, Impairment" } } }, "auth_ref": [] }, "sbra_SECScheduleIIIRealEstateForeignCurrencyTranslation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SECScheduleIIIRealEstateForeignCurrencyTranslation", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONRollforwardofRealEstateandAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation", "label": "SEC Schedule III, Real Estate, Foreign Currency Translation", "documentation": "SEC Schedule III, Real Estate, Foreign Currency Translation" } } }, "auth_ref": [] }, "sbra_SECScheduleIIIRealEstateImpairments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SECScheduleIIIRealEstateImpairments", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONRollforwardofRealEstateandAccumulatedDepreciationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Impairment", "label": "SEC Schedule III, Real Estate, Impairments", "documentation": "SEC Schedule III, Real Estate, Impairments" } } }, "auth_ref": [] }, "sbra_SacramentoCAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SacramentoCAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sacramento, CA", "label": "Sacramento, CA [Member]", "documentation": "Sacramento, CA" } } }, "auth_ref": [] }, "sbra_SaginawMIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SaginawMIMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Saginaw, MI", "label": "Saginaw, MI [Member]", "documentation": "Saginaw, MI" } } }, "auth_ref": [] }, "sbra_SaleOfStockAgreementTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SaleOfStockAgreementTerm", "presentation": [ "http://www.sabrahealth.com/role/EQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forward sale agreement term", "label": "Sale Of Stock, Agreement Term", "documentation": "Sale Of Stock, Agreement Term" } } }, "auth_ref": [] }, "sbra_SaleOfStockAveragePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SaleOfStockAveragePricePerShare", "presentation": [ "http://www.sabrahealth.com/role/EQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average price per share (in dollars per share)", "label": "Sale Of Stock, Average Price Per Share", "documentation": "Sale Of Stock, Average Price Per Share" } } }, "auth_ref": [] }, "sbra_SaleOfStockForwardAgreementInitialWeightedAveragePriceForwardFeature": { "xbrltype": "perShareItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SaleOfStockForwardAgreementInitialWeightedAveragePriceForwardFeature", "presentation": [ "http://www.sabrahealth.com/role/EQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial weighted average price (in dollars per share)", "label": "Sale Of Stock, Forward Agreement, Initial Weighted Average Price, Forward Feature", "documentation": "Sale Of Stock, Forward Agreement, Initial Weighted Average Price, Forward Feature" } } }, "auth_ref": [] }, "sbra_SaleOfStockMaximumProceedsFromCommonStockIssuances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SaleOfStockMaximumProceedsFromCommonStockIssuances", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/EQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate gross proceeds possible from sales of common stock under equity offering program", "label": "Sale Of Stock, Maximum Proceeds From Common Stock Issuances", "documentation": "Sale Of Stock, Maximum Proceeds From Common Stock Issuances" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.sabrahealth.com/role/EQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://www.sabrahealth.com/role/EQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued (in shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://www.sabrahealth.com/role/EQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Price per share (in dollars per share)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "sbra_SaleOfStockRemainingAmountAvailableForIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SaleOfStockRemainingAmountAvailableForIssuance", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/EQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount available for issuance", "label": "Sale Of Stock, Remaining Amount Available For Issuance", "documentation": "Sale Of Stock, Remaining Amount Available For Issuance" } } }, "auth_ref": [] }, "sbra_SalemORMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SalemORMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Salem, OR", "label": "Salem, OR [Member]", "documentation": "Salem, OR" } } }, "auth_ref": [] }, "us-gaap_SalesTypeLeaseNetInvestmentInLease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesTypeLeaseNetInvestmentInLease", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESNetInvestmentinSalesTypeLeaseNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net investment in sales type lease", "label": "Sales-Type Lease, Net Investment in Lease, before Allowance for Credit Loss", "documentation": "Amount, before allowance for credit loss, of net investment in sales-type lease." } } }, "auth_ref": [ "r237", "r417", "r654", "r1021" ] }, "sbra_SalinaKSMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SalinaKSMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Salina, KS", "label": "Salina, KS [Member]", "documentation": "Salina, KS" } } }, "auth_ref": [] }, "sbra_SanDiegoCAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SanDiegoCAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "San Diego, CA", "label": "San Diego, CA [Member]", "documentation": "San Diego, CA" } } }, "auth_ref": [] }, "sbra_SanLuisObispoCAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SanLuisObispoCAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "San Luis Obispo, CA", "label": "San Luis Obispo, CA [Member]", "documentation": "San Luis Obispo, CA" } } }, "auth_ref": [] }, "sbra_SanMarcosTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SanMarcosTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "San Marcos, TX", "label": "San Marcos, TX [Member]", "documentation": "San Marcos, TX" } } }, "auth_ref": [] }, "sbra_SantaAnaCAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SantaAnaCAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Santa Ana, CA", "label": "Santa Ana, CA [Member]", "documentation": "Santa Ana, CA" } } }, "auth_ref": [] }, "sbra_SantaFeNM1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SantaFeNM1Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Santa Fe, NM 1", "label": "Santa Fe, NM 1 [Member]", "documentation": "Santa Fe, NM 1" } } }, "auth_ref": [] }, "sbra_SantaFeNM2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SantaFeNM2Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Santa Fe, NM 2", "label": "Santa Fe, NM 2 [Member]", "documentation": "Santa Fe, NM 2" } } }, "auth_ref": [] }, "sbra_SarasotaFLMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SarasotaFLMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sarasota, FL", "label": "Sarasota, FL [Member]", "documentation": "Sarasota, FL" } } }, "auth_ref": [] }, "sbra_SarniaONMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SarniaONMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sarnia, ON", "label": "Sarnia, ON [Member]", "documentation": "Sarnia, ON" } } }, "auth_ref": [] }, "sbra_SavannahGA1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SavannahGA1Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Savannah, GA 1", "label": "Savannah, GA 1 [Member]", "documentation": "Savannah, GA 1" } } }, "auth_ref": [] }, "sbra_SavannahGA2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SavannahGA2Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Savannah, GA 2", "label": "Savannah, GA 2 [Member]", "documentation": "Savannah, GA 2" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSCompositionofLoansReceivableandOtherInvestmentsDetails", "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSNarrativeDetails", "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSScheduleofAdditionalInformationRegardingtheCompanysLoansReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": [ "r47" ] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Loans Receivable and Other Investments", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": [ "r47" ] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/EQUITYTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accumulated Other Comprehensive Income", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r49", "r1049", "r1050" ] }, "sbra_ScheduleOfAdditionalInformationLoansAndFinancingReceivableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ScheduleOfAdditionalInformationLoansAndFinancingReceivableTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/LOANSRECEIVABLEANDOTHERINVESTMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Additional Information Regarding the Company's Loans Receivable", "label": "Schedule Of Additional Information, Loans And Financing Receivable [Table Text Block]", "documentation": "Schedule Of Additional Information, Loans And Financing Receivable" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHARENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r66" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails", "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r96", "r98", "r594" ] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/INCOMETAXESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Provision for Income Tax Expense", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r206" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.sabrahealth.com/role/DEBTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Debt", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r44", "r88", "r91", "r140", "r141", "r144", "r149", "r201", "r202", "r856", "r858", "r1007" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/INCOMETAXESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Deferred Taxes", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r205" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of Derivatives and Financial Instruments Designated as Hedging Instruments on Income and Equity", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r117", "r122", "r606" ] }, "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Derivative and Financial Instruments Designated as Hedging Instruments", "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]", "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position." } } }, "auth_ref": [ "r115" ] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": [ "http://www.sabrahealth.com/role/IMPAIRMENTOFREALESTATEANDDISPOSITIONSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Dispositions", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r19", "r29", "r40", "r152", "r153", "r154", "r155", "r156", "r157", "r159", "r160", "r161", "r197" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Computation of Basic and Diluted Earnings Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r1011" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESScheduleofInvestmentinJointVenturesDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialInformationforEnlivantJointVentureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]", "documentation": "Information by name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": [ "r401", "r402", "r403" ] }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESScheduleofInvestmentinJointVenturesDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialInformationforEnlivantJointVentureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments [Line Items]", "label": "Schedule of Equity Method Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r324", "r401", "r402", "r403", "r404", "r630" ] }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEquityMethodInvestmentsTable", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESScheduleofInvestmentinJointVenturesDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialInformationforEnlivantJointVentureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments [Table]", "label": "Schedule of Equity Method Investments [Table]", "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available." } } }, "auth_ref": [ "r278", "r324", "r401", "r402", "r403", "r404", "r630" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Items Measured at Fair Value on a Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r621", "r622" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESIntangibleAssetsandLiabilitiesDetails", "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESRealEstateIntangibleAmortizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r79", "r80", "r667" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Assets and Liabilities", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r79", "r80" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/DEBTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Maturities for Outstanding Debt", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r17" ] }, "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/DERIVATIVEANDHEDGINGINSTRUMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Notional Amount of Derivatives Instruments", "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]", "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions." } } }, "auth_ref": [ "r110" ] }, "sbra_ScheduleOfRealEstateIntangiblesAmortizationIncomeAndExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ScheduleOfRealEstateIntangiblesAmortizationIncomeAndExpenseTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Real Estate Intangible Amortization Income (Expense)", "label": "Schedule Of Real Estate Intangibles Amortization Income And Expense [Table Text Block]", "documentation": "Schedule Of Real Estate Intangibles Amortization Income And Expense" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRealEstatePropertiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRealEstatePropertiesTable", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESNetInvestmentinSalesTypeLeaseNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Real Estate Properties Held for Investment [Table]", "label": "Schedule of Real Estate Properties [Table]", "documentation": "Schedule detailing quantitative information concerning real estate properties and units within those properties by ownership of the property." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRealEstatePropertiesTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Real Estate Properties Held for Investment", "label": "Schedule of Real Estate Properties [Table Text Block]", "documentation": "Tabular disclosure of real estate properties and units in those properties that are included in the discussion of the nature of an entity's operations." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Purchase Price Allocation", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [ "r208" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedinTotalStockholderReturnBasedStockUnitsValuationDetails", "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r529", "r531", "r534", "r535", "r536", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r558", "r559", "r560", "r561", "r562" ] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Additional Information Concerning Restricted Stock Units", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [ "r92" ] }, "sbra_ScheduleOfShareBasedPaymentAwardRestrictedStockUnitsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ScheduleOfShareBasedPaymentAwardRestrictedStockUnitsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Assumptions Used in Total Stockholder Return-Based Stock Units Valuation", "label": "Schedule Of Share-Based Payment Award, Restricted Stock Units, Valuation Assumptions [Table Text Block]", "documentation": "Schedule of Share-based Payment Award, Restricted Stock Units, Valuation Assumptions [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.sabrahealth.com/role/EQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r85", "r86", "r87", "r88", "r89", "r90", "r91", "r201", "r202", "r203", "r283", "r284", "r285", "r360", "r502", "r503", "r504", "r506", "r509", "r514", "r516", "r717", "r718", "r719", "r720", "r860", "r975", "r1003" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Remaining Unamortized Balance for Outstanding Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r80" ] }, "sbra_ScottDepotWVMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ScottDepotWVMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scott Depot, WV", "label": "Scott Depot, WV [Member]", "documentation": "Scott Depot, WV" } } }, "auth_ref": [] }, "sbra_SeattleWA1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SeattleWA1Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Seattle, WA 1", "label": "Seattle, WA 1 [Member]", "documentation": "Seattle, WA 1" } } }, "auth_ref": [] }, "sbra_SeattleWAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SeattleWAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Seattle, WA", "label": "Seattle, WA [Member]", "documentation": "Seattle, WA" } } }, "auth_ref": [] }, "us-gaap_SecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredDebt", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Secured debt, net", "label": "Secured Debt", "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower." } } }, "auth_ref": [ "r39", "r217", "r1067" ] }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredDebtMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails", "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessDetails", "http://www.sabrahealth.com/role/DEBTSecuredIndebtednessNarrativeDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails", "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Secured Debt", "terseLabel": "Secured Indebtedness", "label": "Secured Debt [Member]", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": [] }, "sbra_SecuredOvernightFinancingRateSOFRMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SecuredOvernightFinancingRateSOFRMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SOFR", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Secured Overnight Financing Rate (SOFR)" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r894" ] }, "us-gaap_SecurityDepositLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecurityDepositLiability", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Security deposit liability", "label": "Security Deposit Liability", "documentation": "This element represents money paid in advance to protect the provider of a product or service, such as a lessor, against damage or nonpayment by the buyer or tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property, and other contractual breaches. Security deposits held may be interest or noninterest bearing." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r897" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r393", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r449", "r450", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r854", "r977", "r1068" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": [ "r244", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r391", "r392", "r727", "r730", "r732", "r790", "r792", "r796", "r810", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r839", "r862", "r883", "r1039", "r1068" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Industry Segments", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r374", "r375", "r376", "r377", "r378", "r379", "r391", "r850" ] }, "sbra_SeguinTX1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SeguinTX1Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Seguin, TX 1", "label": "Seguin, TX 1 [Member]", "documentation": "Seguin, TX 1" } } }, "auth_ref": [] }, "sbra_SeguinTX2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SeguinTX2Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Seguin, TX 2", "label": "Seguin, TX 2 [Member]", "documentation": "Seguin, TX 2" } } }, "auth_ref": [] }, "sbra_SeguinTX3Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SeguinTX3Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Seguin, TX 3", "label": "Seguin, TX 3 [Member]", "documentation": "Seguin, TX 3" } } }, "auth_ref": [] }, "sbra_SellersburgINMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SellersburgINMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sellersburg, IN", "label": "Sellersburg, IN [Member]", "documentation": "Sellersburg, IN" } } }, "auth_ref": [] }, "sbra_SeniorHousingFacilitiesLeasedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SeniorHousingFacilitiesLeasedMember", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails", "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails", "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Senior housing - leased portfolio", "terseLabel": "Senior Housing - Leased", "label": "Senior Housing Facilities - Leased [Member]", "documentation": "Senior Housing Facilities - Leased [Member]" } } }, "auth_ref": [] }, "sbra_SeniorHousingFacilitiesManagedCommunitiesProprietaryDevelopmentPipelineMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SeniorHousingFacilitiesManagedCommunitiesProprietaryDevelopmentPipelineMember", "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior housing facilities - managed communities, proprietary development pipeline", "label": "Senior Housing Facilities - Managed Communities, Proprietary Development Pipeline [Member]", "documentation": "Senior Housing Facilities - Managed Communities, Proprietary Development Pipeline" } } }, "auth_ref": [] }, "sbra_SeniorHousingFacilitiesManagedPortfolioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SeniorHousingFacilitiesManagedPortfolioMember", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails", "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails", "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior housing - managed portfolio", "verboseLabel": "Senior Housing - Managed", "label": "Senior Housing Facilities - Managed Portfolio [Member]", "documentation": "Senior Housing Facilities - Managed Portfolio [Member]" } } }, "auth_ref": [] }, "sbra_SeniorHousingFacilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SeniorHousingFacilitiesMember", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESScheduleofInvestmentinJointVenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Housing - Managed", "label": "Senior Housing Facilities [Member]", "documentation": "Senior Housing Facilities [Member]" } } }, "auth_ref": [] }, "us-gaap_SeniorNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeniorNotes", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Principal balance", "label": "Senior Notes", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders." } } }, "auth_ref": [ "r147", "r1067" ] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeniorNotesMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTScheduleofMaturitiesforOutstandingDebtDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFaceValuesCarryingAmountsandFairValuesofFinancialInstrumentsDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESFairValueofFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "sbra_SequimWAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SequimWAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sequim, WA", "label": "Sequim, WA [Member]", "documentation": "Sequim, WA" } } }, "auth_ref": [] }, "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember", "presentation": [ "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails", "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Recent Real Estate Acquisitions", "label": "Series of Individually Immaterial Business Acquisitions [Member]", "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period." } } }, "auth_ref": [ "r98" ] }, "sbra_SeymourMOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SeymourMOMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Seymour, MO", "label": "Seymour, MO [Member]", "documentation": "Seymour, MO" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r13" ] }, "sbra_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentage", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting percentage", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Percentage", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Percentage" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r874" ] }, "sbra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsDividendsReinvestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsDividendsReinvestedInPeriod", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends reinvested (in shares)", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Dividends Reinvested In Period", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Dividends Reinvested In Period" } } }, "auth_ref": [] }, "sbra_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsDividendsReinvestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsDividendsReinvestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends reinvested (in dollars per share)", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Dividends Reinvested In Period, Weighted Average Grant Date Fair Value", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Dividends Reinvested In Period, Weighted Average Grant Date Fair Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cancelled/forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r551" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cancelled/forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r551" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r549" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average fair value per share at grant date (in dollars per share)", "verboseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r549" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Unvested, beginning (in shares)", "periodEndLabel": "Unvested, ending (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r546", "r547" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Unvested, beginning (in dollars per share)", "periodEndLabel": "Unvested, ending (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r546", "r547" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Date Fair Value Per Unit", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r204" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r550" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total fair value of units vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": [ "r553" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r550" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedinTotalStockholderReturnBasedStockUnitsValuationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assumptions used in valuation", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedinTotalStockholderReturnBasedStockUnitsValuationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield (assuming full reinvestment)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r560" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedinTotalStockholderReturnBasedStockUnitsValuationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected stock price volatility, maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedinTotalStockholderReturnBasedStockUnitsValuationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected stock price volatility, minimum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "sbra_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsHistoricalVolatilityRatePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsHistoricalVolatilityRatePeriod", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Historical volatility rate period", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Historical Volatility Rate Period", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Historical Volatility Rate Period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedinTotalStockholderReturnBasedStockUnitsValuationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk free interest rate, maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedinTotalStockholderReturnBasedStockUnitsValuationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk free interest rate, minimum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedinTotalStockholderReturnBasedStockUnitsValuationDetails", "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r529", "r531", "r534", "r535", "r536", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r558", "r559", "r560", "r561", "r562" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.sabrahealth.com/role/EQUITYNarrativeDetails", "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedinTotalStockholderReturnBasedStockUnitsValuationDetails", "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONRestrictedStockUnitsActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r534", "r535", "r536", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r558", "r559", "r560", "r561", "r562" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r528", "r537", "r556", "r557", "r558", "r559", "r562", "r570", "r571", "r572", "r573" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedinTotalStockholderReturnBasedStockUnitsValuationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected service period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r558" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "sbra_ShavanoParkTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ShavanoParkTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shavano Park, TX", "label": "Shavano Park, TX [Member]", "documentation": "Shavano Park, TX" } } }, "auth_ref": [] }, "sbra_SheboyganWIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SheboyganWIMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sheboygan, WI", "label": "Sheboygan, WI [Member]", "documentation": "Sheboygan, WI" } } }, "auth_ref": [] }, "sbra_ShermanTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ShermanTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sherman, TX", "label": "Sherman, TX [Member]", "documentation": "Sherman, TX" } } }, "auth_ref": [] }, "sbra_ShorelineWA1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ShorelineWA1Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shoreline, WA 1", "label": "Shoreline, WA 1 [Member]", "documentation": "Shoreline, WA 1" } } }, "auth_ref": [] }, "sbra_ShorelineWAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ShorelineWAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shoreline, WA", "label": "Shoreline, WA [Member]", "documentation": "Shoreline, WA" } } }, "auth_ref": [] }, "sbra_SiennaJointVentureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SiennaJointVentureMember", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESScheduleofInvestmentinJointVenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sienna Joint Venture", "label": "Sienna Joint Venture [Member]", "documentation": "Sienna Joint Venture" } } }, "auth_ref": [] }, "sbra_SiennaSeniorLivingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SiennaSeniorLivingMember", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESInvestmentinUnconsolidatedJointVentureNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sienna Senior Living", "label": "Sienna Senior Living [Member]", "documentation": "Sienna Senior Living" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "lang": { "en-us": { "role": { "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r188", "r321" ] }, "sbra_SilexMOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SilexMOMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Silex, MO", "label": "Silex, MO [Member]", "documentation": "Silex, MO" } } }, "auth_ref": [] }, "sbra_SkilledNursingTransitionalCareFacilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SkilledNursingTransitionalCareFacilitiesMember", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESNetInvestmentinSalesTypeLeaseNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails", "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails", "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Skilled nursing transitional care facility", "terseLabel": "Skilled Nursing/Transitional Care", "label": "Skilled Nursing Transitional Care Facilities [Member]", "documentation": "Skilled Nursing Transitional Care Facilities [Member]" } } }, "auth_ref": [] }, "sbra_SparksNVMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SparksNVMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sparks, NV", "label": "Sparks, NV [Member]", "documentation": "Sparks, NV" } } }, "auth_ref": [] }, "sbra_SpecialtyHospitalsAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SpecialtyHospitalsAndOtherMember", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails", "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Specialty Hospitals and Other", "verboseLabel": "Specialty Hospitals and Other", "label": "Specialty Hospitals And Other [Member]", "documentation": "Specialty Hospitals And Other [Member]" } } }, "auth_ref": [] }, "sbra_SpringTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SpringTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Spring, TX", "label": "Spring, TX [Member]", "documentation": "Spring, TX" } } }, "auth_ref": [] }, "sbra_SpringfieldMAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SpringfieldMAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Springfield, MA", "label": "Springfield, MA [Member]", "documentation": "Springfield, MA" } } }, "auth_ref": [] }, "sbra_St.FrancisWIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "St.FrancisWIMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "St. Francis, WI", "label": "St. Francis, WI [Member]", "documentation": "St. Francis, WI" } } }, "auth_ref": [] }, "sbra_St.LouisMOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "St.LouisMOMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "St. Louis, MO", "label": "St. Louis, MO [Member]", "documentation": "St. Louis, MO" } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails", "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESRealEstatePropertiesHeldforInvestmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r276", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r393", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r447", "r449", "r450", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r854", "r977", "r1068" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY", "http://www.sabrahealth.com/role/EQUITYAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r24", "r46", "r274", "r305", "r306", "r307", "r330", "r331", "r332", "r334", "r340", "r342", "r359", "r405", "r406", "r517", "r567", "r568", "r569", "r587", "r588", "r609", "r610", "r611", "r612", "r613", "r614", "r617", "r633", "r635", "r636", "r637", "r638", "r639", "r655", "r708", "r709", "r710", "r723", "r783" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": [ "r244", "r256", "r391", "r392", "r727", "r730", "r732", "r790", "r792", "r796", "r810", "r818", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r839", "r862", "r883", "r1039", "r1068" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY", "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r330", "r331", "r332", "r359", "r666", "r715", "r724", "r737", "r738", "r739", "r740", "r741", "r742", "r745", "r747", "r748", "r749", "r750", "r751", "r753", "r754", "r755", "r756", "r758", "r759", "r760", "r761", "r762", "r764", "r766", "r767", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r783", "r884" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialInformationforEnlivantJointVentureDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "verboseLabel": "Balance Sheet Amounts", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY", "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r330", "r331", "r332", "r359", "r666", "r715", "r724", "r737", "r738", "r739", "r740", "r741", "r742", "r745", "r747", "r748", "r749", "r750", "r751", "r753", "r754", "r755", "r756", "r758", "r759", "r760", "r761", "r762", "r764", "r766", "r767", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r783", "r884" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r905", "r917", "r927", "r953" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock issuance, net (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r24", "r166", "r167", "r203", "r717", "r783", "r811" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://www.sabrahealth.com/role/EQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued upon vesting (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r24", "r166", "r167", "r203" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock issuance, net", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r24", "r166", "r167", "r203", "r723", "r783", "r811", "r892" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY", "http://www.sabrahealth.com/role/EQUITYAccumulatedOtherComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "verboseLabel": "Accumulated other comprehensive income (loss)", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r167", "r169", "r170", "r190", "r746", "r763", "r784", "r785", "r878", "r893", "r1005", "r1019", "r1048", "r1074" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESSummarizedFinancialInformationforEnlivantJointVentureDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Member\u2019s equity (deficit)", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r101", "r102", "r107", "r274", "r275", "r306", "r330", "r331", "r332", "r334", "r340", "r405", "r406", "r517", "r567", "r568", "r569", "r587", "r588", "r609", "r610", "r611", "r612", "r613", "r614", "r617", "r633", "r635", "r639", "r655", "r709", "r710", "r722", "r746", "r763", "r784", "r785", "r812", "r892", "r1005", "r1019", "r1048", "r1074" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.sabrahealth.com/role/EQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "EQUITY", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r200", "r323", "r501", "r503", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r515", "r517", "r616", "r786", "r787", "r813" ] }, "sbra_StraffordMOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "StraffordMOMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Strafford, MO", "label": "Strafford, MO [Member]", "documentation": "Strafford, MO" } } }, "auth_ref": [] }, "sbra_StrasburgVAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "StrasburgVAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Strasburg, VA", "label": "Strasburg, VA [Member]", "documentation": "Strasburg, VA" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.sabrahealth.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r640", "r659" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.sabrahealth.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r640", "r659" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://www.sabrahealth.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r640", "r659" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.sabrahealth.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r640", "r659" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.sabrahealth.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r640", "r659" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events [Abstract]", "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.sabrahealth.com/role/SUBSEQUENTEVENTS" ], "lang": { "en-us": { "role": { "terseLabel": "SUBSEQUENT EVENTS", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r658", "r660" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.sabrahealth.com/role/EQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "sbra_SudburyMAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SudburyMAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sudbury, MA", "label": "Sudbury, MA [Member]", "documentation": "Sudbury, MA" } } }, "auth_ref": [] }, "sbra_SunCityWestAZMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SunCityWestAZMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sun City West, AZ", "label": "Sun City West, AZ [Member]", "documentation": "Sun City West, AZ" } } }, "auth_ref": [] }, "sbra_SunnyvaleTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "SunnyvaleTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sunnyvale, TX", "label": "Sunnyvale, TX [Member]", "documentation": "Sunnyvale, TX" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r946" ] }, "sbra_TacomaWA1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "TacomaWA1Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tacoma, WA 1", "label": "Tacoma, WA 1 [Member]", "documentation": "Tacoma, WA 1" } } }, "auth_ref": [] }, "sbra_TacomaWA2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "TacomaWA2Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tacoma, WA 2", "label": "Tacoma, WA 2 [Member]", "documentation": "Tacoma, WA 2" } } }, "auth_ref": [] }, "sbra_TacomaWA3Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "TacomaWA3Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tacoma, WA 3", "label": "Tacoma, WA 3 [Member]", "documentation": "Tacoma, WA 3" } } }, "auth_ref": [] }, "sbra_TempeAZMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "TempeAZMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tempe, AZ", "label": "Tempe, AZ [Member]", "documentation": "Tempe, AZ" } } }, "auth_ref": [] }, "sbra_TenantOriginationAndAbsorptionCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "TenantOriginationAndAbsorptionCostsMember", "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESIntangibleAssetsandLiabilitiesDetails", "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails", "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tenant origination and absorption costs", "verboseLabel": "Tenant origination and absorption costs intangible assets", "label": "Tenant Origination and Absorption Costs [Member]", "documentation": "Tenant Origination and Absorption Costs [Member]" } } }, "auth_ref": [] }, "sbra_TenantRelationshipMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "TenantRelationshipMember", "presentation": [ "http://www.sabrahealth.com/role/INTANGIBLEASSETSANDLIABILITIESIntangibleAssetsandLiabilitiesDetails", "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDNarrativeDetails", "http://www.sabrahealth.com/role/RECENTREALESTATEACQUISITIONSCONSOLIDATEDPurchasePriceAllocationforRecentRealEstateAcquisitionsDetails" ], "lang": { "en-us": { "role": { "netLabel": "Tenant relationships", "verboseLabel": "Tenant relationship intangible assets", "terseLabel": "Tenant relationship", "label": "Tenant Relationship [Member]", "documentation": "Tenant Relationship [Member]" } } }, "auth_ref": [] }, "sbra_TerreHauteIN1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "TerreHauteIN1Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Terre Haute, IN 1", "label": "Terre Haute, IN 1 [Member]", "documentation": "Terre Haute, IN 1" } } }, "auth_ref": [] }, "sbra_TerreHauteINMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "TerreHauteINMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Terre Haute, IN", "label": "Terre Haute, IN [Member]", "documentation": "Terre Haute, IN" } } }, "auth_ref": [] }, "sbra_TigardORMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "TigardORMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tigard, OR", "label": "Tigard, OR [Member]", "documentation": "Tigard, OR" } } }, "auth_ref": [] }, "sbra_TompkinsvilleKYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "TompkinsvilleKYMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tompkinsville, KY", "label": "Tompkinsville, KY [Member]", "documentation": "Tompkinsville, KY" } } }, "auth_ref": [] }, "sbra_TopekaKSMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "TopekaKSMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Topeka, KS", "label": "Topeka, KS [Member]", "documentation": "Topeka, KS" } } }, "auth_ref": [] }, "sbra_TotalShareholderReturnUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "TotalShareholderReturnUnitsMember", "presentation": [ "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedinTotalStockholderReturnBasedStockUnitsValuationDetails", "http://www.sabrahealth.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "TSR Units", "label": "Total Shareholder Return Units [Member]", "documentation": "Total Shareholder Return Units [Member]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r938" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r945" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r966" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r968" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.sabrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r969" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r970" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r968" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r968" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r971" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r969" ] }, "sbra_TrinityTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "TrinityTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trinity, TX", "label": "Trinity, TX [Member]", "documentation": "Trinity, TX" } } }, "auth_ref": [] }, "sbra_TripleNetPortfolioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "TripleNetPortfolioMember", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Triple-net portfolio", "label": "Triple-Net Portfolio [Member]", "documentation": "Triple-Net Portfolio [Member]" } } }, "auth_ref": [] }, "sbra_TualatinORMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "TualatinORMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tualatin, OR", "label": "Tualatin, OR [Member]", "documentation": "Tualatin, OR" } } }, "auth_ref": [] }, "us-gaap_TypeOfRevenueExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfRevenueExtensibleList", "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, type, extensible enumeration", "label": "Revenue, Product and Service [Extensible Enumeration]", "documentation": "Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources." } } }, "auth_ref": [] }, "sbra_U.S.DollarTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "U.S.DollarTermLoanMember", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails", "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. dollar Term Loans", "label": "U.S. Dollar Term Loan [Member]", "documentation": "U.S. Dollar Term Loan [Member]" } } }, "auth_ref": [] }, "sbra_UnderwrittenPublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "UnderwrittenPublicOfferingMember", "presentation": [ "http://www.sabrahealth.com/role/EQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Underwritten Public Offering", "label": "Underwritten Public Offering [Member]", "documentation": "Underwritten Public Offering" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r965" ] }, "us-gaap_UnsecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnsecuredDebt", "crdr": "credit", "calculation": { "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Senior unsecured notes, net", "label": "Unsecured Debt", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer)." } } }, "auth_ref": [ "r39", "r217", "r1067" ] }, "us-gaap_UnusualOrInfrequentItemInsuranceProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnusualOrInfrequentItemInsuranceProceeds", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds of insurance", "label": "Unusual or Infrequent Item, or Both, Insurance Proceeds", "documentation": "Amount of insurance proceeds for an event or transaction that is unusual in nature or infrequent in occurrence, or both." } } }, "auth_ref": [ "r180" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r68", "r69", "r70", "r232", "r233", "r234", "r235" ] }, "us-gaap_ValuationAllowanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowanceLineItems", "presentation": [ "http://www.sabrahealth.com/role/INCOMETAXESDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes [Line Items]", "label": "Valuation Allowance [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ValuationAllowanceTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowanceTable", "presentation": [ "http://www.sabrahealth.com/role/INCOMETAXESDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Allowance [Table]", "label": "Valuation Allowance [Table]", "documentation": "A listing of an entity's valuation allowances to reduce deferred tax assets to amounts which it is more likely than not will not be realized, including a description of the deferred tax assets for which the valuation allowance has been recorded and the amount of the valuation allowance." } } }, "auth_ref": [ "r95" ] }, "sbra_VanNuysCAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "VanNuysCAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Van Nuys, CA", "label": "Van Nuys, CA [Member]", "documentation": "Van Nuys, CA" } } }, "auth_ref": [] }, "sbra_VancouverWAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "VancouverWAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vancouver, WA", "label": "Vancouver, WA [Member]", "documentation": "Vancouver, WA" } } }, "auth_ref": [] }, "sbra_VandalismAndTheftMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "VandalismAndTheftMember", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vandalism And Theft", "label": "Vandalism And Theft [Member]", "documentation": "Vandalism And Theft" } } }, "auth_ref": [] }, "sbra_VariableInterestEntityNumberOfEntities": { "xbrltype": "integerItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "VariableInterestEntityNumberOfEntities", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of variable interest entities", "label": "Variable Interest Entity, Number Of Entities", "documentation": "Variable Interest Entity, Number Of Entities" } } }, "auth_ref": [] }, "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableInterestEntityPrimaryBeneficiaryMember", "presentation": [ "http://www.sabrahealth.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Primary beneficiary", "label": "Variable Interest Entity, Primary Beneficiary [Member]", "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity." } } }, "auth_ref": [ "r104", "r596", "r597", "r599", "r600" ] }, "us-gaap_VariableLeaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableLeaseIncome", "crdr": "credit", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable lease revenue", "label": "Variable Lease, Income", "documentation": "Amount of variable lease payments from operating, direct financing, and sales-type leases, excluding amount included in measurement of lease receivable." } } }, "auth_ref": [ "r653" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://www.sabrahealth.com/role/DEBTCreditAgreementNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "sbra_VenturaCAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "VenturaCAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ventura, CA", "label": "Ventura, CA [Member]", "documentation": "Ventura, CA" } } }, "auth_ref": [] }, "sbra_VernonBCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "VernonBCMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vernon, BC", "label": "Vernon, BC [Member]", "documentation": "Vernon, BC" } } }, "auth_ref": [] }, "sbra_W.SpringfieldMAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "W.SpringfieldMAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "W. Springfield, MA", "label": "W. Springfield, MA [Member]", "documentation": "W. Springfield, MA" } } }, "auth_ref": [] }, "sbra_WarrenMIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "WarrenMIMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warren, MI", "label": "Warren, MI [Member]", "documentation": "Warren, MI" } } }, "auth_ref": [] }, "sbra_WarringtonPAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "WarringtonPAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrington, PA", "label": "Warrington, PA [Member]", "documentation": "Warrington, PA" } } }, "auth_ref": [] }, "sbra_WashingtonCourtHouseOHMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "WashingtonCourtHouseOHMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Washington Court House, OH", "label": "Washington Court House, OH [Member]", "documentation": "Washington Court House, OH" } } }, "auth_ref": [] }, "sbra_WaterlooONMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "WaterlooONMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Waterloo, ON", "label": "Waterloo, ON [Member]", "documentation": "Waterloo, ON" } } }, "auth_ref": [] }, "sbra_WaxahachieTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "WaxahachieTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Waxahachie, TX", "label": "Waxahachie, TX [Member]", "documentation": "Waxahachie, TX" } } }, "auth_ref": [] }, "sbra_WebsterTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "WebsterTXMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Webster, TX", "label": "Webster, TX [Member]", "documentation": "Webster, TX" } } }, "auth_ref": [] }, "srt_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "WeightedAverageMember", "presentation": [ "http://www.sabrahealth.com/role/EQUITYNarrativeDetails", "http://www.sabrahealth.com/role/FAIRVALUEDISCLOSURESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average", "label": "Weighted Average [Member]", "documentation": "Average of a range of values, calculated with consideration of proportional relevance." } } }, "auth_ref": [ "r835", "r836", "r1057", "r1059", "r1062" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHAREComputationofBasicandDilutedEarningsPerShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS", "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHAREComputationofBasicandDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average number of common shares outstanding, diluted (in shares)", "totalLabel": "Diluted weighted average common shares (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r345", "r353" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHAREComputationofBasicandDilutedEarningsPerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sabrahealth.com/role/CONSOLIDATEDSTATEMENTSOFINCOMELOSS", "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHAREComputationofBasicandDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average number of common shares outstanding, basic (in shares)", "verboseLabel": "Basic weighted average common shares and common equivalents (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r344", "r353" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://www.sabrahealth.com/role/EARNINGSPERCOMMONSHAREComputationofBasicandDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Denominator", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": [] }, "sbra_WestSenecaNYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "WestSenecaNYMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "West Seneca, NY", "label": "West Seneca, NY [Member]", "documentation": "West Seneca, NY" } } }, "auth_ref": [] }, "sbra_WestminsterMDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "WestminsterMDMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Westminster, MD", "label": "Westminster, MD [Member]", "documentation": "Westminster, MD" } } }, "auth_ref": [] }, "sbra_WilliamsportPAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "WilliamsportPAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Williamsport, PA", "label": "Williamsport, PA [Member]", "documentation": "Williamsport, PA" } } }, "auth_ref": [] }, "sbra_WilliamsvilleNYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "WilliamsvilleNYMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Williamsville, NY", "label": "Williamsville, NY [Member]", "documentation": "Williamsville, NY" } } }, "auth_ref": [] }, "sbra_WilmingtonDEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "WilmingtonDEMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Wilmington, DE", "label": "Wilmington, DE [Member]", "documentation": "Wilmington, DE" } } }, "auth_ref": [] }, "sbra_WilmingtonNCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "WilmingtonNCMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Wilmington, NC", "label": "Wilmington, NC [Member]", "documentation": "Wilmington, NC" } } }, "auth_ref": [] }, "sbra_WinchesterINMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "WinchesterINMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Winchester, IN", "label": "Winchester, IN [Member]", "documentation": "Winchester, IN" } } }, "auth_ref": [] }, "sbra_WinchesterKYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "WinchesterKYMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Winchester, KY", "label": "Winchester, KY [Member]", "documentation": "Winchester, KY" } } }, "auth_ref": [] }, "sbra_WindsorMOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "WindsorMOMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Windsor, MO", "label": "Windsor, MO [Member]", "documentation": "Windsor, MO" } } }, "auth_ref": [] }, "sbra_WindsorONMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "WindsorONMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Windsor, ON", "label": "Windsor, ON [Member]", "documentation": "Windsor, ON" } } }, "auth_ref": [] }, "sbra_WinnebagoILMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "WinnebagoILMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Winnebago, IL", "label": "Winnebago, IL [Member]", "documentation": "Winnebago, IL" } } }, "auth_ref": [] }, "sbra_WinstonSalemNCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "WinstonSalemNCMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Winston-Salem, NC", "label": "Winston-Salem, NC [Member]", "documentation": "Winston-Salem, NC" } } }, "auth_ref": [] }, "sbra_WisconsinDellsWIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "WisconsinDellsWIMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Wisconsin Dells, WI", "label": "Wisconsin Dells, WI [Member]", "documentation": "Wisconsin Dells, WI" } } }, "auth_ref": [] }, "sbra_WolfeboroNHMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "WolfeboroNHMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Wolfeboro, NH", "label": "Wolfeboro, NH [Member]", "documentation": "Wolfeboro, NH" } } }, "auth_ref": [] }, "sbra_WoodlandCA1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "WoodlandCA1Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Woodland, CA 1", "label": "Woodland, CA 1 [Member]", "documentation": "Woodland, CA 1" } } }, "auth_ref": [] }, "sbra_WoodlandCA2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "WoodlandCA2Member", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Woodland, CA 2", "label": "Woodland, CA 2 [Member]", "documentation": "Woodland, CA 2" } } }, "auth_ref": [] }, "sbra_WoodstockVAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "WoodstockVAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Woodstock, VA", "label": "Woodstock, VA [Member]", "documentation": "Woodstock, VA" } } }, "auth_ref": [] }, "sbra_WorcesterMAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "WorcesterMAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Worcester, MA", "label": "Worcester, MA [Member]", "documentation": "Worcester, MA" } } }, "auth_ref": [] }, "us-gaap_WriteOffOfDeferredDebtIssuanceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WriteOffOfDeferredDebtIssuanceCost", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/DEBTSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Write-offs associated with unamortized discount and deferred financing costs", "label": "Deferred Debt Issuance Cost, Writeoff", "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt." } } }, "auth_ref": [ "r178" ] }, "sbra_WriteOffOfNonCashRentReceivableAndIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "WriteOffOfNonCashRentReceivableAndIntangibles", "crdr": "debit", "presentation": [ "http://www.sabrahealth.com/role/INVESTMENTINREALESTATEPROPERTIESOperatingLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Write-off of non-cash rent receivable", "label": "Write-Off Of Non-Cash Rent Receivable And Intangibles", "documentation": "Write-Off Of Non-Cash Rent Receivable And Intangibles" } } }, "auth_ref": [] }, "sbra_WyncotePAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "WyncotePAMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Wyncote, PA", "label": "Wyncote, PA [Member]", "documentation": "Wyncote, PA" } } }, "auth_ref": [] }, "sbra_WynneARMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "WynneARMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Wynne, AR", "label": "Wynne, AR [Member]", "documentation": "Wynne, AR" } } }, "auth_ref": [] }, "sbra_YarmouthMEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "YarmouthMEMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Yarmouth, ME", "label": "Yarmouth, ME [Member]", "documentation": "Yarmouth, ME" } } }, "auth_ref": [] }, "sbra_YumaAZMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "YumaAZMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Yuma, AZ", "label": "Yuma, AZ [Member]", "documentation": "Yuma, AZ" } } }, "auth_ref": [] }, "sbra_ZebulonNCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ZebulonNCMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Zebulon, NC", "label": "Zebulon, NC [Member]", "documentation": "Zebulon, NC" } } }, "auth_ref": [] }, "sbra_ZephyrhillsFLMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sabrahealth.com/20231231", "localname": "ZephyrhillsFLMember", "presentation": [ "http://www.sabrahealth.com/role/SCHEDULEIIIREALESTATEASSETSANDACCUMULATEDDEPRECIATIONSummaryofRealEstatePropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Zephyrhills, FL", "label": "Zephyrhills, FL [Member]", "documentation": "Zephyrhills, FL" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "SubTopic": "10", "Topic": "970", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482170/970-10-05-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "340", "Topic": "970", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482051/970-340-25-13" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "SubTopic": "360", "Topic": "970", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482232/970-360-35-3" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a),(b),(c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(f)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21B", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21B" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(c)(1)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(1)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2C", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2C" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "e", "SubTopic": "470", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-4" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4D" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-13" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-8" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "60", "Paragraph": "1", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.3,4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//310-10/tableOfContent" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "50", "Paragraph": "11B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "50", "Paragraph": "15", "Subparagraph": "(b,d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-29" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-7" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-9" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "2AA", "Subparagraph": "a", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-2AA" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-4" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-5A" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a),(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480870/815-30-50-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "20", "Section": "15", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482960/835-20-15-8" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-4" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(1),(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.16)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-20/tableOfContent" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-7" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483613/220-20-50-1" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483605/220-30-50-1" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483605/220-30-50-1" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r186": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r187": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r188": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r189": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r190": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r191": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r192": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r193": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r194": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r195": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r196": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r197": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A" }, "r198": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r199": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r200": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r201": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r202": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r203": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r204": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r205": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r206": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r207": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r208": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r209": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r210": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r211": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//815/tableOfContent" }, "r212": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r213": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r214": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r215": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r216": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r217": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r218": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r219": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r220": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r221": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r222": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "970", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//970/tableOfContent" }, "r223": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "972", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//972/tableOfContent" }, "r224": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "974", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//974/tableOfContent" }, "r225": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "976", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//976/tableOfContent" }, "r226": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "978", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//978/tableOfContent" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "SubTopic": "360", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479638/944-360-45-3" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "SubTopic": "230", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481160/942-230-45-4" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "SubTopic": "360", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479638/944-360-45-4" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "360", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479607/944-360-50-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-7A" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.M.Q4)", "SubTopic": "20", "Topic": "326", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483530/326-20-S99-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "(a)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "(a)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "(a)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "(c)", "Publisher": "SEC" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Footnote": "2", "Publisher": "SEC" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Footnote": "4", "Publisher": "SEC" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Footnote": "5", "Publisher": "SEC" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Publisher": "SEC" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Footnote": "4", "Publisher": "SEC" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Footnote": "6", "Publisher": "SEC" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Footnote": "8", "Publisher": "SEC" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column B", "Publisher": "SEC" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column E", "Publisher": "SEC" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column F", "Publisher": "SEC" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Publisher": "SEC" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "(a)", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "(a)", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "(a)", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "(a)", "Subparagraph": "(4)(iii)(C)", "Publisher": "SEC" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "(a)", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "(m)", "Subparagraph": "(1)(iii)", "Publisher": "SEC" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "5", "Subsection": "04", "Paragraph": "c", "Subparagraph": "Schedule III", "Publisher": "SEC" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-4" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483605/220-30-50-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-6A" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-4" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479391/326-20-30-4A" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479391/326-20-30-5A" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "8A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479366/326-20-35-8A" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-5" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-17" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-21" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-3C" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-3D" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-6" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479175/326-30-30-1B" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "13A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479148/326-30-35-13A" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479148/326-30-35-7A" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-3A" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-3C" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-3D" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5C" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480627/815-20-45-3" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-2" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//830/tableOfContent" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479016/842-30-45-3" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-6" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-20" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r848": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r850": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r851": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r852": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "79", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-79" }, "r853": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "80", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-80" }, "r854": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r855": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r856": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r857": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r858": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r859": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r860": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r861": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r862": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r863": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r864": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r865": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r866": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r867": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r868": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r869": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r870": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r871": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r872": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r873": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r874": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r875": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r876": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r877": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r878": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r879": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r880": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r881": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r882": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r883": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r884": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r885": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r886": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r887": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r888": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r889": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r890": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r891": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r892": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r893": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r894": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r895": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r896": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r897": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r898": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r899": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r900": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r901": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r902": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r903": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r904": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r905": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r906": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r907": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r908": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r909": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r910": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r911": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r912": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r913": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r914": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r915": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r916": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r917": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r918": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r919": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r920": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r921": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r922": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r923": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r924": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r925": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r926": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r927": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r928": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r929": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r930": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r931": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r932": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r933": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r934": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r935": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r936": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r937": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r938": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r939": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r940": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r941": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r942": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r943": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r944": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r945": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r946": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r947": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r948": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r949": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r950": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r951": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r952": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r953": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r954": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r955": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r956": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r957": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r958": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r959": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r960": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r961": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r962": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r963": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r964": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r965": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r966": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r967": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r968": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r969": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r970": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r971": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r972": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r973": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r974": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r975": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CC", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CC" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1404", "Paragraph": "(a)", "Publisher": "SEC" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(ii)", "Publisher": "SEC" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(iii)", "Publisher": "SEC" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "(a)", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//310-10/tableOfContent" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//310-30/tableOfContent" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//326-20/tableOfContent" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//326-30/tableOfContent" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(14)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" } } } ZIP 120 0001492298-24-000008-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001492298-24-000008-xbrl.zip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

)LO#'O*TLJ]G0,)*LQAT96Y]: M*W1I&\C1%EU6?ST/8=I%;YZ6\4_LJ-)HL V+(EP M?J;>@ 6#4QJR04!P,]O\<*<_4*\9)O?.=$YQFNRA @\_$19<\# \F2;?[5)? M-C O"U#7ECQ>;_UM"1!F*Q:"!NXTOQBWH)^" MN(6AR4)ZDYI.6T;8HM1LE-:*1*EVO+9%:7DHO:+@)TU@A/!!XQ2JMNRTA>H6 M0+50K:HMQ[P!L6B!6WW46,,H;MIBXS7U1L-P9OG5ECB3H7K% R]#JSEJ2UM* MVD+30&@6JC6U)?"UM<1?+RAH$K'R(GV9U:^H9$IBU"=$5JH#M4V0*5O[+I0#?$FHS :X5_;R, )\4G@TMZ0TNB"NSD) M2.V,NUSDCK 2CF/25B,O"5 GL6F=^#"C\T7WM8U*V EA)\0F5@@;NK"H?&[; M5NJJV2;4&WY"@A_FK \V:&*G@]G3H=#50=MXS?-CRFOF=/[$X.NP_WE?VPB& MMI*JK2^I6H&2.C"4U]^@I*KK2ZI:I*0,Y;>SR# 7%&R"]KT[Q%INVZT #[2E M>G46UJ9TH+:\L,["VI0:U)9$WN@9-05[0J:J76T)50N.S:MY;&$ MF 7/!DV_0\,).FWJZI5?&ADM+@#K7CYLH_V3"W?5KNZ7YXN,;B':LT)%62P:G"MB.=%?*0MG?CTN40]K$=!/?SQI1*WF"H: M4]JRC,OKH)R0D(6+G(P04\G:C+E ((Q0"MGC*!:?X_/F"$5;]FYMH;3#B(U@ M(G3ZV2-&2T1;2LRP:5+D!H4C;;DGDZ9)H1+1EN%99:$$C(LK'M'"2G\8-B\+ M59;:O.R]?'9P:04 [#LDJ@@TL!]K13581O#8$M*.E7IVS,%01%+D<'%OF MRD37H% (:$LTZ0L!/11!D/0-EH' MO8@Z\55SH*$MF?=&Z_5K! T3&+Z?AD;=0N,%T-"6^=-P0=&#[RE4_(91?ELA M?FO +,>BMMSC&S5@WJY>K%>T94#?J,7TEK%HJ=@W;*'7*Y:#U5C=O"D3K5[1 ME@S>)!;?DDVH$1:UI<*-Q**!-J%&6-26>]]L_8XWB05MR?:W@@5KO"T'I@E4 M_^9MJ;^Y%2'>DW;X()6 MXMG0H1OUFK8<^S/%DU !9Y1$I91&T4)8VO+>90IK92->7"'>5#AH2S"O@L,U M]%*\IFH]VJT>N5M?)AYMF=5GBN=-J%9M"4;MYM)&Q*,MQ:?S7'K>H7]P MZW$QPM*6Y5HEK*^!1\6=8%%$@^OX%M[6Z?=I.>[PPK2J5G:K^VM.J_RM+Y.4 MMBR/3I+*$1<+@_\BXJ)N+G'Q6JM-?;=2VZW5UYD6"[>^:%K4S>4L7E$R&SA[ MN%XWEZXH43(E,:MU;>F&)MI0#[=%=VD8">:"WR]'_VO HK#;^[JE4T%;[U\K MZ6SFX.MZ75OG7ROI;,B=K.OK[4?0*7RF_5<,[6KQT9@'&)B;EU;3=>-1[.-A MX#>"!*&OC@SW_AV'$3YMSAJCKV-O@"0*+-)>K^OKM3];$I\("RYX&%[1J$7" MX9G/[SY3;T"OB3!JHL*/(X=:TLA@U9VPUM*8%" MI?-3:"/W:Z#-5+EK1SB\^GQ7.RWBP O/!!]U8/BDB1-*2&VIU$UA/EXB&SO7 M%Z6N':.RF;E^PR/B]X9@F VY[U'1I5$L@FV>[MJ1-3\]]:S@GR5X;7F@3=O< M9;E/VM(]&@UXD11"0UM6QRH@%(^V#(]>XME0%&=?.[9'3_%L*(RSKQTI\];L MMDW-2R-8F6T6_*9FO+;$S'G@\A&](??-.!IR 4V;-R1/X=0%Y MR J+& W;]ZX?>]1#CAU#W7$D6?9.OTU$P()!>$V%7(5/ILM?\(8#I_OZ$A#; M*^M-F>7ZLAG;*^L-6>('^E(C9FLI8^:/0-017SWSC(&?1IC0CO[3 M149%^1M^B):$06KB4#N6<*L@\9W(6LV@SZZ;YF!".QYQJS!Q&O=A%'SOFT&( MT)*YW!I$-*'O4DG<_,L<2%CNLDQ(=+G[8PR=,0D1EKPL$Q$7+'"Y'UP99%M: MXK),0)P).H(!OVJ;<[S2H>4M7P41JTY6T@@1EK4L$Q$G1$0^#2?8HLX7$ #VNF:XW,<:-#IVBAHX8"PS&69&N(:.N*3 MP%L)78T089G+,A%QPP9$&(4'2UR6B8?/:9Z$29"PS&69D/A''+CX;6MBQ3 M1US1.TR<,4A''%O*LDQ = 0=&&=9'FO)6FX-)FZ(RT?D>],<&OM82]9RU3CW MAEQ0GP7T^ZID9V/PIQ$D+&U9IHXXH3ZF90_):"5X-<*$I2[+Q$2/_A4SH_!@ M>+A.PVC$0J(BDMSO,^JEGSEJK'^ H(F(>:J75KCLGA,&,E87A/Q@XKP-A:# M[]\L* H'A64MRUP]6BQP61"0B'6,.5^A4=62NEPYU$,B?!Y%2;VGE?5EC0&B M1L"P)&:9RJ()BB+PR!K8U0@26K*86P.):QHEQL\W<[+U&U5+8[X6*,R)=U2- M9#(_ V!$B(,3V$Y(I.H*\MGEHF)3\P7?&H0OUW3 MDLK<&CQ<\CB(KGU*0I!0KV4.++1D,[<&%I^)$'P ]]P84_RT4;-<9JG6A#PZ MV"05H26/N35X."%3](O,.:.G4;/\9:EK!E@2BGPW"1.6P"QUT8"?J# )#Y:[ M+%='C&Y1/YA#9M?,Y"UY',HC%5<-M#'PTP@1EK4L4T5-[^2>#(D[9":YGW4M.8.1SSPSLV)#3" Z6L"Q309QQ M$4ZCH4GZ04NV]:"!MODJ1)08?G* M5UDXC#G>K[%O"'KEA$B:T M9"W7BWW&XF M*X?9&/AIA =+5):I(OXD8L1CHXR(0\M3EHF(2R+\6RYX/!A>FG-8VZ&63.76 M@")U/,VAK@\M4UDF(#KP]0$UZ#3'0RVIRM5!H\ EX3H'V1@#/XT@H259N3II M41ZL:P%1 B L65GFFM'RL0:V:>>T'5K.LE1WP_W"@H"NWI:J$2(L:UDF(C[S M\0^0SZ4YR71'6G*66P.(,Y\+&KCT^[DYB+"L99F(Z$5[9] EX4F8<+REF5B MHLN3K3LF+1R6M2P3$M]9" ,.[3BEOF^4JK#D9:G+QY#>\NF !"9!0DO^X&O_-! MW)\$I<&7/^W*43@JM"0N=9!1(?!M$7\"S6O!P*Y$KT:@L.1EF:"8U< U!Q/[ M%4M?EJPHACQ>O<1I! @MZZ7['D9:D^:!RXS*"3%?8KEKPL M$P\7])8$)A5$WJ\8R5Q>$L%H%)%/MM9I\8BPM&69*N*4J%Q+DXQ*RUN6B8C. M'=R-I6=,@H26O.760 *>@FNA.;&-_8J6E.6J<;[BHL_]']^L&5$\("Q=6::& M^$R$X%YX&XN!0-#BL8AP M=P'M&'/4PGY52P)SU:!_(C[Z[-^WR1$6!:S5&^4 MB*C/A6<0(NJ6Q'PM([-N#B@LD?E:H&B8 PHMFZK92A*@(1E,LO4 M$RWNQZ-;1DPR)[1D,;<&$9LDP5<1J+(1D9M+.G82G+,O'0)3YE@^%5RYQ,B8:6?.7V M(<*8TR#W&Y:N+-7Q9/Y(<>TFK1M:$I:KAUKNQN[!'%R]2!N#0HU0H25EJ8., M"H'O!0M<[@>&:0I+6Y:)B4L>"&[0^?/[#2UYRZW!P__1V]@W2T%8UK)4AX.[ M/Z:7/ XBDS"A)7.Y-9@XI3T><7..CMW?UY*V7)D +U@ ;;5G2Y< ""UYRU6 M^,+$[525&;68*!X3EKDLU=,@(AP2WS=IV;#,99F(^$Z$H,'EN3EXT)*UW!H\ M?"8CK!YP94[>[;Z6A.6J<6Z3,+HFD3OD@YBN'&UC,*@1+"QG6>JZ@>4NR4CM MY3%)6UCJLDQ8M(:4_HCX'1D0DT!AZP+?O2. 9A0M+89:ZAM P MZM& NB9AXD!+&G-K,'%")U3XT\M5AY)I! @M:-"Z,0<2EL8L$Q+M ;!]TP"A.4QRP3$/V,6N$:9$4;2F&+!D99D*XCL7+C4LI'%HZ4NR\0%8@+9JF&K:4Y5HD,MV$!H M25^N#'D1)E2PV4*B>$AH25[J(*-"L'M"?.^.!==$_%B)7GU <:0E@;DUH/@$ M7_=NJ!#$I2:A0DL6<]5@7X-H^W#-+AXE($)+&E,'&16S>,2"T>"[01K"TIAE MXJ%'213Y]+M!+NB193'+1,3G&,9!ED$]06K"'%A8%K-,6+2&) KO6O'PE3-3-P82E+\O%A,=,LB,L:UDF&KIL0J$9GDE\Q+$E M+2"DI!ZK[*BW].( MBJO/YH!@"]G#38/@BH3#F)@$@BWD"S<-@B^4!M0D#&PA0;AI#)QB+3N3,* E M)V@V!CX)4 0G9/K=F+,5#RI;R 1N&@9X=OL8>F!.A."@NH7DWZ9AT"(>>)'$ M->>DU8/J%I)]FX:!7!3D+@>3@+"%#-^F@7!) A9&U"@8;"&UMWD8A-R@T[4.BR>0N>AS_X=)*+#L8?&Z M %K_G4P#:E#<3QT$+1O([#:/F_YF#!,LAEN$S>B #]T=X&XO!-V.V MJ1W4+)-80IPQ#CP,-AH4:*Q9-K'XY0&D0<[HU:4YFTUJ6O*):P_TJKV@>H-. M(QA80K$$$X$$/WP6&)2+5K.,8N$P^$P#L!1#'EQ],P<'EE$L@5&DP9",3#(1 M+:-8?"X:]8C ,V ,PD'=GW3>(Q4T PJ,QMP]**Q=L)%# @ M9*:R22K!$HN%(^$?)!P;5=.V85G%,G8ZCTC0^6(.""REJ*E@M.3XUDK,I<$H MCH8K*W]L# F7)( W>M?PZC[W&3<'$UH2?JLP\8E,??";+!X*Q\.^EL3?*CRT M21C=D#L26D04CX@W0P ^4T2%(/>2B' (P^![!E6_W=>2"5R9IL&Y%T;<_;%R M_Z\I"-0($6^&$-R$DFCZ/@T,BAGMOQE6 B9F'GEH5C;LXY[0?[ M1G*6W['//.C!)!RMG(*FX% C4!A)6E[P8#!A]&[E&FT!\5Q '!C)6GX!R9&P M!?"Z]U8PX@+&=9)AW!W.&(!YY!I5QP8"17 M>3WD(//[E2Z^*=C3!P^'6E*5&HBH$-S^ VR(\)8+WC2G5N.A92I+1$1G /Q MU1P>XM!(JK+C3T=C1K[;S,K"\6")RA*UPW<6>"$7'7.V6!Y:GK)$/%QP/$?2 M)#A8EK)$.'RA/K\+R(DY672'EJ8L<[F GX7/N4D*PA*4)0*B1T3 B$EPL.QD MF>L%&8%V&(+!$.US@,;F06(BP]62(B6L0? M$#%MGIB#!RT)RFW!PP7Y07L1G< S*\E4C3!A2- (D_!@J,7DFGDF(L+QEF?YG)(A$A#E% MA0XKEK8L$1%898H(+^0&'99P6+&D98F0N.9W9&I.O>O#BJ4L2T3#%;T[$20. M^M0/35(1EK0L$13->!!#NS\9I"0L7UDF'@)WR 5\MFG,F;N'%2T9RVU!Q 6? M4)\$7N>S.8"P9&6)@#@// :?'0:L1'BQC M62(>+HE'F2 F+1J6K]1=1-7M(Q!/Z)!,0$C$_PS/12N M)4NX,A^(^S#,'N^-!4R_L-59M0-!.[1IA MF<%G(Z!F$?#3"-"2!ER%@!,_ M[O\EH3?RGWK/OL/N:71,.)WP9=5%?RM^!\7OY;LWDK_APO! M?)CY*VMQ6]$_+GHM>;Q5HL=S.SSB4PW.#S!7\MM'UFW"T[NAH_%J'&HD=BTY MN=5F_H0%9&6>A780TTCN6G)OJ^3^#7Z*A17\"P1?TY+16QWL"$X9'7 K^1=( M7DM.S[@5_HK>J;+]YIPV>U@SD\PC8D1]2^2\0.Y&4G@7/&9J6Z%E<5X@>R-) MO$L>"$YUV5-JKO"-I/ ^Q7[_1%#Z'[KRQ$TK^\=E;R:'!W)7A^_V5A4KM[)_ M7/9:LG@K-U*1*<9L+E?E1UC!/RYX+7F\-RH+([FU7AP$TPGQZF M+@.93S_S<,PBXH?-P.M$0RJ, 4%=2YYM,U(I!)]-Z&TPB(S:;%O?/LIMLR!H M2??0) 08R;QA O,Z,TUCN&D$ 2U).(.5@$KN-$D):$G%&8R CB#!@!I49Z&N M)1]G, (NR?T=]?V;?QESR,!A74M>;ALPL"K)7R,,:,G/;0,&ZN9@8/NHN@W; M@R2X),+E)M78J6O)$9H, CJ(66"2/="P#&$Y$##''&AHR0^N&N-\YG-! U>'++UM4 .6)-11*EH2=RT>A-QG M'L'A/X=)&JI1C\/= 2'C#QWH(Y[9/.BIUX;FC+>6)-FJ\6YQ,>8PXO2*!\F0 MFS/BQE)2^%L++@VXF,[+(WUZ%>[7:LKLVZ"]FJX;CV(?_O!.Z5B@?L.FY%JU M5!-VV82*;PS>4CPNX*4B.H46*614JO#_V7NRWS(1>[-;YT"4_O)S(#*6T[(@ M*E6Y:$ES%2(,ZN*QQM,6?):*L--OCF!@W%6BT0BWAJJ:?2UI,PLIO13/OI;, MVA9+@=U_$-27. ^';.P0X0KNSX\N/K+'Q>!]K5*IOT_N>-\G;K3;YSP*>$3? M.7W!1UW:#_]XU]^M'E<<^._1D?SO\3O'9\&/[M.OE>_$^]XY$4]>%.Q6WSE< M>%3\\0Z!\7ZAM>F5D,?"I:'ZX/XY^NV-> M-/Q0K53^YYV\]>/OX9@$'W^_%>_A!>K?ZCT/WT;$ %X8\?&'.KP));!+?#8( M/KA2=[Q3[TIO=[$JWH>_5>3__=8'D>WVR8CYTP]_OP& ALX5O7.Z?$2"O^^$ M@,S=$(3<5S>&[#_T0Q7;*_^\4WTXA/? &-.T3]4:]N+KU?E-^]3IW31OVKWY M+N0:KTMK>^W6U^[YS7F[YS2O3IWVOUJ?FU>?VDZK M"\<^F8)RD&V2#_V6O/V61Q$??4 9P&(6(6>8?$1^3_V<@O]XK]%H(/XCF&B1 MEWXX^74/^OC^X?7CH[WCRO*?*GM5>?V]?)](?TP&#>;*._D,= 2'Z(]W]7<+ M?4U:#\/C2(_?284X)AX>1_ZAXL!OV2?>RZX_/=3[&YFAC:6 ^=^_50\JOZ4 MV<2L.^MT+QU<+0(>7,72P'&21024-:[=H*H#@NNR1]F'4PZF%(P8#=QVIE]XM4TK.W?'0V.%TK/S'Z=JJ];*H5+,.CM>#[RR41/YQ.0']]@+;7 MENCQ\=[1?OVY$FV \7'PI$#7QD9]KX*(6HV-QX"0"KHVOG<6%B2?]A\. 1^O M/W&;@A'?^1HPEWO4N>S]],Q5]MFS%58S"&+B=^D8C'8P:KD8D0BLQ_OH0Y_= M4V\W$G&FT&JH&HX/&P>_+>JT#&21MXE!_$GM]V#JR#%L7EU];5XXW?9UIWOC M7'_M]KXVKVZYTNDYU_Q?O5Z=SYMQ\;CLY(RTST)JM&_RY M>EQOS(W/TRORZR\"CRR 7#C1D#I]%H)4G"DEPJ&!1[V?6!6OI3/65G3*/,H\ MN+([@E<,\;%=CTQW\5.[-$A1UW@.K%NQ$/#!,]GH/^%%ZWYT]KWZNX^GU)4^ MJEH(T*SEMF#Y''@NV+MT MP,((]&MT!;^D@#]\]['7/.DVG<_MYL7-9Z?5[+9!QYS?[#CG5ZV]QY3J)H9\ M@S3&FBYP^YZXD8/#Z_"^,QMPAX2.3/GJ,[!F6>"<1Z'3&A(!37WH+EMRYBTH MLGG*^?57B$IEKZ*,M&?9P0=[U5JM$$.XL=?8WR_F3=BH>DDFM9IZKV *KM0Q MSS2IE=8_#]PD!0^,)9FWW.)Q$(EI"PS\.>L:&N1^D#'7L> 3?,_,0SUZ]_&2 MB"F>O5N^F:UP6O;P+O=8YG7=S_7)<,35 MQN'QDV#8FCGWBYPWN*3/S:9?+?1U%]SY7G>OM^>T1V.?3\%!G >V<\7W?GV& M]_O:H?6PU'[(- M/_>1:PYKN/]_;*P6^.03]7K_^P)FC9\&V+VT-.K&0IX:[@B)22JHYXQC$<;( ML43<@3ODNEZM_7+[*V(7PXE--_JP%G7;V( ;?GR\MW]0?2YLZX=[!P?%A*-J MU;UZ0:^2K3IZ"VZX:IA'W<03^! ' !.\"VP&%OG25V@3=^BT?!*&9=C4K^,I M/+OS@F WG-YT=,O]+?(EGNITRO=*@;?OW2&6X'- #7T?,KC2S735=GK'ZUM2 MB0*?5FNWI.F,BG GQ8UHLYZ3;A'K.$"83 M3,VO;/PPB'/2?>!";-'\^QF8I5-1A;L6F4X*O\Z3G'CBYPT8#%80&R$Q^J1](.T=W &LP;6%?H-%C_P##_X+ ( M]V 9+58BEM=K\WG@(K3/ A6Y[<8 VD9E/P5_;L[ /-A30_7PO\\E<[Y#@[Y@ M>WI)<\YE:S)5=?SNXY\T7%1)/Y64L&;*U[I02;)U2T@3> Y8'_[WBL_)8]-C MU-CD&#TOD\FHN1SP"*[\%3-TYQ#?SZ9U?K[?TN0&>/&2*3XWJW-K=^:VPTS'GS$OUO%B M/$Y!WHJU"JBD-JHU1^;QA\XO\#[P*IPP!B\_''+,YG+4+G!XAD2+O;@CX4/5 M)!]..O*KY.!_J>4Z>PO^"=QS^V_H"CXC;X<'L27)NV09*]D0V5 21LYQQ?'( M-"S,&DGV.*B4;'0_(Q+%LZE9?<(8L7/3FB1O7G_A3(9)/&)1!%.?^C"9!0_0 M7_6G#L7*)LXY>L4$]-6$.J:E]Z'UE=S[2%/3.U,BJ%J[W:VEYF3>AMQ;L]2((0'G MZN'>P?'SDK4?O[Y??WK[X[J-VJ_N'5>?)F=?OU$U:-3^\UY57*,>NU[;.ZP? MO^*6TW)B:2LUX$^E.TN:(2TKMB1,)&^2^L1-;II%C&KU=Q\OEFLG4]/DUQOD M(G*%B^C3=W@WOC]\46_N-]^1XH6CBXB*[%ES-LM4]Y*IMDU]U$5N1=GQE25V M_ L38'03V=6\06RA:3HTMT12NLBKR)[UE!.GNI9Y%XD5AUER!LCP<#6\S ,#MY53*,Q"]V;'8*/#3P?LD MQZZEAF[U!%BS*M+SMSLF!&>M(2LU;XCC[#]!)NXX;-UL$8S*R%@,^.R8-A)Q M)PX5$0E=597GHJP>51KRP% (?LN?XL?O&'P:&2F5(^WTJ@U2X>N%% M?))A["H X: .$-QW\(2#'&YF++7<:I"AHU%IY#8W]8BX)?#:W^&7 MZK[S=:^'1:\/:P>X$^I7[/BLETE6[ZT/"BB'SCX3(Q70&\.W"=X$@)99D)YL M,8D]%B7MVC04U]>CYVY?-+'E7#1G\COSR6!E\=&#U=5'C9D"?2><9;N <)^[ MA>Y1O9J?13/TAND)B6'ZCGS8*7#]V%/YM.JQ))^E[\LT%[CD.X)PP'H?^-,7FLJ^:@\^T\N$9"WK1*&IC/UM9[Q_#Z?QR?[AZN3<&J$^C M3 83$5 <5FJ%B1E44F#GP"?U69:-@ I=G20#+R+^-&1*'0>X*0'T\^XMP<4; MEW<:A$K18UH$_"03RK*OY^&<*7YZ#S-,)G#P?I^Y5(3Y_ H!IL8$T9\U(3$H M\K-/I6LXM49EKUHYW:W"'-PTDM_&HB\CX>&0^GX6L_YE2>+_H_'>QW-:;'JP M41DGSV8F$#-K^V5'VV-1J)I(. _(8 S"?\:JZ)BCJ8.C*'4KS*SI(_F +PME#,QCI3J!>. RC.544VJ?#50L6"2PXS& M7;;*:,B_%//0?,R&#;GO[3A)?BP!U0L6NW/+/&73AS_0 I(O@Q;+++6Y]\@- M0$E?Y.MN$QH*4VR?6 U&/)2Z'@0%IHKT&"GV!,,HEC?:^\PA6?:G(\P8+X/_UB%TR07!8N.ZXKK#T6EVO@$-A>V5SOYS=<.GS5LK2RF M5RF%M2C9Y1M83SNMKY?MJYL>UJ[M=*\[W28>NW7RI]-MG[6[[:M6>[Y'S[;2 MPUD%..J=3+NI5KJ!YTY\&+Y,2/ X!/VATR54%"ML]OM%* X>5PV=7"JCM M'1T]7?QH_<+(Q]6G2RR7E#KS%$+Z_4+0NBPJ]E1MG=^)-FUQA@(-@[^M<ES[6'D^3YZ-1T3Y_/(?/YL(4-ZD7WC% M+M[_H5K=JSUIAUH$/0-!![ DW[0ODZW(>\[)U][Y5;O7LPIB6\1K%80>4C,4 M0<=S"J*YYW3/>U^Y M^-8^=7HWS;,SI]6YE!2HU1G;(O#:D=496HC-3 C!U=M7:"5J(S5 ('>;MA'VP$YK=+^T;YZS3=;KM3^>]FV[SZB;).N[) M:$?GRFG_\^OYS9\[<,>%S/CNW71:7SYW+D[;77C!S4V[VY,IG>>]WE>X=/VU MV_K<[+5[3N=9)J%!+;VP1D*PNTD1L9D(HC9=4Z;UZ '7-U"L9'<@_HF:\7-_(6C+DT\0=KEFP-8JS2T41L9D)H?RXR M>]C<<_[Y%7RB\QO0$]_:4H' A8OT[QRYZC1/.E]O4I<*,TRM4MD61#1LNH<> M8C,40G.AW*.]G&W2 T725MOJU;;8Z^L+^7>S^Z=SVKQI6B6R+0AHV'P0/<1F M)H0.YH*\QWM.ZW/SZE,;RW%(U0&F2/-3MYTHD^_G-Y^=9JO5^0JJ!"^@]Z/^ M/+_Z)!^8*:&9%6.US;9 Q6H;3<1F*(0:<]H&_*!6Y^JFV[E0=HK,0CNU.27; M)&ZK,301FZ$0F@LN'Y_L.9V;S^TNF"=GG>ZEI%FMKM@60>_;A%4]Q&8FA [3 MS7+'K;V<]X%)*,TNYK9C2DK[_-.5\X^OW?/>Z7E+1FFR1J#0I-Q&8HA.9K@%70JNBV97V? M':?]KW;KJPS7=L[.SEMIOFI6Q-CYU/G6[B(9:OG/K44B:B,U0",W7#*ON MY;1(JW-YW;[J64ICJZ1M%88F8C,30D?SU<-J>^FFES^=SOG3W"?7Z^IN-.=)'M$N4O.^=5I&ZR;T[;UAK8((%;':"(V M0R$TE\!:;6#!LO.KUODU6"^S)#/GK-U.TEC;W6_G+9LMZ>XZ"$W M4S%4!VUQ==K^EW/3P4TKO<[%^:ED/9?MNK6*8T'H9[OFBOU).^.]/+0VO?[H M*<./"^0GSQ1>-0)/G>/[^,G/JWY MZ;V9LZV[Z1'NH1,-!8\'0QY'\$\6.AYW8WE0?<0=+,!4J_S6([>"[,@_JK^E M%^_HXA4>BR67PO02'DR?7(ZSB_(L>?R4_(;SF1(_&CHM/'8^.4H\C2O^BC+4 MY>I^+Y_T+5A["<.&@+P1IB$@00&W&00Q\9TN'7,1.3QPSK@8*??A%WE# CZ\ MDL#O5T2/?%_R6Y^+.R*\79_S'V "I"AE ?PPDD/M$)PR!*8'A;?C?*%]:*7G MW$[A.G6N!9M TYP>=6,!&A4&XP+^9Z >AGF'C6H";GG?J1X?[^]!NZ?Y[LB7 M>UPB5ZIOBM,#VA]Q@5:'PX4#KQ8X1?O$A2?@ K0-V@.0AWFST(?<]CT9 MC7UH$WS]\?N@OZX?>]0AOI^_+.@ 'L![85X[]'X,\P]ZWH^C&+_+ A*X#%J8 MKB4[\$08^Y'\'(?))PR+\C0O![V2G89[W:,!@'#YS?&+@[#J7) MCO;=:!0' M2A"_D)RX*'S^UQTILZPG9,1C["B^,6(CV=,^:)T)\VC@J>M*DW@@#\%NXZ1# M8\'_K5Z![PK"1/NX9(S(5A>ACS!,V'L^&M.(X;J<&ZH!] 94'Q\C?),6PXLY M=#C"067!A(:1%$3^,C0D?0=>QW%3S;S%!L$G0A1T*J.\$&0#H2D^@T&GSAV# MK\MK0Q(,J)Q7 PZV;H#?A"^!]&-?/;SG_,ECZ%W@X,!$K \(YB.*@X7C^02R MDED2AW09!.^X@%$.8W>(TRR9DR!NYK(QO&)Q=0$9,CIYE#9=:M2C!U'IB MG%*]!&^#H4I'.1NCM98PG?1V!Q0&**M8XDCI!!@X0&\?UW^4C T^U.G+_@( M>LVAU[-)A2H//D$!K'*9!Q2A!GIB_ ^)/D2 FT"%@&H!JDPN0!9* T'#^W@ MI,=YCG(+=Q+\^J 2$Z M-&I^_*J-/561@'H*0G!HI6L@R:_T;Q04FAS@5X#[FU 5X$F, M,6AC5Z+7MCYF] 78$DS(2>,.P7E*S$+B_3M.6(W,[(#U":<<<5UD8Q(2!L5( M0+21%>'K:[^9&-&1)K?,9]$TE8J0A"O(32B>",6:BE+0"0UB^L ?;\YDVXO@ M 8*\S]\#U'B*#$#:G_X5([C@ M*8N0UT6(,C%A,A76E+U]1F#"1,\M6!RJ4DSG\-/ MR"?I4"X0#F#.^@Z5.2!YO_,.G-$[&W7>M/V:B5800@&CT3$"56>Y=3QR9V=L*\K99(E;CF8+>\.T_5OG@UX M'@+RN;81=8?TTRU/N/LGVT:EL>BM*7=)9P)^ )6W(QFB&9NX/CZ,0 M-*B4W=>]WEX^MUYMU'2G3M^/3%+25YZM[$FD=!'1,?;7C5.6W4$45SYC# MG/FIJ\6X'6)Y8(LPM>,1KZ,HXBQI<)EPG$B 7Y[E"F*M@"Q94.8#*U5*X5^X M7))[Q0]J*M%MG7J+VXM13&E@)MFGB8E$R9Y^E)*,F,+_YH(VZ=[V7'KP(D;P MO5:K;L3@2>2&LROQQ[-=XKDD?!00S+['I]];+&!3>[R S69JT=@)4[(9,C,@ M?39B:8((>.&8NH6E*53IB&055 E=.'W2FCRI?X'KVR414U_&1,G=C![/<6UI M)FY?[IT77&;R9ID*H)IOP=&0W/YDTL.,@\[5F%#KDOP .&]N4KED M546)).R05%+))I*\GJ5')\4M\CZ@*F8AT^=!DM=$1,[YCG,.[TTJG39WTEHB M7>B$]%ED?![F9]Q.[=TG1#S [<,4Y2Z]4&.?@;J5C< M+*/*:X#$Y2XK_-_;M#B6VLG7REIG"^5!-^X9\Q#!+%*.*26_ZYYWQ'(DSRE I5*&(L M\O6$]-+ASX92EDK"0BP#^!B!D4J*(BGIPGC)*#3 :\?!/4RJS%(F76PE?EJ5 MA)'OD=E_J)MCZ6XJJY>G%5P>;UJJN\,QK/'P .(S3"OIR U1\M\L3 0DNY_4 MATKJU,CFW%&U,.!R C\Z_-9/$MAV4-:QVERU;)CF(NX<(RH^3H]9MUTF8/V! M)LN"<=(,>=@Z.:A[7MM-^ZJ9G -WTNEV.]_;>#H3ECY.3IY.YYYS@]F"OZ0>\+IR M/WCW&JK_R=',%>S?EOYDGW65RE53Q<^E_:3&:=1U2C<:Q(_,'&;1OFB=$P!T-U6;F;$=.OB:I M-$#NE+/Y,-5\JM969;\D-2QF&^^B6:+4PC"J;$2YHJHF07>= >Z QI=G]1/0 M)(8WR]JH,]L(OY*S%Y+6Y6Y(T))4I\UM!$P;K9 B%LI 4^=KP/"Q7B0+N*5A M%@QO9F$6_&(+'O?(WN.\KM88R(63T$;L[ZE8+_!+?!^!9FY+\B460_595U+.N,HV^99,SDWF*@ ON>UBS&D<7"P8O5-F9P M!M_(ETE>()"D@JQ,G\YNN$VUTTX*%[@P':M*# .*6X7'PZED@Y[67CZ1_@5@ M+/$OD/?(E2&>S:IT+1J1A'^82505=??E-M>TQ+O*)I_;IIZIWWFB#3J*J6I\ M+ 2Y8-G$XD\=3EPMF$T](EGS79"Y(VK&D0O3* MX97C.3_"Z3@D'Y?EC9R0^#0_AXD0R+:IXAR\:^ MK,@M-^<1Z8_*+BX7>![E:55P'.2Y]'U5*$JYN(F+[9 ([DXDEH]W2(4RK;18)"\*E?C'&5* MH;U8?4$VU^?!8%<6DP\C[OX8;EJXTB$7O$)'=U" MWZK[.UC0J9+QEA+^:CD""RK"D4$\I)']&1/=A\DS*P>&UDB6X@%J 'E\E3L@ M=WWTN6(IX9+, I]2@EOG8=RDN/Y!@A@,P,1YD2VJRDD_1Y#<)12*I'6X&) M!L-318C))#/'9QSL3%M@U(V!\289)77;CMJ* J,4$NA]G"^7LNA QABXIE0GTZ89C#_ M(R+K>2'9[/OI@"Y6ZU&S""?@D/IRO7]X2L<%!C+AP]?Y=A'GE/KD#G_WD]]S M[9Z+%G2RT$GN#3,+*&/W[A3C)+>%<)"F,I']]+U)>:$[F#ZX>-P%^<- TE)E M(1IWR=D)OBI$+T=OH8V2LDNJBF6'B22$_-+FFCE/LXPK*/46G,G)TBI:^ M^WAW=[<7(N;48K '@"^Y@4\V9\^1=>Q5^$HL"5_MX(Q.8E=+?O_G3G9TQ^*O M1TGL2P;QDNTS/(D=IO=B6$X&]/J@WQBL,]Z5ZW_0G[%VZK[OWB_ MILC-1?&R"%YV#DF],5=2+S]!\S?/?#^11#3)A#!?JM<^V/(RV4!6=TP+@&7( M"F':JM-3%!4-SZ#+@"NRVMFKPDH/".F,4U_2^5F$LMU:VP?=%.L$@W&>4"9& MJHLYXBDCEART5\)%ITPMQKNPGGBQY$Z66]X^=U6=\2!+GIYC%;ZGUE[.=\C? MFSCBT(;1C(^:BSG/>^PJW>9)K_UA.QB.]KPW//N46IMR,:XL,@.+RD022+"* M(CGG91=&=(1IC?+3JHZ:M!.DFZV,W2B)4LWO@$V\A(><@*JCZC$U^Z7YI)Z6 M-'M"%! WQNI\Z4>5;Y%Q!BHG6I ID;K27;->=;965JJ,J#T0! M'U]24GR<+RR&-B]\'DR?U)%%CBWW()Z:(AF"F=&>L_L?VN\Q] !KBJJ@8E) MME:IU9VK- IU/6O"M3I81!JFX_C65]HD.9I&2K]%@S .G1,PG$B\DW1?&J]8 MO'1$\>P)9$U!T1WNJP&59KL*#?X[,V>E;X[9"9))XK'4KLGZD8RR2(+HU M]7] NM$=:CMH>TV^MU:I[^\Y9[% @>TL#-D4/YAMT\*:BDE5-_SWT?[>@31Z MY92L50XJ*OYX>+QWF+]>/=P#S92EVJC>#F'R^]/=OB"#)(]DEBXO;; E,^MQ M/"3B#.=W<>4VT6QN 1\2R4PWULGI!@]H@L%*5V>[D"JY&K MPKQAM*NF-N8"ABX94T OQL63$X1&^?J9,/Y\',VPGCI/L])QRJL!]PT6;QE" M&$-K5+Y]JE9P2Q-NM\>J++NJH!G.3_ 5Y);.G>S\ID6,S/0L3-;9 .Q(L*6= M2[Z7.>]T@@?W@.*_DYDV,VQ%UJSPX!F]- "!N<[KLPU:L/]5%+:7%Y MVR4%+8_-_%\R&O^6_,FPOJ;<_SZC45N7O9D/-:>X\T>1I3'\!7TEM81D8^YE M35<8B?^N'C><6]PZHTI!2/6D*K/D[K*A_9Q2:.B:W?W*YO#RT?GOVE%]'E#U M*AX7F*P4[(9=C)'L:4.K);3=WU/?Q?V>59$<\V<^ES-I!H XR86&((4Q5 M<$6-[IB$T4.R384,D#CUD.J&UTN6%*U-I(RA"4R*>%8N$UN&QQ!FRQ 26AX9 MRWM3!9R%N3&PIO9!/-! MB'SX5B:NRJ4TK86-YK>*RH6R&F0X!=]AM%"A#GJ"EKF)H7=T,]*5.?.CT$RZ M%9QX(+WT?$YE+:E32!_W;19&D"NU+6Y#8.:0Z,MW&D=*-4<8?[_Y,].!B^= 3O2>X.A'*OU M9K;T(#3)PE-2U^-[)TS(TSY_87MT#X_M]:FZY=?LS;/IAO,'SP$ET%F8\"+= MN#1K QB"PUS#53)PVO(DK()GDU!U+DGJC#Q<8Q*]+/5VYENIG-6 3Z0UBNY2 M(*=THFAGNS@RM9 D%2B28BN=VN\RP"F]Q&2;B2=A<(NSXI9+1D9"(:]UDKF? M'@,QS">($M$R8;6*:X-,/=N1(9B:N8G269N';IFCOA M>-E7^1VI+LB52.FS>VG@R4AA4EQ#>93^O'_NS94<5<$AN1U)L=W9\3=).9:' M_$E(9T?-1GQ )=N6T=6S(K6SLQ=E,_)&J$>SPQ=<-QY+MF>^NXN',BP++(0^<*9 M(&H@LM(G4G>K T(7JJ#D1B(MJ6QP>J&*@8]II!2+3%[(TI_R3+G*YI#8D!ND M=_+Z U]! G4(>'*F? [*0^J!BNS'6=JFA%J(/ XT)9"_X'29V229T0SS#2EJ MD4\RR=ZQY_1RV^'2(SYXGBZBJCRQ9ZD K@".G;':,D-]67S4D9?PES%[('41P)B!*Y*6S=2F=8Z1?ECR9& M24)YS$[S?5!A-U\X,S]?DF!+\AV9&K#\WB&&8Q*BF1)7GA_MDMFN: M<#<;CMG\D72ONDVV"&[; ]]+ZMJ=C!N7:D5E>I.I2JY,SD_)7ID[U4-*>&DQ M#-RD*U6%U)5DKKCI[*#E@F$W)]_'P>(H\B4W(3:_S?SI33Q9?B4,TN?9A#J? MK:X_I:UJ>QLU&Q)HI%FWR0'W*KN4YI)*Y]F&O$F1BPTMA-/5,I?Z60]C MY@_SW'-!;661/HQZ+P:Y?S9XK:R+&4'3E%KB%!Q<5"\J>:\NL_=J]9W'LZ"3 MS1TJC[]^>/3880$RSTUY@^E;=IQJ8S&_83')'+>)3.B36>9*6=SQQ5<]>2 B MF!U*!V"3GVYFLFG\L9%1IR#@%E0*VI9%JD9V_;"^F/2G?E,E1L";0P/35XX; M?B_I9J8EGJCHH^LTZ\RE9\\!0SJ[W <[5=J6Z9JT/'GEJ?'^L/:PS-4#:51P M7&Q%E9=75.DE*NPJ46$W>14F\U;/,DEN,J%P+9P<+.)DO[&AV?-4'8/>X['Q MC8[PX^W*M@9D:Z#:WI^$'53,+GE,)>Z3,8TC\.+FXPGH=TMW=T97SL)_.S)N M1']0.I:O">)() [)TBA>LB"J+9V")*D52?OZR:X8:'6,K.DL")G6T,N%%"4] M.PM#(J64BT+"4CJ+<2X?HNDLL0TK+6!>=4"S=0QY0+0XT;U$$QJ; O9WPE>3 MC+20S!Z193T()K1C."*8&:QHW@2+N10VD2"'X'T#$@G,4%$W3Z1^OI=8WJRJ M6MT^1VVI<+%.W%*5)O-JP=%=,EJ>1BZTDFUCESIJ9!R#/ATC\4ZE37*P9 M0USDJV*!IP+AAW><<>R/8,2$++42#<$VA1;MI$R8/$DL)9N3QEVHG5DS[P=I MO$09@I:K5T!33N58RKI$&6\_(O_F(O',LZ:IW48)&0E*#Y]2P;>YG7LR_@#& M?DH-WF;*[I/:R>+CYK#5 'BX9O$L+6S'23?^YY*+1R,JY.HT.[LP;?O:W+JU M4LNQ4N?9G-:,P]'+)BVZ'2^JC6+JXG/^@"7)DW:;77B>;IM<=-"^2$N+8JH7 M'I"5M&;NM$6IJ"D>&^8_M.P65IJE9G=ZH-^BX9PWJ3,C>BY"ZQ,8;C'-Y1=T MDO.@5O0-+%RP\JB7G1%&4KHT_[!* U,Y9W)$DH/&?+FE.$@#J'=@V6-:!KXT MW;"8GE&8;/>8P)NHK*4GB[.FAG!JF*^0QFRA4F1>B#E_\RE+& 5,Z\22A(46 M8,0'T1 [1M?;66S&O&K.[Z_19U(]T; 54V!M)TZ1^&"JX8E*&;.?KZ8?)M%< M!<[\Z9DS:+LT"=I,T[J22:4\%5K$ (6L(*KJT:9;@Y,6[LV2SV]!*G[B .(> M_H N@YX3A[%$;]I;< JIS+D!AW:,99#)5.7S+*@1=!UWDN[/JX9DXN]DQJB@ M(S8+<=<:NT-YVL!"S'4Q_5;&7F9CC?D_2]-VTTS<-#=7)5JHW%T,(/$^E551 MH2%Y2WFN;$8:Y1*S\9AMI4RB,3/-@)%T]B M;J8WTI33666;*/883Q(" ,BID[\+3K[TV$.P^^$5\SY^ZN&G?KUZGF*>").' MGOQ@$30P6,_.-$/;7.;B&MIHFD<:E:X/.>^*IWE41F!"S*4_CYYL*U$I'JDN0[3XWX2)DG/Z@7>;AM8??LQ3_%O>7_/-Q:WL M8<1'RFN?(T=5;1-5WG06*5^U3V)!WV;[!9[LPPV64P$!T#3M+B]F&4Y5,IHI MUUH#5P]<&N1*(\L5AV,>>&EF,CS]5YSN<\B6SFQY7:G,$JH1_6;CU%MKK;W( MF]5VZ[51%O%HM;HMF3\GK2U5XB#=;QV/9OA61GJB$1?37!?]@(_[' MQU2>5#B/1R=D\5U)P0U$HJ5&X]B2-ALF;4YF*0S)UHV'H<1M5 W-QY,T-NQG M/9$]DOI9LU_F8FE@G8ZDX9-WA0(OO]4C?7F8/V,E=5UF&Q*4'LEMIDCXV,0A M\6C$[R6SD*6(PWJ9$@)Q$%(L;+752\O)L@U7&P7.LA9EB'ELKTE"R^.VOKG@ MQ/PVF)D9N+,49/\_>^_>W+:5[(M^%=3 MMA\X(*_15$UG$F[_1_)M7HB<[X!0.+" [P)U4.<4#+_REJ(-'!]:>VZ5*&Y! MX*BQ#XY>J'!B$0:4N(E4_]0X=V03_JNAWL]7*H+##7&40.4>5-6FAZI&_?;U MLY;R/V^$XC@L'VU>F^:H-0*>>[3_Z&(&J1QD2,^D. MJ)JJY@A3748-(N%-C+A!T<-R);'!=A8IUSJ4L;XT1/C/XDO"C6#VYZ90 M<) MS#5'^[8HOYPH>1BGE:Y1H)7;11RF51]G^XB='^UC[]!ES\OVCOED?FQ--SCL46RO1A\=NRZ/KA&M MCD@"[2BCQH+!_*L+0+%%/TX+H@;QB]N=-KLU4O=@4--_ZRXHDEF_J@[JSPB= M_X,@[JL"ZJ-K0_GL]IJ@@4?YM$46,>Z;:0+C,:=Y+7WV8VO4AA[4,+:;C71C M(I:" I,UJC\?V$W5$2JP +L1:M>V(L[W_L',CC?;V,PDND4Z;@CR\M)IJ(&; M#<.ST:44KKZ"MT2$B.AU\"H&2@E@98U,CEB'K[?KLAFM86DBN=$S)0B7DPD^ M9E$EWZE_O)4=^2[-:0OI1V]="8H/N,/R)S",Y"'T//Y:)/7-S>!B.$)A79?P M?[%ZL,CQ ;#$FX[/;P;G%\/.KQ M=+?/1^>CG7ZQ;E&CP+/X)AESIJZP]6'=_>[CIMV5WO'<.#RG[.WKJ6F%;!=:P) MT7+[SLG(ZB:E(LTI$F8]Q?UE_K)O>=GA9>"_3U'ZO2(;WHBZ;SH$6ZGA,7WO*G/9D>/1OW*:IUU$O,X!,/99C_X::3VLZ7F-A:N M)^EN#.J)N<>HER?F'FTJ3\P]FEQMS->B5879X#\IG,;K8Y$,>IU'N4QC[4U0^A;%':GIB^A!Q M/XGI,T$^4]EGDI[YT[[/(K3!I4]A^!3&0VSRL4QNM^IR]PF,WNS9\)%U_3Z" MX4-^+W)?'EEB[_>E!T:TWQV_.WYW.G3-Y@HEOS&'<[PVE^+Y-(9/8P";_!TG M(R#T50'?^6S&M^JG]%$D'^;T8?AG0TS/GYZD_2?I P$[3\W=,NP/&-C>CO:9 M#6"37]*J*IHR];F-8SK<0U_.W,^-\=' /N^.SSSY??'[XJ79\]B=!RJ2_<8< M+)$^>"2TF??)7E)NX_>HFL%2Z[Z-3SGFJ,<#CI&/(?D@I\]K/!MB>O[T).T_ M27WGX+(JBJ:S)HJJ>NOFL7BDQL]L^%]7*//MH'?';\[?G?\ M[OC=\;OC#8)GOC'G@U[MS.$=*Y_HZ&SB@+O\WZ+\XM,<^Z+H(7"WGRTQ?/SU)^T_2H1^ML<\TL<>E\EF.A]GD8SU+RN#5V0T\-ZKAMO\5S1=O M@_=1'L71:Y_V.*8C?]4K7]IOC(ER^(WIY\9<^ +H?F[, [:@WY@^^SU^=P[7 M .^';O1S9RZ&@UYMS>&=JR=PU-370OESX*T>I EVOFRK4?;^48]XU#-\I7X^ MZO BP2=2N]30YZ*.,I]%W=^(4Y^GVJ>1Y#$%]TC-2\^;^W2M-IOOGIH>J>UP M\>4KSYQ[#3Z>/B7TW4'>Z2];&'V'-[0/8+3W/ !P#MP5%\TX2U9A?J*-[)[^)S>*?M=O&IS_TW>] CGO7R=OLYO?%S?*>7MXN' M-[=\W=UN]GA03(-MH['/ML9.#BIOQ$-G]3B)R6V=^!/6XD?>&X6+:KD._6/M^JQ:4ZF#?WH MK=Q=S+318L7@HN?QUV_OT[B>?7=S,QA=#O_R)RTFY,'\[7 IM*;CL]O!N?# M8>=7IX-=/Q^=7^STBW6+&@UN+JY[MB:@T]FH9VNZ'ER=]XU.?DU^37N6!:,' M[]1+_?'DYM]HN$VI!*NC;^.P#T];'OM5I\?^0UK593INZK3(,=G\?1)7;_Z1 MIRTP^^?5.NDO>[&7'5Y^?$-7]* ;<6#Y=[6/TJFSJ^-\K5_+8@&K60:?EXND M7XV<_L1N**_Y.BE MR3;3@/:&5' 4)/OT)^C%F7P4]$0,4^"GY.H2F)/P<=3\) M?D-3^:&ZFLW(1$?0_/$Y^2-ZNI&2VY=K/4S(XRC5&GU=Q\56_-1W2,1GMJ47 MX?G99HP0OZM'N*M77U=1Z?>T?WMZ=;YYT,3+WM,CW-"O@GC>VF$[VAT]SDWU MVO3Y[>DHO!YYV?O<=G4X&O3NJ/:VY>3PL8R7ED+<;N_^)\GK9O)E^;6QO6.& M$3SSH(S[I&9X<7V(B7;/EJ##B\U3J3PY_4#0 W/H P/M/#EW"[[Y^:I[U4?7 MGJ![C2,^X/8\#3D/;_3W(;%Z1)[%>UC"M"CS-#ID O7XCM>YGZC8SXTY"T_] MU+Z>[HV?=MGGW8%-\3O3RYTY'VZ>Y.1WYF#:YI&E4GYCGMP,&'DSH*=[<^EG M]_JDU\-L\B&/TRC?QB]]MD&<,S]S<)\&;G@Y\@3=9\7,A9\[N%<'[,:32@I-RZF:?U)66]_EZ4]0PA_@KX[D4GOQZPG7UH;$?5<#':/.S6$]3'PP_L M+I]O-EX\.3V'>I(^,Y(.P\L;7Y6QURF^OO/+)\$>=C3@+O^W*+_X--AN8XS[ MY,3[C;'38)>/1&_R>],#J\GOSN%$F@\9]W-G_+GQN^-WY]%NY97OFNSGWEP, M-D>B?2K,I\* 37Z/JADLM?[ZT6G'',X9^JS-7M7"^:GOLO$1\3Z3='CI,]^> M0SU)7Q1)A^'%E=?T^P3-&1Q"SQ_>_O=IL)W8Y)>HJJ+)K*F2NC[H$+GC.V%# MWT+1TXT)+QZ $O![TV?3R>^.WQV_.WYW_.[XW?$VP?/?FX=<59\/\_DP8)-_ MIN5MNAU2_[.-ZCQ0?^EC9#M1\_K&AQSW"3_EF7.?1]T/J/,Y&T_2ET7283CT M<\#VZUL<@IR'-_M]&FPW2,1ZEI3!J[,;>&Y4PVW_*YHOW@;OHSR*H]<^+^:Q MQ9[#SER'IP] #/B].1P8\NG%YCYPOS<'*]@/AQ[_M:=[,SKW;:_]W!F?$.OS M[@POPJMSWR'6S\TYO_8IL2?W9]770OESX*U'A4=VOFQH:OU,]''5Y>^'1\EX[Z7-11]I)S\>=7?L#6/@,@E^&5GP"W M5P8-+Q[ @/ $W:W X<$8G2?HKNG.D3_R^SSR-YMS+YZ<.ZKX\/K&@0%\TX2Y[>A_7/VONSGN5+]?19AY<;OBII M-\42%--@VSC+X](GA_[]%ND;X7W>B$WL?SQ6T-7IX)%U.#L1X_F83YZYMJ?G MS>"1]7>>MSQO/5C;^=@Q?IZYOB%S'2%GG0\>6?VX/2$\5[U(D>4EEN>M@T4S M/7?UPV/W)LZ NL(_C=.[_[ZO^@_ M;&R,2[Q$# _U92LS>7$VN!J!#;,HJK1."["=DBRJT[OD[7T:US.Q7^P?BEUV M:GX2C:LB:^KU/[%,LTF2UTFY;RML>/J0&79&P667&O9_9SIENXANDY-QF41? M3J(IK/6[*+N/EA62VWJE>9J?M$C8?OOUV["R&?,( 9PHB35R#7M-+]KD5M(+ MZ)9%BRKY3OWCK6*0-*>WIQ^]E;O+QN$#6J8Q/8^_-F\Q..4W$8DN3Y:O!_#5 MF]7/STX'-\-AYU>G@UT_'YU=[_2+=8L:#:YOKGJVIIO!V<5-S]9T/;B\O/1K M>G!-5X.;\[[QT_7@_&K4NS7U;^]&@YO3S>>NTXH=#;^Z#^&@ZO"J,RKQWTEQ M6T:+63H)WAPQ=*?^UUF9>#T1;K[#!-4$^>G \Z M--DXJA*\P9_^&KP:OFYI78R]'+H^RU_F+]OQLBT;H_KS+F=7VTA+%GW?)DI[ MM564]M>R6,!JEL'GY2+YVOZMOK''08NZMJ/_S\6$],_^27\4[$?E;,'?F_DX M*;&\3=@Q3;:9/K//MM.CH-:G+VF6)3'0JZQ@T<&;X',)=R-+ O5 M%_KN:^KD']LA\%A5U[?V@<_)']%!9_IM37X7GU]Z)\RQ\M"Q\=7D> M7MP\4_OA!8>6AN>#WGGF/>@A.X:L_W;O]1Z6,"W*%SZ^]MS/MMOG6)KS47@Y M]("/?J1EGTDZN@DO/(;F7I&RAU?AU:4GZ3[MZO#J@:B<)^AN!#T[#4^'F[_=R=BZOP^M(+MGYNSO L'(X>&1#UF].#&(G?G<.-++D,KQY;J>IW MYXEWY_*QN-]/[-L=D0OWL4QNO[Y[\J@# 7YDUE[G#@[#\^'F(?*>I+OIH//P M]-3GI?:91+D(SX8^XN\S?9ZD+XJDYQ?7X>C7C^R)=-OCC\Z?G?\[O1R M=\Z'U^'ES2,G*?K=>>IXV .E<#Z/\B )_R?)ZV;R9?F2,REG3UM0^=*H>7$1 MGE]O+MOP)-V-I.?AY:5G4A^D[C-)AZ-P>.F/_5[[),/SH6^>V*LY?QZ.SC?7 M>WJ2[FB#/VW1Q M(I/P>53-8:KU5/9-W_XS&\<'ZGF[,Z#J\O/*[T\_=\1'' M/N_.Q3 <7OB 8S\WQQ\=OSM^=QY;KWX37C]08>UWYV">\6.1QWPJ1=?#%64] MPV%,!7SWH@&^ACX,N-C4*ST8^LNJ9U)/T19$4S?JK M4X_H^0UM<9]2>9"$[\KT/X5'^-HQE>=]\U[NBX]K]7EWAJ?A^87O?>CGYIS? MA)I*BWN^.U3I]W9W@%9\'6A> M2A[%4:"HN-<5C ;7HRT6\7915&F=%D#Z)(OJ]"YYBU-V3LX'0_QYFV)1E> = M_O375V>O]>83^5YB(L@G+7SPTI/T19%T.+H)1R,?#_9OQ@FN9TD9O#H_A>=&=5*]]BFAW<(,'JZLGSMSEWYW#8QZ?A MV84/S_5S=RX1U>?"IX7ZN3O#LYOP^L;O3C]WQZ>%^KP[9^'IY7EX\4 !OM^? M@]D%EP_ )3QU9D@]1U9U#G1_E%N]\V7CHHR3\@1S)[C\JLC2.%#T]H\ZCD<] MPU3__;YZ*.LI?<]G9^U1>,MFU)V#<6^O,6E-N:8H?A@?!T=/K@3%'/ M"<^?$T97Y^'9 R XG@^>/Q\,P[/KF_"B-XBHGA,.!NUSG6^N=_9\\/SY MX.QL%%Y<] 78T_/!P2R$\/)\%%[[YMG]MF.=/E!\_54$/<@[_<5YDQY%\N"A M05PTXRQY^EB*?];>G_4L7^K@SWH!555_"8IIL&V\[W'IG_T3;)[&<98<*FO: MI9!>YLMND=B3$\ M/C#.V#.79Z['ARL&F_OX/'/U@;F.D+.N'SN_;WM">*YZB2+KXK']]UYB>=[Z MZ@"CYZX7Y],^^Y>EH-:;.@)N58 6\!^UKGE4WJ8Y1<@NX0GRJB?X7O1(>MWVMT>#LH1<[6P_E<3:XWHCD,7S-!%G][Y, DUQO\2I_^NMO MR:),*B!H%=2S) !^PP\F:50G<3 NBB_!790U"0;JBJ8,RB3*@H1Z((-9DL7! MM"B#-+^#C^9PDR"J\,H?DDDR'RQ;(,@X:17@^N.@R(D-DC\FLRB_38(2-WK3IN(WIX.KT<5EL$C* M8!B\?_?#^HVV#OA-^X"?7XQ,#XYIN+6KQQ9>,$;I>4 M^^:CX6F+]E>=M/^Y@!\'OP$!TSL4?4&4QP&W%)MMJ8)MR6932*CVY"_6S53O M-G$&OB3\XRPDR9$1#4J7!@71(+5H,"GR*JU0^,"-D16G1985]\ EP:L8_AF5 M%?)M/2L:6'A MNMS6@>%$S^.OW]ZG<3W[[N9F,+H<_N5/.JTC#^9OAP.@Z)N.S\\&%Z/;4;#5_]M$>9W62_);R(NB?W7;R_MGN:.@T:]E 8YC MO0P^+Q?)-Z'!0Q"UZA9/[CUN2Z TGZ2+* N^%[]]HS_^1""W#\9+-F#@.\QRO9/C+)Y.;$O*IWM72-M[L,^"A+^3G\DH&A,L'7"VH\^ W#/F]X?\!,?-;4C=EODW&8@^M\<^8UN_R',@,-XB#OTVG MR03%X]<3_3F>]%\B>'FPFH(?@!J[B\1.^]KX)0]E57?FO;X55;>#S=\]6>)^ MB]_O12CXQ?G%^<7U;G$[-ZA,Z?\=DRS]I2CK6]#>CQ*AK=?=N?:I@US'T3NY M:PUY-U\\&6K<-OOR=6S\+6VJ[;;D^V06W:5%"8;^3TF4U;-]<_17!.>/M NWN=3ZGG-\YKG-<]KSXW7GK=5>+4S9.T^=N:(JMD] M9WC.\!Z+[H\9OCD=OCF[#$X"^-]S^.?5PV%>0P15LYD7>;*>5/XJ?]5^KO+L MZ*_JT56>'?U5/;K*LZ._JD=7O0!H->HN\T,J=QL8=OS3CKZ.B?OG!?[29'6Z MR!Z7@'VQG#PZ#Z^O-@-#'P4W/\_-.0TO+OPXW'YNSL55>'/N9T;V,UZ@[3@\I0S".6801O3/FUTR"$^>AGEL@F_K0O7C M.+O#78_NKF0X=#;_T+]_>2QU?G7V" ?HV/CJ!>[KY_K_W?U\M'N%U^ M7_N^K[L[;$^^IT=DLWN>VFNQF.>I)[0W7T!&[1WB$!+^!F*>(IPA_*>JDLKW MUQ[B]]NCAC\7R?=?_\_UV?#L[>,"7;VPDOR^=NWKJ\OP\G+TVN_HL]K1X?#Y M[NBQ*Z9>+V[O??:]#$H>Z>^?UMGJF\F[%3\/SLV?*PO[W^XXV;@'Q=T31QI7I, >%\3OT[WOML/G%^=_W MQ-4_ L'V:YE,D[)$&-Q_-XB-[Z$R=FD>.'YPFZ]CY_Z5F7[ZDF89L//?F[*" M10=O@D])GA9E\%/1X >>P7=B\*OP\GIX_%S^7#?G^N+&;TX_-V<8GE[YD]// MS1D.=Q[VO8^M>6:529XU/&N\$*OR[V_>?5VSTH8&M^%YOUW$ST4=98=L@'2' MT &U@KAH<%*P>O5G5J\RW-6FVSN=CJ"BY2E^?V!&[-O!WS[3M7_Z]/J 7IR? MAJ/1(WNJX\3JY\="G#FQHGD*JYWM9L]7E4WJ8YD?X27DY^ M?8)&!+TMT3G-XR2OOSN!#_9-T2T&FI]]S4!SYMC5_S[)=/;K+5[%GB,_ECGR M\'?6Q/" : X[6E?!%/8UB8,HA_^;3,H&_MWDBPA.1:H&%;\)%KJ HZ0IQ71Y M\H?<:A(MTAH(\A_<^&":)-7 '>[>S01/L,7#TQ99KCK)\@GV+IW"/N9U\![> M*JUQ+#8&A,L(M[[:E? KCAO"AI-'71P,TQ0 L7W25YL_T& M]XA"GY(DP';:L].WOT1Y=)M@B27UUUZ]K8(?TFK25!40@WC[71YERRK%&=3! MCRD0:Y+"VP.3Q"0;Z)K?DJK):KKDXR(1SI&&78>=\ IAL]_2Z@LM8O@6SE?P M:U36P8QGK]TSH='%&^],A >_3N)Z)RK%_*'KVU/PD&H-*;>KU M/UG)P!R(':Y=:MC_G95J,0M@DY-QF41?3J(IK/6[*+N/EA7J.IOE@=];)&R_ M/;_C7VF>>=>#^R8A31&R8G]@JD_(2,GM,CB^P_][ NIJD4QJ$))1#4H/M!@J M0UUJC:=Q418+U.]XE,QIB_)ED,[AN[N$KX0S6B9Y<<<''@_WI '="*2";_+D M/EN>1)-_-RFJ2_N6]VF6!7&R .DYG!:A1N!,D*^Y?TY)@Q6#=Q6 8E,4\2*NJP97Q:Q;S M>8%;5TR^A)9-(!_$R9A(4% 9>Y4 55)\\T'P(==2#F#;]WMJ&=@BM[.X#WR/$V"7Z(D#'Z$5<3TQX3> 14A MW>N'! E(]X+U2W$>7?*/<@Q<^ .HLZQ8T 6O1#G\](\?1$*_INV(%KB)90JL M'TS2+C]<6&9Y#>@W0#\#FN7#@9$FZ M8;#M 3V0<'E?S!=)G1(M0*8D^6T]JXY3J,#!28&': ^G!:+%T/FT7K#2+PB\ M4I?I&)1C4!D#-%OB%N-1K1KPJZKJN\/O'MWQ.[+I)UOLYP_PGLBVO[*P6P:_ M%F4-U$B+(]S4C[ 3"[U^.(GG5]>6& ]F24;'SE(>043BL=O>!A$:C,LBBF&C M8R(4;#R*W&60%1.V#Z-)6>!15V(+3_9[L%'C:!#0>LSC42"!0BIRY"R4 @5] M#1(>G+L8O+:\J-&10^>.EDDV/"B]/!A>_L4UYL<@YM\T>0IB:-,;\!IND^*V MC!:S=&)>0Y9/6BQ+04S1*R33*2I:N%\$4F^")+:7#48J6[? E^2&E4A+@FE M?@3W@1AP3H++H3*3I.$KB+*#FUAF6H-8(M>XF$. )&[-(JY*7]4>-^ MP>_OX45F]&#ET@11F8AZ)GW!RV)#NA(_02E=>+1\PIXP=34(1X#[J[[3MR;M M-DUB?,50-@Y_B!R0V1H/I/E\C#J _H*-!9K/>^!.[R@1?B[RVY//23D/@\\E MSO(X^3OL],])5)'$;R9D?AV?<'BWX9@PAU7-&,V#.B4&_U=1(F/(J0,_(@L2 MWOT'),HK#JZ@,KDT#_A""V ,YO(/D#XRG)$Z/R M=;* FZ44"$)G%D[T5%F<\BY%XQ!6#0N)RB7>U[8AIQ*IV MWB*Q<5LX9E#.\5YT!6_Y(/AL;@#&.(GHI0HBLN*IB'N 6"1<8_-(NJ%-FSRY M+6JD06Q]-5$Q%;*7C31GBVABP,3XX#@B#D M.,H4/F*Z%JX5(YR>EHIPN/W'IN362F6MX5;>:'T8J!TA4^KN;-!7;;>C1A.9 M$6^KSX0SV%(>#H%=TC(^07=^J1Z%&@5_!^?*UDRM;R624";,E2S2UJZ@TM;) M+9S["L]$#+H(U &P?%'A%Z(7NL4-?F-X6GUBO1>)%B-*28?\AQW(+19U/TOL M.%4@(?O@%HQ2.,'% ET714$*=:$4&X, F\S 467K622LI&T<1R:/WQ1E%WU1 MTI,Y4H'%"F+:"#PP]]-)RH$:=0,,ZF09*C^E#YGLFS>1_T&,93,""#&PAL"# MN37*D^3R0IP,:Y^G":R-]'.%_O2,PDUHF*!;Q!L)1*>M%(&/N\,2&3=4;=CJ MXD2@5]$<-0,8)24*9[D#?2K.!3Q9GBERS[+"M'KY"7P(4,"T/!"32Z7@5YZK M7 GXM$)3"-P'E+VP^Q4JRV0RRS$?B48+/&LBLM5*' 35$GR2.5IO9(* $BV7 M;F;AMBC@N$84OX(?_ZN);^?B)JW9$K7G2$QR@,CE@P.3+4W4:^-[XZ+?.4M5E,<8:T/I,2<]U+6M=1+-E6E#$5W*:/.)K-!^@\-W M7Y1TO,M5POR[ =I25(8<\M#$*) 9\D@LOT+3#VY320MXSBW@;VHPC"IE(T[P M^(O?H^R=BJ7[3*2[S<2;XC^?9VG5\2(S$#,4$!DW:5:K#$&;)$K46T&@TU,V M[26@/Z;XOR7-4;B@-">/#','B:AO^/]Q YIH"0(MBM$TO8WR]#^1B;?@^F,K MHHYA["C_0BE+A^@LHE#K4"Y%OJ*]4&+6I6X7 64Y2J5:D=B*HJ[%RF-IK\TF M@I6R0/V.DHADIZT)'4WJ,Z?V4;PYCLQICX37QZ;+ DTLC*V-EY9-ZI1,=!]A?EZ&H5N'%I.B8AKGP7W19&C,F_B3 MZ\+(/7+@";WBH[,.WHTY%@?L\P%/1CI=!I_!HJ>RGV,V$,!9C="";+)ZC8&@ M:WVZM=U:$X&/BNB^%-0P/#34)])D);@F3H4.,=N7Y@UY >A_2=XB543?U>8@ M)4=)C\0Q<'E8O0.Q!O"1Z@E+AQ<+H-IT$BPPKEO);MRS(CM10- =8YG;)\BK">I)*7)0-(1>] M5?Q2H:%ZR#1S(B!4Z&UERJT5#(*?$TH+<:$5D--9PI@2.R3=*&-O%;UB:%BJ MQ^18H:"?@?U(GIIY1S;[K(2$%J/ E?@$M "G32:\-6=JJ1<%Z9[68M$: 56: M0EQG:V%!'?N+DGV*F3JQ,B5*9]G/EI8F/:?*VQ/*$KHAUD*E/#HBOV2_ND$ MND@J'M"54+I5Z?EZN6 ;0U7&+>T IL7VX.^ M]*93BS8 +H>S<2I8J6UWS+.E0- 4BT)5Z#;ZPCK4A"%T'HO"$_HO>++U5,MP M3.6 ^K[2HA*T.%V,NJ2Q*I5R/-I5X,'[,-><6]LRFL MZ" /9WNFBC*GZB8JL7HIL:(TEB%PA.*FFW<-P5;99#7&)T8L!AC2.[)7\=54 M>2-_1B0$SZ$HQ:]OI=8Z,A)BQJQ]ZH-YD9#"=5S25:-K37S($6V53P=O)047 M/Q-NM#G17I4N#UT;>7&4-!<,<6N&, ZR6-LG<4Y.4:; (E2W910QENTD\;IS M"-SLD;DH1H2^Q0\K)'$U#&/),XK9A8&WE(P2#^GE7Y'K3^>R6 M)=.FI.O-FBDD)[6*TOW2;:D;1\MY"R>-H^-3M@F/!1*2Z<) =19-Z+"H%A]\ M8"FDH_)(AQ7;M)2""XD,8E2,JK/0VXNFJ]TN&WSDE/CIA2!Z]3('^H^.F(%\P:B14CGQ.@A6ZNT M&JFVJ>\)0>[\YS_@^^>)J87#0X5=1-;]V ;]5P$:)KB##ZCB#,W,)SXL-BF2 M?$:Q ,I,MKRS3H-BO!0&9[=5"M&1E:;2C7?A@ .\MG5N.Y-22XPMFY9KO/FKZ+5; M+9.RD,'2V:A<$=&+681%0*_&K[ND=_M&5":34&"\J=?4J6G32Y5,+='8JJ,Q M1=AB7,FK"3^-AF%;+T9-("K"IC**I'2$IYRDRB!XY_I3ZCC9+Z$<7KN0E!ZK M-D8[VSX_;QV X>EQ).@/1)Z-AS>E"FGE*&'$1.O4R8QJVMUXMU,DC5H;(0/N M<\X^47A ]0O!X2;#.:K7V8VL 2OZ6>MT5:_Q6DEHH<%#RY:TV;VV@JU?&%N' M3XD8(\D?23E)*PJ=-PLISBLFTCY*?II*^D_*%,L#HE!B5954GE>52I[!K@2Z MO("\/B5[W*($)-1M ?HUU#'0>5+/"CK0<8*U>F@%T.T5G<'#F<@29[ M I1&5Q"#4I@(@ZO'465:):@D4Q)AF/&D!U)I9L/9 /PN::GP:KT3+958=A&E M(XN5_:N%EA,ZU\ZOW7)&MD0D?1"&6ULPZ11)96\.)5"+RBGT5H;16D.(4R#%Y,NLR+!;@HDNN5AB M(+->3A=;''KX>/>.X;-?5)CT>T';^33#H*[J<29J_)R"U(GQ !^A:245"&Y$ M6"E[4Z5N5R!54J]MER=/,^ ^4XBB,S$S7>C3"JX^U.9$(C#F8N(_TCFP,LC3 M/]]<7 YN J!#1O(B#S)%>VP_RRME[$Y!HF-;/8@O_L!OAJ=JOD&\AZO48M0-)"[K#JZOX[R.)#BG:;H:$9!-4NR*=7Q M5 KYA\2JV,_)7*@P*PZGI23? M%?$[&#!%&SF6+847%R1 V-5&HP,O!16X1+Z.X( R @"+[8$\F@LV1-VN'Z3E-2!@#[-67[3)JL1BR?1(SY%9-==\0[-4W*(BHEJ$/=PSHJ3UX1GUOU M<^,]K;;/$E?%!:4C"CR-L(ZX$5- GW@56UI6E^?M M^,WOZ^+&XJ&0VV'Y!*V:VHJ@K?29E9(8[3Q1(I$3-2WWA>Q'21.X7I5&$+'1 M6USRZZ[YHSM5[\7(_L2=*BBJ4.MB>^61%VX[O3NLO1&:#2M>[7I%.W J)=7& M\]!$L;;;;HA8FZWL9 ^IOJ-T*'D)VGYK^;G=]3FA!%@C4)8QGPFDAY4.H]O& M2DV%.MH:21WN5$?DK?7]]K@?938@S-SQX4\NW>4RK) M526'/MA #T(Z6'G5XC*[6!]:F,( +J.36N9 MIK;8;F'[C"U?QZ>F/G8VKMGP%Y9MSS@M)G=I_)Q!\%LZF45E'/S/ #>V+$#D MO9^ER33XVQ\@$TGP?\1^*@P-_JIA9ZC(=18A*MDT^!2-RRBDQQOTC L+/"-Q M^@E;OJ73'-8&(VTYGMQ*8#E\SP0' M$P -U#N:>07Z'3\EDY)SUK@40X1_8I+=$,"\-KG?RG4!>W&:T&P$N"@M\J=7JAK'8G^;?O-1NO>K.,VH1-8L!+U;;5>S\HDZ;PQ,;Y2NRD&P_&W MRLA6WH/J/M:1,BST!O/@OZ+YXNVOP>CTM!TS& 1@HW$ 1#]VT8Q!ODCWY=() M$70UCU)NT3V(=I\E1<^IT! L&Y,]D A^>^5@!U'D7J+V7%2G4Q><&LZ2U:SR MT7D4*(0Q%WM^P?]YR));')YX?C!0GP+4%YNXNKF&/L^R$LG#R*:SC%7N0 M0I;7]KG@DA1U% L^YQ4.J\DICW<_HVD$=@8O4GVO^(LQ$$UP3'4%^H.Q;? E M&#X,O !8]>A" V2CCP06L$*MF"8,'P@ST\L M>F*/=E4)BHO4(BD?*=9=XA1;-- 'G; ']+R:ZW&QZ!1+M[AVK_.Y>=!&?^7& M+-6!3,Q TDA35-&7C U,RI)J=0)NG^%4MC- NOB:$E4&8A%1A<@]6+"0NTZR=)KHF6]NWY%SG!6\)/7Q MLLA1V1*4%B<*]$6]'SU7ZD*"V7(,!X_9&6.7O&9&FN 4P8?/=IM]P@NDMGBE MYE5[@]TA=)P,RJ5 8(@30!\S15A129--+)Y2818[_),RN\H0 @Y/XC8P!(6O"?1@[JG)L>Q-JA;V)A$ MA6T%Y60M$4:?9/9-@ED5=;03I ^['II)0U/ZC%!' F1#O39 *#QP(!!0QX@Q M;M/S.5DX%20\RTRUYVVD@(]]3/,$4.L9F]I#@N*.:38L8#>]9 M,OD"G$M-_UCWB5++I9M!,7V-FIN$R7LG/6* MUJG3:LK(:X/@>U4F#:P34X:+M_KV%F$':!0 BSM&RZAG* YJM.>6QB\)&)!7 MP=.A,*,#0+W/:&=4M=H*+.$V]#^^LPT,0WW;+K8!,X(%EF SA0SN,' H&3:Q MW*7)?=4M?W6E%IT=J=PN$P$%5?/%N/:!Y B?P94RV=^3P.DP35L=-84+)\@X MUICK723%(K, =/E3BOY6JJ:./T.;GLM2K;?D2E_+%IX4*'>/B56@:>AJ(["(2F!L3%O80N(NH^-W* 2*K ]_U2M,"I.U,!F&SKFAJKF9$'B*@? :;+DTS?R']>1BN">WR M2:SJ9J:/T+E6^AAT'>K0#O]+#\>H$EOOZOKO?Q5C1SDX2M\R8.0;TG7C@K)V MAP_'; R^_+>IX?Q-@WD?']-_M%+NA"5BPA\F%L>%]*B9_U@_9,J*"G;!G+L3 M+^OTY$LZ^8)2,>0_IV74B($Y;BIG],L$3!J*6NB!*,$GYO5/:K[)NXEN2+-^ M"/^.TUG7H6D(NR+=3A=YNJ1+;S*2*(IXT)IVN?%NA1E6WHNQZ,(\:L<4] M<+3D7Q(PRE1.@?](PD@-(]5L+T4Y^&"'M;/)5/$/ :E/ I7=G2MA

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�K]J$(N]0"R"(%+A[3 MXQR>L\&!)ZPR8BC:369X,]L_.7@+TF"7M8;TYK$[E-( PN-7V\!Z2.[,ZO3G ME.+2G5%BS7--L7VRR937O[97BE(I^@T(4I#3KI16%^RRR(W=4N*F66!2C?QF M^P[&'D^%-@.@OX#9-Q*2<9I*8?8>/L8!!50N567I MH7"'^&C\YY2JM9I $BD7:Y-JY4(.5"$,/BQJL@S0 4)P6ET(D.:$.Z/<+[6Z M5F: &L'T]B(DJQ1^(*+ .$M5)EE)XZ":84\/H^ECO.J6FO:PJ34H9Q$MG;8X^&#R)9)0,1^/Q)E@2XD] M">=9;\OI2M3;W/9*.75NQ,NELV0]@>K N\/R,R.^OA=[K"+ M*)648JE5K?B/TR/J.H:=E"N$M7(;J%VV:#W@L]4YI/$9-G (@8 =]PE%!H.9 MC6L58X-G-*74 J3:HJ-B UX$S:6B@+_&(Y6(F8O#*V@V^,MLB4 Y%>NWCO?B M'#,Y3$8;&T!+#1['Z\1J@A3-1JXB45$P@:]'A2#P ZUG44Q=W9608-S8LGM< M.A>ZHL\%C4>!>ML= 88\)D=.EDE:QFS\))5^"KM\@E?/ 6*9>BR!(RRQ,ZEV MU&%1QF7Q93)&[\C1+8QCSSH*W3,LF!?+".G#_87(K H12*7^<7HYN5MKML14 M*+6FA(*FEA%-;,.9-HT"GVQ]'I_3 M],$15)5R*+1E:G =30S>,3VTP-S'IK7,<[$64^-$]IR41.ZMDA&'/@E8HEDJ+FM*9PJS>M+3_* M[KSD@=-8-MY@6$Y7$(JV#1"CLVVVKC%:K;'VA07.U2];]M&0M>)!D[9-%BG_ M82=PE+,=FJ/V(,E>;'QG-3*Q)JI F$02U[&GC;QCC#FJJ:+:627^3&2!8QWZ M159\QZD MI^]E*(8!SNX@GT%O)WP%AT3=XC N$$1!CQ[2!43P,M/HKBC5=8T0F62A#I>C M-8GELF!XT[2.F!&]I'^V-/4.#AUE_M%*T1YW5:R43#,=<*_D=RN3BBN=>D!4 M)4S.C]%LM<6L5<>92UI4P7Z4MX+_8-C7EA2;5)<[&! O;7(T<.&CF.+N+5!B M 7U^F$F4-3# 2D_<58(]1CFG^M>%7JMK%EB/%H9ZGVC].[L;5H27UZMM=B6C MM-D4Z:E[(HOD7"PZ-88FGL]$VYGHBV-L=#VLO6\Y[NE4ZG*B5GM4G%9EL]"& MM8.,HE,.+7ZUV97UX(0#)WR6*Q7R;7M\DBM1A4HEU23B*63]*OE,(;-[GW#6Q1#=:-KT%_4-P6"J5S3I4I<&XDP?+\FJ;'6P(6[&$ MF6M6^#+L,G+7V,><)B@+,GB.SZ?X/9$IO%B93PD0F_Q<-7#_2&_U^)A\E1JJ M>G1_5 GTB LGD&PR2%T!>LO$YX0?P0!)"XU4P4J)!XE?ZES7DXQRIQB%FIU$ MZ&%2J.M%;(]$(9E,,S2LK?9QQ\M9E QJB)%-BG.]-<%&$V-\:Y+E1?ZV51$< MB"W4BW%;=TO^7H+ =R31Q^)8"" M!UVE5^64&UQT58A(X[- +G*9(MI[M\E;6D*3UC8>%'?14"M?$I,2 ]:J&$5, M0S-0 S+ND?0,J''K[8_MT9=%"6_$58^M [T9AY1E'1WZRJ[[0-'JZYD(5;6MGZQR3UTMJR'DU, M7T_&(NDO8ZP#%.S$4YV#!RD,I8=>V..C$,K+A(PPG*0*7J2L V64%'OHAL=> M%O(^9$,IEJ?CV5$DIR=/DGD?31)G5Z@4EQ4%S< ,K4,GT(Q$9V5Q6"CHLR2^ M37CKI/M,5GYF;2KZE'1Z$ .+SZ!05>+?E\"\VDS:@&HCG3 MTS@(*S-WIZ&NSDNCZ'%KYFE!;5P(S>\@(K4F%*]N(L'D%E?$J5,N<_<&*!J]JP;_G?.DM46Y^@5 M1ESG+^SC_2@D\/ MK:IC(.LOI0 I,=)LL/G<[/3Q M;;3I#$%AOI?A&E)@SM,U>%\X1JF8(N)LD>1W.*3A>8YD)>6**)Q]B4Q D=P)0=3U3C0V2U2L%*^$*5910R MRUQ'A;51V@Y 1WIAZC#Y3+63J1X=1Z:Z-RKT(Z,)MZ:N$5V2 U,4$*^3&4"!08'U00>6$0S7[@%1V/G43R:_$@GYWQT M0P>F^H>D7:52$2[)78@F&QS#(LM]F=;)25S<<^J)I/4@^)&:MA'$$#-=\+\, M?)&U@9SRV,8V(7G?!@I6Q?PT+XK$%*>W5ZS8"E7>2BQ7F:/CHOAB87#(_MH0 MBXS3RQ@N6%BYPEN$N$:VF8J(8/U0DI)RH @43<(2VXZ+#!JL":I5X;C;42'0 MR:C7:&8K@B?S]$XU%:M]$)QB)JV7I!<"W]1:,X[3FD@ 37+M!L353IX16C8H M8W5$#,U2.!2)'#UT-="LJLUL&XZSFU$WB3EQ'<57K>6Y^*ZV^;N2S6Q*:Z@$ M@:5PR8G8-D6+1OH9$M"2!>(6RS]#*2\PLJ8KW![\GR:^5;8A0LTH&XGZ;1+Q MISLISIS"F*!,4E?8!'F#(&U4#\9&A2W^Y""8W&RXKM("Y2(E2'1MI1V: ^H7 MF2WRE/=GT+D%V=4FO_5"6!B*N62PNV(-'V4?&>Z[R2W9J#+;R/23J"P)3,E" M<)&6&M<1VJX<>LTNH6@S0IVL:HOPMOUFAER;'X0"1(Y&.L6+WG84JMZ.CYE/:U7&ZGR7N MW:ST.[,MGS2V^S\66(8:O%+PGY_^H>$^STZ'ER>G9V'P$$8GT3M [D$9,,9PZH@3BF5EB^YOD1"YPRAS5 UC+56TAAM H% MXI+TRP<\I,"H0X%R!"HN,I5R44OCM5<5BO4*DSN4O-;]?AAYK1*>NJGA0\4) MY(D41G8;>!HL]9'98ERO'**5I,)\!@AFR5DHT^8AA2FDV*) $,UP8F[& &ED MJ!:+VGI96,[_B7)B&H(#!>>^T9V05LE[+:5R2"T#X"G8PXA#NXH.R=M@,54Z MI9!DOF3CSV1N6BHGI5&JP$-CMM[P,[\L;//S$7MLSQX MG$JY13B)0.+.I;$UL#AF<)_:L2,-IK+E+Y-A2BO #W"-JZ!F!MY2/0AM8;@G MHAP *4K3:T&KEKITC+"IK1H[+X"]"!0K21,5_ZM,SX']-F7,$4!5M$F@IKJ# M%Y:\L-]+!0ZL?9(?LO&.H QL_ULO*^W/I;,B=> 0QY_?%7_L_'!EF2B=M;*4 M((B]34ZW#DLTXF!="I16U#EMG7%5+^84]W;K&DN6%5OJL7:7FZAP*CBAP6-2 M6\;GAVTU2B,JJQ=SAD7.K?M'I^U_7P$)-0!5MO#F$J-<"OOT@$S+R133?6-? MR?'IX(\MMX:&TF_JG%%6.)/10O7J+.^\GQ44!R9D1+MVQ0W3:O2U[[8EX +] MSOSV)$NF^&I(08>H)\/K@]&4++++IX8'V; $ESK#"^:OWY-@!<"&@@3:8YY' M_Q)T5O+2U$P,50PJOXY!P"S1@TI5=RW..BVM2C3\M,4V<5I1@>,%0(9F9#C?#+G 11F-!'I57X#=5$ER3C%9H0D3)GDPJK^ M5YY<:\5*91C\407OV7&Q2F>H. H^P ',L#%45;'MW,S0,/AY*D-&!8_IN&'2 M*ZM4DI?M.[[UQ^;)CLWG;5D2\$*OK>?+J!/B]>KJ]^NB6;5$(M; Q MWFT@'3%Y6KN(\:SX#NSVZ#9!7XS;<0F%!C:QPEEP55IJ4:J0E+G>B9#GG8&U M_'-5=&_2L]KD;K%6YZ(\RWP+K6A' K7T3;ID<[?BZ^8GK-OF0)O&!6%-1AZ* M/+%3Z/M=?UI!(>6\#\@#Y0!V=("FW7:#=&4K$TO54JS,R'#$ _F)1CR0 &'H M?N89W,HQ/!1KCMYN7,)U3W/FB$(U16P*UT>IKB+6XL*'-VJH1W27-*5 MVGMR*LM6?VJ[36UOB[B)8FZA-M"D=VO5'!0VPL.<:MCIR-MC07MP]'5/_(+;G9MNCF\_;Q7T8,!$ M%W06RW%:EQ9PA07C1*6Y"E4+^()J/_GS@NMJ!=L%=.#$9':EV[UJ-WI91>0[ M,99]:@@[#]Q7PB:<8_",^NNUOX@1N8P?S'R/<5WLJ9CS:,&:H-%6<(&$]-RS:902U.G7%(T;W.%>G=!OIM]$G&F M7N?LU0 ;ZAK"(%;,@8&*)T:14)LM*YKS9"%=3#)*[TL1*(>F=$5V$BI@KB@*DBZEF>S$J9\-,84YY'L6:E<[:KKON0P6_2R M;4(9_F2U-NOXY2H0P2#XA!%0Y_DRKJ.[%D9!2G;.;&V!GNR H\F9T#M)A'(9 M=> ,GM8=#!BXJ:P!5KIU2WOY5F\"N6>MJ5U+IS)]?:."&OE"4[BES)C@ BAH M3"M44,NF(RY_H-GZ:7JM^W.@W[L2SQK_PFV]9#*VT5PU<5;A]U5E_2LZ+A1W M;W(-L?RZB[Y(2_575F5>O3T^5MJ/K,2*)[ZJ58 M+[/"#D0AZLJ=EE(2!,]'Z HM&.0 FJ(Y8[=KO2)2 $\_-4 EIJ@K3N;4>%$X M*[(DJ.3P:?6%-,%*+&1)CH81L:=MS>"X-FC\S72D@1C 3MA_ ?@ZO?)5FQ4-.P MM625(9V(&E R9G8L T"LDCJI(/@THV?6#O1NBPI6!RW^5O75& T5"T*E5;]J M)V"+4KAQJL>V+W7EA8QL#UM0MT;2K&WO_>IVN/Z(H'&6N=BJ/R61]\H]QAG3SLW[^H%6U"GY41!E+3! ME@S8BMW6;RW(\N4[#@V58!/B .'(EW<67IO,:I%YJO@1S1%!M<<%NQUHM&8Y M*F"NUT1J4BW,KG8W:6PLF$;D@2C/<0!;(T4M)/2KZ(ZKNQYJ\E=@+(::5!BH M>PNH[->6";O!'A_>E=E]3-EGU?7W_7:P].\-^MC!W_;1X\S:X,F6D6=/R# 0 M%"L1,D+=6!GRU )A?M28'E7$+1Q<[VMFU-$)Y^\3,W91O[(SY]9.Y]'8J"RS M*C ZU7)9+7$??T,E( Q<=28\!A-,2O.Z(ZHF!8%>%9L(S". M5O0'GW^[+;ZD))E %59)QSDU>.%ZN_8@XH_O[#AN'B40-?B]A5BDH;C6C[.\ M3Z2:7!?5LZ%'VE.F2]G87M)CCXX/]TU]#0>IX8%L+),SW87>Q?UN!!^J/%6N M#:%V1V* =8/]J(%#0YD*QDDD3-;M36'D2&9(JK;/EA"RNT]+A6U(TCC?8!T\ M=D1@!Y&ZC?A65R"/0<9E\6NWZW_%/U PGJH;)\8>B$531X:W=!0C6BR2J%0P M0)$BQ#+DXG6^FBI*:9RHP>O!A<"-^2A@\3*M#'^!75=JI%(&_)M3WHXWU>*% M.,D0,V;)CS C2X4YG0A"* M.J>.8,$?QG>"1& 1J#:&HU5CR=COK]B=P6$# M\^*VC# Z;?*>Q4*%1_3@5-C.AD,*&)WY^O- 0]GOV$[DY(@BFN>YR4 >;); MU,D@>, 6M0SE2Y>JJF1VAJ=;8#Q@%:!DB"+8'$,W $DP4S-2U0*7)]Q\J@>" ME$BC>67AI\^Q=M=LB5FM'ECC0N4A-!$5?%D%&M1-EA:";TSQX:\^1E^_,Q00 MS"5[ML8E<:>66,/*>=!;W9Y/I6#?C.PJ*'D?Z:(UY<8F>L(5L#'*9..*I!U. M3RM^+\@HJ<*TH2DETI;OS'O9'.C_E1$9PXY0HMQ%LX0^438GB#'WE'0&/2"SOF5D.&E120;J%?2D>C0R5_N.[7D#X%TWHJ:LT7A6Y]+4LOE#[7FYGS//_KM) M%USK&6%[7<0IBPH/D;+*Q%H66!K]H9G[S0U'8+\R>&++4 ^5E)$) *"0RZB) MFTR*0:,QPRF.$Y"1*3K?E%[4L00+S&*E^TL.+2E#BEUA@_&R!8*KMO.]-7G6 M'%4PE#-,6%!">-54N,7BA9P?J2Q"8!B%1NC(KM(*32R[+KCDI:FP^:(9 MHP"05)Z))< S9U$YWYN7+)#6)'AXX@E5(!CP1=P'XV]:^7\%K(.E1N+EA&JH MBRD,LV4:UU)*BYD[>$((;BE,G'"I"[.4KE\W7*HST?_ X,5V4E BNE;A.J'YJE$GN0R:#HP3?<.MT[7H6OZ^BB;, [[$EUYK*K2/ MNE73T@YW=4MFO"'%'UKV1JCZA<7*8O5KLX0RGMH](;3U&]>EFIQ;]4J68@*% M/D\0#GFGI+>%CF_-F?V*?3EBEZ5U",SXF6VDL384U\IBYA;[3CS]G>Y''$"_ MJ$R;(PV(/4+4QU^04S<*F-9H'YMBCF&E#F!H3A_1=(WF0XVG>_;_)7 #K;P= MNQ1$7!6!6[LKFQ=G5]>JH*62G _9?EICZ$(>6A'/N;)6XQK\.M[>0GMVJ1NV M"@HC]VVW'2*M\YPF8R H@: =U>H_2<3?'R7]VFWO(C=+%98K?[['J M/GB5#&X'H:J%Y*W1=G"$$$9-3L[*&"RB+(G; 6!]=-"!T[]C\"7VB"F_5][" M0?L/D_\U60&"]!71W+=@6322%U!HTRYK2CJ/NH5;HZ1UE;$6(KN=.]G2=QE6 MD-[.< O47,:V?#$TK30Z^?HBCJ(CG]A=:V\LPY5@O#NIEJOJ5Y4;"S^43KE+ M 7W9]D5UKHNTT_09M^MUPP2:U0S)=M0X0JW*8P:ZMHL'2^FZ)JMF2<43%QA/ MG,(Z))9HAJE\C_\CF1P,E>C4%.RG<-FI]/@(?:;?$X[>:.!A_5I48XX= M+S)R:1SE7[!'?$)86FE._=E85=.>5F)-W7/#$&PE$XF+\CC'PZR,D";/'4>+ MTJGIIH.C]-V0H2*J3=(:3K:R.ZQ)-!1&D&H3@RN@YBXU%L0 Y04X(H9SYRHS M-@;CG[&%FZ.[]D *1&1F\^?V,?"I>CM5?^U3]1O(0WB2(CAQ?)6:)R<(\%(X MIKC1DB'<0\UZ@ ]I.VZ1H#:+XTT(IFA>*YA>.&.-S":V[FHF?YOX+TYAJL05)$\7SBVL MN.+2 'D*S:/-%ZC8*1RLNEBIHU#%6Q7@F137-^;%;T'CT62 MM^[U.HKK@B7C>@(:4LK!R+E,B2LE_MWP<*E[!VF-B&)%-.DMU9PQZ]5X&),] M0(@^)L,ORU9,.&L'$/V[K#?06]6MJAVJ9NK]RN0$AVX@;E1)R,T43S (D5J* M4HN4VC)ZA;2R*CUX!X7/V (6*4HWY,FR(0>.)($"G\*%<.9B'@Y@#'KRSV4_ MC]!Q<<(M5&T C(6 Y1/DLJ49LE%MXDOA;#"Q.67?2(R.X^MFI(:0NE2^D\5!$X(]I_/!J[$G='/% M'J&:9M&RW;0F>-L.C8,T[:!?@X_V]EV>C2Z*U+=3FN!4\&>Y;IYW,X[E39B?.M+.E+HH+)Q!0:2,^+R7J&H MSZUHM?OS3F_E?F8&5YJ"FTE3U45,*;FH5 GB(,EB'ECSM[M4"E'$S9M2!E3C M@NC>G'MR\JTR,*K#IVITK/(P75,"[UP94& 2;[&"FK R0VX66QK3]#P\);%P MD4F.K4K)G1P!+. IJHI![H4E#: ^W@%]P8+ -AO)7UN96QWC)@AJYT"[SH 1 MS)7UAM+)W=$]3NRFH-2(H+:U[ :ZK$9;A6RE:L7LD3;@6:/@.DI?;*7+ED$0 M GM@H9")H@VY*N?59W"U2PXNZ)Y6Q<,[W:!,7MRI;B?9&2H&P#MWC\+&I+D. MM)(25>/MCZY$1>B?)R):OY[T4T)[P&$"":>OD.U;!4?:2 8AF[KHV"S42"A) M%-LUI".U(''?!D'P V=62*T0L ">-XV'S+7]=8)CZMA09YP)YVU67UB/(#45 M "82AD4E(';TPF4L@@X5J7K<#DP;!_+"3@"0-%-%])9,5_,[39Q+"6%* M $ M$QD/@R?+9Z/37#R7F@ -@3#I+Q9O!D8'>+A"BI))/@F<0\$K1+M&_H5G7"Y4Y\ M(]-3X* "P7V[4[8FM+-L,F$]'LE*,\_:8M'*&&H3JV-X1:3QA;I? MA(Y*QQHLG6D%=8EB5*AJ1M#T^)<.8),[V\5<;EB%\[DA*C@5OZ,.4P5$UF@A6!$X9-+<^D2-H&EH\O9GMKLQQ\/RP7B@+ M6[G1 M,Y*J6D%DU8134\EQ/U%&*[ N"1\R6#N%@H+R,9V)TR12$TY:H\@7$NI4^0B^ MC>0*[&)TI_WY \V^%B4A3TXKN[!,&>?X)G?1A!-$UI/%4EJ5 6U\(TG*6Y0; M54S+GU=N_F"6'P25P:T7#U MX)]WDWK=&/NV:\#MF"@)*6:M/416D;K+8,5!U#V)SPP#JY5BW!$22V$;.@MM M\99%\7U(]769NZ/SSG[5&3(+C9F8AN?IV25DR+DMT*-MRK0L@2":6@=BZ ]5 M!I.9.9@ZK>8B*:QF.U' Z/Y/FF_J]'Z"^3E->?AQVKX9:M1YKB72OW9>/R8Q."P+C)$M=]Q\:8>@T%$N&&XE( N"3%5 15,+H MGJ9\DF,O,2(R;\E98KS$/+DE,Q)?>)PD.$.YR6.)GUKGP27(MGROT4*$#FJ( M)8_:P[]6B)+']"R[>ZB-M*/Q)]WC,B=W((.-SA11(GE\LDFYVF:Y.Q SHH,/4)JO,*0#X87X&!/H[O"]$=E MC2[15;$'[7WI.)LEX[>S"K,4;-:8P&%VWTSE*:A$*%J'GRU.WH7 MORG?W]IJXY:#M68"??#A+!TCHHR,V-,2I3-#L\[35KC#[?R C?"J.E@EY\&R MP?(FCZ^ P3'\79"Q:5!] :L)]B!ORDK9H"NP9 X20$X(Y07-:,+JCJ:JN6 ' M \"Z5,;*?4C<(;K'W]J!+IT&4J -!EQ+PM\<]);*;:IF,9EL4Y)CA[[?Z+II MIV[X5X.OE%AS&J=NSS-3!'>\._''O8X3&FOOY(GL%(15^,*DH:K'%GE:-$'7 M0PH:N/!:1]$[H^?FE/#=NI(%5#CVBMF<_JVR_IR@,S_1]<^JSBHA-X,&/40Z M86Y=%_$#*(ACCXR-#83[^@38:XY8ZB_"];UFM,_6NXI%@P]G7L#L1VL:@V3/ M3(2)C?*TTB 'S%*4"M,@F=;N$;A>@WM2SZBS8&G'XMR=YBWB)%*'!-/Y*8L, MK;9>['M8!]+ O)EE=S2UT\ =6>+"/SHE1:4);(_Q4 MXJ2UYI+JQ7Y/[/#<5R6,OB97=&Q*[F\VKKL=63:Q7GL^?#NF;9%*FFTEJ2M!8:("/UVSPKQGM\2PG+'0(3@>#](S/VD6RE'2 M>1^.D'&!A(Z/8?I>QT#J&?9!)CF9=_(I9JIFT7^B,L8]$.HEL>7SF(RVP/6T M9N&DK!EQ0F0F@W9@*70I$.D+Y>*F)$<0M5NA0-#CG1I#>>5* Q6Q1'03E+B% M5N(>E;6#>V&E+-00HWQU>H_.W]%IM 8!C1-G2T3]*]!+6I5QOIP4U!1S#Q*F MQJ)/MDS@:5QG8]>:J.E-&A3$2A-5:)>X#+]B**QTM%(Q(^.N8O]II'1JE=84 M024_6QE6ME:K."V(+$[)=(K#5J:.FFNOW!^1ENE4(Z3OS +4;ECB4_'N48HZ M2Y:H1-C&P1ID!M)0>#LN0D7&:.RX>VRI&P;TP;,BI MRY@G;DVC6F-[59RLIZ):U1_A;&6AL+MUA2D78E!FTKER+9!\QWCV3(^>M;4J MKX[# T&C!SG9ET05F48HI:+L\$&!'2V0=YJ.[:XU!X_*X:A=) MATHB"<-J!F5J1?K2=T.R)ET$7:TX948(9_,R/C&8@F*UI%FH %.5#$L M+4#F=+7@Q2HM=3B#T=D+:H*@W3VN=C/@*CR3'4%XU.T[4TY//-MTQX,G2SS< MP-4__77;F8;,R_G68Q9(5\3%0ID%A,;&/!L:L:"YEWD2#2H3BXG:J'B M:@P1C@ZP\B*%Y7P MIK?+\!GIFM]9&6S%VR7:.(2"U$45.(0U JCQKP0IIZTO/F":%RX,636_.L)F1KK#* M$;)+C7H!G1BMLV0^&]<;62L1,Y.;Q-&R0U$S"!AGY'X'LNI2!*6IU?"'D(]X MA\FA9R( )4WBB=2_+4'I7"@+B)E$%AIP2^*'RS-@AYC#RE%^GR:D-S?0A MX2B(,4<0:+0]-<6F91RHH=;;.3H^CWN! Y&ERJ8>E MFFQ*=[!:M0X?3?TLEA+02FE.")] "EO'::4@'JH(.(7G2AJII7"\XD*F@TJ] MV=+*\UMS1YVI9%K8,Q(>U@'1Y)45/8R!J2Y8H8CC# R:$UIPER3]<$!W5>NZ MORF>IVCR1<5;ZK+A7E^9$"PWU7VO]''%X;!UR,XL5? Y,TJYR0/6P!VU.S_Y MUQQ?,XA]+&+^C8!W%/E2CU$WY\!ZJ(IDN:V"JZG+:)'&F>-:<&OR/"EON>M3 M= R%W]1 E0A!B2:,-C#G,FI.*?&HV!J\[O0V4065_VZ "LV<3+&F)M" WX5: M/'<4\S VUIYK74U34/78NTIMN-2&CKP04[J(B^$Z=>(KM"3.3M]^^$S_&+Y] M#=\*6MLLR185%1B3GX&U8GJD*I>HL8[C:.S$X"0KZ4_^,;65A&:,J/5+:AQE M6KIO(YL'9FAM=ZD:0)4USZ/6*QKZE]3D$M&5]$]5S8/C!SL?QCI"SD8;?B!? M&OLM%QXL=8U/T=0W&=)C'R=K_N=B4]K>2*_UD8*M@'3F!=U?O'R M4'<>2?64@[87.H55G?3FQA$YVE,T+I8\+QD+F"I=8EM2HQTE-@M& 20_Q>FV MPRVW9G/;HE'>$CM17!-%O[]ED%,G)8L<9@<5(6@>@K%R1; ,)/[*AZI63F.9 M.3%#7M"_D@)8,<8Q52:VJ&/JML_@G?\-SK\JCR74Q V 7YVC'CO R?;%-#!99>*U07!P4BJB-"BO+AX=-SPJKRZZ5;'V M*:LKE(7M(VC[1J[-I\AA0 /5_!'8QA36PW@YH@DYM>7-M2TTY!63H&A M4UN)51)/F.= )DD6E="B5E4+FAX=NZ8V1%E,)+F4[Y?(A!C,DQO7>8UVMB:. MZP?JN(X6V%:+]*)4U2GZ[CK",>=T':*:3%27E\Z/F1H0=9G8XVQC3[*BDN&N MRE_>L ':K/4N M+9N*AQ.ZIJYU#:P5MAL+/M20/7W-/=J5>.D=PR'!DRPDWSFZ8R9\C3?CO55A M$#+GF"K:E#=^#2RL%"5LS01"FI(9+KH_*])::H#0F ^FW'D];FXK*\ZIS!>K M2T5_=P]DR24"XDSX=AQ\U^-7/CY'+Z+Y7*/:JJ8(P7*A@AIF"(R^IEAS787! MRKW(_,AC4%W5?#5XP*4-[*6])F.$,KZ*594SQQV/U:RIX^*>*[T=3]'E1T?( M.'F'=Y:Q29$DB;ZTSD$KCBQBTAEPMMZZ)%PB]D";TL'.E/X?#G2;F9_*FFN( M#4PKBBE/MNN1G7DUN^!_/G$W^($*D3_HPB)ZA1\UW-A1EB7_KL;;-RC2MFG%C#'[,H;K]8%X,$GZS7"&U^?'B%+/16>S#JM6,H6TG@!Q*2 MCK*T;VIKC-*:7Z('7A,NM71IMGV:/>!RM'$;=Z99%TKS.D@YG<-H5[/8E]0* MUJ!@V'N"]$&K8%$K47.<(,T<2K5J)%%(C>LD)G[7/5,M[EC-_EJ5R2MWD*8C M4^=TE.5BQ*0_)!."P.71Q/C@+ MYO(3.!R?$=+KYP+1,3I_<',!:U#7VXOE%@<\!;\E*G3T'H=EU<&/JOV;+,3; M6ZP,K<4+3&+W-:GBT\F9P6M=7 ^&YJ&F":,+W%'%]V-8Z^EH<*E_YP[>8!&W MY<(9% 61<*3B@4:46*O6Z1 JDRAPOB9MX!QSKES:8)4HT%'_;BL./L=D'YZ, M_/8D2Z; 6E>#LU&+K4^&HT/R-87L+P\80W,I-#PC"H&]6ZOHA\#!-:5NO-?; M_W:?VW#M]T#VX&)@;X& UKH:4J$,&+%O ) 5?*RT^$:3?S2J!>.VUE0XVV5X-4U^2VCA:E3*KI)?)BI"L!JEM5TO)W@1N52 LD75+RENL%O%S M;[#EG[%;MDE0O\CBJ.$1%$?Y8_M5QY:@*BGQ6U,?UWR1X+SC.\2IK"(];$S5 ME%"K74:-A#*+F:['L^-E[)-O%EH>92J!HGOR.TP#-XJ]IA720L@!;.DB1 63 M4#6U[6CB%G<2EA-1:E8D=#$#!#;TV+$,UF25Q@] @T1Q;C'ARD/[9 MZQ5<'^0B)RZD@I?L+2''4+N.YY=O(#(T>*J*&&.=H@3AW> Q9@WR@FKXFSPA M_+!CC(&N-/0XK/B!EDCN^VKP$6LGT(QM[.ZA;F0+9&*[CD5%&LF?? 6_9L&\ M\GR%F6_73,(CJ 4.RU<9%>4^D:>O/%'ZV#7R(;Y"-2G3,1[/<7&76'GOO$JG MRXY^K74$$; "-2DZ7UKPZRK+M!)?=YN(D8T$A(S"QN!BM\.O!JUGS3J.,%\I MB./D?C) G= 5P_.EMRE9F#-$-".M%4H<"*"0G>,.9^583"J*HB3P8:ACE%& M=0&@&S5K3P^1+JLRX5U>?7TI4= 7ITX(BXHV92CN&@/0FAZD,CYH"9)[73F3 MVI6K+8@G O$C?K?%AZ'M2(3&&C5IMFE$#C=L\+(0VT!*V]MM:NUJ'Q/ %7.5 MS)A<]6GBC#-EHJJ8+8<:9)Z'7@SR%Q8?(97XQ3!?U A">8T P+-@"EJ!*SMM M9#!-4AWBKRQVU3D@&TEV<](*[T@/X<9PQN>@*H1< 3%8*\.*>SX52JN;@R%* MHLTPI)48WX""WL88TS*"T+0JI7U<."C*SYO[6';E-O<,3?6ZX'62(P/.BG2) MFK5&C,\0!=3+7NCT&SZ7"F=7I(+U6S,IIZV<\;.-64<-/L+4KG9-.X8KQ;P\ MZXA727EX?"TUXL[4[E@T1AE@3GZY9@([Y7#J@MQU!HIR@$/IK:$08F$=:BOVIX.28=MN(704 M+F$NF>.4KI;^4ZY,-*\@A;AJ0P1C8440F_E0-25RD[*=F_MR,1FN>M<(3SRLJGM(&POHT3=L@V MCQU)2AQ]E[;':FPJ@SI6 M.JNKZ1!UJU9-G(/C1IK]EEMD]9V=SGC]4KZVX\EK.W+=KF:<<.7F-> @YXC3&(#>U&25M=5:!#3:E3;[X(_34>_=&,!0UP[NU?8'NCOGI MAFREC;IDR:,%BOGKOV?+1;(,-E6 7>C%NSW=1DIEYCEY\JR?7*$EAA\?>0KZXEYE,3\Q*A8%"CIA@D(;VU6_[$KF?_2;)2%#*$! MD4]>5%LM7BK0^13VL^[)A:$/>&A?__=Q+1^BWQWTM/.!(%(6/1#:S^"(-Q9\ M*?6F<42B:8-Q)7#FVB%A?1$NHN4D5M\BQS?!KB&-3Z!77_#J;2:8"^FGBOL&YD.#<%?G!!X PSG@G-8G*9Y@]=4JC 1@A8YN67$E+[F]!6O++ M83;6981S,(F'[R+L$B+RH9Z'('78==AOB;JZN0!T330'\)U$?LP#6C+H-FH2 M)PZ@L4WR<:Y:8U<0+%,N+OO&8%:](QVVJM(5#J #! Q<@(+-QV)^Z2+#/:MN M SC;H;\P!L5PZ4.4)\KUH=(N 41I6#("(]A"U'K6Z1,OVH4T>^<5 M9NLD=CTL[#G$:@*O\A5WZ9*#HAB ;D4$AU+(S\M28&FS;4?;TY',(@$#M"X Z9O.86;O5$B@,Y""5,O3]V. MK798B?H3W3.GGYB.N.MVI_+O&*(/9DJN7O/1I@YIM3BXX=2(D0-HNR3>P5N= MW\=2OGOP;;5RB38W907 )PAJ!(Z*;@Q M&726FNA,@?!KHO$O20*T^5L,J>[JHO@F]Q%K (/TEV 7D(18Z*KLG!/.:C:P M6I,,I!?68+MY0Y+-J/%X&K; ;CC9\@JQ5"Q\$+_&-\,M"$METG'DUF.2U#95 M2BOT7FJ4&MF"FTCZC%4FUIA"IR\&>VBK7W)2M>+H*[=N'@LDA'+!)"I]RFXM MA"X,52L+X>Z6F 9^HYK%BR-.W(0S4^GCIOJQDV VB\3[L6WB^103.JL('6ZD MDC(I4U0NX2BIIE[27FM/L\E'ZQ&%[1[;3-4.X+Y'Z9P)HC 7HL/)S1']\0Z^K%9DA9O3==NY7*U MVCA*EMH:'L%!- UJKF2UT(]!=A>34.=^PQ;?[HVW$^URF5] ^F[^%GZ1GQHJ M#.BO\.>Z@J(#^K4T:'S\1L9WMV_B7 ?R9L7R7)JJ#@/">,8!>N/JUJ)XV5D; MLXRL&E"$2IQAEJ'8%XB.G1M8# EI)4FWO*\79^=7"%D?FWY%]&RT6W6^LNWC M;B\WI,)'<1,K6>\"&]% ,F1L3)6@5I7HC4QS1C#A0HXP)EB#=G:81 M6RB.'[GOLF./WW)=/.)L_23&/&H^PZN0H9JZ:<"NWCPN5GC<:>M%'ZP7O>(6 M@J6N]IO("9#>!1FE/"@-$\=:L#"/-1X]<7Q@"$CW9V7*+CRZ4#LI ^1Y*=J! M9+E;W YC'#TRQ:_E@Q7XX',5Y=]>N!+)"4POD$8TSY8T3T>:4X.(Z_J5;4": MBJ9 6$8I(7O;IF@&?A2='"V%GIA"&5YIH[0LFIJ4&EA(I]UA8_VNE8XU5W:9 MB+.^N)/^YYP<%-3%>RTXGSINI9V!QBK- MJ55>-N/DNKME'ACK%,LU[$93G&,)%(?;CJ M_X/YEOFN[X9#XN#6;_)@+/4MH5\I-XZE[P!@:KES!>Z\L-$LKK#A^(D55W1% M%,$W:G^^A>ZE*^L2,CT+ EJ5Z0U<[ MTX?'MGMY\ YGH,M%ZWP+I;7Q3%!/.T,(T T4=8;TJ^JS04W'EGTI4/\.I50J M4ESD\6^=RPX6#.2FNUL08MYI+BXJZCT9(E(I]M>+P4B"0W.-W2JF2K"9)S$+ M4#-Z+ MJ4IQA05U,B3W,X?A*(6D.B>P$^(T0>!;??%5IX80N2*;.]Y[,N<#["/M2VX/ M+)=*2T:JN,4VQ!6?8 IQ2Z6(&3[*GQ7>_ M2*\Z$T)H[#@=.2>(QW::/I7G7/ M)5]^D'Y,9(GYHE/C)8;:.9U68RVYW['^2V<;JA& &"LQ,PW$P$A?=S4XN$KK MKV4]E>XJPL% M,(U/-=$SL6/Y0ANP+7"#&5&LVD6J]C5)MI@H:?>*>:.A CHA.F%A//SPZR)9 M*XVU[M$JA,H\J25"]WL%[<;<@)]O0;G-KZ.Y..^8TY"4V*/7"$V4+]4^DYBT MQ:WH8+-UGS?&]Z1V;MR/-LCS=!Q1_HP!W:(!*PQI7<>L"X/P-@'8[>S+K%N MU;PMIT$2A &S_4*>!&^R4E^I$<&8BY=,:NA?35QQ8)BXZ[FRQ.5D3H^A^1>0"A&B\]*O@:Z4GP22U-NI#=.IPEU<:U_U+%=U3=)F617FT[XYC29 M.Z<00'QO!4$:Z$;V,^P)H8&JV:7&S1/3C-Y+S4!\ATOB).4I@V M8VS2+J,Y0W[B_7;ZSF$Y(]PB8^1W*Z;Y@J7EL*&Q8VRP >ZZ2QHD%AFMLRN=]0">%(R>7+T9RA;&7JMN:LN ME1Q&6?AXE2ZV/-!I XR3J.(C+UU*933N^+/:?=34\]%TM$^7(.UNH>"L5-4Z M=#$,9U1?W\F_EF;8B];:6QPCCI4>!N;'F!EF/+M;E6>I#326SOZ$W?VW'Z89[W3K1+"]@W5+@^-&SF$?V[;TTEK<_4>_56[R7G MPEU9Z\$K,'1WQ@W@V ;-S05Z;BB915'"\$625>H 9 M/;^2S$R]U,=CW%1)@DGSPO22KX3?*W5#W(TU;,$M0L+FJ)WI;B5+73@:BT=JFF(N5+%]2I_\ M,&S?#7"Q9"^M&Q[N>"%3GL+^P8Z.ORX@,E"98,6ESGT+FK%"'!(C.#658SK6 M,-K1Y.MV7/4B9"KE]@O5)SQ38(\PBN_,C,LDYK;7BC5/OF4:6[^2P9K(=REA M'PU[4\I98U;LN*^!-+D1G.>0.$[/Z$I':<%,J(" MB\BN&&*J..5*08+CY@";=2JX;&F]#9$RMI\)"0NV.5%/FV':UP=S68@I$5^' MW,!OH:25-MM)"UVD\]/+X1>_#>^]^RY(@3FI6468 799,U]??!V/*.5P++6* M:5ZID7$L=.:TJK>+U-L)L%Y&G=C91Q!\JU[D]TLW.A770:;RQL@I85#H+SN7 M%!S+DN7$@[5JXF=Q:P)?"MR[^6K?0GOT\R*CH* )OBUP#;:+$-E,&0(U&<4) ME ECFF%M-0K049!'I*BS=T;7>7'2EG7&B4RQJ!?5&;&S"B&,)@3 Y)IDFF=- MWD;U(IIBB80IY([5-R\)N,D%,VQ6QA44)BJQX/O+=&63?NXL62>R!IVZU&01 MNRV&<%X%VE$SP>9H _IN0'_XV@/Z]VZ/:QZ0%_2KL@XZH'8>.?K00@D_B>!J M[Q'T+>980(O)3>MMV,: MWEB'E.F.[,7IF(7)KM;3]+[+$$$A7JO,[7GO1'L-TBH%3ANN4IFR6%PA7LL% M(=]1JJ,N)"L+G<]9F\!.H#WNC!=COH<9#0B.A.-H^8YPOG::[%L+OL'VX#RL M5<(SLL8AVI>VDQ:JWHJ]59'$0$FLR]VUZ]1O1_>3D4O8D>RF(1)' SS07]2= M1N/4M?&N.80D#1)=:$[R/_C&Y>S2.DA:WFLZWU8#O@[HB4&M8(*NI0?5++[J M>E?1"FD+0#Q0.D76P+X<0FJ\/IN M@TIK-;@I(S6Y;Z8^]^75?)ZI/17+RXNC TUP_RCW:8)1%/>0VQI8>H)^1UC0MKG351(7W7/!+40F%DZG?5 6G9FD7>MM2Q09X1W#J$=0# MJ56QX[?OTKBJ0F4B?QQW_UKG_*7;6D78L46_*/)NTHAO?Y2@CHQ6W\:$840F MFP1T&Q T&D_;U3W]O2KM5S%C*. &<5KL&80/;CFAY$=76*%B$>4@6#&Q#?UW M=8E$3"9QY$C =*=33. MU$*B#?E<4*0XR3CGKD-1%/LO@7%D8@[RA4!#P)&\ M=''(M<$B(,QX2Z')@M/Z*(&M/^&; MAD4$1XC& 5:1K2/=\[/CH@4##"U8-W=O!Q*C[HOL6'Z%][ M;W?]VOV$S: 4YO =,RD7E1G?K4S!,XS%9#:CG.-.HM_LD3XE1U',9SB-NE0T MN2.(69T/CG%SJ\)_-A8PL&NA$U4:NEY%>46/;#[9?$@#O)9JO<>+AT1YQ_MG M>HNA.+\V[%(1GJ$;B/P DH)F&B4V9;FE#/]//791D1,G1V-SD%%244<)C0*NDXC@*,-RSY;>M]4%-]V6JE=*$'Z:JT M]Q&G#!B,[G]@?Z10YFL_!=BN>!=P":,ZD-$\1DX3H@U)K;R'G.?0)2 FW.\W*FM!>- M,KZO \Q;@RWY#T^ER$H9D/VIRQR"<,;A2K;%\6N$[3SJ3:S=:_@#%P@\2KSW M.R\GW7\C,\ QB!V,<"$-:OI./W/V7CJ4-\X<,N%NE3GWNIMKM1K<9N8DLSBW+6.2OOU=[:-6GJDH'^.&XV\*N8DXE0#\X.8&82YHQH3$@@ MQY\IS,*[D6L$BYD"M@+XJF#\' &*=N CFW#5&W>JLD/DK4$V42HWJ_T1YY>U M@Z5"K);9Q2G;8N C'HUN")]5^8J9B?3T0*:][! \CK<$,EG&\3T5%=Q-% $, M8G*+.QT&["%%=#IS@9;4MAY!$&XIPMI#H]M*5SUS4\DMR(5:06$TI$E4+)2" M-WOQC>/:\0LOH]#22$J#[*Q*X27N^Q42&'2PI0EOM@T-NZ'A_=<>&EZWUKN: MSD^WWD+/F(I1"4=PFCHN>(LJZ3I=:DW%C+5)X;:F=RO>&S=_R$F4O(Y(<)"; MR*:N;9^".AK8SF:HGI0XLM7I:<@Q_&BAMS_,E@!P;#="7IC,"A(^6T MT17O.-RHU]&(:PT=(UL3JKX-^CFEX61 M3K9DD]$XK20QX!V$O3B"&#<9DP?.G13S9:.@8L:[:[RN581^6^WL&YS)@.O_ M,(N9ZH?, ]>*.DU&L->8QT\9U0'''\<@HV!-F4DUIN0ZC..!4,?T8:?_9+7L M,DQ)$R4 ]U#K/IP^Y'C];>[S2"TJVS2Q=:=336,6RR^0E.W*/NEL"*7QXK7@ M)1=I(LG]2RZRK5-(S,4K;7)63O\!)B6;C*3$/D=&%ZI7W*@[ MNSWE'L?M"_V*:8A1=;"5I6282JPGJ!YB?PF"MX#M0L6F<#8U7B\Z6-@V9R&ZPZ?TR,:3Z/41'F@?H'"OG#,42 MDV+@$)X;!M9?XW$1$C)1SM-4?PG*]S4U]$'R>M2S8"2&U!?U4XNJU98G3W%O"B2 M"-J'H[,C0NR46$3CJAV#A>C83L'E,M[M*'<23V'&'6\Y#4&!TND3-G:O'8@J MCKB#=)VR MIC5"9\N%YBHTT\4Y!AVD"DF1/?6IP0H1FBT+#!1>&BRMXNY@PW M;'.EX:>%X[V]3MD_N'0/,3\602.C1:087@2??J>"F%4UZTL@D5=[E4Q>)")) MHB4$1ST'D]3L(A;X:C=&\9KT3B\&)WO7O[]2X,1(+]:;*IB*EX/&R"ORG2N<( MM_\?M9!(J"\N"XSF.*GU21+CRR9/;I\892.46U[>)AY44 MT_;&U<6E%J^[6"D-_TT?01A5(Z^M[28AAX4P*X81\!5731C=":H"A2(X /+W M5.AK)G-7A6XG5QE%@V $D[1-9WKA/51J8;XX;4#N.&J.B MRJ TT_]UF^0N:"ZF2B%*(S9/,HK98-_L>4$YH3KEG<3]ITO6J%W^AKJ4:N5Y2QT*YN@369YDO*HB[)%]%U%.O$OFVA[3JII%(\5M,HY[N:2\$-HC9NK2X]HXW2[^#W1:W3O1:E@M5 M$)O RQ)/IQC"=K;D MC-YI:+HB2W4 R=ZT_H(Z)8 ^)3LO%PH2_E!UT 8W) X3NKU67->%<#4^U]T$ M%-6><7XP M&&K5G[-ID&@O+1[;2W)]@,*[;9?%EX5L+--O]1]L!WNGC@KS(;CE(HWG:0W1 M/&?1;U\*.*)Y4A__EMV&;PE516E40;R[?>B2\!1T[(>\NEG$Q\B0A M&R9P$U'=Z64PR@)65HPJ4G%I?X?R\;+X\:+%5C,BW7['_L+&46",-\^DJZ/R MFA31'J+?,10]W9@=V;EJM+)RQ"WD8CH;Z7@7!\ZT(Z71Y4XFO,'-T(KZ#*5$ MFD7E#%7JIK%SOM;E &MT?)"K[FVM78*8.3"9@/["CBC0%A2")&#P 94!K-19 M;\AN1<&@G5+TUU L'R>/3#:D,I3=APD5.#I6L ZS@,DH%FK=K<\%0&"YFS), M04RBPDNN.6B,!*297E"LC'(JM5ZHK=&!)0]^K"I_H^2";RHC,XVL2EP^QC>= M)E)9H)%+*Y8U!G%B<96:WDJ[ML2,Z-"T1VYJB=XN=W>XS"\C;"SK#JBF1DUT M?UP^7M::OX\HNWSRP$"7A61XKG.)1>ES!I)&JH&![G8[*ZJIWF+@]&S&Y@$, MR=:]KG(L;M,]@G7+3>VL. *H2$/($>I(#+YB^O\4!=+-*6>,8\\]>+0J,KXS M$]FN8(Q(@#O*^6@\_CRXB:VZX!/#02A,&)89K7-T1E+%KO0L(4R4+13N&EZ= M?!E!F,[)TT G;T9VG#:S.9?IJT)/");'(2@+I_<&'A'=8RP_S.$:D4QR[L:R MXK&N"I_*U5$6UR"9_Z/]V@VMS':0,W2EK,.BPKY!O,OP>< 9&.2B^]C\5Q4U MC 4*AJL=[])"@).*>CDB055ZP'$:HLF1WPTC^Z:6?J;D2M3K=)J<4'C%3?*M M!W6KTM+XN&6K>,=)-/#%H#\A-T.^+/G Q(6)# ;;#VT\S+S" !=/A'J+6#W& M<2,V;*9A%1VI-XEU&0L6/#B/*!3:H!/CW+ZZ]"T(;X@E0&J(S\EE3,R+27/= M/T5SLI1351#[[<&@- 5=.&$Z%RP[-493]077,@[NL+)\@C*5\MJY.B%P/9%$ M&:W*.L>525C+?1P923?"/D%:,E>IK]TJVV9<.A2M:#Z4&X*P5B#R3F&5+.[^ M'L0@^5%4G$:8T6:T5 FZ_I90? GQ'F'2[R(I1;0#X$/F9T>3]IVA,0*<&V?\ M2)! TUC9JO\\XD@7J+$3J7JO8N%@]EGI=D 01^BO% MQM5.KJ:(^\ ) /\)@IZR6^S\S&QL'IE,13QA1L1CF@I<+Z1SZHS#0@6SV>,K MRS9%8+CLY3N58NBHQ0.*_D4,>CCE7ZQQ2A0Q<9M)\.;Z:[(I"@2?Z[G8>8YE MHZG*;;']GV46Y2%?#?Z/9VE_=9[>B789YD41@#J7"VC99='[O1&!/I(V.5+7 M03QQW/[(8CZ,)$/IAIQPQV?%T3UM6N&Z;[T'QU8XS:Z(^>: !$%R1B5' X&L,9M"**[C7Z MY1#K:XB(=_/,2Q H/_[?WH'W;>,M&FMF4CGO8()$T38$S<= [\F2DK9Z_QG MUQWEDEG,I@MZ\N]$QXQFN=DXCK"8'>+((UHB%H^6\FYJKVO>=?<=YWNF^YN< ML%7(->\F)GK"!ZUW/!CX>M-X=WAO\?BP-"?S1()$=-QS*=DT"W8/_(.[8=2Z.\[05W3 J.P\=1:0PQRF-"V^HWW5<54PQ;'3"!: MW6W %;'"'K5:C5P)2%OCA[?PCGF :+;.(G!WT 22G=M\E+E'E.[UVFV.K@@L M#;I.TURCHO^@V[W2W2/*D5W1&$%:E?C-)HFA.:/I"[9'ME4@:LT-*OQTC=E[ MBUNPIB*HD03&%0\?-MMAT N"FJ<$,SKT&KV)$S'PF[X#>XI!3/*BW.G\3>ZZ MR0@37H)P@/K+G)RPQDQ-!Q>^^6Q/%B#YU!1&:816RN]@22:BAL1)I>L<"YA; M,U]D4P*XA]E68Z]=$P5$J"X'8WS$/NREG18NVFYB4P3"IT!H"+?5P(; M-%8.W'\.YP230I:>IMS "G1[T-FU!G:E&V[VN7[:+)4JD$U[MW3B-P%12+\C%*GP M%?;H:6^!JWQQM;2>X:WB9#J9H[I')HF#@C?#B186KT(VWM4 MP&?HH-6;E,'*TYBR^AG!A_430U3W.ES7F&T*&+_VP/WA\L ]3C<*__9+M#\8 M'.]WCWJ'?;4_/.X. Q7LJX/1<*0.C\-N;_*__?XO+QOM?YEPZ?G5V4?69WM_ M[WB_?;HXN_S\X?>S=][EU73:+P:<<[_=??SRXNSTY_NSB_^M?VJ:%_*-M%E*VN2DN# M0">S@LI ?<,Y@93?"U"XR(^XHC MX$_C"&S,DIB<9Y$T3^5),0:9SE8^N_AH8FMPETVS8,;IJZ1 -HVM%X)XUZ2X M\2US*GJ*7B:I?*:8BE-K>1:\,)J%9.2)I[_R,6K53N$*PVL1AO$I@T)/G+YUI<;7"?#M5+H\5=OP5E*;4,?5 M+[OI3M*SRBH2T@+]SN[1%MIZ2'L*=J'*'F'1^[B4.GRG8%%BG!,^"T%,BK_A MEJ8^5V1$!04WI<_O\D+-.$62^R]CF1XRH9)>BJA>53E0,QO02]-.=Q^3X +C MQD9&Y5,3[+/"OQ*76\%@I8*2_@YX4%X^MO!@%AY85T9J2,X=@B;>;2>C+9"8 M9($TE>;,!8M/_U51Q009;&]66>\ E6#4UY/I7JPF,)%C5$HJ>[#7.WJQ'2!1 M?_#4V6KW3*&Z.[TAJVRG#.2"F'*S-(DPF0D#YGR$$U6PW-4M5,JDS*D9DN[L M3+6R(>8[,]H6!G4)V"7TL/I !;.5CEE+O$<1[T**3FPN?LY0IHZV097?AK!< MOC*5]MP$ (CIZI(_-%,8=B$9:F1G7N9ST :003356Y(^'4G/;'=I])[@Y8>% M4P1G@7@!)EZA;4)M340*4=7VNHPO&84_WXIJQD *"N!MKI.+N;NX@; MU& U,R@YD?2O)!=AH7VI4<[PK3R^.)6X2QIC.$E3KN^%>F7.J2*'$ M.689[R.V#=I[3YU!O9,2KFX$A)=GL-A"0L?DU6!2,>%Y@?M]JJF'+HH^\L^BN0A/>5EN99$K; MR%?CJDJ>0R8(\80!12$, X0^!JY%T]R*LIH=ZXT4(DA9NR.PH8&J)"2;13=_ M(4$XBPI*8T3AJ'M!8S0U49*$-2>KP_2/<(NU1<6=<64QS!'C."US/>7M&99. M0] 3S@EO9-53Z4!)GAG;BZLYRP3I\"^(@B-^>FPTTT4<$""[FK%S1=&:?K5 MMZ)D',SF031-=-]D0FD'CHH( )&9H] )X,!USJO&CT0&$U9+)Z$;?UP0Z"U' M/1U'?0PH84.['9DDV*6!4\7)(9%Q]K;^S?")Y3K."G#*,N@*UNV0I)L/?J40 M0E./G92%WCC($"# ":.%8":#VN]@^-:F-2:OWU15XZG\FV19Z33KJ.6?)[6O M002!RETSKH$+,K+!:EY>>]37;A;4TN=Q-X;V*%>[IM@3'U!D/E.@XN8,"30F MVUCZVV.J=1P(*.*TC-"3A:?9_)7@,JMD-D., G&VNGYM[K_!=TBAIFFF'9]& M+^$Z%M)>C .=>L*!U(C2,!JO!^.P06["/Y19 T4#!+NU(JT$H(F0>&PF'J5] MRG_,X=(O,MN&&_:RWHI%P\Q5?54:(2.W.VF^<%/&6!PL/FX;2#$9]XQR3+>] M_:.%-R:,7JXVU'R@T^15 B9*FA@.M#W :3%47<0KUS$LG8XH'5O=2!B6 M@? ]PRX^C*2@>Y_*%[$Z2W_OU]1-;!-4$LF/X?YVR)#*]-]=K*2Q.77?&4@* M=(/"P.V]:(X)K];NI-@&.A:$99!PUQ$P-).]3HXM/!)7*8% ^$MD2*[+\@H7 M'IJAOS0TE6F!$>0IMMC"!+ZO*I:FEK67N&\21Q2=!*>1XKJE9;,@:-]TI@I: MNZWJHLY&;(ZCJA1@LA!*6,S) W&9JU"W$T\&]B>MA)[,7UB\&@)FT$6?\,0Y M>DIZ)[YY%$-&[)3).[7J^,T,C.+UF1]2APGN><6>)5)=4?;@8:S84=_\72XYY3+ M-CA:[V8SR/FA/G\Y*&,YYZQ."1$/JW<+;!04C%*$6,;'!). +N5K;!1_]@V^ M28[]SU+,@M_BO[TW=XS^&Q=C_BDN,K@" M::LE[E=.C3*55L%G"LN,<\;^LK1@Z&HTQRJ0MN:Z=7J0-)EV5'QFXES)--58 MU]9K:/95=M"7;F&BJ@,]2S$NV0W )=(FZN&+4D+_.K/)_:P?P B1F6>CJ.=, M-:N\?(%+82[-+H'O*3?+;B_WA-:E DM,4R[=50BK>*]QBA5U.<@PJ4;0KGCJ M_6S-!@?&E!KBB24'VIN8+)'-W6ZF MQFN7-FY(04]Y!=%T@^=*4%]5M2MIW> ML6H>HK9QKM0\BX+"M/E=O$U_4)[WBLG,^YN4=]H'WKOX_.7LXNK\[/+E7#WH M;<+I+/YS^]3,$^+K=Z ,(9/S*@8]W^MW^P-?#HQ&FJ9@U 2,[E3CH"IBS<'A M$5I_,1WEPO10P2-H>I4XH^S(R^*LW(EVA;K#GI=_C0@G)RDSU#]_E6P!J9&@ M9-!@C)H8F?U8*\OO#@>ZS>X_TY(TUSWO@R+#7D2I>2/:]0YZBT]S+MS"XS>[ M7N^(:G5OX'F8Q#4L%*2QG0:=YQU\;I]]Z-2TYCK-J5F?&UFQ[^SZ7F]8Q_#F M/HZL*Y,2.+IGGC@7U69%#=KF,*&9.D\:/632/ MU1ZV/K*>-MU'%"]RT%HB;8@C?I.QL["V"74;@JL^9C5GY8*##9(I5Y54RX)X M&@>XA!TO1LK%UEU.N75]4M#_4/,?K<@A^18ZE@;W("X4KD=#L0)P#_P(3R2[[+"B A? MF%4]A@_Z!F5H&MU8OZZNB\<@]2UV"N&>+F]6XB@3VZF9D(7T7Q>S%-OJ[(UQ MFO-MV#H:':PVU_/?]03NI=E*; M.ZG]^S_^*YU!/H=PTE&&_.V7P2_6A4/QSS?]^3>O5Y4>&!*M'W8^Y\]_0W6M M_F[D8!$^8E$L$I]G64I2E.=/K#Q[OWI7KOJ,N0)K++F+"Q9^V/J=J>AR M9!%K^^"5[LC?C45#N_%/LFI>Z5Y<:JN-M\*UW.B7SVA>O=*]N:(.*"=619=F MG/DKW0]J&4.;4MF !^[&43#^BBW_DG!/YCD>*]#2WV[3I0E6SK!.]8?6)Q8" M6A2P/(^<"YZ>JKOXKK<-6_"7IUN_NV["/MZHA1_X_<.#9JWIAVT!_G6MK5@J M41X\;JY$:EGX=; P007TZX[ZU\[$KYJ#6_;=:MY][>S;/K+W.T:81]64VXJ_?Y]:8T/_;-K?&_E)GUGU'H6&M6\+M M!_Z@UUN3WYLI^V1RJO:YM>74]A*G[^_W]EOB;"9Q'J?#MN1YKFO<'QZW9V=3 MB=/U!_WVVME0ZO0[QR] FJU4NYW. MW,-7YLSM#_U!=]WH16M6/Q-UAGY_<-@29S.)TWIS6_*TY'GTQ7/D[P];;_N& M4N=H;3VW]>=NE9Y[],K\N?VN?WS0^G,WE#H'?K^[[EW0$F>C%:F6/,]$GH$_ M/.ZVQ-E0XG3]@_UU0^,M=9Y-RUW7N=)Z<[=*RSU^9=[ZVWMP-)4[K+MQH\ASXO4$;IMI0XNP?^8?[Z]H@+76>+95Q;36W=>9NDYH[ MZ+XR9V[KD6K)TY*G)<]/29Z!W]M_9#EY2YR6.*^8.-VUB]!:=^Y6Z;F]5^;. M/3CRCUJHA4VESKY_T&V)LZ'$Z?G[:U_4+7$VV@)IR?-,Y#G<]X\/6W?NAE*G MW^N\1(1W*]7<[73G]E^9.W??/SQJLS\WE#@]_^#@);*D6N*LXH[J^T=K@R*U MU'DV9^'AL,W]W%#B#(=^M]]BR&PH=7K]M97[54KNX)7YYI__IS6F_[?;_7NJ4VE3J]OC\\;#T?&TH=,$0.VZ.SH<0Y'+;(K!M*FH,C M?]AK<3 VE#J]X[4UW9_,GZLG(4\.@/++&.=>_G#X:Y7F<0^,L46?^@F7]-*? M>L (VRI;*RV"V#M)DA(F\Q\5>A?J1B6ERI?)&]XHGC.>1B],RU&L?L:NJFLM M=;-%:W]X[/<>6UP3XV(AYL"[,U>5^^F_$VCRKP MS\X#+K(GI(Z*+P@CKUTXJ5EYLVS=([;#1\+,N4%H?IW M&10JO@.V!CJ +3RZ\Z(D+[,@&R\N(=L&;I!F,J:(,'BH4+#;TRAP' MR[U0Y>,L&L$O4>)AHD>_^_;O90ZSRW/)^_B29L4DC:,4I_-/%<3%]1B'/T]N M5%[,8.?HR7[O+8[Q)<@*[]SWS@LU\WH=0YDZ'63MPS[M^=MYFD=%E )WJ3@H MHAOU]C8*BVLAL/NB<&[7OA*,\C0NB^6O.,P[ANFJ[(5([*"5TG:X_[S.K/B: MJKU1IH*O>Q1:?A/$M\%=CH+,Y6-@XMH>UI?/B_SO_QIEZ E:_/#24_'DVW/8 MN#V?Q^,2/CN^\ZXRX-)\*>]L[!F^NL;#%L?I+4A0CP]?KHH<3V!QC6?02\TB MX4@C-P*UZ>_UDRZ'%A^+TC"'LQ6"O"U4^&:5?=FOWE2&[65.E;L =B<.YKEZ MH__E;1CE\SBX>Q,EM$9ZZ:V,+N/CSM'^ -E1?)#R8>'4 M#NS9KXN_#[J=_J#?^*=NI[?F[_MKCK1L4KU>YWC0_*=V4J]L4H.C_1\WJ?N' M6M&!_SVQA?[A=\<#GO.N/5I));1WR1_T5YA0@WZ#4GJOWSE: ME*.C(%WT=FLW]PJI=<\=KFO@%B;]\Q@)JS%$O]M?7I#R X.3/\]V M+2]2;[>K8;N60U>UV]6P7\?>]EUM._U'W&P_1=+XY=2IW@\752U#O6J&.NP\$)]M&:IEJ'4JC?MK-PW_ M^1GJ-:"Y7*HD2C/OGRE&AJ?>GO=!@2$7/NI@O=Y:\.,'E*W# M5XL4T#+'@YK@]UJ+=^N/1,L<**OE+P$VTS+$ES/$2"$LM6^98 M(;S=,D?+'$LNV6[G)3"Q6^;8!N8X/'BU#19;YE@A#>^U,L=K\)@OI+)\#))@ M^LA.G9XY'V/0M<[P6YCA:/T6R98Y7PQR' MG9?H4[T)S+$RIMD!8FGQ:O=0]UX 2-I[ GRG%0J%^X\O%.[M,M$7__DD5<\/ M5EW7L*HLC).7J7FF<@1$(^2F23".X@C!G A)[?"M%\ J\4$$>8(= /O#PD%5 M\9XLW!,%#Z+<@[T9ES'],KKS@/I12"!3\$HP+LH@]F :>9E[DRR=N2/)G/@] M>OPFB&+"@1JI,/^U3*+"PDWEP4R_V?$:5QDEX[@,82?3)+YS%NFEMPE_Y#(8 M90&BRZ43&E/!"N1?82YS-4;BZ^GI#X32) M<%-R('@PBA@*WGD0=TM]DQDZO^-G;J\C,B@ W-$D+9RO@SS,5)+"EDS)V M5Q[)0F79!)2G,;GRP,5Z1$H!7,/YW&3&;:\+9_==++3+X*A'O5L6P M$S-@MVN]'_A6FBCOWV60%0HA^[P@RU20Y3XN3('XPG&6V;&^K++QPPN\A;-T MIG.=*3T;.(!1WO%.XECO(M Z2F!+(F U& C&G!'<8)30O]*2;P/\; J\29S@ MX[:&\-$;^,\\C1&RD-C3?:?Z/.QAH> S!9.23TJ: 0=$Q75:%CAY-5_"W4,VB\7)R;2S&W[_2TLN!$^.0)$B&/%W.@?\:D?W@S$88^*4S!VP. M3^E8DRR>3C,UA;/HXQZ%"D[\##ZI3ZLY9" ^ W,0.QQ,QO^FHT$2Q(D$]#^X0RQ/F 5.@7S(5S49EEBO\G4XC7S8ECA*K M&Q5KJ3X'QJ5K;R?JJ(Y/OXU36#$=3!I<'J"IFF7R/6F&R@49(V%D#/IDIJY) MS!?Z<@!Y,+_S@'@W$> R.,X"[$O=]"%CHA\J@ KGSXWW=JK&8CE;$X'O1\#W'/B)R(Z(72 M"%YM(/BUBEE-B Q_L^\L.^*L3I(@OLLC6L1[HUZ<&MF!SURHO(P+>N0S*\YIHH_)APB.?X@""9\\ M#2CA!M]@P29/-=%ZX?3HXW/X\/'!S6O:#="7\I7(X Z KZ.TA%T@E8Q%JH61 MW0D1EC7+^B@7MQ"XKA&2 MM:5YEYL8X'_ +78BGJZSR43=#QH!#'\L(N\VM&]< MC3&JU+\"L^)[\#^[B\ Q&P]X^EWHP^Z"?T2#T&W9M%4PB%_COK3,]++,M%5+ M_Q@4988F\CN0O3\DX>^Q;+%QV8#OHV_82;B^+S\2QW/+6]9]__HW.\X^//)[ MPQ\-D]AP#'Y0;[NU\D%:'GX=/+S?]7O]GY2'U\EI^ME0I@>=00M>_O*ICG-#!6W,>/P9W7[PXDZ7]/F O[3IZ4TS('7NCN]]:Q/'0L M*DD3M7QKVZ>^[ZF6"!OP5)O:NV&IO39N-9*X59@J3A?5J5.AFJ@,8_>2$9E, M@=)YD?M>HBB[XB_=SI$'4XMU#@/\<,PK,[^NEBE@$V;CNU>4W+B!?&%B6SJ+ M6YG85J2C&QE&-TR"]#R+;O"'69H54TZ=EA[=J^8]OE!NU&F:S5-:R^?))((3 ML'UY47\HZH%^K8)0,JDEE?X:R$?Y-V.SR)07&27>%2@K4>)[I\"2DS1+HJ#C M_8$9BD&^Y"5*9X;EE4D /\01I57;C*A[SFPCI9NZ=>,[4?BW7Z+]P>!XOWO4 M.^RK_>%Q=QBH8%\=C(8C=7@<=GN3_^T?_>*\]#*\ MEXO/IV=G[\X__>/R48S4[[P<'[U/,R\ @9^/LVBNTUF1$V(UQ43X+ 5M'F4O M"/]<*>]3"KS1V_=U"MQI.IM%G*_)*6KP17A:P:UATM,^T% ?@P*XU,U+PSPP M'(^R[.!%,A&(P6RJW&4!/_#P;H4"<&#NG21)2=EPP+(%YOK#8F9>K[OW/TZ5 M +RE>9J*-S*\VQ0G]M/M ]]5DN8'3\/'ULWL_#Z>'O0VB:>''>_C^:G'SY?_G9QMGV<_0GK7^;S&*Y@T#U_D)R2=^1#PSY= 0UJ@&15 MD?7HOBB)AEW[2C "MB^+Y:\\>>K+BOLYZ-;R09Q_KL'N0\/NUYE5[Z9J;Y2I MX.M>,($5O@GBV^ N1_/!)110J;;Q]3U;3KS:"7N OL^_Y\T'\\O)Q95W?KXP MSQ\B> XW2?#L@^ YN?B?LROO_><+[^+L'^>75Q/G3][9 M__?;^=6_?'CBP\G5V3OO\NKSZ?_\\_.'=V<7,,#5U=G%I7?RZ9UW?GGY&_ST MY;>+TW^>7)Y=>I_?R[O>Y=GI;Q?G5^?PXV:KJ9=%.OYZG<:ARKQSIZ)L^[35 MSZ1:SF8I?AD6A1=S+/G@H)6B'A#D8?!OCY8,JD+V%0S-#Q].N5(C"[@>DS4& M?O(?<3I"_4!A199^HTQPKZCRYVXV2F.MI5S^_>*D(YK']NW>2>&]5Z,,U/P[ M/BS]+MG10U!SP 0(0KSGLO1;!/R!Y5I#OSL<\D8S]TBY$RA"X3:6$8&%$D:Z M'&U>9N-K-%>"Y,[+K\$(RK7*6N&PL,QT)9 N-<6JRG"92P)K0_*\?'#<2$I* MDSP8VWI>+ SE^4V1K=$8L[Q(Y1E<470R)O])[W@P>"0E7E*ENDJ]61 E!?P? M".#S*_A^4)0YL2%:H[I8C>MU[E1 E9$A[$@6C4#'H2H;ERUAY]#V++SC[E_U M;@>BU>/X1?"-:CM0B9_!-U Y\,8JHQD$X9^EE(IQ(:_Y$!;0>+<1_#12,.-0 MF#3SHUPJ+!D0]+%_"D MIH#']\9!?NU-XO26_ITK=V2':-*^+HVYD8+@'3%:Q L71S.L7(76BX-;G^N)*X63Z(-K7EVHU R+"V-U Y_NH.7DJ6_!;!XKLIUB)9Q+5=AL MI)T3!Y:94S]W"L2."N]DFBFNHIQCX6.!>TWEGN,8V0*?G@=W=+*H2I3V,P/* M?%7RHUT?GR>L7X=SFN<@\W HPW:XG@KK%==IKFH[%%0+NS3#6-K!R#8X4@IXEI] M[E.L1T,6T&R3:\M>-C))DST0[S&A)OA>G";3/2R^-0=N&J"_"[[H/(4O&3ZL MTF\'Y$*9)4Q=&F'7(P\)3',$4S%%NBJ=X*G116P1E_HZ"PU<^2(R31A&EH(G MN[);<'CXYGFSP;5OA]W#=6O?]@>=X7#_AU4\K5=EMK3B:=#IK5F0]RR3&O8. M-G%21T]6&[;B8[W][,[:AG;3:INV5DK2SU\,\FI[^.]/1NY^!H\$CDQDU/3V]Y M^+7P\-'A\)$-_UH>WBA2OF(>/NCO/Q)>^4EYN,U#;E.SVRWY\5OR4_13_+34 M&=TV-EI3_._W#M8M_/H1K8W6T%)>,W4&_?VCECJ;2IW]P[55IQ]$G>_MRO78 M^L3O,!4D9#: U89IB0$X3:+6EOAA&[39)Z;7Z<,'OLO8^ &;M-D6=7M,VF/2 M'I/VF+3'Y.<])O>7=[_*.IE>-7O+_>?+E+PT)Q6^9%&#]R7#XM(O3A./?V3! M_'K[CD@WHVVW A=5+W-)K FWN4 M2BW=C51"&/W-:>S;F-Z/6\@;-U*PCUZ0Y^5,=]_X"W Z9==SXP8L;^P*AS%&4!_R-,H#A MP6A7BD\R%172L,0[Q43C+]QEX@[3_ L@VE7*+1J(LG8,NRK,DW?:4&#W&DI> MES2$CA3!S.F(.'UN,IP!%A[H;.F(6GE1_RMD.1A\4F(N<\-P M:Y1$1K.IEV?CO_V2C[)@#QFM!___?Z>]SI_SZ2\P_^)OO_"L3Z^QV42OWQG MG3;@/]G#]:9>.G" M7\^^C:^#9*J6FE*U$]!G%&WI)RGTB!OV@+:98I!?[EBL'K9YK"[ M$06TSZTVV$K1@XYW<79Y=O'[V;M5[[I5X6.^KZ!V.-BD@MI#+*C]=/*/LX]G M3A4M%O3_=GEY_OD35W3PRX:I)H^0Z4[/)-98QBD5)U$7SML@"_?B-/V* M CRWZ!5W^!/[ASJ2H$G"' M5C(_DCM&[7) 56SYF\L*4LF7, X+5C85Z>;TMEM>3OZ$O=>H)VXV#1(J5T-5 MAXB3KU26-:C?-\,NUNM5KYS>T8OM'9VD@ZN>"XP#/DLS7_!5]VO@I68NPI,O6J%CWZFV]4G,YU^$&0-_9&91072UJA MDWV9,]B6O Y[16L*T+)'B. D=)>&&V@6QN@S#V\O[6=UA_4^R,>#/%>%EP>Q M**V,>!-D&3JT>7N,+&Z'0/.9$S2SJXQ@0G"5O[ENHE66<[!11Q$- M=@N-Q!C%(Z7$PY'I@\HQ$/2F14FI).01S>;!6 (2"OZ6SJ(QO2>!O[$VZ($; MSY-QAEC&U$R\@EJ=^UX5;.!;KI&N8. M[T_BP'@*(ADZ]&Y2_)D8%-Z;ER,@JH>X3J+>3*CIFB#;\"1ER3$OT Y%J.KT MDB ",<+031#!9/D3%HEF)3;>++K;")CQ+1;I5-&1-4$L)C#I)I]_/W^WUSOV M>;O80\F^QE#I/4O'XQ*6,KZKD47X2V/54P#=$0+T-# W ,J,S!"])U$30-& MH+?,!A.+,F=,[8UEQH-OARC,["OR@J8:059]A667<(& IGYTG,N-+A&Z )VR.5;6M%,5EKT M#:\JBS!F:6=/TL LS#=X8#05RB(PBR91P?AA!>/'H7]_GJD]^'NH4/3$>/MA ME%YOK09,^P&SGZ5T<8N+P%U+/@OBV.*A5Q%@M M MB9C^L![^LS1S$('(4A"&I1!&C+.F=YC0_#M)1 HS@Q!IW(YS8#84>&/<<$($ MQ&-"JP+N0#F!Q3T28SF:386[T/XBCRB%^4$ MG.BN-F(OH.X0]*U&_$.YU<3N]VG"H7C>F2'@'59LX13 =(N(>;JZ(."L]V6& M%X:/8/3(%RKDS8U2L6IEQQ=EC;X"W T6#,$53N0&477[;OX_4(Y-2[Y[9FD2 M%9*&PEU%:)?NU^8TXF:-I9H . ,$7D0*&)#@!U_25%JB'2"79)17DTJ3@%#X M/Y@7W"T /I),4[H1*9G&L);E0Y7<1%F:("7AOE!JI8BI#G4B\^H3$\1N6-!< MH11&KBP?IU4)*1,T*UX 2V4"RE+0SI0;%5[.<*\R<6>P/''G=63TKFF_GEL? M"YP)L%W=,/3_@S-3>+\SQ.KV :!:6&E*RKT/4]JG4_&U\M6#]CW,+)W M.:>Q=G P$035OU2V2N3"+J47Q\H8BV.X8AV9EBA7:N1\S5W+-8?YKV6"2B'- M(T"W6)Y[U6S4TY-WWE\&W4ZWTM#+!W54^Y#<;Y*62.J?_BS#Y-ZS$LF%#1W1 M3/_A!=-IAF:$XCGT!YV#:E,Q]"*A @8#I&/N163,2&?5SOS89!+K/*KPY?*7 M*.&8IG#0Z55FP&* M 9E)MN%^-V8^6^'PPJ^$1Z_) M77/=^B03%O3=#]H#I24":0E-3VK-V#Y*_&7.*O)P%"H;8OK+<;;&_O]9A\78LM^)AB/F48%A#1R@XWS[@$,0>A2CHJ5V^S@CRO?G6Q?'O M.3JFNR:6MC@]-_%$]8]ZG;YG+B'TJ^+#,/N,PBDW05PJ,0PX1*(-9:X(40LN'*QHZ UG^%!73>%AO/=.%8&UIVVFOT"V@]6#2EMW9FM MMU+8OF-[9OJ% AO\OR#!?C6H)=DK#)V*UO=*)Z4%7!.ZN>#]J27RU$==27.*$/P73A<.>6#A4^MU"]H8-CHI]D X[$D$T87C MQEZGB@0K:*73+)AM'X=]3DPC) ]YRG 6AKE'<91?B_0_N?JH5^GM!.3WA,%" M=N?O8L [+U&6%ZD(NGL:_EP'-Z2[N.*/S28.0G-A';Q9SG&\O^QWZZ:3;E8! MVDDH:?O1C'M.PO\^@JDWACD?D&@_,M]TLSCQ[Q07BM!CMN"8HQ1\6>]Q:6@SAF>#= MQ0ALB6]3_U4;&8D2S/:G\(=Q&;)O4(V#,E<\$7H2HS4%3@%O:U* _ Z:%D5"SW5RS!EL MQJI)19LE@W_K7'8\..T4V;Y#QE!S.JH.A\"A'$=SO*9WA"_^<7+RQ;A215;F MTK ,"_"+:'*'FJ@UUW2<+BFR-":9SQENH4E-NTDY[(B3HS/-AVVF HD_43,T MCASJ:CK-_ZSUPD0Q)8(#.)P#B"I# GH+\!RS\8VFG4EL,M/4B_O]_$S'CW9! M 'CPWSCH*$N#D$/MI 9AI"?AM\43C+:N/H1:+IJ*--O5"J3#.'\#*A6C(3"@ MQ:)S%20'AJ:X_79>8B?Y2+&Z)>Y>#@72!$SY%O93O+'9AGAGN9[L%;;V>TRQ$L!,F9LP_:Z7Y)WULZT3@ 16]',![J.3RA&D0.M6)!ZS!\-.)1U(9Z2T.-=Q=W!WL$4NY&E;6-[H#!;+"ZZ:(C\K#%%F4V MJ*NY5+KHH:6'*H3D$L1Q=2I-6ZDBMN]9%:)UX[=@/BI+(N2)L"*N%69C? ;/(9[3B3^"8X8F2"W=#D[ M_OQZUH$\3+X1O%<%@H$BQC"/2/M$\MS @M#Y#;4+A0:B' U8%^>FC.6V%>4G MD]+A2C8LT\RJ6;733+L: O&#\=T2DBR1Q#&*-9D(]\V37Z3G@Q+S5R$/WW!7Z>LB:;P)> M<+$X.6-(N-:E^-QX:ERLP+/A2*&I0Z=\:)/[,@K@M\VLPK^_IS;(9,S'B@-1 M]FO2.DZ#)%_(6J,"^XJ,1HV+,VJO):V96R'?>VN@780OLN]*^\;Q%?RL9##: MX@8*(2?X0A(]K/_#*1:I)BS0W5@=]3JH M-SN5BV1RWT!N'#"BZQ:]_0);H>_'6? GW(6%N8ATEI(]*0N*#=SNP./.%2Q+ M-0!JKKJ7UY9"S;R73IE(@)J.W2\G7NZ=+9D+JKV.IEWM&6RF*V0#DS9FES=? MCDB0A,F>!#/EFPL?%7:^A[]&XZ^8#LF)]33_''0;M SL=\R %"E1*J^46 !' MJ"!+N*@"EH81MFS[NA$_=(@KU)0VY71Z"D&::%TZM+DP_AM%]#TMH35C$+= !/8IM$N/"JPUJ M!]/#ZV@27?,F/7XV3Q.E[_@]*EKA_!.4K)RA(NX$4[I(UL+<[A9?*=RB&6*=8R/*LLYK"?8&W!2N)CEK>L"@6% 4;J$Y=&8C4I/:V30_U3C67\8=3DQ250^< M#DVRMYVR@DXPX^\[GA%KP> ',;&,"ZDW6!-K/E'G MMH@+%K-,+]L^2=%8V"7.:1*PMAAJ'&7C@-S?%V,9$;58!-A MH3#,=YU8@G6M;"V>.?RU>CQ7QKMVHE-+ZI3G84FR2O3P*0>1&NL4\W(ZQ>.\ M. &CVJSW:==.Y7P"^1,;6@B#P)(#O^&XG4CZR,-+)G+?/NC %9>0:=&(>AP# MB(\Q4K@/WS];^KPN.7>__] J9VFH8@P-BT;)%*E1 W4 ([]S1676%0FK$2Y M_H[D)3E@J%>XDK]R*5"5LFPE*>$H[(U UGDT[H?X> 'W -^C-8L[;.\TS.[P MFU)7"!D'52"^ A?N/A]S2D:4)Q*Z1?086[4Y+N8[1N&2) X9%;\G*S.EGJ)= MF#T('+S.6'&RDGBR<.[S,@/9DO/D.6-8)VOR+G/=O&3EP9X%Q#PZ9R4V]S3[ M3/!T.^0W=$=+0I/<>EFM.N1+RI?1&QPBL!62IS0 W\ 55LB4DZ]@UCU;1#*U ME?\$9%)@6?Z8HKCV[ JRB%5-G,I:*6QODIT6RS14Z3]:/#D.7APC"VN%TI1^KD,8WPK*-E@BD-6W ML5*AQ'T,4U:-T7MF0IJ"\= HSY'6;B'OC,T/2=TSBE2U,C0(L<6Y#*!0A!S,<8#[A">:G.D=9*! M_1BJD4$$4\\E.G6SN]:Q:T.[;FAW?SM"NQNC4C=X+K=5@:8%_$=I9!%]+_/I MUA@R5F'6 "0CG7GHBS4<$;HC(<>Q=\,F@1@8*G&VGU$?K < M!L#9[N',V0/F&9%-B"S:TT]AEU#>1D44;RJ\ EG5B>466$S\R>C*-H/&T41Q M\)#7Q#D^,:*]1:2)GU9K1N2#Z%L#LU.DC8A5C2<52,DIN"1SROM0@_4W^ MKF3!:&A!M*0JCACMHZ/7?+FYV$Z>S^'0T"X[TVN8W39VA/JC8O\(+SB!)F&@ M1+/,WNANCWF'^%5\EZ#?48I"GOK&N46#P*&-W'^E'' M5!-T"Z2Z)N^?;_0JHR\5!-'G@$(VVK/ZM!H,)%_&]E1RC0^P$NMXN*[SB0 MK_;FJK"M!$ !*>POXSB(9O0MWAE='& 5P$6V=J4JY_"P)P(S, J*IU+=$-:Z M!@EJVU8+Y>XB3R!]_?H5I35Z1\2E27Q7T[UQ@S3&G:0CB0.>IZ 7M^B*ISG1 M3/27;K,(. T9"-@BL[!X-&N1RK7DALKU<9+<:S SB8,YZR+$H/J7@6MNT-4!&R;+PI>K+V;.5#!^%OY9 M&A]-6B/'%H8:+EQ=AU)GR*Y1LF>"K9;K:Y2V80:C7B/_YO;OXE1!'2#48(4L M=\R@60J?(&E&7,V 8LB&(*QCS,8R@\G?G*0K,XC&(=M+NE@N2S U=1P:34CV0KPQ;6*T%D'R7:L@*,6)+\M/8 M-GR2IC53Q74:DI R!2D=H ,_!MS=] !#!E$U:M5@5\HZAX(L(?T%'02< 1H9 M]Y^I":OL@U/91JX$@J;=P9=WV4W%U?;Q$D !-V,N=[U 1N^=#?V3M?W;'.AH"Y90$\9#Q1H_UY]GPVM+%DFBW.LJ28AJ)UDC)%2HR]( M%HG+6)A$6 SSM4:)H4(2%*7E&$E+)GCP2F4*[![OD$;)<.>Q?>E_SQ&*\MU1 MW#YK5?_WDT2LJH*D'C@2:&R,QZ*.L_1I(S?X2",+RVMLFRYFXBP>^9AML8!] MT34A(7C"KC)*15/D0(!=,]^EBW4/A]G3 +!W+'Z<[T>YHR,;)F]R;)H(C;36 MHW-)^J6C9./#**1UV"HM"_L?J)_99PE9#!2T651RHJ/^*)ZO MYIBP7/!M:V&M4WX_8/D&.HK%K&(<#?:Y?""=:7-7U'S9U5>T?88?KR!S:$*6KJ/:6:6- M5,&T09,=!3%EB.372FG!7']MHJLUG&]):;6;[UTFI+5*C3AY &.^\@6'JTSL MR.8N\)T<2C):3?N5)D^&FXHI-RO.; O-=J:>R0#C]J.)>B#P6Z,K"Z/'^Q$L@1Q NI)W(JN)Q#@Z54,0JCS+F7[K2&H@TK M8UUTR"7UH*,JAZC5$HXQEE)%T\ERNJ>$<<.L^>L=KK0HT() MNU+2::\0/<8.Y]*84:QA_,U?4598GB5-C["J(IR*G4WG. M"AXIHW.VG69A^Y)LRJ9'H%,B4V[^&?'>F=8CU<[HKB3)=,2V-7PSZIZ8,.UNJM#'N>\:H M<'MHW,*O]E/W;F 581B6)T:HZ'?ZH[[.47.BZ,N,(4UB+84E&8ZU2+JM:5D8#X@X2Y%*@S%TA)V][ M4X@.G5>?JV4/3AP'&T]2'0>K9YC4P4@D)BM;ET?KJ+06$-IKQ\ G6G Z &75 M7!#TC^9J;$'' MK@HA19>]^P+4I[T']Q!#FT;AB,)'ZMSA3DO@.GA6=2T(TG*1\L/54*O$Q M?#]OM-+NB3=PJ"YW6HZ-[B3&QG%4/&"ZXL6)BVZP"Z+YN#W&V_"32 OB& /% M7.\^ZL "E@-A5R/Q<->D!3_FUX6->[(H#XSWG)E5G /+'T V' ?Q MN.10D-6O3'#(C?WD8[#O2BJ-U,)&LH?D7. :@)![?(N0G)$Y6"@UVU^.C)]Z MFCG=T 9EM@8#ICV6;F!<6Y7+%\D(-H&YOS.R1BE;.)#^7%97E(1V!I[AUS!" MA#"-H2USR[!%FO%*DWZ4I$W+)^'"K>AB2IPGGR4YR9%;Z&/XB&R%;L)F+O>E MLS.QJP=F1D:QL_!*^#) 7_U4.<*'?=<*#L._,:BKVP%*SK7RWJN0W/L7+/NL MPUE$HB&N^08<91"MV1V)RR##NPI><;+.W*HG8*F\K0 P^1JW MBC1U3#F07L6P[QY4)1_\#!73 MV]BGO<.ET"C*;8#EWF0&R7^N!DB_*PGA4=D'Y(0+G!J#:CK)\Y7;W;/K+U!R M=\]LMNYB/N>+X2KXMIT)EBIV#3!0M25?#MCVXNS\RL8X)V#[8<$QDY!0N2>B M*,OE6 3?]'6I4?G@)V)2:O T4K )E,ROV\908Z=>CR[?.I-35DJ6/3"&/-T41]@($G,=TYS/=(UPB-(95FTFF*U:@I M-0EGP$L<.4P5N_<2A8537.[*U5<6O ,WSC&THT1&\W2W2[OZ03#%C=S 28!W%>[U7<'K3&[9 M01 3ID8X,LKH2@=*99@U5*C*\6';TF89UG9ECAZ$0LZKGC<=-CRX!OV25X&_ M-\QL7L*'4EK]R>W*7#]&=2]R,WB/M MF:#UNJFP]6/4\?Z9WJ+7PE_(_!(%MRJ)1+I0W(8FK24,!\H>(,\]%7NO,B9] MV,:DU\=%U9V\*58HQZH.IR!:G2,!=-9HFFGPZ(4JNEH#-Y.>;EH#P#CBF!3! M02*GTNB-3[L]V\;I9;K&.*DAI,96):,!5D'A9Z.$]"%'8FRCUN6B%ULCV%"( M6I5HZ2N8=XD+"ROY-H*'(DX+,Q#2>$EK)"WSC=-9LI+P%72W*7*)2F;5C3*= M!:PV5J^,:&RLE&:.-I@WU,/XU5C[*E.O.%K"AN(2UE)M+RK=GXGQ=K'MA7C?8_-O?**X]6TLRXR\GJ?.#7RV)$OW<\NU1H0%>A M=DU@;GG6\=XULCAAZ(B/F@UX06*>N*@%:9X;"HKSF\Q.H,4M:+8(*[DL:\\D M'D257&XNH*4F.''T51%*7]] DN<%9*&)EX#T- !_?ND1+ MN#1BP3Z-66[!B!B>,*F SC)SKO[^3=^V@YZY&0ER\I M I@WT4-AXAGBKZ%+7/C2*,96T<"UNW20+9NHVS;YZF/;%SS^%Z@[U^K1#O_SW!RHD[[W!(@2=IO#O,BTH:,B@% E75)NB M0VOW8O])(#"=CF;>XB@6(26/32H'14VMK?&V)?*S$+G_ID;9B=.IT16H"Q3W M&UZT1%T^R@+#4&3Y)D8AEE*S'C"&?/)AN"_J3;6\MYU5J @[E* MR-*AFBM:@>="G>9@[7%CIB848$ZSX!O]C@W=J% ,^$7D_K__IW?0?=M#,CK_ MW6^LM:"[@B='^4N-JITN-M02@\-WL8 5DCN0%V^,>%+V1A'G'#7L@5\5#<1! M,^HA:)P6 C''T)*<"+#0P2&H]G"H5 ^Q,,,5-3)>O4>Y;D!0$5(^A4_LM/52 MEA+08P)B9DJF*$$F(^57T"+(H2W+=?(T;>-Q>\@LL!FE>#1^1RJB%@ P'B8H M]IO2S6W8S 3[D5)>/>HZ;1571Z==?E%)2@@HH^B#%'78U.-@)PB-3F&%#S-Y M!7F0B@L2]RFG48:;^6+QNI$]FL[8KG3Q,*4A;HWO^80)0Y8VZK_U66D@;AM? MQ=,VQ:V69L2I.,P8/'YA577NHAW51-(^]%IEL>/T74B>,M=P4-$ /-V.R>%9 M UMO] +'7)%S7!%5VK1SIL.^I9UHET5'T'1G,&>238*+J4Q+YSXU3(%Q7[) M(\PYEM9RIB]O*T128T10I [*9(S6!"9GK MT$6JNR,T)6;I[@E4;E92'3K8TGL!I^1L" &?%+!;)UF/:DNM1-7: M,771(FTYN4-9PVUY[NI^='U5Z)IPQQ5GD_ZT;-Q&&O^A+&9MU2T@]6;ZRJ@T M*%F\/=]8"5*0LH'J(79 %]AV]VKQG7-JKUJGV14105^9&EG'N3H%,G[)"#>$ MN%C!(Y4.[YRCB-BF7#/(V$)X3%'#P#0F%$3HNIZCO*3XRRA+OY+W13AGUROXVDO";#DJ[F)NX ]>PS=2M+-,A#IO*MMCURDA&*SX#:A,/TT2L[!'"^R?U MP61WA3JZX-#U*.DF]8OCPT)N*B2C6HXV)\3-"3G:CIR0%]J>JI_ QA>C&1=: ML99))5@(>*(QSWSO+E)QR+U4W<(D1\CLZ"MVL4Q*TO]U?5>$"B"R.5L9Z,)V MU=@%7>.6@07P@M"GB!),G'*D!G@2"^U-D3C4$HWZ[AK/'.R4,+$M+ (+R5TH M;8>.Y3>?S&CQ:-XB#/TH"O<">#N'W0Q"UI":J4"%4I6G:=R&@=T1-((82DC8 M4%,OYBB/>>);JJ7:.#DGU5.%\]87%8N"94 MQ/CDW 6E!/5_#%*R*L0#"PJ!58,6(4+F^'HN;0S)-$0O\H6K^S80TR'$!%LN M$$W);!!3J&)S"C"EX-\T^J.Y3RJ8L&2YZK7BB>Q7VD[1&TQ:J[!G9$1L/E MN5$^_)FC?4KG!%,J++4#FM;2R/D3HO1@'X(4+%_\AF[/8R?O!L;$<&6\PK* M2R%KE+]2?+F@*1H!D@>LM-TK,C8@=OU T^PQ5XJ=@_"$M9\8.&;O$FOV,)G( M^VV.1V;[9-*E4MXGN&>]ON^1@[S[]K*ZFL+ M!R(A=NH6X+XWWJU+F^C'[4_ME2"00=S-1O8[XOVV\-=>;O:[I/UN2N*,PK_] M$NT/!L?[W:/>85_M#X^[PT %^^I@-!RIP^.PVYO\[_#XE\WE-\[D@OW_; !) MMH^S3F@%[X"86(#*@F9 A3O]@2^H,:;NSE:+:^\.(9\/#H\J4*ZV5UA3$UW? MZPV]&N)[/34!9"#G^=Q7,XPI MZ)(5KOG\QIGD4C6IJS)T\V:3=BCE.78+R04\B;&!CM16U)IT1$G-O\0 )=0Q M).4H"-Q[;-K0"T$U3;[68]3M:6H0U1DUVJ* :^A&ZY&K3-J@'^CS[@ 0S1'4 M@%SJVK5BD$2=YGFAU*LETY15,POEN&R2;FD9@25(Z18,?C>.V<>/:/_H'-A" M&*L3BD:4>>XTIF[>X4I2MB*A*=: MH:5G&B4^#=A_>]_?3BO%S0^O,J\MT].BB6:!2]47>BZX=;#:+Z#Q>N?GOG<. M=[=WJ/?T1*H,N<\&//H>[G*OU]W[GY4WMM^6,E7=5L>OW6VU9@[I]_)_52G1 MAZ#O[80([I=Q>[/KM(19A_GN&[U)W"/1\!O:YGL$!SC/U1O]+V]1]L;!W9LH MH8G32V]E(X5)D2HW>*&/@U@8D'B1_RP$.S[N#'O[2+,B@_\+]8>%G!W8B%\7 M?Q_T.@?'P\8_=3N]QM^7#774&>X?K372\M_W!_OMG%[YG'K#SL&:0SW+1AW< M?UQ^I>-GQ+ 61*SI%-2P#\7#WWX9_&)%->5[O>EZ/7CJU^ICQPN/]>??\,&W M"_=174BP?/C18OCPH4N*;H[W(D__A9?[V8(Z82Z2(GS4KL!C67K+_][?SATZ MU\[\7[V==U*^M=ONRW]_L9UV;8NO9]\7S+UQ]$ZL MA9?[WF<+YLT6^#MK\-E2FA\Z[6%G?W^%F3=H[*@][O4[P^&BUH-9 SC"+_^] MT]NMZ:(M8S0RQH7I<&M89"OIW6^B]Y*[MO_8N]8^)NHZS@V>\\@OY>GMV2IQ MBB;+"M)SI06_IDWK_X KYWD>DU.PE"K!^.LT2\LDW)/=&X^5FDSNHTB3D .R M/K_#H^OT^LW?K,+'RU;[0QC\H:U\[/OMY-K);?;DUA8R$_I_=2'CT?_VG:*O MS10XU!V=X6\XD"1=,?.Z"%IG_5UO77WR)1;_E^]:HKNT#$?=J+4-#@_\_L$! M.W2_9YV:E5=>[QKGL_8Y]WRWW+9-W :_^OM'+;=M#D5^9F[;Z0_]0;^[X$+< M D8S[_?74R@:F6X#*7/PO$1YF57^]5'662M^?A;QTSOT![W];10_+:-M%:,= M^MWN\_/9#_*R;8L!G%/%-_3:3/,-C?WC4:ZFSF=3I'[X 9;;)-GF] MK-$[]@?[K5C=4.H,NGZO?_PRU'E5<:!SW2+;EOISL=&CM.#M=6 -]OWN\?[6 M^K%_=NH<^OMKFR@M=9[-+>\/]X^VT2WVLQ/FL/7*MURQP!4#?[_;'M?-(TS/ M[^YW7^:2^^D3+,^D;/Z[$BQ?.I^M?;]]__6F++Y3\TR-H\" !00S;"W&781? MF;G:.QKXW:-UO9OM3?YLY#GT#X_6]2ZVY'DN#7CH'QQO91['STZ806NPMERQ MF%SH'PR?V971'M>5#-;CM4-HFV6P;H?FJX,TKRPSJ=?K^\<'PS9&NZ'DZ>[[ MP\,V]V5#R7/H#X_;K+Y-)4Z;E]1R1N-^":!E>W WDSPO*%5?E;/W*L,>9GN) MM6W%3J7/L'_3;+*4-II,TCS''K M]&VYHN&X]MM2_TTDS/#P^:7HJW+W7JH$NV\@W#KJNGO8XS688H>X'ZT);Z\= MUCO$6OS6O[6IY!GV_>/C=9,96_(\5ST%XNBTAV=#J=-_B9#7-FG%KYKU' M@/NU!_>Y#N[ [^Z_1&CGM7F'_\%]\C@+.)Q%"7:-):SU5^80'A[ZP[7!05I3 M^;G4K&-__W#=R[RESK.%\HZ.CUKB;"9Q^B]1"+=-.O#K98W'94BT)_?G%ZL/ MZ,"Z#V62)FHY+=NG-N>I5^7V_Y*E-Q%U2\9.K=A_'/Z1YX).R=@\V H[NWE] MWO[C-LUX4TDS;$FSH:19&TRBIT!^T>=Z;2IWCH=\=MM39 M4.KL'![[A[TVQGEU]J.#=7H<= ] MVWMS[/3\_6%;;+F!A!GV6K)L(%EZ?F_0VJR;1YC^X4LTA6D-UVW@C381;:/) M\T(R]57E+'UV.H998_:592?U_?VU,Q[;H.WS28'N\1K@P2UAGBL'!C'8VU.S MF<39&0R>^OFB1:?<:/*\H$Q]5;[>3ZJ@W'ST]^9!# ._ZG2EG<,# M_Z#?-E390,KT^GZW]?AN(F4.AOY!;]A29N,HLS]XB9R';=)_7R]OM*=V4RGS MHL[XGSY;B9(;)EDZ\\IDG"9Y&DI.WS]J?8N; M2)CC([\[>/YBG98R#]9.[/N]%ZE^;*FSTKEIO;XM6[2'=JNH\Z(^^1_D]MU< MS?><5@7:"B MUJW[6EBCS>3=:/*\B$ ES?;7(AC%"OXWC&[^^[_@'_JSLR";1LD>Z*5O#F - M\K$]U%W?'.O]C))0)<6;/?CA1^_S!,N2]ZK M>NH<%\LMNBE@@-MW^M,<64IC=M?1&2FE++E#8PM@_KTI<#6DAE[ M1,;276$K'[[>L FV/_3C2(M'3',"S[-"S1H#[F-,00X9;$ [/C= 67&7!ZR/-#V*@+\<-F1T_C\SX&R2M:7.)31%IKT!9F:BG M)WYV8R />R7\^+$8]7"#U,;PWP?F)\IQT^*MY+@&0-!ZS=TMW,M)$@([KR:4 M=.V1 <+MX-Z'-P@Z^=CHM&L-#9;F ;;Y9Y1Z1C 2=1@*L8F[8#6UMKQK/0(& MBKD;,?$U5)-F*;S]P [5^!/X';I(DR1S0X0@1A8,]?(R $0@7T$N:%_CWP)R6;:.NA,M0L,!+ 1SP69B M, #E[Q+ 'HC_.[5FX=)PG@]<"$NP612)U;GTF"!T+-]FVJ,;CTAJ@3P84[XM M_C%FXP!PY21C_ 3 SL(HAK]I/[ FE(*N#\N'AYEUHT-;/G@XW"DYHB!4Y&B> M'H>6[7HNIT>5"NG+.'0G'CM"R4OX0,2(::'?TVFA/\2T4!##X\2G1Y$,A\OE MJR)"(2B)V+4\[PE@-XS@F8.G5%"W%'VA8@KG+.%>CG!?4R(?"(>Y#^ PE9(S M@(1"-V9'N%?@>A=L!'B)YB1,&F5(6:YO(< E?5T&(9!=?PROM+$?.P<>$9-I MED#8 ZH:BDI-S56Q*TXD%IB)SCCE>,OWD34SW F20$/=0?ZU1Q8P-FT387 , M9F4"$-"N 0A,.PE/T M]YBO/N26H"JH;&N"MB479XY+>4GS/:RR6HI7"3;[QX&_L*LP,X'E1L7&T=Y_ MT@9,BY+!/]%#D/ A7#X B5L#%"=/$IG#! &B33FM@DZX($,S#RYA!#-5\^#K;CP%%UN7>+Y$6@"MYO9Q4"P\&C!P8 ]T7-G8CUQBN=" M"2D/29]6(*04DF44!;9+ $WU"U^(?!'*#'@F2DA=8"T] P S_DKKY5XH%T:D MFCG6:R"2^*N1)TCMY74C;A3^"8"*!&#O0\:$# ASY&(#+8:6'2>J,-#I]?@5 M+ 5!FI?T@NC@M01:XG8;6-UR_9GWU4"(P@VP-*""^8]\!)*4SW/R;E*TT$^B ME2X.HRQB\F:MLVLNS[E-OF11OG-)ARZX=$1BH*,5^>SZ0X\45DT[%O"?A_8) MCA=Q&!EI:*%E6D!CD6UY:-MF.@!A#\+;QL7=,_'*11I!.Q@D,44K/#3A@/U] M[=\L# YUE=AP5.,8C;402.(7_3IT?^%H\_1=PL8,Z85$64:M_AO>W()_YR-9 M +9I$D(+0E2/KA./1$19O9&'?#_7LUNL011X23S_%B6*;).9N2/Z:=;SX%!_ MCL(LBGC/C@; V#^/2/U^MKQ'ZRG"(+?*), A4S"_#$*,C\^^>-5@ MTC9LP;6C3)&+ D$[8V+@SBT+'X"ZGQ=D*I0J.S>!7QY^,AMMQ=RCR). VU#" M+1)P4\-08-!UV[7.2R)0VL=FK\C2=2-I%^[6&.>V<$-QF](E*L:IC^:2ZN+- M#3FLXM8):[J4[M:J(;OM1>:DPV36E0!)WF,9HN9<#?)YAZ9"P4J!#_+P!!J, MNA(#*>*5S(\);#N!]=I/PG]5N-\'0R%&@[B4&.!1E\S%GA=UV256*(30G0WV M*)@ F51*\*8<^20$*?@0MD='!T(G6&!>HKN+9(-1A8+3A_P^EW/_TXKG$ZNZ M(Z4Y:#NG>&D4$[1X8R^>_+I_?E5N*X':HRP+_&$9FQO%$3]-I2]%A!PMFX1/ M8(R4<(%ZYDH/GH1LR,*0HC'@LL'%^0=DWS-0%A2#21]0TS9P%MC*HF3I4: [ M=^NSQX*-3F:N\(^>8YCES@%A!1]-U4Z+,E;\V*S5"X/*8H&D@E4@AVQBN4MC MAKGWB;"X$LE-(T$9ZJ=8/OH)-\.??A(BSW_*3#$,6*#,%A:;$#/@'#I9#'A! M%-U4Y&K>T%!WN>3$/C-9STL6D(;CQVZ1J2/? M&0'["I]L9#TP;< 8AN.0MU-H,8=O(G^4-L/Z'66+T[QJV3;SY*DK B]D8\OU M\:\D8O ^)2R>ESP\2#H./#<:,2>3#.TB4_KY9S#IR5)]SE,Q+8VG&\%VE+Y' M^R<@4DOA=*JX9V]DPI^"RS-AK?)NZ K>L -AZPR", P>24-,O(0GO>58GV2# M,%R&H$5]&RF3WZ]J3GHESC9@CL^BYU@T4CH)<\0P%(J;-6@*1)*\L=[*3("< M7.)_K)_HU)E^'HHI->94:$PHH V2.$U$R,YGCF'9;JSU952^R)]-]\L=VWUC MJ#N>HH =TJZ!J(8@JP+M*DTR$6SVKE+W0)6I.3EXFI?E<4Q2(,UDXDR'4'L+ M<_B*UR)5KK% Y0H*+J>+O^/ +D4-S+DFP]J&B,YM[FXQ,L13IP/$9(R :V(O MR4S3'D>!2,YZ1+]'$JQ8Y1-6L=)*,9G8X]&TO/TAS_DR.\SY9\(]")3W();< ML=+?L%2DDM-.^2T_4XJ6\)QJ;GAJX\+VK1YA&9V.8BT#L\X%Z1JBN:G:RL_R MB1K3J=4%)UPRK& NB9R_RBG3XMA$SEDK6M.SCU;FOE>\N/!0$!S8\<0+GA@W M%P%E(A@TG?='M^Q4P:#*\"PP';G!Q\]08VLXE$E ,B=N7J3&X:([I8/ M4F1"Z/*CB:D,/S5L5\ 54Y&UM>/SG=D7;2(^7TI]5;;CN;US-3!K/!1YD7T' M4XLP.YF2\S:O^;:%!7535GY3*96OKZ?H7-HQZ394TS;GK!&4=O^HR#9Q?RW]=6TZHC-ZVE9^N=VD510-?/ M(4X7Z"1QCU*^E;LTB@/[YQ'/R\O?1M46H%1C9HW'7'7DLWJ5/$&0U'#Y&--- MQ;/ /0B2F+)0QQ,>RX-%9AB>'\E[EXEVQEXFVFT+/#/T+.R-G!TC,DXCR\/: M9^Y8TH&4>L)5S"^N+W*E\4QU[";CF4.LYAP^\X<@+O!&\G5#<*2](DM)85T4 M"917?&L-0DL+2FD["(]?V>#>:>]KS$>.I+]T$<":L,NLL(!Y_L$-0V6UCVK\ MY%DI[(4>*]&WF==A<(/0;_7I'(!)#JZ8Q$"C*@1BO# 4 _M$>UW[VCU'*P*-Y3SG&_PP.LT/^AC M7PESS3AV,Q\Z<7-P40X"\P(U9&LD6>2CGLPE@J64"RQG,2/,3=:3YNZ#]J5"3MW#:NTHT2M7IHI-5 M;JWX*(OAL=SIPKI-:3V%1(YR^4-W*"\0I6W\>_@C =/&3O 5-C]M3&N \A71 M@R=Z4A8MOK;"&-RO:.1.> $$V3_'X!$X+N#J.U P'FWJVL7%<7ITP/4)!8Z( MWN'Y%*C1;MDDYBU->@A0HZ<=8)]!@,@"&B6(BY5Z:H+F;/R@H?A#I?1#[JGB,.^@!39CCE)X6W0J MYUACZUY)3\,*8^W!LBVL)!(I3\(MI(B( K(!!GZQQ) 2)<*$@A?* F:!N6+8 M>'F(FON;'^M31M#,"P&I.ZVS0(NR M)Z3)-1OTG'+DLTOQ1J.YV@G4S+DZ3_9M%(.PA,)GUMXU\LF?7.YD&564"D^G M_,/I$Q_P(F$5H/>04[$&AV!J<0U("G8J*2RU&+)TJ.(LZ>)%S;(37!Y[W(*9 M+>O/M:BYMV!]QVB$'XLN$-=9@H::?;]O"A33J:0U?BL'3KY7/U2&0,"RO#&WE!F\+4533LE%92&>0A'L[F65Z<+CW9&E%PP&:7/SK(QY+*2^GFA MW3L'&'0P7U\1#D9C 1QF?%O7?^N MJAY=I!!F$;,)X Y/&^7%!WB!<'E/?<]]0"L_QTC2\U6IJ936*MA&+:4&AILL M1]CLY"AFXTD0XM&6$DM$!(0.FVEI,X6ZK.WK0<2PZQA L:E+F)VGA@L:H@KH M%>M&0%!V:,$GD!U[K JO,Q[-@/MO\79N25$_&%'/07UHZ* XYNI"[4N4;6NG M[?-JVNEP*'HPY1LI!3PY*&MX)31B,7F2 MT**&A\ RZ"$J?+48L7F!JB[]AY5?-C*:$P*(1# /3&[,8 *&'-.3*"PGL+M@ ME;QC(JP(CW.R'HT4@P9)/=(X \W,+( M^@"S?N"Y]Y9()!CRM83\RI )&E%- MT=[6.IA3!RLS\Y.F4F?SKN;T2TNI!8HU[FZ%(F4GU8L*CK/\X1'<@95(UB]Q MD$M%O56BCYKH8[[W1)^YXJY3"+ S8$/A*HFC)-0 /"43,WS0["BZ9/_,[S^Q M(-ASV8/(&B:8V-1,&>\(\(OF@\>+(-K(!E))L?9IGI2N)C3?O&;"NA!!6P8]PH M#K"KKT='>ZHM".8CNC\IN% MJ?Z-J!,79DTTU1,YY_4>8$?K28QA.P_V2FC> JWRPO(1-9R2(]SLN)1&]5=ZSV M'N6U8^HSZ,$1M^8R4& FG!MAN]-0&\*?3)QQ D_^9&I+$0"1J #7W_&M(1(6( OSX$1OO'P%(/WEDQ=E >&>B^!-7!BQ!-O[NB< M7?%DV"(JR2]1(1!Z+RY2( !PAVG6T%QW*11NE?E/E%KU?1GQL90FA-).,! M=-:[?2K\OW! O,YKSG//6@Q,!('2:E>M<@I\ZET;@+U#'4ZX3R/?D=O1XF87 MZ^V RZML XJ[;\/[[IDHLP>\Y)Z#]TT]&J4,A;$>1\R?SQINE5T220CO( F" #ADMH/-NY,I/9QN0 M4!P0V::V3AIL("LAIYMTY"Y /T]4FIH6,6,Y2-W%I3D_/,2S8"I\L7ZF):!N M-%?M\5NY1@%Y@^,J+#3^AHE'<*!S5TSUR6V<-Q$7G6!2RX8;(0\N>Q0A<'@U MQW_V7GXD(V-\JF8;<,M'1^[/6)M:?X""!,U&_B!1H.>2!6<- %!Z?F78O!QD MR$2!AO#EYUM=\.KX$?OHP&=NX)!:L?+EL]*D@$]\&E;QY\B%Y>1>C>\ 0F 4 M(,)/P9-B(!C)0,N9?X6+0*L6T4#!:LS1$H$I01]\*,K0"QYGC598[V)+GW*@ M1V2AX$,'&5[%P9P'_.1S7%&H*XA8MF0L547A;:5%]IX+%.Q@F"Z8:\GF88/> M@]A22E*(V^):KJ(!"=,\7&!N^FB4!1Q^DR24D3OL30Y/L2W9%)^+AP?+]:2R M0F> GBHZFPO91'PJFN&=)2$2@4Z7<4LG=4=R>\7.\RF4B0?$2W)7I9,3 $>< MNA2S3D"*HY$;7<5N$\]XB*5QJ7A1%*?"F03KH50MKP"^R#3ZO$F#BN.*02EDF!/&)@67/FD3LL_SE"_H\ MGO7TV?4)\G33%_$LP6>MV>F71!W\:T%SO5ZM4^\@V>& V6R0K:#(&F#RT^SG MK5;-K#<+OZK7C,+/YST*6S5TVFL]:O[GK4;CC2^JN_!1-"58(+)@BO/"8!T:6!$>'U]O_^J^0WQEJ39N-/1.JYT?*KYQ M&."W:\%BOMA9QGRJV*IH^'W0\$&GH[?KK=>3817]5O3[FO1K@!0V6^UR$?#: M9I!(*MLG,VAFW,%T8^_9N.Y<^]I<#S2%/%D^VC2Z#;W>[:QI(!23PJO)T*G7 M%;HN;Q4]';W3-2OTE!0]G:[>ZQF[0<\2 2[CLW[@L_G8W)>KWH/3KFHK/:^J M4'?-;\F3)N"E9Y8+I>(*X+DG3-K5V[UU%5PQ]>S"27CCR#%-O=YK5=@I M*7;:NF'V=H.=]^"?7,K*] -,9CO$1+9(=C-0!/P[\TDZ;;UMKBL3*IMW6S8O M2&QC1R9OA9WEL293;]2-U4--VW%&WH1]CM):"&J9=EPDK2L[O!A\6.%DF%\J M6Z^H*+:^-ED:C,K]?"[;G\R(J[\S@-IIZHU$%F4N*G5Y3KST:5UE-:Y#1;.PI<5\A9A7.:U:G"JQT3K]#@ZYT=,!Q@#F9OZTD) M5?1ZJ86J&TML_@HY.W0?]*ZY(^R\!X/ZZPL[6ROT: M[76/V"NC>7T1O7*/\7=F3AMZJ[EN>4QENVT).7AOUO:N.GA4QMSRRH0*-25%34/O-7;DHE:=;S;O5.R4ED[DP" < MBRJF?V#7&^S=;_%1;55);97NOV_H,7IZVZC28$J*G9TRSWMP.:AV:]YDM,V+ M\?TUI5KUJKRSI*@Y:.E&:XU3V HQVT-,O?5F^]R40&X7C;9\9^9U8^TSV,IX MVUKB8K.SHQSF"CE+0_F]=>V9O2VBK:]>A+KOKWI#E;']@M+8@FWL]UR-W$[* M+3 :1ETWZV4IZ*TH89?MS@R]:RQ6'Q4EO =*,'L=W6C6MU$\O3DU"J:&Y@0) MSL]=85CB%LEFQ8AH$:Q?&S ;MV56>==[2-7#&=8X"-IQ<<(Y%8V/L6T7J1D[BK=6=F )[, *,&\* M,'L9+BS>7?\9EO3;42U[I4&6M,NO0D?O@PR:%1E49 #28+$]69F-;\ ZJL*' MK\0^?](?8.U8L"KKGFE^,AZ $10,<_9/I 5)',66CQO3I8GT>04R>%[*Q'N\ M?SU;FNN77LG)Z^UVIVZ8>J=G+NWTOSTCY*W U="[+2RO+\OQ\!N!JUG7C;JI MM]JO:S1O(SFK;';"'MHD^Z$]BC*XWGA6I=EH8(=^W>SL:")WE?BZDNKO-D%% M555_9441:+N6V=9;2Y+,WL19TS;U4!6@6$E!?XHMN C^==R'KW^!'_)A8RN\ M=WUZ6*I\7=]A?OS9;-8Z+;*3MLPQ)D+M;L2T88"E^+ ;C9:O12R.L)%,C.5! MCHO5^I:GN3Y\-.:U^TJIIPT48+F^:#+CQFP<8:==+W'@>_C<9[+SKG: /6D. M-6L0/#"=.M/ /;+5& W:9I8]@@^M6+-"EGL,'M+@'6@:Z-KCR(4+Q]:3-F#: MB'F388(+U"SL>1/A3H(DU(()"RUL6H:];Q(OCFK:M<>L"#L.#&&QL'HL$S;K M7T2U\ V_#%=RQ>^%==$EQA>^;.JO,Q?BHPRQP MLH! 6GD^LQFVRT0SFB,G1YU )IXUB=AG^MU/X5;UF%'X^[U&M6J-A MKO6D^9^W&L7OJ-:4?X-AM$JVIC+"J8QKJG"W@S4U%TNZEUB#+6.5; JN'+9C MAG57,L/^P:Q0._51;9\PF]&A0L/0GY,]LHD"M[V F5DW&ZL% \0U@" MLX]Y4T U*Z!N'JC&=H'Z-H!6L7?%WOL!U(J]*_8N!U K]GYU]GZ)(6ZTWB O M7[)8.Q?1R@N,5KXTGOPFH;3H>/8]PV7FW'JO&XKU5MKSS?PYJ"]*$]R(9*\> M7IZ'EWIQU<,K@J@>ONF';Z@/,L\],6MFJ]RJ<(79X-ICZ,;L*!@.(^V3Q@^C M7;C8OW?Q<-<:XV'XOT6#?("Y)TZA7]()=<9R;RT%XX(R*D"RCEV?9U%PH?I69D[O M@9>T 8_\;6-GGT^UWC9F*KZIL%-AIY)J;PLS%=]4V*FP4TFUMX69ZB2HNJJZ MJCH)JJYZTU>]@Y.@ZS!X<".,56)S42^ !6"C5'A^=C04,GCV XO>2E?TU2!3 MK^VHC?,FH_9O%#-&A9E28J91JP8(E!,SE30K+V8J:59.S%32K*R8>5[\I<). MA9T*.SO%SH8R@LKL46/G/@W\:5@AK#AQH]&8^3&.]7#8('Y?N4!&=8)14LS4 M:\T*,Z7$3*-9:U>H*25J*G%65LQ4XJRLF*G$66E14V7_5-BIL/-,L;9^0'T[ MZ3]OX5#Z2JE(U [8KPGS(W98U296]U?W5_>7L#:Q46YY>NY'26CY-GN7!8G- M76GJRHBJ3-P*.Q5V*JGVKC!3\4V%G0H[E51[6YBI^*;"SNM&)/?"E>:AR30F M^1*'>F\SR Z,6GMF-FF5U[=[K!@55LJ&E?43$RK,5%+L76.EDF*EPTHEQ; M#CX:]6711Y./8$_#C@0.]2S5FQ:S6JP]: Y8 MI^?4C>'_MLP/\J91*+[9T2!DUL\C:P@[_&QYC]93A'A0 #%V_:,IP$_# MC$/FZU\&(:)P=K7JTZSP'AX8!Q.,OKXZ3#N%,+UP_Y6XCAL_4/$\DNOZ#I#'9[-)H-D1D?0C+1CR(/4)L]EXP$+^5\/0-;-N M-G3MD6DCR]&LR20,?KEC*V;>$[_F8Z_9KO4T6);'!Y!IGH2/#CSK1VZ$;8FP M'5'BXPC(T+5C!NQL12,"(/W"X)8'RP-89&OYV#1JC?3!>*GU8+D>(3G1O!4AX4:P!Y0\!!X#_BRXY#! K0SRW8]1%3ZR%Z]56O+9]:TNQ&3U_;O M0\:H<9+E10&N/+9<'[L2:Y9M!Z%#+8N9%2PP9/B FA M<)%QH'U$\M<&8CL'PS 8:W_4;FO:1T,>$<@O)UX2:Z M%B6#?S([QH?B[#?>.1D6[)!PBFK[1X%_(GD],&WH>D :EA:-F#?40G8/Q!/R MR791#$1'^'ETXQ'!^_;TF&."_9JX0%I(?)?! Q$PTFT+Z';DVD!FGA<\ J40 M'H+A$+Y&D$7,\^!5%MX*Y&D'XS&]*+!_ZMHD9' =T(;\X-$*0POH4]?HX 7^ M37P7_R'HLQ#)!1^#E @8BH %K-!E1>_$OESPFYV$@#$&CXA'89#V$"[#['G6P3D$7$\DGB=D)AIU:=%!F#H21LP#6P61R.Y0SA%\8'_ M'KB'VN")N$.0(1%2%(2QFXSQR0/+_PF48I,@M^2+BVD2MSY]/2S1M]T)"%:\ M^L#E+USVEF$0 L]QEB$V\&$3(PL$ UQL^4_I!1D;Y"!K94^ ]<)RA8#?0_(\ M28B^$+9/S HU!HMRM'G*V@\D/3VR4*"=:TE\@$*0Q/S(\ZX#-\5:$H.Z_#=7 M9A)V4N4)":#<7=/(<)B[#&$S%!%DIB,+U[6'&+I"J3\"8CY"\9G90*#$X+>0 M""^2]A R!.P$5D$"T+9!C"6H8H4&"A]0=DRL)[Z\S)2BN0PIQZ N MLV&[9/2!4DM4,S@E.N7" ]Y+AT+5=7!KBB(0:? @2 M/P<+_!1YP =ZUN)'YL&:00/$HZBFG0,B'*Y9:4].0+R:VQK>*VUKU,#*&F^9 M[\+3+X,84'%.K$)DWU_')I=V@CP&HS2,ZR'MI1$6,_-?YP7$+FQMT#5$*?>Y @%NTI]$K;Z@Q$ MNTDS%8H01.^!((S6?$YMP3 M(AJ(UK.\7X^1Z(F?44NY]@JQ%!+R9R1U"9)7J3SNPQ8?B!#V3V!11RFI MHPP!GDK5/ACOC*Y5]#\%-50# '0&&@# 2$SH=&$^1,!SL30/;>!3%DT";HX4 M639X9VJ9I$N@M7$F1S-^VA ACI5R0WA=BE"=@420Q!P40BKGX !+G5T .A>* MRL<7\J_P\A6L')75 0B3($3F19$P8I:#HH0'BG@XH,CJR!9( 6FR-D!T3CR& MR\]V*\E'2#*'/>?!&#D7P>ST>7G4B(T)>2Y6K]A%^=M&0/W404W%6+Q49 ?0@19%"(%G1/Q!Q ^!?3TF#!Q:%A)(S'R,RBA&&Q(0&<5> M8L>)T)[P1@I@I&^%929>G+KPH>@&H Y]=;+D0'0.+>A2PBL&V^&BV:JW5;J9X2FH@">%K M\><>Q4\3QM4!/+.G!.2!HT*6R<\AB6JI3- -@.M;M:YZO9NV!9,+H6M:\Y^Y M2.H3M#[6\[MT4#2[@R3E>O8+5!0]"W#GDW2GS0,=)3X%H#S7L5#>_#, \:4] M< <)#%4+K$#+(X4QC !X@,>/W:9RUI&@0$1U+64<\78>"YVNLK[T!H2\8K>1 MJX 21>" 3,>/AE%KYF_%D*]P+*7'+X[JVO=.]R +=J9O$&%)6$-NMB M>.Z]+#M+3?YW*,L([X#DS._)R['TP*X^=6*G"+-.1R%GXE0>40*-:;E$G^00 MC@+/H0,-$(U-Y6E"@N7%P\(@##ZBJPA7%"?*O8XD_&Q3=A"1.>P1_8I@]G1( M!!_;4:3 U&/Y$0R&QKGQZ3!^@*5KH;'8113Y0XC;Q>HY_8P?GC-O>F(,:'X$="6 M_\1%CJ(QTS-N+DDRGV)(I[FQY7JIV$M="UVU+OV<.*,4BU10[YT*GG\4L'\T M@#'DL=P/(287/19Z4IR\8;J"((XXM-!3])13E& XMLJ\4G[7#07@T:XWG_X M4DK0646ZM5U@2Z/C/+ZN)%V73V[89$+J2ALT<5F=[6UPY44UMP>K);GDI9@3T5VIF/_.C;WY MO==FM[2D>?PFQN4ZZMB-I^IU'=[PO,9!*P-A<_V>7L4NW/AL[AT*_&YWF;SO3,O[SL;D_2I-JKCL(12_8?UI!D=$NF=9XGT-]@F?$70&<^29*_:Q7U+PNJ%4Q!W)JP:M5Y] MF;#J30NKWELV3O=+6%W9<8 %<,(&[;W:$,L]:]>X*OFW7F!Z[;7 VE?KJE$S MEPFLAC$EL."#RKHJ"VXTDO TVYQ8>A=UYB\6P"0J40/'/;!BD'ZVW,SN,+ M/T+BGDFM.'J%])D5SFC,EYS1<+S/_GR5 Z>EIU]F_O1K($Z_G #KC((X390! M'-K8RT*7U4$TR^DT74 MHAZ&EP7'@7:LYJ&)7&> _VV6D88PE=DLLKW)DW8>18EH;?)[8F&#%##"L_O/ M_6$0CBE9*5>^G4N;A^O<[#I,L+$9I>KS+B]*ZHQ:9:7>@FTQ0D?>X695SE2Q ME5:QB1K-HB?G_(,Y-=/261"-#Y9V3*(Z/*K8'$\\E^B85VQBV>P$/K)Y)3HL MBM,@N56&:>#]58IU[X]ST? 4&(+P;,SU" MJ*B:)\%IO/!>EH):\WIC9=B8N6]^:EZ66IP!XRP).?)$3YW&[*M$\M_\%A"B MZ4Y:,J.4EZ),$ VCX!N@1E^4]MM49;CUKF0YO"[M+_8L&636=J<+[Q;B:40E MF&.9D>10W>YP2AIT=+6YF2]_2 M+:=\7PI<)2-9\L6WJ5KNHDH:S0JQ& T+ 1"X5#XF+0+X[)[;$XPY.J\E$]=% M[ &KL9&- U%W)F6?Z'3&NUGQSF9,)LR#M7^4U>.J'=IR% _F,[$.7[9D4SN) MP/% 3.7Z,>PAOC9O&*YNRLV64BTSYS+;2(@^7H=6]+ :EV)+>U*]P"J;>64I MT;]V^CWG';0R!X!DGT4[3KY?C$*Z5#)UUJU%&S&/*UJE+I7W/\N86\H)5]DK MKY1RL8^<)3OHB'(GM6QI8=[_XES]C0)QZ=0QDX_GS@5S%I!G:W^*!1I&K=-K MEC"7?IL)_F^^@F$G&VR:"Y?U=BH8SF6'EANT0.^>)E7Z_;M*OZ_J59Y##W_2 M'Z#Z^^AZW#,MQT950= K%@1MO%ZDX/2IU(>69^XO(+P5Z:RJ)JBJ"68VWNSJ M1K.Q-\4$NT_46"&S\66\43X: 6.B538*V0TD?GNUA-FRU-0MT8 E3!'$ @Q, M#>04>B0(%9OYB(([L]XRUC$;=C^KJKJJ&C6W=U=5F5)[F"FU- ^JKG3IM)9E MMKR),P_ION^^R1 V[AI;O,.S""E0$R]Y.CUDRGR.@1QYD?59$Q.=>$-#;(*? MQ'@VZ8@9.@O.492SKGS;9NJ:2EDQRYZ0GHBGF5?4NSG789OZ8$>/UD2F$?"3 M$CSZ_6C4S9J93ZN =\/#FSKOC-LJ^K*UZ,LV?-ENUXRB[SKP7;->:Q=]U^7] M[/!DHI?_GG)QJ/O@?-)_EQT_E";&$H-"&72P6&L^BEF7G-)D*U?1FEOD&]:GE5LV2T@V[U;AZC.> MY)BU %>2(,H)S37EY(EL%KU;:7>'TRY=2D32;D[/[S3,ODTB0BI:-**GIZ,Q M"UB5.FSS81N\)SV;[G*-,S91",0:UMR+G!8^5H(_/[9^"70B^VJD0M.D-,OY M9Y).0.F3*%";WTMF'EM 6"(ECH\*P^*)D,G.\_C.08"S_J@K-TJ30(S0X *& M(3O+26O#- 5,FBQZ;I;&1/2[!J!D#6SU5#;DQ\>)Q!J9:77 19ST7&C:&/4/ MSF^,]G*8LV ]ZU%7I#-(8;Z':-[N',;&))S8@U56'EDV,I?ZIF=MU-&5F^JR M[L^.$W76Z !?TY2YJ/PK_DU3GP]7&^Q[&N+[+[@+R!54#!%".D&0NYR-NC;! M>5\XJ'*Z.35/GTUOD(1,^PVF5V3V^)+$O)ST(9+%:# &IDH+N3RU'S[LM?D\ M"GCEK.9U,_F>4Y:S6Q?X?':>V=RJ"\Q0-3I?D*NC9#R1X@NOS]KC9?IUE<3B MJ9LYW67M3(2E*IL%D(C'ANK9<*+YY2%J]O+^2@B1(\ M<@ B$W8)9M2R7Z[2FIR;,*)5 PE_GM!-?RM/PVG&?)+AO:1>8;J&+$OW)D,4 MX9E@J )>)I49VI:4V2GG&5,Y(,Y#TQ[<$-MI(SJR&X1V36=*JC\-$Q#9"Q<$&GWYC).#_)1$[78Z["XT;=0PJ0,*?W,U M&H5SR&56J[(!,?E-SB8MW/_^J<9S61R3)7??L/O$X\GEMT?_HT_E[V;N'P@6 MG)7V[RQ<.I71[BH#OM!!Y%5@LHJK4!P@!;G1.B_!DI0!8QCG8Q/2INF\ID$0 M_(Q$Z1=N,4H-4BZ41-W#PL6P==8R$T_.C_[!:"%.G.:.8F[$DIXG/T[3\=]B?$-X-,#D5IB(!WI'$(:0[N5A. "8,MP?33"T:LJP!=V MA<_%4 H?G,Z0X".YHBCW\)6'2R+L:0:[1P,H#HHSV[>;-M[KUX*)ZFTB$7C%1N/"RWGYF,.:#C!KPT3KY M")L G)(24O9NRJN!%.70*LDX2W?[;L!E;B1U=LWL6(#;CM*"[GAINL?&.J7<:^]-INZ+ABH9G:;BIU]ME3/#>;-W<#PEN47OW!(T&AV]:9IELP/?LSZZ9#$=^U1C/]8"VX'1Z.GM1N]P70&\ M5^2]^PJR#=>9O>JX^H7#Z8^QM1V.9Y?Y%J(YW(T;_=R_E(G<;N@D2_1T#6$[ MF@4_F?8X8KYF:7Y"O@.>OHNTS4"DJF#^WU2ZMYHH@+D[S+^G;&\7=NC"/BPE M6P=/TA]6?R^*J>1ZLAZJE+H44E(*WC@.?!AT^2_J-0*V7<*O5'MO:16,YF$E<6MU_W R&>.$$@LV"* M3\@F( \P..-H!J;KY,'1UGK_79D#]S^=#T/J.HR M":FR*>TO?@_04Y8-P%27U:K=/4,+PX M0#QW/-K$#7X/2PW%@GT^+C^<(BIKYB8=XS[%*\SZT:]IL&ZA=G![0>0 MA@[#)N^ <;#M1 JSJ"JG HT)?XM.?S@6IJS+*G3L9Q[^A!W!)S\IB]%AOP!) MGIUP'4R=H3V/*GQH- 'V'=C#A.(K7TNG:B*9&ST<6F #'([&+NS8 S.-S 1" M0L1)!>#@B0J#.23Y)%%X=(*,X:?$]B-PF)?1VLGU#TEL8"G9: 6S=&J%2C26 M=OSCEO)>08DE'@-\P[V !CM!SL"&W+ YM("H7)37/LEB*1U+]=,4W0=02F.0 MY(1KP2,Z(532"VXD929!..*%O# MFOE:Z6! !7(63Y$'ZK0PC1>K?>*TR@-O M%&0/QAE9?OAZ;...R[0F6%$!.T8E&C$30PM2YD;S3G%-$"F4QAUE M123TQ"BA96E.F-SS1XQI#QY\@]5F^"+*3QX\<\O" L*^[)R-#;E%A8^+DSI=D&^:SYC#(7T?6-Z> M2H>_)H!448AFZL2%HD[(4MA1Z6L_=",D*E*GE&Z=:3)"!U+Z D7&2Q!X68W2 M0L0G(2QF?Z#,KW5^(UJC&@(LT\Z_UJ0OT;FGJCQU<@@-Q1 5Y?RK9$)#*R3W M"%'%EPM7M&K&;VD!I\+H!^YA@:+(UMBH]7[3)EZ".>8%EV(=@(T%LBP,@U I M>2456FO]1J3C\:H:_@ #E8$8?#@:>J&>JWQ&RAL:O1.C!@,AQ&^[$F4$@!T MW $O B!)!E?./L6$I_ 9-]Q?F',E0*%9:_\F^J30WP.&.)N,"#C@:5*%O873 M1(X()\#5;N#P:3P15OG<4_C""60%AF18[J/R H@,_P^6ETB9#7K!AO?P4G&" M!^K[Q73%ZQ5\8(L\>F>43C"E$$USC_DV,UW7YMOFZ_!M$RWH!7S;V"#?MFO- M9_)M_=E\VP"V6)-OS45\&V&$S>%\E94%K1:XW-J=XV.R5K-7KUI,:O%VH/F@'5Z3MT8_F^K]4&Y:3V_ M_^A?WIW?]>_._WZJ]2]/\(,+^??)^>WQQ=7M'S>GMUK_V]4?=]J/_LW?3N^T MF_/;O^V?Z/J3MYM@OR9!Q"4$F'QND$22"RDHJ6.?L#&OFU.,7\O!J"%3(]13 M#II\Q%2A^,B_G.G'N\YSQ[] NG)DF+'_MQ)%&D%.X6@[.D@5MZ MXOK-]SB:.49WV81@A6&>,Q7'4!1V?PX^+;75!M[*%W^LKC5_!EWO$56MV;()_"EPGI6FHA$D0/1 M=$9H0>4,@]R_F6KSX-%?=4[JR!+!_(_M1F>J/5^Z4'7+*.PHP!5RL:$L':X0 MS^K56[6LLU4V_S WBU% #U<_%WI[:-K^R93>7&,Z9Z,]DL(@ESV8DK9TSHM! M#5%-3C:JAM$M;#U%(PB0B'*0YT)LFC>R]F X 9._G)_1@OQD>L%[9TZ-U1&5 MHH7#;#])I9VD,N)W#9HK[%%)Q S[%1$2]0+9NI(N0>L30X!\&4,O0'$>R.&] MG*>N:-@P8$5J ( IC=V1D;W;J[.;-+*'AX=*2Y/\N_'114-24:+ 0X01JL M MDPKJ'-54HF G*$M[E&--+#'6)!1C*"+)9!<[^#TR M/EJ68+"2]"<'TJ=V Z(#2[Y_@R+,U50']'G<,;JLPF0)\#S'#QZ4)!%Q5(]Q M6?:(,5!;-D-1'BE80XPX3BVN;XSG8A1B<_YN!N@$IT0C^J&HVF%&[1*M$W6Q M?V%J!T7*>?^'2%!443-<3A3DX^I$?446L+)ZGK42K]# B$^)I<>IW*D^BKD$ MK0/K4#NQT("_I2,FXG8Z<7+8<-$T3%K,P0#]:MPAWWYZU$,M+O VN-R*>38/ M.OS4%H4Y.%Y5](2A^\C-K]=:O^G<& %(E?JT+#YX8;O7UT4.Q%0$/D!VX M#X?X)_X]*Q9P;J?H I;VV\&VB< ( 4_8H,B]0DI3K>MB2E[*L)PY.LA,&# ' MS:'$46:=(IO2AZCEC]*!!S!,898G-8.#]V&A\P$,P6,/TAN7G/_"9Y*RI&9W M\^W[=YEQT*TR#A: 9Z:7DQ3RW($3YW_.A"M3?QM%2'IX(0.> M3NK=(IDE/#(Z;5\"P@/13HP+=3IS),.8W*1>L];(3^]8U#N,I\NFZR,_.A=@ M_";/?W#C6:=RV60M%1@CL..DO%B<#^9R1J/#$LEUTYN45HQD.=4JI@;P%*\H MEFC&U%D9WB_]V7P 6VE].[O^Y0' K)VQD+&4="Z7XO!L-O$'F<"9N:D+T9N& M]U86H9LYK.F6Z;"F6]/.SB_[E\?G_0OM]JX/7YQ>WMW2FG@C[^/+_[KO6/CZ_^ .K #ZXNY9_G ME[_3#1E=90=^>VBL7 8^VRXA-$M%"'V@A*O+NYNK"RX5KF^NCD]/Z/!V/:AL M>P\G8%]Z7.,?8RU1X/$8PW48@&=$/MC^42/O;$CGP;Q[.X5_*%,IS>RE1 PJ MT\'HKB["_CS0DT4428N.7#8$QA 6DY(8 M02<^8D$.PV(=WN18MH%-3U,SM-@J6B8I6J3A@XZO<-&R)_.@. ]+B97PNK/G M;8^BP#:GI(A.Z'D> MO/CV]O0XC9AB&E8D4P+&@*Z3Y0 39[0ZO1&S7RG$)G W[R9.1AP\:X.0Q_U> M $C,)AZ+Y'E^O$5#<6SU<.QYK)5]7\!>FW;9PSNH-4[+JBU$KA"KT>B@W ?/^A/CF&9J9!<>O1 #LGQQ7 MZBV)9Z,)YF7+(W'T8P>>&XUDN"]W$NS@R8E,T?%Y'6H&'[4;O8 /$17%Y/'( M 5^H' CDR/X&,RR-AD5(,;X8K8,A;X)OM!SULYKV1\HW43+!S/Y(UKRD@R/( MR<;#'U7\;U@9/:9#!XA+%960ZLEI!<6C""N"3N.CL2CT%+IPDVNA6(+?!YEP M-.M&8X9:"5SF%_SXGB<^GH76F#T&X<^IN17'8O@4>>2W2 @!^<97X;WEN__. M3OCPXCOP:9U'ZXG?Q<-GZV5/-F=BAXH<%FVHS4VHD^AM$B;K@YJ+$M; M3:?N823[[N6DN-#*2,<46,!1HNS].@0F><0S1>P6SXX#-,8B[>+B6A[K94WU ML7X_BLE^G"0@>VP:VY#X,<^T#L<9+I\E8Q!L@:LY 59,WS:50 M+.:KRJI_H/LHEJJ<)'^:_IP^"FM\7']-)VSK/2BR:.9;5EPT@(7;OWXNA+L> M+2OA/S&::O$$!"(^BO%ANG?(8[>RQ0,_[*?*T[0Q@>?^1'.)4JZF;M#76^N& MG/_W?';Z'(4H,TA5[%TW^B_L+NR)=)F.XGSK(X-)NV!"6<-3\H/E@ M%OW7!V8[G]&.-NJ#E@'[O0O'?NR<>=;]!XW[K4#MO^+/E,@)"_4B]H%88'C4 M:*_SDLO 5]_3=X()",/57M1YP8O6V5#WN5!;:S<]'J;]RZ?CG"O%KON*9&Z&].?^_?G& 0'V3,Z?GOE]I?_[@YOSTY/T9Q_?:='ZUCT=6I[]L-J'>5>EXO 'S@D?I]15$3WD85$F4J0L/3%9= M2B\,_),"B%DUS> B,,?CUE#J$(RV+058D,W9X>R] SK!@[F40B M#4LYV> #CK-:V\43TF9GE^+]5!8L HL_&(M%BNBM,I.V[)'2X\#AN2ARMB9 MYQ1 9^_C\=6?8AZLQ;4[-DF9OST><."=/N0(T_0029V,'3-KC%Y>-!U2S++/ MB\.*V?1+1@=39 #RD;VY#*0. Y)2?!LD3,[#BM6?X=O4N>$1H)(A5; M>60#\.<8)B&\;M6$*)$FNAN94O(J"RA MUZ#MKEDJVC9KB OP=._^H5W]>0D>P??S:_ .-' .[OKGE]JWT\M3)=)%-RGUQ[?SRY!3TR,GI?KK: MJ[-(HV*1K;%(J5+LC69-N[XYOSP^OP;=D>5,:V>GIR+1_O3F[^?'JR?4[B7] M-]\-_5=GOPJ!M.J;./OM&:4X^]VKN/[?7R6LW\M5)Q3(I\;NSIHSD=M"3_7[ M^;=S4DXJWCW!];A M+D,Q'/"S/[>SICD5(($MN\Z1NK!XX6>NQNOS2DIW#]!O5.B?KH0NJO5;%=NE M.::>*6%E_R)&Y8DW M"R.M5I^>O\N_:(".-UO%W\V]:>X79HLO8B,/:[0WN3)S@RMK=9<_K'@HN=%< M82KY/DPUGL>Y\WZB@YOU8"E(>=>BE,=HWD4^:5W*XG5&TZX+QF(/A$9=[@C( M9T=_L;;[3@XL!VL?*1#!IU=JHQ#3#/]CN5MC=#L?OC9Z?_ED37N F\?7+C B MFIN\+A56Q+8:L9GUUH>OK=:;);:\S?DY1W0K3Y-ME,H(%S(>LR6U(^T&FPV= M\@&2_2AB,<\FZ"L5PR/OX&:@<-]<;!2RLH^^'R-RN>;R?0=N0-WM5*:4G%2 MWJQF8AO$+3Q6AZ3+3UU":5=G)T?JD1$O*TW[5L4!<\!AO81( :G77_FG3J>OI3E+$&$T;6+\]N[LL80>KU:I][Y;7X( MX;=/GRBKGMFU^^#A4S^T1SC1 M]1-S[JWP$UCYUB>CV3/-7O<3+-

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